PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	BRENNAN, JA; BOYLE, JO; KOCH, WM; GOODMAN, SN; HRUBAN, RH; EBY, YJ; COUCH, MJ; FORASTIERE, AA; SIDRANSKY, D				BRENNAN, JA; BOYLE, JO; KOCH, WM; GOODMAN, SN; HRUBAN, RH; EBY, YJ; COUCH, MJ; FORASTIERE, AA; SIDRANSKY, D			ASSOCIATION BETWEEN CIGARETTE-SMOKING AND MUTATION OF THE P53 GENE IN SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ORAL CAVITY; COLORECTAL TUMORIGENESIS; ALCOHOL-DRINKING; TOBACCO SMOKING; POINT MUTATIONS; HUMAN CANCERS; LUNG-CANCER; EXPRESSION; PROTEIN; LARYNX	Background. Although epidemiologic studies have long associated tobacco and alcohol use with the development of squamous-cell carcinoma of the head and neck, the molecular targets of these carcinogens have yet to be identified. We performed a molecular analysis to determine the pattern of mutations in the p53 gene in neoplasms from patients with squamous-cell carcinoma of the head and neck and a history of tobacco or alcohol use. Methods. Sequence analysis of the conserved regions of the p53 gene was performed in tumor samples from 129 patients with primary squamous-cell carcinoma of the head and neck. We then used statistical analysis to identify any patient characteristics associated with mutation of the p53 gene. Results. We found p53 mutations in 42 percent of the patients (54 of 129). Fifty-eight percent of the patients who smoked cigarettes and used alcohol (37 of 64; 95 percent confidence interval, 45 to 70 percent), 33 percent of the patients who smoked but abstained from alcohol (13 of 39; 95 percent confidence interval, 19 to 50 percent), and 17 percent of the patients who neither smoked nor drank alcohol (4 of 24, 95 percent confidence interval, 5 to 37 percent) had p53 mutations (P = 0.001). (Two patients used alcohol but did not smoke, and neither had a p53 mutation.) Furthermore, 100 percent of the mutations in the patients who neither drank nor smoked occurred at sites containing cytidine phosphate guanosine dinucleotides (potentially representing endogenous mutations) within the p53 gene (5 of 5 mutations; 95 percent confidence interval, 48 to 100 percent), whereas only 23 percent of those in cigarette smokers consisted of such changes (12 of 53 mutations; 95 percent confidence interval, 12 to 36 percent; P = 0.001). Conclusions. In our study, a history of tobacco and alcohol use was associated with a high frequency of p53 mutations in patients with squamous-cell carcinoma of the head and neck. Preliminary evidence linked cigarette smoking to p53 mutations at nonendogenous mutation sites. Our findings suggest a role for tobacco in the molecular progression of squamous-cell carcinoma of the head and neck and support the epidemiologic evidence that abstinence from smoking is important to prevent head and neck cancer.	JOHNS HOPKINS UNIV, SCH MED, DEPT OTOLARYNGOL HEAD & NECK SURG, DIV HEAD & NECK CANC RES, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, CTR ONCOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DIV BIOSTAT, BALTIMORE, MD USA; JOHNS HOPKINS UNIV HOSP, DEPT PATHOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine				Goodman, Steven/0000-0002-3872-5723	NCI NIH HHS [CA-58184-01, CA-54672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054672, P50CA058184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAAS IO, 1994, J PATHOL, V172, P5, DOI 10.1002/path.1711720104; BAKER SJ, 1990, CANCER RES, V50, P7717; Beahrs OH, 1988, MANUAL STAGING CANCE, P27; BOFFETTA P, 1992, INT J CANCER, V52, P530, DOI 10.1002/ijc.2910520405; BONGIORNO PF, 1994, J THORAC CARDIOV SUR, V107, P590, DOI 10.1016/S0022-5223(94)70107-5; BOREK C, 1993, ENVIRON HEALTH PERSP, V101, P237, DOI 10.2307/3431732; BOYLE JO, 1993, CANCER RES, V53, P4477; BRACHMAN DG, 1991, CANCER RES, V51, P6393; BREIMER LH, 1988, BRIT J CANCER, V57, P6, DOI 10.1038/bjc.1988.2; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; BUCHMAN GW, 1992, FOCUS, V14, P41; CARBONE D, 1992, AM J MED, V93, pS13, DOI 10.1016/0002-9343(92)90621-H; CHOI SY, 1991, INT J EPIDEMIOL, V20, P878, DOI 10.1093/ije/20.4.878; CHRISTEN AG, 1992, AM J MED, V93, pS25, DOI 10.1016/0002-9343(92)90624-K; CULLEN J, 1986, HDB PREVENTION, P308; CUNNINGHAM J, 1992, CANCER RES, V52, P1974; DUFFY MJ, 1993, CLIN BIOCHEM, V26, P439, DOI 10.1016/0009-9120(93)80007-H; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIELD JK, 1991, BRIT J CANCER, V64, P573, DOI 10.1038/bjc.1991.352; FISHER CJ, 1994, BRIT J CANCER, V69, P26, DOI 10.1038/bjc.1994.4; GOSNEY JR, 1993, INT J ONCOL, V2, P1071; HABUCHI T, 1993, CANCER RES, V53, P3795; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1991, CANCER RES, V51, P4102; HONG WK, 1993, CANCER RES, V53, P5113; LESMES GR, 1992, AM J MED, V93, pS55, DOI 10.1016/0002-9343(92)90629-P; MAESTRO R, 1992, ONCOGENE, V7, P1159; MASHBERG A, 1993, CANCER-AM CANCER SOC, V72, P1369, DOI 10.1002/1097-0142(19930815)72:4<1369::AID-CNCR2820720436>3.0.CO;2-L; PUISIEUX A, 1991, CANCER RES, V51, P6185; RENAN MJ, 1992, RADIAT RES, V131, P227, DOI 10.2307/3578445; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; SPRUCK CH, 1993, CANCER RES, V53, P2427; SPRUCK CH, 1993, CANCER RES, V53, P1162; STRAUSS BS, 1992, CANCER RES, V52, P249; SUZUKI H, 1992, CANCER RES, V52, P734; THOMAS S, 1994, CANCER RES, V54, P3588; VAHAKANGAS KH, 1992, LANCET, V339, P576, DOI 10.1016/0140-6736(92)90866-2; VOGELSTEIN B, 1992, NATURE, V355, P209, DOI 10.1038/355209a0; WAGATA T, 1993, CANCER RES, V53, P846; WOGAN GN, 1992, ENVIRON HEALTH PERSP, V98, P167, DOI 10.2307/3431264; WYNFORDTHOMAS D, 1992, J PATHOL, V166, P329, DOI 10.1002/path.1711660402; ZHANG ZF, 1994, CANCER EPIDEM BIOMAR, V3, P19; 1989, DHHS CDC898411 PUBL	47	505	512	1	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 16	1995	332	11					712	717		10.1056/NEJM199503163321104	http://dx.doi.org/10.1056/NEJM199503163321104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL788	7854378				2022-12-28	WOS:A1995QL78800004
J	ROWE, PM				ROWE, PM			SOMETHING BETTER THAN ZIDOVUDINE FOR CHILDREN	LANCET			English	Editorial Material																		1995, LANCET          0218, P446	1	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 25	1995	345	8948					511	511		10.1016/S0140-6736(95)90602-9	http://dx.doi.org/10.1016/S0140-6736(95)90602-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7861883				2022-12-28	WOS:A1995QH92900029
J	MILLAR, AJ; CARRE, IA; STRAYER, CA; CHUA, NH; KAY, SA				MILLAR, AJ; CARRE, IA; STRAYER, CA; CHUA, NH; KAY, SA			CIRCADIAN CLOCK MUTANTS IN ARABIDOPSIS IDENTIFIED BY LUCIFERASE IMAGING	SCIENCE			English	Article							THALIANA	The cycling bioluminescence of Arabidopsis plants carrying a firefly luciferase fusion construct was used to identify mutant individuals with aberrant cycling patterns. Both long- and short-period mutants were recovered. A semidominant short-period mutation, timing of CAB expression (toc1), was mapped to chromosome 5. The toc1 mutation shortens the period of two distinct circadian rhythms, the expression of chlorophyll a/b-binding protein (CAB) genes and the movements of primary leaves, although toc1 mutants do not show extensive pleiotropy for other phenotypes.	UNIV VIRGINIA, DEPT BIOL, NSF, CTR BIOL TIMING, CHARLOTTESVILLE, VA 22903 USA; ROCKEFELLER UNIV, PLANT MOLEC BIOL LAB, NEW YORK, NY 10021 USA	National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia; Rockefeller University			Kay, Steve A/F-6025-2011; CARRE, Isabelle A/D-8802-2011; Millar, Andrew J/G-2423-2012	Kay, Steve A/0000-0002-0402-2878; CARRE, Isabelle A/0000-0002-0548-7378; Millar, Andrew J/0000-0003-1756-3654	NIGMS NIH HHS [GM44640] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM044640, R01GM044640] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; CHORY J, 1991, PLANT CELL, V3, P445, DOI 10.1105/tpc.3.5.445; DEITZER GF, 1984, LIGHT FLOWERING PROC, P51; DENG XW, 1992, PLANT J, V2, P83, DOI 10.1111/j.1365-313X.1992.00083.x; DUNLAP JC, 1983, ANNU REV PHYSIOL, V55, P683; ENGELMANN W, 1992, Z NATURFORSCH C, V47, P925; HALL JC, 1990, ANNU REV GENET, V24, P659; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KOOMEEF M, 1992, METHODS ARABIDOPSIS, P83; MCCLUNG CR, 1994, ARABIDOPSIS THALIANA, P615; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; MILLAR AJ, 1994, ANNU REV GENET, V28, P325, DOI 10.1146/annurev.ge.28.120194.001545; MILLAR AJ, UNPUB; MILLAR AJ, 1994, THESIS ROCKEFFELLER; Millar AJ, 1992, PLANT MOL BIOL REP, V10, P324, DOI 10.1007/BF02668909; PEPPER A, 1994, CELL, V78, P109, DOI 10.1016/0092-8674(94)90577-0; REITER RS, 1992, P NATL ACAD SCI USA, V89, P1477, DOI 10.1073/pnas.89.4.1477; TEAKLE GR, UNPUB	19	446	467	2	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 24	1995	267	5201					1161	1163		10.1126/science.7855595	http://dx.doi.org/10.1126/science.7855595			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855595				2022-12-28	WOS:A1995QJ23700035
J	STITT, TN; CONN, G; GORE, M; LAI, C; BRUNO, J; RADZIEJEWSKI, C; MATTSSON, K; FISHER, J; GIES, DR; JONES, PF; MASIAKOWSKI, P; RYAN, TE; TOBKES, NJ; CHEN, DH; DISTEFANO, PS; LONG, GL; BASILICO, C; GOLDFARB, MP; LEMKE, G; GLASS, DJ; YANCOPOULOS, GD				STITT, TN; CONN, G; GORE, M; LAI, C; BRUNO, J; RADZIEJEWSKI, C; MATTSSON, K; FISHER, J; GIES, DR; JONES, PF; MASIAKOWSKI, P; RYAN, TE; TOBKES, NJ; CHEN, DH; DISTEFANO, PS; LONG, GL; BASILICO, C; GOLDFARB, MP; LEMKE, G; GLASS, DJ; YANCOPOULOS, GD			THE ANTICOAGULATION FACTOR PROTEIN-S AND ITS RELATIVE, GAS6, ARE LIGANDS FOR THE TYRO 3/AXL FAMILY OF RECEPTOR TYROSINE KINASES	CELL			English	Article							HEPATOCYTE GROWTH-FACTOR; K-DEPENDENT PROTEIN; C4B-BINDING PROTEIN; BLOOD-COAGULATION; NERVOUS-SYSTEM; MESSENGER-RNA; CELLS; COMPONENT; DEFICIENCY; CNTF	We report the identification of ligands for Tyro 3 (alternatively called Sky, rse, brt, or tif) and Axl (alternatively, Ark or UFO), members of a previously orphan family of receptor-like tyrosine kinases. These ligands correspond to protein S, a protease regulator that is a potent anticoagulant, and Gas6, a protein related to protein S but lacking any known function. Our results are reminiscent of recent findings that the procoagulant thrombin, a protease that drives clot formation by cleaving fibrinogen to form fibrin, also binds and activates intracellular signaling via a G protein-coupled cell surface receptor. Proteases and protease regulators that also activate specific cell surface receptors may serve to integrate coagulation with associated cellular responses required for tissue repair and growth, as well as to coordinate protease cascades and associated cellular responses in other systems, such as those involved in growth and remodeling of the nervous system.	SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT NEUROSCI, LA JOLLA, CA 92093 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; UNIV VERMONT, COLL MED, DEPT BIOCHEM, BURLINGTON, VT 05405 USA; NYU, SCH MED, DEPT MICROBIOL, NEW YORK, NY 10016 USA; NYU, SCH MED, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	Salk Institute; University of California System; University of California San Diego; Scripps Research Institute; University of Vermont; New York University; New York University	STITT, TN (corresponding author), REGENERON PHARMACEUT INC, 777 OLD SAW MILL RIVER RD, TARRYTOWN, NY 10591 USA.		Glass, David/AAI-3910-2021; Glass, David/C-4782-2012	Glass, David/0000-0001-6187-4164				BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; COLLINS MKL, 1988, J CELL PHYSIOL, V137, P293, DOI 10.1002/jcp.1041370212; COUGHLIN SR, 1993, THROMB HAEMOSTASIS, V70, P184; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAI W, 1994, ONCOGENE, V9, P975; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; FAGERSTAM L, 1991, TECHNIQUES PROTEIN C, V2, P65; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; HESSING M, 1991, BIOCHEM J, V277, P581, DOI 10.1042/bj2770581; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1994, J BIOL CHEM, V269, P1839; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; LAI C, 1994, ONCOGENE, V9, P2567; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; MAHASANDANA C, 1990, J PEDIATR-US, V117, P750, DOI 10.1016/S0022-3476(05)83335-9; MAILLARD C, 1992, ENDOCRINOLOGY, V130, P1599, DOI 10.1210/en.130.3.1599; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MARK MR, 1994, J BIOL CHEM, V269, P10720; Monard D, 1993, Perspect Dev Neurobiol, V1, P165; NELSON RM, 1992, J BIOL CHEM, V267, P8140; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1994, ONCOGENE, V9, P699; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PEGELOW CH, 1992, PEDIATRICS, V89, P674; PHILLIPS DJ, 1993, J NEUROCHEM, V61, P344, DOI 10.1111/j.1471-4159.1993.tb03574.x; RESCIGNO J, 1991, ONCOGENE, V6, P1909; RUDGE JS, 1994, EUR J NEUROSCI, V6, P693, DOI 10.1111/j.1460-9568.1994.tb00981.x; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; ZHAN X, 1987, ONCOGENE, V1, P369	43	595	638	1	20	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					661	670		10.1016/0092-8674(95)90520-0	http://dx.doi.org/10.1016/0092-8674(95)90520-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867073	hybrid			2022-12-28	WOS:A1995QJ60200018
J	HOUSMAN, DE				HOUSMAN, DE			DNA ON TRIAL - THE MOLECULAR-BASIS OF DNA-FINGERPRINTING	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											HOUSMAN, DE (corresponding author), MIT,CAMBRIDGE,MA 02139, USA.							[Anonymous], 1992, DNA TECHNOLOGY FOREN; LANDER ES, 1994, NATURE, V371, P735, DOI 10.1038/371735a0	2	8	9	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 23	1995	332	8					534	535		10.1056/NEJM199502233320812	http://dx.doi.org/10.1056/NEJM199502233320812			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH288	7830738				2022-12-28	WOS:A1995QH28800011
J	LINEHAN, WM; LERMAN, MI; ZBAR, B				LINEHAN, WM; LERMAN, MI; ZBAR, B			IDENTIFICATION OF THE VONHIPPEL-LINDAU (VHL) GENE - ITS ROLE IN RENAL-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TUMOR-SUPPRESSOR GENE; CELL CARCINOMA; CYSTIC-DISEASE; RISK-FACTORS; ALLELIC LOSS; SHORT ARM; CHROMOSOME-3; RETINOBLASTOMA; TRANSLOCATION; PAPILLARY		NCI, FREDERICK CANC RES & DEV CTR, IMMUNOBIOL LAB, FREDERICK, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	LINEHAN, WM (corresponding author), NCI, DIV CANC THERAPY,UROL ONCOL SECT,SURG BRANCH, CLIN ONCOL PROGRAM,BLDG 10, ROOM 2B47, BETHESDA, MD 20892 USA.							ANGLARD P, 1992, CANCER RES, V52, P348; ANGLARD P, 1991, CANCER RES, V51, P1071; BARD RH, 1982, UROLOGY, V19, P16, DOI 10.1016/0090-4295(82)90037-1; BASSIL B, 1985, J UROLOGY, V134, P450, DOI 10.1016/S0022-5347(17)47235-1; BOLDOG F, 1991, GENE CHROMOSOME CANC, V3, P403, DOI 10.1002/gcc.2870030513; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BRENNAN JF, 1991, BRIT J UROL, V67, P342, DOI 10.1111/j.1464-410X.1991.tb15158.x; BROOKS JD, 1993, J UROLOGY, V150, P1278, DOI 10.1016/S0022-5347(17)35760-9; BUTLER TP, 1975, CANCER RES, V35, P512; CARROLL PR, 1987, CANCER GENET CYTOGEN, V26, P253, DOI 10.1016/0165-4608(87)90059-8; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; CHEN F, IN PRESS HUM GENET; CHUNGPARK M, 1989, NEPHRON, V53, P157, DOI 10.1159/000185730; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; COMINGS DE, 1973, P NATL ACAD SCI USA, V70, P3324, DOI 10.1073/pnas.70.12.3324; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; DEJONG B, 1988, CANCER GENET CYTOGEN, V30, P53, DOI 10.1016/0165-4608(88)90092-1; FOSTER K, IN PRESS HUM MOL GEN; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; Glenn G., 1990, PROBLEMS UROLOGIC SU, P312; GLENN GM, 1992, JAMA-J AM MED ASSOC, V267, P1226, DOI 10.1001/jama.267.9.1226; GLENN GM, 1991, HUM GENET, V87, P207, DOI 10.1007/BF00204184; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HOSOE S, 1990, GENOMICS, V8, P634, DOI 10.1016/0888-7543(90)90249-T; ISHIKAWA I, 1993, HISTOPATHOLOGY, V22, P135, DOI 10.1111/j.1365-2559.1993.tb00091.x; KINZLER KW, 1993, NATURE, V363, P495, DOI 10.1038/363495a0; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KOVACS G, 1989, AM J PATHOL, V134, P27; KOVACS G, 1989, INT J CANCER, V43, P422, DOI 10.1002/ijc.2910430313; KOVACS G, 1989, CANCER RES, V49, P651; KOVACS G, 1989, J NATL CANCER I, V81, P527, DOI 10.1093/jnci/81.7.527; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; KOVACS G, 1991, GENE CHROMOSOME CANC, V3, P249, DOI 10.1002/gcc.2870030403; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LAVECCHIA C, 1990, CANCER RES, V50, P5231; LERMAN MI, 1991, HUM GENET, V86, P567; Linehan W M, 1993, Important Adv Oncol, P47; LINEHAN WM, 1993, CANCER PRINCIPLES PR, P1023; LIOTTA LA, 1974, CANCER RES, V34, P997; MACLURE M, 1987, ENVIRON RES, V42, P353, DOI 10.1016/S0013-9351(87)80200-1; MAHER ER, 1991, J MED GENET, V28, P443, DOI 10.1136/jmg.28.7.443; MALKER HR, 1984, LANCET, V1, P56; MATSON MA, 1990, MEDICINE, V69, P217, DOI 10.1097/00005792-199007000-00003; MELLEMGAARD A, 1994, CANCER CAUSE CONTROL, V5, P105, DOI 10.1007/BF01830256; MELMON KL, 1964, AM J MED, V36, P595, DOI 10.1016/0002-9343(64)90107-X; MORITA R, 1991, CANCER RES, V51, P820; OGAWA O, 1991, CANCER RES, V51, P949; PATHAK S, 1982, SCIENCE, V217, P939, DOI 10.1126/science.7112106; PONTES JE, 1990, PROG CLIN BIOL RES, V348, P11; POSTON CD, IN PRESS J UROL; PRESTI JC, 1991, CANCER RES, V51, P1544; REITER R, 1993, CAMPBELLS UROLOGY UP, P1; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; SELLI C, 1983, CANCER, V52, P899, DOI 10.1002/1097-0142(19830901)52:5<899::AID-CNCR2820520526>3.0.CO;2-#; SHUIN T, 1994, CANCER RES, V54, P2852; SIDEN TS, 1994, SOMAT CELL MOLEC GEN, V20, P137, DOI 10.1007/BF02290683; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; STANBRIDGE EJ, 1976, NATURE, V260, P17, DOI 10.1038/260017a0; SZUCS S, 1987, CANCER GENET CYTOGEN, V26, P369, DOI 10.1016/0165-4608(87)90072-0; TORY K, 1989, J NATL CANCER I, V81, P1097, DOI 10.1093/jnci/81.14.1097; VANDERHOUT AH, 1993, INT J CANCER, V53, P353; WHALEY JM, 1994, AM J HUM GENET, V55, P1092; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YAO M, 1993, HUM GENET, V92, P605, DOI 10.1007/BF00420947; YOSHIDA MA, 1986, CANCER RES, V46, P2139; YU MC, 1986, JNCI-J NATL CANCER I, V77, P351; Zbar B, 1989, Important Adv Oncol, P41; ZBAR B, 1994, J UROLOGY, V151, P561, DOI 10.1016/S0022-5347(17)35015-2; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; ZBAR B, IN PRESS J UROL; ZHUANG Z, 1994, MODERN PATHOLOGY, V7	76	249	253	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	1995	273	7					564	570						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF686	7837390				2022-12-28	WOS:A1995QF68600027
J	SATO, S; SUZUKI, K; AKAHANE, Y; AKAMATSU, K; AKIYAMA, K; YUNOMURA, K; TSUDA, F; TANAKA, T; OKAMOTO, H; MIYAKAWA, Y; MAYUMI, M				SATO, S; SUZUKI, K; AKAHANE, Y; AKAMATSU, K; AKIYAMA, K; YUNOMURA, K; TSUDA, F; TANAKA, T; OKAMOTO, H; MIYAKAWA, Y; MAYUMI, M			HEPATITIS-B VIRUS-STRAINS WITH MUTATIONS IN THE CORE PROMOTER IN PATIENTS WITH FULMINANT-HEPATITIS	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS B E ANTIGENS; GENETIC CODE	COMPLETE NUCLEOTIDE-SEQUENCE; PRECORE-REGION DEFECTS; E-ANTIGEN; PREGENOME ENCAPSIDATION; HBV-DNA; PROTEIN; EXPRESSION; ANTIBODY; MUTANTS; INFECTION	Objective: Fulminant hepatitis B can be induced by hepatitis B virus (HBV) strains with mutations in the precore region that cannot encode hepatitis B e antigen (HBeAg). Such mutations are rarely seen in HBV DNA clones from patients with fulminant hepatitis B in the United States and France. Thus, the other mutations in HBV strains causing fulminant hepatitis B need to be identified. Design: Retrospective clinical, serologic, and molecular biological studies of patients with fulminant hepatitis B. Setting: University and city hospitals in Japan. Patients: 43 patients with fulminant hepatitis B. Measurements: The precore region coding fora part of the HBeAg precursor and the core promoter regulating the transcription of precore messenger RNA were sequenced in HBV DNA clones. Results: A point mutation from G to A at nucleotide 1896 in the precore region was detected in 519 (98%) of 529 HBV DNA clones from 38 patients. Two point mutations in the core promoter, from A to T at nucleotide 1762 and from G to A at nucleotide 1764, were detected in all 130 clones from the remaining 5 patients, who did not have mutations in the precore region, and in 20 (63%) of 32 clones from a patient with chronic hepatitis B who had transmitted HBV to 1 of these other 5 patients. Mutations in the core promoter were also detected in clones from 26 (68%) of the 38 patients with the precore mutation at nucleotide 1896. Neither HBeAg nor antibody to HBeAg was detected in 37 (90%) of the 41 patients tested. Conclusions: In Japan, fulminant hepatitis B is closely associated with HBV strains that do not produce HBeAg because of mutations in the precore region, which affect translation of HBeAg, or because of mutations in the core promoter, which affect transcription of the HBeAg coding region.	JICHI MED SCH, DIV IMMUNOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; IWATE MED UNIV, SCH MED, DEPT INTERNAL MED 1, MORIOKA, IWATE 020, JAPAN; YAMANASHI MED UNIV, DEPT INTERNAL MED 1, TAMAHO, YAMANASHI 40938, JAPAN; EHIME UNIV, SCH MED, DEPT INTERNAL MED 3, SHIGENOBU, EHIME 79102, JAPAN; ASAHIKAWA MED COLL, DEPT INTERNAL MED 2, ASAHIKAWA, HOKKAIDO 078, JAPAN; DOKKYO UNIV, SCH MED, DEPT INTERNAL MED 2, MIBU, TOCHIGI 32102, JAPAN; TOSHIBA GEN HOSP, DEPT MED SCI, TOKYO 140, JAPAN; MITA INST, TOKYO 108, JAPAN; JAPANESE RED CROSS, SAITAMA BLOOD CTR, URAWA, SAITAMA 338, JAPAN	Jichi Medical University; Iwate Medical University; University of Yamanashi; Ehime University; Asahikawa Medical College; Dokkyo Medical University; Toshiba Corporation; Japanese Red Cross Medical Center			Okamoto, Hiroaki/H-4371-2011	Okamoto, Hiroaki/0000-0003-0827-0964				BRUNETTO MR, 1991, P NATL ACAD SCI USA, V88, P4186, DOI 10.1073/pnas.88.10.4186; BRUSS V, 1988, VIROLOGY, V163, P268, DOI 10.1016/0042-6822(88)90266-8; CARMAN WF, 1989, LANCET, V2, P588; CARMAN WF, 1991, HEPATOLOGY, V14, P219, DOI 10.1002/hep.1840140203; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; FERAY C, 1993, J HEPATOL, V18, P119, DOI 10.1016/S0168-8278(05)80019-4; GIMSON AES, 1983, GUT, V24, P615, DOI 10.1136/gut.24.7.615; IIZUKA H, 1992, VOX SANG, V63, P107, DOI 10.1111/j.1423-0410.1992.tb02495.x; JUNKERNIEPMANN M, 1990, EMBO J, V9, P3389, DOI 10.1002/j.1460-2075.1990.tb07540.x; KOJIMA M, 1991, VOX SANG, V60, P34, DOI 10.1111/j.1423-0410.1991.tb00868.x; KOSAKA Y, 1991, GASTROENTEROLOGY, V100, P1087, DOI 10.1016/0016-5085(91)90286-T; LASKUS T, 1993, GASTROENTEROLOGY, V105, P1173, DOI 10.1016/0016-5085(93)90964-E; LASKUS T, 1994, J HEPATOL, V20, P837, DOI 10.1016/S0168-8278(05)80158-8; LI JS, 1993, J VIROL, V67, P5402, DOI 10.1128/JVI.67.9.5402-5410.1993; LIANG TJ, 1991, NEW ENGL J MED, V324, P1705, DOI 10.1056/NEJM199106133242405; MCLACHLAN A, 1987, J VIROL, V61, P683, DOI 10.1128/JVI.61.3.683-692.1987; MILICH DR, 1990, P NATL ACAD SCI USA, V87, P6599, DOI 10.1073/pnas.87.17.6599; MISKA S, 1993, J HEPATOL, V18, P53, DOI 10.1016/S0168-8278(05)80009-1; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; OGATA N, 1993, VIROLOGY, V194, P263, DOI 10.1006/viro.1993.1257; OKAMOTO H, 1988, J GEN VIROL, V69, P2575, DOI 10.1099/0022-1317-69-10-2575; OKAMOTO H, 1990, J VIROL, V64, P1298, DOI 10.1128/JVI.64.3.1298-1303.1990; OMATA M, 1991, NEW ENGL J MED, V324, P1699, DOI 10.1056/NEJM199106133242404; PREISLERADAMS S, 1994, GASTROENTEROLOGY, V106, pA965; TAKAHASHI K, 1983, J IMMUNOL, V130, P2903; TERAZAWA S, 1991, PEDIATR RES, V29, P5, DOI 10.1203/00006450-199101000-00002; TONG SP, 1993, J VIROL, V67, P5651, DOI 10.1128/JVI.67.9.5651-5655.1993; TREPO CG, 1976, GUT, V17, P10, DOI 10.1136/gut.17.1.10; TREY C, 1968, NEW ENGL J MED, V279, P798, DOI 10.1056/NEJM196810102791504; TSUDA F, 1984, GASTROENTEROLOGY, V87, P159; VAUDIN M, 1988, J GEN VIROL, V69, P1383, DOI 10.1099/0022-1317-69-6-1383; WANG Y, 1990, J VIROL, V64, P3977, DOI 10.1128/JVI.64.8.3977-3981.1990; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; WILL H, 1987, J VIROL, V61, P904, DOI 10.1128/JVI.61.3.904-911.1987; WOOLF IL, 1976, BMJ-BRIT MED J, V2, P669, DOI 10.1136/bmj.2.6037.669; YAGINUMA K, 1987, P NATL ACAD SCI USA, V84, P2678, DOI 10.1073/pnas.84.9.2678; YOTSUMOTO S, 1992, HEPATOLOGY, V16, P31, DOI 10.1002/hep.1840160107; YUH CH, 1992, J VIROL, V66, P4073, DOI 10.1128/JVI.66.7.4073-4084.1992	38	257	279	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1995	122	4					241	248		10.7326/0003-4819-122-4-199502150-00001	http://dx.doi.org/10.7326/0003-4819-122-4-199502150-00001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF769	7825758				2022-12-28	WOS:A1995QF76900001
J	BURKLY, L; HESSION, C; OGATA, L; REILLY, C; MARCONI, LA; OLSON, D; TIZARD, R; CATE, R; LO, D				BURKLY, L; HESSION, C; OGATA, L; REILLY, C; MARCONI, LA; OLSON, D; TIZARD, R; CATE, R; LO, D			EXPRESSION OF RELB IS REQUIRED FOR THE DEVELOPMENT OF THYMIC MEDULLA AND DENDRITIC CELLS	NATURE			English	Article							ANTIGEN-PRESENTING CELLS; EPITHELIAL-CELLS; T-CELLS; GENE; MOUSE	DENDRITIC cells (DC) derived from bone marrow are critical in the function of the immune system, for they are the primary antigen-presenting cells in the activation of T-lymphocyte response. Their differentiation from precursor cells has not been defined at a molecular level, but recent studies have shown an association between expression of the relB subunit of the NF-kappa B complex(1-5) and the presence of DC in specific regions of normal unstimulated lymphoid tissues(4-6). Here we show that relB expression also correlates with differentiation of DC in autoimmune infiltrates in situ, and that a mutation disrupting the relB gene results in mice with impaired antigen-presenting cell function, and a syndrome of excess production of granulocytes and macrophages. Thymic UEA-1(+) medullary epithelial cells from normal mice show striking similarities to DC and, interestingly, these cells are also absent in relB mutant mice. Taken together, these results suggest that relB is critical in the coordinated activation of genes necessary for the differentiation of two unrelated but phenotypically similar cells (DC and thymic UEA-1(+) medullary epithelial cells) and is therefore a candidate for a gene determining lineage commitment in the immune system.	Scripps Res Inst, RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; BIOGEN INC, CAMBRIDGE, MA 02142 USA	Scripps Research Institute; Biogen								ARNOLD B, 1984, NUCLEIC ACIDS RES, V12, P9473, DOI 10.1093/nar/12.24.9473; BURKLY LC, 1993, J IMMUNOL, V151, P3954; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; COUTELIER JP, 1987, J EXP MED, V165, P64, DOI 10.1084/jem.165.1.64; DEGERMANN S, 1994, J IMMUNOL, V152, P3254; FARR AG, 1985, J IMMUNOL, V134, P2971; GRILLI M, 1993, INT REV CYTOL, V143, P1; HOCART MJ, 1989, J GEN VIROL, V70, P809, DOI 10.1099/0022-1317-70-4-809; HOFFMAN MW, 1992, P NATL ACAD SCI USA, V89, P2536; INABA K, 1993, P NATL ACAD SCI USA, V90, P3038, DOI 10.1073/pnas.90.7.3038; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; JANEWAY CA, 1988, IMMUNOL REV, V101, P39, DOI 10.1111/j.1600-065X.1988.tb00732.x; KNIGHT SC, 1993, CURR OPIN IMMUNOL, V5, P374, DOI 10.1016/0952-7915(93)90056-X; LARSEN CP, 1990, J EXP MED, V172, P1483, DOI 10.1084/jem.172.5.1483; LERNBECHER T, 1994, EMBO J, V13, P4060, DOI 10.1002/j.1460-2075.1994.tb06723.x; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LEVIN D, 1993, J IMMUNOL, V151, P6742; LO D, 1992, AM J PATHOL, V141, P1237; LO D, 1993, EUR J IMMUNOL, V23, P1693, DOI 10.1002/eji.1830230744; METLAY JP, 1989, J EXP MED, V169, P239, DOI 10.1084/jem.169.1.239; MIZUOCHI T, 1992, J EXP MED, V175, P1601, DOI 10.1084/jem.175.6.1601; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; NELSON AJ, 1993, J IMMUNOL, V151, P2453; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; POIRIER B, 1994, J IMMUNITY, V1, P385; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCOTT B, 1994, IMMUNITY, V1, P73, DOI 10.1016/1074-7613(94)90011-6; Sprent J, 1989, Int Immunol, V1, P517, DOI 10.1093/intimm/1.5.517; SURH CD, 1992, J EXP MED, V176, P495, DOI 10.1084/jem.176.2.495	29	648	670	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 9	1995	373	6514					531	536		10.1038/373531a0	http://dx.doi.org/10.1038/373531a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7845467				2022-12-28	WOS:A1995QF72400062
J	WESTLEY, MS; BARAGIOLA, RA; JOHNSON, RE; BARATTA, GA				WESTLEY, MS; BARAGIOLA, RA; JOHNSON, RE; BARATTA, GA			PHOTODESORPTION FROM LOW-TEMPERATURE WATER ICE IN INTERSTELLAR AND CIRCUMSOLAR GRAINS	NATURE			English	Article							MOLECULAR CLOUDS; RADIATION-FIELD; DENSE CLOUDS; LIGHT-IONS; DUST; MAGNETOSPHERE; DESORPTION	Dust grains in the interstellar medium(1) and the outer Solar System(2-4) commonly have a coating of water ice, which affects their optical properties and surface chemistry, The thickness of these icy mantles may be determined in part by the extent of photodesorption (photosputtering) by background ultraviolet radiation, But this process is poorly understood, with theoretical estimates of the photodesorption rate spanning several orders of magnitude(5,6). Here we report measurements of the absolute ultraviolet photodesorption yield of low-temperature water ice, Our results indicate that the rate of photodesorption is appreciable. In particular, it can account for the absence of icy mantles on grains in diffuse interstellar clouds, it exceeds solar-wind ion erosion and sublimation in the outer Solar System, and it is important in determining the lifetimes of icy mantles in dense molecular clouds.	UNIV CATANIA,OSSERVATORIO ASTROFIS,CATANIA,ITALY	Istituto Nazionale Astrofisica (INAF); University of Catania	WESTLEY, MS (corresponding author), UNIV VIRGINIA,THORNTON HALL,CHARLOTTESVILLE,VA 22901, USA.		Baratta, Giuseppe/AAY-6188-2021	Baratta, Giuseppe/0000-0002-3688-160X				BROWN WL, 1980, PHYS REV LETT, V45, P1632, DOI 10.1103/PhysRevLett.45.1632; BROWN WL, 1982, SCIENCE, V218, P525, DOI 10.1126/science.218.4572.525; BROWN WL, 1978, PHYS REV LETT, V40, P1027, DOI 10.1103/PhysRevLett.40.1027; CARLSON RW, 1980, NATURE, V283, P461, DOI 10.1038/283461a0; COMBI MR, 1987, ICARUS, V71, P178, DOI 10.1016/0019-1035(87)90171-0; DHENDECOURT LB, 1982, ASTRON ASTROPHYS, V109, pL12; DRAINE BT, 1979, ASTROPHYS J, V231, P438, DOI 10.1086/157206; EVIATAR A, 1986, ASTRON J, V300, pL9; FLOURNOY JM, 1962, J CHEM PHYS, V36, P2229, DOI 10.1063/1.1732861; HAMILTON DP, 1994, SCIENCE, V264, P550, DOI 10.1126/science.264.5158.550; HARRISON H, 1967, SCIENCE, V157, P1175, DOI 10.1126/science.157.3793.1175; HARTQUIST TW, 1990, MON NOT R ASTRON SOC, V247, P343; HEIDE HG, 1984, ULTRAMICROSCOPY, V14, P271, DOI 10.1016/0304-3991(84)90095-0; Johnson R. E., 1993, EOS, V74, P572; JOHNSON RE, 1990, ENERGETIC PARTICLE I; LEGER A, 1985, ASTRON ASTROPHYS, V144, P147; MATHIS JS, 1983, ASTRON ASTROPHYS, V128, P212; MORFILL GE, 1993, J GEOPHYS RES-SPACE, V98, P11285, DOI 10.1029/93JA00308; NISHI N, 1984, J CHEM PHYS, V80, P3898, DOI 10.1063/1.447172; NORMAN C, 1980, ASTROPHYS J, V238, P158, DOI 10.1086/157969; PRASAD SS, 1983, ASTROPHYS J, V267, P603, DOI 10.1086/160896; SACK NJ, 1993, PHYS REV B, V48, P9973, DOI 10.1103/PhysRevB.48.9973; SHEMANSKY DE, 1993, NATURE, V363, P329, DOI 10.1038/363329a0; SMITH RG, 1993, MON NOT R ASTRON SOC, V263, P749, DOI 10.1093/mnras/263.3.749; STERNBERG A, 1987, ASTROPHYS J, V320, P676, DOI 10.1086/165585; TAUB IA, 1968, J CHEM PHYS, V49, P2499, DOI 10.1063/1.1670446; WARREN SG, 1984, APPL OPTICS, V23, P1206, DOI 10.1364/AO.23.001206; WATSON WD, 1972, ASTROPHYS J, V174, P321, DOI 10.1086/151492; Whittet D. C. B., 1992, DUST GALACTIC ENV	29	219	220	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 2	1995	373	6513					405	407		10.1038/373405a0	http://dx.doi.org/10.1038/373405a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7830792				2022-12-28	WOS:A1995QE67000048
J	GODLEE, F				GODLEE, F			THE WORLD-HEALTH-ORGANIZATION - WHOS SPECIAL PROGRAMS - UNDERMINING FROM ABOVE .6.	BRITISH MEDICAL JOURNAL			English	Article							TIME	Despite the World Health Organisation's spoken commitment to developing integrated primary health care. its most visible and successful activities are not integrated within countries; they are its disease specific intervention programmes, such as the Global Programme on AIDS and the programmes for the control of diarrhoeal and acute respiratory diseases. The 10 or so special programmes, all but one of which (the onchocerciasis control programme) are based in Geneva, have found increasing favour among donors, but critics say that they undermine WHO's attempts to integrate its activities at country level and discourage countries from developing their own capacity.			GODLEE, F (corresponding author), HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,126 BROOKLINE AVE,BOSTON,MA 02215, USA.							BERN C, 1992, B WORLD HEALTH ORGAN, V70, P705; CASSELS A, 1992, HEALTH POLICY PLANN, V7, P144, DOI 10.1093/heapol/7.2.144; SPIELMAN A, 1993, J MED ENTOMOL, V30, P6, DOI 10.1093/jmedent/30.1.6; STENSON B, 1994, HEALTH POLICY, V28, P235, DOI 10.1016/0168-8510(94)90063-9; TSALIKIS G, 1993, HEALTH POLICY PLANN, V8, P349, DOI 10.1093/heapol/8.4.349; WALT G, 1993, HLTH POLICY, V34, P125; 1993, 1992 MIN HLTH EP UN	7	24	28	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 21	1995	310	6973					178	182		10.1136/bmj.310.6973.178a	http://dx.doi.org/10.1136/bmj.310.6973.178a			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD201	7833762	Green Published			2022-12-28	WOS:A1995QD20100031
J	SALENIUS, JP; HARJU, E; JOKELA, H; RIEKKINEN, H; SILVASTI, M				SALENIUS, JP; HARJU, E; JOKELA, H; RIEKKINEN, H; SILVASTI, M			LONG-TERM EFFECTS OF GUAR GUM ON LIPID-METABOLISM AFTER CAROTID ENDARTERECTOMY	BRITISH MEDICAL JOURNAL			English	Article							HYPERCHOLESTEROLEMIA		TAMPERE UNIV HOSP,DEPT SURG,SF-33520 TAMPERE,FINLAND; UNIV TAMPERE,SF-33520 TAMPERE,FINLAND; ORION FARMOS,SF-70701 KUOPIO,FINLAND	Tampere University; Tampere University Hospital								ARO A, 1984, AM J CLIN NUTR, V39, P91; RAPP JH, 1987, SURGERY, V101, P277; Salenius J P, 1989, Eur J Vasc Surg, V3, P271, DOI 10.1016/S0950-821X(89)80094-5; SIMONS LA, 1982, ATHEROSCLEROSIS, V45, P101, DOI 10.1016/0021-9150(82)90175-7; TODD PA, 1990, DRUGS, V39, P917, DOI 10.2165/00003495-199039060-00007	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 14	1995	310	6972					95	96		10.1136/bmj.310.6972.95	http://dx.doi.org/10.1136/bmj.310.6972.95			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC223	7833735	Green Published			2022-12-28	WOS:A1995QC22300021
J	POWDERLY, WG; FINKELSTEIN, DM; FEINBERG, J; FRAME, P; HE, WL; VANDERHORST, C; KOLETAR, SL; EYSTER, ME; CAREY, J; WASKIN, H; HOOTON, TM; HYSLOP, N; SPECTOR, SA; BOZZETTE, SA				POWDERLY, WG; FINKELSTEIN, DM; FEINBERG, J; FRAME, P; HE, WL; VANDERHORST, C; KOLETAR, SL; EYSTER, ME; CAREY, J; WASKIN, H; HOOTON, TM; HYSLOP, N; SPECTOR, SA; BOZZETTE, SA			A RANDOMIZED TRIAL COMPARING FLUCONAZOLE WITH CLOTRIMAZOLE TROCHES FOR THE PREVENTION OF FUNGAL-INFECTIONS IN PATIENTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; AEROSOLIZED PENTAMIDINE; CRYPTOCOCCAL MENINGITIS; TRIMETHOPRIM SULFAMETHOXAZOLE; AMPHOTERICIN-B; PROPHYLAXIS; AIDS; COMPLEX; THERAPY; RELAPSE	Background. Cryptococcal meningitis and other serious fungal infections are common complications in patients infected with the human immunodeficiency virus (HIV). Fluconazole is effective for long-term suppression of many fungal infections, but its effectiveness as primary prophylaxis had not been adequately evaluated. Methods. We conducted a prospective, randomized trial that compared fluconazole (200 mg per day) with clotrimazole troches (10 mg taken five times daily) in patients who were also participating in a randomized trial of primary prophylaxis for Pneumocystis carinii pneumonia. Results. After a median follow-up of 35 months, invasive fungal infections had developed in 4.1 percent of the patients in the fluconazole group (9 of 217) and in 10.9 percent of those in the clotrimazole group (23 of 211, relative hazard, as adjusted for the CD4+ count, 3.3; 95 percent confidence interval, 1.5 to 7.6). Of the 32 invasive fungal infections, 17 were cryptococcosis (2 in the fluconatole group and 15 in the clotrimazole group; adjusted relative hazard, 8.5; 95 percent confidence interval, 1.9 to 37.6). The benefit of fluconazole was greater for the patients with 50 or fewer CD4+ cells per cubic millimeter than for the patients with higher counts. Fluconazole was also effective in preventing esophageal candidiasis (adjusted relative hazard, 5.8; 95 percent confidence interval, 1.7 to 20.0; P=0.004) and confirmed and presumed oropharyngeal candidiasis (5.7 and 38.1 cases per 100 person-years of follow-up in the fluconazole and clotrimazole groups, respectively; P < 0.001). Survival was similar in the two groups. Conclusions. Fluconazole taken prophylactically reduces the frequency of cryptococcosis, esophageal candidiasis, and superficial fungal infections in HIV-infected patients, especially those with 50 or fewer CD4+ lymphocytes per cubic millimeter, but the drug does not reduce overall mortality.	VET AFFAIRS MED CTR, SAN DIEGO, CA 92161 USA; WASHINGTON UNIV, SCH MED, ST LOUIS, MO USA; HARVARD UNIV, SCH PUBL HLTH, CTR STAT & DATA ANAL, BOSTON, MA 02115 USA; NIAID, BETHESDA, MD 20892 USA; JOHNS HOPKINS UNIV, BALTIMORE, MD USA; UNIV CINCINNATI, CINCINNATI, OH USA; UNIV N CAROLINA, CHAPEL HILL, NC USA; OHIO STATE UNIV, COLUMBUS, OH 43210 USA; PENN STATE UNIV, COLL MED, HERSHEY, PA USA; CASE WESTERN RESERVE UNIV, SCH MED, CLEVELAND, OH USA; DUKE UNIV, DURHAM, NC USA; UNIV WASHINGTON, SEATTLE, WA 98195 USA; TULANE UNIV, NEW ORLEANS, LA 70118 USA; UNIV CALIF SAN DIEGO, LA JOLLA, CA 92093 USA; RAND CORP, SANTA MONICA, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Washington University (WUSTL); Harvard University; Harvard T.H. Chan School of Public Health; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University; University System of Ohio; University of Cincinnati; University of North Carolina; University of North Carolina Chapel Hill; University System of Ohio; Ohio State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Case Western Reserve University; Duke University; University of Washington; University of Washington Seattle; Tulane University; University of California System; University of California San Diego; RAND Corporation				, M. Elaine Eyster/0000-0001-8248-6793; Powderly, William/0000-0001-7808-3086; feinberg, judith/0000-0003-4206-7214				BOZZETTE SA, 1991, NEW ENGL J MED, V324, P580, DOI 10.1056/NEJM199102283240902; BOZZETTE SA, 1995, NEW ENGL J MED, V332, P693, DOI 10.1056/NEJM199503163321101; CAMERON ML, 1993, ANTIMICROB AGENTS CH, V37, P2449, DOI 10.1128/AAC.37.11.2449; CHUCK SL, 1989, NEW ENGL J MED, V321, P794, DOI 10.1056/NEJM198909213211205; DISMUKES WE, 1988, J INFECT DIS, V157, P624, DOI 10.1093/infdis/157.4.624; GALGIANI JN, 1990, J INFECT DIS, V162, P1165, DOI 10.1093/infdis/162.5.1165; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; JUSTNUBLING G, 1991, EUR J CLIN MICROBIOL, V10, P917, DOI 10.1007/BF02005444; KOBAYASHI GS, 1990, ANTIMICROB AGENTS CH, V34, P524, DOI 10.1128/AAC.34.4.524; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; NIGHTINGALE SD, 1993, NEW ENGL J MED, V329, P828, DOI 10.1056/NEJM199309163291202; OSMOND D, 1994, JAMA-J AM MED ASSOC, V271, P1083, DOI 10.1001/jama.271.14.1083; POWDERLY WG, 1994, AIDS RES HUM RETROV, V10, P925, DOI 10.1089/aid.1994.10.925; POWDERLY WG, 1992, NEW ENGL J MED, V326, P793, DOI 10.1056/NEJM199203193261203; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; STEVENS DA, 1991, ARCH INTERN MED, V151, P2458, DOI 10.1001/archinte.151.12.2458; WHEAT J, 1993, ANN INTERN MED, V118, P610, DOI 10.7326/0003-4819-118-8-199304150-00006; WHEAT LJ, 1994, 34TH INT C ANT AG CH, P214	18	256	266	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 16	1995	332	11					700	705		10.1056/NEJM199503163321102	http://dx.doi.org/10.1056/NEJM199503163321102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL788	7854376				2022-12-28	WOS:A1995QL78800002
J	WOLFGOULD, C				WOLFGOULD, C			BEGINNINGS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	1995	273	11					832	832						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL402	7869538				2022-12-28	WOS:A1995QL40200001
J	GREENBERG, DL; ROOT, RK				GREENBERG, DL; ROOT, RK			DECISION-MAKING BY ANALOGY	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							MYOCARDIAL-INFARCTION; PERICARDIAL-EFFUSION; PULMONARY-EMBOLISM; ANTICOAGULATION; TAMPONADE				GREENBERG, DL (corresponding author), UNIV WASHINGTON,SCH MED,DEPT GEN INTERNAL MED,4245 ROOSEVELT WAY NE,SEATTLE,WA 98105, USA.							CORREALE E, 1993, AM J CARDIOL, V71, P1377, DOI 10.1016/0002-9149(93)90596-5; COTTON DWK, 1987, CLIN EXP RHEUMATOL, V5, P367; DALEN JE, 1993, ARCH INTERN MED, V153, P1415, DOI 10.1001/archinte.153.12.1415; DALEN JE, 1975, PROG CARDIOVASC DIS, V17, P257; GALVE E, 1986, CIRCULATION, V73, P294, DOI 10.1161/01.CIR.73.2.294; GARTY I, 1994, CLIN NUCL MED, V19, P519, DOI 10.1097/00003072-199406000-00011; GOLDSTEIN R, 1951, JAMA-J AM MED ASSOC, V146, P616, DOI 10.1001/jama.1951.03670070008004; GORHAM LW, 1961, ARCH INTERN MED, V108, P8, DOI 10.1001/archinte.1961.03620070010003; GREGORATOS G, 1990, Cardiology Clinics, V8, P601; JERJESSANCHEZ C, 1987, CHEST, V92, P115, DOI 10.1378/chest.92.1.115; KHAN AH, 1992, CLIN CARDIOL, V15, P67, DOI 10.1002/clc.4960150203; LANGE HF, 1958, AM HEART J, V56, P257, DOI 10.1016/0002-8703(58)90237-0; LEUNG WH, 1990, AM HEART J, V119, P422, DOI 10.1016/S0002-8703(05)80047-X; MABEY B E, 1985, Journal of Emergency Medicine, V3, P457, DOI 10.1016/0736-4679(85)90005-8; MALOUF JF, 1993, EUR HEART J, V14, P1451, DOI 10.1093/eurheartj/14.11.1451; MALOUF JF, 1994, EUR HEART J, V15, P583, DOI 10.1093/oxfordjournals.eurheartj.a060551; PAUKER SG, 1994, NEW ENGL J MED, V331, P1511, DOI 10.1056/NEJM199412013312209; ROSE OA, 1953, JAMA-J AM MED ASSOC, V152, P1221, DOI 10.1001/jama.1953.63690130015007d; SKLAROFF HJ, 1979, AM HEART J, V98, P772, DOI 10.1016/0002-8703(79)90477-0; Spodick DH, 1959, ACUTE PERICARDITIS	20	5	5	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 2	1995	332	9					592	596		10.1056/NEJM199503023320909	http://dx.doi.org/10.1056/NEJM199503023320909			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ090	7838195				2022-12-28	WOS:A1995QJ09000009
J	PIETTE, JC; FRANCES, C				PIETTE, JC; FRANCES, C			IMAGES IN CLINICAL MEDICINE - RELAPSING POLYCHONDRITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											PIETTE, JC (corresponding author), HOP LA PITIE SALPETRIERE,F-75651 PARIS 13,FRANCE.								0	5	5	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 2	1995	332	9					580	580		10.1056/NEJM199503023320906	http://dx.doi.org/10.1056/NEJM199503023320906			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ090	7838192				2022-12-28	WOS:A1995QJ09000006
J	KEEFE, AD; NEWTON, GL; MILLER, SL				KEEFE, AD; NEWTON, GL; MILLER, SL			A POSSIBLE PREBIOTIC SYNTHESIS OF PANTETHEINE, A PRECURSOR TO COENZYME-A	NATURE			English	Article							PURINE NUCLEOSIDES; ACIDS	THE involvement of coenzyme A in many enzyme reactions suggests that it acted in this capacity very early in the development of life on Earth. Particularly relevant in this regard is its role in the activation of amino acids and hydroxy acids in the biosynthesis of some peptide antibiotics(1,2)-a mechanism of peptide synthesis that forms the basis for the proposal that a thioester world(3) could have preceded the RNA world(4), The components of coenzyme A have been shown to be probable prebiotic compounds: beta-alanine, pantoyl lactone and cysteamine(5,6) and possibly adenosine(7,8). We show here that the pantetheine moiety of coenzyme A (which also occurs in a number of enzymes) can be synthesized in yields of several per cent by heating pantoyl lactone, beta-alanine and cysteamine at temperatures as low as 40 degrees C. These components are extremely soluble and so would have been preferentially concentrated in evaporating bodies of water, for example on beaches and at lagoon margins. Our results show that amide bonds can be formed at temperatures as low as 40 degrees C, and provide circumstantial support for the suggestion that pantetheine and coenzyme A were important in the earliest metabolic systems.			KEEFE, AD (corresponding author), UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093, USA.							BISHOP MJ, 1972, NATURE, V237, P162, DOI 10.1038/237162a0; de Duve C, 1991, BLUEPRINT CELL NATUR; FAHEY RC, 1987, METHOD ENZYMOL, V143, P85; Fox SW, 1972, MOL EVOLUTION ORIGIN; FULLER WD, 1972, J MOL EVOL, V1, P249, DOI 10.1007/BF01660244; FULLER WD, 1972, J MOL BIOL, V67, P25, DOI 10.1016/0022-2836(72)90383-X; GESTELAND RF, 1993, RNA WORLD; GUNNING HE, 1966, ADV PHOTOCHEM, V4, P143; KVENVOLDEN KA, 1971, P NATL ACAD SCI USA, V68, P486, DOI 10.1073/pnas.68.2.486; LAKINTHOMAS PL, 1985, EUR J BIOCHEM, V146, P141, DOI 10.1111/j.1432-1033.1985.tb08630.x; LOHRMANN R, 1977, J MOL EVOL, V10, P137, DOI 10.1007/BF01751807; Miller S. L., 1974, ORIGINS LIFE EARTH; MILLER SL, 1953, SCIENCE, V117, P528, DOI 10.1126/science.117.3046.528; Peltzer E T, 1984, Adv Space Res, V4, P69, DOI 10.1016/0273-1177(84)90546-5; ROHLFING DL, 1976, SCIENCE, V193, P68, DOI 10.1126/science.935858; SCHLESINGER G, 1993, J MOL EVOL, V36, P308; SCHLESINGER G, 1993, J MOL EVOL, V36, P302; Smith ERB, 1940, J BIOL CHEM, V132, P47; Torchinsky Y, 1981, SULFUR PROTEINS	19	59	59	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					683	685		10.1038/373683a0	http://dx.doi.org/10.1038/373683a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854449				2022-12-28	WOS:A1995QH92800049
J	DAVIS, JG; OBERHOLTZER, JC; BURNS, FR; GREENE, MI				DAVIS, JG; OBERHOLTZER, JC; BURNS, FR; GREENE, MI			MOLECULAR-CLONING AND CHARACTERIZATION OF AN INNER EAR-SPECIFIC STRUCTURAL PROTEIN	SCIENCE			English	Article							TRIPLE-HELICAL DOMAINS; X COLLAGEN GENE; TECTORIAL MEMBRANE; HAIR-CELLS; MONOCLONAL-ANTIBODIES; OTOLITHIC MEMBRANE; V COLLAGEN; LOCALIZATION; ORGANIZATION; COCHLEA	Molecular biological studies of the mammalian inner ear have been limited by the relatively small size of the sensory endorgans contained within. The saccular otolithic organ in teleostian fish is structurally similar to its mammalian counterpart but can contain an order of magnitude more sensory cells. The prospect of the evolutionary conservation of proteins utilized in the vertebrate inner ear and the relative abundance of teleostian saccular sensory tissue made this an attractive system for molecular biological studies. A complementary DNA obtained by differential screening of a saccular complementary DNA library was identified that encodes an inner ear-specific collagen molecule.	UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DIV NEUROPATHOL,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania				Burns, Frank/0000-0001-9528-4808	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K08DC000069] Funding Source: NIH RePORTER; NIDCD NIH HHS [K08-DC00069] Funding Source: Medline; NINDS NIH HHS [5 T32 NS07064-13] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIGES M, 1983, ACTA OTO-LARYNGOL, V95, P522, DOI 10.3109/00016488309139436; CORWIN JT, 1981, J COMP NEUROL, V201, P541, DOI 10.1002/cne.902010406; CORWIN JT, 1991, ANNU REV NEUROSCI, V14, P301, DOI 10.1146/annurev.neuro.14.1.301; DAVIS JG, 1994, THESIS U PENNSYLVANI; DOHLMAN GF, 1960, NEURAL MECHANISMS AU, P258; DRESCHER DG, 1989, BRAIN RES, V485, P225, DOI 10.1016/0006-8993(89)90565-9; GILLESPIE PG, 1991, J CELL BIOL, V112, P625, DOI 10.1083/jcb.112.4.625; GOODYEAR R, 1994, HEARING RES, V80, P93, DOI 10.1016/0378-5955(94)90013-2; HASKO JA, 1988, HEARING RES, V35, P21, DOI 10.1016/0378-5955(88)90037-8; HOPPE HJ, 1994, PROTEIN SCI, V3, P1143, DOI 10.1002/pro.5560030801; HUDSPETH AJ, 1989, NATURE, V341, P397, DOI 10.1038/341397a0; KACHAR B, 1990, HEARING RES, V45, P179, DOI 10.1016/0378-5955(90)90119-A; KAWAMATA S, 1993, ACTA OTOLARYNGOL S S, V504, P30; KHAN KM, 1990, HEARING RES, V43, P149, DOI 10.1016/0378-5955(90)90224-D; KILLICK R, 1992, HEARING RES, V64, P21, DOI 10.1016/0378-5955(92)90165-J; KILLICK R, 1994, MAY MECH SENS REG C; KWAN APL, 1991, J CELL BIOL, V114, P597, DOI 10.1083/jcb.114.3.597; Lewis E. R., 1985, VERTEBRATE INNER EAR; Lim D J, 1973, Adv Otorhinolaryngol, V19, P35; Lim D J, 1973, Ann Otol Rhinol Laryngol, V82, P23; LIM DJ, 1990, ACTA OTO-LARYNGOL, V110, P224, DOI 10.3109/00016489009122541; LUVALLE P, 1988, J BIOL CHEM, V263, P18378; MURAGAKI Y, 1991, J BIOL CHEM, V266, P7721; NINOMIYA Y, 1986, J BIOL CHEM, V261, P5041; OBERHOLTZER JC, 1986, HEARING RES, V23, P161, DOI 10.1016/0378-5955(86)90013-4; PICKLES JO, 1992, TRENDS NEUROSCI, V15, P254, DOI 10.1016/0166-2236(92)90066-H; Platt C., 1981, HEARING SOUND COMMUN; POPPER AN, 1984, HEARING RES, V15, P133, DOI 10.1016/0378-5955(84)90044-3; POPPER AN, 1993, BRAIN BEHAV EVOLUT, V41, P14, DOI 10.1159/000113821; PRIETO JJ, 1991, HEARING RES, V54, P59, DOI 10.1016/0378-5955(91)90136-W; PRIETO JJ, 1990, HEARING RES, V45, P51, DOI 10.1016/0378-5955(90)90182-O; REID KBM, 1990, IMMUNOL TODAY, V11, P387, DOI 10.1016/0167-5699(90)90150-8; RICH A, 1961, J MOL BIOL, V3, P483, DOI 10.1016/S0022-2836(61)80016-8; RICHARDSON GP, 1987, HEARING RES, V25, P45, DOI 10.1016/0378-5955(87)90078-5; SAWADA H, 1984, EUR J CELL BIOL, V35, P226; SAWADA H, 1990, J CELL BIOL, V110, P219, DOI 10.1083/jcb.110.1.219; SCHMID TM, 1984, J ULTRA MOL STRUCT R, V86, P186, DOI 10.1016/S0022-5320(84)80057-X; SHEPHERD GMG, 1989, P NATL ACAD SCI USA, V86, P4973, DOI 10.1073/pnas.86.13.4973; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SLEPECKY NB, 1992, ACTA OTO-LARYNGOL, V112, P611, DOI 10.3109/00016489209137449; SLEPECKY NB, 1992, CELL TISSUE RES, V267, P413, DOI 10.1007/BF00319363; SOKOLOWSKI BHA, 1986, SCANNING ELECTRON MI, V4, P1635; SPRINGER J, 1991, J HISTOCHEM CYTOCHEM, V39, P23; STEEL K, 1980, ACTA OTO-LARYNGOL, V89, P27, DOI 10.3109/00016488009127104; STEEL KP, 1983, HEARING RES, V9, P327, DOI 10.1016/0378-5955(83)90035-7; SUMMERS TA, 1988, J BIOL CHEM, V263, P581; TAKUMIDA M, 1992, ACTA OTO-LARYNGOL, V112, P643, DOI 10.3109/00016489209137454; THALMANN I, 1987, LARYNGOSCOPE, V97, P357; THALMANN I, 1980, ARCH OTO-RHINO-LARYN, V226, P123, DOI 10.1007/BF00455126; TILNEY MS, 1989, J CELL BIOL, V109, P1711, DOI 10.1083/jcb.109.4.1711; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; YAMAGUCHI N, 1991, J BIOL CHEM, V266, P4508; YAMAGUCHI N, 1989, J BIOL CHEM, V264, P1602; ZAJIC G, 1991, HEARING RES, V52, P59, DOI 10.1016/0378-5955(91)90187-E	57	67	69	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 17	1995	267	5200					1031	1034		10.1126/science.7863331	http://dx.doi.org/10.1126/science.7863331			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG990	7863331				2022-12-28	WOS:A1995QG99000041
J	HOSKINS, KF; STOPFER, JE; CALZONE, KA; MERAJVER, SD; REBBECK, TR; GARBER, JE; WEBER, BL				HOSKINS, KF; STOPFER, JE; CALZONE, KA; MERAJVER, SD; REBBECK, TR; GARBER, JE; WEBER, BL			ASSESSMENT AND COUNSELING FOR WOMEN WITH A FAMILY HISTORY OF BREAST-CANCER - A GUIDE FOR CLINICIAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LINE P53 MUTATIONS; OVARIAN-CANCER; INDIVIDUALIZED PROBABILITIES; RISK; DISEASE; ONSET; PREVENTION; LINKAGE; AGE	More women in all risk categories are seeking information regarding their individual breast cancer risk, and there is a need for their primary care clinicians to be able to assess familial risk factors for breast cancer, provide individualized risk information, and offer surveillance recommendations. Estimates of the number of women with a family history of breast cancer range from approximately 5% to 20%, depending on the population surveyed. Many of these women will not have a family history that suggests the presence of a highly penetrant breast cancer susceptibility gene. However, it small subset of such women will come from families with a striking incidence of breast and other cancers often associated with inherited mutations. The development and refinement of risk prediction models provide an epidemiologic basis for counseling women with a family history that does not appear related to a dominant susceptibility gene. In contrast, the recent isolation of BRCA1, the localization of BRCA2, and the acknowledgment that additional breast cancer susceptibility genes must exist provide a molecular basis for counseling some high-risk women. We present a guide for primary care clinicians that may be helpful in defining families as moderate or high risk, in determining individual risk in women with a family history of breast cancer based on this distinction, and for counseling women in a setting where the data necessary to design surveillance and prevention strategies are lacking. We include criteria for selecting women who may be candidates for detection of inherited mutations in breast cancer susceptibility genes.	UNIV PENN, MED CTR, DEPT INTERNAL MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT EPIDEMIOL & BIOSTAT, PHILADELPHIA, PA USA; UNIV MICHIGAN, DEPT INTERNAL MED, ANN ARBOR, MI USA; DANA FARBER CANC INST, BOSTON, MA USA	University of Pennsylvania; University of Pennsylvania; University of Michigan System; University of Michigan; Harvard University; Dana-Farber Cancer Institute			Rebbeck, Timothy/GLU-8348-2022	Rebbeck, Timothy/0000-0002-4799-1900; Calzone, Kathleen/0000-0002-2354-6810				ANDERSON DE, 1985, CANCER, V56, P383, DOI 10.1002/1097-0142(19850715)56:2<383::AID-CNCR2820560230>3.0.CO;2-0; ANDREWS LB, 1994, ASSESSING GENETIC RI, P1; Becker MH, 1974, HLTH BELIEF MODEL PE; BENICHOU J, 1993, COMPUT BIOMED RES, V26, P373, DOI 10.1006/cbmr.1993.1026; BIESECKER BB, 1993, JAMA-J AM MED ASSOC, V269, P1970, DOI 10.1001/jama.269.15.1970; BONDY ML, 1994, J NATL CANCER I, V86, P620, DOI 10.1093/jnci/86.8.620; BOWCOCK AM, 1994, AM J HUM GENET, V55, pR1; BROWNSTEIN MH, 1978, CANCER, V41, P2393, DOI 10.1002/1097-0142(197806)41:6<2393::AID-CNCR2820410644>3.0.CO;2-K; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Champion V L, 1991, Oncol Nurs Forum, V18, P733; CLAUS EB, 1991, AM J HUM GENET, V48, P232; CLAUS EB, 1994, CANCER, V73, P643, DOI 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5; CLAUS EB, 1990, AM J EPIDEMIOL, V131, P961, DOI 10.1093/oxfordjournals.aje.a115616; COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P338, DOI 10.1001/jama.270.3.338; COLLINS FS, 1994, JAMA-J AM MED ASSOC, V271, P785, DOI 10.1001/jama.1994.03510340075038; EASTON DF, 1994, LANCET, V344, P761, DOI 10.1016/S0140-6736(94)92256-X; EASTON DF, 1993, AM J HUM GENET, V52, P678; EVANS DGR, 1993, BRIT J CANCER, V67, P612, DOI 10.1038/bjc.1993.112; FEUER EJ, 1993, J NATL CANCER I, V85, P892, DOI 10.1093/jnci/85.11.892; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HALL NR, 1994, EUR J CANCER, V30A, P180, DOI 10.1016/0959-8049(94)90083-3; HARTLEY AL, 1986, BRIT J CANCER, V54, P819, DOI 10.1038/bjc.1986.245; HOLFORD TR, 1991, J CLIN EPIDEMIOL, V44, P29, DOI 10.1016/0895-4356(91)90198-I; HUGGINS M, 1990, AM J HUM GENET, V47, P4; KASH KM, 1992, J NATL CANCER I, V84, P24, DOI 10.1093/jnci/84.1.24; Kelly P T, 1992, Semin Oncol Nurs, V8, P288, DOI 10.1016/0749-2081(92)90042-2; KELSEY JL, 1991, CA-CANCER J CLIN, V41, P146, DOI 10.3322/canjclin.41.3.146; LERMAN C, 1990, PREV MED, V19, P279, DOI 10.1016/0091-7435(90)90028-I; LERMAN C, 1991, HEALTH PSYCHOL, V10, P259, DOI 10.1037/0278-6133.10.4.259; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LI FP, 1992, J NATL CANCER I, V84, P1156, DOI 10.1093/jnci/84.15.1156; LYNCH HT, 1994, P ASCO, V13, P56; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCINTYRE JF, 1994, J CLIN ONCOL, V12, P925, DOI 10.1200/JCO.1994.12.5.925; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MORRELL D, 1986, J NATL CANCER I, V77, P89; MUIR EG, 1967, BRIT J SURG, V54, P191, DOI 10.1002/bjs.1800540309; MULVIHILL JJ, 1989, CLIN GENET, V36, P313; MURRAY TH, 1991, FASEB J, V5, P55, DOI 10.1096/fasebj.5.1.1825074; NAROD SA, 1991, LANCET, V338, P82; OFFIT K, 1994, J CLIN ONCOL, V12, P1724, DOI 10.1200/JCO.1994.12.8.1724; POLEDNAK AP, 1991, CANCER DETECT PREV, V15, P257; SATTIN RW, 1985, JAMA-J AM MED ASSOC, V253, P1908, DOI 10.1001/jama.253.13.1908; SHAPIRO DE, 1992, HEALTH PSYCHOL, V11, P61, DOI 10.1037/0278-6133.11.1.61; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; SKINNER CS, 1994, AM J PUBLIC HEALTH, V84, P43, DOI 10.2105/AJPH.84.1.43; SLATTERY ML, 1993, JAMA-J AM MED ASSOC, V270, P1563, DOI 10.1001/jama.270.13.1563; SPIGELMAN AD, 1989, GUT, V30, P1588, DOI 10.1136/gut.30.11.1588; STARINK TM, 1984, J AM ACAD DERMATOL, V11, P1127, DOI 10.1016/S0190-9622(84)70270-2; STEFANEK ME, 1992, CANCER EPIDEM BIOMAR, V1, P591; STRATTON MR, 1994, NAT GENET, V7, P103, DOI 10.1038/ng0594-103; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TAPLIN S, 1989, AM J PUBLIC HEALTH, V79, P1494, DOI 10.2105/AJPH.79.11.1494; WELLISCH DK, 1992, PSYCHOSOMATICS, V33, P171, DOI 10.1016/S0033-3182(92)71993-8; WENDER RC, 1993, CANCER, V72, P1093, DOI 10.1002/1097-0142(19930801)72:3+<1093::AID-CNCR2820721326>3.0.CO;2-B; Wood DA, 1943, CANCER RES, V3, P509; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231	63	263	268	1	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	1995	273	7					577	585		10.1001/jama.273.7.577	http://dx.doi.org/10.1001/jama.273.7.577			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QF686	7837392				2022-12-28	WOS:A1995QF68600029
J	GOODE, GK; MILLER, JP; HEAGERTY, AM				GOODE, GK; MILLER, JP; HEAGERTY, AM			HYPERLIPIDEMIA, HYPERTENSION, AND CORONARY HEART-DISEASE	LANCET			English	Review							CHOLESTEROL-LOWERING THERAPY; BLOOD-PRESSURE; ENDOTHELIAL DYSFUNCTION; RISK-FACTORS; HYPERCHOLESTEROLEMIC PATIENTS; ARTERY DISEASE; NITRIC-OXIDE; L-ARGININE; ATHEROSCLEROSIS; LIPOPROTEINS				GOODE, GK (corresponding author), UNIV S MANCHESTER HOSP, DEPT MED, NELL LANE, MANCHESTER M20 8LR, LANCS, ENGLAND.			Heagerty, Anthony/0000-0002-9043-2119				[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; [Anonymous], 1993, Am J Cardiol, V72, P1031; ARNTZENIUS AC, 1985, NEW ENGL J MED, V312, P805, DOI 10.1056/NEJM198503283121301; ATARASHI K, 1992, 11 INT S DRUGS AFF L; BELCHER JD, 1993, CIRCULATION, V88, P563; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BONAA KH, 1991, CIRCULATION, V83, P1305, DOI 10.1161/01.CIR.83.4.1305; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; BUCHWALD H, 1992, JAMA-J AM MED ASSOC, V268, P1429, DOI 10.1001/jama.268.11.1429; CASTELLI WP, 1986, AM J MED, V80, P23, DOI 10.1016/0002-9343(86)90157-9; CERIELLO A, 1991, CLIN SCI, V81, P739, DOI 10.1042/cs0810739; CHIN JH, 1992, J CLIN INVEST, V89, P10, DOI 10.1172/JCI115549; CHOWIENCZYK PJ, 1992, LANCET, V340, P1430, DOI 10.1016/0140-6736(92)92621-L; COHEN RA, 1988, CIRC RES, V63, P903, DOI 10.1161/01.RES.63.5.903; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CRIQUI MH, 1986, CIRCULATION, V73, P40; CRIQUI MH, 1980, PREV MED, V9, P525, DOI 10.1016/0091-7435(80)90047-X; DESPRES JP, 1990, ARTERIOSCLEROSIS, V10, P497, DOI 10.1161/01.ATV.10.4.497; DETRE KM, 1974, CIRCULATION, V50, P998, DOI 10.1161/01.CIR.50.5.998; DREXLER H, 1991, LANCET, V338, P1546, DOI 10.1016/0140-6736(91)92372-9; DUFFIELD RGM, 1983, LANCET, V2, P639; FLAVAHAN NA, 1992, CIRCULATION, V85, P1927, DOI 10.1161/01.CIR.85.5.1927; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GOODE GK, 1993, CIRCULATION, V88, P369; GORDON JB, 1989, J CLIN INVEST, V83, P1946, DOI 10.1172/JCI114103; HARRISON DG, 1989, CIRCULATION, V80, P703, DOI 10.1161/01.CIR.80.3.703; HAYNES WG, 1993, LANCET, V342, P931, DOI 10.1016/0140-6736(93)91981-Q; KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514; LEUNG WH, 1993, LANCET, V341, P1496, DOI 10.1016/0140-6736(93)90634-S; LOPEZ JAG, 1989, CIRC RES, V65, P1078, DOI 10.1161/01.RES.65.4.1078; LOVAT LB, 1993, J HUM HYPERTENS, V7, P403; MCCAUGHAN D, 1981, ARCH INTERN MED, V141, P1428, DOI 10.1001/archinte.141.11.1428; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MORGAN T, 1990, J HYPERTENS        S, V8, P525; MORRIS MC, 1993, CIRCULATION, V88, P523, DOI 10.1161/01.CIR.88.2.523; NEATON JD, 1992, ARCH INTERN MED, V152, P56, DOI 10.1001/archinte.152.1.56; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; OSTRANDER LD, 1976, CIRCULATION, V53, P152, DOI 10.1161/01.CIR.53.1.152; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; SHIMOKAWA H, 1988, CIRCULATION, V78, P1421, DOI 10.1161/01.CIR.78.6.1421; TANNER FC, 1991, CIRCULATION, V83, P2012, DOI 10.1161/01.CIR.83.6.2012; Trial of clofibrate in the treatment of ischaemic heart disease, 1971, BRIT MED J, V4, P767, DOI DOI 10.1136/BMJ.4.5790.767; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; WILLIAMS RR, 1988, JAMA-J AM MED ASSOC, V259, P3579, DOI 10.1001/jama.259.24.3579; ZAVARONI I, 1989, NEW ENGL J MED, V320, P702, DOI 10.1056/NEJM198903163201105; ZEIHER AM, 1991, CIRCULATION, V83, P391, DOI 10.1161/01.CIR.83.2.391; 1971, BRIT MED J, V4, P775	48	120	130	1	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 11	1995	345	8946					362	364		10.1016/S0140-6736(95)90345-3	http://dx.doi.org/10.1016/S0140-6736(95)90345-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF722	7845119				2022-12-28	WOS:A1995QF72200013
J	TONG, P; THOMAS, T; BERRISH, T; HUMPHRISS, D; BARRIOCANAL, L; STEWART, M; WALKER, M; WILKINSON, R; ALBERTI, KGMM				TONG, P; THOMAS, T; BERRISH, T; HUMPHRISS, D; BARRIOCANAL, L; STEWART, M; WALKER, M; WILKINSON, R; ALBERTI, KGMM			CELL-MEMBRANE DYNAMICS AND INSULIN-RESISTANCE IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS	LANCET			English	Note							FLUIDITY; PROTEINS	Insulin resistance in non-insulin-dependent diabetes mellitus (NIDDM) could be ralated to changes in cell membrane properties. We measured insulin sensitivity and mononuclear leucocyte membrane fluidity by fluorescence polarisation in fifteen NIDDM patients and twenty-one normal subjects. Core-region anisotropy was significantly lower in leucocytes from diabetic subjects (mean 0.164 vs 0.174, p<0.001). Insulin sensitivity was positively correlated with such anisotropy before and after acute invitro insulin treatment. There was no difference in superficial membrane anisotropy. This study suggests that altered membrane dynamics in NIDDM may contribute to insulin resistance.	UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT MED,SUBDEPT NEPHROL,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK	TONG, P (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT MED,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.							AKINMOKUN A, 1992, DIABETIC MED, V9, P432, DOI 10.1111/j.1464-5491.1992.tb01813.x; BECKNIELSEN H, 1977, DIABETOLOGIA, V13, P563, DOI 10.1007/BF01236308; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; DANEMAN D, 1992, DIABETES, V41, P227, DOI 10.2337/diabetes.41.2.227; KINNUNEN PKJ, 1991, CHEM PHYS LIPIDS, V57, P375, DOI 10.1016/0009-3084(91)90087-R; LONNROTH P, 1991, J INTERN MED, V229, P23; TONG P, 1994, BIOCHEM MED METAB B, V52, P132, DOI 10.1006/bmmb.1994.1044; WATALA C, 1992, EUR J CLIN CHEM CLIN, V30, P513; WATALA C, 1993, DIABETIC MED, V10, P13, DOI 10.1111/j.1464-5491.1993.tb01990.x; WINOCOUR PD, 1992, J LAB CLIN MED, V120, P921	10	56	59	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 11	1995	345	8946					357	358		10.1016/S0140-6736(95)90343-7	http://dx.doi.org/10.1016/S0140-6736(95)90343-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF722	7845118				2022-12-28	WOS:A1995QF72200011
J	COOK, A				COOK, A			MANAGEMENT FOR DOCTORS - FINANCIAL ACCOUNTING IN THE NHS .5.	BRITISH MEDICAL JOURNAL			English	Article											COOK, A (corresponding author), ANTHONY COOK ASSOCIATES,COPLAND,FIELD LANE,STOURBRIDGE DY8 2JQ,W MIDLANDS,ENGLAND.								0	0	0	2	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 4	1995	310	6975					312	316		10.1136/bmj.310.6975.312	http://dx.doi.org/10.1136/bmj.310.6975.312			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF717	7866176	Green Published			2022-12-28	WOS:A1995QF71700039
J	NEWMANTAYLOR, A				NEWMANTAYLOR, A			ENVIRONMENTAL DETERMINANTS OF ASTHMA	LANCET			English	Review							HOUSE-DUST MITE; RESPIRATORY-DISEASE; HAY-FEVER; ALLERGY; SMOKING; PREVALENCE; SENSITIVITY; CHILDHOOD; HISTAMINE; CHILDREN				NEWMANTAYLOR, A (corresponding author), ROYAL BROMPTON HOSP, SYDNEY ST, LONDON SW3, ENGLAND.							ANTO JM, 1989, NEW ENGL J MED, V320, P1097, DOI 10.1056/NEJM198904273201701; BIAGINI RE, 1986, AM REV RESPIR DIS, V134, P719; BJORKSTEN F, 1980, CLIN ALLERGY, V10, P585, DOI 10.1111/j.1365-2222.1980.tb02140.x; BURNEY P, 1987, CHEST, V91, pS143, DOI 10.1378/chest.91.6.143S; BURNEY PGJ, 1986, BRIT MED J, V292, P1483, DOI 10.1136/bmj.292.6534.1483; BURNEY PGJ, 1989, THORAX, V44, P36, DOI 10.1136/thx.44.1.36; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; BURR ML, 1989, J EPIDEMIOL COMMUN H, V43, P125, DOI 10.1136/jech.43.2.125; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; CULLINAN P, 1994, OCCUP ENVIRON MED, V51, P589, DOI 10.1136/oem.51.9.589; CULLINAN P, 1988, THORAX, V43, P949, DOI 10.1136/thx.43.12.949; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; HAAHTELA T, 1990, BRIT MED J, V301, P266, DOI 10.1136/bmj.301.6746.266; JOHNSTON SL, 1994, IN PRESS BMJ; JUNIPER CP, 1977, J SOC OCCUP MED, V27, P3; KEELEY DJ, 1991, THORAX, V46, P549, DOI 10.1136/thx.46.8.549; KOENIG JQ, 1990, AM REV RESPIR DIS, V141, P377, DOI 10.1164/ajrccm/141.2.377; KORSGAARD J, 1983, CLIN ALLERGY, V13, P529, DOI 10.1111/j.1365-2222.1983.tb02634.x; MAGNUSSON CGM, 1986, J ALLERGY CLIN IMMUN, V78, P898, DOI 10.1016/0091-6749(86)90237-X; MEREDITH SK, 1991, BRIT J IND MED, V48, P292; MIYAMOTO T, 1988, PROGR ALLERGY CLIN I, P265; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; ORDMAN D, 1955, INT ARCH ALLER A IMM, V7, P10, DOI 10.1159/000228201; RIEDEL F, 1988, J ALLERGY CLIN IMMUN, V82, P527, DOI 10.1016/0091-6749(88)90961-X; SCHACHTER EN, 1984, ARCH ENVIRON HEALTH, V39, P34, DOI 10.1080/00039896.1984.10545831; SEATON A, 1994, THORAX, V49, P171, DOI 10.1136/thx.49.2.171; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; TAYLOR AJN, 1990, CHEST, V98, pS209; VANNIEKERK CH, 1979, CLIN ALLERGY, V9, P319; VENABLES KM, 1985, BRIT MED J, V290, P201, DOI 10.1136/bmj.290.6463.201; VENABLES KM, 1989, BMJ-BRIT MED J, V299, P939, DOI 10.1136/bmj.299.6705.939; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WAITE DA, 1980, CLIN ALLERGY, V10, P71, DOI 10.1111/j.1365-2222.1980.tb02082.x; WARNER JO, 1978, ARCH DIS CHILD, V53, P710, DOI 10.1136/adc.53.9.710; WOOLCOCK AJ, 1981, AM REV RESPIR DIS, V123, P564; 1985, LANCET, V1, P965	39	77	77	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 4	1995	345	8945					296	299						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE731	7837865				2022-12-28	WOS:A1995QE73100014
J	TADDIO, A; GOLDBACH, M; IPP, M; STEVENS, B; KOREN, G				TADDIO, A; GOLDBACH, M; IPP, M; STEVENS, B; KOREN, G			EFFECT OF NEONATAL CIRCUMCISION ON PAIN RESPONSES DURING VACCINATION IN BOYS	LANCET			English	Note							STRESS; SLEEP	Using date from one of our randomised trials, we investigated post-hoc whether male neonatal circumcision is associated with a greater pain response to routine vaccination at 4 or 6 months. Pain response during routine vaccination with diphtheria-pertussis-tetanus (DPT) alone or DPT followed by Haemophilus influenzae type b conjugate (HIB) was scored blind. 42 boys received DPT acid 18 also received HIB. After DPT, median visual analogue scores by an observer were higher in the circumcised group (40 vs 26 mm. p=0.03) After HIB, circumcised infants had higher behavioural pain scores (8 vs 6, p=0.01) and cried longer (53 vs 19 s, p=0.02). Thus neonatal circumcision may affect pain response several months after the event.	UNIV TORONTO,HOSP SICK CHILDREN,DEPT PEDIAT,TORONTO,ON M5G 1X8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Koren, Gideon/AAG-7726-2019	Koren, Gideon/0000-0002-9234-0875				ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; ANDERS TF, 1974, PSYCHOSOM MED, V36, P174, DOI 10.1097/00006842-197403000-00009; BRACKBILL Y, 1975, CHILD DEV, V46, P364; DIXON S, 1984, J DEV BEHAV PEDIATR, V5, P246; EMDE RN, 1971, PSYCHOSOM MED, V33, P491, DOI 10.1097/00006842-197111000-00002; MARSHALL RE, 1980, INFANT BEHAV DEV, V3, P1, DOI 10.1016/S0163-6383(80)80003-8; MARSHALL RE, 1982, EARLY HUM DEV, V7, P367, DOI 10.1016/0378-3782(82)90038-X; TADDIO A, 1994, J PEDIATR-US, V124, P643, DOI 10.1016/S0022-3476(05)83150-6; ZELTZER LK, 1992, PEDIATRICS, V90, P816	9	282	285	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					291	292		10.1016/S0140-6736(95)90278-3	http://dx.doi.org/10.1016/S0140-6736(95)90278-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QE731	7837863				2022-12-28	WOS:A1995QE73100012
J	WEIH, F; CARRASCO, D; DURHAM, SK; BARTON, DS; RIZZO, CA; RYSECK, RP; LIRA, SA; BRAVO, R				WEIH, F; CARRASCO, D; DURHAM, SK; BARTON, DS; RIZZO, CA; RYSECK, RP; LIRA, SA; BRAVO, R			MULTIORGAN INFLAMMATION AND HEMATOPOIETIC ABNORMALITIES IN MICE WITH A TARGETED DISRUPTION OF RELB, A MEMBER OF THE NF-KAPPA-B/REL FAMILY	CELL			English	Article							DENDRITIC CELLS; TRANSCRIPTION FACTORS; BONE-MARROW; B PROTEINS; STEM-CELLS; GENE; EXPRESSION; ANTIGEN; TRANSACTIVATION; DISEASE	RelB, a member of the NF-kappa B/Rel family of transcription factors, has been implicated in the constitutive expression of kappa B-regulated genes in lymphoid tissues. We have generated mice carrying a germline mutation of the relB gene, resulting in the absence of RelB protein and a dramatic reduction of constitutive kappa B-binding activity in thymus and spleen. Mice homozygous for the disrupted relB locus had phenotypic abnormalities including multifocal, mixed inflammatory cell infiltration in several organs, myeloid hyperplasia, splenomegaly due to extramedullary hematopoiesis, and a reduced population of thymic dendritic cells. RelB-deficient animals also had an impaired cellular immunity, as observed in contact sensitivity experiments. Thus, RelB plays a decisive role in the hematopoietic system, and its absence cannot be functionally compensated by any other member of the NF-kappa B/Rel family.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT EXPTL PATHOL, PRINCETON, NJ 08543 USA	Bristol-Myers Squibb	WEIH, F (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, POB 4000, PRINCETON, NJ 08543 USA.							AGGER R, 1992, J LEUKOCYTE BIOL, V52, P34, DOI 10.1002/jlb.52.1.34; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BREEL M, 1987, EUR J IMMUNOL, V17, P1555, DOI 10.1002/eji.1830171105; CARRASCO D, 1994, DEVELOPMENT, V120, P2991; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; COLIGAN JE, 1992, CURRENT PROTOCOLS IM; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRUSCHWITZ MS, 1992, J INVEST DERMATOL, V99, P114, DOI 10.1111/1523-1747.ep12611890; HESTDAL K, 1991, J IMMUNOL, V147, P22; INABA K, 1993, P NATL ACAD SCI USA, V90, P3038, DOI 10.1073/pnas.90.7.3038; ISSEKUTZ TB, 1992, CURR OPIN IMMUNOL, V4, P287, DOI 10.1016/0952-7915(92)90078-S; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LERNBECHER T, 1994, EMBO J, V13, P4060, DOI 10.1002/j.1460-2075.1994.tb06723.x; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Muller H K, 1992, Semin Immunol, V4, P205; OGARRA A, 1993, CURR OPIN IMMUNOL, V5, P880, DOI 10.1016/0952-7915(93)90100-7; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Sambrook J, 1989, MOL CLONING LABORATO; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; WEIH F, 1994, ONCOGENE, V9, P3289; Wurst W., 1993, Gene targeting: a practical approach., P33	37	683	695	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	1995	80	2					331	340		10.1016/0092-8674(95)90416-6	http://dx.doi.org/10.1016/0092-8674(95)90416-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7834753	Bronze			2022-12-28	WOS:A1995QD92400016
J	CUMMINGS, SR; NEVITT, MC; BROWNER, WS; STONE, K; FOX, KM; ENSRUD, KE; CAULEY, JC; BLACK, D; VOGT, TM				CUMMINGS, SR; NEVITT, MC; BROWNER, WS; STONE, K; FOX, KM; ENSRUD, KE; CAULEY, JC; BLACK, D; VOGT, TM			RISK-FACTORS FOR HIP FRACTURE IN WHITE WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MIDDLE-AGED WOMEN; BONE-DENSITY; OSTEOPOROTIC FRACTURES; PHYSICAL-ACTIVITY; DIETARY CALCIUM; ALCOHOL INTAKE; FOLLOW-UP; CAFFEINE; FOREARM; PREMENOPAUSAL	Background. Many risk factors for hip fractures have been suggested but have not been evaluated in a comprehensive prospective study. Methods. We assessed potential risk factors, including bone mass, in 9516 white women 65 years of age or older who had had no previous hip fracture. We then followed these women at 4-month intervals for an average of 4.1 years to determine the frequency of hip fracture. All reports of hip fractures were validated by review of x-ray films. Results. During the follow-up period, 192 women had first hip fractures not due to motor vehicle accidents. In multivariable age-adjusted analyses, a maternal history of hip fracture doubled the risk of hip fracture (relative risk, 2.0; 95 percent confidence interval, 1.4 to 2.9), and the increase in risk remained significant after adjustment for bone density. Women who had gained weight since the age of 25 had a lower risk. The risk was higher among women who had previous fractures of any type after the age of 50, were tall at the age of 25, rated their own health as fair or poor, had previous hyperthyroidism, had been treated with long-acting benzodiazepines or anticonvulsant drugs, ingested greater amounts of caffeine, or spent four hours a day or less on their feet. Examination findings associated with an increased risk included the inability to rise from a chair without using one's arms, poor depth perception, poor contrast sensitivity, and tachycardia at rest. Low calcaneal bone density was also an independent risk factor. The incidence of hip fracture ranged from 1.1 (95 percent confidence interval, 0.5 to 1.6) per 1000 woman-years among women with no more than two risk factors and normal calcaneal bone density for their age to 27 (95 percent confidence interval, 20 to 34) per 1000 woman-years among those with five or more risk factors and bone density in the lowest third for their age. Conclusions. Women with multiple risk factors and low bone density have an especially high risk of hip fracture. Maintaining body weight, walking for exercise, avoiding long-acting benzodiazepines, minimizing caffeine intake, and treating impaired visual function are among the steps that may decrease the risk.	UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV MARYLAND,DEPT EPIDEMIOL & PREVENT MED,BALTIMORE,MD 21201; UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,MINNEAPOLIS,MN 55455; UNIV PITTSBURGH,DEPT EPIDEMIOL,PITTSBURGH,PA 15261; KAISER PERMANENTE CTR HLTH RES,PORTLAND,OR	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University System of Maryland; University of Maryland Baltimore; University of Minnesota System; University of Minnesota Twin Cities; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Kaiser Permanente	CUMMINGS, SR (corresponding author), PREVENT SERV GRP,74 NEW MONTGOMERY ST,SUITE 600,SAN FRANCISCO,CA 94105, USA.		Cauley, Jane A/N-4836-2015	Cauley, Jane A/0000-0003-0752-4408; Ensrud, Kristine/0000-0002-9069-3036	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005407, R01AG005394] Funding Source: NIH RePORTER; NIAMS NIH HHS [1-RO1-AR35582] Funding Source: Medline; NIA NIH HHS [1-RO1-AG05407, 5-RO1-AG05394] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANNEGERS JF, 1989, EPILEPSIA, V30, P348, DOI 10.1111/j.1528-1157.1989.tb05308.x; BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740; BAUER DC, 1993, ANN INTERN MED, V118, P657, DOI 10.7326/0003-4819-118-9-199305010-00001; BOHANNON RW, 1986, ARCH PHYS MED REHAB, V67, P390; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; COOPER C, 1988, BRIT MED J, V297, P1443, DOI 10.1136/bmj.297.6661.1443; COOPER C, 1992, J BONE MINER RES, V7, P465; CUMMINGS SR, 1989, ARCH INTERN MED, V149, P2445, DOI 10.1001/archinte.149.11.2445; CUMMINGS SR, 1987, AM J EPIDEMIOL, V126, P796, DOI 10.1093/oxfordjournals.aje.a114716; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; ENSRUD KE, 1992, ARCH INTERN MED, V152, P1058, DOI 10.1001/archinte.152.5.1058; FALLON MD, 1983, ARCH INTERN MED, V143, P442, DOI 10.1001/archinte.143.3.442; FARMER ME, 1989, J AM GERIATR SOC, V37, P9, DOI 10.1111/j.1532-5415.1989.tb01562.x; FAULKNER KG, 1993, J BONE MINER RES, V8, P1211, DOI 10.1002/jbmr.5650081008; FELSON DT, 1988, AM J EPIDEMIOL, V128, P1102; FINSEN V, 1987, ANN CHIR GYNAECOL FE, V76, P114; FITTI JE, 1987, DHSS PHS871323 PUBL, V21, P49; FRANKLYN JA, 1992, LANCET, V340, P9, DOI 10.1016/0140-6736(92)92423-D; FRASER SA, 1971, LANCET, V1, P981; Gibson JJ, 1950, PERCEPTION VISUAL WO; GINSBERG AP, 1984, AM J OPTOM PHYSL OPT, V64, P403; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRISSO JA, 1991, NEW ENGL J MED, V324, P1326, DOI 10.1056/NEJM199105093241905; GRISSO JA, 1994, NEW ENGL J MED, V330, P1555, DOI 10.1056/NEJM199406023302202; HAYES WC, 1993, CALCIFIED TISSUE INT, V52, P192, DOI 10.1007/BF00298717; HEMENWAY D, 1988, AM J PUBLIC HEALTH, V78, P1554, DOI 10.2105/AJPH.78.12.1554; HERNANDEAVILA M, 1993, EPIDEMIOLOGY, V4, P563; HERNANDEZAVILA M, 1993, EPIDEMIOLOGY, V4, P128, DOI 10.1097/00001648-199303000-00008; HERNANDEZAVILA M, 1991, AM J CLIN NUTR, V54, P157, DOI 10.1093/ajcn/54.1.157; HERNANDEZAVILA M, 1993, EPIDEMIOLOGY, V4, P279; HOLBROOK TL, 1988, LANCET, V2, P1046, DOI 10.1016/S0140-6736(88)90065-7; Hosmer D. W., 1989, APPL LOGISTIC REGRES, P118; KIEL DP, 1990, AM J EPIDEMIOL, V132, P675, DOI 10.1093/oxfordjournals.aje.a115709; KRISKA AM, 1988, AM J EPIDEMIOL, V127, P1053, DOI 10.1093/oxfordjournals.aje.a114881; Lohman TG, 1988, ANTHROPOMETRIC STAND, P177, DOI DOI 10.1002/AJHB.1310040323; MAGAZINER J, 1987, J AM GERIATR SOC, V35, P996, DOI 10.1111/j.1532-5415.1987.tb04002.x; MALLMIN H, 1993, CALCIFIED TISSUE INT, V52, P269, DOI 10.1007/BF00296650; MEYER HE, 1993, AM J EPIDEMIOL, V137, P1203, DOI 10.1093/oxfordjournals.aje.a116622; NELSON HD, 1994, JAMA-J AM MED ASSOC, V272, P1825, DOI 10.1001/jama.272.23.1825; NEVITT MC, 1993, J AM GERIATR SOC, V41, P1226, DOI 10.1111/j.1532-5415.1993.tb07307.x; NEVITT MC, 1992, AM J EPIDEMIOL, V135, P490, DOI 10.1093/oxfordjournals.aje.a116315; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; Paganini-Hill A, 1991, Epidemiology, V2, P16; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; PAUL TL, 1988, JAMA-J AM MED ASSOC, V259, P3137, DOI 10.1001/jama.259.21.3137; RAY WA, 1989, JAMA-J AM MED ASSOC, V262, P3303, DOI 10.1001/jama.262.23.3303; SOWERS M, 1993, JAMA-J AM MED ASSOC, V269, P3130, DOI 10.1001/jama.269.24.3130; STEIGER P, 1992, J BONE MINER RES, V7, P625; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314	50	2774	2839	2	129	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 23	1995	332	12					767	773		10.1056/NEJM199503233321202	http://dx.doi.org/10.1056/NEJM199503233321202			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN442	7862179				2022-12-28	WOS:A1995QN44200002
J	SZANKASI, P; SMITH, GR				SZANKASI, P; SMITH, GR			A ROLE FOR EXONUCLEASE-I FROM S-POMBE IN MUTATION AVOIDANCE AND MISMATCH CORRECTION	SCIENCE			English	Article							DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; MEIOTIC RECOMBINATION; NUCLEOTIDE-SEQUENCE; GENE-PRODUCT; DNA; REPAIR; ENDONUCLEASE; EXCISION	Exonuclease I (Exo I) from Schizosaccharomyces pombe, a 5' --> 3' double-stranded DNA exonuclease, is induced during meiotic prophase I. The exo1 gene is a member of a family of related DNA repair genes, including RAD2/rad13/xpgc and YKL510/rad2, conserved from yeast to humans. An exo1 mutant displays a mutator phenotype and alters activity of the ade6-M387 marker effect. These results suggest that Exo I acts in a pathway that corrects mismatched base pairs.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Fred Hutchinson Cancer Center				Smith, Gerald/0000-0002-8747-1352	NCI NIH HHS [P30 CA15704-20] Funding Source: Medline; NIGMS NIH HHS [GM32194] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA015704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AU KG, 1988, P NATL ACAD SCI USA, V85, P9163, DOI 10.1073/pnas.85.23.9163; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARR AM, 1993, NUCLEIC ACIDS RES, V21, P145; CLAVERYS JP, 1983, P NATL ACAD SCI-BIOL, V80, P5956, DOI 10.1073/pnas.80.19.5956; COMPTON T, 1990, PCR PROTOCOLS GUIDE, P39; DETLOFF P, 1992, GENETICS, V132, P113; DEVEAUX LC, 1992, GENETICS, V130, P251; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FLECK O, IN PRESS NUCLEIC ACI; GRIMM C, 1994, GENETICS, V136, P41; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HENNECKE F, 1991, NATURE, V353, P776, DOI 10.1038/353776a0; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JACQUIER A, 1992, YEAST, V8, P121, DOI 10.1002/yea.320080207; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIEB M, 1986, GENETICS, V114, P1041; MADURA K, 1986, J BACTERIOL, V166, P914, DOI 10.1128/jb.166.3.914-923.1986; MARYON E, 1989, MOL CELL BIOL, V9, P4862, DOI 10.1128/MCB.9.11.4862; MCGREADY SJ, 1989, CURR GENET, V15, P27; MOORE CW, 1988, GENETICS, V119, P21; MUNZ P, 1975, MUTAT RES, V29, P155, DOI 10.1016/0027-5107(75)90030-5; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PETES TD, 1991, MOL CELLULAR BIOL YE, V1, P407; Phipps J, 1985, Adv Genet, V23, P1, DOI 10.1016/S0065-2660(08)60511-8; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; REENAN RAG, 1992, GENETICS, V132, P963; REYNOLDS RJ, 1981, J BACTERIOL, V146, P692, DOI 10.1128/JB.146.2.692-704.1981; Sambrook J, 1989, MOL CLONING LABORATO; SCHAR P, 1993, GENETICS, V133, P825; SCHAR P, 1993, GENETICS, V133, P815; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SMITH GR, 1988, MICROBIOL REV, V52, P1; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SZANKASI P, 1992, J BIOL CHEM, V267, P3014; SZANKASI P, 1988, J MOL BIOL, V204, P917, DOI 10.1016/0022-2836(88)90051-4; SZANKASI P, UNPUB; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WHITE JH, 1985, NATURE, V315, P350, DOI 10.1038/315350a0; WILCOX DR, 1981, J BACTERIOL, V148, P618, DOI 10.1128/JB.148.2.618-623.1981; WILLIAMSON MS, 1985, GENETICS, V110, P609	49	179	183	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1166	1169		10.1126/science.7855597	http://dx.doi.org/10.1126/science.7855597			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855597				2022-12-28	WOS:A1995QJ23700037
J	HEBERLEIN, U; SINGH, CM; LUK, AY; DONOHOE, TJ				HEBERLEIN, U; SINGH, CM; LUK, AY; DONOHOE, TJ			GROWTH AND DIFFERENTIATION IN THE DROSOPHILA EYE COORDINATED BY HEDGEHOG	NATURE			English	Article							CELL-CELL COMMUNICATION; POLARITY GENE HEDGEHOG; BETA FAMILY; HAIRY GENE; EXPRESSION; PROTEIN; HOMOLOG; DIRECTS; RETINA	DIFFERENTIATION Of the Drosophila retina is asynchronous: it starts at the posterior margin of the eye imaginal disc and progresses anteriorly over two days. During this time the disc continues to grow, increasing in size by approximately eightfold, An indentation in the epithelium, the morphogenetic furrow(1), marks the front edge of the differentiation wave. Anterior progression of the furrow is thought to be driven by signals emanating from differentiating photoreceptor cells in the posterior eye disc(2,3). A good candidate for such a signal is the product of the hedgehog (hh) gene(4-7); it is expressed, and presumably secreted, by differentiating photoreceptors and its function is required for continued furrow movement(2,3). Here we show that ectopic expression of hedgehog sets in motion ectopic furrows in the anterior eye disc, In addition to changes in cell shape, these ectopic furrows are associated with a tightly orchestrated series of events, including proliferation, cell cycle synchronization and pattern formation, that parallel normal furrow progression. We propose that the morphogenetic furrow coincides with a transient boundary that coordinates growth and differentiation of the eye disc, and that hedgehog is necessary and sufficient to propagate this boundary across the epithelium.	UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,PROGRAM NEUROSCI,SAN FRANCISCO,CA 94110	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	HEBERLEIN, U (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DEPT NEUROL,GALLO CTR BLDG 1,RM 101,SAN FRANCISCO,CA 94110, USA.							ALPHEY L, 1992, CELL, V69, P977, DOI 10.1016/0092-8674(92)90616-K; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BROWN NL, 1991, DEVELOPMENT, V113, P1245; BROWN NL, IN PRESS CELL; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CARROLL SB, 1989, GENE DEV, V3, P905, DOI 10.1101/gad.3.6.905; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; Ingham PW, 1991, CURR OPIN GENET DEV, V1, P261, DOI 10.1016/S0959-437X(05)80080-2; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JARMAN AP, 1994, NATURE, V369, P398, DOI 10.1038/369398a0; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LEBOVITZ RM, 1986, DEV BIOL, V117, P663, DOI 10.1016/0012-1606(86)90335-0; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOSES K, 1989, NATURE, V340, P531, DOI 10.1038/340531a0; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; SIMON JA, 1985, CELL, V40, P805, DOI 10.1016/0092-8674(85)90340-X; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TASHIRO S, 1993, GENE, V124, P183; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Thomas Barbara J., 1994, Trends in Cell Biology, V4, P389, DOI 10.1016/0962-8924(94)90051-5; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5	30	176	182	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					709	711		10.1038/373709a0	http://dx.doi.org/10.1038/373709a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854455				2022-12-28	WOS:A1995QH92800057
J	MALNATI, MS; PERUZZI, M; PARKER, KC; BIDDISON, WE; CICCONE, E; MORETTA, A; LONG, EO				MALNATI, MS; PERUZZI, M; PARKER, KC; BIDDISON, WE; CICCONE, E; MORETTA, A; LONG, EO			PEPTIDE SPECIFICITY IN THE RECOGNITION OF MHC CLASS-I BY NATURAL-KILLER-CELL CLONES	SCIENCE			English	Article							VIRUS-INFECTED CELLS; COMPLEX CLASS-I; NK CLONES; HLA-C; MOLECULES; BINDING; HLA-B27; LYSIS; SELF; BETA-2-MICROGLOBULIN	Recognition by natural killer (NK) cells of major histocompatibility complex (MHC) class I molecules on target cells inhibits NK-mediated lysis. Here, inhibition of NK clones by HLA-B*2705 molecules mutated at single amino acids in the peptide binding site varied among HLA-B*2705-specific NK clones. In addition, a subset of such NK clones was inhibited by only one of several self peptides loaded onto HLA-B*2705 molecules expressed in peptide transporter-deficient cells, showing that recognition was peptide-specific. These data demonstrate that specific self peptides, complexed with MHC class I, provide protection from NK-mediated lysis.	NIAID,IMMUNOGENET LAB,ROCKVILLE,MD 20852; NIAID,MOLEC STRUCT LAB,ROCKVILLE,MD 20852; NINCDS,NEUROIMMUNOL BRANCH,BETHESDA,MD 20892; IST NAZL RIC CANC,I-16132 GENOA,ITALY; UNIV GENOA,IST ISTOL & EMBRIOL GEN,I-16132 GENOA,ITALY	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Genoa; IRCCS AOU San Martino IST; University of Genoa			Malnati, Mauro/AAN-4207-2020; Long, Eric O/G-5475-2011	Long, Eric O/0000-0002-7793-3728; Malnati, mauro/0000-0001-5355-1680; Parker, Kenneth/0000-0002-6282-2478				ANDERSON KS, 1993, J IMMUNOL, V151, P3407; BELLONE G, 1993, J EXP MED, V177, P1117, DOI 10.1084/jem.177.4.1117; CARBONE E, 1993, EUR J IMMUNOL, V23, P1752, DOI 10.1002/eji.1830230803; CARRENO BM, 1992, MOL IMMUNOL, V29, P1131, DOI 10.1016/0161-5890(92)90046-Z; CARRENO BM, 1993, INT IMMUNOL, V5, P353, DOI 10.1093/intimm/5.4.353; CHADWICK BS, 1992, J IMMUNOL, V149, P3150; CICCONE E, 1992, J EXP MED, V176, P963, DOI 10.1084/jem.176.4.963; CICCONE E, 1994, EUR J IMMUNOL, V24, P1003, DOI 10.1002/eji.1830240434; COLONNA M, 1993, P NATL ACAD SCI USA, V90, P12000, DOI 10.1073/pnas.90.24.12000; COLONNA M, 1993, SCIENCE, V260, P1121, DOI 10.1126/science.8493555; DIBRINO M, 1994, J IMMUNOL, V152, P620; DIBRINO M, 1994, J BIOL CHEM, V269, P32426; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KAUFMAN DS, 1992, P NATL ACAD SCI USA, V89, P8337, DOI 10.1073/pnas.89.17.8337; LITWIN V, 1993, J EXP MED, V178, P1321, DOI 10.1084/jem.178.4.1321; LITWIN V, 1994, J EXP MED, V180, P537, DOI 10.1084/jem.180.2.537; LJUNGGREN HG, 1994, P NATL ACAD SCI USA, V91, P6520, DOI 10.1073/pnas.91.14.6520; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MALNATI MS, 1993, J EXP MED, V178, P961, DOI 10.1084/jem.178.3.961; MORETTA A, 1993, J EXP MED, V178, P597, DOI 10.1084/jem.178.2.597; MORETTA A, 1994, J EXP MED, V180, P545, DOI 10.1084/jem.180.2.545; PARKER KC, 1994, BIOCHEMISTRY-US, V33, P7736, DOI 10.1021/bi00190a029; PARKER KC, 1992, J IMMUNOL, V149, P1896; STORKUS WJ, 1991, CRIT REV IMMUNOL, V10, P393; STORKUS WJ, 1991, P NATL ACAD SCI USA, V88, P5989, DOI 10.1073/pnas.88.14.5989; STORKUS WJ, 1992, J IMMUNOL, V149, P1185; TRINCHIERI G, 1994, J EXP MED, V180, P417, DOI 10.1084/jem.180.2.417; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941	31	282	288	1	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 17	1995	267	5200					1016	1018		10.1126/science.7863326	http://dx.doi.org/10.1126/science.7863326			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG990	7863326				2022-12-28	WOS:A1995QG99000036
J	GODLEE, F				GODLEE, F			THE WORLD-HEALTH-ORGANIZATION - WHO IN EUROPE - DOES IT HAVE A ROLE .7.	BRITISH MEDICAL JOURNAL			English	Article								WHO is under pressure from ali sides to justify its existence. Donors want to know what they are getting for their money, and health professionals question the relevance of the organisation's work. The pressure to justify itself is perhaps strongest of all in Europe, where most member countries have fully fledged health infrastructures and high overall levels of health. Now there is the additional threat of encroachment into the field of public health by the European Union, The disintegration of the Soviet bloc has given WHO's regional office in Europe a new sense of purpose and led to a major shift in resources towards the countries of central and eastern Europe. But WHO's critics are calling for a different shift in the way its European office works: from its current concentration on broad based policy issues to the nitty-gritty of health care management and delivery.										TOLLISON RD, 1993, PUBLICATION, V53; 1992, HLTH NATION STRATEGY	2	3	5	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 11	1995	310	6976					389	393		10.1136/bmj.310.6976.389	http://dx.doi.org/10.1136/bmj.310.6976.389			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG721	7866220	Green Published			2022-12-28	WOS:A1995QG72100027
J	KOHN, MA; FARLEY, TA; ANDO, T; CURTIS, M; WILSON, SA; JIN, Q; MONROE, SS; BARON, RC; MCFARLAND, LM; GLASS, RI				KOHN, MA; FARLEY, TA; ANDO, T; CURTIS, M; WILSON, SA; JIN, Q; MONROE, SS; BARON, RC; MCFARLAND, LM; GLASS, RI			AN OUTBREAK OF NORWALK VIRUS GASTROENTERITIS ASSOCIATED WITH EATING RAW OYSTERS - IMPLICATIONS FOR MAINTAINING SAFE OYSTER BEDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFECTIOUS NONBACTERIAL GASTROENTERITIS; POLYMERASE CHAIN-REACTION; TO-PERSON TRANSMISSION; VIRAL GASTROENTERITIS; WATER-SYSTEM; CRUISE SHIP; CONSUMPTION; COMMUNITY; SPECIMENS; ILLNESS	Objective.-To determine the characteristics and the cause of an outbreak of gastroenteritis associated with eating raw oysters. Design.-Survey of groups of persons reporting illness to the health department after eating oysters; survey of convenience sample of oyster harvesters; and tracing of implicated oysters. Setting.-General community. Main Outcome Measures.-Relative risk for illness after oyster consumption, source bed of contaminated oysters, presence of antibodies to Norwalk virus in serum, presence of a Norwalk virus in stool by direct electron microscopy and reverse transcription-polymerase chain reaction (RT-PCR), and DNA sequences of RT-PCR products. Results.-Seventy (83%) of 84 persons who ate raw oysters became ill vs three (7%) of 43 people who did not eat raw oysters (relative risk, 11.9; 95% confidence interval, 4.0 to 34.2). Eleven (79%) of 14 serum pairs had at least a fourfold increase in antibody to Norwalk virus. All 12 stool samples tested were positive by electron microscopy and/or RT-PCR for Norwalk virus. The RT-PCR products from all seven stool samples tested had identical DNA sequences. Implicated oysters were harvested November 9 through 13, 1993, from a remote oyster bed. Crews from 22 (85%) of 26 oyster harvesting boats working in this area reported routine overboard disposal of sewage. One harvester with a high level of antibodies to Norwalk virus reported having gastroenteritis November 7 through 10 and overboard disposal of feces into the oyster bed. Conclusions.-This outbreak was caused by contamination of oysters in the oyster bed, probably by stool from one or more ill harvesters. Education of oyster harvesters and enforcement of regulations governing waste disposal by oyster harvesting boats might prevent similar outbreaks.	CTR DIS CONTROL & PREVENT, DIV VIRAL & RICKETTSIAL DIS, ATLANTA, GA USA; CTR DIS CONTROL & PREVENT, DIV FIELD EPIDEMIOL, EPIDEM INTELLIGENCE SERV, ATLANTA, GA USA; CTR DIS CONTROL & PREVENT, MED STUDENT ELECT PROGRAM, EPIDEMIOL PROGRAM OFF, ATLANTA, GA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	KOHN, MA (corresponding author), LOUISIANA DEPT HLTH & HOSP, OFF PUBL HLTH, EPIDEMIOL SECT, POB 60630, NEW ORLEANS, LA 70160 USA.			Monroe, Stephan/0000-0002-5424-716X				ADLER JL, 1969, J INFECT DIS, V119, P668, DOI 10.1093/infdis/119.6.668; ANDO T, 1994, ARCH VIROL, V135, P217, DOI 10.1007/BF01309781; ANDO T, 1995, J CLIN MICROBIOL, V33, P64, DOI 10.1128/JCM.33.1.64-71.1995; APPLETON H, 1977, LANCET, V1, P409; ATMAR RL, 1993, APPL ENVIRON MICROB, V59, P631, DOI 10.1128/AEM.59.2.631-635.1993; BARON RC, 1982, AM J EPIDEMIOL, V115, P163, DOI 10.1093/oxfordjournals.aje.a113287; BLACKLOW NR, 1991, NEW ENGL J MED, V325, P252, DOI 10.1056/NEJM199107253250406; Burkhardt W, 1992, J SHELLFISH RES, V11, P105; CANNON RO, 1991, J INFECT DIS, V164, P860, DOI 10.1093/infdis/164.5.860; DELEON R, 1992, J CLIN MICROBIOL, V30, P3151, DOI 10.1128/JCM.30.12.3151-3157.1992; DOANE FW, 1987, ELECTRON MICROS, P15; DOLIN R, 1972, P SOC EXP BIOL MED, V140, P578, DOI 10.3181/00379727-140-36508; ERDMAN DD, 1989, J CLIN MICROBIOL, V27, P1417, DOI 10.1128/JCM.27.6.1417-1418.1989; GILL ON, 1983, BRIT MED J, V287, P1532, DOI 10.1136/bmj.287.6404.1532; GOODMAN RA, 1982, ARCH ENVIRON HEALTH, V37, P358, DOI 10.1080/00039896.1982.10667591; GOYAL SM, 1979, APPL ENVIRON MICROB, V37, P572, DOI 10.1128/AEM.37.3.572-581.1979; GREENBERG HB, 1979, J INFECT DIS, V139, P564, DOI 10.1093/infdis/139.5.564; GRIFFIN MR, 1982, AM J EPIDEMIOL, V115, P178, DOI 10.1093/oxfordjournals.aje.a113289; GUNN RA, 1982, AM J EPIDEMIOL, V115, P348, DOI 10.1093/oxfordjournals.aje.a113311; GUNN RA, 1980, AM J EPIDEMIOL, V112, P820, DOI 10.1093/oxfordjournals.aje.a113054; HERWALDT BL, 1994, J CLIN MICROBIOL, V32, P861, DOI 10.1128/JCM.32.4.861-866.1994; HO MS, 1989, LANCET, V2, P961; JIANG X, 1990, Science (Washington D C), V250, P1580; KAPIKIAN AZ, 1972, J VIROL, V10, P1075, DOI 10.1128/JVI.10.5.1075-1081.1972; Kapikian AZ, 1990, VIROLOGY, P671; KAPLAN JE, 1982, AM J EPIDEMIOL, V116, P940, DOI 10.1093/oxfordjournals.aje.a113496; KAPLAN JE, 1982, J INFECT DIS, V146, P190, DOI 10.1093/infdis/146.2.190; KAPLAN JE, 1982, AM J PUBLIC HEALTH, V72, P1329, DOI 10.2105/AJPH.72.12.1329; KAPLAN JE, 1982, ANN INTERN MED, V96, P756, DOI 10.7326/0003-4819-96-6-756; KHAN AS, 1994, J CLIN MICROBIOL, V32, P318, DOI 10.1128/JCM.32.2.318-322.1994; KOOPMAN JS, 1982, AM J EPIDEMIOL, V115, P173, DOI 10.1093/oxfordjournals.aje.a113288; KURITSKY JN, 1984, ANN INTERN MED, V100, P519, DOI 10.7326/0003-4819-100-4-519; LAWSON HW, 1991, LANCET, V337, P1200, DOI 10.1016/0140-6736(91)92868-3; LIU OC, 1966, P SOC EXP BIOL MED, V123, P481, DOI 10.3181/00379727-123-31520; LOWRY PW, 1989, J INFECT DIS, V160, P978, DOI 10.1093/infdis/160.6.978; MATSUI SM, 1991, J CLIN INVEST, V87, P1456, DOI 10.1172/JCI115152; MOE CL, 1994, J CLIN MICROBIOL, V32, P642, DOI 10.1128/JCM.32.3.642-648.1994; MONROE SS, 1993, J CLIN MICROBIOL, V31, P2866, DOI 10.1128/JCM.31.11.2866-2872.1993; MORSE DL, 1986, NEW ENGL J MED, V314, P678, DOI 10.1056/NEJM198603133141103; MURPHY AM, 1979, MED J AUSTRALIA, V2, P329, DOI 10.5694/j.1326-5377.1979.tb104133.x; NELSON M, 1986, J ENVIRON HEALTH, V49, P7; REEVE G, 1989, NEW ENGL J MED, V321, P224, DOI 10.1056/NEJM198907273210404; SAWYER LA, 1988, AM J EPIDEMIOL, V127, P1261, DOI 10.1093/oxfordjournals.aje.a114918; WILSON R, 1982, AM J PUBLIC HEALTH, V72, P72, DOI 10.2105/AJPH.72.1.72; XI J, 1992, J CLIN MICROBIOL, V30, P2529, DOI 10.1128/JCM.30.10.2529-2534.1992	45	125	130	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	1995	273	6					466	471		10.1001/jama.273.6.466	http://dx.doi.org/10.1001/jama.273.6.466			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE498	7837364				2022-12-28	WOS:A1995QE49800029
J	JOHN, SWM; KREGE, JH; OLIVER, PM; HAGAMAN, JR; HODGIN, JB; PANG, SC; FLYNN, TG; SMITHIES, O				JOHN, SWM; KREGE, JH; OLIVER, PM; HAGAMAN, JR; HODGIN, JB; PANG, SC; FLYNN, TG; SMITHIES, O			GENETIC DECREASES IN ATRIAL-NATRIURETIC-PEPTIDE AND SALT-SENSITIVE HYPERTENSION	SCIENCE			English	Article							SODIUM-EXCRETION; LOCUS; RATS; POLYMORPHISM; ATRIOPEPTIN; DISRUPTION; RENIN; CELLS; HPND; SITE	To determine if defects in the atrial natriuretic peptide (ANP) system can cause hypertension, mice were generated with a disruption of the proANP gene. Homozygous mutants had no circulating or atrial ANP, and their blood pressures were elevated by 8 to 23 millimeters of mercury when they were fed standard (0.5 percent sodium chloride) and intermediate (2 percent sodium chloride) salt diets. On standard salt diets, heterozygotes had normal amounts of circulating ANP and normal blood pressures. However, on high (8 percent sodium chloride) salt diets they were hypertensive, with blood pressures elevated by 27 millimeters of mercury. These results demonstrate that genetically reduced production of ANP can lead to salt-sensitive hypertension.	UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT INTERNAL MED,CHAPEL HILL,NC 27599; QUEENS UNIV,DEPT ANAT & CELL BIOL,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Queens University - Canada; Queens University - Canada					NHLBI NIH HHS [HL49277] Funding Source: Medline; NIGMS NIH HHS [GM20069] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049277] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020069, R01GM020069] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLERMANN BJ, 1991, KIDNEY, pCH14; BARLEY J, 1991, J HYPERTENS, V9, P993, DOI 10.1097/00004872-199111000-00003; BLAINE EH, 1990, HYPERTENSION, V15, P2036; FERRARI P, 1990, J CLIN ENDOCR METAB, V71, P944, DOI 10.1210/jcem-71-4-944; GARCIA R, 1982, EXPERIENTIA, V38, P1071, DOI 10.1007/BF01955373; GOETZ KL, 1990, HYPERTENSION, V15, P9, DOI 10.1161/01.HYP.15.1.9; GRANGER JP, 1986, HYPERTENSION, V8, P112; GREENWALD JE, 1988, J CLIN INVEST, V81, P1036, DOI 10.1172/JCI113414; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JOHN S., COMMUNICATION; KREGE JH, IN PRESS HYPERTENSIO; LARAGH JH, 1990, HYPERTENSION PATHOPH, V1; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MORRIS BJ, 1993, CLIN SCI, V85, P189, DOI 10.1042/cs0850189; NARUSE M, 1985, BIOCHEM BIOPH RES CO, V132, P954, DOI 10.1016/0006-291X(85)91900-X; NEMER M, 1986, NUCLEIC ACIDS RES, V14, P8696, DOI 10.1093/nar/14.21.8696; NEMER M, 1986, NUCLEIC ACIDS RES, V14, P8697, DOI 10.1093/nar/14.21.8697; PANG SC, 1986, J HYPERTENS, V4, pS119; RAMASAWMY R, 1993, HUM GENET, V91, P509; RAMASAWMY R, 1994, HUM GENET, V93, P355, DOI 10.1007/BF00212041; RAMASAWMY R, 1992, HUM GENET, V90, P323; RICHARDS AM, 1988, J CLIN ENDOCR METAB, V66, P465, DOI 10.1210/jcem-66-3-465; SARDA IR, 1989, CLIN BIOCHEM, V22, P11, DOI 10.1016/S0009-9120(89)80063-3; SHEHEE WR, 1993, P NATL ACAD SCI USA, V90, P3177, DOI 10.1073/pnas.90.8.3177; VENANCE SL, 1989, HISTOL HISTOPATHOL, V4, P325; WEIDMANN P, 1991, CAN J PHYSIOL PHARM, V69, P1582, DOI 10.1139/y91-235; 1988, BRIT MED J, V297, P319	27	507	524	0	16	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 3	1995	267	5198					679	681		10.1126/science.7839143	http://dx.doi.org/10.1126/science.7839143			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839143				2022-12-28	WOS:A1995QE73300038
J	SHIVDASANI, RA; MAYER, EL; ORKIN, SH				SHIVDASANI, RA; MAYER, EL; ORKIN, SH			ABSENCE OF BLOOD FORMATION IN MICE LACKING THE T-CELL LEUKEMIA ONCOPROTEIN TAL-1/SCL	NATURE			English	Article							DNA-BINDING MOTIF; CHROMOSOMAL TRANSLOCATION; ERYTHROID-DIFFERENTIATION; TARGETED MUTATION; GENE SCL; EXPRESSION; LEUKEMIA; PROTEIN; HEMATOPOIESIS; RECOMBINATION	CHROMOSOMAL translocations associated with malignancies often result in deregulated expression of genes encoding transcription factors(1). In human T-cell leukaemias such regulators belong to diverse protein families and may normally be expressed widely (for example, Ttg-1/rbtn1, Ttg-2/rbtn2)(2'3), exclusively outside the haematopoietic system (for example, Hox11)(4), or specifically in haematopoietic cells and other selected sites (for example, tal-1/ SCL, lyl-1)(5,6). Aberrant expression within T cells is thought to interfere with programmes of normal maturation. The most frequently activated gene in acute T-cell leukaemias, tal-1 (also called SCL)(7,8), encodes a candidate regulator of haematopoietic development(9), a basic-helix-loop-helix protein(5), related to critical myogenic(10) and neurogenic(11) factors. Here we show by targeted gene disruption in mice(12) that tal-1 is essential for embryonic blood formation in vivo. With respect to embryonic erythropoiesis, tal-1 deficiency resembles loss of the erythroid transcription factor GATA-(13,14) or the LIM protein rbtn2(15). Profound reduction in myeloid cells cultured in vivo from tal-1 null yolk sacs suggests a broader defect manifest at the myelo-erythroid or multipotential progenitor cell level.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT,BOSTON,MA 02115; HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute	SHIVDASANI, RA (corresponding author), HARVARD UNIV,CHILDRENS HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02115, USA.							APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; AUSUBEL FM, 1987, CURR PROT MOL BIOL; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HWANG LY, 1993, ONCOGENE, V8, P3043; KALLIANPUR AR, 1994, BLOOD, V83, P1200; KELLER G, 1993, MOL CELL BIOL, V13, P472; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROBERTS CWM, 1994, NATURE, V368, P747, DOI 10.1038/368747a0; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VISVADER J, 1991, ONCOGENE, V6, P187; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851	30	747	774	1	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 2	1995	373	6513					432	434		10.1038/373432a0	http://dx.doi.org/10.1038/373432a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7830794				2022-12-28	WOS:A1995QE67000057
J	ROBERTSON, GS				ROBERTSON, GS			MAKING AN ADVANCE DIRECTIVE	BRITISH MEDICAL JOURNAL			English	Article							LIFE-SUSTAINING TREATMENT; PHYSICIANS; RESUSCITATION	The introduction in Britain of advance directives-which allow a person to state in advance of becoming incompetent that they wish to take part in treatment decisions when no longer mentally competent-has now been advocated by the medical and legal establishments. The practical application of directives relating to health care would be simplified by the adoption of a standard model document together with guidelines summarising the background clinical conditions and any subsequent acute events that may make it appropriate to trigger the use of a directive. As no specific legislation exists, good communication is needed at the various stages between the drafting and implementation of directives if the system of directives is to be successful.			ROBERTSON, GS (corresponding author), ABERDEEN ROYAL INFIRM,DEPT ANAESTHESIA,ABERDEEN AB9 2ZB,SCOTLAND.							DAVIDSON KW, 1989, JAMA-J AM MED ASSOC, V262, P2415, DOI 10.1001/jama.262.17.2415; DOYAL L, 1993, BRIT MED J, V306, P1593, DOI 10.1136/bmj.306.6892.1593; DYER C, 1993, BRIT MED J, V307, P1023; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FAIRMAN RP, 1992, ARCH INTERN MED, V152, P25, DOI 10.1001/archinte.152.1.25; GILLICK MR, 1993, ARCH INTERN MED, V153, P2542, DOI 10.1001/archinte.153.22.2542; HEAP MJ, 1993, ANAESTHESIA, V48, P1027; HOPE T, 1992, BRIT MED J, V304, P398, DOI 10.1136/bmj.304.6824.398; LAPUMA J, 1991, JAMA-J AM MED ASSOC, V266, P402, DOI 10.1001/jama.266.3.402; MITCHELL KR, 1993, J MED ETHICS, V19, P71, DOI 10.1136/jme.19.2.71; MOWER WR, 1993, ARCH INTERN MED, V153, P375, DOI 10.1001/archinte.153.3.375; ROBERTSON GS, 1982, J MED ETHICS, V8, P173, DOI 10.1136/jme.8.4.173; ROBERTSON GS, 1993, J MED ETHICS, V19, P104, DOI 10.1136/jme.19.2.104; ROBERTSON GS, 1983, BRIT MED J, V287, P1775, DOI 10.1136/bmj.287.6407.1775; SCHNEIDERMAN LJ, 1992, ARCH INTERN MED, V152, P2114, DOI 10.1001/archinte.152.10.2114; STELTER KL, 1992, ARCH INTERN MED, V152, P954, DOI 10.1001/archinte.152.5.954; VIRMANI J, 1994, ARCH INTERN MED, V154, P909, DOI 10.1001/archinte.154.8.909; 1992, STATEMENT ADV DIRECT; 1994, CM2553; 1994, HMSO HL21I HOUS LORD; 1993, HMSO129 LAW COMM CON; 1988, LIVING WILL CONSENT; 1994, HMSO HL21III HOUS LO	23	29	31	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 28	1995	310	6974					236	238		10.1136/bmj.310.6974.236	http://dx.doi.org/10.1136/bmj.310.6974.236			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE496	7866130	Green Published			2022-12-28	WOS:A1995QE49600030
J	RUDIMAN, R; GILBERT, FJ; RITCHIE, LD				RUDIMAN, R; GILBERT, FJ; RITCHIE, LD			COMPARISON OF UPTAKE OF BREAST SCREENING, CERVICAL SCREENING, AND CHILDHOOD IMMUNIZATION	BRITISH MEDICAL JOURNAL			English	Article									GRAMPIAN HEALTHCARE TRUST,NE SCOTLAND BREAST SCREENING SERV,ABERDEEN AB9 2XR,SCOTLAND; UNIV ABERDEEN,DEPT PUBL HLTH,ABERDEEN AB9 2ZD,SCOTLAND; UNIV ABERDEEN,DEPT GEN PRACTICE,ABERDEEN AB9 2ZD,SCOTLAND	University of Aberdeen; University of Aberdeen			Rudiman, Reno/GLU-0014-2022	Rudiman, Reno/0000-0001-6826-6313; Gilbert, Fiona/0000-0002-0124-9962				Carstairs V., 1991, DEPRIVATION HLTH SCO; CHAMBERLAIN J, 1993, BRIT MED J, V307, P353, DOI 10.1136/bmj.307.6900.353; RITCHIE LD, 1992, BRIT MED J, V304, P816, DOI 10.1136/bmj.304.6830.816; 1989, GENERAL PRACTICE NAT; 1988, LANCET, V2, P411	5	16	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 28	1995	310	6974					229	229		10.1136/bmj.310.6974.229	http://dx.doi.org/10.1136/bmj.310.6974.229			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE496	7866127	Green Published			2022-12-28	WOS:A1995QE49600025
J	TAKAYAMA, S; SATO, T; KRAJEWSKI, S; KOCHEL, K; IRIE, S; MILLAN, JA; REED, JC				TAKAYAMA, S; SATO, T; KRAJEWSKI, S; KOCHEL, K; IRIE, S; MILLAN, JA; REED, JC			CLONING AND FUNCTIONAL-ANALYSIS OF BAG-1 - A NOVEL BCL-2-BINDING PROTEIN WITH ANTI-CELL DEATH ACTIVITY	CELL			English	Article							GENE CED-3; BCL-2; APOPTOSIS; UBIQUITIN; ELEGANS; PATHWAY; ENCODES; ENZYME; LINES; DNA	Using a protein interaction cloning technique, we identified cDNAs that encode a novel Bcl-2-binding protein, termed BAG-1. The BAG-1 protein shares no significant homology with Bcl-2 or other Bcl-2 family proteins, which can form homo- and heterodimers. In gene transfer experiments using a human lymphoid cell line, Jurkat, coexpression of BAG-1 and Bcl-2 provided markedly increased protection from cell death induced by several stimuli, including staurosporine, anti-fas antibody, and cytolytic T cells, relative to cells that contained gene transfer-mediated elevations in either BAG-1 or Bcl-2 protein alone. BAG-transfected 3T3 fibroblasts also exhibited prolonged cell survival in response to an apoptotic stimulus, The findings indicate that bag-1 represents a new type of anti-cell death gene and suggest that some routes of apoptosis induction previously ascribed to Bcl-5-independent pathways may instead reflect a need for the combination of Bcl-2 and BAG-1.	LA JOLLA CANC RES FDN,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [R01CA060181] Funding Source: NIH RePORTER; NCI NIH HHS [CA-60181] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DELIC J, 1993, MOL CELL BIOL, V13, P4875, DOI 10.1128/MCB.13.8.4875; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; ITOH N, 1993, J IMMUNOL, V151, P621; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KITADA S, 1994, ANTISENSE RES DEV, V4, P71, DOI 10.1089/ard.1994.4.71; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1992, CANCER RES, V52, P5407; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; OITVAI ZN, 1993, CELL, V74, P609; OWENSCHAUB LB, 1994, CANCER RES, V54, P1580; PALAZZOLO MJ, 1990, GENE, V66, P25; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; REED JC, 1992, ANAL BIOCHEM, V205, P70, DOI 10.1016/0003-2697(92)90580-Z; REED JC, 1991, CANCER RES, V51, P6529; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SARIN A, 1994, J IMMUNOL, V153, P862; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TAKAHASHI S, 1993, EUR J IMMUNOL, V23, P1935, DOI 10.1002/eji.1830230831; TONIOLO D, 1988, P NATL ACAD SCI USA, V85, P851, DOI 10.1073/pnas.85.3.851; TORIGOE T, 1994, CANCER RES, V54, P4851; TORIGOE T, 1994, J EXP MED, V180, P1115, DOI 10.1084/jem.180.3.1115; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VAUX DL, 1992, INT IMMUNOL, V4, P821, DOI 10.1093/intimm/4.7.821; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	29	786	838	2	17	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 27	1995	80	2					279	284		10.1016/0092-8674(95)90410-7	http://dx.doi.org/10.1016/0092-8674(95)90410-7			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7834747	Bronze			2022-12-28	WOS:A1995QD92400010
J	BALFOUR, HH				BALFOUR, HH			NO REASON NOT TO TREAT	BRITISH MEDICAL JOURNAL			English	Article							VARICELLA-ZOSTER VIRUS; ACYCLOVIR TREATMENT; HEALTHY-CHILDREN; CONTROLLED TRIAL; CHICKENPOX; RESISTANT; RESPONSES				BALFOUR, HH (corresponding author), UNIV MINNESOTA,SCH MED,BOX 437,UMHC,15-144 PWB HARVARD ST & E RIVER PKWY,MINNEAPOLIS,MN 55455, USA.							ABZUG MJ, 1993, J PEDIATR-US, V123, P577, DOI 10.1016/S0022-3476(05)80954-0; BALFOUR HH, 1990, J PEDIATR-US, V116, P633, DOI 10.1016/S0022-3476(05)81618-X; BALFOUR HH, 1992, J PEDIATR-US, V120, P627, DOI 10.1016/S0022-3476(05)82495-3; COLE NL, 1986, J INFECT DIS, V153, P605, DOI 10.1093/infdis/153.3.605; DUNKLE LM, 1991, NEW ENGL J MED, V325, P1539, DOI 10.1056/NEJM199111283252203; ENGLUND JA, 1990, J CLIN MICROBIOL, V28, P2327, DOI 10.1128/JCM.28.10.2327-2330.1990; ENGLUND JA, 1990, ANN INTERN MED, V112, P416, DOI 10.7326/0003-4819-76-3-112-6-416; ROTBART HA, 1993, J INFECT DIS, V167, P195, DOI 10.1093/infdis/167.1.195; WALLACE MR, 1992, ANN INTERN MED, V117, P358, DOI 10.7326/0003-4819-117-5-358	9	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 14	1995	310	6972					109	110		10.1136/bmj.310.6972.109	http://dx.doi.org/10.1136/bmj.310.6972.109			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC223	7833701	Green Published			2022-12-28	WOS:A1995QC22300028
J	DONALDSON, L				DONALDSON, L			CONFLICT, POWER, NEGOTIATION .4.	BRITISH MEDICAL JOURNAL			English	Article											DONALDSON, L (corresponding author), NO & YORKSHIRE REG HLTH AUTHOR,NEWCASTLE TYNE NE6 4PY,TYNE & WEAR,ENGLAND.							HICKSON DJ, 1971, ADMIN SCI QUART, V16, P216, DOI 10.2307/2391831; MERSON RM, 1962, AM SOCIOL REV, V27, P31; Pettigrew A, 1973, POLITICS ORG DECISIO; Pfeffer J., 1981, PFEFFERPOWER ORG, V48, P255	4	7	7	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 14	1995	310	6972					104	107		10.1136/bmj.310.6972.104	http://dx.doi.org/10.1136/bmj.310.6972.104			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QC223	7833699	Green Published			2022-12-28	WOS:A1995QC22300026
J	NAISH, J; STURDY, P; TOON, P				NAISH, J; STURDY, P; TOON, P			APPROPRIATE PRESCRIBING IN ASTHMA AND ITS RELATED COST IN EAST LONDON	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; MANAGEMENT	Objectives-To determine the patterns of preventive to reactive prescribing for asthma among general practices in the City and East London Family Health Services Authority area and their relation to prescribing cost. Design-Descriptive study of asthma prescribing during April 1992 to March 1993. Prescribing data were linked with general practice and population data on one database. Setting-City and East London Family Health Services Authority area, including all general practices in contract with the authority, which covers the inner city London Boroughs of Hackney, Tower Hamlets, and Newham and the Corporation of the City of London. Subjects-All 163 general practices as at 1 June 1993. Main outcome measures-Ratios of prescribed inhaled corticosteroids plus cromoglycates (prophylactic treatment) to bronchodilators; distribution of the cost of asthma prescribing; distribution of overall generic prescribing; proportion of asthma generic prescribing; distribution of cost of overall drugs prescribed per prescribing unit. Results-Practices approved for band 3 health promotion or asthma surveillance and those with a general practitioner trainer had on average higher ratios of prophylactic to bronchodilator treatment and significantly higher asthma drug costs than other practices. Those practices with high levels of overall generic prescribing had significantly higher prophylactic to bronchodilator ratios than those with lower levels of generic prescribing. Practices with higher levels of asthma drug generic prescribing also had significantly higher prophylactic prescribing. However, the proportion of generically prescribed asthma drugs was lower than overall generic prescribing. There was no correlation between the ratio of prophylactic to bronchodilator asthma prescribing and the proportion of overall drugs expenditure, but high spending practices spent significantly more on asthma drugs. Conclusions-Pressure to reduce the cost of asthma prescribing may lead to a lowering of the ratio of prophylactic to bronchodilator treatments. However, reducing prophylactic prescribing would run contrary to the British Thoracic Society guidelines and might worsen the quality of asthma care.	UNIV LONDON QUEEN MARY & WESTFIELD COLL,LONDON E1 4NS,ENGLAND	University of London; Queen Mary University London	NAISH, J (corresponding author), UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT GEN PRACTICE & PRIMARY CARE,LONDON E1 4NS,ENGLAND.							BAKER D, 1991, BRIT MED J, V303, P225, DOI 10.1136/bmj.303.6796.225; BOGLE SM, 1994, BRIT MED J, V308, P637, DOI 10.1136/bmj.308.6929.637; GELLERT AR, 1990, BRIT J GEN PRACT, V40, P197; HARRIS CM, 1990, ANAL PRESCRIBING GEN; HAY IFC, 1987, LANCET, V2, P609; HORN CR, 1989, RESP MED, V83, P67, DOI 10.1016/S0954-6111(89)80062-9; Jones K, 1992, Qual Health Care, V1, P110, DOI 10.1136/qshc.1.2.110; MCGAVOCK H, 1988, BRIT MED J, V296, P90; NEVILLE RG, 1993, BRIT MED J, V306, P559, DOI 10.1136/bmj.306.6877.559; PANTON R, 1993, BRIT MED J, V306, P310, DOI 10.1136/bmj.306.6873.310; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; TURNERWARWICK M, 1989, J ROY COLL GEN PRACT, V39, P239; 1994, PRESCRIPTION IMPROVE; 1993, BRIT MED J, V306, P776; 1992, BRIT NATIONAL FORMUL, V23; 1994, HLTH E END ANN PUBLI; 1993, HLTH SERVICE INDICAT	17	45	46	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 14	1995	310	6972					97	100		10.1136/bmj.310.6972.97	http://dx.doi.org/10.1136/bmj.310.6972.97			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC223	7833736	Green Published			2022-12-28	WOS:A1995QC22300023
J	WILLIAMS, RS				WILLIAMS, RS			BOOSTING CARDIAC CONTRACTILITY WITH GENES	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											WILLIAMS, RS (corresponding author), UNIV TEXAS,SW MED CTR,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.							MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017	1	7	7	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 23	1995	332	12					817	818		10.1056/NEJM199503233321212	http://dx.doi.org/10.1056/NEJM199503233321212			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN442	7862189				2022-12-28	WOS:A1995QN44200012
J	BAKER, TA				BAKER, TA			REPLICATION ARREST	CELL			English	Review							COLI TUS PROTEIN; ESCHERICHIA-COLI; DNA-REPLICATION; TERMINATOR PROTEIN; BACILLUS-SUBTILIS; INVITRO; HELICASES		MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	BAKER, TA (corresponding author), MIT,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.							BUSSIERE DE, 1995, CELL, V80, P651; GOTTLIEB PA, 1992, J BIOL CHEM, V267, P7434; HENCKES G, 1989, P NATL ACAD SCI USA, V86, P8660, DOI 10.1073/pnas.86.22.8660; HIASA H, 1994, J BIOL CHEM, V269, P26959; HIASA H, 1992, J BIOL CHEM, V267, P11379; HIDAKA M, 1992, J BIOL CHEM, V267, P5361; HILL TM, 1990, P NATL ACAD SCI USA, V87, P2481, DOI 10.1073/pnas.87.7.2481; HILL TM, 1992, ANNU REV MICROBIOL, V46, P603, DOI 10.1146/annurev.micro.46.1.603; HORIUCHI T, 1994, J BACTERIOL, V176, P4656, DOI 10.1128/JB.176.15.4656-4663.1994; KAUL S, 1994, P NATL ACAD SCI USA, V91, P11143, DOI 10.1073/pnas.91.23.11143; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; LANGLEY DB, 1993, MOL MICROBIOL, V10, P771, DOI 10.1111/j.1365-2958.1993.tb00947.x; LEE EH, 1992, J BIOL CHEM, V267, P8778; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; LOUARN J, 1994, J BACTERIOL, V176, P7524, DOI 10.1128/JB.176.24.7524-7531.1994; NATARAJAN S, 1993, CELL, V72, P113, DOI 10.1016/0092-8674(93)90055-U; SAHOO T, 1995, IN PRESS EMBO J; SISTA PR, 1991, GENE DEV, V5, P74, DOI 10.1101/gad.5.1.74; SMITH MT, 1994, J MOL BIOL, V241, P335, DOI 10.1006/jmbi.1994.1510; YOUNG PA, 1994, J MOL BIOL, V240, P275, DOI 10.1006/jmbi.1994.1444	20	29	30	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					521	524		10.1016/0092-8674(95)90504-9	http://dx.doi.org/10.1016/0092-8674(95)90504-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867058	Bronze			2022-12-28	WOS:A1995QJ60200002
J	STRUTT, DI; WIERSDORFF, V; MLODZIK, M				STRUTT, DI; WIERSDORFF, V; MLODZIK, M			REGULATION OF FURROW PROGRESSION IN THE DROSOPHILA EYE BY CAMP-DEPENDENT PROTEIN-KINASE-A	NATURE			English	Article							POLARITY GENE HEDGEHOG; DECAPENTAPLEGIC GENE; PATCHED GENE; BETA FAMILY; MELANOGASTER; EXPRESSION; RETINA	THE earliest physical sign of differentiation in the Drosophila retina is the passage of the morphogenetic furrow across the epithelium of the eye disc(1,2). Secreted factors encoded by hedgehog (hh)(3-7) and decapentaplegic (dpp)(8-10) have been implicated in propagation of the furrow(11,12) and the subsequent initiation of photoreceptor differentiation. The morphogenetic furrow initiates at the posterior edge of the third larval instar eye imaginal disc, Its continued progression towards the anterior is believed to depend upon secretion of Hh protein by the differentiating clusters of photoreceptors that emerge posterior to the moving furrow(11,12). This progression is marked by the initiation of expression of the transforming growth factor-beta homologue Dpp in cells entering the furrow anteriorly, and loss of dpp expression in cells emerging posteriorly(16,17). Although the transmembrane protein encoded by the patched gene has been genetically implicated as the Hh receptor(12,18-20), the intercellular signalling pathways involved in these inductive processes remain uncharacterized. Here we show that the catalytic subunit of cyclic AMP-dependent protein kinase A (Pka-C1)(13-15) is required for the correct spatial regulation of dpp expression during eye development. Loss of Pka-C1 function is sufficient to produce an ectopic morphogenetic wave marked by premature ectopic photoreceptor differentiation and non-autonomous propagation of dpp expression. Our results indicate that Pka-C1 lies in a signalling pathway that controls the orderly temporal progression of differentiation across the eye imaginal disc.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Strutt, David/E-6196-2010	Strutt, David/0000-0001-8185-4515; Wiersdorff, Volker/0000-0003-1460-334X				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; FOSTER JL, 1988, J BIOL CHEM, V263, P1676; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEBERLEIN U, 1995, NATURE, V373, P709, DOI 10.1038/373709a0; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; LANE ME, 1993, GENESDEV, V7, P129; LEBOVITZ RM, 1986, DEV BIOL, V117, P663, DOI 10.1016/0012-1606(86)90335-0; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOROK T, 1993, GENETICS, V135, P71; VINCENT JP, 1994, DEV BIOL, V164, P328, DOI 10.1006/dbio.1994.1203; XU T, 1993, DEVELOPMENT, V117, P1223	28	116	118	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					705	709		10.1038/373705a0	http://dx.doi.org/10.1038/373705a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854454				2022-12-28	WOS:A1995QH92800056
J	XUE, QF; YEUNG, ES				XUE, QF; YEUNG, ES			DIFFERENCES IN THE CHEMICAL-REACTIVITY OF INDIVIDUAL MOLECULES OF AN ENZYME	NATURE			English	Article							CONFORMATIONAL CHANGES; DENATURED PROTEINS; KINETIC ASPECTS	MUCH attention has been focused recently on the detection and physical characterization of individual molecules(1-11). Using such methods to study the chemical properties, such as reactivity, of single molecules offers the potential to investigate how these might vary from molecule to molecule, and for individual molecules as a function of time, The complex structures of biomolecules such as enzymes make them particularly attractive targets for studying how subtle changes or differences at the molecular level might influence chemical reactivity. We have shown previously(12,13) that very small (zeptomole) amounts of enzymes can be studied using a fluorescence microassay; single enzyme molecules have also been detected in oil-dispersed droplets by fluorescence microscopy(14,15). Here we report the observation of reactions of individual molecules of lactate dehydrogenase (LDH-1), which produces NADH from lactate and nicotinamide adenine dinucleotide (NAD(+)), When they are present at very low concentrations in a narrow capillary, each enzyme molecule produces a discrete zone of NADH; these can be manipulated electrophoretically and monitored by fluorescence spectroscopy, We find that the activity of individual electrophoretically pure enzyme molecules can vary by up to a factor of four, and that these activities remain unchanged over a two-hour period. We suggest that the origin of the activity differences may lie in the presence of several stable forms of the enzyme.	IOWA STATE UNIV SCI & TECHNOL,US DOE,AMES LAB,AMES,IA 50011; IOWA STATE UNIV SCI & TECHNOL,DEPT CHEM,AMES,IA 50011	Iowa State University; United States Department of Energy (DOE); Ames National Laboratory; Iowa State University								AMBROSE WP, 1994, SCIENCE, V265, P364, DOI 10.1126/science.265.5170.364; BARNES MD, 1993, ANAL CHEM, V65, P2360, DOI 10.1021/ac00065a032; BETZIG E, 1993, SCIENCE, V262, P1422, DOI 10.1126/science.262.5138.1422; BEZRUKOV SM, 1994, NATURE, V370, P279, DOI 10.1038/370279a0; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; EVERSE J, 1973, ADV ENZYMOL RAMB, V37, P61; HOLBROOK JJ, 1975, ENZYMES, P280; ISHIKAWA M, 1994, JPN J APPL PHYS 1, V33, P1571, DOI 10.1143/JJAP.33.1571; LEVI AS, 1971, J BIOL CHEM, V246, P6409; MILLER KJ, 1993, ANAL CHEM, V65, P3267, DOI 10.1021/ac00070a017; MOERNER WE, 1994, SCIENCE, V285, P46; ORITT M, 1993, J PHYS CHEM-US, V97, P10256; PERKINS TT, 1994, SCIENCE, V264, P819, DOI 10.1126/science.8171335; ROTMAN B, 1961, P NATL ACAD SCI USA, V47, P1981, DOI 10.1073/pnas.47.12.1981; Rotman B., 1973, FLUORESCENCE TECHNIQ, P333; SMITH RD, 1994, NATURE, V369, P137, DOI 10.1038/369137a0; SMITH SB, 1989, SCIENCE, V243, P203, DOI 10.1126/science.2911733; STRANFORD PE, 1962, JAMA-J AM MED ASSOC, V182, P123; TEIPEL JW, 1971, BIOCHEMISTRY-US, V10, P792, DOI 10.1021/bi00781a011; TEIPEL JW, 1971, BIOCHEMISTRY-US, V10, P798, DOI 10.1021/bi00781a012; XIE XS, 1994, SCIENCE, V265, P361, DOI 10.1126/science.265.5170.361; XUE QF, 1994, ANAL CHEM, V66, P1175, DOI 10.1021/ac00079a036; ZUBAY G, 1993, BIOCHEMISTRY-US, P859	23	293	318	1	59	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					681	683		10.1038/373681a0	http://dx.doi.org/10.1038/373681a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854448				2022-12-28	WOS:A1995QH92800048
J	FISHER, ES; WELCH, HG				FISHER, ES; WELCH, HG			THE FUTURE OF THE DEPARTMENT-OF-VETERANS-AFFAIRS HEALTH-CARE SYSTEM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-EDUCATION; HOSPITALS; DISEASE; ANGINA		DEPT VET AFFAIRS MED CTR, WHITE RIVER JCT, VT USA; DARTMOUTH COLL SCH MED, CTR EVALUAT CLIN SCI, HANOVER, NH USA	Dartmouth College								[Anonymous], 1967, J AMER MED ASSOC, V202, P1028, DOI 10.1001/jama.1967.03130240070013; ANTHONY CR, 1988, HEALTH AFFAIR, V7, P158, DOI 10.1377/hlthaff.7.2.158; DETRE KM, 1984, NEW ENGL J MED, V311, P1333; EISENBERG JM, 1989, NEW ENGL J MED, V320, P1525, DOI 10.1056/NEJM198906083202305; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FISHER ES, 1994, VA OUTCOMES GROUP 19; FLEMING C, 1992, MED CARE, V30, P377, DOI 10.1097/00005650-199205000-00001; GREENBERG DS, 1990, LANCET, V335, P1391, DOI 10.1016/0140-6736(90)91257-B; GRONVALL JA, 1988, HEALTH AFFAIR, V7, P163, DOI 10.1377/hlthaff.7.2.163; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; Hinshaw LPP, 1987, NEW ENGL J MED, V317, P659; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; HOLLINGSWORTH JW, 1990, NEW ENGL J MED, V322, P1851, DOI 10.1056/NEJM199006283222605; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; LUCHI RJ, 1987, NEW ENGL J MED, V316, P977, DOI 10.1056/NEJM198704163161603; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; PEDUZZI P, 1979, CIRCULATION, V60, P888, DOI 10.1161/01.CIR.60.4.888; SCHWARTZ H, 1989, VA PRACTITIONER  JAN, P19; SPECHLER SJ, 1992, NEW ENGL J MED, V326, P786, DOI 10.1056/NEJM199203193261202; SUNSHINE J, 1990, VA PRACTITIONER  JAN, P103; TUCKER WILLIAM B., 1960, ADVANCES TUBERC RES, V10, P1; WASSON JH, 1995, NEW ENGL J MED, V332, P75, DOI 10.1056/NEJM199501123320202; WEISSENSTEIN E, 1993, MOD HLTH CARE   1011, P32; 1992, STRATEGY 2000 VA RES; 1993, ED TRAINING SUMMARY, P2; 1995, DEPT VET AFFAIRS FY, V2; 1993, STATISTICAL ABSTRACT; 1991, ANN INTERN MED, V115, P896; 1993, 1993 DATA COMPENDIUM, P13	30	56	56	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	1995	273	8					651	655		10.1001/jama.273.8.651	http://dx.doi.org/10.1001/jama.273.8.651			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG748	7844876				2022-12-28	WOS:A1995QG74800031
J	PAVORD, ID; TATTERSFIELD, AE				PAVORD, ID; TATTERSFIELD, AE			BRONCHOPROTECTIVE ROLE FOR ENDOGENOUS PROSTAGLANDIN E(2)	LANCET			English	Note							INHALED PROSTAGLANDIN-E2; BRONCHIAL REACTIVITY; ASTHMATIC-PATIENTS; INDOMETHACIN; EXERCISE; ASPIRIN; TRANSMISSION; METHACHOLINE; INHIBITION; CHALLENGE	The possibility that impaired production of bronchoprotective factors contributes to the pathogenesis of asthma cannot be excluded. Prostaglandin E(2) (PGE(2)) could be such a factor. It is a dominant cyclo-oxygenase product of airway epithelium and smooth muscle; it has inhibitory effects on inflammatory cells and pathways involved in bronchoconstriction at concentrations known to occur in the airway; inhalation of PGE(2) has considerable bronchoprotective effects in patients with asthma; and manoeuvres that increase or decrease endogenous production of PGE(2) have beneficial and deleterious effects on airway function.			PAVORD, ID (corresponding author), UNIV NOTTINGHAM,CITY HOSP,DIV RESP MED,NOTTINGHAM NG5 1PB,ENGLAND.			Pavord, Ian/0000-0002-4288-5973				ALAM R, 1993, AM REV RESPIR DIS, V148, P1066, DOI 10.1164/ajrccm/148.4_Pt_1.1066; BECKETT WS, 1992, CHEST, V102, P775, DOI 10.1378/chest.102.3.775; BELCHER NG, 1987, AM REV RESPIR DIS, V135, P822, DOI 10.1164/arrd.1987.135.4.822; CHOUAIB S, 1987, J CLIN INVEST, V80, P333, DOI 10.1172/JCI113077; CHURCHILL L, 1989, AM REV RESPIR DIS, V140, P449, DOI 10.1164/ajrccm/140.2.449; CRAVEN PA, 1982, J PHARMACOL EXP THER, V222, P306; DELAMERE F, 1994, BRIT J PHARMACOL, V111, P983, DOI 10.1111/j.1476-5381.1994.tb14840.x; GARDINER PJ, 1980, PROSTAGLANDINS, V19, P819, DOI 10.1016/0090-6980(80)90116-1; HOLGATE S, 1993, THORAX, V48, P103, DOI 10.1136/thx.48.2.103; ITO I, 1990, PROSTAGLANDINS, V39, P639, DOI 10.1016/0090-6980(90)90024-P; ITO Y, 1981, J PHYSIOL-LONDON, V319, P379, DOI 10.1113/jphysiol.1981.sp013915; LEE TH, 1991, J ALLERGY CLIN IMMUN, V88, P827, DOI 10.1016/0091-6749(91)90237-I; MATHE AA, 1975, AM REV RESPIR DIS, V111, P313; MATTOLI S, 1987, J ALLERGY CLIN IMMUN, V79, P678, DOI 10.1016/S0091-6749(87)80165-3; MELILLO E, 1994, AM J RESP CRIT CARE, V149, P1138, DOI 10.1164/ajrccm.149.5.8173753; OBYRNE PM, 1986, AM REV RESPIR DIS, V134, P69; OCONNOR BJ, 1994, THORAX, V49, P307, DOI 10.1136/thx.49.4.307; OZAKI T, 1987, J APPL PHYSIOL, V62, P219, DOI 10.1152/jappl.1987.62.1.219; PASARGIKLIAN M, 1977, RESPIRATION, V34, P79, DOI 10.1159/000193780; PASARGIKLIAN M, 1976, ADV PROSTAG THROMB R, V1, P461; PAVORD I, 1994, THORAX, V49, P245, DOI 10.1136/thx.49.3.245; PAVORD I, 1992, THORAX, V47, P895; PAVORD ID, 1994, EUR RESPIR J, V7, P50, DOI 10.1183/09031936.94.07010050; PAVORD ID, 1991, THORAX, V46, P633, DOI 10.1136/thx.46.9.633; PAVORD ID, 1992, THORAX, V47, P797, DOI 10.1136/thx.47.10.797; PAVORD ID, 1993, AM REV RESPIR DIS, V148, P87, DOI 10.1164/ajrccm/148.1.87; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PETERS SP, 1982, AM REV RESPIR DIS, V126, P1034; POLOSA R, 1992, THORAX, V47, P853; SWEATMAN WJ, 1968, NATURE, V217, P69, DOI 10.1038/217069a0; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; VERLEDEN GM, 1994, THORAX, V49, P657, DOI 10.1136/thx.49.7.657; 1990, LANCET, V335, P944	33	188	192	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					436	438		10.1016/S0140-6736(95)90409-3	http://dx.doi.org/10.1016/S0140-6736(95)90409-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853958				2022-12-28	WOS:A1995QG90400017
J	LI, XT; NICKLAS, RB				LI, XT; NICKLAS, RB			MITOTIC FORCES CONTROL A CELL-CYCLE CHECKPOINT	NATURE			English	Article							ANAPHASE	EVERY time a cell divides, the chromosomes must be distributed accurately to the daughter cells. Errors in distribution arise if chromosomes are improperly attached to the mitotic spindle. Improper attachment is detected by a cell-cycle checkpoint in many cells(1,2) and the completion of cell division is delayed, allowing time for error correction. How is an improperly attached chromosome detected? An absence of tension from mitotic forces is one possibility(3). Here we test this possibility directly by applying tension to an improperly attached chromosome with a micromanipulation needle, In the absence of tension, the entry into anaphase and the completion of mitosis was delayed by 5-6 hours. When the misattached chromosome was placed under tension, however, the cell entered anaphase in 56 minutes, on average. Tension from mitotic forces or from a micromanipulator's needle evidently signals to the checkpoint that all is in order and that cell division can proceed.			LI, XT (corresponding author), DUKE UNIV,DEPT ZOOL,BOX 91000,DURHAM,NC 27708, USA.							CALLAN H. G., 1957, JOUR GENETICS, V55, P200, DOI 10.1007/BF02981625; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; Hughes-Schrader S, 1943, BIOL BULL-US, V85, P265, DOI 10.2307/1538227; LUCA FC, 1993, CURR BIOL, V3, P716, DOI 10.1016/0960-9822(93)90078-3; MCINTOSH JR, 1991, COLD SH Q B, V56, P613; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NICKLAS RB, 1994, J CELL BIOL, V126, P1241, DOI 10.1083/jcb.126.5.1241; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; VANDRE DD, 1989, J CELL SCI, V94, P245; ZIRKLE RE, 1970, RADIAT RES, V41, P516, DOI 10.2307/3572841	11	460	466	0	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					630	632		10.1038/373630a0	http://dx.doi.org/10.1038/373630a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854422				2022-12-28	WOS:A1995QG99700059
J	BOEHMELT, G; MADRUGA, J; DORFLER, P; BRIEGEL, K; SCHWARZ, H; ENRIETTO, PJ; ZENKE, M				BOEHMELT, G; MADRUGA, J; DORFLER, P; BRIEGEL, K; SCHWARZ, H; ENRIETTO, PJ; ZENKE, M			DENDRITIC CELL PROGENITOR IS TRANSFORMED BY A CONDITIONAL V-REL ESTROGEN-RECEPTOR FUSION PROTEIN V-REIER	CELL			English	Article							AVIAN RETICULOENDOTHELIOSIS VIRUS; ANTIVIMENTIN MONOCLONAL-ANTIBODY; MOUSE BONE-MARROW; RETROVIRAL TRANSFORMATION; LYMPHOID-CELLS; EXPRESSION; ONCOGENE; GENE; DIFFERENTIATION; INVITRO	A conditional v-Rel estrogen receptor fusion protein, v-RelER, causes estrogen-dependent but otherwise unaltered v-rel-specific transformation of chicken bone marrow cells. Here, we demonstrate that such v-relER-transformed cells exhibit B lymphoid determinants in line with earlier studies on v-rel-transformed cells. However, following inactivation of v-RelER oncoprotein activity by administration of an estrogen antagonist, cells differentiate into antigen-presenting dendritic cells as judged by several morphological and functional criteria. Additionally, under yet different culture conditions, v-relER cells differentiate into cells resembling polymorphonuclear neutrophils. Our studies therefore suggest that the conditional v-RelER, and probably also the authentic v-Rel, transform a common progenitor for neutrophils and dendritic cells.	INST MOLEC PATHOL, A-1030 VIENNA, AUSTRIA; MAX PLANCK INST ENTWICKLUNGSBIOL, D-72076 TUBINGEN, GERMANY; SUNY STONY BROOK, DEPT MICROBIOL, STONY BROOK, NY 11794 USA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Max Planck Society; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL CANCER INSTITUTE [R01CA051792] Funding Source: NIH RePORTER; NCI NIH HHS [CA 51792] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; BARKA T, 1962, J HISTOCHEM CYTOCHEM, V10, P741, DOI 10.1177/10.6.741; BARTH CF, 1988, MOL CELL BIOL, V8, P5358, DOI 10.1128/MCB.8.12.5358; BARTH CF, 1990, J VIROL, V64, P6054, DOI 10.1128/JVI.64.12.6054-6062.1990; BENATAR T, 1991, EUR J IMMUNOL, V21, P2529, DOI 10.1002/eji.1830211033; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BEUG H, 1982, J CELL PHYSIOL, P195; BEUG H, 1989, EUR J CLIN INVEST, V19, P491, DOI 10.1111/j.1365-2362.1989.tb00265.x; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOEHMELT G, 1994, IN PRESS P AVIAN IMM; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; CAPOBIANCO AJ, 1993, VIROLOGY, V193, P160, DOI 10.1006/viro.1993.1112; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; CHEN CLH, 1982, J IMMUNOL, V129, P2580; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; INABA K, 1993, P NATL ACAD SCI USA, V90, P3038, DOI 10.1073/pnas.90.7.3038; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JEURISSEN SHM, 1992, IMMUNOLOGY, V77, P75; KAUFMAN J, 1990, J IMMUNOL, V144, P2258; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; Lucas AM, 1961, AGR MONOGRAPH, V25; MARMOR MD, 1993, J EXP MED, V177, P647, DOI 10.1084/jem.177.3.647; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1989, ONCOGENE, V4, P677; MORRISON LE, 1992, ONCOGENE, V7, P1137; MUSSMAN HC, 1971, AVIAN DIS, V15, P483, DOI 10.2307/1588725; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; OLAH I, 1992, ANAT RECORD, V232, P121, DOI 10.1002/ar.1092320113; OLAH I, 1992, ANAT RECORD, V233, P111, DOI 10.1002/ar.1092330115; OLAH I, 1992, ANAT RECORD, V233, P577, DOI 10.1002/ar.1092330412; OLSON LD, 1967, AM J VET RES, V28, P1501; PAGLIA P, 1993, J EXP MED, V178, P1893, DOI 10.1084/jem.178.6.1893; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAPPERSBERGER K, 1990, J INVEST DERMATOL, V94, P700, DOI 10.1111/1523-1747.ep12876275; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SCHAT KA, 1992, AVIAN DIS, V36, P432, DOI 10.2307/1591524; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SEVOIAN M, 1964, AVIAN DIS, V8, P336, DOI 10.2307/1587964; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; THEILEN GH, 1966, J NATL CANCER I, V37, P731; WHITE DW, 1993, J VIROL, V67, P6876, DOI 10.1128/JVI.67.11.6876-6881.1993; ZHANG J, 1991, VIROLOGY, V183, P457, DOI 10.1016/0042-6822(91)90975-H; ZOOROB R, 1990, IMMUNOGENETICS, V31, P179, DOI 10.1007/BF00211553; ZUCKERFRANKLIN D, 1988, ATLAS BLOOD CELLS FU, V1, P157	53	52	54	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	1995	80	2					341	352		10.1016/0092-8674(95)90417-4	http://dx.doi.org/10.1016/0092-8674(95)90417-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7834754	Bronze			2022-12-28	WOS:A1995QD92400017
J	YAN, Q; MATHESON, C; LOPEZ, OT				YAN, Q; MATHESON, C; LOPEZ, OT			IN-VIVO NEUROTROPHIC EFFECTS OF GDNF ON NEONATAL AND ADULT FACIAL MOTOR-NEURONS	NATURE			English	Article							OCCURRING MOTONEURON DEATH; FACTOR PREVENTS; CELL-DEATH; IN-VIVO; AXOTOMY; DEGENERATION; SURVIVAL; RATS	MOTOR neurons require neurotrophic factor(s) for their survival during development and for maintenance of function in adulthood(1-3). In vivo studies have shown that motor neurons respond to a variety of molecules, including ciliary neurotrophic factor, members of the neurotrophin family, and the insulin growth factor IGF-1 (refs 3-13). Here we investigate the potential motor neuron neurotrophic effects of glial-cell-line-derived neurotrophic factor (GDNF), initially identified as a neurotrophic factor for substantia nigra dopaminergic neurons(14). We find that GDNF is retrogradely transported, in a receptor-mediated fashion, by spinal cord motor neurons in neonatal rats. Local application of GDNF to the transected nerve prevents the massive motor neuron cell death and atrophy that normally follows axotomy in the neonatal period. In adult rats, GDNF administered locally or systemically can markedly attenuate the lesion-induced decrease of choline acetyltransferase immunoreactivity in the facial nucleus. Our data indicate that GDNF has very profound neurotrophic effects in vivo on developing as well as on adult motor neurons, and is the most potent motor neuron trophic factor found so far.			YAN, Q (corresponding author), AMGEN INC,AMGEN CTR,DEPT NEUROBIOL,1840 DEHAVILLAND DR,THOUSAND OAKS,CA 91320, USA.							HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; KOLIATSOS VE, 1994, P NATL ACAD SCI USA, V91, P3304, DOI 10.1073/pnas.91.8.3304; LAMS BE, 1988, BRAIN RES, V475, P401, DOI 10.1016/0006-8993(88)90635-X; LI L, 1994, J NEUROBIOL, V35, P759; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P229; NEFF NT, 1993, J NEUROBIOL, V24, P1578, DOI 10.1002/neu.480241203; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; OPPENHEIM RW, 1993, J NEUROBIOL, V24, P1065, DOI 10.1002/neu.480240806; OPPENHEIM RW, 1989, TRENDS NEUROSCI, V12, P252, DOI 10.1016/0166-2236(89)90021-0; SCHAAR DG, 1993, EXP NEUROL, V124, P368, DOI 10.1006/exnr.1993.1207; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; THOENEN H, 1993, EXP NEUROL, V124, P47, DOI 10.1006/exnr.1993.1173; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YAN Q, 1993, J NEUROBIOL, V24, P1555, DOI 10.1002/neu.480241202; YAN Q, 1994, J NEUROSCI, V14, P5281; YAN Q, 1988, J NEUROSCI, V8, P3481	21	548	616	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					341	344		10.1038/373341a0	http://dx.doi.org/10.1038/373341a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830768				2022-12-28	WOS:A1995QD40400059
J	FALL, CHD; VIJAYAKUMAR, M; BARKER, DJP; OSMOND, C; DUGGLEBY, S				FALL, CHD; VIJAYAKUMAR, M; BARKER, DJP; OSMOND, C; DUGGLEBY, S			WEIGHT IN INFANCY AND PREVALENCE OF CORONARY HEART-DISEASE IN ADULT LIFE	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; GROWTH; DEATH; FETAL	Objective-To determine whether low birth weight and low weight at 1 year are followed by an increased prevalence of coronary heart disease in adult life. Design-A follow up study of men horn during 1920-30 whose birth weights and weights at 1 year were recorded. Setting-Hertfordshire, England. Subjects-290 men born and still living in East Hertfordshire, Main outcome measure-The prevalence of coronary heart disease, defined by the Rose/WHO chest pain questionnaire, standard electrocardiographic criteria, or history of coronary artery angioplasty or graft surgery. Results-42 (14%) men had coronary heart disease, Their mean birth weight, 7.9 lb (3600 g), was the same as that of the other men, Their mean weight at 1 year, 21.8 lb (9.9 kg), was 1 lb (454 g) lower (95% confidence interval 0.1 to 1.8, P=0.02). Percentages of men with coronary heart disease fell from 27% in those who weighed 18 lb (8.2 kg) or less at 1 year to 9% in those who weighed more than 26 lb (11.8 kg) (P value for trend=0.03). This trend occurred in both smokers and non-smokers and within each social class. Conclusion-These findings add to the evidence that coronary heart disease is ''programmed'' during early growth.			FALL, CHD (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.			Osmond, Clive/0000-0002-9054-4655				[Anonymous], 1980, CLASSIFICATION OCCUP; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; ELFORD J, 1991, INT J EPIDEMIOL, V20, P833, DOI 10.1093/ije/20.4.833; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; LUCAS A, 1991, CIBA F S, V156; LYNCH JW, 1994, LANCET, V343, P524, DOI 10.1016/S0140-6736(94)91468-0; MARMOT MG, 1986, LANCET, V2, P274; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; Prineas R., 1982, MINNESOTA CODE MANUA; REID DD, 1974, LANCET, V1, P469; ROSE GA, 1968, WHO MONOGRAPH SERIES, V56; SHAPER AG, 1984, BRIT HEART J, V51, P595, DOI 10.1136/hrt.51.6.595; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/s001250050157	19	166	170	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 7	1995	310	6971					17	19		10.1136/bmj.310.6971.17	http://dx.doi.org/10.1136/bmj.310.6971.17			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB060	7827546	Green Published			2022-12-28	WOS:A1995QB06000020
J	WHEELER, DB; RANDALL, A; TSIEN, RW				WHEELER, DB; RANDALL, A; TSIEN, RW			ROLES OF N-TYPE AND Q-TYPE CA2+ CHANNELS IN SUPPORTING HIPPOCAMPAL SYNAPTIC TRANSMISSION	SCIENCE			English	Article							LONG-TERM POTENTIATION; OMEGA-CONOTOXIN GVIA; CALCIUM CHANNELS; TRANSMITTER RELEASE; PERIPHERAL NEURONS; SENSORY NEURONS; P-TYPE; CURRENTS; INVITRO; DEPRESSION	Several types of calcium channels found in the central nervous system are possible participants in triggering neurotransmitter release. Synaptic transmission between hippocampal CA3 and CA1 neurons was mediated by N-type calcium channels, together with calcium channels whose pharmacology differs from that of L- and P-type channels but resembles that of the Q-type channel encoded by the alpha1A subunit gene. Blockade of either population of channels strongly increased enhancement of synaptic transmission with repetitive stimuli. Even after complete blockade of N-type channels, transmission was strongly modulated by stimulation of neurotransmitter receptors or protein kinase C. These findings suggest a role for alpha1A subunits in synaptic transmission and support the idea that neurotransmitter release may depend on multiple types of calcium channels under physiological conditions.	STANFORD UNIV, MED CTR,SCH MED,BECKMAN CTR MOLEC & GENET MED, DEPT MOLEC & CELLULAR PHYSIOL, STANFORD, CA 94305 USA	Stanford University				Randall, Andrew/0000-0001-8852-3671	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH048108] Funding Source: NIH RePORTER; NIMH NIH HHS [MH48108-02] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alger B.E., 1984, BRAIN SLICES, P381; ANWYL R, 1991, BRAIN RES REV, V16, P265, DOI 10.1016/0165-0173(91)90010-6; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1986, J PHYSIOL-LONDON, V377, P391, DOI 10.1113/jphysiol.1986.sp016193; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CREAGER R, 1980, J PHYSL, V299, P400; DEISZ RA, 1985, NEUROSCI LETT, V56, P205, DOI 10.1016/0304-3940(85)90130-2; DINGLEDINE R, 1981, BRAIN RES, V207, P218, DOI 10.1016/0006-8993(81)90697-1; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; DUTAR P, 1989, EUR J PHARMACOL, V174, P261, DOI 10.1016/0014-2999(89)90318-X; ELLINOR PT, 1993, NATURE, V363, P455, DOI 10.1038/363455a0; GAHWILER BH, 1987, NEUROSCI LETT, V76, P301, DOI 10.1016/0304-3940(87)90419-8; GROSS RA, 1989, J PHYSIOL-LONDON, V411, P585, DOI 10.1113/jphysiol.1989.sp017592; HORNE AL, 1991, BRIT J PHARMACOL, V103, P1733, DOI 10.1111/j.1476-5381.1991.tb09855.x; KAMIYA H, 1988, NEUROSCI LETT, V91, P84, DOI 10.1016/0304-3940(88)90253-4; KASAI H, 1987, Neuroscience Research, V4, P228, DOI 10.1016/0168-0102(87)90014-9; LEMOS JR, 1989, NEURON, V2, P1419, DOI 10.1016/0896-6273(89)90187-6; LESTER RAJ, 1990, NEURON, V4, P741, DOI 10.1016/0896-6273(90)90200-Y; LLINAS R, 1992, TRENDS NEUROSCI, V15, P351, DOI 10.1016/0166-2236(92)90053-B; MALENKA RC, 1986, NATURE, V321, P175, DOI 10.1038/321175a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANABE T, 1993, J NEUROPHYSIOL, V70, P1451, DOI 10.1152/jn.1993.70.4.1451; MCCLESKEY EW, 1987, P NATL ACAD SCI USA, V84, P4327, DOI 10.1073/pnas.84.12.4327; MCKECHNIE K, 1989, BRIT J PHARMACOL, V98, pP673; MILLER RJ, 1993, CURR BIOL, V3, P481, DOI 10.1016/0960-9822(93)90364-T; MILLER RJ, 1990, INTRACELLULAR CALCIU, P97; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MINTZ IM, 1993, NEUROPHARMACOLOGY, V32, P1161, DOI 10.1016/0028-3908(93)90010-Z; MINTZ IM, 1993, NEURON, V10, P889, DOI 10.1016/0896-6273(93)90204-5; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; MULKEEN D, 1988, BRAIN RES, V447, P234, DOI 10.1016/0006-8993(88)91124-9; MULLER D, 1989, BRAIN RES, V479, P290, DOI 10.1016/0006-8993(89)91631-4; NIIDOME T, 1992, FEBS LETT, V308, P7, DOI 10.1016/0014-5793(92)81038-N; PARFITT KD, 1993, J PHYSIOL-LONDON, V471, P245, DOI 10.1113/jphysiol.1993.sp019900; Randall A. D., 1993, Society for Neuroscience Abstracts, V19, P1478; RANDALL AD, 1993, FUNCT NEUROL S, V8, P44; REGAN LJ, 1991, NEURON, V6, P269, DOI 10.1016/0896-6273(91)90362-4; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SCHOLZ KP, 1992, NEURON, V8, P1139, DOI 10.1016/0896-6273(92)90134-Y; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; Swartz K. J., 1993, Society for Neuroscience Abstracts, V19, P1478; SWARTZ KJ, 1993, NATURE, V361, P165, DOI 10.1038/361165a0; SWARTZ KJ, 1993, NEURON, V11, P305, DOI 10.1016/0896-6273(93)90186-U; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; TURNER TJ, 1993, P NATL ACAD SCI USA, V90, P9518, DOI 10.1073/pnas.90.20.9518; TURNER TJ, 1992, SCIENCE, V258, P310, DOI 10.1126/science.1357749; WHEELER D, UNPUB; Wu L. G., 1993, Society for Neuroscience Abstracts, V19, P1518; WU LG, 1994, J NEUROSCI, V14, P645; YANG J, 1993, NEURON, V10, P127, DOI 10.1016/0896-6273(93)90305-B; ZHANG J, UNPUB; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L	57	863	873	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 1	1994	264	5155					107	111		10.1126/science.7832825	http://dx.doi.org/10.1126/science.7832825			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND536	7832825				2022-12-28	WOS:A1994ND53600042
J	SIMONDS, RJ; LINDEGREN, ML; THOMAS, P; HANSON, D; CALDWELL, B; SCOTT, G; ROGERS, M				SIMONDS, RJ; LINDEGREN, ML; THOMAS, P; HANSON, D; CALDWELL, B; SCOTT, G; ROGERS, M			PROPHYLAXIS AGAINST PNEUMOCYSTIS-CARINII PNEUMONIA AMONG CHILDREN WITH PERINATALLY ACQUIRED HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION IN THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIV-INFECTION; CHEMOPROPHYLAXIS; POPULATION; AIDS	Background. Pneumocystis carinii pneumonia (PCP) remains a common and often fatal opportunistic infection among children infected with the human immunodeficiency virus (HIV). HIV-infected infants between three and six months of age are particularly vulnerable. Current guidelines recommend prophylaxis in children from birth to 11 months old who have CD4+ counts below 1500 cells per cubic millimeter. Methods. We used national surveillance data to estimate the annual incidence of PCP among children less than one year old. We reviewed the medical records of 300 children given a diagnosis of PCP between January 1991 and June 1993 to determine why treatment according to the 1991 guidelines for prophylaxis against PCP either was not given or failed to prevent the disease. Results. In our study the incidence of PCP in the first year of life among infants born to HIV-infected mothers changed little between 1989 and 1992. Among 7080 children born to HIV-infected mothers in 1992, PCP developed in 2.4 percent. Of 300 children with PCP diagnosed from January 1991 through June 1993, 199 (66 percent) had never received prophylaxis, and for 118 of those children (59 percent) exposure to HIV was first identified 30 days or less before the diagnosis of PCP, Among 129 children less than one year old, the CD4+ count declined by an estimated 967 cells per cubic millimeter (95 percent confidence interval, 724 to 1210 cells per cubic millimeter) during the three months before the diagnosis of PCP, Among infants in whom CD4+ counts were determined within one month of the diagnosis of PCP, 18 percent (20 of 113) had at least 1500 cells per cubic millimeter, a level higher than the currently recommended threshold for prophylaxis. Conclusions. In the United States the incidence of PCP among HIV-infected infants has not declined. If this infection is to be prevented, infants exposed to HIV must be identified earlier, and prophylaxis must be offered to more children than the guidelines currently recommend.	NEW YORK CITY DEPT HLTH, NEW YORK, NY 10013 USA; UNIV MIAMI, SCH MED, DEPT PEDIAT, MIAMI, FL USA	New York City Department of Health & Mental Hygiene; University of Miami	SIMONDS, RJ (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV HIV AIDS, 1600 CLIFTON RD, MAILSTOP E-45, ATLANTA, GA 30333 USA.							[Anonymous], 1991, MMWR Recomm Rep, V40, P1; CALDWELL B, 1994, 34TH INT C ANT AG CH; CALDWELL B, 1994, 34TH INT C ANT AG CH, P36; CALDWELL MB, 1992, PEDIATRICS, V90, P603; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; CONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1693, DOI 10.1001/jama.265.13.1693; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DENNY T, 1992, JAMA-J AM MED ASSOC, V267, P1484, DOI 10.1001/jama.267.11.1484; DENNY T, 1992, JAMA-J AM MED ASSOC, V267, P3154; Efron B., 1994, MONOGRAPHS STAT APPL; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; HSU HW, 1992, PEDIATR INFECT DIS J, V11, P941, DOI 10.1097/00006454-199211110-00007; HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602; ISRAELE V, 1992, pB233; Karon J M, 1992, MMWR Recomm Rep, V41, P1; KOVACS A, 1991, JAMA-J AM MED ASSOC, V265, P1698, DOI 10.1001/jama.265.13.1698; MCKINNEY RE, 1992, PEDIATR INFECT DIS J, V11, P639; MOFENSON LM, 1993, J ACQ IMMUN DEF SYND, V6, P1103; NEWELL ML, 1994, BRIT MED J, V308, P437; OLESKE J, 1994, CLIN INFECT DIS, V19, P611; ROSENBLUM L, 1992, AM J PUBLIC HEALTH, V82, P1495, DOI 10.2105/AJPH.82.11.1495; RUEBUSH TK, 1978, AM J DIS CHILD, V132, P143, DOI 10.1001/archpedi.1978.02120270041009; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; SIMONDS RJ, 1993, JAMA-J AM MED ASSOC, V270, P470, DOI 10.1001/jama.270.4.470; WADE AM, 1992, PEDIATR INFECT DIS J, V11, P1018, DOI 10.1097/00006454-199211120-00006	26	67	67	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 23	1995	332	12					786	790		10.1056/NEJM199503233321206	http://dx.doi.org/10.1056/NEJM199503233321206			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN442	7862183				2022-12-28	WOS:A1995QN44200006
J	RODWIN, MA				RODWIN, MA			CONFLICTS IN MANAGED CARE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							FINANCIAL INCENTIVES; INFORMED CONSENT; PHYSICIANS; HMOS; DISCLOSURE				RODWIN, MA (corresponding author), INDIANA UNIV,SCH PUBL & ENVIRONM AFFAIRS,BLOOMINGTON,IN 47405, USA.							Angell M, 1993, Kennedy Inst Ethics J, V3, P279; [Anonymous], 1987, RANDOM HOUSE DICT EN; APPELBAUM P, 1987, INFORMED CONSENT LEG; APPELBAUM PS, 1993, MILBANK Q, V71, P669, DOI 10.2307/3350424; Balbus ID, 1971, POLIT SOC, V1, P151; CLARK Robert Charles, 1986, CORPORATE LAW; CONNOLLY W, 1972, POLIT SOC, V2, P459; DARR K, 1987, ETHICS HLTH SERVICES, P87; Finn P. D., 1977, FIDUCIARY OBLIGATION; Fisher R., 2011, GETTING YES NEGOTIAT; FRANKEL T, 1983, CALIF LAW REV, V71, P795, DOI 10.2307/3480303; FRANKLIN JL, 1987, AM J PUBLIC HEALTH, V77, P674, DOI 10.2105/AJPH.77.6.674; GLD M, 1994, IN PRESS ARRANGEMENT; GOLD M, 1994, RESULTS 1994 MANAGED; GOLD M, 1987, RES BRIEFS, V1, P1; HALL MA, 1993, MILBANK Q, V71, P645, DOI 10.2307/3350423; Henderson M G, 1988, QRB Qual Rev Bull, V14, P33; HENDERSON MG, 1987, EVALUATING CASE MANA, P7; HENDERSON MG, 1988, HEALTH CARE FINANC R, P89; HILLMAN AL, 1987, NEW ENGL J MED, V317, P1743, DOI 10.1056/NEJM198712313172725; HILLMAN AL, 1992, MED CARE, V30, P136, DOI 10.1097/00005650-199202000-00005; HILLMAN AL, 1991, HEALTH AFFAIR, V10, P138, DOI 10.1377/hlthaff.10.4.138; HURLEY RE, 1993, MANAGED CARE MED LES; Johnson J., 1994, Artificial Intelligence in Mathematics, P3; JOHNSSON J, 1994, AM MED NEWS     0912, P31; JOHNSSON J, 1994, AM MED NEWS     1024, P1; Katz J., 1984, SILENT WORLD DOCTOR; LEVINSON DF, 1987, NEW ENGL J MED, V317, P1729, DOI 10.1056/NEJM198712313172708; Mechanic D, 1986, ADVOCACY ALLOCATION; Merrill J C, 1985, Bus Health, V2, P5; Raiffa H., 1982, ART SCI NEGOTIATION; Rodwin M. A., 1993, MED MONEY MORALS PHY; RODWIN MA, 1989, NEW ENGL J MED, V321, P1405, DOI 10.1056/NEJM198911163212010; Scott AW, 1949, CALIF LAW REV, V37, P539, DOI 10.2307/3477686; Sealy L., 1968, CLJ, V21, P119, DOI 10.1017/S0008197300085767; Stone DA., 1988, POLICY PARADOX POLIT; SULLIVAN L, 1990, DHHS90202646AS PUBL; Susskind L., 1987, BREAKING IMPASSE CON; WEINRIB EJ, 1975, U TORONTO LAW J, V25, P1, DOI 10.2307/824874; WELCH WP, 1990, MILBANK Q, V68, P221, DOI 10.2307/3350097; 1993, MOLINA MED CARE CTR; 1969, NATIONAL C UNIFORM S, V6; 1985, MODEL BUSINESS CORPO; 1986, A I86 AM MED ASS REP	44	119	119	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 2	1995	332	9					604	607		10.1056/NEJM199503023320913	http://dx.doi.org/10.1056/NEJM199503023320913			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QJ090	7838199				2022-12-28	WOS:A1995QJ09000013
J	KRAMER, MHH; KLUIN, PM; WIJBURG, ER; FIBBE, WE; KLUINNELEMANS, HC				KRAMER, MHH; KLUIN, PM; WIJBURG, ER; FIBBE, WE; KLUINNELEMANS, HC			DIFFERENTIATION OF FOLLICULAR LYMPHOMA-CELLS AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION AND HEMATOPOIETIC GROWTH-FACTOR TREATMENT	LANCET			English	Note							RECOMBINANT HUMAN INTERLEUKIN-3	A patient with follicular lymphoma developed a striking but transient plasmacytosis in blood and bone marrow with paraproteinaemia after treatment by autologous bone marrow transplantation and interleukin-3 (IL-3). By immunophenotyping, cytogenetics and Southern blotting, we proved that the plasma cells were clonally related to the original lymphoma cells. This event was preceded by fever accompanied by high IL-6 concentrations. The patient recovered spontaneously and had a long-lasting remission. We speculate that the bone marrow-derived malignant B cells were stimulated by IL-3 and IL-6 into terminally differentiated plasma cells.	LEIDEN UNIV,MED CTR,DEPT PATHOL,2300 RC LEIDEN,NETHERLANDS; LEIDEN UNIV,MED CTR,DEPT HAEMATOL,2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC			Kramer, Mark/GWQ-3502-2022; Kluin-Nelemans, Johanna C/F-8658-2018	Kluin-Nelemans, Johanna C/0000-0003-2617-9427				BERGUI L, 1989, J EXP MED, V170, P613, DOI 10.1084/jem.170.2.613; CLAYBERGER C, 1992, J EXP MED, V175, P371, DOI 10.1084/jem.175.2.371; DEJONG D, 1988, NEW ENGL J MED, V318, P1373, DOI 10.1056/NEJM198805263182106; GANSER A, 1990, BLOOD, V76, P666; KAWANO M, 1988, NATURE, V323, P83; KONTOZOGLOU T, 1983, ARCH PATHOL LAB MED, V107, P232; KRAMER MHH, 1991, LEUKEMIA, V5, P473; LINDEMANN A, 1991, J CLIN ONCOL, V9, P2120, DOI 10.1200/JCO.1991.9.12.2120; SCHMID U, 1985, VIRCHOWS ARCH A, V405, P473, DOI 10.1007/BF00737173; TADMORI W, 1989, J IMMUNOL, V142, P1950	10	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 25	1995	345	8948					488	490		10.1016/S0140-6736(95)90585-5	http://dx.doi.org/10.1016/S0140-6736(95)90585-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7861876				2022-12-28	WOS:A1995QH92900012
J	TRUSWELL, AS				TRUSWELL, AS			CHOLESTEROL-LOWERING IN INFANCY	LANCET			English	Editorial Material											TRUSWELL, AS (corresponding author), UNIV SYDNEY,HUMAN NUTR UNIT,SYDNEY,NSW,AUSTRALIA.							FARQUHARSON J, 1992, LANCET, V340, P810, DOI 10.1016/0140-6736(92)92684-8; HANSEN D, 1992, ACTA PAEDIATR, V81, P1023, DOI 10.1111/j.1651-2227.1992.tb12167.x; JAMES WPT, 1988, EUROEPAN SERIES, V24; RASANEN L, 1992, ACTA PAEDIATR, V81, P7, DOI 10.1111/j.1651-2227.1992.tb12069.x; TRUSWELL AS, 1976, EARLY NUTRITION LATE, P229; WIDDOWSON EM, 1975, BRIT MED J, V1, P653, DOI 10.1136/bmj.1.5959.653; 1989, DIET HLTH; 1992, REPORT AGE LIMIT ADO; 1991, REPORT HLTH SOCIAL S, V41; 1992, PEDIATRICS, V90, P469; 1994, NUTRITIONAL ASPECTS, V46; 1991, NIH N4LB1 US DHEW NA	12	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 25	1995	345	8948					468	469		10.1016/S0140-6736(95)90577-4	http://dx.doi.org/10.1016/S0140-6736(95)90577-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7861871				2022-12-28	WOS:A1995QH92900004
J	HECHT, A; LAROCHE, T; STRAHLBOLSINGER, S; GASSER, SM; GRUNSTEIN, M				HECHT, A; LAROCHE, T; STRAHLBOLSINGER, S; GASSER, SM; GRUNSTEIN, M			HISTONE H3 AND H4 N-TERMINI INTERACT WITH SIR3 AND SIR4 PROTEINS - A MOLECULAR-MODEL FOR THE FORMATION OF HETEROCHROMATIN IN YEAST	CELL			English	Article							SILENT MATING LOCI; POSITION EFFECT VARIEGATION; SACCHAROMYCES-CEREVISIAE; SHUTTLE VECTORS; DNA; TELOMERES; TRANSCRIPTION; REPRESSION; DROSOPHILA; SEQUENCE	The silent mating loci and chromosomal regions adjacent to telomeres of S. cerevisiae have features similar to heterochromatin of more complex eukaryotes. Transcriptional repression at these sites depends on the silent information regulators SIR3 and SIR4 as well as histones H3 and H4. We show here that the SIR3 and SIR4 proteins interact with specific silencing domains of the H3 and H4 N-termini in vitro. Certain mutations in these factors, which affect their silencing functions in vivo, also disrupt their interactions in vitro. Immunofluorescence studies with antibodies against RAP1 and SIR3 demonstrate that the H3 and H4 N-termini are required for the association of SIR3 with telomeric chromatin and the perinuclear positioning of yeast telomeres. Based on these interactions, we propose a model for heterochromatin-mediated transcriptional silencing in yeast, which may serve as a paradigm for other eukaryotic organisms as well.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90095; SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; Swiss Institute Experimental Cancer Research				Gasser, Susan/0000-0003-3610-9123; Hecht, Andreas/0000-0003-2262-2575	NIGMS NIH HHS [GM42421] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042421] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANNWEILER A, 1991, NUCLEIC ACIDS RES, V19, P3750, DOI 10.1093/nar/19.13.3750; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; CHICOINE LG, 1987, J CELL BIOL, V105, P127, DOI 10.1083/jcb.105.1.127; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHIEN CT, 1993, CELL, V75, P531, DOI 10.1016/0092-8674(93)90387-6; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DIFFLEY JFX, 1989, NATURE, V342, P24, DOI 10.1038/342024a0; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; EBRALIDSE KK, 1988, NATURE, V331, P365, DOI 10.1038/331365a0; EISSENBERG JC, 1989, BIOESSAYS, V11, P14, DOI 10.1002/bies.950110105; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JOHNSON LM, 1992, EMBO J, V11, P2201, DOI 10.1002/j.1460-2075.1992.tb05279.x; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; KURTZ S, 1991, GENE DEV, V5, P616, DOI 10.1101/gad.5.4.616; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; MANN RK, 1992, EMBO J, V11, P3297, DOI 10.1002/j.1460-2075.1992.tb05408.x; MARSHALL M, 1987, MOL CELL BIOL, V7, P4441, DOI 10.1128/MCB.7.12.4441; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; MOORE GD, 1983, GENETICS, V105, P327; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; RIVIER DH, 1994, CELL, V76, P963, DOI 10.1016/0092-8674(94)90373-5; SCHUSTER T, 1986, CELL, V45, P445, DOI 10.1016/0092-8674(86)90330-2; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TARTOF KD, 1990, DEVELOPMENT S, V120, P35; THOMPSON JS, 1993, COLD SPRING HARB SYM, V58, P247, DOI 10.1101/SQB.1993.058.01.029; THOMPSON JS, 1994, NATURE, V369, P245, DOI 10.1038/369245a0; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197	43	690	707	0	16	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					583	592		10.1016/0092-8674(95)90512-X	http://dx.doi.org/10.1016/0092-8674(95)90512-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867066	Bronze			2022-12-28	WOS:A1995QJ60200010
J	HUANG, ZJ; CURTIN, KD; ROSBASH, M				HUANG, ZJ; CURTIN, KD; ROSBASH, M			PER PROTEIN INTERACTIONS AND TEMPERATURE COMPENSATION OF A CIRCADIAN CLOCK IN DROSOPHILA	SCIENCE			English	Article							MESSENGER-RNA LEVELS; PERIOD GENE-PRODUCT; B P50 PRECURSOR; NEUROSPORA-CRASSA; VISUAL-SYSTEM; DNA-BINDING; MELANOGASTER; RHYTHMS; MUTANTS; DIMERIZATION	The periods of circadian clocks are relatively temperature-insensitive. Indeed, the per(L) mutation in the Drosophila melanogaster period gene, a central component of the clock, affects temperature compensation as well as period length. The per protein (PER) contains a dimerization domain (PAS) within which the per(L) mutation is located. Amino acid substitutions at the per(L) position rendered PER dimerization temperature-sensitive. In addition, another region of PER interacted with PAS, and the per(L) mutation enhanced this putative intramolecular interaction, which may compete with PAS-PAS intermolecular interactions. Therefore, temperature compensation of circadian period in Drosophila may be due in part to temperature-independent PER activity, which is based on competition between inter- and intramolecular interactions with similar temperature coefficients.			HUANG, ZJ (corresponding author), BRANDEIS UNIV,HOWARD HUGHES MED INST,WALTHAM,MA 02254, USA.			Huang, Z. Josh/0000-0003-0592-028X	NIGMS NIH HHS [GM-33205] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; BAYLIES MK, 1987, NATURE, V326, P390, DOI 10.1038/326390a0; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; COTE GG, 1986, J THEOR BIOL, V121, P487, DOI 10.1016/S0022-5193(86)80104-7; CURTIN K, 1994, NEURON, V13, P1167; DELABROUSSE FC, 1993, TRENDS GENET, V9, P151, DOI 10.1016/0168-9525(93)90149-C; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; EDERY I, 1994, SCIENCE, V263, P237, DOI 10.1126/science.8284676; EWER J, 1990, J NEUROGENET, V7, P31, DOI 10.3109/01677069009084151; Feldman J.F., 1986, J BIOL RHYTHM, V1, P18767; GARDNER GF, 1981, PLANT PHYSIOL, V68, P1244, DOI 10.1104/pp.68.6.1244; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HASTINGS JW, 1957, P NATL ACAD SCI USA, V43, P804, DOI 10.1073/pnas.43.9.804; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUANG Z, UNPUB; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; KLEIN ES, 1993, GENE DEV, V7, P55, DOI 10.1101/gad.7.1.55; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KONOPKA RJ, 1989, J NEUROGENET, V6, P1, DOI 10.3109/01677068909107096; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAKINTHOMAS PL, 1990, CRIT REV MICROBIOL, V17, P365, DOI 10.3109/10408419009114762; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; MATTERN DL, 1982, P NATL ACAD SCI-BIOL, V79, P825, DOI 10.1073/pnas.79.3.825; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; PITTENDRIGH CS, 1954, P NATL ACAD SCI USA, V40, P1018, DOI 10.1073/pnas.40.10.1018; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; REPPERT SM, 1994, NEURON, V13, P1167, DOI 10.1016/0896-6273(94)90054-X; RUTILA JE, 1992, J NEUROGENET, V8, P101, DOI 10.3109/01677069209084155; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; SMITH RF, 1982, MOL GEN GENET, V189, P30; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; Worden, 1974, NEUROSCIENCES 3RD ST, P437; YU Q, 1987, P NATL ACAD SCI USA, V84, P784, DOI 10.1073/pnas.84.3.784; ZERR DM, 1990, J NEUROSCI, V10, P2749	38	127	127	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1169	1172		10.1126/science.7855598	http://dx.doi.org/10.1126/science.7855598			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855598	Green Submitted			2022-12-28	WOS:A1995QJ23700038
J	NEGLIA, JP; FITZSIMMONS, SC; MAISONNEUVE, P; SCHONI, MH; SCHONIAFFOLTER, F; COREY, M; LOWENFELS, AB; BOYLE, P; DOZOR, AJ; DURIE, P				NEGLIA, JP; FITZSIMMONS, SC; MAISONNEUVE, P; SCHONI, MH; SCHONIAFFOLTER, F; COREY, M; LOWENFELS, AB; BOYLE, P; DOZOR, AJ; DURIE, P			THE RISK OF CANCER AMONG PATIENTS WITH CYSTIC-FIBROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN FETAL TISSUES; MESSENGER-RNA; ADENOCARCINOMA; CARCINOMA; MALIGNANCY; EXPRESSION; LOCALIZATION; ADULT; GENE	Background. Anecdotal reports suggest an increased frequency of certain cancers in patients with cystic fibrosis, the commonest genetic disorder of whites. One third of patients with cystic fibrosis now reach adulthood, when cancer is more frequent, implying that cancer rates in these patients will increase over time. We investigated the relation between cystic fibrosis and cancer in North American and European patients with cystic fibrosis. Methods. We performed a retrospective cohort study of the occurrence of cancer in 28,511 patients with cystic fibrosis from 1985 through 1992 in the United States and Canada. The number of cases observed was compared with the number expected, calculated from population-based data on the incidence of cancer. We also analyzed proportional incidence ratios to assess the association between specific cancers and cystic fibrosis in Europe. Results. Thirty-seven cancers were observed in the North American cohort during 164,764 person-years of follow-up, as compared with an expected number of 45.6, yielding a ratio of observed to expected cancers of 0.8 (95 percent confidence interval, 0.6 to 1.1). Thirteen digestive tract tumors were observed, as compared with an expected number of two, for a ratio of observed to expected cancers of 6.5 (95 percent confidence interval, 3.5 to 11.1). In Europe, 11 of 39 cancers originated in the digestive tract, yielding a positive association between digestive tract tumors and cystic fibrosis (odds ratio, 6.4; 95 percent confidence interval, 2.9 to 14.0). Conclusions. Although the overall risk of cancer in patients with cystic fibrosis is similar to that of the general population, there is an increased risk of digestive tract cancers. Persistent or unexplained gastrointestinal symptoms in these patients should be carefully investigated.	NEW YORK MED COLL,DEPT SURG,VALHALLA,NY 10595; NEW YORK MED COLL,DEPT COMMUNITY & PREVENT MED,VALHALLA,NY 10595; UNIV MINNESOTA,SCH MED,DEPT PEDIAT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT EPIDEMIOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH PUBL HLTH,MINNEAPOLIS,MN 55455; CYST FIBROSIS FDN,BETHESDA,MD; EUROPEAN INST ONCOL,DIV EPIDEMIOL & BIOSTAT,MILAN,ITALY; HOSP SICK CHILDREN,TORONTO,ON M5G 1X8,CANADA; ALPINE CHILDRENS HOSP,DAVOS,SWITZERLAND	New York Medical College; New York Medical College; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Cystic Fibrosis Foundation; IRCCS European Institute of Oncology (IEO); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Lowenfels, Albert/ABD-8388-2021; Maisonneuve, Patrick/U-9789-2018; Boyle, Peter/A-4380-2014	Maisonneuve, Patrick/0000-0002-5309-4704; Boyle, Peter/0000-0001-6251-0610; Neglia, Joseph/0000-0002-5525-0598				ABDULKARIM FW, 1982, GASTROENTEROLOGY, V82, P758; BAILAR JC, 1964, BIOMETRICS, V20, P639; BIGGS BG, 1986, CANCER, V57, P2441, DOI 10.1002/1097-0142(19860615)57:12<2441::AID-CNCR2820571232>3.0.CO;2-W; BOSTICK RM, 1993, CANCER RES, V53, P4230; COLE WQ, 1970, CYST FIBR CLUB ABSTR, P33; DAVIS TME, 1985, THORAX, V40, P199, DOI 10.1136/thx.40.3.199; ENGELHARDT JF, 1994, J CLIN INVEST, V93, P737, DOI 10.1172/JCI117028; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; FITZSIMMONS SC, 1993, J PEDIATR-US, V122, P1, DOI 10.1016/S0022-3476(05)83478-X; GORVOY JD, 1981, 22ND ANN M CYST FIBR, P117; HASSALL E, 1993, AM J GASTROENTEROL, V88, P1934; MCCRAY PB, 1992, J CLIN INVEST, V90, P619, DOI 10.1172/JCI115901; MCINTOSH JC, 1988, AM J MED, V85, P592; MILLER RW, 1969, PEDIATR RES, V3, P389, DOI 10.1203/00006450-196909000-00001; MOSS RB, 1985, PEDIATRICS, V76, P814; NEGLIA JP, 1991, J PEDIATR-US, V119, P764, DOI 10.1016/S0022-3476(05)80296-3; PARKIN DM, 1992, IARC SCI PUBLICATION, V120; REDINGTON AN, 1985, BRIT MED J, V290, P1871, DOI 10.1136/bmj.290.6485.1871; RIES LAG, 1991, NIH912789 PUBL; ROBERTS JA, 1986, SCOT MED J, V31, P109, DOI 10.1177/003693308603100210; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P73; SHELDON CD, 1993, BRIT J CANCER, V68, P1025, DOI 10.1038/bjc.1993.474; SIRAGANIAN PA, 1987, LANCET, V2, P1158; STEAD RJ, 1985, LANCET, V2, P862; SWINSON CM, 1983, LANCET, V1, P111; TEDESCO FJ, 1986, GASTROINTEST ENDOSC, V32, P25, DOI 10.1016/S0016-5107(86)71723-9; TESLUK H, 1991, J CLIN GASTROENTEROL, V13, P485; TIZZANO EF, 1994, AM J RESP CELL MOL, V10, P355, DOI 10.1165/ajrcmb.10.4.7510983; TIZZANO EF, 1993, HUM MOL GENET, V2, P219, DOI 10.1093/hmg/2.3.219; TREZISE AEO, 1993, HUM MOL GENET, V2, P213, DOI 10.1093/hmg/2.3.213; WARREN N, 1991, BRIT MED J, V302, P760, DOI 10.1136/bmj.302.6779.760; 1993, NEW ENGL J MED, V329, P1308	32	267	274	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 23	1995	332	8					494	499		10.1056/NEJM199502233320803	http://dx.doi.org/10.1056/NEJM199502233320803			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH288	7830730				2022-12-28	WOS:A1995QH28800003
J	DEBERKER, D; IBBOTSON, S; SIMPSON, NB; MATTHEWS, JNS; IDLE, JR; REES, JL				DEBERKER, D; IBBOTSON, S; SIMPSON, NB; MATTHEWS, JNS; IDLE, JR; REES, JL			REDUCED EXPERIMENTAL CONTACT SENSITIVITY IN SQUAMOUS-CELL BUT NOT BASAL-CELL CARCINOMAS OF SKIN	LANCET			English	Note							EXPOSURE; BIOLOGY	Basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) show clinical and epidemiological differences not accounted for by different ultraviolet radiation exposure. We have studied experimentally induced contact sensitivity to dinitrochlorobenzene by measuring increases in skin-fold thickness. Patients (n=37) with squamous tumours had impaired responses compared with controls (33) and patients with BCCs (31) (mean increase 4.5 vs 7.8 and 8.6 mm, respectively; p=0.002). This diminished immunological response may be causally related to the development of SCC. Because glutathione S-transferase (GST) metabolises dinitrochlorobenzene and polymorphisms of GST are associated with multiple skin tumours, variations in GST may underlie these differences.	UNIV NEWCASTLE UPON TYNE,DEPT DERMATOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT MED STAT,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT PHARMACOL SCI,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK			Ibbotson, Sally H/H-7061-2019; Matthews, John N S/H-7502-2013	Ibbotson, Sally H/0000-0001-5685-752X; Matthews, John N S/0000-0003-2559-037X				BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; COOPER KD, 1992, P NATL ACAD SCI USA, V89, P8497, DOI 10.1073/pnas.89.18.8497; FRIEDMANN PS, 1990, CLIN EXP IMMUNOL, V81, P507; GRANSTEIN RD, 1990, SEMIN DERMATOL, V9, P16; HEAGERTY AHM, 1994, LANCET, V343, P266, DOI 10.1016/S0140-6736(94)91115-0; JONES SM, 1988, CARCINOGENESIS, V9, P395, DOI 10.1093/carcin/9.3.395; KWA RE, 1992, J AM ACAD DERMATOL, V26, P1, DOI 10.1016/0190-9622(92)70001-V; MILLER SJ, 1991, J AM ACAD DERMATOL, V24, P1, DOI 10.1016/0190-9622(91)70001-I; REES JL, 1989, BRIT J DERMATOL, V120, P371, DOI 10.1111/j.1365-2133.1989.tb04162.x	9	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					425	426		10.1016/S0140-6736(95)90406-9	http://dx.doi.org/10.1016/S0140-6736(95)90406-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853955				2022-12-28	WOS:A1995QG90400014
J	VOLBEDA, A; CHARON, MH; PIRAS, C; HATCHIKIAN, EC; FREY, M; FONTECILLACAMPS, JC				VOLBEDA, A; CHARON, MH; PIRAS, C; HATCHIKIAN, EC; FREY, M; FONTECILLACAMPS, JC			CRYSTAL-STRUCTURE OF THE NICKEL-IRON HYDROGENASE FROM DESULFOVIBRIO-GIGAS	NATURE			English	Article							SULFATE-REDUCING BACTERIA; ESR-DETECTABLE NICKEL; ACTIVE-SITE NICKEL; ELECTRON-TRANSFER; NIFE HYDROGENASE; METHANOCOCCUS-VOLTAE; CHROMATIUM-VINOSUM; REDOX PROPERTIES; SULFUR CENTERS; BACULATUS	The X-ray structure of the heterodimeric Ni-Fe hydrogenase from Desulfovibrio gigas, the enzyme responsible for the metabolism of molecular hydrogen, has been solved at 2.84 Angstrom resolution. The active site, which appears to contain, besides nickel, a second metal ion, is buried in the 60K subunit. The 28K subunit, which coordinates one [3Fe-4S] and two [4Fe-4S] clusters, contains an amino-terminal domain with similarities to the redox protein flavodoxin. The structure suggests plausible electron and proton transfer pathways.	INST BIOL STRUCT,CRISTALLOG & CRISTALLOGENESE PROT LAB,F-38027 GRENOBLE 1,FRANCE; CNRS,UNITE BIOENERGET & INGN PROT,F-13402 MARSEILLE 20,FRANCE	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite				Volbeda, Anne/0000-0002-6038-0979				ADAMS MWW, 1990, BIOCHIM BIOPHYS ACTA, V1020, P115, DOI 10.1016/0005-2728(90)90044-5; ADAMS MWW, 1981, BIOCHIM BIOPHYS ACTA, V594, P105; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BAGYINKA C, 1993, J AM CHEM SOC, V115, P3576, DOI 10.1021/ja00062a022; BARONDEAU DP, 1994, J AM CHEM SOC, V116, P3442, DOI 10.1021/ja00087a033; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOXER SG, 1994, STRUCT BIOL, V11, P749; BRICOGNE G, 1991, ISOMORPHOUS REPLACEM, P60; BRUNGER A, 1988, CRYSTALLOGRAPHIC COM, V4, P127; CAMMACK R, 1982, FEBS LETT, V142, P289, DOI 10.1016/0014-5793(82)80154-3; CAMMACK R, 1987, BIOCHIM BIOPHYS ACTA, V912, P98, DOI 10.1016/0167-4838(87)90252-4; CERIOTTI A, 1984, INORG CHEM, V23, P1363, DOI 10.1021/ic00178a013; CHAPMAN A, 1988, FEBS LETT, V242, P134, DOI 10.1016/0014-5793(88)81001-9; EIDSNESS MK, 1989, P NATL ACAD SCI USA, V86, P147, DOI 10.1073/pnas.86.1.147; FAN CL, 1991, J AM CHEM SOC, V113, P20, DOI 10.1021/ja00001a003; FAUQUE G, 1988, FEMS MICROBIOL LETT, V54, P299, DOI 10.1111/j.1574-6968.1988.tb02748.x; FERNANDEZ VM, 1986, BIOCHIM BIOPHYS ACTA, V883, P145, DOI 10.1016/0304-4165(86)90145-5; HATCHIKIAN EC, 1978, BIOCHEM BIOPH RES CO, V82, P451, DOI 10.1016/0006-291X(78)90896-3; HE SH, 1989, J BIOL CHEM, V264, P2678; Hendrickson W. A., 1980, COMPUTING CRYSTALLOG; HIGUCHI Y, 1994, ACTA CRYSTALLOGR D, V50, P781, DOI 10.1107/S0907444994002416; HUYNH BH, 1987, J BIOL CHEM, V262, P795; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1990, ACTA CRYSTALLOGR A, V47, P110; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOLODZIEJ AF, 1994, PROG INORG CHEM, V41, P493, DOI 10.1002/9780470166420.ch7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1992, ESFCCP4 NEWSL, V27, P30; MENON NK, 1993, FEBS LETT, V331, P91, DOI 10.1016/0014-5793(93)80303-C; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NIVIERE V, 1988, BIOCHIM BIOPHYS ACTA, V935, P34, DOI 10.1016/0005-2728(88)90105-3; ODOM JM, 1984, ANNU REV MICROBIOL, V38, P551, DOI 10.1146/annurev.mi.38.100184.003003; ONUCHIC JN, 1992, ANNU REV BIOPH BIOM, V21, P349, DOI 10.1146/annurev.biophys.21.1.349; Otwinowski Z, 1991, ISOMORPHOUS REPLACEM, P60; PRZYBYLA AE, 1992, FEMS MICROBIOL LETT, V88, P109, DOI 10.1016/0378-1097(92)90687-J; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SMITH WW, 1977, J MOL BIOL, V117, P195, DOI 10.1016/0022-2836(77)90031-6; SORGENFREI O, 1993, FEBS LETT, V332, P291, DOI 10.1016/0014-5793(93)80652-B; SORGENFREI O, 1993, EUR J BIOCHEM, V213, P1355, DOI 10.1111/j.1432-1033.1993.tb17888.x; TEIXEIRA M, 1989, J BIOL CHEM, V264, P16435; VANDERZWAAN JW, 1985, FEBS LETT, V179, P271, DOI 10.1016/0014-5793(85)80533-0; VANDERZWAAN JW, 1986, BIOCHIM BIOPHYS ACTA, V872, P208, DOI 10.1016/0167-4838(86)90273-6; VELLIEUX FMD, IN PRESS J APPL CRYS; VOLBEDA A, 1993, ESF CCP4 NEWSLETTER, V28, P30; VOORDOUW G, 1992, ADV INORG CHEM, V38, P397, DOI 10.1016/S0898-8838(08)60069-0; VOORDOUW G, 1989, J BACTERIOL, V171, P2894, DOI 10.1128/jb.171.5.2894-2899.1989; WHITEHEAD JP, 1993, J AM CHEM SOC, V115, P5629, DOI 10.1021/ja00066a032; WU LF, 1993, FEMS MICROBIOL LETT, V104, P243	50	1344	1366	5	217	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					580	587		10.1038/373580a0	http://dx.doi.org/10.1038/373580a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854413				2022-12-28	WOS:A1995QG99700044
J	KANTARJIAN, HM; SMITH, TL; OBRIEN, S; BERAN, M; PIERCE, S; TALPAZ, M; ROBERTSON, L; KOLLER, C; ESTEY, E; KEATING, MJ				KANTARJIAN, HM; SMITH, TL; OBRIEN, S; BERAN, M; PIERCE, S; TALPAZ, M; ROBERTSON, L; KOLLER, C; ESTEY, E; KEATING, MJ			PROLONGED SURVIVAL IN CHRONIC MYELOGENOUS LEUKEMIA AFTER CYTOGENETIC RESPONSE TO INTERFERON-ALPHA THERAPY	ANNALS OF INTERNAL MEDICINE			English	Article						LEUKEMIA, MYELOID, CHRONIC; INTERFERON-ALPHA; CYTOGENETICS; BASOPHILS; SPLENOMEGALY	PHILADELPHIA-CHROMOSOME; CHRONIC-PHASE; REMISSION	Objective: To determine whether a cytogenetic response after interferon-alpha therapy in patients with chronic myelogenous leukemia is independently associated with improved survival. Design: Retrospective analysis. Patients: 274 patients with a diagnosis of Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase who were treated with interferon-alpha-based programs between 1982 and 1990. Intervention: Therapy with daily subcutaneous interferon-alpha given at 5 x 10(6) U/m(2) body surface area (highest dose schedule allowed on studies) or the maximally tolerated lower-dose schedule. Results: Overall, 219 (80%) patients achieved a complete hematologic response and 104 (38%) achieved a major cytogenetic response (<35% Philadelphia chromosome-positive cells). Estimated median survival was 89 months. Several pretreatment factors were associated with failure to achieve a major cytogenetic response and with worse survival. The existing prognostic models were generally predictive of which patients were likely to achieve a major cytogenetic response (P less than or equal to 0.01) and of survival outcomes (P less than or equal to 0.01). Multivariate analysis identified bone marrow basophilia (P < 0.01) and splenomegaly (P < 0.01) as independent poor prognostic factors for survival. Achievement of a major cytogenetic response, entered as a time-dependent variable while accounting for the other independent factors, was associated with improved survival (P < 0.001). Comparison of survival (dated from 12 months into therapy) with cytogenetic response at 12 months showed that a cytogenetic response was associated with longer survival (P < 0.001). Conclusion: Achieving a cytogenetic response with interferon-alpha therapy in patients with chronic myelogenous leukemia was independently associated with improved survival when tested as a time-dependent variable in a multivariate analysis, and this association was confirmed by landmark analysis at 12 months.			KANTARJIAN, HM (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, DEPT HEMATOL, BOX 61, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.			Talpaz, Moshe/0000-0003-3361-3981	NCI NIH HHS [CA19639] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALIMENA G, 1988, BLOOD, V72, P642; ANDERSON JR, 1983, J CLIN ONCOL, V1, P710, DOI 10.1200/JCO.1983.1.11.710; COX DR, 1972, J R STAT SOC B, V34, P187; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; GOLDMAN JM, 1993, BLOOD, V82, P2235; GOLDMAN JM, 1990, LEUKEMIA, V4, P163; HEHLMANN R, 1993, BLOOD, V82, P398, DOI 10.1182/blood.V82.2.398.bloodjournal822398; KANTARJIAN HM, 1993, BLOOD, V82, P691; KANTARJIAN HM, 1990, AM J MED, V88, P1, DOI 10.1016/0002-9343(90)90119-X; KANTARJIAN HM, 1985, BLOOD, V66, P1326; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; OZER H, 1993, BLOOD, V82, P2975; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SOKAL JE, 1984, BLOOD, V63, P789, DOI 10.1182/blood.V63.4.789.789; TALPAZ M, 1987, BLOOD, V69, P1280; TALPAZ M, 1986, NEW ENGL J MED, V314, P1065, DOI 10.1056/NEJM198604243141701; TURA S, 1994, NEW ENGL J MED, V330, P820; TURA S, 1994, NEW ENGL J MED, V331, P402; 1988, GUIDELINES REPORTING	21	422	428	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1995	122	4					254	261		10.7326/0003-4819-122-4-199502150-00003	http://dx.doi.org/10.7326/0003-4819-122-4-199502150-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF769	7825760				2022-12-28	WOS:A1995QF76900003
J	BENHAMOU, Y; DOHIN, E; LUNELFABIANI, F; POYNARD, T; HURAUX, JM; KATLAMA, C; OPOLON, P; GENTILINI, M				BENHAMOU, Y; DOHIN, E; LUNELFABIANI, F; POYNARD, T; HURAUX, JM; KATLAMA, C; OPOLON, P; GENTILINI, M			EFFICACY OF LAMIVUDINE ON REPLICATION OF HEPATITIS-B VIRUS IN HIV-INFECTED PATIENTS	LANCET			English	Letter											BENHAMOU, Y (corresponding author), HOP LA PITIE SALPETRIERE,SERV HEPATOGASTROENTEROL,F-75651 PARIS 13,FRANCE.		Poynard, Thierry/C-1355-2010	Poynard, Thierry/0000-0002-3726-7230; Poynard, Thierry/0000-0002-2050-640X				ASHMAN C, 1994, 6 INT S VIR HEP MADR, P65; DIENSTAG JL, 1994, HEPATOLOGY, V20, pA412; DOONG SL, 1991, P NATL ACAD SCI USA, V88, P8495, DOI 10.1073/pnas.88.19.8495; Tyrrell D. L. J., 1993, Clinical and Investigative Medicine, V16, pB77	4	97	97	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 11	1995	345	8946					396	397		10.1016/S0140-6736(95)90388-7	http://dx.doi.org/10.1016/S0140-6736(95)90388-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF722	7845151				2022-12-28	WOS:A1995QF72200067
J	GERASIMENKO, OV; GERASIMENKO, JV; TEPIKIN, AV; PETERSEN, OH				GERASIMENKO, OV; GERASIMENKO, JV; TEPIKIN, AV; PETERSEN, OH			ATP-DEPENDENT ACCUMULATION AND INOSITOL TRISPHOSPHATE-MEDIATED OR CYCLIC ADP-RIBOSE-MEDIATED RELEASE OF CA2+ FROM THE NUCLEAR-ENVELOPE	CELL			English	Article							RAT-LIVER NUCLEI; IP(3) RECEPTOR; CALCIUM; CELLS; OSCILLATIONS; CHANNELS; MEMBRANE; WAVES; EGGS	Uptake and release of Ca2+ from isolated liver nuclei were studied with fluorescent probes. We show with the help of digital imaging and confocal microscopy that the Ca2+-sensitive fluorescent probe Fura 2 is concentrated in or around the nuclear envelope and that the distribution of Fura 2 fluorescence is similar to that of an endoplasmic reticulum marker. The previously demonstrated ATP-dependent uptake of Ca2+ into isolated nuclei and release of the accumulated Ca2+ by inositol 1,4,5-trisphosphate (IP3) are therefore due to transport of Ca2+ into and out of the nuclear envelope and not the nucleoplasm. Dextrans labeled with fluorescent Ca2+ indicators (calcium-Green 1 and Fura 2) are distributed uniformly in the nucleoplasm and can be used to show that changes in the external Ca2+ concentration produce rapid changes in the nucleoplasmic Ca2+ concentration. Nevertheless, IP3 and cyclic ADP-ribose evoke transient intranuclear Ca2+ elevations. The release from the Ca2+ stores in or around the nuclear envelope appears to be directed into the nucleoplasm from where it can diffuse out through the permeable nuclear pore complexes.			GERASIMENKO, OV (corresponding author), UNIV LIVERPOOL,PHYSIOL LAB,MRC,SECRETORY CONTROL RES GRP,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.		Gerasimenko, Oleg/A-6622-2010; Gerasimenko, Julia/A-7688-2010; Petersen, Ole H/E-8708-2010	Gerasimenko, Oleg/0000-0003-2573-8258; Petersen, Ole/0000-0002-6998-0380; Gerasimenko, Julia/0000-0002-2262-2543; Tepikin, Alexei/0000-0002-8172-7513				ALMOHANNA FA, 1994, NATURE, V367, P745, DOI 10.1038/367745a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRINI M, 1993, EMBO J, V12, P4813, DOI 10.1002/j.1460-2075.1993.tb06170.x; BURGOYNE RD, 1989, NATURE, V342, P72, DOI 10.1038/342072a0; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; GILLOT I, 1993, J EXP BIOL, V184, P213; HECHTENBERG S, 1993, BIOCHEM J, V289, P757, DOI 10.1042/bj2890757; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; LANG I, 1986, J CELL BIOL, V102, P1183, DOI 10.1083/jcb.102.4.1183; LANINI L, 1992, J BIOL CHEM, V267, P11548; LEE HC, 1989, J BIOL CHEM, V264, P1608; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; NEWPORT JW, 1987, ANNU REV BIOCHEM, V56, P535; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P8858; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; SULLIVAN KMC, 1993, CELL, V73, P1411, DOI 10.1016/0092-8674(93)90366-X; THOMAS AP, 1991, CELL CALCIUM, V12, P111, DOI 10.1016/0143-4160(91)90013-5; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; TOMBES RM, 1992, J CELL BIOL, V117, P799, DOI 10.1083/jcb.117.4.799	27	332	343	3	13	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					439	444		10.1016/0092-8674(95)90494-8	http://dx.doi.org/10.1016/0092-8674(95)90494-8			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859285	Bronze			2022-12-28	WOS:A1995QG47000010
J	NAITO, T; KUSANO, K; KOBAYASHI, I				NAITO, T; KUSANO, K; KOBAYASHI, I			SELFISH BEHAVIOR OF RESTRICTION-MODIFICATION SYSTEMS	SCIENCE			English	Article							GENES; ENDONUCLEASE	Plasmids carrying gene pairs encoding type II DNA restriction endonucleases and their cognate modification enzymes were shown to have increased stability in Escherichia coli. The descendants of cells that had lost these genes appeared unable to modify a sufficient number of recognition sites in their chromosomes to protect them from lethal attack by the remaining restriction enzyme molecules. The capacity of these genes to act as a selfish symbiont is likely to have contributed to the evolution of restriction-modification gene pairs.	UNIV TOKYO,INST MED SCI,DEPT MOLEC BIOL,TOKYO 108,JAPAN	University of Tokyo			Kobayashi, Ichizo/GVT-8377-2022	Kobayashi, Ichizo/0000-0002-3854-1879				BETLACH M, 1976, FED PROC, V35, P2037; GILLEN JR, 1981, J BACTERIOL, V157, P521; GINGERAS TR, 1983, P NATL ACAD SCI-BIOL, V80, P402, DOI 10.1073/pnas.80.2.402; HASHIMOTOGOTOH T, 1981, GENE, V16, P227, DOI 10.1016/0378-1119(81)90079-2; HEITMAN J, 1989, P NATL ACAD SCI USA, V86, P2281, DOI 10.1073/pnas.86.7.2281; Kobayashi I, 1992, Adv Biophys, V28, P81, DOI 10.1016/0065-227X(92)90023-K; KUSANO K, 1989, J MOL BIOL, V209, P623, DOI 10.1016/0022-2836(89)90000-4; KUSANO K, 1994, GENE, V138, P17; KUSANO K, 1994, P NATL ACAD SCI USA, V91, P1173, DOI 10.1073/pnas.91.3.1173; LEHNHERR H, 1993, J MOL BIOL, V233, P414, DOI 10.1006/jmbi.1993.1521; Nordstrom K., 1993, PLASMIDS PRACTICAL A, P1; OGURA T, 1983, P NATL ACAD SCI-BIOL, V80, P4784, DOI 10.1073/pnas.80.15.4784; ROBBINS LG, 1994, GENETICS, V138, P401; Roberts R, 1993, NUCLEASES, P35; ROSE RE, 1988, NUCLEIC ACIDS RES, V16, P355, DOI 10.1093/nar/16.1.355	15	277	284	0	31	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 10	1995	267	5199					897	899		10.1126/science.7846533	http://dx.doi.org/10.1126/science.7846533			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG207	7846533				2022-12-28	WOS:A1995QG20700062
J	DERIJARD, B; RAINGEAUD, J; BARRETT, T; WU, IH; HAN, JH; ULEVITCH, RJ; DAVIS, RJ				DERIJARD, B; RAINGEAUD, J; BARRETT, T; WU, IH; HAN, JH; ULEVITCH, RJ; DAVIS, RJ			INDEPENDENT HUMAN MAP KINASE SIGNAL-TRANSDUCTION PATHWAYS DEFINED BY MEK AND MKK ISOFORMS	SCIENCE			English	Article							PROTEIN-KINASE; CLONING; YEAST	Mammalian mitogen-activated protein (MAP) kinases include extracellular signal-regulated protein kinase (ERK), c-Jun amino-terminal kinase (JNK), and p38 subgroups. These MAP kinase isoforms are activated by dual phosphorylation on threonine and tyrosine. Two human MAP kinase kinases (MKK3 and MKK4) were cloned that phosphorylate and activate p38 MAP kinase. These MKK isoforms did not activate the ERK subgroup of MAP kinases, but MKK4 did activate JNK. These data demonstrate that the activators of p38 (MKK3 and MKK4), JNK (MKK4), and ERK (MEK1 and MEK2) define independent MAP kinase signal transduction pathways.	UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA; HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA; SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; Scripps Research Institute			Ulevitch, Richard J/Q-3393-2017; Han, J/G-4671-2010		NCI NIH HHS [CA58396] Funding Source: Medline; NIAID NIH HHS [AI15136] Funding Source: Medline; NIGMS NIH HHS [GM37696] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM037696] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BOGUSLAWSKI G, 1987, P NATL ACAD SCI USA, V84, P5848, DOI 10.1073/pnas.84.16.5848; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, UNPUB; DRESSLER H, 1992, BIOTECHNIQUES, V13, P866; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GUPTA S, 1995, SCIENCE, V389; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; RAINGEAUD J, UNPUB; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; YAN MH, 1994, NATURE, V372, P798; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	31	1398	1442	0	32	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 3	1995	267	5198					682	685		10.1126/science.7839144	http://dx.doi.org/10.1126/science.7839144			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839144				2022-12-28	WOS:A1995QE73300039
J	MASON, A; MORGAN, K				MASON, A; MORGAN, K			PURCHASER PROVIDER - THE INTERNATIONAL DIMENSION	BRITISH MEDICAL JOURNAL			English	Article								Purchaser-provider systems in health care are being implemented in several countries and are under consideration in many more. These new arrangements are described for the United Kingdom, Finland, New Zealand, and Australia, and in each case responsibility for funding, purchasing, providing, and ownership is identified. The four systems, along with managed care organisations in the United States, are also compared with regard to several important features. There is a fundamental similarity between these purchaser-provider arrangements but several key differences are well worth systematic study. This is a major challenge for academic bodies in Britain and other countries, and the opportunity to learn from each other should not be missed.	BRISTOL & DIST HLTH AUTHOR,BRISTOL BS2 8EE,AVON,ENGLAND; SW REG HLTH AUTHOR,BRISTOL BS2 8EE,AVON,ENGLAND										0	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 28	1995	310	6974					231	235		10.1136/bmj.310.6974.231	http://dx.doi.org/10.1136/bmj.310.6974.231			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE496	7866129	Green Published			2022-12-28	WOS:A1995QE49600028
J	CLAPHAM, DE				CLAPHAM, DE			CALCIUM SIGNALING	CELL			English	Review							XENOPUS-LAEVIS OOCYTES; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; INTRACELLULAR CA2+ STORES; CYCLIC ADP-RIBOSE; PHOSPHOLIPASE-C; PLASMA-MEMBRANE; SARCOPLASMIC-RETICULUM; ENDOPLASMIC-RETICULUM; BINDING PROTEINS; SMOOTH-MUSCLE				CLAPHAM, DE (corresponding author), MAYO CLIN & MAYO FDN, DEPT PHARMACOL, 200 1ST ST SW, ROCHESTER, MN 55905 USA.			Clapham, David/0000-0002-4459-9428				ALLBRITTON NL, 1993, CELL CALCIUM, V14, P691, DOI 10.1016/0143-4160(93)90095-N; ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; ATRI A, 1993, BIOPHYS J, V65, P1727, DOI 10.1016/S0006-3495(93)81191-3; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BAIMBRIDGE KG, 1992, TRENDS NEUROSCI, V15, P303, DOI 10.1016/0166-2236(92)90081-I; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOOTMAN M, 1994, CURR BIOL, V4, P169, DOI 10.1016/S0960-9822(94)00041-2; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CAMACHO P, 1993, SCIENCE, V260, P226, DOI 10.1126/science.8385800; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; Clapham David E., 1995, V30, P1; CLAPHAM DE, 1993, NATURE, V364, P763, DOI 10.1038/364763a0; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; FINCH EA, 1994, SCIENCE, V265, P813, DOI 10.1126/science.265.5173.813-a; FRIEL DD, 1995, IN PRESS BIOPHYS J; GALIONE A, 1993, SCIENCE, V259, P325, DOI 10.1126/science.8380506; GIRARD S, 1993, SCIENCE, V260, P229, DOI 10.1126/science.8385801; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; HEIZMANN CW, 1991, TRENDS BIOCHEM SCI, V16, P98, DOI 10.1016/0968-0004(91)90041-S; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HU YF, 1994, BIOCHEM BIOPH RES CO, V201, P1050, DOI 10.1006/bbrc.1994.1808; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LEE CH, 1992, J BIOL CHEM, V267, P16044; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; LUCKHOFF A, 1994, BIOPHYS J, V67, P177, DOI 10.1016/S0006-3495(94)80467-9; MACLENNAN DH, 1992, ANN NY ACAD SCI, V671, P1, DOI 10.1111/j.1749-6632.1992.tb43779.x; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIKOSHIBA K, 1993, TRENDS PHARMACOL SCI, V14, P86, DOI 10.1016/0165-6147(93)90069-V; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; NAYAL M, 1994, P NATL ACAD SCI USA, V91, P817, DOI 10.1073/pnas.91.2.817; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; NICOTERA P, 1994, CELL CALCIUM, V16, P279, DOI 10.1016/0143-4160(94)90091-4; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PAULING L, 1947, GENERAL CHEM; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; SHARP AH, 1993, J NEUROSCI, V13, P3051; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHUTTLEWORTH TJ, 1992, J BIOL CHEM, V267, P3573; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STEHNOBITTEL L, 1995, NEURON, V14, P163, DOI 10.1016/0896-6273(95)90250-3; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; STREHLER EE, 1995, IN PRESS PRINCIPLES, V3; TAYLOR CW, 1992, TRENDS BIOCHEM SCI, V17, P403, DOI 10.1016/0968-0004(92)90009-X; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; TSCHARNER V, 1986, NATURE, V324, P369; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VACA L, 1994, AM J PHYSIOL, V267, pC9210; VAJANAPHANICH M, 1994, NATURE, V371, P711, DOI 10.1038/371711a0; YOO SH, 1991, BIOCHEM J, V278, P381, DOI 10.1042/bj2780381; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	84	2202	2257	6	147	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	1995	80	2					259	268		10.1016/0092-8674(95)90408-5	http://dx.doi.org/10.1016/0092-8674(95)90408-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7834745	Bronze			2022-12-28	WOS:A1995QD92400008
J	COHEN, GB; REN, RB; BALTIMORE, D				COHEN, GB; REN, RB; BALTIMORE, D			MODULAR BINDING DOMAINS IN SIGNAL-TRANSDUCTION PROTEINS	CELL			English	Review							GROWTH-FACTOR RECEPTOR; TYROSINE-PHOSPHORYLATED PEPTIDES; AFFINITY PHOSPHOTYROSYL PEPTIDE; GTPASE-ACTIVATING PROTEIN; SRC SH2 DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; BETA-RECEPTOR; C-SRC; IDENTIFICATION; PHOSPHOPEPTIDES		MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)					NATIONAL CANCER INSTITUTE [R01CA051462] Funding Source: NIH RePORTER; NCI NIH HHS [5RO1 CA51462-06] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; ANDEREM A, 1992, TRENDS BIOCHEM SCI, V17, P438; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CASE RD, 1994, J BIOL CHEM, V269, P10467; CHEN JK, 1993, J AM CHEM SOC, V115, P12591, DOI 10.1021/ja00079a051; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOWNING AK, 1994, CURR BIOL, V4, P884, DOI 10.1016/S0960-9822(00)00197-4; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FINAN P, 1994, J BIOL CHEM, V269, P13752; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; FUSHMAN D, 1995, IN PRESS P NATL ACAD, V92; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GOUDREAU N, 1994, NAT STRUCT BIOL, V1, P898, DOI 10.1038/nsb1294-898; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HU P, 1994, MOL CELL BIOL, V14, P2577, DOI 10.1128/MCB.14.4.2577; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MILLER C, 1993, SCIENCE, V261, P1692, DOI 10.1126/science.8397443; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; MUSACCHIO A, 1994, PROG BIOPHYS MOL BIO, V61, P283, DOI 10.1016/0079-6107(94)90003-5; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TERASAWA H, 1994, NAT STRUCT BIOL, V1, P891, DOI 10.1038/nsb1294-891; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; YE ZS, 1995, IN PRESS P NATL ACAD, V92; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	77	934	959	0	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	1995	80	2					237	248		10.1016/0092-8674(95)90406-9	http://dx.doi.org/10.1016/0092-8674(95)90406-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7834743	Bronze			2022-12-28	WOS:A1995QD92400006
J	MANSONHING, M; WELLS, G				MANSONHING, M; WELLS, G			METAANALYSIS OF EFFICACY OF QUININE FOR TREATMENT OF NOCTURNAL LEG CRAMPS IN ELDERLY PEOPLE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							VITAMIN-E; TRIAL; SULFATE; PLACEBO	Objective-To assess quantitatively the efficacy of quinine (as quinine sulphate) compared with placebo in the treatment of nocturnal leg cramps. Design-A meta-analysis of six randomised, double blind, crossover trials. Setting-Randomised trials that were available as of April 1994. Subjects-A total of 107 general ambulatory patients who suffered from regular nocturnal leg cramps from six clinical trials. Results-Data from individual patients were used to calculate point estimates and 95% confidence intervals for each of the outcome measures reported by these studies, Treatment with quinine resulted in a significant reduction in the number of cramps for a four week period compared with placebo (8.83 fewer cramps; 95% confidence interval 4.16 to 13.49). Treatment with quinine reduced the number of nights with cramps by 27.4% (24.0% to 30.8%) compared with placebo. Treatment did not produce a significant change in the severity or duration of individual nocturnal leg cramps. Side effects were uncommon. Conclusions-The results indicate that quinine can prevent nocturnal leg cramps in general ambulatory populations. Given the possible serious side effects of treatment with quinine, the benefits and risks in patients taking this drug should be closely monitored.	UNIV OTTAWA, OTTAWA CIVIC HOSP, DEPT MED, CLIN EPIDEMIOL UNIT, OTTAWA, ON, CANADA	University of Ottawa; Ottawa Hospital Research Institute	MANSONHING, M (corresponding author), UNIV OTTAWA, OTTAWA CIVIC HOSP, DIV GERIATR MED, GERIATR ASSESSMENT UNIT, OTTAWA, ON K1Y 4E9, CANADA.							AYRES S, 1974, SOUTHERN MED J, V67, P1308, DOI 10.1097/00007611-197411000-00011; BACON P, 1988, BRIT J OPHTHALMOL, V72, P219, DOI 10.1136/bjo.72.3.219; BALTODANO N, 1988, ARCH INTERN MED, V148, P1969, DOI 10.1001/archinte.148.9.1969; BATEMAN DN, 1985, Q J MED, V54, P125; CONNOLLY PS, 1992, ARCH INTERN MED, V152, P1877, DOI 10.1001/archinte.152.9.1877; DANIELL HW, 1979, NEW ENGL J MED, V301, P216; DUNN NR, 1993, BRIT J GEN PRACT, V43, P127; FUNG MC, 1989, WESTERN J MED, V151, P42; GORLICH HD, 1991, ARZNEIMITTEL-FORSCH, V41-1, P167; HALL AJ, 1947, LANCET, V253, P231; JONES K, 1983, AGE AGEING, V12, P155, DOI 10.1093/ageing/12.2.155; KAJI DM, 1976, LANCET, V2, P66; LIM SH, 1986, BRIT J CLIN PRACT, V40, P462; MAGUIRE RB, 1993, ANN INTERN MED, V119, P215, DOI 10.7326/0003-4819-119-3-199308010-00006; MCGEE SR, 1990, ARCH INTERN MED, V150, P511, DOI 10.1001/archinte.150.3.511; MORL H, 1980, MED KLIN, V75, P40; Moss HK, 1940, J AMER MED ASSOC, V115, P1358, DOI 10.1001/jama.1940.72810420002011a; PEER G, 1983, DIALYSIS TRANSPLANT, V12, P180; Roca A O, 1992, ASAIO J, V38, pM481, DOI 10.1097/00002480-199207000-00081; SIDOROV J, 1993, J AM GERIATR SOC, V41, P498, DOI 10.1111/j.1532-5415.1993.tb01884.x; WARBURTON A, 1987, BRIT J CLIN PHARMACO, V23, P459, DOI 10.1111/j.1365-2125.1987.tb03076.x	21	65	65	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 7	1995	310	6971					13	17		10.1136/bmj.310.6971.13	http://dx.doi.org/10.1136/bmj.310.6971.13			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB060	7827545	Green Published			2022-12-28	WOS:A1995QB06000019
J	WALKER, P				WALKER, P			CONTROVERSIES IN MANAGEMENT - SHOULD OBSTETRICIANS SEE WOMEN WITH NORMAL PREGNANCIES - OBSTETRICIANS SHOULD BE INCLUDED IN INTEGRATED TEAM CARE .15.	BRITISH MEDICAL JOURNAL			English	Article											WALKER, P (corresponding author), ROYAL FREE HOSP,POND ST,LONDON NW3 2QG,ENGLAND.							STEER PJ, 1992, BRIT J OBSTET GYNAEC, V99, P415; STREET P, 1991, BRIT MED J, V302, P698, DOI 10.1136/bmj.302.6778.698; 1993, CHANGING CHILDBIRTH; 1992, CHANGING CHILDBIRTH	4	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 7	1995	310	6971					36	37		10.1136/bmj.310.6971.36	http://dx.doi.org/10.1136/bmj.310.6971.36			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB060	7827554	Green Published			2022-12-28	WOS:A1995QB06000031
J	DOWSETT, M; JOHNSTON, SRD; IVESON, TJ; SMITH, IE				DOWSETT, M; JOHNSTON, SRD; IVESON, TJ; SMITH, IE			RESPONSE TO SPECIFIC ANTIESTROGEN (ICI182780) IN TAMOXIFEN-RESISTANT BREAST-CANCER	LANCET			English	Letter											DOWSETT, M (corresponding author), ROYAL MARSDEN NATL HLTH SERV TRUST,BREAST UNIT,LONDON SW3 6JJ,ENGLAND.							CHANDER SK, 1991, CANCER RES, V51, P5851; HOWELL, 1995, LANCET          0107, P29; IVESON TJ, 1993, CANCER RES, V53, P266; JOHNSTON SRD, 1994, CANCER RES, V54, P5875	4	9	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 25	1995	345	8948					525	525		10.1016/S0140-6736(95)90624-X	http://dx.doi.org/10.1016/S0140-6736(95)90624-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7861903				2022-12-28	WOS:A1995QH92900059
J	LEESMILLER, SP; GODBOUT, R; CHAN, DW; WEINFELD, M; DAY, RS; BARRON, GM; ALLALUNISTURNER, J				LEESMILLER, SP; GODBOUT, R; CHAN, DW; WEINFELD, M; DAY, RS; BARRON, GM; ALLALUNISTURNER, J			ABSENCE OF P350 SUBUNIT OF DNA-ACTIVATED PROTEIN-KINASE FROM A RADIOSENSITIVE HUMAN CELL-LINE	SCIENCE			English	Article							TERMINAL TRANSACTIVATION DOMAIN; RNA POLYMERASE-II; KU-PROTEIN; HUMAN CHROMOSOME-8; BINDING PROTEIN; SCID MUTATION; BREAK REPAIR; MICE; PHOSPHORYLATES; RADIATION	The radiosensitive rodent mutant cell line xrs-5 is defective in DNA double-strand break repair and lacks the Ku component of the DNA-activated protein kinase, DNA-PK. Here radiosensitive human cell lines were analyzed for DNA-PK activity and for the presence of related proteins. The radiosensitive human malignant glioma M059J cell line was found to be defective in DNA double-strand break repair, but fails to express the p350 subunit of DNA-PK. These results suggest that DNA-PK kinase activity is involved in DNA double-strand break repair.	CROSS CANC INST,RADIOBIOL PROGRAM,EDMONTON,AB T6G 1Z2,CANADA; UNIV CALGARY,DEPT BIOL SCI,CALGARY,AB T2N 1N4,CANADA; CROSS CANC INST,MOLEC ONCOL PROGRAM,EDMONTON,AB T6G 1Z2,CANADA	University of Alberta; University of Calgary; University of Alberta			Godbout, Roseline/I-4639-2016; Chan, Doris/O-1227-2014	Godbout, Roseline/0000-0002-4779-9265; Chan, Doris/0000-0002-4990-986X; Lees-Miller, Susan/0000-0001-5809-2516				ALLALUNISTURNER MJ, 1993, RADIAT RES, V134, P349, DOI 10.2307/3578196; ALLALUNISTURNER MJ, UNPUB; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; ANDERSON CC, COMMUNICATION; ANDERSON CW, IN PRESS METHODS PRO; ANDERSON CW, 1994, TRENDS BIOCHEM SCI, V18, P433; BANGA SS, 1994, MUTAT RES-DNA REPAIR, V315, P239, DOI 10.1016/0921-8777(94)90035-3; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLIER PR, 1993, J BIOL CHEM, V268, P7594; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CHAN D, UNPUB; CHEN YR, 1991, J VIROL, V10, P5131; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; DVIR A, 1993, J BIOL CHEM, V268, P10440; FELDMANN H, 1993, J BIOL CHEM, V268, P12895; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; ILIAKIS G, 1991, INT J RADIAT BIOL, V59, P927, DOI 10.1080/09553009114550821; ITOH M, 1993, RADIAT RES, V134, P364, DOI 10.2307/3578198; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KIRCHGESSNER CU, 1993, CANCER RES, V53, P6011; KOMATSU K, 1993, HUM MOL GENET, V2, P1031, DOI 10.1093/hmg/2.7.1031; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; KURIMASA A, 1994, HUM GENET, V93, P21; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1989, J BIOL CHEM, V264, P17275; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, UNPUB; LIU SH, 1993, J BIOL CHEM, V268, P21147; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; MITSIS PG, 1989, J BIOL CHEM, V264, P5195; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; REEVES WH, 1985, J EXP MED, V161, P18, DOI 10.1084/jem.161.1.18; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TACCIOLI GE, 1994, SCIENCE, V265, P1422; THACKER J, 1990, MUTAT RES, V235, P49, DOI 10.1016/0921-8777(90)90057-C; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; WANATABE F, 1994, BIOCHIM BIOPHYS ACTA, V1223, P255; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2	52	497	504	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1183	1185		10.1126/science.7855602	http://dx.doi.org/10.1126/science.7855602			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855602				2022-12-28	WOS:A1995QJ23700042
J	BHATNAGAR, D; ANAND, IS; DURRINGTON, PN; PATEL, DJ; WANDER, GS; MACKNESS, MI; CREED, F; TOMENSON, B; CHANDRASHEKHAR, Y; WINTERBOTHAM, M; BRITT, RP; KEIL, JE; SUTTON, GC				BHATNAGAR, D; ANAND, IS; DURRINGTON, PN; PATEL, DJ; WANDER, GS; MACKNESS, MI; CREED, F; TOMENSON, B; CHANDRASHEKHAR, Y; WINTERBOTHAM, M; BRITT, RP; KEIL, JE; SUTTON, GC			CORONARY RISK-FACTORS IN PEOPLE FROM THE INDIAN SUBCONTINENT LIVING IN WEST LONDON AND THEIR SIBLINGS IN INDIA	LANCET			English	Article							ISCHEMIC-HEART-DISEASE; INSULIN RESISTANCE; ARTERY DISEASE; ASIAN INDIANS; A-I; HYPERTENSION; PREVALENCE; MEN; LIPOPROTEIN(A); DYSLIPIDEMIAS	Several reports have shown that migrants from southeast Asia tend to have an increased risk of coronary heart disease when settled in their new country. We compared coronary risk factors in a randomly selected group of 247 migrants from the Indian subcontinent of Punjabi origin living in West London and 117 of their siblings living in the Punjab in India. The West London cohort had a greater body mass index (p < 0.001), systolic-blood pressure (p = 0.0087), serum cholesterol (p < 0.001), apolipoprotein B (p < 0.001), lower high-density lipoprotein cholesterol (p < 0.05) and higher fasting blood glucose (p < 0.05) than their siblings in the Punjab. Insulin sensitivity, derived from the homoeostatic assessment mathematical model, was lower in men in West London than in their counterparts in India (p < 0.05). Indians in West London had lower beta cell function than those in the Punjab (p < 0.001). Serum lipoprotein (a) concentrations were similar in both the West London and Punjab population, but were significantly higher (p = 0.01) than those of white European populations in the UK. Increases in serum cholesterol after migration from India lead to increased coronary risk conferred by high serum lipoprotein (a) concentrations and greater insulin resistance. Such between-country comparisons are an important means of establishing the importance of coronary risk factors.	UNIV MANCHESTER,MANCHESTER ROYAL INFIRM,DEPT PSYCHIAT,MANCHESTER M13 9WL,LANCS,ENGLAND; HILLINGDON HOSP,DEPT CARDIOL,UXBRIDGE,MIDDX,ENGLAND; HILLINGDON HOSP,DEPT HAEMATOL,UXBRIDGE,MIDDX,ENGLAND; POSTGRAD INST MED EDUC & RES,DEPT CARDIOL,CHANDIGARH,INDIA; MED UNIV S CAROLINA,DEPT EPIDEMIOL,CHARLESTON,SC	University of Manchester; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Medical University of South Carolina	BHATNAGAR, D (corresponding author), UNIV MANCHESTER,MANCHESTER ROYAL INFIRM,DEPT MED,OXFORD RD,MANCHESTER M13 9WL,LANCS,ENGLAND.							ADOLPHSON JL, 1989, J LIPID RES, V30, P597; BALARAJAN R, 1991, BMJ-BRIT MED J, V302, P560, DOI 10.1136/bmj.302.6776.560; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; Bhatnagar Deepak, 1993, Current Opinion in Lipidology, V4, P299, DOI 10.1097/00041433-199308000-00006; CHADHA SL, 1993, B WORLD HEALTH ORGAN, V71, P67; CREMER P, 1994, EUR J CLIN INVEST, V24, P444, DOI 10.1111/j.1365-2362.1994.tb02373.x; DURRINGTON PN, 1988, LANCET, V1, P1070; ENAS EA, 1992, AM J CARDIOL, V70, P945, DOI 10.1016/0002-9149(92)90744-J; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FONTBONNE AM, 1991, DIABETES CARE, V14, P461, DOI 10.2337/diacare.14.6.461; GORDON C, 1985, DIABETOLOGIA, V28, P291, DOI 10.1007/BF00271688; KEIL JE, 1980, HUM BIOL, V52, P423; KEIL JE, 1980, J EPIDEMIOL COMMUN H, V34, P45, DOI 10.1136/jech.34.1.45; KNIGHT TM, 1992, BRIT HEART J, V67, P343; MACKNESS MI, 1992, LIPOPROTEIN ANAL PRA, P1; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; MBEWU AD, 1990, ATHEROSCLEROSIS, V85, P1, DOI 10.1016/0021-9150(90)90177-K; MCKEIGUE PM, 1988, BRIT HEART J, V60, P390; MCKEIGUE PM, 1992, BRIT HEART J, V67, P341, DOI 10.1136/hrt.67.5.341; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; MILLER GJ, 1988, ATHEROSCLEROSIS, V70, P63, DOI 10.1016/0021-9150(88)90100-1; RAJADURAI J, 1992, AUST NZ J MED, V22, P345, DOI 10.1111/j.1445-5994.1992.tb02145.x; RAMACHANDRAN A, 1992, DIABETES CARE, V15, P1348, DOI 10.2337/diacare.15.10.1348; SANDHOLZER C, 1991, HUM GENET, V86, P607; SCHUMACHER MC, 1992, DIABETES CARE, V15, P1285, DOI 10.2337/diacare.15.10.1285; SMITH U, 1993, INSULIN RESISTANCE, P335; WATKINS LO, 1986, AM J CARDIOL, V57, P538, DOI 10.1016/0002-9149(86)90831-3; 1986, LANCET, V1, P1307; [No title captured]; 1991, LANCET, V331, P397	30	262	268	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					405	409						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853948				2022-12-28	WOS:A1995QG90400006
J	HUNT, DM; DULAI, KS; BOWMAKER, JK; MOLLON, JD				HUNT, DM; DULAI, KS; BOWMAKER, JK; MOLLON, JD			THE CHEMISTRY OF DALTON,JOHN COLOR-BLINDNESS	SCIENCE			English	Article							ABSORPTION-SPECTRA; HUMAN RED; MOLECULAR-GENETICS; CONE PIGMENTS; VISION; GREEN; GENES; POLYMORPHISM; BLUE	John Dalton described his own color blindness in 1794. In common with his brother, he confused scarlet with green and pink with blue. Dalton supposed that his vitreous humor was tinted blue, selectively absorbing longer wavelengths. He instructed that his eyes should be examined after his death, but the examination revealed that the humors were perfectly clear. In experiments presented here, DNA extracted from his preserved eye tissue showed that Dalton was a deuteranope, lacking the middlewave photopigment of the retina. This diagnosis is shown to be compatible with the historical record of his phenotype, although it contradicts Thomas Young's belief that Dalton was a protanope.	UNIV LONDON,INST OPHTHALMOL,DEPT VISUAL SCI,LONDON EC1V 9EL,ENGLAND; UNIV CAMBRIDGE,DEPT EXPTL PSYCHOL,CAMBRIDGE CB2 3EB,ENGLAND	University of London; University College London; University of Cambridge	HUNT, DM (corresponding author), UNIV LONDON,INST OPHTHALMOL,DEPT MOLEC GENET,LONDON EC1V 9EL,ENGLAND.		Mollon, John/U-2631-2019; Hunt, David M/K-6024-2012; Mollon, John/C-3520-2009	Mollon, John/0000-0001-8533-033X; Hunt, David M/0000-0002-9264-3948; Mollon, John/0000-0001-8533-033X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASENJO AB, 1994, NEURON, V12, P1131, DOI 10.1016/0896-6273(94)90320-4; BARRETT C, 1904, DIARY LETT MADAME DA; BREWSTER D, 1842, COMMUNICATION; BROCKBANK EM, 1929, J DALTON; DALTON, 1794, COMMUNICATION   0222; DARTNALL HJA, 1983, PROC R SOC SER B-BIO, V220, P115, DOI 10.1098/rspb.1983.0091; DEEB SS, 1992, AM J HUM GENET, V51, P687; DULAI KS, 1994, VISION RES, V34, P2483, DOI 10.1016/0042-6989(94)90233-X; HAGELBERG E, 1991, NATURE, V352, P427, DOI 10.1038/352427a0; HArgrave PA, 1982, PROGR RET RES, V1, P1; Henry William Charles, 1854, MEMOIRS LIFE SCI RES; IBBOTSON RE, 1992, P ROY SOC B-BIOL SCI, V247, P145, DOI 10.1098/rspb.1992.0021; Kohlrausch A, 1923, PFLUG ARCH GES PHYS, V200, P216, DOI 10.1007/BF01723330; LONSDALE H, 1874, WORTHIES CUMBERLAND, V5; MARTYN T, 1799, 38 PLATES INTENDED I; MERBS SL, 1992, SCIENCE, V258, P464, DOI 10.1126/science.1411542; MERBS SL, 1993, PHOTOCHEM PHOTOBIOL, V58, P706, DOI 10.1111/j.1751-1097.1993.tb04956.x; MERBS SL, 1992, NATURE, V356, P433, DOI 10.1038/356433a0; MOLLON JD, 1984, COLOUR VISION DEFICI, V7, P303; MOLLON JD, 1993, DICT NATIONAL BIOGRA; NATHANS J, 1993, AM J HUM GENET, V53, P987; NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NEITZ J, 1990, VISION RES, V30, P621, DOI 10.1016/0042-6989(90)90073-T; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; PREVOST P, 1827, BIBL U SCI B, V35, P320; RUSHTON WAH, 1965, NATURE, V206, P1087, DOI 10.1038/2061087a0; SCHNAPF JL, 1987, NATURE, V325, P439, DOI 10.1038/325439a0; VOIGT J, 1781, MAGAZIN NEUSTE PHY 2, V1, P57; WALLS G L, 1956, J Hist Med Allied Sci, V11, P66; WARTMANN E, 1846, TAYLORS SCI MEM, V4, P156; WILLIAMS AJ, 1992, EMBO J, V11, P2039, DOI 10.1002/j.1460-2075.1992.tb05261.x; WILSON G, 1845, BR Q REV, V1, P157; WINDERICKX J, 1993, HUM MOL GENET, V2, P1413, DOI 10.1093/hmg/2.9.1413; WINDERICKX J, 1992, NATURE, V356, P431, DOI 10.1038/356431a0; WRIGHT WD, 1967, RAYS NOT COLOURED; Wyszecki G., 1982, COLOR SCI, V8; YOUNG T, 1807, COURSE LECTURES NATU; 1798, MEM MANCH LIT PHILOS, V5, P28; 1831, EDINB J SCI, V5, P88	40	42	45	3	17	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 17	1995	267	5200					984	988		10.1126/science.7863342	http://dx.doi.org/10.1126/science.7863342			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG990	7863342				2022-12-28	WOS:A1995QG99000027
J	LIFSON, AR; ALLEN, S; WOLF, W; SERUFILIRA, A; KANTARAMA, G; LINDAN, CP; HUDES, ES; NSENGUMUREMYI, F; TAELMAN, H; BATUNGWANAYO, J				LIFSON, AR; ALLEN, S; WOLF, W; SERUFILIRA, A; KANTARAMA, G; LINDAN, CP; HUDES, ES; NSENGUMUREMYI, F; TAELMAN, H; BATUNGWANAYO, J			CLASSIFICATION OF HIV-INFECTION AND DISEASE IN WOMEN FROM RWANDA - EVALUATION OF THE WORLD-HEALTH-ORGANIZATION HIV STAGING SYSTEM AND RECOMMENDED MODIFICATIONS	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; REPRESENTATIVE SAMPLE; CHILDBEARING WOMEN; SEDIMENTATION-RATE; ORAL CANDIDIASIS; LYMPHOCYTE COUNT; HOMOSEXUAL MEN; AIDS; TUBERCULOSIS; PROGRESSION	Objective: To develop a human immunodeficiency virus (HIV) staging system for sub-Saharan Africa on the basis of an evaluation of the World Health Organization (WHO) system and predictors of mortality. Design: Prospective cohort study with 4 years of follow-up. Setting: Kigali, Rwanda. Patients: 412 HIV-infected women recruited from prenatal and pediatric clinics. Measurements: Clinical signs and symptoms of HIV disease, laboratory assays (including complete blood count and erythrocyte sedimentation rate), and cumulative mortality. Results: The WHO staging system includes a clinical and a laboratory axis. The clinical axis was revised by inclusion of oral candidiasis, chronic oral or genital ulcers, and pulmonary tuberculosis as ''severe'' disease (clinical stage IV); in addition, body mass index was substituted for weight loss in the definition for the wasting syndrome. The 36-month cumulative mortality was 7% for women in modified clinical stage I (''asymptomatic''), 15% for those in stage II, 19% for those in stage III, and 36% for those in stage IV (P < 0.001). The laboratory axis was revised by replacing lymphocyte count with hematocrit and erythrocyte sedimentation rate. The 36-month mortality was 10% for women in modified stage A (''normal'' laboratory results) and 33% for those in stage B (erythrocyte sedimentation rate >65 mm/h or hematocrit <0.38) (P < 0.001). A single staging system combining clinical and laboratory criteria is proposed, with a 36-month mortality of 7% for women in combined stage I, 10% for those in stage II, 29% for those in stage III, and 62% for those in stage IV (P < 0.001). Conclusions: On the basis of this analysis, a staging system relevant for sub-Saharan Africa is proposed that reflects the range of HIV-related outcomes, has strong prognostic significance, includes inexpensive and available laboratory tests, and can be used by both clinicians and researchers.	UNIV CALIF SAN FRANCISCO, CTR AIDS PREVENT STUDIES, SAN FRANCISCO, CA 94105 USA; CENT HOSP, KIGALI, RWANDA; MINIST HLTH, KIGALI, RWANDA	University of California System; University of California San Francisco					NIAID NIH HHS [AI23980] Funding Source: Medline; NIMH NIH HHS [MH42459] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLEN S, 1992, AM REV RESPIR DIS, V146, P1439, DOI 10.1164/ajrccm/146.6.1439; ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; ALLEN S, 1992, JAMA-J AM MED ASSOC, V268, P3338, DOI 10.1001/jama.268.23.3338; ALLEN S, 1991, J INFECT DIS, V164, P67, DOI 10.1093/infdis/164.1.67; [Anonymous], 1993, MMWR Recomm Rep, V42, P1; [Anonymous], 1994, Wkly Epidemiol Rec, V69, P273; [Anonymous], 1990, Wkly Epidemiol Rec, V65, P221; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; AYLWARD RB, 1994, AIDS, V8, P1129, DOI 10.1097/00002030-199408000-00015; BATUNGWANAYO J, 1993, AIDS, V7, P73, DOI 10.1097/00002030-199301000-00011; BATUNGWANAYO J, 1994, AM J RESP CRIT CARE, V149, P1591, DOI 10.1164/ajrccm.149.6.8004318; BLATT SP, 1993, JAMA-J AM MED ASSOC, V269, P622, DOI 10.1001/jama.269.5.622; CAHN P, 1993, AIDS, V7, P711; DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTATIS, P186; FERROLUZZI A, 1992, EUR J CLIN NUTR, V46, P173; HAVERKOS HW, 1985, J INFECT DIS, V152, P1095, DOI 10.1093/infdis/152.5.1095; HOOVER DR, 1993, J ACQ IMMUN DEF SYND, V6, P537; KATZ MH, 1992, AIDS, V6, P95, DOI 10.1097/00002030-199201000-00013; KERLIKOWSKE KM, 1994, AIDS, V8, P963, DOI 10.1097/00002030-199407000-00014; LEDERMAN MM, 1994, J ACQ IMMUN DEF SYND, V7, P727; LEFRERE JJ, 1988, AIDS, V2, P63, DOI 10.1097/00002030-198802000-00013; LIMA LAA, 1993, AIDS, V7, P295, DOI 10.1097/00002030-199302000-00031; LIN RY, 1993, AM J MED SCI, V305, P345, DOI 10.1097/00000441-199306000-00001; LINDAN CP, 1992, ANN INTERN MED, V116, P320, DOI 10.7326/0003-4819-116-4-320; Mann J, 1992, AIDS WORLD, P11; MONTANER JSG, 1992, AIDS, V6, P719, DOI 10.1097/00002030-199207000-00016; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; MUKADI Y, 1993, LANCET, V342, P143, DOI 10.1016/0140-6736(93)91346-N; MUNOZ A, 1988, J ACQ IMMUN DEF SYND, V1, P396; OKWERA A, 1994, LANCET, V344, P1323, DOI 10.1016/S0140-6736(94)90693-9; RABENECK L, 1993, J GEN INTERN MED, V8, P5, DOI 10.1007/BF02600284; REDFIELD RR, 1986, NEW ENGL J MED, V314, P131, DOI 10.1056/NEJM198601093140232; REVICKI DA, 1986, AM J PUBLIC HEALTH, V76, P992, DOI 10.2105/AJPH.76.8.992; ROYCE RA, 1991, AIDS, V5, P355, DOI 10.1097/00002030-199104000-00001; SCHECHTER M, 1994, J ACQ IMMUN DEF SYND, V7, P163; SCHWARTLANDER B, 1993, AIDS, V7, P813, DOI 10.1097/00002030-199306000-00009; SELWYN PA, 1992, NEW ENGL J MED, V327, P1697, DOI 10.1056/NEJM199212103272401; VANDENBRUAENE M, 1993, AIDS, V7, P1613, DOI 10.1097/00002030-199312000-00011; VANDEPERRE P, 1988, SCAND J INFECT DIS, V20, P277, DOI 10.3109/00365548809032451; WALLIS RS, 1993, J INFECT DIS, V167, P43, DOI 10.1093/infdis/167.1.43; WENIGER BG, 1992, J ACQ IMMUN DEF SYND, V5, P1212; 1986, MMWR-MORBID MORTAL W, V35, P334	42	58	59	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1995	122	4					262	270		10.7326/0003-4819-122-4-199502150-00004	http://dx.doi.org/10.7326/0003-4819-122-4-199502150-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF769	7825761				2022-12-28	WOS:A1995QF76900004
J	KENNEDY, BK; AUSTRIACO, NR; ZHANG, JS; GUARENTE, L				KENNEDY, BK; AUSTRIACO, NR; ZHANG, JS; GUARENTE, L			MUTATION IN THE SILENCING GENE SIR4 CAN DELAY AGING IN SACCHAROMYCES-CEREVISIAE	CELL			English	Article							HEAT-SHOCK PROTEINS; SACCHAROMYCES-CEREVISIAE; LIFE-SPAN; CAENORHABDITIS-ELEGANS; TRANSCRIPTIONAL STATES; INDEFINITE DIVISION; CELLULAR SENESCENCE; HUMAN FIBROBLASTS; YEAST TELOMERES; DNA-SEQUENCES	Aging in S. cerevisiae is exemplified by the fixed number of cell divisions that mother cells undergo (termed their life span). We have exploited a correlation between life span and stress resistance to identify mutations in four genes that extend life span. One of these, SIR4, encodes a component of the silencing apparatus at HM loci and telomeres. The sir4-42 mutation extends life span by more than 30% and is semidominant. Our findings suggest that sir4-42 extends life span by preventing recruitment of the SIR proteins to HM loci and telomeres, thereby increasing their concentration at other chromosomal regions. Maintaining silencing at these other regions may be critical in preventing aging. Consistent with this view, expression of only the carboxyl terminus of SIR4 interferes with silencing at HM loci and telomeres, which also extends life span. Possible links among silencing, telomere maintenance, and aging in other organisms are discussed.			KENNEDY, BK (corresponding author), MIT, DEPT BIOL, 77 MASSACHUSETTS AVE, CAMBRIDGE, MA 02139 USA.			Austriaco, Nicanor/0000-0003-1854-8181; Kennedy, Brian/0000-0002-5754-1874	NIA NIH HHS [AG11119] Funding Source: Medline; NIGMS NIH HHS [GM3054] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG011119, R37AG011119] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; ARKING R, 1991, DEV GENET, V12, P362, DOI 10.1002/dvg.1020120505; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; CHAN CSM, 1983, CELL, V33, P563, DOI 10.1016/0092-8674(83)90437-3; COMPANY M, 1988, MOL CELL BIOL, V8, P2545, DOI 10.1128/MCB.8.6.2545; DMELLO NP, 1991, J BACTERIOL, V173, P6709, DOI 10.1128/jb.173.21.6709-6713.1991; EGILMEZ NK, 1989, J BACTERIOL, V171, P37, DOI 10.1128/jb.171.1.37-42.1989; EGILMEZ NK, 1990, J GERONTOL, V45, pB9, DOI 10.1093/geronj/45.1.B9; Finch CE, 1990, LONGEVITY SENESCENCE; FRIEDMAN DB, 1988, J GERONTOL, V43, pB102, DOI 10.1093/geronj/43.4.B102; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; Gompertz B., 1825, PHILOS T R SOC LOND, V115, P513, DOI [10.1098/rstl.1825.0026, DOI 10.1098/RSTL.1825.0026]; GOTO M, 1992, NATURE, V355, P735, DOI 10.1038/355735a0; GROVE GL, 1977, J CELL PHYSIOL, V90, P415, DOI 10.1002/jcp.1040900305; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARTWELL LH, 1980, J CELL BIOL, V85, P811, DOI 10.1083/jcb.85.3.811; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; HERSKOWITZ I, 1991, P132; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; JAZWINSKI SM, 1989, EXP GERONTOL, V24, P423; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; JOHNSON TE, 1990, SCIENCE, V249, P908, DOI 10.1126/science.2392681; JOHNSTON JR, 1966, ANTON VAN LEE J M S, V32, P94, DOI 10.1007/BF02097448; KENNEDY BK, 1994, IN PRESS J CELL BIOL; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; KURTZ S, 1986, SCIENCE, V231, P1154, DOI 10.1126/science.3511530; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LUCKINBILL LS, 1984, EVOLUTION, V38, P996, DOI 10.1111/j.1558-5646.1984.tb00369.x; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; MAHONEY DJ, 1989, MOL CELL BIOL, V9, P4621, DOI 10.1128/MCB.9.11.4621; MARSHALL M, 1987, MOL CELL BIOL, V7, P4441, DOI 10.1128/MCB.7.12.4441; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; MULLER I, 1980, MECH AGEING DEV, V12, P47, DOI 10.1016/0047-6374(80)90028-7; MULLER I, 1971, ARCH MIKROBIOL, V77, P20, DOI 10.1007/BF00407985; MULLER I, 1985, A VAN LEEUW J MICROB, V51, P1, DOI 10.1007/BF00444223; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; NORWOOD TH, 1974, P NATL ACAD SCI USA, V71, P2231, DOI 10.1073/pnas.71.6.2231; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; PLESSET J, 1982, BIOCHEM BIOPH RES CO, V108, P1340, DOI 10.1016/0006-291X(82)92147-7; POHLEY HJ, 1987, MECH AGEING DEV, V38, P231, DOI 10.1016/0047-6374(87)90092-3; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; RILES L, 1993, GENETICS, V134, P81; RINE J, 1987, GENETICS, V116, P9; ROSE MR, 1981, GENETICS, V97, P172; SALK D, 1981, CYTOGENET CELL GENET, V30, P108, DOI 10.1159/000131597; SCHWARTZ HS, 1993, CANCER GENET CYTOGEN, V71, P132, DOI 10.1016/0165-4608(93)90018-H; Sherman F, 1979, METHODS YEAST GENETI; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; SIKORSKI RS, 1989, GENETICS, V122, P19; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; VANVOORHIES WA, 1992, NATURE, V360, P456, DOI 10.1038/360456a0; VAZIRI H, 1993, AM J HUM GENET, V52, P661; VOWELS JJ, 1992, GENETICS, V130, P105; WALMSLEY RM, 1984, NATURE, V310, P157, DOI 10.1038/310157a0; WAREHAM KA, 1987, NATURE, V327, P725, DOI 10.1038/327725a0; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WILSON VL, 1983, SCIENCE, V220, P1054	65	382	392	1	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	1995	80	3					485	496		10.1016/0092-8674(95)90499-9	http://dx.doi.org/10.1016/0092-8674(95)90499-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859289	Bronze			2022-12-28	WOS:A1995QG47000015
J	PUSCH, M; LUDEWIG, U; REHFELDT, A; JENTSCH, TJ				PUSCH, M; LUDEWIG, U; REHFELDT, A; JENTSCH, TJ			GATING OF THE VOLTAGE-DEPENDENT CHLORIDE CHANNEL CIC-O BY THE PERMEANT ANION	NATURE			English	Article							POTASSIUM CHANNEL; SODIUM-CHANNEL; AMINO-ACIDS; K+ CHANNELS; INACTIVATION; ACTIVATION; EXPRESSION; MUTATIONS; CLONING	CHLORIDE channels of the ClC family are important for the control of membrane excitability(1-3), cell volume regulation(4,5), and possibly transepithelial transport lacking the typical voltage-sensor found in cation gating of ClC channels is clearly voltage-dependent. For the prototype Torpedo channel ClC-0 (refs 11-15) we now show that channel opening is strongly facilitated by external chloride. Other less permeable anions can substitute for chloride with less efficiency. ClC-0 conductance shows an anomalous mole fraction behaviour with Cl-/NO3- mixtures, suggesting a multi-ion pore. Gating shows a similar anomalous behaviour, tightly linking permeation to gating. Eliminating a positive charge at the cytoplasmic end of domain D12 changes kinetics, concentration dependence and halide selectivity of gating, and alters pore properties such as ion selectivity, single-channel conductance and rectification. Taken together, our results strongly suggest that in these channels voltage-dependent gating is conferred by the permeating ion itself, acting as the gating charge.	UNIV HAMBURG,CTR MOLEC NEUROBIOL,D-20246 HAMBURG,GERMANY	University of Hamburg				Pusch, Michael/0000-0002-8644-8847; Jentsch, Thomas/0000-0002-3509-2553				BAUER CK, 1991, P NATL ACAD SCI USA, V88, P11052, DOI 10.1073/pnas.88.24.11052; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; HAGIWARA S, 1979, J GEN PHYSIOL, V67, P621; HANKE W, 1983, J GEN PHYSIOL, V82, P25, DOI 10.1085/jgp.82.1.25; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEINEMANN SH, 1992, METHOD ENZYMOL, V207, P131; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; Hille B., 1992, IONIC CHANNELS EXCIT; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KIEFERLE S, 1994, P NATL ACAD SCI USA, V91, P6943, DOI 10.1073/pnas.91.15.6943; KIRSCH GE, 1992, NEURON, V8, P499, DOI 10.1016/0896-6273(92)90278-L; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PUSCH M, 1994, BIOPHYS J, V86, P149; RICHARD EA, 1990, SCIENCE, V247, P1208, DOI 10.1126/science.2156338; SIGWORTH FJ, 1994, Q REV BIOPHYS, V27, P1, DOI 10.1017/S0033583500002894; STEINMEYER K, 1994, EMBO J, V13, P737, DOI 10.1002/j.1460-2075.1994.tb06315.x; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; UCHIDA S, 1993, J BIOL CHEM, V268, P3821; WHITE MM, 1979, J BIOL CHEM, V254, P161; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	29	301	305	2	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 9	1995	373	6514					527	531		10.1038/373527a0	http://dx.doi.org/10.1038/373527a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7845466				2022-12-28	WOS:A1995QF72400061
J	SAVVA, R; MCAULEYHECHT, K; BROWN, T; PEARL, L				SAVVA, R; MCAULEYHECHT, K; BROWN, T; PEARL, L			THE STRUCTURAL BASIS OF SPECIFIC BASE-EXCISION REPAIR BY URACIL-DNA GLYCOSYLASE	NATURE			English	Article							SIMPLEX VIRUS TYPE-1; ESCHERICHIA-COLI; N-GLYCOSIDASE; SEQUENCE; PURIFICATION; NUCLEAR; ENZYME; ERRORS; CELLS; GENE	The 1.75-Angstrom crystal structure of the uracil-DNA glycosylase from herpes simplex virus type-L reveals a new fold, distantly related to dinucleotide-binding proteins. Complexes with a trideoxynucleotide, and with uracil, define the DNA-binding site and allow a detailed understanding of the exquisitely specific recognition of uracil in DNA. The overall structure suggests binding models for elongated single- and double-stranded DNA substrates. Conserved residues close to the uracil-binding site suggest a catalytic mechanism for hydrolytic base excision.	UCL, DEPT BIOCHEM & MOLEC BIOL, STRUCT BIOCHEM SECT, LONDON WC1E 6BT, ENGLAND; UNIV EDINBURGH, DEPT CHEM, EDINBURGH EH9 3JJ, MIDLOTHIAN, SCOTLAND	University of London; University College London; University of Edinburgh			Brown, Tom/B-8521-2008; Brown, Tom/C-9185-2016	Brown, Tom/0000-0003-4683-1873; Pearl, Laurence/0000-0002-6910-1809; McAuley, Katherine/0000-0002-9545-072X; Brown, Tom/0000-0002-6538-3036; Savva, Renos/0000-0001-7375-2340	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENNETT SE, 1994, J BIOL CHEM, V269, P21870; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CARADONNA S, 1987, J VIROL, V61, P3040, DOI 10.1128/JVI.61.10.3040-3047.1987; CONE R, 1977, BIOCHEMISTRY-US, V16, P3194, DOI 10.1021/bi00633a024; CROSBY B, 1981, NUCLEIC ACIDS RES, V9, P5797, DOI 10.1093/nar/9.21.5797; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DIANOV G, 1994, NUCLEIC ACIDS RES, V22, P993, DOI 10.1093/nar/22.6.993; EFTEDAL I, 1993, NUCLEIC ACIDS RES, V21, P2095, DOI 10.1093/nar/21.9.2095; FLORES TP, 1994, PROTEIN ENG, V7, P31, DOI 10.1093/protein/7.1.31; FOCHER F, 1992, CHROMOSOMA, V102, pS67, DOI 10.1007/BF02451788; HATAHET Z, 1994, J BIOL CHEM, V269, P18814; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABOEV OK, 1985, J BACTERIOL, V164, P421, DOI 10.1128/JB.164.1.421-424.1985; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KROKAN H, 1981, NUCLEIC ACIDS RES, V9, P2599, DOI 10.1093/nar/9.11.2599; KROKAN HE, 1993, JUL P NY AC SCI ABST; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1994, MOSFLM USERS GUIDE; LINDAHL T, 1977, J BIOL CHEM, V252, P3286; LINDAHL T, 1974, P NATL ACAD SCI USA, V71, P3649, DOI 10.1073/pnas.71.9.3649; Lindahl T, 1979, Prog Nucleic Acid Res Mol Biol, V22, P135; MAURO DJ, 1993, MOL PHARMACOL, V43, P854; MOSBAUGH DW, 1988, REV BIOCHEM TOXICOL, V9, P69; MULLANEY J, 1989, J GEN VIROL, V70, P449, DOI 10.1099/0022-1317-70-2-449; OLSEN LC, 1989, EMBO J, V8, P3121, DOI 10.1002/j.1460-2075.1989.tb08464.x; OTWINOWSKI Z, 1991, ISOMORPHOUS REPLACEM, P23; PFLUGRATH JW, 1992, MUNICH AREA DETECTOR; PYLES RB, 1994, J VIROL, V68, P4963, DOI 10.1128/JVI.68.8.4963-4972.1994; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; SAVVA R, 1993, J MOL BIOL, V234, P910, DOI 10.1006/jmbi.1993.1642; SLUPPHAUG G, 1993, NUCLEIC ACIDS RES, V21, P2579, DOI 10.1093/nar/21.11.2579; UPTON C, 1993, P NATL ACAD SCI USA, V90, P4518, DOI 10.1073/pnas.90.10.4518; VERRI A, 1990, NUCLEIC ACIDS RES, V18, P5775, DOI 10.1093/nar/18.19.5775	38	355	398	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	1995	373	6514					487	493		10.1038/373487a0	http://dx.doi.org/10.1038/373487a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7845459				2022-12-28	WOS:A1995QF72400048
J	PEREDNIA, DA; ALLEN, A				PEREDNIA, DA; ALLEN, A			TELEMEDICINE TECHNOLOGY AND CLINICAL-APPLICATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE; HEALTH; SYSTEM; TELEPATHOLOGY; TELERADIOLOGY; SERVICES; PATHOLOGY; RECORD; VIDEO		OREGON HLTH SCI UNIV, DEPT DERMATOL, PORTLAND, OR USA; UNIV KANSAS, MED CTR, CTR CANC, KANSAS CITY, KS USA	Oregon Health & Science University; University of Kansas; University of Kansas Medical Center	PEREDNIA, DA (corresponding author), OREGON HLTH SCI UNIV, CTR BIOMED INFORMAT COMMUN, 3181 SW SAM JACKSON PK RD, PORTLAND, OR 97201 USA.				NATIONAL CANCER INSTITUTE [K07CA058969] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [N01LM043516] Funding Source: NIH RePORTER; NCI NIH HHS [1-K07-CA58969-02] Funding Source: Medline; NLM NIH HHS [N01-LM-4-3516] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Allen A, 1992, Kans Med, V93, P323; ALLEN A, IN PRESS AM J PUBLIC; BALL CJ, 1993, BRIT J CLIN PSYCHOL, V32, P303, DOI 10.1111/j.2044-8260.1993.tb01060.x; BARNETT GO, 1993, ANN INTERN MED, V119, P1046, DOI 10.7326/0003-4819-119-10-199311150-00014; Bashshur R., 1975, TELEMEDICINE EXPLORA; BATNITZKY S, 1990, RADIOLOGY, V177, P11, DOI 10.1148/radiology.177.1.2204957; BRAUER GW, 1992, MED PROG TECHNOL, V18, P151; COMPTON MV, 1982, ANN EMERG MED, V11, P324, DOI 10.1016/S0196-0644(82)80136-4; CONRATH DW, 1975, BEHAV SCI, V20, P296, DOI 10.1002/bs.3830200503; CUNNINGHAM N, 1978, JAMA-J AM MED ASSOC, V240, P2749, DOI 10.1001/jama.240.25.2749; DONGIER M, 1986, CAN J PSYCHIAT, V31, P32, DOI 10.1177/070674378603100107; DOYLE MD, 1994, 2 S ENT MED MEETS VI; DUNN E, 1980, CAN MED ASSOC J, V122, P484; ELJAMEL MS, 1992, BRIT J NEUROSURG, V6, P559, DOI 10.3109/02688699209002373; Farman A G, 1993, Dent Clin North Am, V37, P669; FAVROT M, 1993, PEDIATRIE, V48, P151; FINTOR L, 1993, J NATL CANCER I, V85, P183, DOI 10.1093/jnci/85.3.183; FRISSE ME, 1992, ACAD MED, V67, P441, DOI 10.1097/00001888-199207000-00005; FUCHS M, 1979, MED CARE, V17, P59, DOI 10.1097/00005650-197901000-00005; GAGNER M, 1994, LANCET, V343, P596, DOI 10.1016/S0140-6736(94)91546-6; Garden J W, 1991, J Ky Med Assoc, V89, P115; Goldberg M, 1989, J Digit Imaging, V2, P92; GRIGSBY J, 1993, 1 CTR HLTH POL RES R; HARZER W, 1989, J STOMATOL DDR, V39, P181; HOUSE AM, 1981, CAN MED ASSOC J, V124, P801; HUBBLE JP, 1993, MOVEMENT DISORD, V8, P380, DOI 10.1002/mds.870080326; HUNTER I, 1994, 2 S ENT MED MEETS VI; JOHNSON J, 1992, HOSPITALS, V66, P26; JUTRAS A, 1959, AMER J ROENTGENOL RA, V82, P1099; KELLY PJ, 1994, 2 S ENT MED MEETS VI; KHALFAN HK, 1992, WORLD HEALTH FORUM, V13, P84; Kohn D, 1994, Health Manag Technol, V15, P26; LIPSEDGE M, 1990, EUR J CANCER, V26, P1025, DOI 10.1016/0277-5379(90)90042-R; Mattioli L, 1992, Kans Med, V93, P347; MICHAELS E, 1989, CAN MED ASSOC J, V141, P612; MIGLIAU G, 1987, COR VASA, V29, P388; MURPHY RLH, 1973, CHEST, V63, P578, DOI 10.1378/chest.63.4.578; MURPHY RLH, 1974, AM J PUBLIC HEALTH, V64, P113, DOI 10.2105/AJPH.64.2.113; MURPHY RLH, 1972, ARCH DERMATOL, V105, P833, DOI 10.1001/archderm.105.6.833; NORDRUM I, 1991, HUM PATHOL, V22, P514, DOI 10.1016/0046-8177(91)90226-F; OBERHOLZER M, 1993, HUM PATHOL, V24, P1078, DOI 10.1016/0046-8177(93)90187-L; Ohashi N, 1982, J Hum Ergol (Tokyo), V11 Suppl, P527; Park, 1974, INTRO TELEMEDICINE I; PATEL U H, 1992, Journal of Medical Systems, V16, P101, DOI 10.1007/BF00996591; PEREDNIA DA, 1991, J AM ACAD DERMATOL, V25, P89, DOI 10.1016/0190-9622(91)70178-5; PEREDNIA DA, IN PRESS J MED SYST; PEREDNIA DA, IN PRESS B MED LIBR; RADWIN HM, 1986, UROL CLIN N AM, V13, P59; RAYMAN RB, 1992, AVIAT SPACE ENVIR MD, V63, P135; SHULTZ EK, 1992, ANN NY ACAD SCI, V670, P141, DOI 10.1111/j.1749-6632.1992.tb26084.x; SIMON IB, 1993, SURG ENDOSC-ULTRAS, V7, P462, DOI 10.1007/BF00311745; SLOVIS TL, 1991, PEDIATR RADIOL, V21, P333, DOI 10.1007/BF02011480; SOBCZYK WL, 1993, J PEDIATR-US, V122, pS84, DOI 10.1016/S0022-3476(09)90049-X; SOUTHARD TE, 1986, MIL MED, V151, P413, DOI 10.1093/milmed/151.8.413; SPERLING G, 1980, SCIENCE, V210, P797, DOI 10.1126/science.7433998; STAUB JF, 1977, AORN J, V25, P1169; TEMPLETON AW, 1991, AM J ROENTGENOL, V157, P1331, DOI 10.2214/ajr.157.6.1950884; TILLEY PL, 1986, J SEMIN VET MED SURG, V1, P1762; VALENSISE AH, 1991, J CLIN EXP OBSTET GY, V18, P191; WEINSTEIN RS, 1987, ARCH PATHOL LAB MED, V111, P646; WHITTEN P, 1994, 1994 P ANN HLTH CAR, P137; WITTSON CL, 1961, MENT HOSPITALS, V12, P22; WITTSON CL, 1961, USE 2 WAY TELEVISION; 1994, TELEMEDICINE TODAY, V2, P12; 1993, ATI; 1994, TELEMEDICINE, V2, P5; 1994, TELEMEDICINE, V2; 1994, BUSINESS WEEK   1003, P117; 1994, TELEMEDICINE TODAY, V2, P24; 1994, TELEMEDICINE, V2, P1; 1994, GLOBAL TELEMEDICINE, V1, P14; 1994, TELEMEDICINE TODAY, V2, P21; 1993, TELEMEDICINE TOD FAL	73	478	502	3	85	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	1995	273	6					483	488		10.1001/jama.273.6.483	http://dx.doi.org/10.1001/jama.273.6.483			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QE498	7837367				2022-12-28	WOS:A1995QE49800032
J	LYONS, JR				LYONS, JR			METAL-IONS IN THE ATMOSPHERE OF NEPTUNE	SCIENCE			English	Article							PLANETARY-ATMOSPHERES; INTERSTELLAR CLOUDS; POSITIVE-IONS; VOYAGER-2; LAYERS; IONOSPHERE; MESOSPHERE; CATIONS	Microwave propagation experiments performed with Voyager 2 at Neptune revealed sharp layers of electrons in Neptune's lower ionosphere with densities of similar to 10(4) per cubic centimeter. These layers are reminiscent of the sporadic-E layers in the Earth's ionosphere, and when taken together with data from the other giant planets, these data confirm the importance of the magnetic field in layer formation, A photochemical model that incorporates species produced by meteoroid ablation predicts that singly ionized magnesium is the most likely metal to be found in the layers, although laboratory data on the kinetics of metallic atoms and ions in a reducing environment are lacking. The metal chemistry discussed here is directly relevant to the abundant metals observed at the impact site of the G fragment of comet Shoemaker Levy 9 on Jupiter.			LYONS, JR (corresponding author), CALTECH, DIV GEOL & PLANETARY SCI, PASADENA, CA 91125 USA.							ALLEN M, 1981, J GEOPHYS RES-SPACE, V86, P3617, DOI 10.1029/JA086iA05p03617; ANICICH VG, 1993, J PHYS CHEM REF DATA, V22, P1469, DOI 10.1063/1.555940; ATREYE SK, 1986, ATMOSPHERES IONOSPHE; BARTH CA, 1992, MARS, P1054; BAUSCHLICHER CW, 1990, INT REV PHYS CHEM, V9, P149, DOI 10.1080/01442359009353245; BRACE LH, 1991, SPACE SCI REV, V55, P81, DOI 10.1007/BF00177136; BRISTOW WA, 1991, GEOPHYS RES LETT, V18, P404, DOI 10.1029/90GL02588; CANOSA A, 1992, J CHEM PHYS, V97, P1028, DOI 10.1063/1.463282; CHEN RH, 1981, J GEOPHYS RES-SPACE, V86, P7792, DOI 10.1029/JA086iA09p07792; CONNERNEY JEP, 1984, NATURE, V312, P136, DOI 10.1038/312136a0; CONNERNEY JEP, 1991, J GEOPHYS RES-PLANET, V96, P19023, DOI 10.1029/91JA01165; FERGUSON EE, 1968, J GEOPHYS RES, V73, P6215, DOI 10.1029/JA073i019p06215; FJELDBO G, 1965, J GEOPHYS RES, V70, P3701, DOI 10.1029/JZ070i015p03701; HAIL GA, IN PRESS INT J IMAGI; HUNTEN DM, 1980, J ATMOS SCI, V37, P1342, DOI 10.1175/1520-0469(1980)037<1342:SADPOM>2.0.CO;2; HUNTRESS WT, 1977, ASTROPHYS J SUPPL S, V33, P495, DOI 10.1086/190439; JESSBERGER EK, 1991, ASTROPHYS SPACE SC L, V167, P1075, DOI 10.1017/S0252921100012823; Kelley M. C., 1989, EARTHS IONOSPHERE, V43; KIM YH, 1991, GEOPHYS RES LETT, V18, P123, DOI 10.1029/90GL02587; KIRKWOOD S, 1989, J ATMOS TERR PHYS, V51, P259, DOI 10.1016/0021-9169(89)90077-9; LINDAL GF, 1992, ASTRON J, V103, P967, DOI 10.1086/116119; LINDAL GF, 1987, J GEOPHYS RES, V92, P14987, DOI 10.1029/JA092iA13p14987; Lyons J. L., UNPUB; MAJEED T, 1991, PLANET SPACE SCI, V39, P1715, DOI 10.1016/0032-0633(91)90031-5; MOSES JI, 1992, ICARUS, V99, P368, DOI 10.1016/0019-1035(92)90153-X; NOLL K, 1994, 6038 INT ASTR UN CIR; OHANESSIAN G, 1990, ACCOUNTS CHEM RES, V23, P386, DOI 10.1021/ar00179a007; ROMANL PN, 1994, ICARUS, V106, P442; ROQUES F, 1994, ASTRON ASTROPHYS, V288, P985; SICARDY B, 1992, B AM ASTRON SOC, V24, P963; STONE EC, 1989, SCIENCE, V246, P1417, DOI 10.1126/science.246.4936.1417; STROBEL DF, 1991, URANUS, P65; TYLER GL, 1989, SCIENCE, V246, P1466, DOI 10.1126/science.246.4936.1466; WEAST RC, 1986, CRC HDB CHEM PHYSICS, pF167; WHITEHEAD J, 1961, J ATMOS TERR PHYS, V20, P49, DOI 10.1016/0021-9169(61)90097-6	35	46	46	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 3	1995	267	5198					648	651						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839139				2022-12-28	WOS:A1995QE73300029
J	BECK, KD; VALVERDE, J; ALEXI, T; POULSEN, K; MOFFAT, B; VANDLEN, RA; ROSENTHAL, A; HEFTI, F				BECK, KD; VALVERDE, J; ALEXI, T; POULSEN, K; MOFFAT, B; VANDLEN, RA; ROSENTHAL, A; HEFTI, F			MESENCEPHALIC DOPAMINERGIC-NEURONS PROTECTED BY GDNF FROM AXOTOMY-INDUCED DEGENERATION IN THE ADULT BRAIN	NATURE			English	Article							NEUROTROPHIC FACTOR PREVENTS; FIBROBLAST GROWTH-FACTOR; MOTOR NEURONS; IN-VIVO; FIMBRIAL TRANSECTIONS; MOTONEURONS; SURVIVAL; SYSTEM; DEATH; PROMOTES	GLIAL-CELL-LINE-DERIVED neurotrophic factor (GDNF) promotes survival of embryonic dopaminergic neurons in culture(1), and its expression pattern suggests a role as a transient target-derived trophic factor for dopaminergic neurons of the substantia nigra(2-4). These neurons participate in the control of motor activity, emotional status and cognition(5), and they degenerate in Parkinson's disease for unknown reasons. To test whether GDNF has a trophic effect on dopaminergic neurons in the adult brain, we used a rat model in which these neurons are induced to degenerate by transecting their axons within the medial forebrain bundle(6). We report here that axotomy resulted in loss of half the tyrosine hydroxylase-expressing neurons in the substantia nigra. This loss was largely prevented by repeated injections of GDNF adjacent to the substantia nigra. Our findings suggest that GDNF or related molecules may be useful for the treatment of Parkinson's disease.	GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080; UNIV SO CALIF,ETHEL PERCY ANDRUS GERONTOL CTR,LOS ANGELES,CA 90089	Roche Holding; Genentech; Roche Holding; Genentech; University of Southern California	BECK, KD (corresponding author), GENENTECH INC,DEPT NEUROSCI,S SAN FRANCISCO,CA 94080, USA.							ALEXI T, 1993, NEUROSCIENCE, V55, P903, DOI 10.1016/0306-4522(93)90307-2; ARAUJO DM, 1993, J NEUROCHEM, V61, P899, DOI 10.1111/j.1471-4159.1993.tb03601.x; Bjorklund A, 1984, HDB CHEM NEUROANATOM, P55; CLATTERBUCK RE, 1993, P NATL ACAD SCI USA, V90, P2222, DOI 10.1073/pnas.90.6.2222; CUMMINGS BJ, 1992, BRAIN RES, V591, P271, DOI 10.1016/0006-8993(92)91707-L; GROTHE C, 1992, J NEUROSCI RES, V32, P317, DOI 10.1002/jnr.490320304; HAGG T, 1993, P NATL ACAD SCI USA, V90, P6315, DOI 10.1073/pnas.90.13.6315; HAGG T, 1994, SOC NEUR ABS, V20; HEFTI F, 1986, J NEUROSCI, V6, P2155; HUGHES RA, 1993, J NEUROSCI RES, V36, P663, DOI 10.1002/jnr.490360607; HYNES MA, 1994, J NEUROSCI RES, V37, P144, DOI 10.1002/jnr.490370118; KNUSEL B, 1990, J NEUROSCI, V10, P558; KNUSEL B, 1992, J NEUROSCI, V12, P4391; KOLIATSOS VE, 1993, NEURON, V10, P359, DOI 10.1016/0896-6273(93)90326-M; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; OTTO D, 1990, J NEUROSCI, V10, P1912; POULSEN KT, 1994, NEURON, V13, P1245, DOI 10.1016/0896-6273(94)90062-0; SCHAAR DG, 1993, EXP NEUROL, V124, P368, DOI 10.1006/exnr.1993.1207; SCHMIDTKASTNER R, 1994, MOL BRAIN RES, V26, P325, DOI 10.1016/0169-328X(94)90106-6; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; STROMBERG I, 1993, EXP NEUROL, V124, P401, DOI 10.1006/exnr.1993.1214; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YAN Q, 1993, J NEUROBIOL, V24, P1555, DOI 10.1002/neu.480241202	24	612	654	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					339	341		10.1038/373339a0	http://dx.doi.org/10.1038/373339a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830767				2022-12-28	WOS:A1995QD40400058
J	NADEAU, JH; GRANT, PL; MANKALA, S; REINER, AH; RICHARDSON, JE; EPPIG, JT				NADEAU, JH; GRANT, PL; MANKALA, S; REINER, AH; RICHARDSON, JE; EPPIG, JT			A ROSETTA-STONE OF MAMMALIAN GENETICS	NATURE			English	Article							MAP	Mammalian Comparative Database provides genetic maps of mammalian species. Comparative maps are valuable aids for predicting linkages, developing animal models and studying genome organization and evolution.	LINNEAN TECHNOL,ENFIELD,NH 03748		NADEAU, JH (corresponding author), JACKSON LAB,BAR HARBOR,ME 04609, USA.							[Anonymous], 1994, MOUSE GENOME DATABAS; ARCHIBALD AL, 1994, CURR OPIN GENET DEV, V4, P395, DOI 10.1016/0959-437X(94)90027-2; BROAD TE, 1994, BRIT VET J, V150, P237, DOI 10.1016/S0007-1935(05)80004-1; Castle WE, 1924, GENETICS, V9, P1; CHAPMAN VM, 1993, MAMM GENOME, V4, pS1; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; EPPIG JT, IN PRESS MAMMAL GENO; HETZEL J, 1993, NAT GENET, V4, P327, DOI 10.1038/ng0893-327; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; NADEAU JH, 1992, MAMM GENOME, V3, P480, DOI 10.1007/BF00778825; OBRIEN SJ, 1993, GENETIC MAPS	11	25	25	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					363	365		10.1038/373363a0	http://dx.doi.org/10.1038/373363a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830773				2022-12-28	WOS:A1995QD40400066
J	SIVENIUS, J; RIEKKINEN, PJ; LAAKSO, M				SIVENIUS, J; RIEKKINEN, PJ; LAAKSO, M			ANTIPLATELET TREATMENT IN ELDERLY PEOPLE WITH TRANSIENT ISCHEMIC ATTACKS OR ISCHEMIC STROKES	BMJ-BRITISH MEDICAL JOURNAL			English	Article									UNIV KUOPIO, DEPT MED, SF-70210 KUOPIO, FINLAND	University of Eastern Finland	SIVENIUS, J (corresponding author), KUOPIO UNIV HOSP, DEPT NEUROL, POB 1627, SF-70211 KUOPIO, FINLAND.							ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1987, Lancet, V2, P1351; SIVENIUS J, 1993, ACTA NEUROL SCAND, V87, P111	3	18	18	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 7	1995	310	6971					25	26		10.1136/bmj.310.6971.25	http://dx.doi.org/10.1136/bmj.310.6971.25			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB060	7827549	Green Published			2022-12-28	WOS:A1995QB06000024
J	ANDERSON, EL; DECKER, MD; ENGLUND, JA; EDWARDS, KM; ANDERSON, P; MCINNES, P; BELSHE, RB				ANDERSON, EL; DECKER, MD; ENGLUND, JA; EDWARDS, KM; ANDERSON, P; MCINNES, P; BELSHE, RB			INTERCHANGEABILITY OF CONJUGATED HAEMOPHILUS-INFLUENZAE TYPE-B VACCINES IN INFANTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OUTER-MEMBRANE PROTEIN; 6-MONTH-OLD INFANTS; POLYSACCHARIDE; IMMUNOGENICITY; DISEASE; 2-MONTH-OLD; CHILDREN; TRIAL	Objective.-To evaluate the safety and immunogenicity of two Haemophilus influenzae type b (Hib) conjugate vaccines when administered in serial combination, These vaccines consisted of Hib capsular polysaccharide polyribosyl-ribitol phosphate (PRP) conjugated to the meningococcal outer membrane protein (OMP) complex (PRP-OMP) and H influenzae oligosaccharide conjugated to a mutant toxin (CRM197) isolated from Corynebacterium diphtheriae (HbOC). Design.-Randomized, double-blind, clinical trial evaluating five Hib vaccination regimens. Setting.-Vaccine Treatment and Evaluation Units and affiliated private pediatric practices at Saint Louis (Mo) University, Vanderbilt University, Nashville, Tenn, and Baylor College of Medicine, Houston, Tex. Patients.-A total of 497 healthy 2-month-old infants scheduled to receive routine immunization. Intervention.-Participants received either PRP-OMP or HbOC given as recommended by the manufacturer, PRP-OMP at 2 and 6 months, HbOC at 2 months, then PRP-OMP at 4 and 6 months, or PRP-OMP at 2 months and then HbOC at 4 and 6 months. Unconjugated PRP was given at 15 months to evaluate priming. Results.-Geometric mean antibody concentrations differed significantly among the groups following the second and third immunizations of the primary series and following booster immunization with unconjugated PRP. On each occasion, the groups receiving serial combinations of PRP-OMP and HbOC achieved mean antibody concentrations that equalled or exceeded those of the groups receiving a single product. Adverse reactions did not vary by group. Conclusions.-The studied sequential combinations of Hib vaccines were safe and at least as immunogenic as either vaccine alone.	ST LOUIS UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; VANDERBILT UNIV,SCH MED,DEPT PREVENT MED,NASHVILLE,TN 37212; VANDERBILT UNIV,SCH MED,DEPT MED,NASHVILLE,TN 37212; VANDERBILT UNIV,SCH MED,DEPT PEDIAT,NASHVILLE,TN 37212; BAYLOR COLL MED,DEPT MICROBIOL & IMMUNOL,HOUSTON,TX 77030; UNIV ROCHESTER,SCH MED & DENT,DEPT PEDIAT,ROCHESTER,NY 14642; NIAID,DIV MICROBIOL & INFECT DIS,RESP DIS BRANCH,BETHESDA,MD 20892	Saint Louis University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Baylor College of Medicine; University of Rochester; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	ANDERSON, EL (corresponding author), ST LOUIS UNIV,HLTH SCI CTR,SCH MED,DEPT MED,DIV INFECT DIS,3635 VISTA AVE,FDT-8N,POB 15250,ST LOUIS,MO 63110, USA.			Decker, Michael/0000-0003-1008-7472	NIAID NIH HHS [N01-AI-72629, N01-AI-05051, N01-AI-02645] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI005051, N01AI072629, N01AI002645] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221; ANDERSON P, 1985, J PEDIATR-US, V107, P346, DOI 10.1016/S0022-3476(85)80504-7; BROADHURST LE, 1993, JAMA-J AM MED ASSOC, V269, P227, DOI 10.1001/jama.269.2.227; DECKER MD, 1992, J PEDIATR-US, V120, P184, DOI 10.1016/S0022-3476(05)80424-X; EINHORN MS, 1986, LANCET, V2, P299; ESKOLA J, 1990, NEW ENGL J MED, V323, P1381, DOI 10.1056/NEJM199011153232004; GRANOFF DM, 1993, VACCINE, V11, pS46, DOI 10.1016/0264-410X(93)90160-Y; GRANOFF DM, 1993, J INFECT DIS, V168, P663, DOI 10.1093/infdis/168.3.663; GRANOFF DM, 1992, J PEDIATR-US, V121, P187, DOI 10.1016/S0022-3476(05)81186-2; GREENBERG DP, 1993, 33RD INT C ANT AG CH; HARRISON LH, 1994, J PEDIATR-US, V125, P571, DOI 10.1016/S0022-3476(94)70009-5; LENOIR AA, 1987, PEDIATRICS, V80, P283; MADORE DV, 1990, PEDIATRICS, V85, P331; SANTOSHAM M, 1991, NEW ENGL J MED, V324, P1767, DOI 10.1056/NEJM199106203242503; WEINBERG GA, 1987, J PEDIATR-US, V111, P22, DOI 10.1016/S0022-3476(87)80336-0; WEINBERG GA, 1988, J PEDIATR-US, V113, P621, DOI 10.1016/S0022-3476(88)80369-X; WHO, 1991, WHO TECHN REP SER, V814, P15; 1994, MMWR-MORBID MORTAL W, V43, P1; 1991, PEDIATRICS, V88, P169; 1991, MMWR-MORBID MORTAL W, V40, P1	20	30	35	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	1995	273	11					849	853		10.1001/jama.273.11.849	http://dx.doi.org/10.1001/jama.273.11.849			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL402	7869554				2022-12-28	WOS:A1995QL40200021
J	CALLAHAN, CM; HENDRIE, HC; TIERNEY, WM				CALLAHAN, CM; HENDRIE, HC; TIERNEY, WM			DOCUMENTATION AND EVALUATION OF COGNITIVE IMPAIRMENT IN ELDERLY PRIMARY-CARE PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article						COGNITION DISORDERS; DEMENTIA; AGE FACTORS; CEREBROVASCULAR DISORDERS; NUTRITIONAL STATUS	REVERSIBLE DEMENTIA; ALZHEIMERS-DISEASE; OLDER PERSONS; OUTPATIENTS; PREVALENCE; MORTALITY; RISK; POPULATION; QUESTIONNAIRE; MALNUTRITION	Objective: To describe the prevalence of cognitive impairment among elderly primary care patients and to compare diagnostic evaluations and use of health services among patients with and those without cognitive impairment. Design: Prospective cohort study. Setting: Academic primary care group practice. Patients: 3954 patients aged 60 years and older who completed the Short Portable Mental Status Questionnaire during routine office visits. Measurements: Demographics and comorbid illness at baseline, diagnostic evaluations for cognitive impairment, use of standard and preventive health services, use of psychoactive drugs, and death in the year after the screening date. Results: The prevalence of cognitive impairment among all patients aged 60 years and older at baseline was 15.7%; 10.5% had mild impairment and 5.2% had moderate to severe impairment. Patients with moderate to severe impairment were significantly older than patients with no impairment (76.2 years and 67.4 years, respectively), were more likely to be black (85.8% and 61.3%), had fewer years of education (7.3 years and 9.2 years), and were more likely to have cerebrovascular disease (20.4% and 6.3%) and evidence of undernutrition (30.6% and 16.9%). Dementia was recorded as a diagnosis for less than 25% of patients with moderate to severe cognitive impairment, but patients with documented impairment were more likely to have been evaluated for reversible causes. In the year after screening, patients with moderate to severe impairment were more likely than those with no impairment both to be hospitalized (29.1% and 16.5%) and to visit the emergency department (55.8% and 38.5%) but had fewer outpatient visits (6.0 and 7.6) and greater mortality (8.2% and 2.8%). Conclusions: Cognitive impairment is associated with increased use of health services and increased mortality. Patients with undocumented cognitive impairment were significantly less likely to be evaluated for reversible causes. Research is needed to determine if better documentation of cognitive impairment would improve not only diagnostic evaluations but also patient management, counseling, and outcomes.	INDIANA UNIV, SCH MED, INDIANAPOLIS, IN USA	Indiana University System; Indiana University-Purdue University Indianapolis	CALLAHAN, CM (corresponding author), RICHARD L ROUDEBUSH VET ADM MED CTR, REGENSTRIEF INST HLTH CARE, RG5, 1001 W 10TH ST, INDIANAPOLIS, IN 46202 USA.				AHRQ HHS [HS07676, HS07632] Funding Source: Medline; NIA NIH HHS [K08 AG00538-01] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007632] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADOLFSSON R, 1981, ACTA PSYCHIAT SCAND, V63, P225, DOI 10.1111/j.1600-0447.1981.tb00670.x; APPLEGATE WB, 1990, NEW ENGL J MED, V322, P1207; ARONSON MK, 1991, ARCH INTERN MED, V151, P989, DOI 10.1001/archinte.1991.00400050129024; BARRETTCONNOR E, 1993, JAMA-J AM MED ASSOC, V269, P2637, DOI 10.1001/jama.269.20.2637; BARRY PP, 1988, ARCH INTERN MED, V148, P1914, DOI 10.1001/archinte.148.9.1914; BERNSTEIN MJ, 1987, JAMA-J AM MED ASSOC, V258, P3411; BREITNER JCS, 1994, NEUROLOGY, V44, P227, DOI 10.1212/WNL.44.2.227; CASSEL CK, 1981, ANN INTERN MED, V94, P802, DOI 10.7326/0003-4819-94-6-802; CLARFIELD AM, 1988, ANN INTERN MED, V109, P476, DOI 10.7326/0003-4819-109-6-476; CONSTANS T, 1992, J AM GERIATR SOC, V40, P263, DOI 10.1111/j.1532-5415.1992.tb02080.x; CUMMINGS J, 1980, JAMA-J AM MED ASSOC, V243, P2434, DOI 10.1001/jama.243.23.2434; ERKINJUNTTI T, 1986, ARCH INTERN MED, V146, P1923, DOI 10.1001/archinte.146.10.1923; ERNST RL, 1994, AM J PUBLIC HEALTH, V84, P1261, DOI 10.2105/AJPH.84.8.1261; FARLOW M, 1992, JAMA-J AM MED ASSOC, V268, P2523, DOI 10.1001/jama.268.18.2523; FOLSTEIN MF, 1991, J GERONTOL, V46, pM132, DOI 10.1093/geronj/46.4.M132; FORETTE B, 1989, LANCET, V1, P868; FOX JH, 1975, J GERONTOL, V30, P557, DOI 10.1093/geronj/30.5.557; GALLO JJ, 1988, HDB GERIATRIC ASSESS, P24; George L, 1991, PSYCHIAT DISORDERS A, P291; GLOSSER G, 1985, J AM GERIATR SOC, V33, P383, DOI 10.1111/j.1532-5415.1985.tb07147.x; GOODWIN JS, 1983, JAMA-J AM MED ASSOC, V249, P2917, DOI 10.1001/jama.249.21.2917; HENDERSON VW, 1994, ARCH NEUROL-CHICAGO, V51, P896, DOI 10.1001/archneur.1994.00540210068014; HEYMAN A, 1991, ARCH NEUROL-CHICAGO, V48, P594, DOI 10.1001/archneur.1991.00530180046016; KATZMAN R, 1993, NEUROLOGY, V43, P13, DOI 10.1212/WNL.43.1_Part_1.13; KOKMEN E, 1989, NEUROLOGY, V39, P773, DOI 10.1212/WNL.39.6.773; KRAMER M, 1985, J AM GERIATR SOC, V33, P236, DOI 10.1111/j.1532-5415.1985.tb07110.x; KRONMAL RA, 1993, ARCH INTERN MED, V153, P1065, DOI 10.1001/archinte.153.9.1065; LACHS MS, 1990, ANN INTERN MED, V112, P699, DOI 10.7326/0003-4819-112-9-699; LARSON EB, 1986, ARCH INTERN MED, V146, P1917, DOI 10.1001/archinte.146.10.1917; LARSON EB, 1984, ANN INTERN MED, V100, P417, DOI 10.7326/0003-4819-100-3-417; LARSON EB, 1985, J GERONTOL, V40, P536, DOI 10.1093/geronj/40.5.536; MARTIN DC, 1987, ARCH INTERN MED, V147, P77, DOI 10.1001/archinte.147.1.77; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; MCDONALD CJ, 1992, M D COMPUT, V9, P206; MEYER JS, 1986, JAMA-J AM MED ASSOC, V256, P2203, DOI 10.1001/jama.256.16.2203; MORLEY JE, 1991, J AM GERIATR SOC, V39, P1139, DOI 10.1111/j.1532-5415.1991.tb02884.x; OCONNOR DW, 1991, BRIT MED J, V302, P871, DOI 10.1136/bmj.302.6781.871; OVERMAN W, 1988, AM J PSYCHIAT, V145, P1495; PAYKEL ES, 1994, ARCH GEN PSYCHIAT, V51, P325; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RAMSDELL JW, 1990, J GEN INTERN MED, V5, P55, DOI 10.1007/BF02602310; RICE DP, 1993, HEALTH AFFAIR, V12, P164, DOI 10.1377/hlthaff.12.2.164; ROBINSON BE, 1991, GERIATRIC REV SYLLAB; ROBINSON D, 1994, J AM GERIATR SOC, V42, P919, DOI 10.1111/j.1532-5415.1994.tb06580.x; RUBENSTEIN L, 1988, J AM GERIATR SOC, V36, P578; SIU AL, 1991, ANN INTERN MED, V115, P122, DOI 10.7326/0003-4819-115-2-122; SOLOMON D, 1988, J AM GERIATR SOC, V36, P342; SOX HC, 1994, NEW ENGL J MED, V330, P1589, DOI 10.1056/NEJM199406023302208; STERN Y, 1994, JAMA-J AM MED ASSOC, V271, P1004, DOI 10.1001/jama.271.13.1004; SULLIVAN DH, 1991, AM J CLIN NUTR, V53, P599, DOI 10.1093/ajcn/53.3.599; SWAN GE, 1992, ARCH NEUROL-CHICAGO, V49, P476, DOI 10.1001/archneur.1992.00530290058012; TIERNEY WM, 1991, MED CARE, V29, pJS57; Torian L, 1992, Int Psychogeriatr, V4, P231, DOI 10.1017/S1041610292001066; WALSH JS, 1990, ANN INTERN MED, V113, P429, DOI 10.7326/0003-4819-113-6-429; WHITE H, 1990, J GEN INTERN MED, V5, P438, DOI 10.1007/BF02599435; WILLIAMS ME, 1986, J AM GERIATR SOC, V34, P37, DOI 10.1111/j.1532-5415.1986.tb06337.x; 1980, JAMA-J AM MED ASSOC, V244, P259	58	396	400	1	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1995	122	6					422	429		10.7326/0003-4819-122-6-199503150-00004	http://dx.doi.org/10.7326/0003-4819-122-6-199503150-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QM266	7856990				2022-12-28	WOS:A1995QM26600004
J	SKEGG, DCG; NOONAN, EA; PAUL, C; SPEARS, GFS; MEIRIK, O; THOMAS, DB				SKEGG, DCG; NOONAN, EA; PAUL, C; SPEARS, GFS; MEIRIK, O; THOMAS, DB			DEPOT MEDROXYPROGESTERONE ACETATE AND BREAST-CANCER - A POOLED ANALYSIS OF THE WORLD-HEALTH-ORGANIZATION AND NEW-ZEALAND STUDIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ORAL-CONTRACEPTIVE USE; MENSTRUAL-CYCLE; RISK; HORMONE; GROWTH; AGE	Background.-Although depot medroxyprogesterone acetate (DMPA) (Depo-Provera) has now been approved for marketing as a contraceptive in the United States, there are still unresolved issues about the relation between DMPA and risk of breast cancer. The two substantial case-control studies of this association yielded similar but inconclusive results. Because their designs were compatible, these studies were pooled to obtain more adequate data for analysis. Design.-Pooled results from two case-control studies. Setting.-New Zealand (entire country), Thailand (three centers), Mexico (one center), and Kenya (one center). Participants.-A total of 1768 women with breast cancer and 13905 controls, most of whom were younger than 55 years. Main Outcome Measure.-Relative risk (RR) of breast cancer in women who had used DMPA. Results.-The RR of breast cancer for women who had ever used DMPA was 1.1 (95% confidence interval [CI], 0.97 to 1.4). There was no increase in risk with increasing duration of use of DMPA, but RR estimates were higher in certain subgroups of women. Further analyses suggested that recent (or current) use was the key factor, with women who had started using DMPA within the previous 5 years estimated to have an RR of 2.0 (95% CI, 1.5 to 2.8). Conclusions.-The increased risk of breast cancer observed in recent (or current) users could be due to enhanced detection of breast tumors in women using DMPA or to acceleration of the growth of preexisting tumors. Women who had used DMPA more than 5 years previously had no increase in risk of breast cancer, regardless of their duration of use.	FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA; WHO, SPECIAL PROGRAMME RES DEV & RES TRAINING HUMA, CH-1211 GENEVA, SWITZERLAND	Fred Hutchinson Cancer Center; World Health Organization	SKEGG, DCG (corresponding author), UNIV OTAGO, SCH MED, DEPT PREVENT & SOCIAL MED, POB 913, DUNEDIN, NEW ZEALAND.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD052901] Funding Source: NIH RePORTER; NICHD NIH HHS [N01-HD-52901] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON TJ, 1989, HUM PATHOL, V20, P1139, DOI 10.1016/S0046-8177(89)80003-6; BRAUNSBERG H, 1986, CANCER LETT, V30, P213, DOI 10.1016/0304-3835(86)90091-1; BRESLOW NE, 1980, IARC SCI PUBLICATION, V82; BRUZZI P, 1988, BRIT MED J, V297, P1096, DOI 10.1136/bmj.297.6656.1096; CHILVERS C, 1994, CONTRACEPTION, V49, P211, DOI 10.1016/0010-7824(94)90039-6; DALING JR, 1994, JNCI-J NATL CANCER I, V86, P1584, DOI 10.1093/jnci/86.21.1584; ELELTREBY MF, 1989, SAFETY REQUIREMENTS, P179; GRAY RH, 1989, BRIT MED J, V299, P1099, DOI 10.1136/bmj.299.6707.1099-b; JORDAN A, 1994, CONTRACEPTION, V49, P189, DOI 10.1016/0010-7824(94)90037-X; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; KING RJB, 1991, CONTRACEPTION, V43, P527, DOI 10.1016/0010-7824(91)90002-W; LAMBE M, 1994, NEW ENGL J MED, V331, P5, DOI 10.1056/NEJM199407073310102; LAVECCHIA C, 1990, ORAL CONTRACEPTIVES, P245; LEE NC, 1987, J NATL CANCER I, V79, P1247; LINDEFORSHARRIS BM, 1991, AM J EPIDEMIOL, V134, P1003, DOI 10.1093/oxfordjournals.aje.a116173; LONGACRE TA, 1986, AM J SURG PATHOL, V10, P382, DOI 10.1097/00000478-198606000-00003; MALONE KE, 1993, EPIDEMIOL REV, V15, P80, DOI 10.1093/oxfordjournals.epirev.a036119; Michal F, 1989, SAFETY REQUIREMENTS; PAUL C, 1989, BRIT MED J, V299, P759, DOI 10.1136/bmj.299.6702.759; POTTEN CS, 1988, BRIT J CANCER, V58, P163, DOI 10.1038/bjc.1988.185; ROMIEU I, 1989, JNCI-J NATL CANCER I, V81, P1313, DOI 10.1093/jnci/81.17.1313; Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718; SKEGG DCG, 1988, AM J EPIDEMIOL, V127, P205, DOI 10.1093/oxfordjournals.aje.a114796; SPELLACY WN, 1972, FERTIL STERIL, V23, P239; THOMAS DB, 1991, LANCET, V338, P833; WEISZ J, 1984, REPORT PUBLIC BOARDI; WINGO PA, 1991, OBSTET GYNECOL, V78, P161; 1982, B WORLD HEALTH ORGAN, V60, P199	28	69	70	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	1995	273	10					799	804						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ750	7861575				2022-12-28	WOS:A1995QJ75000032
J	HANSEN, P				HANSEN, P			CRISTINA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	1995	273	9					686	686						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH814	7853608				2022-12-28	WOS:A1995QH81400002
J	LIU, B; ALBERTS, BM				LIU, B; ALBERTS, BM			HEAD-ON COLLISION BETWEEN A DNA-REPLICATION APPARATUS AND RNA-POLYMERASE TRANSCRIPTION COMPLEX	SCIENCE			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; FORK; TERMINATION; ELONGATION; SEQUENCE; HELICASE; PROTEIN; GENES; CHROMOSOME	An in vitro system reconstituted from purified proteins has been used to examine what happens when the DNA replication apparatus of bacteriophage T4 collides with an Escherichia coli RNA polymerase ternary transcription complex that is poised to move in the direction opposite to that of the moving replication fork. In the absence of a DNA helicase, the replication fork stalls for many minutes after its encounter with the RNA polymerase. However, when the T4 gene 41 DNA helicase is present, the replication fork passes the RNA polymerase after a pause of a few seconds. This brief pause is longer than the pause observed for a codirectional collision between the same two polymerases, suggesting that there is an inherent disadvantage to having replication and transcription directions oriented head to head. As for a codirectional collision, the RNA polymerase remains competent to resume faithful RNA chain elongation after the DNA replication fork passes; most strikingly, the RNA polymerase has switched from its original template strand to use the newly synthesized daughter DNA strand as the template.			LIU, B (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.				NIGMS NIH HHS [GM-24020] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024020, R01GM024020] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1987, PHILOS T R SOC B, V317, P385; BARRY J, 1994, J BIOL CHEM, V269, P33049; BAUTZ EKF, 1976, RNA POLYMERASE, P273; BREWER BJ, 1988, CELL, V53, P679, DOI 10.1016/0092-8674(88)90086-4; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BURLAND V, 1993, GENOMICS, V16, P551, DOI 10.1006/geno.1993.1230; CAMPBELL AM, 1993, CURR OPIN GENET DEV, V3, P837, DOI 10.1016/0959-437X(93)90002-7; CHA TA, 1986, J BIOL CHEM, V261, P7001; CHAMBERL.M, 1973, J BIOL CHEM, V248, P2245; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DARST SA, 1991, NATURE, V340, P730; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; FRENCH S, 1992, SCIENCE, V258, P1362, DOI 10.1126/science.1455232; HERNANDEZ P, 1993, EMBO J, V12, P1475, DOI 10.1002/j.1460-2075.1993.tb05791.x; HIDAKA M, 1992, J BIOL CHEM, V267, P5361; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KOBAYASHI T, 1992, MOL GEN GENET, V233, P355, DOI 10.1007/BF00265431; LEE EH, 1992, J BIOL CHEM, V267, P8778; LINSKENS MH, 1988, MOL CELL BIOL, V8, P492; LIU B, 1994, P NATL ACAD SCI USA, V91, P10660, DOI 10.1073/pnas.91.22.10660; LIU B, 1993, NATURE, V366, P33, DOI 10.1038/366033a0; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; MEDIGUE C, 1990, MOL MICROBIOL, V4, P1443, DOI 10.1111/j.1365-2958.1990.tb02055.x; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; SANDERSON KE, 1988, MICROBIOL REV, V52, P485, DOI 10.1128/MMBR.52.4.485-532.1988; SELICK HE, 1987, DNA REPLICATION RECO, P183; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; ZEIGLER DR, 1990, GENETICS, V125, P703	38	161	163	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1131	1137		10.1126/science.7855590	http://dx.doi.org/10.1126/science.7855590			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855590				2022-12-28	WOS:A1995QJ23700027
J	KARRE, K				KARRE, K			EXPRESS YOURSELF OR DIE - PEPTIDES, MHC MOLECULES, AND NK CELLS	SCIENCE			English	Editorial Material							CLASS-I MOLECULES; COMPLEX; RECEPTORS; GENE				KARRE, K (corresponding author), KAROLINSKA INST, CTR MICROBIOL & TUMOR BIOL, S-17177 STOCKHOLM, SWEDEN.							BEZOUSKA K, 1994, NATURE, V372, P150, DOI 10.1038/372150a0; BIX M, 1991, NATURE, V349, P329, DOI 10.1038/349329a0; CORREA I, 1995, IMMUNITY, V2, P61, DOI 10.1016/1074-7613(95)90079-9; FRANKSSON L, 1993, J EXP MED, V177, P201, DOI 10.1084/jem.177.1.201; KARLHOFER FM, 1994, J IMMUNOL, V153, P2407; LITWIN V, 1994, J EXP MED, V180, P537, DOI 10.1084/jem.180.2.537; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; MALNATI MS, 1995, SCIENCE, V267, P1016, DOI 10.1126/science.7863326; MORETTA A, 1993, J EXP MED, V178, P597, DOI 10.1084/jem.178.2.597; MORETTA A, 1994, J EXP MED, V180, P545, DOI 10.1084/jem.180.2.545; MORETTA L, 1994, ADV IMMUNOL, V55, P341; OLSSON MY, IN PRESS P NATL ACAD; STORKUS WJ, 1991, CRIT REV IMMUNOL, V10, P393; STORKUS WJ, 1989, J IMMUNOL, V143, P3853; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; TRINCHIERI G, 1994, J EXP MED, V180, P417, DOI 10.1084/jem.180.2.417; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145	19	134	138	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 17	1995	267	5200					978	979		10.1126/science.7863341	http://dx.doi.org/10.1126/science.7863341			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG990	7863341				2022-12-28	WOS:A1995QG99000025
J	DICKSON, BJ; DOMINGUEZ, M; VANDERSTRATEN, A; HAFEN, E				DICKSON, BJ; DOMINGUEZ, M; VANDERSTRATEN, A; HAFEN, E			CONTROL OF DROSOPHILA PHOTORECEPTOR CELL FATES BY PHYLLOPOD, A NOVEL NUCLEAR-PROTEIN ACTING DOWNSTREAM OF THE RAF KINASE	CELL			English	Article							RECEPTOR TYROSINE KINASE; SEVENLESS PROTEIN; POSITIONAL INFORMATION; COMPOUND EYE; R7 CELL; EXPRESSION; GENE; ACTIVATION; DISK; RAS1	The phyllopod (phyl) gene regulates the fates of a subset of cells in the developing Drosophila eye; in the absence of phyl function, the R1, R6, and R7 photoreceptors are transformed into additional cone cells, whereas ectopic phyl expression in the cone cell precursors transforms these cells into additional R7 cells. Within this group of cells, phyl expression thus mimics activation of the Raf pathway in its ability to induce photoreceptor rather than cone cell development. Furthermore, the transformation of cone cells into R7 cells in response to Raf activation is both accompanied by and dependent upon ectopic phyl expression. phyl thus represents a possible target gene of the Raf pathway during eye development, controlling the fates of a novel subset of photoreceptors.	UNIV ZURICH,INST ZOOL,CH-8057 ZURICH,SWITZERLAND	University of Zurich			Dickson, Barry/AAE-7632-2019; Dominguez, Maria/G-2171-2014	Dickson, Barry/0000-0003-0715-892X; Dominguez, Maria/0000-0002-3329-7862				BASLER K, 1989, EMBO J, V8, P2381, DOI 10.1002/j.1460-2075.1989.tb08367.x; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BLOCHLINGER K, 1993, DEVELOPMENT, V117, P441; BOHMANN D, 1994, CELL, V78, P973, DOI 10.1016/0092-8674(94)90273-9; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; Cagan Ross Leigh, 1992, P189; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CHANG HC, 1995, CELL, V80, P463, DOI 10.1016/0092-8674(95)90497-2; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEILER R, 1992, J NEUROSCI, V12, P3862; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HIGASHIJIMA SI, 1992, GENE DEV, V6, P50, DOI 10.1101/gad.6.1.50; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; MEINICK MB, 1993, DEVELOPMENT, V118, P127; MLODZIK M, 1992, MECH DEVELOP, V37, P37, DOI 10.1016/0925-4773(92)90013-A; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; NILSSON DE, 1983, CELL TISSUE RES, V230, P401; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PIROTTA V, 1988, VECTORS SURVEY MOL C, P438; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; Wolff Tanya, 1993, P1277; XU T, 1993, DEVELOPMENT, V117, P1223; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	41	93	94	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					453	462		10.1016/0092-8674(95)90496-4	http://dx.doi.org/10.1016/0092-8674(95)90496-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859287	Bronze, Green Accepted			2022-12-28	WOS:A1995QG47000012
J	ALTMAN, DG; BLAND, JM				ALTMAN, DG; BLAND, JM			THE NORMAL-DISTRIBUTION	BRITISH MEDICAL JOURNAL			English	Note											ALTMAN, DG (corresponding author), IMPERIAL CANC RES FUND,MED STAT LAB,POB 123,LONDON WC2A 3PX,ENGLAND.							Altman DG., 1991, PRACTICAL STAT MED R, P132; GARDNER MJ, 1989, STATISTICS CONFIDENC, P17; Gardner MJ, 1989, STAT CONFIDENCE, P28	3	179	182	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 4	1995	310	6975					298	298		10.1136/bmj.310.6975.298	http://dx.doi.org/10.1136/bmj.310.6975.298			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF717	7866172	Bronze, Green Published			2022-12-28	WOS:A1995QF71700027
J	DIVECHA, N; IRVINE, RF				DIVECHA, N; IRVINE, RF			PHOSPHOLIPID SIGNALING	CELL			English	Review							PROTEIN-KINASE-C; EPIDERMAL GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; SACCHAROMYCES-CEREVISIAE; SUPEROXIDE GENERATION; CELL-DIFFERENTIATION; HUMAN-PLATELETS; ACTIVATION				DIVECHA, N (corresponding author), BABRAHAM INST, INOSITIDE LAB, CAMBRIDGE CB2 4AJ, ENGLAND.			divecha, nullin/0000-0001-9695-6039				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BANFIC H, 1993, BIOCHEM J, V290, P633, DOI 10.1042/bj2900633; BAULDRY SA, 1991, J BIOL CHEM, V266, P4173; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BREARLEY CA, 1993, BIOCHEM J, V290, P145, DOI 10.1042/bj2900145; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CARTER AN, 1994, BIOCHEM J, V301, P415, DOI 10.1042/bj3010415; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COOK SJ, 1992, BIOCHEM J, V285, P247, DOI 10.1042/bj2850247; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; DESAI NN, 1993, J CELL BIOL, V121, P1385, DOI 10.1083/jcb.121.6.1385; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FUKAMI MH, 1995, IN PRESS EUR J BIOCH; GIESELMANN R, 1992, FEBS LETT, V298, P149, DOI 10.1016/0014-5793(92)80043-G; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; GOSS VL, 1994, J BIOL CHEM, V269, P19074; GRAZIANI A, 1992, BIOCHEM J, V284, P39, DOI 10.1042/bj2840039; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JARPE MB, 1994, J BIOL CHEM, V33, P526; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KIM MY, 1991, J BIOL CHEM, V266, P484; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KODAKI T, 1994, EUR J BIOCHEM, V219, P775, DOI 10.1111/j.1432-1033.1994.tb18557.x; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KOVAL M, 1991, BIOCHIM BIOPHYS ACTA, V1082, P113, DOI 10.1016/0005-2760(91)90184-J; KRAMER RM, 1983, J BIOL CHEM, V258, P3806; LAM K, 1994, J BIOL CHEM, V269, P20648; LASSING I, 1988, EXP CELL RES, V174, P1, DOI 10.1016/0014-4827(88)90136-X; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MACHESKY LM, 1990, CELL REGUL, V1, P937, DOI 10.1091/mbc.1.12.937; MCNULTY S, 1992, NEUROSCI LETT, V139, P183, DOI 10.1016/0304-3940(92)90547-K; MUNNIK T, 1994, BIOCHEM J, V298, P269, DOI 10.1042/bj2980269; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; OLIVERA A, 1994, J BIOL CHEM, V269, P17924; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; PETTITT TR, 1994, BIOCHEM J, V298, P655, DOI 10.1042/bj2980655; Piomelli D, 1993, CURR OPIN CELL BIOL, V5, P274, DOI 10.1016/0955-0674(93)90116-8; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; STEPHENS L, 1993, BIOCHEM J, V296, P481, DOI 10.1042/bj2960481; STEPHENS L, 1994, CURR BIOL, V4, P203, DOI 10.1016/S0960-9822(00)00049-X; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS LR, 1990, BIOCHEM J, V265, P435, DOI 10.1042/bj2650435; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; SU Y, 1994, J BIOL CHEM, V269, P16512; SULLIVAN KMC, 1993, CELL, V73, P1411, DOI 10.1016/0092-8674(93)90366-X; SYLVIA V, 1988, CELL, V54, P651, DOI 10.1016/S0092-8674(88)80009-6; VOJTEK A, 1991, CELL, V66, P497, DOI 10.1016/0092-8674(81)90013-1; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; YORK JD, 1994, J BIOL CHEM, V269, P19992; YORK JD, 1994, J BIOL CHEM, V269, P7847; ZHANG J, 1992, J BIOL CHEM, V267, P4686	77	579	600	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	1995	80	2					269	278		10.1016/0092-8674(95)90409-3	http://dx.doi.org/10.1016/0092-8674(95)90409-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7834746	Bronze			2022-12-28	WOS:A1995QD92400009
J	FORGACS, I				FORGACS, I			CLINICAL GASTROENTEROLOGY	BRITISH MEDICAL JOURNAL			English	Article							HELICOBACTER-PYLORI INFECTION; DUODENAL-ULCER; CONTROLLED TRIAL; ACID-SECRETION; CROHNS-DISEASE; ERADICATION; CANCER; ADENOCARCINOMA; METRONIDAZOLE; RECURRENCE				FORGACS, I (corresponding author), UNIV LONDON KINGS COLL HOSP,DEPT GASTROENTEROL,LONDON SE5 9RS,ENGLAND.							ADAMEK RJ, 1994, AM J GASTROENTEROL, V89, P39; ATKIN WS, 1993, LANCET, V341, P736, DOI 10.1016/0140-6736(93)90499-7; AUSTOKER J, 1994, BRIT MED J, V309, P382, DOI 10.1136/bmj.309.6951.382; AXON ATR, 1994, GUT, V35, P587, DOI 10.1136/gut.35.5.587; BAYERDORFFER E, 1994, GASTROENTEROLOGY S2, V106, P370; CAMPIERI M, 1993, DIGEST DIS SCI, V38, P1843, DOI 10.1007/BF01296108; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; ELOMAR E, 1993, GUT, V34, P1060, DOI 10.1136/gut.34.8.1060; FEAGAN BG, 1994, NEW ENGL J MED, V330, P1846, DOI 10.1056/NEJM199406303302602; FORBES GM, 1994, LANCET, V343, P258, DOI 10.1016/S0140-6736(94)91111-8; FRANCIS CY, 1994, LANCET, V344, P39, DOI 10.1016/S0140-6736(94)91055-3; GILLEN CD, 1994, GUT, V35, P1590, DOI 10.1136/gut.35.11.1590; GORARD DA, 1993, GUT, V34, P1198, DOI 10.1136/gut.34.9.1198; GRAHAM DY, 1992, ANN INTERN MED, V116, P705, DOI 10.7326/0003-4819-116-9-705; GREENBERG GR, 1994, NEW ENGL J MED, V331, P836, DOI 10.1056/NEJM199409293311303; HABAL FM, 1993, GASTROENTEROLOGY, V105, P1057, DOI 10.1016/0016-5085(93)90949-D; HAMELIN R, 1994, GASTROENTEROLOGY, V106, P42, DOI 10.1016/S0016-5085(94)94217-X; HAMILTON SR, 1993, GASTROENTEROLOGY, V105, P3, DOI 10.1016/0016-5085(93)90003-U; HANSSON LE, 1993, GASTROENTEROLOGY, V105, P1098, DOI 10.1016/0016-5085(93)90954-B; HENTSCHEL E, 1993, NEW ENGL J MED, V328, P308, DOI 10.1056/NEJM199302043280503; HOSKING SW, 1994, LANCET, V343, P508, DOI 10.1016/S0140-6736(94)91460-5; JARNEROT G, 1994, GUT, V35, P1155, DOI 10.1136/gut.35.9.1155; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; JEN J, 1994, NEW ENGL J MED, V35, P213; KNYRIM K, 1993, NEW ENGL J MED, V329, P1302, DOI 10.1056/NEJM199310283291803; KUIPERS EJ, 1993, SCAND J GASTROENTERO, V28, P433, DOI 10.3109/00365529309098245; LABENZ J, 1993, GUT, V34, P1167, DOI 10.1136/gut.34.9.1167; LABENZ J, 1994, GUT, V35, P19, DOI 10.1136/gut.35.1.19; LICHTIGER S, 1994, NEW ENGL J MED, V330, P1841, DOI 10.1056/NEJM199406303302601; LOGAN RPH, 1994, GUT, V35, P332; MANDEL JS, 1993, NEW ENGL J MED, V328, P1363; MARSHALL BJ, 1994, AM J GASTROENTEROL, V89, pS116; MAULE WF, 1994, NEW ENGL J MED, V330, P183, DOI 10.1056/NEJM199401203300307; MOERTEL CG, 1994, NEW ENGL J MED, V330, P1136; MOSS SF, 1993, GUT, V34, P888, DOI 10.1136/gut.34.7.888; OREILLY S, 1994, BRIT MED J, V308, P1249, DOI 10.1136/bmj.308.6939.1249; PENSTON JG, 1994, ALIMENT PHARM THER, V8, P369; REX DK, 1994, GASTROENTEROLOGY, V106, P593, DOI 10.1016/0016-5085(94)90690-4; RIORDAN AM, 1993, LANCET, V342, P1131, DOI 10.1016/0140-6736(93)92121-9; RUTGEERTS P, 1994, NEW ENGL J MED, V331, P842, DOI 10.1056/NEJM199409293311304; STOLTE M, 1993, LANCET, V342, P568, DOI 10.1016/0140-6736(93)91404-A; SUELING HM, 1993, BMJ-BRIT MED J, V307, P591, DOI 10.1136/bmj.307.6904.591; SWIFT GL, 1994, GUT, V35, P363, DOI 10.1136/gut.35.3.363; TALLEY NJ, 1994, GASTROENTEROLOGY, V106, P1174, DOI 10.1016/0016-5085(94)90007-8; The EUROGAST Study Group, 1993, GUT, V34, P1672; THOMPSON GB, 1993, LANCET, V342, P713, DOI 10.1016/0140-6736(93)91711-T; TYTGAT GNJ, 1994, ALIMENT PHARM THERAP, V8, P359; VANZWET AA, 1993, EUR J GASTROEN HEPAT, V5, P185; WINTER TA, 1993, SCAND J GASTROENTERO, V28, P701, DOI 10.3109/00365529309098276; WITHERSPOON AC, 1993, LANCET, V342, P575; XIANG Z, 1993, LANCET, V341, P90; 1994, JAMA-J AM MED ASSOC, V272, P65; 1993, LANCET, V341, P1359	53	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 14	1995	310	6972					113	116		10.1136/bmj.310.6972.113	http://dx.doi.org/10.1136/bmj.310.6972.113			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC223	7833703	Green Published			2022-12-28	WOS:A1995QC22300031
J	ROSENTHAL, N				ROSENTHAL, N			FINE-STRUCTURE OF A GENE - DNA-SEQUENCING	NEW ENGLAND JOURNAL OF MEDICINE			English	Article														Rosenthal, Nadia/0000-0002-7599-7365				ROSENTHAL N, 1994, NEW ENGL J MED, V331, P315, DOI 10.1056/NEJM199408043310508	1	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 2	1995	332	9					589	591		10.1056/NEJM199503023320908	http://dx.doi.org/10.1056/NEJM199503023320908			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ090	7838194				2022-12-28	WOS:A1995QJ09000008
J	FIROUZI, A; KUMAR, D; BULL, LM; BESIER, T; SIEGER, P; HUO, Q; WALKER, SA; ZASADZINSKI, JA; GLINKA, C; NICOL, J; MARGOLESE, D; STUCKY, GD; CHMELKA, BF				FIROUZI, A; KUMAR, D; BULL, LM; BESIER, T; SIEGER, P; HUO, Q; WALKER, SA; ZASADZINSKI, JA; GLINKA, C; NICOL, J; MARGOLESE, D; STUCKY, GD; CHMELKA, BF			COOPERATIVE ORGANIZATION OF INORGANIC-SURFACTANT AND BIOMIMETIC ASSEMBLIES	SCIENCE			English	Article							SILICATE SOLUTIONS; CETYLTRIMETHYLAMMONIUM BROMIDE; TETRAMETHYLAMMONIUM SILICATE; ORGANIC INTERFACES; MAGNETIC-RESONANCE; COUNTERION BINDING; AQUEOUS-SOLUTIONS; X-RAY; MICELLES; CHLORIDE	A model that makes use of the cooperative organization of inorganic and organic molecular species into three dimensionally structured arrays is generalized for the synthesis of nanocomposite materials. In this model, the properties and structure of a system are determined by dynamic interplay among ion-pair inorganic and organic species, so that different phases can be readily obtained through small variations of controllable synthesis parameters, including mixture composition and temperature. Nucleation, growth, and phase transitions may be directed by the charge density, coordination, and steric requirements of the inorganic and organic species at the interface and not necessarily by a preformed structure. A specific example is presented in which organic molecules in the presence of multiply charged silicate oligomers self-assemble into silicatropic liquid crystals. The organization of these silicate-surfactant mesophases is investigated with and without interfacial silicate condensation to separate the effects of self-assembly from the kinetics of silicate polymerization.	UNIV CALIF SANTA BARBARA,DEPT CHEM ENGN,SANTA BARBARA,CA 93106; UNIV CALIF SANTA BARBARA,MAT RES LAB,SANTA BARBARA,CA 93106; UNIV CALIF SANTA BARBARA,DEPT CHEM,SANTA BARBARA,CA 93106; NIST,GAITHERSBURG,MD 20899	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; National Institute of Standards & Technology (NIST) - USA			Kalra, D/H-6661-2019	Kalra, D/0000-0001-5254-4067	NIGMS NIH HHS [GM 47334] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFREDSSON V, 1994, J CHEM SOC CHEM COMM, P921, DOI 10.1039/c39940000921; ARCHIBALD DD, 1993, NATURE, V364, P430, DOI 10.1038/364430a0; AUVRAY X, 1989, J PHYS CHEM-US, V93, P7458, DOI 10.1021/j100358a040; BACKLUND S, 1982, ACTA CHEM SCAND A, V36, P698, DOI 10.3891/acta.chem.scand.36a-0698; BARAL S, 1993, CHEM MATER, V5, P145, DOI 10.1021/cm00026a001; BECK JS, 1992, J AM CHEM SOC, V114, P10834, DOI 10.1021/ja00053a020; BLACKMORE ES, 1990, LIQ CRYST, V8, P131, DOI 10.1080/02678299008047336; BUNKER BC, 1994, SCIENCE, V264, P48, DOI 10.1126/science.264.5155.48; CHEN CY, 1993, MICROPOROUS MATER, V2, P17, DOI 10.1016/0927-6513(93)80058-3; CHEN CY, 1993, MICROPOROUS MATER, V2, P27, DOI 10.1016/0927-6513(93)80059-4; DAVIS ME, IN PRESS MATER RES S; EKWALL P, 1971, J COLLOID INTERF SCI, V35, P519, DOI 10.1016/0021-9797(71)90210-4; ENGELHARDT G, 1984, J MOL LIQ, V27, P125; Engelhardt G., 1987, HIGH RESOLUTION SOLI; EVANS DF, 1989, WATER SCI REV, V4, P1; FEHR FJ, 1989, J AM CHEM SOC, V111, P1288; FIROUZI A, UNPUB; GAMBOA C, 1989, J PHYS CHEM-US, V93, P5540, DOI 10.1021/j100351a043; GROENEN EJJ, 1986, ZEOLITES, V6, P403, DOI 10.1016/0144-2449(86)90070-9; HARRIS RK, 1982, J MOL STRUCT, V78, P273, DOI 10.1016/0022-2860(82)80013-6; HENDRICKS WM, 1991, J PHYS CHEM-US, V95, P9519, DOI 10.1021/j100176a088; HERRINGTON KL, 1993, J PHYS CHEM-US, V97, P13792, DOI 10.1021/j100153a058; HEYWOOD BR, 1994, ADV MATER, V6, P9, DOI 10.1002/adma.19940060103; HUO QS, 1994, NATURE, V368, P317, DOI 10.1038/368317a0; HUO QS, 1994, CHEM MATER, V6, P1176, DOI 10.1021/cm00044a016; IKEDA S, 1991, COLLOID POLYM SCI, V269, P49, DOI 10.1007/BF00654659; ISRAELACHVILI JN, 1976, J CHEM SOC FARAD T 2, V72, P1525, DOI 10.1039/f29767201525; JACOBSON K, 1975, BIOCHEMISTRY-US, V14, P152, DOI 10.1021/bi00672a026; KALER EW, 1992, J PHYS CHEM-US, V96, P6698, DOI 10.1021/j100195a033; KALER EW, 1989, SCIENCE, V245, P1371, DOI 10.1126/science.2781283; KNIGHT CTG, 1989, ZEOLITES, V9, P448, DOI 10.1016/0144-2449(89)90103-6; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; Kumar D., UNPUB; LANGEVIN D, 1992, ANNU REV PHYS CHEM, V43, P341, DOI 10.1146/annurev.pc.43.100192.002013; LINDEMUTH PM, 1993, J PHYS CHEM-US, V97, P7769, DOI 10.1021/j100131a055; MANN S, 1993, NATURE, V365, P499, DOI 10.1038/365499a0; MANN S, 1993, SCIENCE, V261, P1286, DOI 10.1126/science.261.5126.1286; Mann S., 1989, BIOMINERALIZATION CH; MONNIER A, 1993, SCIENCE, V261, P1299, DOI 10.1126/science.261.5126.1299; MURTHY AK, 1991, J COLLOID INTERF SCI, V145, P598, DOI 10.1016/0021-9797(91)90391-K; OGAWA M, 1994, J AM CHEM SOC, V116, P7941, DOI 10.1021/ja00096a079; OZEKI S, 1981, B CHEM SOC JPN, V54, P552, DOI 10.1246/bcsj.54.552; PAPAHADJOPOULOS D, 1975, BIOCHIM BIOPHYS ACTA, V394, P483, DOI 10.1016/0005-2736(75)90299-0; QUIRION F, 1986, J PHYS CHEM-US, V90, P5435, DOI 10.1021/j100412a108; REISSHUSSON F, 1964, J PHYS CHEM-US, V68, P3504, DOI 10.1021/j100794a011; SEELIG J, 1977, Q REV BIOPHYS, V10, P353, DOI 10.1017/S0033583500002948; STEEL A, 1994, J CHEM SOC CHEM COMM, P1571, DOI 10.1039/c39940001571; STEIN A, UNPUB; STUCKY GD, 1994, MOL CRYST LIQ CRYS A, V240, P187, DOI 10.1080/10587259408029730; SZLEIFER I, 1990, J CHEM PHYS, V92, P6800, DOI 10.1063/1.458267; VERKLEIJ AJ, 1974, BIOCHIM BIOPHYS ACTA, V339, P432, DOI 10.1016/0005-2736(74)90171-0; VONHOEBBEL D, 1982, Z ANORG ALLG CHEM, V494, P31; WARNHEIM T, 1988, J COLLOID INTERF SCI, V125, P627, DOI 10.1016/0021-9797(88)90030-6; WEINER S, 1986, CRC CR REV BIOCH MOL, V20, P365, DOI 10.3109/10409238609081998; WEINER S, 1984, PHILOS T ROY SOC B, V304, P425, DOI 10.1098/rstb.1984.0036; WIEBCKE M, 1992, J CHEM SOC DA, V16, P2451; ZASADZINSKI JAN, 1989, J ELECTRON MICR TECH, V13, P309, DOI 10.1002/jemt.1060130406	57	707	739	6	310	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1138	1143		10.1126/science.7855591	http://dx.doi.org/10.1126/science.7855591			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855591				2022-12-28	WOS:A1995QJ23700028
J	BERLINER, E; YOUNG, EC; ANDERSON, K; MAHTANI, HK; GELLES, J				BERLINER, E; YOUNG, EC; ANDERSON, K; MAHTANI, HK; GELLES, J			FAILURE OF A SINGLE-HEADED KINESIN TO TRACK PARALLEL TO MICROTUBULE PROTOFILAMENTS	NATURE			English	Article							LIGHT-MICROSCOPY; MOVEMENT; MOLECULES; DENSITIES; DOMAINS	KINESIS, a two-headed motor enzyme molecule, hydrolyses ATP to direct organelle transport along microtubules. As it moves along a microtubule, kinesin remains associated with, or (tracks', microtubule protofilaments(1,2). We have prepared truncated kinesin derivatives that contain either two mechanochemical head domains(3) or only a single head. Unlike intact kinesin and the two-headed derivatives, the one-headed enzyme frequently fails to track protofilaments, suggesting that it detaches from microtubules during movement. In this way, the one-headed kinesin derivative is similar to the motor enzyme myosin, which frequently detaches from the actin filament during movement(4). For myosin (which has two heads), the consequence of this detachment is that single molecules do not appear to drive continuous movement along the filament(5). Our observations suggest that the ability of single two-headed kinesin molecules to drive continuous movement(6,7) results from a 'hand-over-hand' mechanism(6-8) in which one head remains bound to the microtubule while the other detaches and moves forwards.	BRANDEIS UNIV, GRAD DEPT BIOCHEM, WALTHAM, MA 02254 USA; BRANDEIS UNIV, BIOPHYS PROGRAM, WALTHAM, MA 02254 USA; BRANDEIS UNIV, CTR COMPLEX SYST, WALTHAM, MA 02254 USA	Brandeis University; Brandeis University; Brandeis University				Young, Edgar C./0000-0002-8453-088X; Gelles, Jeff/0000-0001-7910-3421				BERLINER E, 1994, J BIOL CHEM, V269, P8610; BERLINER E, 1994, J BIOL CHEM, V269, P23382; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; CHRETIEN D, 1991, BIOL CELL, V71, P161, DOI 10.1016/0248-4900(91)90062-R; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; GELLES J, 1989, Journal of Cell Biology, V109, p157A; GELLES J, IN PRESS BIOPHYS J; HACKNEY DD, 1994, J BIOL CHEM, V269, P16508; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUANG TG, 1994, J BIOL CHEM, V269, P16493; Qian H, 1991, BIOPHYS J, V60, P910, DOI 10.1016/S0006-3495(91)82125-7; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; SCHAFER DA, 1991, NATURE, V352, P444, DOI 10.1038/352444a0; SCHNAPP BJ, 1986, METHOD ENZYMOL, V134, P561; SCHNAPP BJ, 1990, P NATL ACAD SCI USA, V87, P10053, DOI 10.1073/pnas.87.24.10053; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4; STEIN LA, 1979, BIOCHEMISTRY-US, V18, P3895, DOI 10.1021/bi00585a009; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; Summers MD, 1987, MANUAL METHODS BACUL; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; YOUNG EC, IN PRESS J BIOL CHEM	28	164	165	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 23	1995	373	6516					718	721		10.1038/373718a0	http://dx.doi.org/10.1038/373718a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854458				2022-12-28	WOS:A1995QH92800060
J	CHIN, CT; SARNO, RC				CHIN, CT; SARNO, RC			CORTICOSTEROID OSTEONECROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											CHIN, CT (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR,BOSTON,MA 02111, USA.								0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 23	1995	332	8					511	511		10.1056/NEJM199502233320806	http://dx.doi.org/10.1056/NEJM199502233320806			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH288	7830733				2022-12-28	WOS:A1995QH28800006
J	KARLSON, P				KARLSON, P			BUTENANDT,ADOLF (1903-1995) - OBITUARY	NATURE			English	Item About an Individual											KARLSON, P (corresponding author), UNIV MARBURG,EMIL MANNKOPFF STR 2,D-35037 MARBURG,GERMANY.								0	2	3	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					660	660		10.1038/373660b0	http://dx.doi.org/10.1038/373660b0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854440	Bronze			2022-12-28	WOS:A1995QH92800031
J	NEITZ, M; NEITZ, J				NEITZ, M; NEITZ, J			NUMBERS AND RATIOS OF VISUAL PIGMENT GENES FOR NORMAL RED-GREEN COLOR-VISION	SCIENCE			English	Article							BEARING AMINO-ACIDS; ABSORPTION-SPECTRA; CONE PIGMENTS; MOLECULAR-GENETICS; PHOTOPIGMENT; POLYMORPHISM	Red-green color vision is based on middle-wavelength- and long-wavelength-sensitive visual pigments encoded by an array of genes on the X chromosome. The numbers and ratios of genes in this cluster were reexamined in men with normal color vision by means of newly refined methods. These methods revealed that many men had more pigment genes on the X chromosome than had previously been suggested and that many had more than one long-wave pigment gene. These discoveries challenge accepted ideas that are the foundation for theories of normal and anomalous color vision.	MED COLL WISCONSIN,DEPT ANAT,MILWAUKEE,WI 53226	Medical College of Wisconsin	NEITZ, M (corresponding author), MED COLL WISCONSIN,DEPT OPHTHALMOL,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53226, USA.			Neitz, Maureen/0000-0002-5404-3343	NEI NIH HHS [EY01931, EY09303, EY09620] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY001931, R01EY009303, R01EY009620] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ASENJO AB, 1994, NEURON, V12, P1131, DOI 10.1016/0896-6273(94)90320-4; CHAN T, 1992, J BIOL CHEM, V267, P9478; MERBS SL, 1992, SCIENCE, V258, P464, DOI 10.1126/science.1411542; MERBS SL, 1993, PHOTOCHEM PHOTOBIOL, V58, P706, DOI 10.1111/j.1751-1097.1993.tb04956.x; MERBS SL, 1992, NATURE, V356, P433, DOI 10.1038/356433a0; NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NEITZ J, 1989, NATURE, V342, P679, DOI 10.1038/342679a0; NEITZ J, 1986, NATURE, V323, P623, DOI 10.1038/323623a0; NEITZ J, 1993, VISION RES, V33, P117, DOI 10.1016/0042-6989(93)90064-4; NEITZ J, 1994, MOL GENETICS INHERIT, pCH9; NEITZ J, 1990, VISION RES, V30, P620; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; VOLLRATH D, 1988, SCIENCE, V240, P1669, DOI 10.1126/science.2837827; WILLIAMS AJ, 1992, EMBO J, V11, P2039, DOI 10.1002/j.1460-2075.1992.tb05261.x; WINDERICKX J, 1993, HUM MOL GENET, V2, P1413, DOI 10.1093/hmg/2.9.1413; WINDERICKX J, 1992, NATURE, V356, P431, DOI 10.1038/356431a0	17	93	97	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 17	1995	267	5200					1013	1016		10.1126/science.7863325	http://dx.doi.org/10.1126/science.7863325			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG990	7863325				2022-12-28	WOS:A1995QG99000035
J	BRADLEY, DC; QIAN, N; ANDERSEN, RA				BRADLEY, DC; QIAN, N; ANDERSEN, RA			INTEGRATION OF MOTION AND STEREOPSIS IN MIDDLE TEMPORAL CORTICAL AREA OF MACAQUES	NATURE			English	Article							VISUAL AREA; FUNCTIONAL-PROPERTIES; NEURONS; MONKEY; DIRECTION; SELECTIVITY; ORIENTATION; SENSITIVITY; PERCEPTION; DISPARITY	THE primate visual system incorporates a highly specialized subsystem for the analysis of motion in the visual field(1-6). A key element of this subsystem is the middle temporal (MT) cortical area, which contains a majority of direction-selective neurons(1-3). MT neurons are also selective for binocular disparity (depth), which is perplexing given that they are not sensitive to motion through depth(7). What is the role of disparity in MT? Our data suggest an important link between disparity and transparent motion detection. Motion signals in different directions tend to inhibit each other within a given MT receptive field(8). This inhibition has an averaging effect which minimizes MT responses to random motion signals created by light intensity changes and other non-motion stimuli (motion noise)9. But, in the absence of disparity cues, inhibition may also occur between surfaces moving in different directions through the same part of the visual field (transparent motion), thus impairing the detection of either surface. Here we show that inhibition in MT occurs mainly between motion signals with similar disparities. Transparent surface movements at different depths are thus represented independently in MT (that is, without inhibiting each other) whereas spurious motion signals from a given surface tend to cancel out. To our knowledge, these results provide the first evidence for a functional integration of motion and disparity in MT.			BRADLEY, DC (corresponding author), CALTECH,DIV BIOL 21676,PASADENA,CA 91125, USA.							ALBRIGHT TD, 1984, J NEUROPHYSIOL, V52, P1106, DOI 10.1152/jn.1984.52.6.1106; ALLMAN JM, 1971, BRAIN RES, V31, P84; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; LINIDSEY DT, 1994, INVEST OPHTH VIS SCI, V35, P1389; LIVINGSTONE MS, 1987, J NEUROSCI, V7, P3416; LOGOTHETIS NK, 1989, SCIENCE, V245, P761, DOI 10.1126/science.2772635; MATHER G, 1983, Q J EXP PSYCHOL-A, V35, P513, DOI 10.1080/14640748308402485; MAUNSELL JHR, 1983, J NEUROPHYSIOL, V49, P1148, DOI 10.1152/jn.1983.49.5.1148; MAUNSELL JHR, 1983, J NEUROPHYSIOL, V49, P1127, DOI 10.1152/jn.1983.49.5.1127; NAKAYAMA K, 1985, VISION RES, V25, P625, DOI 10.1016/0042-6989(85)90171-3; NEWSOME WT, 1989, NATURE, V341, P52, DOI 10.1038/341052a0; QIAN N, 1994, J NEUROSCI, V14, P7367; QIAN N, 1994, J NEUROSCI, V14, P7357; ROY JP, 1992, J NEUROSCI, V12, P2478; SNOWDEN RJ, 1991, J NEUROSCI, V11, P2768; SNOWDEN RJ, 1989, J OPT SOC AM A, V6, P1096, DOI 10.1364/JOSAA.6.001096; STONER GR, 1992, NATURE, V358, P412, DOI 10.1038/358412a0; VANESSEN DC, 1990, COLD SPRING HARB SYM, V55, P679	19	181	182	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					609	611		10.1038/373609a0	http://dx.doi.org/10.1038/373609a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854417				2022-12-28	WOS:A1995QG99700053
J	HERRINTON, LJ; FRIEDMAN, GD				HERRINTON, LJ; FRIEDMAN, GD			SERUM-CHOLESTEROL CONCENTRATION AND RISK OF BRAIN CANCER	BRITISH MEDICAL JOURNAL			English	Article							TUMORS				HERRINTON, LJ (corresponding author), KAISER PERMANENTE MED CTR,DIV RES,3505 BROADWAY AVE,OAKLAND,CA 96411, USA.				NCI NIH HHS [R35 CA49761] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA049761] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		HIATT RA, 1986, J CHRON DIS, V39, P861, DOI 10.1016/0021-9681(86)90034-2; KNEKT P, 1991, BRIT MED J, V302, P90, DOI 10.1136/bmj.302.6768.90; NEUGUT AI, 1989, INT J EPIDEMIOL, V18, P798, DOI 10.1093/ije/18.4.798; SMITH GD, 1989, BMJ-BRIT MED J, V299, P26, DOI 10.1136/bmj.299.6690.26; SMITH GD, 1992, AM J EPIDEMIOL, V135, P259, DOI 10.1093/oxfordjournals.aje.a116279	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 11	1995	310	6976					367	368		10.1136/bmj.310.6976.367	http://dx.doi.org/10.1136/bmj.310.6976.367			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG721	7866214	Green Published			2022-12-28	WOS:A1995QG72100019
J	BRABIN, L; KEMP, J; OBUNGE, OK; IKIMALO, J; DOLLIMORE, N; ODU, NN; HART, CA; BRIGGS, ND				BRABIN, L; KEMP, J; OBUNGE, OK; IKIMALO, J; DOLLIMORE, N; ODU, NN; HART, CA; BRIGGS, ND			REPRODUCTIVE-TRACT INFECTIONS AND ABORTION AMONG ADOLESCENT GIRLS IN RURAL NIGERIA	LANCET			English	Article							FEMALE ADOLESCENTS; SEXUAL-BEHAVIOR; PREVALENCE; POPULATION; COMMUNITY; DISEASES; HEALTH; WOMEN	Few studies from developing countries have investigated reproductive tract infections or other indicators of sexual health among unmarried adolescent girls in rural areas. We have obtained baseline demographic, clinical, and microbiological data on reproductive tract infections and induced abortion in girls in a rural area of southeast Nigeria, in order to assess the need for health care for adolescents. 868 females attended for interview and examination: 458 aged 20 and above and 410 aged 12-19, the latter representing 93.4% of the adolescent population. 43.6% of those <17 and 80.1% aged 17-19 years were sexually active and at least 24.1% had undergone an induced abortion; only 5.3% had ever used in modern contraceptive. Vaginal discharge was reported by 82.4%, though few sought treatment. 94.1% of sexually active adolescents and 97.6% of sexually active women 20 years old or older were gynaecologically examined and screened for reproductive tract infections. Of those aged less than 17, 19.8% had symptomatic candida and 11.1% trichomonas infections. Among those aged 17-19 years, chlamydia was detected in 10.5%, and symptomatic candidosis in 25.6%; this was the group most likely to have any infection (43.8%). 42.1% of sexually active adolescents had experienced either an abortion or a sexually transmitted disease. Syphilis was the only infection for which the incidence clearly increased with age. Health-care services for adolescents in this community are needed and should include sex education, contraceptive provision (especially barrier methods), and access to treatment for reproductive tract infections. Investments in health for this age group will have an effect on subsequent reproductive health.	UNIV PORT HARCOURT,PORT HARCOURT,NIGERIA; COMMISS WOMEN,PORT HARCOURT,NIGERIA; UNIV LIVERPOOL,DEPT MED MICROBIOL & GENITOURINARY MED,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Port Harcourt; University of Liverpool	BRABIN, L (corresponding author), UNIV LIVERPOOL,LIVERPOOL SCH TROP MED,PEMBROKE PL,LIVERPOOL L3 5QA,MERSEYSIDE,ENGLAND.		Harry, Tubonye/A-2107-2012	Harry, Tubonye/0000-0003-3773-5230; Brabin, Loretta/0000-0003-4478-6503				ADETORO O O, 1991, African Journal of Medicine and Medical Sciences, V20, P149; [Anonymous], 1993, WORLD DEV REPORT; Anosike J. C., 1993, Applied Parasitology, V34, P19; ARNO JN, 1994, SEX TRANSM DIS, V21, P47, DOI 10.1097/00007435-199401000-00010; ARYA OP, 1973, B WORLD HEALTH ORGAN, V49, P587; BANG RA, 1989, LANCET, V1, P85; BARKER GK, 1992, STUD FAMILY PLANN, V23, P199, DOI 10.2307/1966728; BLACKWELL AL, 1993, LANCET, V342, P206, DOI 10.1016/0140-6736(93)92299-9; BLYTHE MJ, 1988, J PEDIATR-US, V112, P1000, DOI 10.1016/S0022-3476(88)80236-1; BLYTHE MJ, 1992, J PEDIATR-US, V121, P487, DOI 10.1016/S0022-3476(05)81812-8; CATES W, 1993, SEX TRANSM DIS, V20, P174, DOI 10.1097/00007435-199305000-00011; Feachem RGA, 1992, HLTH ADULTS DEV WORL; KINSMAN OS, 1986, INFECT IMMUN, V53, P498, DOI 10.1128/IAI.53.3.498-504.1986; LAGA M, 1994, SEX TRANSM DIS, V21, pS45; LAGA M, 1993, AIDS, V3, P95; MOSHA F, 1993, GENITOURIN MED, V69, P415; NICHOLS D, 1986, STUD FAMILY PLANN, V17, P100, DOI 10.2307/1967070; OGBONNA C I C, 1991, Angewandte Parasitologie, V32, P198; OH MK, 1993, SEX TRANSM DIS, V20, P45, DOI 10.1097/00007435-199301000-00009; OLALEYE OD, 1993, J INFECT DIS, V167, P710, DOI 10.1093/infdis/167.3.710; OSOBU AO, 1973, W AFR MED J, V22, P23; ROSENBERG MJ, 1993, SEX TRANSM DIS, V20, P41, DOI 10.1097/00007435-199301000-00008; Singh B, 1977, ADV PLANNED PARENTHO, V12, P45; SINGLETON AF, 1980, CLIN PEDIATR, V19, P799, DOI 10.1177/000992288001901204; SOBEL J, 1990, SEXUALLY TRANSMITTED; VUYLSTEKE B, 1993, CLIN INFECT DIS, V17, P82, DOI 10.1093/clinids/17.1.82; WASSERHEIT JN, 1989, STUD FAMILY PLANN, V20, P69, DOI 10.2307/1966461; YOUNIS N, 1993, STUD FAMILY PLANN, V24, P175, DOI 10.2307/2939232; WHOADH931 DIV FAM HL; 1987, BARRIER CONTRACEPTIV; 1991, PREVENTION ORBIDITY; 1990, GUIDELINES TRAINING; 1992, 1990 NIG DEM HLTH SU	33	91	93	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					300	304		10.1016/S0140-6736(95)90281-3	http://dx.doi.org/10.1016/S0140-6736(95)90281-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QE731	7837866				2022-12-28	WOS:A1995QE73100015
J	MCKEIGUE, P				MCKEIGUE, P			TRANS-FATTY-ACIDS AND CORONARY HEART-DISEASE - WEIGHING THE EVIDENCE AGAINST HARDENED FAT	LANCET			English	Editorial Material							ADIPOSE-TISSUE; DIET				MCKEIGUE, P (corresponding author), LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1,ENGLAND.							ARO A, 1995, LANCET, V345, P273, DOI 10.1016/S0140-6736(95)90273-2; ASCHERIO A, 1994, CIRCULATION, V89, P94, DOI 10.1161/01.CIR.89.1.94; Bates CJ, 1991, DESIGN CONCEPTS NUTR, P192; BINGHAM SA, 1991, ANN NUTR METAB, V35, P117, DOI 10.1159/000177635; GIOVANNUCCI E, 1993, AM J EPIDEMIOL, V137, P502, DOI 10.1093/oxfordjournals.aje.a116703; HUNTER DJ, 1992, AM J EPIDEMIOL, V135, P418, DOI 10.1093/oxfordjournals.aje.a116302; KATAN MB, 1986, PROG LIPID RES, V25, P193, DOI 10.1016/0163-7827(86)90039-1; MENSINK RP, 1993, PROG LIPID RES, V32, P111, DOI 10.1016/0163-7827(93)90007-J; ROBERTS TL, 1995, LANCET, V345, P278, DOI 10.1016/S0140-6736(95)90274-0; THOMAS LH, 1981, J EPIDEMIOL COMMUN H, V35, P251, DOI 10.1136/jech.35.4.251; THOMAS LH, 1975, BRIT J PREV SOC MED, V29, P82; WAHLE KWJ, 1993, EUR J CLIN NUTR, V47, P828; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P	13	21	21	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					269	270		10.1016/S0140-6736(95)90269-4	http://dx.doi.org/10.1016/S0140-6736(95)90269-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE731	7837857				2022-12-28	WOS:A1995QE73100003
J	MULHOLLAND, K				MULHOLLAND, K			MEASLES AND PERTUSSIS IN DEVELOPING-COUNTRIES WITH GOOD VACCINE COVERAGE	LANCET			English	Editorial Material							EPIDEMIC; IMMUNITY; CHILDREN; IMMUNIZATION; POLICY; AGE				MULHOLLAND, K (corresponding author), MRC LABS,POB 273,BANJUL,GAMBIA.							ADCOCK LM, 1992, INFECT DIS CLIN N AM, V6, P133; BAKER CJ, 1988, NEW ENGL J MED, V319, P1180, DOI 10.1056/NEJM198811033191802; BASS JW, 1994, PEDIATR INFECT DIS J, V13, P343, DOI 10.1097/00006454-199405000-00002; BLACK FL, 1984, B WORLD HEALTH ORGAN, V62, P315; BLACK FL, 1986, AM J EPIDEMIOL, V124, P442, DOI 10.1093/oxfordjournals.aje.a114415; BOTTIGER M, 1993, SCAND J INFECT DIS, V25, P239, DOI 10.3109/00365549309008490; CARTER H, 1992, BRIT MED J, V304, P637, DOI 10.1136/bmj.304.6827.637; Clements C. John, 1992, World Health Statistics Quarterly, V45, P285; COHEN P, 1946, J PEDIATR-US, V29, P609, DOI 10.1016/S0022-3476(46)80128-8; ENGLUND JA, IN PRESS J INFECT DI; KAMBARAMI RA, 1991, B WORLD HEALTH ORGAN, V69, P213; LAMB WH, 1988, REV INFECT DIS, V10, P457; LINNEMANN CC, 1982, PEDIATRICS, V69, P332; MCLEAN AR, 1995, LANCET, V345, P272, DOI 10.1016/S0140-6736(95)90272-4; PABST HF, 1992, PEDIATR INFECT DIS J, V11, P525, DOI 10.1097/00006454-199207000-00004; PRESTON NW, 1994, LANCET, V344, P491, DOI 10.1016/S0140-6736(94)91894-5; PROVENZANO RW, 1965, NEW ENGL J MED, V273, P959, DOI 10.1056/NEJM196510282731804; REYNOLDS DW, 1972, AM J DIS CHILD, V124, P848, DOI 10.1001/archpedi.1972.02110180050006; SCHOUB BD, 1993, S AFR MED J, V83, P82; TULCHINSKY TH, 1993, B WORLD HEALTH ORGAN, V71, P93; 1994, CVI FORUM, V7, P2; 1992, LANCET, V340, P232	22	37	38	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					305	307		10.1016/S0140-6736(95)90282-1	http://dx.doi.org/10.1016/S0140-6736(95)90282-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE731	7837867				2022-12-28	WOS:A1995QE73100016
J	BLAND, JM; ALTMAN, DG				BLAND, JM; ALTMAN, DG			MULTIPLE SIGNIFICANCE TESTS - THE BONFERRONI METHOD .10.	BRITISH MEDICAL JOURNAL			English	Article							TRIAL		IMPERIAL CANC RES FUND,MED STAT LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	BLAND, JM (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.							LEE KL, 1980, CIRCULATION, V61, P508, DOI 10.1161/01.CIR.61.3.508; NEWNHAM JP, 1993, LANCET, V342, P887, DOI 10.1016/0140-6736(93)91944-H; WILLIAMS EI, 1992, J PUBLIC HEALTH MED, V14, P138	3	2498	2529	2	85	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 21	1995	310	6973					170	170		10.1136/bmj.310.6973.170	http://dx.doi.org/10.1136/bmj.310.6973.170			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD201	7833759	Bronze, Green Published			2022-12-28	WOS:A1995QD20100026
J	GATRAD, AR				GATRAD, AR			MUSLIM CUSTOMS SURROUNDING DEATH, BEREAVEMENT, POSTMORTEM EXAMINATIONS AND ORGAN TRANSPLANTS	BRITISH MEDICAL JOURNAL			English	Article								Muslims are always buried, never cremated. It is a religious requirement that the body be ritually washed and draped before burial, which should be as soon as possible after death. Those carrying out this duty should be immunised against hepatitis B and be aware of the hazards of AIDS. Muslim women never attend burials and it is rare for funeral directors to be involved. Muslim jurists from the Arab world can justify organ transplantation, but those from the Indian subcontinent are against it. They are united in the belief of the sacredness of the human body and thus deplore postmortem examinations.			GATRAD, AR (corresponding author), MANOR HOSP,WALSALL WS2 9PS,W MIDLANDS,ENGLAND.							ALBUKHARI MI, SAHIH ALBUKHARI; ALSIJISTANI, SUNAN ABI DAUD; BLACK J, 1987, BRIT MED J, V295, P538; DARSH S, 1986, ISLAMIC HLTH RULES; EBRAHIM AFM, 1989, SHARIAH ORGAN TRANSP; FAULCONBRIDGE J, 1982, OBSTETRIC PROBLEMS A; MCDERMOTT MY, 1980, MUSLIM GUIDE TEACHER; MUHAMMED AA, FUNERAL REGULATIONS; Rahman F., 1987, HLTH MED ISLAMIC TRA; 1992, 1991 CENSUS; [No title captured]; 1987, DEATH BURIAL	12	75	75	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 20	1994	309	6953					521	523		10.1136/bmj.309.6953.521	http://dx.doi.org/10.1136/bmj.309.6953.521			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD308	7848419	Green Published			2022-12-28	WOS:A1994PD30800027
J	CONLISK, E; SIEGEL, M; LENGERICH, E; MACKENZIE, W; MALEK, S; ERIKSEN, M				CONLISK, E; SIEGEL, M; LENGERICH, E; MACKENZIE, W; MALEK, S; ERIKSEN, M			THE STATUS OF LOCAL SMOKING REGULATIONS IN NORTH-CAROLINA FOLLOWING A STATE PREEMPTION BILL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							RISK	Objective.-To determine the number and protectiveness of local smoking regulations adopted before the implementation of a preemptive statewide smoking control bill. Method.-Review of local smoking control regulations from all 100 counties and 85 municipalities with populations greater than 5000 in North Carolina. Main Outcome Measures.-Adoption of local smoking control regulations before and during the 3-month delay in enactment of the preemptive bill. Protectiveness of regulations was based on restrictions on smoking and requirements for separate ventilation systems at private work sites: none (smoking unrestricted); minimal (smoking restricted to designated areas); partial (smoking restricted to designated areas served by separate ventilation systems); and complete (smoking prohibited). Because some regulations would be phased in gradually over the next 5 years, we evaluated the requirements that will be in effect by January 1, 2000. Results.-Between July 15 and October 15, 1993, the number of local smoking regulations in North Carolina increased from 16 to 105. By the year 2000, 59% of private employees still will not be guaranteed any protection from work site environmental tobacco smoke; 19% will have minimal protection, 22% will have partial protection, and none will have complete protection. Conclusions.-The 3-month delay in preemption created an unnatural time frame for communities to organize, debate, and adopt smoking restrictions. Despite the adoption of 89 new regulations, no private employees will be guaranteed complete protection from work site environmental tobacco smoke by the year 2000; new regulations can no longer be adopted. HB 957 has been a setback for public health in North Carolina.	CTR DIS CONTROL & PREVENT,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,DIV FIELD EPIDEMIOL,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,EPIDEM INTELLIGENCE SERV,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,OFF SMOKING & HLTH,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,OFF SURVEILLANCE & ANAL,ATLANTA,GA 30341	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	CONLISK, E (corresponding author), N CAROLINA DEPT ENVIRONM HLTH & NAT RESOURCES,OFF EPIDEMIOL,DIV ADULT HLTH PROMOT,POB 27687,RALEIGH,NC 27611, USA.			Lengerich, Eugene/0000-0001-9872-1647				JACOBSON PD, 1993, J HEALTH POLIT POLIC, V18, P787; LEFCOE NM, 1983, CHEST, V94, P90; OLSHANSKY SJ, 1982, AM J PUBLIC HEALTH, V72, P737, DOI 10.2105/AJPH.72.7.737; REPACE JL, 1985, ENVIRON INT, V11, P3, DOI 10.1016/0160-4120(85)90098-4; REPACE JL, 1985, NEW YORK STATE J MED, V85, P381; Repace JL, 1994, ST LOUIS U PUB L REV, VXIII, P763; VAUGHAN WM, 1993, J AIR WAST MANAGE AS, V40, P1012; 1991, DHHS PHS9150212 US D; 1991, NIOSH91108 NAT I OCC; 1992, EPA600690006F PUBL; 1986, HLTH CONSEQUENCES IN; 1994, 100 PERCENT SMOKEFRE; 1989, N CAROLINA DEP AGR P, V166; 1994, EMPLOYMENT WAGES N C; 1993, NIH933532 US DEP HLT	15	16	16	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	1995	273	10					805	807		10.1001/jama.273.10.805	http://dx.doi.org/10.1001/jama.273.10.805			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ750	7861576	Green Submitted			2022-12-28	WOS:A1995QJ75000033
J	BUSSIERE, DE; BASTIA, D; WHITE, SW				BUSSIERE, DE; BASTIA, D; WHITE, SW			CRYSTAL-STRUCTURE OF THE REPLICATION TERMINATOR PROTEIN FROM BACILLUS-SUBTILIS AT 2.6-ANGSTROM	CELL			English	Article							BACILLUS-SUBTILIS; ESCHERICHIA-COLI; CHROMOSOME-REPLICATION; NUCLEOTIDE-SEQUENCE; LAMBDA-REPRESSOR; DNA; BINDING; OPERATOR; INVITRO; FORK	The crystal structure of the replication terminator protein (RTP) of B. subtilis has been determined at 2.6 Angstrom resolution. As previously suggested by both biochemical and biophysical studies, the molecule exists as a symmetric dimer and is in the alpha+beta protein-folding class. The protein has several uncommon features, including an antiparallel coiled-coil, which serves as the dimerization domain, and both an alpha-helix and a beta-ribbon suitably positioned to interact with the major and minor grooves of B-DNA. A site has been identified on the surface of RTP that is biochemically and positionally suitable for interaction with the replication-specific helicase. Other features of the structure are consistent with the polar contrahelicase mechanism of the protein. A model of the interaction between RTP and its cognate DNA is presented.	DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,CELL & MOLEC BIOL PROGRAM,DURHAM,NC 27710	Duke University; Duke University			White, Stephen W/N-8164-2018		NIGMS NIH HHS [GM49264] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASTIA D, 1981, P NATL ACAD SCI-BIOL, V78, P2095, DOI 10.1073/pnas.78.4.2095; BEDROSIAN CL, 1991, P NATL ACAD SCI USA, V88, P2618, DOI 10.1073/pnas.88.7.2618; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1988, X PLOR SYSTEM XRAY C; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; CARRIGAN CM, 1991, J MOL BIOL, V222, P197, DOI 10.1016/0022-2836(91)90206-L; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DREW HR, 1984, CELL, V37, P491, DOI 10.1016/0092-8674(84)90379-9; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GOTTLIEB PA, 1992, J BIOL CHEM, V267, P7434; Hendrickson W. A., 1970, Acta Crystallographica, Section B (Structural Crystallography and Crystal Chemistry), Vb26, P136, DOI 10.1107/S0567740870002078; HIASA H, 1992, J BIOL CHEM, V267, P11379; HOSHINO T, 1987, P NATL ACAD SCI USA, V84, P653, DOI 10.1073/pnas.84.3.653; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAUL S, 1994, P NATL ACAD SCI USA, V91, P11143, DOI 10.1073/pnas.91.23.11143; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; KRALICEK AV, 1993, BIOCHEMISTRY-US, V32, P10216, DOI 10.1021/bi00089a043; KRALICEK AV, 1991, BIOCHEM J, V275, P823, DOI 10.1042/bj2750823; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUEMPEL PL, 1977, P NATL ACAD SCI USA, V74, P3927, DOI 10.1073/pnas.74.9.3927; LANGLEY DB, 1993, MOL MICROBIOL, V10, P771, DOI 10.1111/j.1365-2958.1993.tb00947.x; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE EH, 1992, J BIOL CHEM, V267, P8778; LEVITT M, 1976, NATURE, V261, P552, DOI 10.1038/261552a0; LEWIS PJ, 1989, J BACTERIOL, V171, P3564, DOI 10.1128/jb.171.6.3564-3567.1989; LEWIS PJ, 1991, RES MICROBIOL, V142, P893, DOI 10.1016/0923-2508(91)90070-Q; LEWIS PJ, 1990, J MOL BIOL, V244, P73; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MACALLISTER T, 1990, P NATL ACAD SCI USA, V72, P2905; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MEHTA PP, 1992, J BIOL CHEM, V267, P18885; NATARAJAN S, 1993, CELL, V72, P113, DOI 10.1016/0092-8674(93)90055-U; NICHOLLS A, 1993, GRASP; OAS TG, 1994, TRENDS BIOCHEM SCI, V19, P51, DOI 10.1016/0968-0004(94)90030-2; OLLIS DL, 1987, CHEM REV, V87, P981, DOI 10.1021/cr00081a006; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PABO CO, 1982, NATURE, V298, P443, DOI 10.1038/298443a0; PABO CO, 1982, NATURE, V298, P441, DOI 10.1038/298441a0; Pathak D., 1992, CURR OPIN STRUC BIOL, V2, P116, DOI [10.1016/0959-440X(92)90186-B, DOI 10.1016/0959-440X(92)90186-B]; PODJARNY AD, 1987, ANNU REV BIOPHYS BIO, V16, P351; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; SAHOO T, 1995, IN PRESS EMBO J, V14; SATO Y, 1991, J BACTERIOL, V173, P7732, DOI 10.1128/jb.173.23.7732-7735.1991; SCHOLTZ JM, 1993, BIOCHEMISTRY-US, V32, P9668, DOI 10.1021/bi00088a019; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHARP KA, 1994, CURR OPIN STRUC BIOL, V4, P234, DOI 10.1016/S0959-440X(94)90314-X; SISTA PR, 1991, GENE DEV, V5, P74, DOI 10.1101/gad.5.1.74; SMITH MT, 1992, J MOL BIOL, V227, P648, DOI 10.1016/0022-2836(92)90214-5; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUEOKA N, 1968, COLD SPRING HARB SYM, V33, P695, DOI 10.1101/SQB.1968.033.01.078; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISS AS, 1984, CELL, V39, P683, DOI 10.1016/0092-8674(84)90475-6; WHITE SW, 1988, STRUCT FUNC GENET, V5, P281; WONACOTT AJ, 1977, ROTATION METHOD CRYS, P75; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	62	75	75	0	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					651	660						10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867072				2022-12-28	WOS:A1995QJ60200017
J	LI, W; OHLMEYER, JT; LANE, ME; KALDERON, D				LI, W; OHLMEYER, JT; LANE, ME; KALDERON, D			FUNCTION OF PROTEIN KINASE-A IN HEDGEHOG SIGNAL-TRANSDUCTION AND DROSOPHILA IMAGINAL DISC DEVELOPMENT	CELL			English	Article							POLARITY GENE HEDGEHOG; SEGMENT-POLARITY; CATALYTIC SUBUNIT; PATCHED GENE; EXPRESSION; WINGLESS; TRANSCRIPTION; MUTATIONS; DIRECTS; EMBRYO	Reduced protein kinase A (PKA) activity in anterior imaginal disc cells leads to cell-autonomous induction of decapentaplegic (dpp), wingless (wg), and patched (ptc) transcription that is independent of hedgehog (hh) gene activity. The resulting nonautonomous adult wing and leg pattern duplications are largely due to induced dpp and wg expression and resemble phenotypes elicited by ectopic hh expression. Inhibition of PKA in anterior cells close to the posterior compartment can substitute for hh activity to promote growth of imaginal discs, whereas overexpression of PKA can counteract transcriptional induction of ptc by hh in these cells. PKA therefore appears to be an integral component of the mechanism by which hh regulates the expression of key patterning molecules in imaginal discs.			LI, W (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.		Li, Willis/ABC-5695-2020; Li, Willis X/AAL-7212-2020	Li, Willis/0000-0001-9041-7341; Li, Willis X/0000-0001-9041-7341	NIGMS NIH HHS [GM41815] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041815] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER NE, 1988, DEVELOPMENT, V102, P489; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BOND BJ, 1986, MOL CELL BIOL, V6, P2080, DOI 10.1128/MCB.6.6.2080; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRYANT PJ, 1980, GENETICS BIOL DROS C, V2, P230; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CHANG DT, 1994, DEVELOPMENT, V120, P3339; COHEN B, 1993, DEVELOPMENT, V117, P597; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; HANNAH-ALAVA ALOHA, 1958, J MORPH, V103, P281, DOI 10.1002/jmor.1051030205; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LANE ME, 1993, GENE DEV, V7, P1229, DOI 10.1101/gad.7.7a.1229; LANE ME, 1994, GENE DEV, V8, P2986, DOI 10.1101/gad.8.24.2986; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MEINHARDT H, 1983, DEV BIOL, V96, P375, DOI 10.1016/0012-1606(83)90175-6; MOHLER J, 1988, GENETICS, V120, P1061; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SAMPEDRO J, 1991, NATURE, V353, P187, DOI 10.1038/353187a0; SCHUSKE K, 1994, DEV BIOL, V164, P300, DOI 10.1006/dbio.1994.1200; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; WALSH DA, 1971, J BIOL CHEM, V246, P1977; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; XU T, 1993, DEVELOPMENT, V117, P1223	52	284	296	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					553	562		10.1016/0092-8674(95)90509-X	http://dx.doi.org/10.1016/0092-8674(95)90509-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867063	hybrid			2022-12-28	WOS:A1995QJ60200007
J	PARK, IS; HAUSINGER, RP				PARK, IS; HAUSINGER, RP			REQUIREMENT OF CARBON-DIOXIDE FOR IN-VITRO ASSEMBLY OF THE UREASE NICKEL METALLOCENTER	SCIENCE			English	Article							KLEBSIELLA-AEROGENES UREASE; 1-AMINOCYCLOPROPANE-1-CARBOXYLATE OXIDASE; MOLECULAR CHARACTERIZATION; BINDING PROTEIN; PURIFICATION; ACTIVATION; GENE; UREE	Assembly of protein metallocenters is not well understood. Urease offers a tractable system for examination of this process. Formation of the urease metallocenter in vivo is known to require four accessory proteins: UreD, postulated to be a urease-specific molecular chaperone; UreE, a nickel(II)-binding protein; and UreF and UreG, of unknown function. Activation of purified Klebsiella aerogenes urease apoprotein was accomplished in vitro by providing carbon dioxide (half-maximal activation at similar to 0.2 percent carbon dioxide) in addition to nickel ion. Activation coincided with carbon dioxide incorporation into urease in a pH-dependent reaction (pK(a) greater than or equal to 9, where K-a is the acid constant). The concentration of carbon dioxide also affected the amount of activation of UreD-urease apoprotein complexes. These results suggest that carbon dioxide binding to urease apoprotein generates a ligand that facilitates productive nickel binding.	MICHIGAN STATE UNIV,DEPT MICROBIOL,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University; Michigan State University				Hausinger, Robert/0000-0002-3643-2054	NIDDK NIH HHS [DK45686] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045686] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Butler J. N., 1982, CARBON DIOXIDE EQUIL; DIXON NE, 1975, J AM CHEM SOC, V97, P4131, DOI 10.1021/ja00847a045; DONG JG, 1992, P NATL ACAD SCI USA, V89, P9789, DOI 10.1073/pnas.89.20.9789; FERNANDEZMACULE.JC, 1993, BIOCHEM BIOPH RES CO, V193, P1168; HARTMAN FC, 1994, ANNU REV BIOCHEM, V63, P197, DOI 10.1146/annurev.biochem.63.1.197; Hausinger R.P., 1993, BIOCH NICKEL, V12, P23; LEE MH, 1993, PROTEIN SCI, V2, P1042, DOI 10.1002/pro.5560020617; LEE MH, 1992, J BACTERIOL, V174, P4324, DOI 10.1128/JB.174.13.4324-4330.1992; LORIMER GH, 1976, BIOCHEMISTRY-US, V15, P529, DOI 10.1021/bi00648a012; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTZ S, 1991, MOL MICROBIOL, V5, P123, DOI 10.1111/j.1365-2958.1991.tb01833.x; MAIER T, 1993, J BACTERIOL, V175, P630, DOI 10.1128/JB.175.3.630-635.1993; MOBLEY HLT, 1989, MICROBIOL REV, V53, P85, DOI 10.1128/MMBR.53.1.85-108.1989; PARK IS, 1994, P NATL ACAD SCI USA, V91, P3233, DOI 10.1073/pnas.91.8.3233; Sumner JB, 1926, J BIOL CHEM, V69, P435; TODD MJ, 1989, J BIOL CHEM, V264, P15835; WANG S, 1994, INORG CHEM, V33, P1589, DOI 10.1021/ic00086a006; WEATHERBURN MW, 1967, ANAL CHEM, V39, P971, DOI 10.1021/ac60252a045	18	140	148	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1156	1158		10.1126/science.7855593	http://dx.doi.org/10.1126/science.7855593			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855593				2022-12-28	WOS:A1995QJ23700033
J	HE, JL; FURMANSKI, P				HE, JL; FURMANSKI, P			SEQUENCE SPECIFICITY AND TRANSCRIPTIONAL ACTIVATION IN THE BINDING OF LACTOFERRIN TO DNA	NATURE			English	Article							NUCLEAR-LOCALIZATION; ENRICHED POPULATION; CELLS; PROTEIN; INFECTION; FRAGMENTS; AFFINITY; INVITRO; IRON	LACTOFERRIN, an iron-binding glycoprotein found in high concentrations in human milk and other epithelial secretions' and in the secondary (specific) granules of neutrophils(2), is thought to be responsible for primary defence against microbial infection, mainly as a result of lactoferrin sequestration of iron required for microbial growth(3). Many other functions have been attributed to lactoferrin, including immunomodulation and cell growth regulation (reviewed in ref. 4). Some of these functions appear to be at least in part independent of the iron-binding activity of lactoferrin, It also has been consistently observed that lactoferrin interacts avidly with nucleic acids(5-7). Lactoferrin enhancement of the activity of natural killer and lymphokine-activated killer cells in vitro is inhibited by RNA and DNA(8). Lactoferrin taken up by K562 human myelogenous leukaemia cells appears in the nucleus where it is bound to DNA(9) The report here that binding of lactoferrin to DNA occurs under stringent conditions with distinct sequence specificity, and that interaction between lactoferrin and these sequences intracellularly leads to transcriptional activation.	NYU,DEPT BIOL,NEW YORK,NY 10003	New York University								AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; BENNETT RM, 1983, J CLIN INVEST, V71, P611, DOI 10.1172/JCI110807; BENNETT RM, 1981, J IMMUNOL, V127, P1211; BEZAULT J, 1994, CANCER RES, V54, P2310; BROXMEYER HE, 1987, BLOOD CELLS, V13, P31; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GARRE C, 1992, J CELL PHYSIOL, V153, P477, DOI 10.1002/jcp.1041530306; GREEN I, 1971, P SOC EXP BIOL MED, V137, P1311; HASHIZUME S, 1983, BIOCHIM BIOPHYS ACTA, V763, P377, DOI 10.1016/0167-4889(83)90099-X; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HUTCHENS TW, 1991, PEDIATR RES, V29, P243, DOI 10.1203/00006450-199103000-00005; LONNERDAL B, 1988, NUTR RES, V8, P853; Lyer S, 1993, EUR J CLIN NUTR, V47, P232; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; MIYAUCHI J, 1987, CELL TISSUE RES, V247, P249; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHAU HY, 1992, J LEUKOCYTE BIOL, V51, P343, DOI 10.1002/jlb.51.4.343; SLEBENLIST U, 1984, CELL, V37, P381; SPIK G, 1978, BRIT MED J, V5, P69; WALMER DK, 1992, ENDOCRINOLOGY, V131, P1458, DOI 10.1210/en.131.3.1458; WEINBERG ED, 1978, MICROBIOL REV, V42, P45, DOI 10.1128/MMBR.42.1.45-66.1978; WEINBERG ED, 1992, LIFE SCI, V50, P1289, DOI 10.1016/0024-3205(92)90279-X; ZHANG XY, 1992, ANAL BIOCHEM, V201, P366, DOI 10.1016/0003-2697(92)90353-9; ZIERE GJ, 1993, J BIOL CHEM, V268, P27069; ZUCALI JR, 1987, BLOOD, V69, P33; ZUCALI JR, 1987, BLOOD, V70, pA191	27	314	333	2	33	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					721	724		10.1038/373721a0	http://dx.doi.org/10.1038/373721a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854459				2022-12-28	WOS:A1995QH92800061
J	LEGALL, JR; LEMESHOW, S; LELEU, G; KLAR, J; HUILLARD, J; RUE, M; TERES, D; ARTIGAS, A				LEGALL, JR; LEMESHOW, S; LELEU, G; KLAR, J; HUILLARD, J; RUE, M; TERES, D; ARTIGAS, A			CUSTOMIZED PROBABILITY-MODELS FOR EARLY SEVERE SEPSIS IN ADULT INTENSIVE-CARE PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEPTIC SHOCK; FAILURE; TRIAL	Objective.-To develop customized versions of the Simplified Acute Physiology Score II (SAPS II) and the 24-hour Mortality Probability Model II (MPM II24) to estimate the probability of mortality for intensive care unit patients with early severe sepsis. Design and Setting.-Logistic regression models developed for patients with severe sepsis in a database of adult medical and surgical intensive care units in 12 countries. Patients.-Of 11 458 patients in the intensive care unit for at least 24 hours, 1130 had severe sepsis based on criteria of the American College of Chest Physicians and the Society of Critical Care Medicine (systemic inflammatory response syndrome in response to infection, plus hypotension, hypoperfusion, or multiple organ dysfunction). Results.-In patients with severe sepsis, mortality was higher (48.0% vs 19.6% among other patients) and 28-day survival was lower. The customized SAPS II was well calibrated (P=.92 for the goodness-of-fit test) and discriminated well (area under the receiver operating characteristic [ROC] curve, 0.78). Performance in the validation sample was equally good (P=.85 for the goodness-of-fit test; area under the ROC curve, 0.79). The customized MPM II24 was well calibrated (P=.92 for the goodness-of-fit test) and discriminated well (area under the ROC curve, 0.79). Performance in the validation sample was equally good (P=.52 for the goodness-of-fit test; area under the ROC curve, 0.75). The models are independent of each other; either can be used alone to estimate the probability of mortality of patients with severe sepsis. Conclusions.-Customization provides a simple technique to apply existing models to a subgroup of patients. Accurately assessing the probability of hospital mortality is a useful adjunct for clinical trials.	FAC MED LARIBOISIERE,PARIS,FRANCE; UNIV MASSACHUSETTS,SCH PUBL HLTH,AMHERST,MA 01003; BAYSTATE MED CTR,SPRINGFIELD,MA 01107; HOSP SABADELL,SABADELL,SPAIN	UDICE-French Research Universities; Universite Paris Cite; University of Massachusetts System; University of Massachusetts Amherst; Baystate Medical Center; Autonomous University of Barcelona; Parc Tauli Hospital Universitari			Rue, Montserrat/B-5663-2009	Rue, Montserrat/0000-0002-7862-9365				[Anonymous], 1992, CRIT CARE MED, V20, P864; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BONE RC, 1991, ANN INTERN MED, V114, P332, DOI 10.7326/0003-4819-114-4-332; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; HOSMER DW, 1994, REANIMATION URGENCES, V3, P173; KNAUS WA, 1993, JAMA-J AM MED ASSOC, V270, P1233, DOI 10.1001/jama.270.10.1233; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; LEMESHOW S, 1994, CRIT CARE MED, V22, P1351, DOI 10.1097/00003246-199409000-00003; SELKER HP, 1993, ANN INTERN MED, V118, P820, DOI 10.7326/0003-4819-118-10-199305150-00010; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; 1987, NEW ENGL J MED, V317, P659	14	136	141	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	1995	273	8					644	650		10.1001/jama.273.8.644	http://dx.doi.org/10.1001/jama.273.8.644			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG748	7844875				2022-12-28	WOS:A1995QG74800030
J	HUNG, J; KISHIMOTO, Y; SUGIO, K; VIRMANI, A; MCINTIRE, DD; MINNA, JD; GAZDAR, AF				HUNG, J; KISHIMOTO, Y; SUGIO, K; VIRMANI, A; MCINTIRE, DD; MINNA, JD; GAZDAR, AF			ALLELE-SPECIFIC CHROMOSOME 3P DELETIONS OCCUR AT AN EARLY-STAGE IN THE PATHOGENESIS OF LUNG-CARCINOMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SMALL-CELL; BRONCHIAL EPITHELIUM; SHORT ARM; CANCER; DNA; ABNORMALITIES; AMPLIFICATION; HYPERPLASIA; TUMORS; GENE	Background.-Deletions in the short arm of chromosome 3 (3p) are present in most lung carcinomas. Objective.-To investigate the role of these chromosome 3p deletions in the pathogenesis of non-small cell lung carcinomas. Design.-Seven archival, paraffin-embedded, surgically resected lung cancer specimens were studied. Fifty precisely identified malignant and preneoplastic lesions present in bronchi, bronchioles, and alveoli were microdissected from stained slides and analyzed for allele loss using polymerase chain reaction-based assays for dinucleotide repeat polymorphisms at three chromosome 3p loci (3p14, 3p21.3, and 3p25). Setting.-University-based medical center and affiliated hospitals. Subjects.-Samples were analyzed from seven patients who underwent surgical resection with curative intent for non-small cell lung cancer and whose specimens included extensive multifocal areas of preneoplastic lesions (hyperplasia, metaplasia, dysplasia, or noninvasive cancer). Results.-Lymphocytes from all seven cases were heterozygous (ie, informative) for all three microsatellites analyzed. Six (86%) of seven invasive cancers had loss of heterozygosity at one or more chromosome 3p sites. In the accompanying preneoplastic lesions, loss of heterozygosity was detected in none of two normal bronchioles, 13 (76%) of 17 hyperplasias, six (86%) of seven dysplasias, and four (100%) of four noninvasive cancers. Loss of heterozygosity was detected throughout the respiratory tract, in bronchi, bronchioles, and alveoli. In 18 (78%) of 23 preneoplastic lesions, the specific alleles lost were identical to those lost in the corresponding carcinomas. The probability of this happening by chance is 5.3x10(-3). Conclusions.-Deletions in the short arm of chromosome 3 occur at the earliest stage (hyperplasia) in the pathogenesis of lung cancer and involve all regions of the respiratory tract. Allele loss is highly specific, but its mechanism remains unknown. Our findings may be of considerable biologic, prognostic, and clinical significance.	UNIV TEXAS,SW MED CTR,SIMMONS CANC CTR,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PATHOL,DALLAS,TX; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX; UNIV TEXAS,SW MED CTR,ACAD COMP SERV,DALLAS,TX	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NCI NIH HHS [P20 CA58220-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P20CA058220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUERBACH O, 1979, NEW ENGL J MED, V300, P381, DOI 10.1056/NEJM197902223000801; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; CHEN B, 1994, CARCINOGENESIS, V15, P2031, DOI 10.1093/carcin/15.9.2031; CHENG JM, 1993, NAT GENET, V4, P191, DOI 10.1038/ng0693-191; DALY MC, 1993, ONCOGENE, V8, P1271; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FERGUSONSMITH AC, 1990, CANCER SURV, V9, P487; GAZDAR AF, 1994, BIOL GENETICS LUNG C; GREENBERG SD, 1987, LUNG CARCINOMAS, P287; HALL JG, 1992, NEW ENGL J MED, V326, P827, DOI 10.1056/NEJM199203193261210; HEGI ME, 1994, CANCER RES, V54, P6257; HIBI K, 1992, ONCOGENE, V7, P445; Jones Michael H., 1992, Human Molecular Genetics, V1, P131, DOI 10.1093/hmg/1.2.131; KNUDSON AG, 1989, BRIT J CANCER, V59, P661, DOI 10.1038/bjc.1989.137; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; LITT M, 1993, BIOTECHNIQUES, V15, P280; MINNA JD, 1993, CHEST, V103, pS449, DOI 10.1378/chest.103.4_Supplement.449S; NAKANISHI K, 1990, ARCH PATHOL LAB MED, V114, P363; OCONNELL P, 1994, BREAST CANCER RES TR, V32, P5, DOI 10.1007/BF00666201; PAABO S, 1989, P NATL ACAD SCI USA, V86, P1939, DOI 10.1073/pnas.86.6.1939; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; SACCOMANNO G, 1976, ANN NY ACAD SCI, V271, P377, DOI 10.1111/j.1749-6632.1976.tb23134.x; SARKAR G, 1990, NUCLEIC ACIDS RES, V18, P7465, DOI 10.1093/nar/18.24.7465; SATO S, 1994, CANCER RES, V54, P5652; SEKIDO Y, 1994, ONCOGENE, V9, P853; SIEGEL S, 1956, NONPARAMETRIC STAT, P36; SLAUGHTER DP, 1954, CANCER, V6, P963; SOZZI G, 1991, CANCER RES, V51, P400; STRONG MS, 1984, J OTOLARYNGOL, V13, P1; SUGIO K, 1994, CANCER RES, V54, P5811; SUNDARESAN V, 1992, ONCOGENE, V7, P1989; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; WENG S, 1990, HISTOPATHOLOGY, V16, P101, DOI 10.1111/j.1365-2559.1990.tb01073.x; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; WHETSELL L, 1992, ONCOGENE, V7, P2355; YAMAKAWA K, 1993, ONCOGENE, V8, P327; [No title captured]	38	288	307	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	1995	273	7					558	563		10.1001/jama.273.7.558	http://dx.doi.org/10.1001/jama.273.7.558			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF686	7837389				2022-12-28	WOS:A1995QF68600026
J	ERICKSON, HP				ERICKSON, HP			FTSZ, A PROKARYOTIC HOMOLOG OF TUBULIN	CELL			English	Review							DIVISION PROTEIN FTSZ; ESCHERICHIA-COLI; BINDING-PROTEIN; GTPASE; RING; GENE				ERICKSON, HP (corresponding author), DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710, USA.							BAIROCH A, 1993, NUCLEIC ACIDS RES, V21, P3097, DOI 10.1093/nar/21.13.3097; BERMUDES D, 1994, MICROBIOL REV, V58, P387, DOI 10.1128/MMBR.58.3.387-400.1994; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRAMHILL D, 1994, P NATL ACAD SCI USA, V91, P5813, DOI 10.1073/pnas.91.13.5813; DAI K, 1994, J BACTERIOL, V175, P130; DEBOER P, 1992, NATURE, V359, P254, DOI 10.1038/359254a0; ERICKSON HP, 1992, ANNU REV BIOPH BIOM, V21, P145, DOI 10.1146/annurev.bb.21.060192.001045; ERICKSON HP, 1976, P NATL ACAD SCI USA, V73, P2813, DOI 10.1073/pnas.73.8.2813; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; LUTKENHAUS J, 1993, MOL MICROBIOL, V9, P403, DOI 10.1111/j.1365-2958.1993.tb01701.x; MARGOLIN W, 1994, J BACTERIOL, V176, P2033, DOI 10.1128/jb.176.7.2033-2043.1994; MUKHERJEE A, 1994, J BACTERIOL, V176, P2754, DOI 10.1128/JB.176.9.2754-2758.1994; MUKHERJEE A, 1993, P NATL ACAD SCI USA, V90, P1053, DOI 10.1073/pnas.90.3.1053; NEUFELD TP, 1994, CELL, V77, P371, DOI 10.1016/0092-8674(94)90152-X; PHOENIX P, 1988, J BACTERIOL, V170, P4338, DOI 10.1128/jb.170.9.4338-4342.1988; RAYCHAUDHURI D, 1994, J BIOL CHEM, V269, P22941; RAYCHAUDHURI D, 1992, NATURE, V359, P251, DOI 10.1038/359251a0; SANDERS SL, 1994, CURR BIOL, V4, P907, DOI 10.1016/S0960-9822(00)00201-3	19	240	254	0	19	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					367	370		10.1016/0092-8674(95)90486-7	http://dx.doi.org/10.1016/0092-8674(95)90486-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859278	Bronze			2022-12-28	WOS:A1995QG47000002
J	MOSIALOS, G; BIRKENBACH, M; YALAMANCHILI, R; VANARSDALE, T; WARE, C; KIEFF, E				MOSIALOS, G; BIRKENBACH, M; YALAMANCHILI, R; VANARSDALE, T; WARE, C; KIEFF, E			THE EPSTEIN-BARR-VIRUS TRANSFORMING PROTEIN LMP1 ENGAGES SIGNALING PROTEINS FOR THE TUMOR-NECROSIS-FACTOR RECEPTOR FAMILY	CELL			English	Article							FACTOR TNF RECEPTOR; LYMPHOCYTE GROWTH TRANSFORMATION; MEMBRANE-PROTEIN; CELL-LINES; NASOPHARYNGEAL CARCINOMA; MONOCLONAL-ANTIBODIES; NUCLEAR PROTEIN-2; HODGKINS-DISEASE; B TRANSFORMATION; SOLUBLE FORM	The cytoplasmic C-terminus of Epstein-Barr virus (EBV) latent infection membrane protein 1 (LMP1) is essential for B lymphocyte growth transformation and is now shown to interact with a novel human protein (LMP1-associated protein 1 [LAP1]). LAP1 is homologous to a murine protein, tumor necrosis factor receptor-associated factor 2 (TRAF2), implicated in growth signaling from the p80 TNFR. A second novel protein (EBI6), induced by EBV infection, is the human homolog of a second murine TNFR-associated protein (TRAF1). LMP1 expression causes LAP1 and EBI6 to localize to LMP1 clusters in lymphoblast plasma membranes, and LMP1 coimmunoprecipitates with these proteins. LAP1 binds to the p80 TNFR, CD40, and the lymphotoxin-p receptor, while EBI6 associates with the pan TNFR. The interaction of LMP1 with these TNFR family-associated proteins is further evidence for their role in signaling and links LMP1-mediated transformation to signal transduction from the TNFR family.	UNIV CHICAGO, MARJORIE B KOVLER VIRAL ONCOL LABS, DEPT PATHOL, CHICAGO, IL 60637 USA; UNIV CALIF RIVERSIDE, DIV BIOMED SCI, RIVERSIDE, CA 92521 USA	University of Chicago; University of California System; University of California Riverside	MOSIALOS, G (corresponding author), HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, DEPT MED, BOSTON, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R35CA047006, K11CA001341, R01CA047006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008548] Funding Source: NIH RePORTER; NCI NIH HHS [5K11CA01341, CA47006] Funding Source: Medline; NIAID NIH HHS [AI08548-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BAICHWAL VR, 1989, ONCOGENE, V4, P67; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; BOUSSIOTIS VA, 1994, P NATL ACAD SCI USA, V91, P7007, DOI 10.1073/pnas.91.15.7007; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; BUSSON P, 1992, J VIROL, V66, P3257, DOI 10.1128/JVI.66.5.3257-3262.1992; CARDE P, 1990, EUR J CANCER, V26, P474, DOI 10.1016/0277-5379(90)90019-P; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; DARNAY BG, 1994, J BIOL CHEM, V269, P20299; DARNAY BG, 1994, J BIOL CHEM, V269, P19687; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESTROV Z, 1993, J EXP MED, V177, P763, DOI 10.1084/jem.177.3.763; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FENNEWALD S, 1984, J VIROL, V51, P411, DOI 10.1128/JVI.51.2.411-419.1984; FROESE P, 1987, J IMMUNOL, V139, P2081; GALIBERT L, 1994, J IMMUNOL, V152, P22; GIBBONS DL, 1994, EUR J IMMUNOL, V24, P1879, DOI 10.1002/eji.1830240825; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GOODING LR, 1992, CELL, V71, P5; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; HARPER JW, 1993, CELL, V75, P805; HENNESSY K, 1984, P NATL ACAD SCI-BIOL, V81, P7207, DOI 10.1073/pnas.81.22.7207; HERBST H, 1991, P NATL ACAD SCI USA, V88, P4766, DOI 10.1073/pnas.88.11.4766; IZUMI KM, 1994, J VIROL, V68, P4369, DOI 10.1128/JVI.68.7.4369-4376.1994; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KIEFF E, 1990, VIROLOGY, P1889; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; LOETSCHER H, 1991, J BIOL CHEM, V266, P18324; LONGNECKER R, 1993, J VIROL, V67, P5068, DOI 10.1128/JVI.67.8.5068-5074.1993; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; MANNICK JB, 1991, J VIROL, V65, P6826, DOI 10.1128/JVI.65.12.6826-6837.1991; MARCHINI A, 1991, J VIROL, V65, P5991, DOI 10.1128/JVI.65.11.5991-6000.1991; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MASSUNG RF, 1993, NATURE, V366, P748, DOI 10.1038/366748a0; MILLER G, 1990, VIROLOGY, P1921; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOSIALOS G, 1994, J VIROL, V68, P7320, DOI 10.1128/JVI.68.11.7320-7328.1994; NAGATA S, 1994, ADV IMMUNOL, V57, P129, DOI 10.1016/S0065-2776(08)60672-0; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; OGRADY JT, 1994, AM J PATHOL, V144, P21; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PENNICA D, 1992, BIOCHEMISTRY-US, V31, P1134, DOI 10.1021/bi00119a023; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PFREUNDSCHUH M, 1989, ONKOLOGIE, V12, P30, DOI 10.1159/000216681; POLI G, 1990, P NATL ACAD SCI USA, V87, P782, DOI 10.1073/pnas.87.2.782; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; ROBERTSON ES, 1994, J VIROL, V68, P1449, DOI 10.1128/JVI.68.3.1449-1458.1994; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; SAELAND S, 1993, J EXP MED, V178, P113, DOI 10.1084/jem.178.1.113; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SWAMINATHAN S, 1991, P NATL ACAD SCI USA, V88, P1546, DOI 10.1073/pnas.88.4.1546; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TOMKINSON B, 1992, J VIROL, V66, P2893, DOI 10.1128/JVI.66.5.2893-2903.1992; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; TRUMPER L, 1994, ANN ONCOL, V5, pS93, DOI 10.1093/annonc/5.suppl_1.S93; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG D, 1988, J VIROL, V62, P2337, DOI 10.1128/JVI.62.7.2337-2346.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WARE CF, 1991, J IMMUNOL, V147, P4229; WARE CF, 1995, CURRENT TOPICS MICRO, V198; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806; YOUNG LS, 1989, INT J CANCER, V43, P786, DOI 10.1002/ijc.2910430508	83	882	925	2	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	1995	80	3					389	399		10.1016/0092-8674(95)90489-1	http://dx.doi.org/10.1016/0092-8674(95)90489-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859281	Bronze			2022-12-28	WOS:A1995QG47000005
J	OLEMOIYOI, OK				OLEMOIYOI, OK			CASEIN KINASE-II IN THEILERIOSIS	SCIENCE			English	Editorial Material							BOVINE LYMPHOCYTES INVITRO; MICROSCOPIC OBSERVATIONS; ALPHA-SUBUNIT; PARVA; CELLS; SPOROZOITES; INDUCTION; PROTEIN; ENTRY; PHOSPHORYLATION				OLEMOIYOI, OK (corresponding author), INT LIVESTOCK RES INST, NAIPOSHA RD, POB 30709, NAIROBI, KENYA.							BALDWIN CL, 1988, INFECT IMMUN, V56, P462, DOI 10.1128/IAI.56.2.462-467.1988; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BARNETT SF, 1960, J INFECT DIS, V107, P253, DOI 10.1093/infdis/107.3.253; BOUSSET K, 1993, ONCOGENE, V8, P3211; BROWN CGD, 1983, IN VITRO CULTIVATION, P243; CARDENAS ME, 1993, J CELL SCI, V104, P533; COOPER GM, 1991, ONCOGENES, P255; DEBENEDETTE M, 1991, J IMMUNOL, V147, P2839; DOBROWOLSKA G, 1992, EUR J BIOCHEM, V204, P299, DOI 10.1111/j.1432-1033.1992.tb16637.x; EMERY DL, 1988, PARASITE IMMUNOL, V10, P379, DOI 10.1111/j.1365-3024.1988.tb00228.x; FAWCETT DW, 1982, EUR J CELL BIOL, V27, P10; FELL AH, 1990, PARASITE IMMUNOL, V12, P335, DOI 10.1111/j.1365-3024.1990.tb00959.x; FILHOL O, 1994, BIOCHEM BIOPH RES CO, V198, P660, DOI 10.1006/bbrc.1994.1096; GEAHLEN RL, 1984, BIOCHIM BIOPHYS ACTA, V804, P169, DOI 10.1016/0167-4889(84)90146-0; HELLERHARRISON RA, 1991, J BIOL CHEM, V266, P14435; IRVIN AD, 1982, RES VET SCI, V33, P298, DOI 10.1016/S0034-5288(18)32305-1; IRVIN AD, 1975, NATURE, V255, P713, DOI 10.1038/255713a0; KREBS EG, 1988, COLD SPRING HARB SYM, V99, P77; LORENZ P, 1993, J BIOL CHEM, V268, P2733; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; OHTSUKI K, 1993, J BIOCHEM-TOKYO, V113, P334, DOI 10.1093/oxfordjournals.jbchem.a124048; OLEMOIYOI OK, 1993, EMBO J, V12, P1621, DOI 10.1002/j.1460-2075.1993.tb05807.x; OLEMOIYOI OK, 1992, BIOCHEMISTRY-US, V31, P6193, DOI 10.1021/bi00142a004; OLEMOIYOI OK, UNPUB; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; SAXENA A, 1987, MOL CELL BIOL, V7, P3409, DOI 10.1128/MCB.7.10.3409; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SHAW MK, 1991, J CELL BIOL, V113, P87, DOI 10.1083/jcb.113.1.87; STIGARE J, 1993, MOL CELL BIOCHEM, V129, P77, DOI 10.1007/BF00926578; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; TURMAN MA, 1993, BIOCHEM MED METAB B, V50, P210, DOI 10.1006/bmmb.1993.1063; ULLOA L, 1993, EMBO J, V12, P1633, DOI 10.1002/j.1460-2075.1993.tb05808.x; WEBSTER P, 1985, EUR J CELL BIOL, V36, P157	37	30	32	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	1995	267	5199					834	836		10.1126/science.7846527	http://dx.doi.org/10.1126/science.7846527			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG207	7846527				2022-12-28	WOS:A1995QG20700043
J	STRUBIN, M; NEWELL, JW; MATTHIAS, P				STRUBIN, M; NEWELL, JW; MATTHIAS, P			OBF-1, A NOVEL B-CELL-SPECIFIC COACTIVATOR THAT STIMULATES IMMUNOGLOBULIN PROMOTER ACTIVITY THROUGH ASSOCIATION WITH OCTAMER-BINDING PROTEINS	CELL			English	Article							REMOTE ENHANCER POSITION; TRANSCRIPTION FACTOR; POU-DOMAIN; CONSERVED REGION; GENETIC-EVIDENCE; CYCLE REGULATION; TATA ELEMENT; HOMEO DOMAIN; HELA-CELLS; STEM-CELLS	Recent biochemical and genetic studies indicate that in addition to the octamer-binding proteins Oct-1 and Oct-2, other B cell components are required for lymphoid-restricted, octamer site-mediated immunoglobulin gene promoter activity. Using a genetic screen in yeast, we have isolated a cell-derived cDNAs encoding Oct-binding factor 1 (OBF-1), a novel protein that specifically associates with Oct-1 and Oct-2. Biochemical studies demonstrate that OBF-1 has no intrinsic DNA-binding activity and recognizes the POU domains of Oct-1 and Oct-2, but not those of Oct-4 and Oct-6. The OBF-1 mRNA is expressed in a highly cell-specific manner, being most abundant in B cells and essentially absent In most of the other cells or tissues tested. Furthermore, expression of OBF-1 in HeLa cells selectively stimulates the activity of a natural immunoglobulin promoter in an octamer site-dependent manner. Thus, OBF-1 has all the properties expected for a B cell-specific transcriptional coactivator protein.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research	STRUBIN, M (corresponding author), UNIV GENEVA,MED CTR,DEPT GENET & MICROBIOL,CH-1211 GENEVA 4,SWITZERLAND.							ANNWEILER A, 1992, MOL CELL BIOL, V12, P3107, DOI 10.1128/MCB.12.7.3107; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DREYFUS M, 1987, EMBO J, V6, P1685, DOI 10.1002/j.1460-2075.1987.tb02418.x; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; FELDHAUS AL, 1993, EMBO J, V12, P2763, DOI 10.1002/j.1460-2075.1993.tb05937.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GERSTER T, 1987, EMBO J, V6, P1323, DOI 10.1002/j.1460-2075.1987.tb02371.x; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; JENUWEIN T, 1991, GENE DEV, V5, P932, DOI 10.1101/gad.5.6.932; JOHNSON DG, 1990, MOL CELL BIOL, V10, P982, DOI 10.1128/MCB.10.3.982; JUNKER S, 1990, CELL, V61, P467, DOI 10.1016/0092-8674(90)90528-M; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LEBOWITZ JH, 1988, GENE DEV, V2, P1227, DOI 10.1101/gad.2.10.1227; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MASON JO, 1985, CELL, V41, P479, DOI 10.1016/S0092-8674(85)80021-0; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MIZUSHIMASUGANO J, 1986, P NATL ACAD SCI USA, V83, P8511, DOI 10.1073/pnas.83.22.8511; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MULLERIMMERGLUC.MM, 1990, EMBO J, V9, P1625; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PFEUFFER I, 1994, J IMMUNOL, V153, P5572; PFISTERER P, 1994, EMBO J, V13, P1654, DOI 10.1002/j.1460-2075.1994.tb06429.x; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TANESE N, 1993, COLD SPRING HARB SYM, V58, P179, DOI 10.1101/SQB.1993.058.01.022; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; WIRTH T, 1991, NUCLEIC ACIDS RES, V19, P43, DOI 10.1093/nar/19.1.43; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0	58	353	361	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					497	506		10.1016/0092-8674(95)90500-6	http://dx.doi.org/10.1016/0092-8674(95)90500-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859290	Bronze			2022-12-28	WOS:A1995QG47000016
J	LILLY, B; ZHAO, B; RANGANAYAKULU, G; PATERSON, BM; SCHULZ, RA; OLSON, EN				LILLY, B; ZHAO, B; RANGANAYAKULU, G; PATERSON, BM; SCHULZ, RA; OLSON, EN			REQUIREMENT OF MADS DOMAIN TRANSCRIPTION FACTOR D-MEF2 FOR MUSCLE FORMATION IN DROSOPHILA	SCIENCE			English	Article							ENHANCER-BINDING-FACTOR; FACTOR MEF-2; GENE; EXPRESSION; PROTEINS; ENCODES; MEMBER; FAMILY; EMBRYOGENESIS; TRANSPOSITION	Members of the myocyte enhancer binding factor-2 (MEF2) family of MADS (MCM1, agamous, deficiens, and serum response factor) box transcription factors are expressed in the skeletal, cardiac, and smooth muscle lineages of vertebrate and Drosophila embryos. These factors bind an adenine-thymidine-rich DNA sequence associated with muscle-specific genes. The function of MEF2 was determined by generating a loss-of-function of the single mef2 gene in Drosophila (D-mef2). In loss-of-function embryos, somatic, cardiac, and visceral muscle cells did not differentiate, but myoblasts were normally specified and positioned. These results demonstrate that different muscle cell types share a common myogenic differentiation program controlled by MEF2.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030; NCI,BIOCHEM LAB,BETHESDA,MD 20892	University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			LILLY, BRENDA/N-6867-2015	LILLY, BRENDA/0000-0002-3125-7496				AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BATE M, 1993, DEV DROSOPHILA MELAN, V3, P1013; BODMER R, 1993, DEVELOPMENT, V118, P719; BOURGOUIN C, 1992, NEURON, V9, P549, DOI 10.1016/0896-6273(92)90192-G; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; CHAMBERS AE, 1992, EMBO J, V11, P4981, DOI 10.1002/j.1460-2075.1992.tb05605.x; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DAVIS R, COMMUNICATION; DOHRMANN C, 1990, GENE DEV, V4, P2098, DOI 10.1101/gad.4.12a.2098; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Emerson CP, 1990, CURR OPIN CELL BIOL, V2, P1065, DOI 10.1016/0955-0674(90)90157-A; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; KAISER K, 1990, P NATL ACAD SCI USA, V87, P1686, DOI 10.1073/pnas.87.5.1686; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; KIEHART DP, 1986, J CELL BIOL, V103, P1517, DOI 10.1083/jcb.103.4.1517; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEIBHAM D, 1994, MOL CELL BIOL, V14, P686, DOI 10.1128/MCB.14.1.686; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; LILLY B, 1995, THESIS U TEXAS HOUST; Martin J., UNPUB; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; OBRIEN MA, 1994, GENETICS, V137, P121; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PATERSON BM, 1991, P NATL ACAD SCI USA, V88, P3782, DOI 10.1073/pnas.88.9.3782; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RANGANAYAKULU G, UNPUB; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J, 1989, MOL CLONING LABORATO; SHISHIDO E, 1993, DEVELOPMENT, V117, P751; TOWER J, 1993, GENETICS, V133, P347; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WRIGHT WE, 1993, CURR OPIN GENET DEV, V2, P243; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; ZHANG P, 1993, GENETICS, V133, P361	46	412	426	0	21	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 3	1995	267	5198					688	693		10.1126/science.7839146	http://dx.doi.org/10.1126/science.7839146			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839146				2022-12-28	WOS:A1995QE73300041
J	MENINI, A; PICCO, C; FIRESTEIN, S				MENINI, A; PICCO, C; FIRESTEIN, S			QUANTAL-LIKE CURRENT FLUCTUATIONS INDUCED BY ODORANTS IN OLFACTORY RECEPTOR-CELLS	NATURE			English	Article							MONKEY MACACA-FASCICULARIS; VISUAL TRANSDUCTION; TIGER SALAMANDER; RETINAL RODS; CONDUCTANCE; CHANNELS; CILIA	MANY sensory systems have evolved signal detection capabilities that are limited only by the physical attributes of the stimulus(1). For example, 'hair' cells of the inner ear can detect displacements of atomic dimensions(2). Likewise, both in vertebrates and in invertebrates photoreceptors can detect a single photon(3,4). The olfactory stimulus also has a quantal unit, the single odorant molecule, Insects are reportedly able to detect a single pheromone molecule(5), whereas quantal responses in vertebrate olfactory receptor cells have not been reported yet. Psychophysical measurements indicate that a minimum of 50 odorant molecules are necessary for human olfactory detection, suggesting that an individual receptor may be activated ba a single odorant molecule(6). We report here measurements of current fluctuations induced by odorants that suggest a quantal event of about 03-1 pA, presumably triggered by the binding of a single odorant molecule.	COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA	Columbia University	MENINI, A (corresponding author), CNR, IST CIBERNET & BIOFIS, I-16146 GENOA, ITALY.			Picco, Cristiana/0000-0002-6512-1802; Menini, Anna/0000-0001-9304-0412				BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BLOCK SM, 1992, SOC GEN PHY, V47, P1; CRAWFORD AC, 1985, J PHYSIOL-LONDON, V364, P359, DOI 10.1113/jphysiol.1985.sp015750; DEVRIES H, 1961, SENS COMMUN, P159; FIRESTEIN S, 1993, J PHYSIOL-LONDON, V468, P1; FIRESTEIN S, 1987, P NATL ACAD SCI USA, V84, P6292, DOI 10.1073/pnas.84.17.6292; FUORTES MGF, 1964, J GEN PHYSIOL, V47, P443, DOI 10.1085/jgp.47.3.443; KALSSLING KE, 1986, A REV NEUROSCI, V9, P121; KLEENE SJ, 1991, J NEUROSCI, V11, P3624; KURAHASHI T, 1989, J PHYSIOL-LONDON, V419, P177, DOI 10.1113/jphysiol.1989.sp017868; KURAHASHI T, 1993, NATURE, V363, P71, DOI 10.1038/363071a0; LAMB TD, 1992, TRENDS NEUROSCI, V15, P291, DOI 10.1016/0166-2236(92)90079-N; LYNCH JW, 1989, BIOPHYS J, V55, P755, DOI 10.1016/S0006-3495(89)82874-7; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NUNN BJ, 1982, NATURE, V299, P726, DOI 10.1038/299726a0; SCHNAPF JL, 1990, J PHYSIOL-LONDON, V427, P681, DOI 10.1113/jphysiol.1990.sp018193; TROTIER D, 1986, PFLUG ARCH EUR J PHY, V407, P589, DOI 10.1007/BF00582636; ZUFALL F, 1991, J NEUROSCI, V11, P3573	19	69	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 2	1995	373	6513					435	437		10.1038/373435a0	http://dx.doi.org/10.1038/373435a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7830795				2022-12-28	WOS:A1995QE67000058
J	HENRY, JA; ALEXANDER, CA; SENER, EK				HENRY, JA; ALEXANDER, CA; SENER, EK			RELATIVE MORTALITY FROM OVERDOSE OF ANTIDEPRESSANTS	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; FLUOXETINE; SUICIDE; DEPRESSION; TOXICITY; RISK; GUIDELINES; INGESTION	Objective-To compare the fatal toxicities of antidepressant drugs in 1987-92. Design-Retrospective epidemiological review of prescription data of the Department of Health, Scottish Office Home and Health Department, and Welsh Health Common Services Authority (excluding data fi om most private general practices and most hospitals), and mortality data from the Office of Population Censuses and Surveys and General Register Office in Scotland. Setting-General practice, England, Scotland, and Wales. Main outcome measures-Deaths per million prescriptions and deaths per defined daily dose. Results-81.6% (1310/1606) of deaths from antidepressant overdose were due to two drugs, amitriptyline and dothiepin. The overall average of deaths per million prescriptions was 30.1. The overall rate for tricyclic drugs was 34.14 (95% confidence interval 32.47 to 38.86; P<0.001), monoamine oxidase inhibitors 13.48 (6.93 to 22.19; P<0.001), atypical drugs 6.19 (4.04 to 8.80; P<0.001), and selective serotonin reuptake inhibitors 2.02 (0.64 to 4.17; P<0.001). The numbers of deaths per million prescriptions of amoxapine, dothiepin, and amitriptyline were significantly higher than expected, while nine drugs had a significantly lower number of deaths per million prescriptions than expected. Analysis of deaths per defined daily dose showed a similar pattern. Conclusions-Safety in overdose should be considered in risk-benefit and cost-benefit considerations of antidepressants. A switch in prescribing, from drugs with a high number of deaths per million prescriptions to drugs with a low number, could reduce the numbers of deaths from overdose. Although this form of suicide prevention can be implemented easily and immediately, its introduction needs to be considered against the higher costs of some of the newer drugs.			HENRY, JA (corresponding author), GUYS HOSP,NATL POISONS UNIT,LONDON SE1 9RT,ENGLAND.		anand, amit/A-7222-2009; rivas, carol/Q-1196-2015	rivas, carol/0000-0002-0316-8090				BORYS DJ, 1990, J TOXICOL-CLIN TOXIC, V28, P331, DOI 10.3109/15563659008994434; BOYER WF, HLTH EC DEPRESSION P, V4, P65; CALLAHAM M, 1985, ANN EMERG MED, V14, P1, DOI 10.1016/S0196-0644(85)80725-3; CASSIDY S, 1987, BRIT MED J, V295, P1021, DOI 10.1136/bmj.295.6605.1021; FORSTER DP, 1985, ACTA PSYCHIAT SCAND, V71, P567, DOI 10.1111/j.1600-0447.1985.tb02550.x; FREEMANTLE N, 1994, BRIT MED J, V309, P249, DOI 10.1136/bmj.309.6949.249; HALE AS, 1993, J CLIN PSYCHIAT, V54, P61; HATZIANDREU EJ, 1994, PHARMACOECONOMICS, V5, P249, DOI 10.2165/00019053-199405030-00008; Henry J A, 1992, Eur J Med, V1, P343; HENRY JA, 1992, INT CLIN PSYCHOPHARM, V6, P22, DOI 10.1097/00004850-199206006-00004; HENRY JA, 1992, BRIT J PSYCHIAT, V160, P439, DOI 10.1192/bjp.160.4.439; ISACSSON G, 1994, BRIT MED J, V308, P506, DOI 10.1136/bmj.308.6927.506; JOHNSON DAW, 1981, ACTA PSYCHIAT SCAND, V63, P447, DOI 10.1111/j.1600-0447.1981.tb00751.x; JOHNSON DAW, 1984, ANTIDEPRESSANTS PROG; JONSSON B, 1994, BRIT J PSYCHIAT, V164, P665, DOI 10.1192/bjp.164.5.665; KAPUR S, 1992, JAMA-J AM MED ASSOC, V268, P3441, DOI 10.1001/jama.268.24.3441; MARTIN AJ, 1987, PHARMATHERAPEUTICA, V5, P40; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; MCCARTHY M, 1993, LANCET, V341, P1087, DOI 10.1016/0140-6736(93)92441-U; MOLCHO A, 1992, J CLIN PSYCHOPHARM, V12, pS13; MONTGOMERY SA, 1993, J PSYCHOPHARMACOL, V7, P19, DOI 10.1177/0269881193007001041; MONTGOMERY SA, 1989, INT CLIN PSYCHOPHARM, V4, P113; MONTGOMERY SA, 1994, INT CLIN PSYCHOPHARM, V9, P47, DOI 10.1097/00004850-199400910-00008; MONTGOMERY SA, 1990, ANXIETY DEPRESSION, P46; NORDENTOFT M, 1993, BRIT MED J, V306, P1637, DOI 10.1136/bmj.306.6893.1637; PAYKEL ES, 1988, PHARMACOPSYCHIATRY, V21, P15, DOI 10.1055/s-2007-1014639; SPILLER HA, 1990, VET HUM TOXICOL, V32, P153; THOMPSON C, 1989, Human Psychopharmacology, V4, P191, DOI 10.1002/hup.470040305; THOMPSON C, 1989, Human Psychopharmacology, V4, P91, DOI 10.1002/hup.470040204; WAKELIN JS, 1988, ADV BIOL PSYCHIAT, V17, P70; WINOKUR G, 1992, NEW ENGL J MED, V327, P490, DOI 10.1056/NEJM199208133270710; WORKMAN EA, 1993, J CLIN PSYCHIAT, V54, P5; 1994, ANATOMICAL THERAPEUT; 1975, ANN REPORT MORTALITY; 1991, MORTALITY STATISTICS; 1982, NORDIC STATISTICS ME	36	207	207	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 28	1995	310	6974					221	224		10.1136/bmj.310.6974.221	http://dx.doi.org/10.1136/bmj.310.6974.221			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QE496	7866123	Green Published, Green Submitted			2022-12-28	WOS:A1995QE49600021
J	VANDAELE, PLA; STOLK, RP; BURGER, H; ALGRA, D; GROBBEE, DE; HOFMAN, A; BIRKENHAGER, JC; POLS, HAP				VANDAELE, PLA; STOLK, RP; BURGER, H; ALGRA, D; GROBBEE, DE; HOFMAN, A; BIRKENHAGER, JC; POLS, HAP			BONE-DENSITY IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS - THE ROTTERDAM STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						DIABETES MELLITUS, NON-INSULIN-DEPENDENT; BONE DENSITY; FRACTURES; DIABETES MELLITUS, INSULIN-DEPENDENT; SEX FACTORS	HORMONE-BINDING GLOBULIN; POSTMENOPAUSAL WOMEN; MINERAL DENSITY; ELDERLY WOMEN; MASS; FRACTURES; ESTROGENS; MEN; OSTEOPOROSIS	Objective: To investigate the relation between noninsulin-dependent diabetes mellitus and bone mineral density at the lumbar spine and hip. Design: Population-based study with a cross-sectional survey, Setting: A district of Rotterdam, the Netherlands. Participants: 5931 residents (2481 men, 3450 women) of the district aged 55 years or more. Measurements: Participants were classified as having non-insulin-dependent diabetes mellitus if they were receiving antidiabetic medication or if they had a serum glucose level of 11.1 mmol/L or more after a nonfasting oral glucose tolerance test. Bone mineral density, measured at the lumbar spine and proximal femur using dual-energy x-ray absorptiometry and the frequency of nonvertebral fractures during the preceding 5 years were compared between persons with and without non-insulin-dependent diabetes mellitus. Results: 243 men and 335 women had non-insulin-dependent diabetes mellitus. Both men and women with this condition had substantially higher mean bone mineral density values at all four sites measured than those with normal glucose tolerance. The increase could not be explained by age; obesity; use of estrogens, thiazides, or loop diuretics; impairment in abilities of daily living; smoking; or osteoarthritis. Women with non-insulin-dependent diabetes mellitus reported having had fewer fractures in the 5 preceding years than women without this condition (adjusted odds ratio, 0.63; 95% CI, 0.44 to 0.90). The frequency of fractures in men was similar for those with and without noninsulin-dependent diabetes mellitus (adjusted odds ratio, 0.96; CI, 0.60 to 1.52). Conclusions: Men and women with non-insulin-dependent diabetes mellitus have increased bone mineral density. Non-insulin-dependent diabetes mellitus in women is associated with a lower frequency of nonvertebral fractures.	ERASMUS UNIV ROTTERDAM,SCH MED,DEPT INTERNAL MED 3,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam			Stolk, Ronald P/B-2341-2013; Grobbee, Diederick/C-7651-2014	Stolk, Ronald P/0000-0002-0518-1205; Grobbee, Diederick/0000-0003-4472-4468				[Anonymous], 1985, DIABETES MELLITUS RE; BARRETTCONNOR E, 1992, JAMA-J AM MED ASSOC, V268, P3333; BAUER DC, 1993, ANN INTERN MED, V118, P657, DOI 10.7326/0003-4819-118-9-199305010-00001; BIRKELAND KI, 1993, J CLIN ENDOCR METAB, V76, P275, DOI 10.1210/jc.76.2.275; CLEGHORN DB, 1992, J EPIDEMIOL COMMUN H, V46, P133, DOI 10.1136/jech.46.2.133; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DELEEUW I, 1977, DIABETES, V26, P1130, DOI 10.2337/diabetes.26.12.1130; ERNST M, 1987, CALCIFIED TISSUE INT, V40, P27, DOI 10.1007/BF02555725; GIACCA A, 1988, BONE, V9, P29, DOI 10.1016/8756-3282(88)90024-5; HAFFNER SM, 1993, METABOLISM, V42, P735, DOI 10.1016/0026-0495(93)90241-F; HEATH H, 1980, NEW ENGL J MED, V303, P567, DOI 10.1056/NEJM198009043031008; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; ISAIA G, 1987, ACTA DIABETOL LAT, V24, P305, DOI 10.1007/BF02742962; ISHIDA H, 1985, METABOLISM, V34, P797, DOI 10.1016/0026-0495(85)90101-5; JOHNSTON CC, 1985, METABOLISM, V34, P544, DOI 10.1016/0026-0495(85)90192-1; Kellgren, 1963, EPIDEMIOLOGY CHRONIC, V2; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; LEVIN ME, 1976, NEW ENGL J MED, V294, P241, DOI 10.1056/NEJM197601292940502; LINDSAY R, 1991, BAILLIERE CLIN OB GY, V5, P837, DOI 10.1016/S0950-3552(05)80291-3; MCNAIR P, 1988, DAN MED BULL, V35, P109; MEEMA HE, 1967, CAN MED ASSOC J, V96, P132; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; MURPHY S, 1993, BONE MINER, V20, P133, DOI 10.1016/S0169-6009(08)80022-0; NEVITT MC, 1992, AM J EPIDEMIOL, V135, P490, DOI 10.1093/oxfordjournals.aje.a116315; PEIRIS AN, 1993, J CLIN ENDOCR METAB, V76, P279, DOI 10.1210/jc.76.2.279; PINCUS T, 1983, ARTHRITIS RHEUM-US, V26, P1346, DOI 10.1002/art.1780261107; PLYMATE SR, 1988, J CLIN ENDOCR METAB, V67, P460, DOI 10.1210/jcem-67-3-460; PREZIOSI P, 1993, J CLIN ENDOCR METAB, V76, P283, DOI 10.1210/jcem.76.2.8432770; REID IR, 1993, AM J PHYSIOL, V265, P655; RUWAARD D, 1993, VOLKSGEZONDHEID TOEK, P303; SAMBROOK PN, 1988, J RHEUMATOL, V15, P1415; SEELEY DG, 1991, ANN INTERN MED, V115, P837, DOI 10.7326/0003-4819-115-11-837; SMYTHE HA, 1987, J RHEUMATOL, V14, P91; VANHEMERT AM, 1989, CLIN ENDOCRINOL, V31, P499; WAKASUGI M, 1993, BONE, V14, P29, DOI 10.1016/8756-3282(93)90252-6; WEINSTOCK RS, 1989, J BONE MINER RES, V4, P97; YKIJARVINEN H, 1994, LANCET, V343, P91, DOI 10.1016/S0140-6736(94)90821-4; 1987, MEASURING OBESITY CL	38	251	255	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	MAR 15	1995	122	6					409	414		10.7326/0003-4819-122-6-199503150-00002	http://dx.doi.org/10.7326/0003-4819-122-6-199503150-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM266	7856988				2022-12-28	WOS:A1995QM26600002
J	LEE, JO; RIEU, P; ARNAOUT, MA; LIDDINGTON, R				LEE, JO; RIEU, P; ARNAOUT, MA; LIDDINGTON, R			CRYSTAL-STRUCTURE OF THE A-DOMAIN FROM THE A-SUBUNIT OF INTEGRIN CR3 (CD11B/CD18)	CELL			English	Article							AMINO-ACID-SEQUENCE; BETA-SUBUNIT; VONWILLEBRAND-FACTOR; EXTRACELLULAR-MATRIX; ADHESION RECEPTOR; ALPHA-SUBUNIT; MONOCLONAL-ANTIBODIES; FIBRONECTIN RECEPTOR; MOLECULAR-CLONING; GLOBULAR DOMAINS	We have determined the high resolution crystal structure of the A domain from the a chain of integrin CR3. The domain adopts a classic alpha/beta ''Rossmann'' fold and contains an unusual Mg2+ coordination site at its surface. One of the coordinating ligands is the glutamate side chain from another A domain molecule. We suggest that this site represents a general metal ion-dependent adhesion site (MIDAS) for binding protein ligands. We further propose that the beta subunits of integrins contain a MIDAS motif within a modified A domain. Our crystal structure will allow reliable models to be built for other members of the A domain superfamily and should facilitate development of novel adhesion modulatory drugs.	MASSACHUSETTS GEN HOSP,DEPT MED,DIV NEPHROL,LEUKOCYTE BIOL & INFLAMMAT PROGRAM,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,XRAY CRYSTALLOG LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			Lee, Jie-Oh/AAG-4302-2020	Lee, Jie-Oh/0000-0001-6519-6049	NCI NIH HHS [5P30CA0651] Funding Source: Medline; NIAID NIH HHS [P01 AI-28465] Funding Source: Medline; NIDDK NIH HHS [R01 DK-48549] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI028465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048549] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBELDA SM, 1994, FASEB J, V8, P504, DOI 10.1096/fasebj.8.8.8181668; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ARGRAVES WS, 1987, P NATL ACAD SCI USA, V84, P464, DOI 10.1073/pnas.84.2.464; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; ARNAOUT MA, 1990, BLOOD, V75, P1037; ARNAOUT MA, 1983, J CLIN INVEST, V72, P171, DOI 10.1172/JCI110955; ARNAOUT MA, 1985, NEW ENGL J MED, V312, P457, DOI 10.1056/NEJM198502213120801; ARNAOUT MA, 1990, IMMUNOL REV, V114, P145, DOI 10.1111/j.1600-065X.1990.tb00564.x; ARNAOUT MA, 1988, J CELL BIOL, V106, P2153, DOI 10.1083/jcb.106.6.2153; ARNAOUT MA, 1993, CONCEPTS IMMUNODEFIC, P191; ARNAOUT MA, 1993, CURR OPIN HEMATOL, V1, P113; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BELLSOLELL L, 1994, J MOL BIOL, V238, P489, DOI 10.1006/jmbi.1994.1308; BENTLEY DR, 1986, BIOCHEM J, V239, P339, DOI 10.1042/bj2390339; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P43; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CAMPBELL RD, 1983, P NATL ACAD SCI-BIOL, V80, P4464, DOI 10.1073/pnas.80.14.4464; CARLOS TM, 1990, IMMUNOL REV, V114, P5, DOI 10.1111/j.1600-065X.1990.tb00559.x; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; CHU ML, 1989, EMBO J, V8, P1939, DOI 10.1002/j.1460-2075.1989.tb03598.x; COBBOLD S, 1994, IMMUNOL TODAY, V15, P347, DOI 10.1016/0167-5699(94)90171-6; COLOMBATTI A, 1993, MATRIX, V13, P297, DOI 10.1016/S0934-8832(11)80025-9; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; ERLE DJ, 1991, J BIOL CHEM, V266, P11009; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; GAMMON WR, 1992, J INVEST DERMATOL, V99, P691, DOI 10.1111/1523-1747.ep12614080; GEBHARD W, 1989, EUR J BIOCHEM, V181, P571, DOI 10.1111/j.1432-1033.1989.tb14762.x; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P41; HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JUST M, 1991, J BIOL CHEM, V266, P17326; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KONNERT JH, 1980, ACTA CRYSTALLOGR A, V36, P344, DOI 10.1107/S0567739480000794; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LAW SKA, 1987, EMBO J, V6, P915, DOI 10.1002/j.1460-2075.1987.tb04838.x; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MACKRELL AJ, 1988, P NATL ACAD SCI USA, V85, P2633, DOI 10.1073/pnas.85.8.2633; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOYLE M, 1991, J BIOL CHEM, V266, P19650; MOYLE M, 1994, J BIOL CHEM, V269, P10008; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PERKINS SJ, 1994, J MOL BIOL, V238, P104, DOI 10.1006/jmbi.1994.1271; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; RIEU P, 1994, J CELL BIOL, V127, P2081, DOI 10.1083/jcb.127.6.2081; RIEU P, 1995, IN PRESS LUNG BIOL H; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SHAW SK, 1994, J BIOL CHEM, V269, P6016; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; SIMMONS D, 1988, NATURE, V331, P625; SMITH JW, 1988, J BIOL CHEM, V263, P18726; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TANIGUCHISIDLE A, 1994, J IMMUNOL, V153, P5285; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TOMLEY FM, 1991, MOL BIOCHEM PARASIT, V49, P277, DOI 10.1016/0166-6851(91)90071-D; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; YAMAGATA M, 1991, J CELL BIOL, V115, P209, DOI 10.1083/jcb.115.1.209; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	74	784	807	2	18	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					631	638		10.1016/0092-8674(95)90517-0	http://dx.doi.org/10.1016/0092-8674(95)90517-0			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867070	Bronze			2022-12-28	WOS:A1995QJ60200015
J	STREBEL, PM; IONNEDELCU, N; BAUGHMAN, AL; SUTTER, RW; COCHI, SL				STREBEL, PM; IONNEDELCU, N; BAUGHMAN, AL; SUTTER, RW; COCHI, SL			INTRAMUSCULAR INJECTIONS WITHIN 30 DAYS OF IMMUNIZATION WITH ORAL POLIOVIRUS VACCINE - A RISK FACTOR FOR VACCINE-ASSOCIATED PARALYTIC POLIOMYELITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENGLAND; SYSTEM; WALES	Background. In Romania the rate of vaccine-associated paralytic poliomyelitis is for unexplained reasons 5 to 17 times higher than in other countries. Long ago it was noted that intramuscular injections administered during the incubation period of wild-type poliovirus infection increased the risk of paralytic disease (a phenomenon known as ''provocation'' poliomyelitis). We conducted a case-control study to explore the association between intramuscular injections and vaccine-associated poliomyelitis in Romania. Methods. The patients were 31 young children in whom vaccine-associated paralytic poliomyelitis developed from 1988 through 1992. Eighteen were vaccine recipients, and 13 had acquired the disease by contact with vaccine recipients. Each of these children was matched with up to five controls according to health center, age, and in the case of vaccine recipients, history of receipt of the live attenuated oral poliovirus vaccine. Data were abstracted from medical records that documented the injections administered in the 30 days before the onset of paralysis. Results. Of the 31 children with vaccine-associated disease, 27 (87 percent) had received one or more intramuscular injections within 30 days before the onset of paralysis, as compared with 77 of the 151 controls (51 percent) (matched odds ratio, 31.2; 95 percent confidence interval, 4.0 to 244.2). Nearly all the intramuscular injections were of antibiotics, and the association was strongest for the patients who received 10 or more injections (matched odds ratio for greater than or equal to 10 injections as compared with no injections, 182.1; 95 percent confidence interval, 15.2 to 2186.4). The risk of paralytic disease was strongly associated with injections given after the oral poliovirus vaccine, but not with injections given before or at the same time as the vaccine (matched odds ratio, 56.7; 95 percent confidence interval, 8.9 to infinity). The attributable risk in the population for intramuscular injections given in the 30 days before the onset of paralysis was 86 percent (95 percent confidence interval, 66 to 95 percent); that is, we estimate that 86 percent of the cases of vaccine-associated paralytic poliomyelitis in this population might have been prevented by the elimination of intramuscular injections within 30 days after exposure to Oral poliovirus vaccine. Conclusions. Provocation paralysis, previously described only for wild-type poliovirus infection, may rarely occur in a child who receives multiple intramuscular injections shortly after exposure to oral poliovirus vaccine, either as a vaccine recipient or through contact with a recent recipient. This phenomenon may explain the high rate of vaccine-associated paralytic poliomyelitis in Romania, where the use of intramuscular injections of antibiotics in infants with febrile illness is common.	CTR DIS CONTROL & PREVENT,NATL IMMUNIZATION PROGRAM,DIV DATA MANAGEMENT,ATLANTA,GA 30333; MINIST HLTH,EXPANDED PROGRAMME IMMUNIZAT,BUCHAREST,ROMANIA	Centers for Disease Control & Prevention - USA	STREBEL, PM (corresponding author), CTR DIS CONTROL & PREVENT,NATL IMMUNIZATION PROGRAM,DIV EPIDEMIOL & SURVEILLANCE,MAILSTOP E-61,ATLANTA,GA 30333, USA.							ANDERSON GW, 1951, PEDIATRICS, V7, P741; ANDRUS JK, IN PRESS B WHO; BANKS HS, 1950, BRIT MED J, V2, P251, DOI 10.1136/bmj.2.4673.251; BODIAN D, 1954, AM J HYG, V60, P358, DOI 10.1093/oxfordjournals.aje.a119727; BRESLOW NE, 1980, IARC SCI PUBL, V32, P247; COCKBURN WC, 1988, B WORLD HEALTH ORGAN, V66, P143; COLLINGHAM KE, 1978, LANCET, V1, P976; CRAINIC R, 1983, INFECT IMMUN, V41, P1217, DOI 10.1128/IAI.41.3.1217-1225.1983; Deivanayagam N, 1993, Indian Pediatr, V30, P335; ESTEVES K, 1988, B WORLD HEALTH ORGAN, V66, P739; FLEISS JL, 1991, STATISTICAL METHODS; GREENBERG M, 1952, AM J PUBLIC HEALTH, V42, P142; GREENLAND S, 1987, STAT MED, V6, P701, DOI 10.1002/sim.4780060607; GUYER B, 1980, B WORLD HEALTH ORGAN, V58, P285; HERSH BS, 1993, AIDS, V7, P1617, DOI 10.1097/00002030-199312000-00012; HILL AB, 1950, BMJ-BRIT MED J, V2, P1; HIRJI KF, 1989, AM STAT, V43, P7, DOI 10.2307/2685158; HIRJI KF, 1988, BIOMETRICS, V44, P803, DOI 10.2307/2531592; Hollander M., 1973, NONPARAMETRIC STAT, P68; JOCE R, 1992, BRIT MED J, V305, P79, DOI 10.1136/bmj.305.6845.79; MCCLOSKEY BP, 1950, LANCET, V1, P659; NATHANSON N, 1961, B JOHNS HOPKINS HOSP, V108, P308; REN R, 1993, J INFECT DIS, V166, P747; ROSEN L, 1953, AM J HYG, V57, P237, DOI 10.1093/oxfordjournals.aje.a119571; SIMOES EAF, 1994, 34TH INT C ANT AG CH, P66; STREBEL PM, 1994, AM J EPIDEMIOL, V140, P1111, DOI 10.1093/oxfordjournals.aje.a117211; SUTTER RW, 1989, AM J PUBLIC HEALTH, V79, P495, DOI 10.2105/AJPH.79.4.495; SUTTER RW, 1992, J INFECT DIS, V165, P444, DOI 10.1093/infdis/165.3.444; TOWNSENDCOLES WF, 1953, T ROY SOC TROP MED H, V47, P77, DOI 10.1016/0035-9203(53)90027-3; Wyatt H V, 1986, Dev Biol Stand, V65, P123; WYATT HV, 1990, REV INFECT DIS, V12, P547; WYATT HV, 1984, SOC SCI MED, V19, P911, DOI 10.1016/0277-9536(84)90320-4; WYATT HV, 1985, T ROY SOC TROP MED H, V79, P355, DOI 10.1016/0035-9203(85)90379-7; YANG CF, 1991, VIRUS RES, V20, P159; 1981, INFECT DIS, P35; 1982, B WORLD HEALTH ORGAN, V60, P231; 1956, LANCET, V2, P1223; 1976, B WORLD HEALTH ORGAN, V53, P319; 1993, LOGXACT TURBO USER M; 1989, EXPANDED PROGRAMME I, P35	40	61	61	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 23	1995	332	8					500	506		10.1056/NEJM199502233320804	http://dx.doi.org/10.1056/NEJM199502233320804			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH288	7830731				2022-12-28	WOS:A1995QH28800004
J	WAISEL, DB; TRUOG, RD				WAISEL, DB; TRUOG, RD			THE CARDIOPULMONARY RESUSCITATION-NOT-INDICATED ORDER - FUTILITY REVISITED	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CARE	This paper reviews the advent of unilateral do-not-resuscitate orders. Unilateral do-not-resuscitate policies presume that cardiopulmonary resuscitation is a medical therapy and that physicians have no obligation to undertake a medical therapy that does not offer achievable and appropriate goals. Four do-not-resuscitate policies from U.S. hospitals and some of the significant published proposals are reviewed. We conclude that anything other than a physiologic definition of futility is indefensible because of imposed value judgments, imprecise definitions of quantitative and qualitative futility, inexact data, lack of certitude of economic benefit, and the role of autonomy for the patient and physician.	HARVARD UNIV, CHILDRENS HOSP, SCH MED, MULTIDISCIPLINARY INTENS CARE UNIT, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School	WAISEL, DB (corresponding author), WILFORD HALL USAF MED CTR, DEPT ANESTHESIOL PSSA, LACKLAND AFB, TX 78236 USA.			Waisel, David/0000-0002-5307-4092				[Anonymous], 1974, JAMA-J AM MED ASSOC, V227, P864; BEAUCHAMP TL, 1989, PRINCIPLES BIOMEDICA, P71; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; BRETT AS, 1986, NEW ENGL J MED, V315, P1347, DOI 10.1056/NEJM198611203152109; CHAMBERS CV, 1994, ARCH INTERN MED, V154, P541, DOI 10.1001/archinte.154.5.541; DANIELS N, 1986, NEW ENGL J MED, V314, P1380, DOI 10.1056/NEJM198605223142109; DORNETTE WH, 1972, LEGAL ASPECTS ANESTH, P14; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; EMANUEL EJ, 1994, NEW ENGL J MED, V330, P540, DOI 10.1056/NEJM199402243300806; FOWLER MDM, 1989, HEART LUNG, V18, P314; FRIED C, 1976, NEW ENGL J MED, V295, P390, DOI 10.1056/NEJM197608122950711; JUDE JR, 1965, FUNDAMENTALS CARDIOP, P4; Karni E., 1985, DECISION MAKING UNCE; MORREIM EH, 1994, HASTINGS CENT REP, V24, P33, DOI 10.2307/3562386; MURPHY DJ, 1988, JAMA-J AM MED ASSOC, V260, P2098, DOI 10.1001/jama.260.14.2098; MURPHY DJ, 1993, ARCH INTERN MED, V153, P1641, DOI 10.1001/archinte.153.14.1641; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; POSES RM, 1989, CRIT CARE MED, V17, P827, DOI 10.1097/00003246-198908000-00021; RABKIN MT, 1976, NEW ENGL J MED, V295, P364, DOI 10.1056/NEJM197608122950705; ROSENBERG M, 1993, ARCH INTERN MED, V153, P1370, DOI 10.1001/archinte.153.11.1370; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; TOMLINSON T, 1990, JAMA-J AM MED ASSOC, V264, P1276, DOI 10.1001/jama.264.10.1276; TRUOG RD, 1992, NEW ENGL J MED, V326, P1560, DOI 10.1056/NEJM199206043262310; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; VANMCCRARY S, 1994, J CLIN ETHIC, V5, P100; YOUNGER SJ, 1988, JAMA-J AM MED ASSOC, V260, P2094, DOI 10.1001/jama.260.14.2094; 1991, JAMA-J AM MED ASSOC, V265, P1868; 1993, OP10100NR VET AFF ME; 1991, 1136 VET AFF MED CTR, P1; 1987, GUIDELINS TERMINATIO, P32; 1993, NY TIMES        1017; 1993, OP10101NR VET AFF ME; 1991, GUIDELINES WITHHOLDI; 1992, POLICY MANUAL; 1992, J HOPKINS HOSPITAL P	35	92	93	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1995	122	4					304	308		10.7326/0003-4819-122-4-199502150-00011	http://dx.doi.org/10.7326/0003-4819-122-4-199502150-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF769	7825768				2022-12-28	WOS:A1995QF76900011
J	COOK, A				COOK, A			MANAGEMENT FOR DOCTORS - MANAGEMENT ACCOUNTING .7.	BRITISH MEDICAL JOURNAL			English	Article											COOK, A (corresponding author), UNIV BIRMINGHAM,DEPT ACCOUNTING & FINANCE,BIRMINGHAM B15 2RT,W MIDLANDS,ENGLAND.							GARBUTT D, 1992, MAKING BUDGETS WORK; HENLEY D, 1986, PUBLIC SECTOR ACCOUN; 1993, COSTING CONTRACTING; 1994, CAPITAL INVESTMENT M; 1991, MANAGEMENT ACCOUNTAN; 1978, 2 ROYAL COMM NHS RES; 1960, TERMINOLOGY COST ACC	7	0	0	2	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 11	1995	310	6976					381	385		10.1136/bmj.310.6976.381	http://dx.doi.org/10.1136/bmj.310.6976.381			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG721	7866218	Green Published			2022-12-28	WOS:A1995QG72100025
J	PAN, WH; LI, LA; TSAI, MJ				PAN, WH; LI, LA; TSAI, MJ			TEMPERATURE EXTREMES AND MORTALITY FROM CORONARY HEART-DISEASE AND CEREBRAL INFARCTION IN ELDERLY CHINESE	LANCET			English	Article							SEASONAL-VARIATION	We studied the relation between outdoor temperature and mortality rates from cardiovascular disease in Taiwan from 1981 to 1991. In 11 years, there were 30 085, 21 750, and 39 818 deaths from coronary artery disease, cerebral infarction, and cerebral haemorrhage, respectively, among 7.6 million residents aged 25 and over in selected areas where climate was recorded. A temperature-mortality relation was especially apparent in the elderly. A U-shaped relation was observed between temperature and mortality from coronary artery disease and cerebral infarction. The range corresponding to least deaths from coronary artery disease (26-29 degrees C) and cerebral infarction (27-29 degrees 0) was higher than that in countries with colder climates. In the elderly, the risk of cerebral infarction at 32 degrees C was 66% higher than that at 27-29 degrees C; the risk increased by 3.0% per 1 degrees C reduction from 27-29 degrees C. The risk of coronary artery disease at 32 degrees C was 22% higher than that at 26-29 degrees C; below 26-29 degrees C, the risk increased by 2.8% per 1 degrees C reduction. Mortality from cerebral haemorrhage decreased with increasing temperature at a rate of 3.3% per 1 degrees C. These results imply a pathophysiological difference between thromboembolic and haemorrhagic cardiovascular diseases. Poor thermoregulation in older people may precipitate cardiovascular disease events.	ACAD SINICA,INST STAT,TAIPEI 115,TAIWAN; NATL TAIWAN UNIV,COLL PUBL HLTH,INST EPIDEMIOL,TAIPEI 10764,TAIWAN	Academia Sinica - Taiwan; National Taiwan University	PAN, WH (corresponding author), ACAD SINICA,INST BIOMED SCI,DIV EPIDEMIOL & PUBL HLTH,TAIPEI 115,TAIWAN.		Pan, Wen-Harn/F-9972-2010	Pan, Wen-Harn/0000-0001-9136-0658				Clark R.P., 1985, MAN HIS THERMAL ENV; DOUGLAS AS, 1991, SCOT MED J, V36, P76, DOI 10.1177/003693309103600304; GORDON DJ, 1988, J CLIN EPIDEMIOL, V41, P679, DOI 10.1016/0895-4356(88)90120-5; KEATINGE WR, 1986, AM J MED, V81, P795, DOI 10.1016/0002-9343(86)90348-7; KUNST AE, 1993, AM J EPIDEMIOL, V137, P331, DOI 10.1093/oxfordjournals.aje.a116680; NATSUME K, 1992, INT J BIOMETEOROL, V36, P1, DOI 10.1007/BF01208726; STOUT RW, 1991, LANCET, V338, P9, DOI 10.1016/0140-6736(91)90004-9; WOO J, 1991, NEUROEPIDEMIOLOGY, V10, P260, DOI 10.1159/000110282; WOODHOUSE PR, 1993, AGE AGEING, V22, P273, DOI 10.1093/ageing/22.4.273; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1	10	203	218	2	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 11	1995	345	8946					353	355		10.1016/S0140-6736(95)90341-0	http://dx.doi.org/10.1016/S0140-6736(95)90341-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF722	7845116				2022-12-28	WOS:A1995QF72200009
J	GALLAY, P; SWINGLER, S; AIKEN, C; TRONO, D				GALLAY, P; SWINGLER, S; AIKEN, C; TRONO, D			HIV-I INFECTION OF NONDIVIDING CELLS - C-TERMINAL TYROSINE PHOSPHORYLATION OF THE VIRAL MATRIX PROTEIN IS A KEY REGULATOR	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEAR LOCATION; PLASMA-MEMBRANE; GROWTH-FACTOR; DNA; ACID; TRANSCRIPTION; SEQUENCE; IMPORT; CYCLE	The HIV-1 matrix (MA) protein contains two subcellular localization signals with opposing effects. A myristoylated N-terminus governs particle assembly at the plasma membrane, and a nucleophilic motif facilitates import of the viral preintegration complex into the nucleus of nondividing cells. Here, we show that myristoylation acts as the MA dominant targeting signal in HIV-1 producer cells. During virus assembly, a subset of MA is phosphorylated on the C-terminal tyrosine by a virion-associated cellular protein kinase. Tyrosine-phosphorylated MA is then preferentially transported to the nucleus of target cells. An MA tyrosine mutant virus grows normally in dividing cells, but is blocked for nuclear import in terminally differentiated macrophages. MA tyrosine phosphorylation thus reveals the karyophilic properties of this protein within the HIV-1 preintegration complex, thereby playing a critical role for infection of nondividing cells.			GALLAY, P (corresponding author), SALK INST BIOL STUDIES, INFECT DIS LAB, 10010 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; AIDEN C, 1994, CELL, V76, P853; ALOIA RC, 1993, P NATL ACAD SCI USA, V90, P5181, DOI 10.1073/pnas.90.11.5181; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BUKRINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125, DOI 10.1073/pnas.90.13.6125; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; DORFMAN T, 1994, J VIROL, V68, P1689, DOI 10.1128/JVI.68.3.1689-1696.1994; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; GARTNER S, 1990, RETROVIRUSES, V8, P1017; GELDERBLOM HR, 1987, VIROLOGY, V156, P171, DOI 10.1016/0042-6822(87)90449-1; GELDERBLOM HR, 1991, AIDS, V5, P617, DOI 10.1097/00002030-199106000-00001; GULIZIA J, 1994, J VIROL, V68, P2021, DOI 10.1128/JVI.68.3.2021-2025.1994; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; HUMPHRIES EH, 1972, J VIROL, V10, P82, DOI 10.1128/JVI.10.1.82-87.1972; HUMPHRIES EH, 1974, J VIROL, V14, P531, DOI 10.1128/JVI.14.3.531-546.1974; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; LIN PH, 1991, METHOD ENZYMOL, V198, P251; MATTHEWS S, 1994, NATURE, V370, P666, DOI 10.1038/370666a0; MICHAUD N, 1993, EXP CELL RES, V208, P128, DOI 10.1006/excr.1993.1230; MYERS G, 1992, HUMAN RETROVIRUSES A; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHAROVA N, 1991, AIDS RES HUM RETROV, V7, P303, DOI 10.1089/aid.1991.7.303; SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SPEARMAN P, 1994, J VIROL, V68, P3232, DOI 10.1128/JVI.68.5.3232-3242.1994; SUGASAWA K, 1990, J VIROL, V64, P4820, DOI 10.1128/JVI.64.10.4820-4829.1990; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TRONO D, 1992, J VIROL, V66, P4893, DOI 10.1128/JVI.66.8.4893-4900.1992; VARMUS H, 1984, RNA TUMOR VIRUSES, P369; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; VONSCHWEDLER U, 1994, P NATL ACAD SCI USA, V91, P6992, DOI 10.1073/pnas.91.15.6992; WALKER F, 1993, J BIOL CHEM, V268, P19552; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; YU XF, 1992, J VIROL, V66, P4966, DOI 10.1128/JVI.66.8.4966-4971.1992; YU XF, 1992, J VIROL, V66, P5667, DOI 10.1128/JVI.66.9.5667-5670.1992; ZHOU WJ, 1994, J VIROL, V68, P2556, DOI 10.1128/JVI.68.4.2556-2569.1994	45	297	306	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	1995	80	3					379	388		10.1016/0092-8674(95)90488-3	http://dx.doi.org/10.1016/0092-8674(95)90488-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859280	Bronze			2022-12-28	WOS:A1995QG47000004
J	MATIC, I; RAYSSIGUIER, C; RADMAN, M				MATIC, I; RAYSSIGUIER, C; RADMAN, M			INTERSPECIES GENE EXCHANGE IN BACTERIA - THE ROLE OF SOS AND MISMATCH REPAIR SYSTEMS IN EVOLUTION OF SPECIES	CELL			English	Article							ESCHERICHIA-COLI K-12; CONSTITUTIVELY ACTIVATED RECA; SALMONELLA-TYPHIMURIUM; HOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; CODON USAGE; STRAINS; PROTEIN; INDUCTION; MUTANTS	Analysis of interspecies matings between S. typhimurium and E. coli indicates that the genetic barrier that separates these (and perhaps many other) related species is primarily recombinational. The structural component of this barrier is genomic sequence divergence. The mismatch repair enzymes act as potent inhibitors of interspecies recombination, whereas the SOS system acts as an inducible positive regulator. Interspecies mating triggers a RecBC-dependent SOS response in female bacteria that increases recombination mainly through overproduction of the RecA protein. Mismatch repair acts to reduce the mutation rate and recombination between similar sequences, whereas SOS acts to increase both. These opposing activities allow mismatch repair and SOS systems to determine both the rate of accumulation of sequence divergence and the extent of genetic isolation, which are the key components of the speciation process.			MATIC, I (corresponding author), INST JACQUES MONOD,MUTAGENESE LAB,2 PL JUSSIEU,F-75251 PARIS 05,FRANCE.		; Radman, Miroslav/HDM-5955-2022	Radman, Miroslav/0000-0002-7034-4365; Radman, Miroslav/0000-0003-0216-3148				BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; BAGDASARIAN M, 1986, P NATL ACAD SCI USA, V83, P5723, DOI 10.1073/pnas.83.15.5723; BARON LS, 1968, BACTERIOL REV, V32, P362, DOI 10.1128/MMBR.32.4_Pt_1.362-369.1968; BIANCHI ME, 1983, CELL, V35, P511, DOI 10.1016/0092-8674(83)90185-X; BOULAIN JC, 1986, MOL GEN GENET, V205, P339, DOI 10.1007/BF00430448; BUVINGER WE, 1984, J BACTERIOL, V159, P618, DOI 10.1128/JB.159.2.618-623.1984; CAILLETFAUQUET P, 1984, EMBO J, V3, P707, DOI 10.1002/j.1460-2075.1984.tb01873.x; CASAREGOLA S, 1982, MOL GEN GENET, V185, P430, DOI 10.1007/BF00334135; CHAO L, 1983, EVOLUTION, V37, P125, DOI 10.1111/j.1558-5646.1983.tb05521.x; CHAUDHURY AM, 1985, MOL GEN GENET, V201, P525, DOI 10.1007/BF00331350; CRAIG NL, 1980, NATURE, V283, P26, DOI 10.1038/283026a0; DASGUPTA C, 1982, P NATL ACAD SCI-BIOL, V79, P762, DOI 10.1073/pnas.79.3.762; DIMPFL J, 1989, GENETICS, V123, P255; ECHOLS H, 1981, CELL, V25, P1, DOI 10.1016/0092-8674(81)90223-3; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; GOULD SJ, 1993, NATURE, V366, P223, DOI 10.1038/366223a0; GROSS MD, 1981, MUTAT RES, V91, P107, DOI 10.1016/0165-7992(81)90081-6; HEINEMANN JA, 1991, TRENDS GENET, V7, P181, DOI 10.1016/0168-9525(91)90122-7; HERRLICH P, 1984, HUM GENET, V67, P360, DOI 10.1007/BF00291392; HORII ZI, 1973, J MOL BIOL, V80, P327, DOI 10.1016/0022-2836(73)90176-9; HOWARDFLANDERS P, 1966, GENETICS, V53, P1137; JACOB F, 1961, SEXUALITY GENETICS B, P93; JONES AL, 1992, MOL MICROBIOL, V6, P605, DOI 10.1111/j.1365-2958.1992.tb01507.x; JYSSUM K., 1960, ACTA PATHOL ET MICROBIOL SCAND, V48, P113; KAHN PL, 1968, J BACTERIOL, V96, P205; KARU AE, 1982, MOL GEN GENET, V185, P275, DOI 10.1007/BF00330798; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KRICKER MC, 1992, P NATL ACAD SCI USA, V89, P1075, DOI 10.1073/pnas.89.3.1075; KUAN CT, 1992, J BACTERIOL, V174, P6872, DOI 10.1128/JB.174.21.6872-6877.1992; Kucherlapati R, 1988, GENETIC RECOMBINATIO, P1; KUSHNER SR, 1971, P NATL ACAD SCI USA, V67, P824; LEHNER AF, 1985, GENETICS, V110, P365; LEHNER AF, 1984, J BACTERIOL, V160, P682, DOI 10.1128/JB.160.2.682-686.1984; LENSKI RE, 1992, ENCY MICROBIOLOGY, V2, P125; LICHTEN M, 1984, P NATL ACAD SCI-BIOL, V81, P7180, DOI 10.1073/pnas.81.22.7180; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; LLOYD RG, 1987, J GEN MICROBIOL, V133, P2531; LLOYD RG, 1983, MOL GEN GENET, V190, P156, DOI 10.1007/BF00330339; LLOYD RG, 1978, J BACTERIOL, V134, P929, DOI 10.1128/JB.134.3.929-935.1978; LOVETT ST, 1984, J BACTERIOL, V157, P190, DOI 10.1128/JB.157.1.190-196.1984; MAHAJAN SK, 1988, GENETIC RECOMBINATIO, P87; MARKLUND BI, 1992, MOL MICROBIOL, V6, P2225, DOI 10.1111/j.1365-2958.1992.tb01399.x; MATIC I, 1994, GENETICS, V136, P17; MAYNARDSMITH J, 1991, NATURE, V349, P29; Mayr E., 1982, GROWTH BIOL THOUGHT; MEDIGUE C, 1991, J MOL BIOL, V222, P851, DOI 10.1016/0022-2836(91)90575-Q; Miller J.H., 1972, EXPT MOL GENETICS; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MOUNT DW, 1972, J BACTERIOL, V112, P886, DOI 10.1128/JB.112.2.886-893.1972; NINIO J, 1991, GENETICS, V129, P957; OHKI M, 1969, COLD SPRING HARB SYM, V33, P651; OISHI M, 1988, RECOMBINATION GENETI, P445; PALAS KM, 1990, J BIOL CHEM, V265, P3447; PETIT MA, 1991, GENETICS, V129, P327; RADMAN M, 1989, GENOME, V31, P68, DOI 10.1139/g89-014; RADMAN M, 1980, PHOTOCHEM PHOTOBIOL, V32, P823, DOI 10.1111/j.1751-1097.1980.tb04062.x; RADMAN M, 1993, GENOME ANAL, V7, P139; RADMAN M, 1993, CHROMOSOMA, V102, P369, DOI 10.1007/BF00360400; Radman M, 1974, MOL ENV ASPECTS MUTA, P128; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; RAYSSIGUIER C, 1991, BIOCHIMIE, V73, P371, DOI 10.1016/0300-9084(91)90103-8; REENAN RAG, 1992, GENETICS, V132, P963; Roberts Michael S., 1993, Genetics, V134, P401; ROMAN LJ, 1991, P NATL ACAD SCI USA, V88, P3367, DOI 10.1073/pnas.88.8.3367; RYDER L, 1994, J BACTERIOL, V176, P1570, DOI 10.1128/jb.176.6.1570-1577.1994; SANDERSON KE, 1972, BACTERIOL REV, V36, P608, DOI 10.1128/MMBR.36.4.608-637.1972; SASSANFAR M, 1990, J MOL BIOL, V212, P79, DOI 10.1016/0022-2836(90)90306-7; SEDGWICK SG, 1982, MOL GEN GENET, V185, P93, DOI 10.1007/BF00333796; SEDGWICK SG, 1988, J BACTERIOL, V170, P1610, DOI 10.1128/jb.170.4.1610-1616.1988; SERVICE RF, 1994, SCIENCE, V263, P1559, DOI 10.1126/science.8128240; SHARP PM, 1987, MOL BIOL EVOL, V4, P222; SHARP PM, 1991, J MOL EVOL, V33, P23, DOI 10.1007/BF02100192; SHEN P, 1986, GENETICS, V112, P441; SHEN P, 1989, MOL GEN GENET, V218, P358, DOI 10.1007/BF00331291; SIEGEL EC, 1982, MUTAT RES, V92, P25; SMITH GR, 1989, CELL, V58, P807, DOI 10.1016/0092-8674(89)90929-X; SMITH NH, 1990, J BACTERIOL, V172, P2209, DOI 10.1128/jb.172.5.2209-2216.1990; SOMMER S, 1993, MOL MICROBIOL, V10, P963, DOI 10.1111/j.1365-2958.1993.tb00968.x; TAYLOR AF, 1988, GENETIC RECOMBINATIO, P231; TROBNER W, 1984, MOL GEN GENET, V198, P177, DOI 10.1007/BF00328720; VERMA N, 1989, J BACTERIOL, V171, P5694, DOI 10.1128/jb.171.10.5694-5701.1989; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WEST SC, 1994, CELL, V76, P9, DOI 10.1016/0092-8674(94)90168-6; WHITTAM TS, 1993, MECHANISMS OF MOLECULAR EVOLUTION, P223; WITKIN EM, 1976, BACTERIOL REV, V40, P869, DOI 10.1128/MMBR.40.4.869-907.1976; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238	86	245	252	0	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					507	515		10.1016/0092-8674(95)90501-4	http://dx.doi.org/10.1016/0092-8674(95)90501-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859291	Bronze			2022-12-28	WOS:A1995QG47000017
J	SONGYANG, Z; CARRAWAY, KL; ECK, MJ; HARRISON, SC; FELDMAN, RA; MOHAMMADI, M; SCHLESSINGER, J; HUBBARD, SR; SMITH, DP; ENG, C; LORENZO, MJ; PONDER, BAJ; MAYER, BJ; CANTLEY, LC				SONGYANG, Z; CARRAWAY, KL; ECK, MJ; HARRISON, SC; FELDMAN, RA; MOHAMMADI, M; SCHLESSINGER, J; HUBBARD, SR; SMITH, DP; ENG, C; LORENZO, MJ; PONDER, BAJ; MAYER, BJ; CANTLEY, LC			CATALYTIC SPECIFICITY OF PROTEIN-TYROSINE KINASES IS CRITICAL FOR SELECTIVE SIGNALING	NATURE			English	Article							SUBSTRATE-SPECIFICITY; PHOSPHORYLATION; DOMAINS; INVITRO; ANTIGEN; SITES	How do distinct protein-tyrosine kinases activate specific downstream events? Src-homology-2 (SH2) domains on tyrosine kinases or targets of tyrosine kinases recognize phosphotyrosine in a specific sequence context and thereby provide some specificity(1-3). The role of the catalytic site of tyrosine kinases in determining target specificity has not been fully investigated. Here we use a degenerate peptide library to show that each of nine tyrosine kinases investigated has a unique optimal peptide substrate. We find that the cytosolic tyrosine kinases preferentially phosphorylate peptides recognized by their own SH2 domains or closely related SH2 domains (group I; ref. 3), whereas receptor tyrosine kinases preferentially phosphorylate peptides recognized by subsets of group In SH2 domains(3). The importance of these findings for human disease is underscored by our observation that a point mutation in the RET receptor-type tyrosine kinase, which causes multiple endocrine neoplasia type 2B, results in a shift in peptide substrate specificity.	BETH ISRAEL HOSP, DEPT MED, DIV SIGNAL TRANSDUCT, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02215 USA; TUFTS UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02111 USA; CHILDRENS HOSP, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; CHILDRENS HOSP, MOLEC MED LAB, BOSTON, MA 02115 USA; UNIV MARYLAND, SCH MED, DEPT MICROBIOL & IMMUNOL, BALTIMORE, MD 21201 USA; UNIV MARYLAND, MARYLAND BIOTECHNOL INST, CTR MED BIOTECHNOL, BALTIMORE, MD 21201 USA; NYU, MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA; COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA; UNIV CAMBRIDGE, DEPT PATHOL, CRC, HUMAN CANC GENET RES GRP, CAMBRIDGE CB2 1QP, ENGLAND; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Tufts University; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; New York University; Columbia University; University of Cambridge; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			kasaei, fahime/T-7197-2018; Cantley, Lewis C/D-1800-2014; Mohammadi, Moosa/ABA-6745-2020	Cantley, Lewis C/0000-0002-1298-7653; Mohammadi, Moosa/0000-0003-2434-9437; Feldman, Ricardo A./0000-0001-6090-0439; Eng, Charis/0000-0002-3693-5145; Lorenzo, Maria Jesus/0000-0003-4416-0615				ARECES LB, 1994, MOL CELL BIOL, V14, P4606, DOI 10.1128/MCB.14.7.4606; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CARRAWAY KL, 1993, J BIOL CHEM, V268, P23860; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DUYSTER J, IN PRESS P NATN ACAD; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HUNTER T, 1982, J BIOL CHEM, V257, P4843; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TILT JH, 1994, J BIOL CHEM, V269, P7423; TINKER DA, 1992, ANTICANCER RES, V12, P123; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	25	817	843	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	1995	373	6514					536	539		10.1038/373536a0	http://dx.doi.org/10.1038/373536a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7845468				2022-12-28	WOS:A1995QF72400063
J	BHAN, MK; WOO, EC; FONTAINE, O; MAULENRADOVAN, I; PIERCE, NF; RIBEIRO, H; RIBEIRO, T; PALMEIRA, C; REIS, Z; SINGH, KD; BHATNAGAR, S; MEJIA, HFV; BASTIDAS, MA; SALAZARLINDO, E; MIRANDALANGSCHWAGER, P				BHAN, MK; WOO, EC; FONTAINE, O; MAULENRADOVAN, I; PIERCE, NF; RIBEIRO, H; RIBEIRO, T; PALMEIRA, C; REIS, Z; SINGH, KD; BHATNAGAR, S; MEJIA, HFV; BASTIDAS, MA; SALAZARLINDO, E; MIRANDALANGSCHWAGER, P			MULTICENTER EVALUATION OF REDUCED-OSMOLARITY ORAL REHYDRATION SALTS SOLUTION	LANCET			English	Article							ACUTE DIARRHEA; THERAPY; INFANTS	In developed countries, use of oral rehydration salts (ORS) solution with osmolarity lower than that of plasma has been recommended because of the risk of hypernatraemia. We compared the clinical efficacy of reduced-osmolarity ORS and standard ORS solutions in children with acute diarrhoea in four developing countries. 447 boys aged 1-24 months, admitted to hospitals in four countries with acute diarrhoea and signs of dehydration, were randomly assigned either standard ORS (311 mmol/L) or reduced-osmolarity ORS (224 mmol/L) solution. Total stool output was 39% greater (95% CI 11-75), total ORS intake 18% greater (3-33), and duration of diarrhoea 22% longer (2-45) in the standard ORS group than in the reduced-osmolarity ORS group. The risk of requiring intravenous infusion after completion of the initial oral rehydration was greater in children given standard ORS solution than in those given reduced-osmolarity ORS solution in three of the four countries (all-country relative risk 1.4 [0.9-2.4]). This relative risk was significantly increased only in non-breastfed children (2.0 [1.0-3.8], p<0.05). in breastfed children, the relative risk of requiring intravenous infusion was not affected by the ORS solution (0.9 [0.4-2.0]). The mean sodium concentration 24 h after admission was significantly lower in the reduced-osmolarity ORS group than in the standard ORS group (135 [134-136] vs 138 [136-139] mmol/L, p<0.01). Reduced-osmolarity ORS solution has beneficial effects on the clinical course of acute diarrhoea. Our findings support the use of reduced-osmolarity ORS solution in children with acute non-cholera diarrhoea in developing countries. Further studies are needed to find the best formulation and whether such a solution would be satisfactory for the treatment of cholera.	WHO,DIARRHOEAL DIS CONTROL PROGRAMME,CH-1211 GENEVA,SWITZERLAND	World Health Organization								AVERY ME, 1990, NEW ENGL J MED, V323, P891, DOI 10.1056/NEJM199009273231307; ELLIOTT E J, 1989, Acta Paediatrica Scandinavica Supplement, P31; ELMOUGI M, 1994, J PEDIATR GASTR NUTR, V19, P83, DOI 10.1097/00005176-199407000-00013; Farthing M J, 1989, Acta Paediatr Scand Suppl, V364, P23; FINBERG L, 1973, NEW ENGL J MED, V289, P196, DOI 10.1056/NEJM197307262890407; GARDNER MJ, 1989, BMJ; HIRSCHHORN N, 1980, AM J CLIN NUTR, V33, P637, DOI 10.1093/ajcn/33.3.637; HUNT JB, 1992, GUT, V33, P1652, DOI 10.1136/gut.33.12.1652; MAHALANABIS D, 1970, PEDIATRICS, V45, P374; MANTEL N, 1959, J NATL CANCER I, V22, P719; PIZARRO D, 1986, J PEDIATR GASTR NUTR, V5, P6, DOI 10.1097/00005176-198601000-00003; POCOCK SJ, 1987, CLIN TRIALS PRACTICA, P123; RAHAMAN MM, 1979, LANCET, V2, P908; RAUTANEN T, 1993, ACTA PAEDIATR, V82, P52, DOI 10.1111/j.1651-2227.1993.tb12516.x; Sandhu B K, 1989, Acta Paediatr Scand Suppl, V364, P17; 1990, WHOCDDSER802REV2; 1992, J PEDIATR GASTROENTE, V14, P113	17	84	86	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					282	285						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE731	7837862				2022-12-28	WOS:A1995QE73100009
J	HERMAN, J				HERMAN, J			POINTING TO THE WORD	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					332	332		10.1016/S0140-6736(95)90330-5	http://dx.doi.org/10.1016/S0140-6736(95)90330-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE731	7837902				2022-12-28	WOS:A1995QE73100072
J	ROBERTS, I; NORTON, R; JACKSON, R; DUNN, R; HASSALL, I				ROBERTS, I; NORTON, R; JACKSON, R; DUNN, R; HASSALL, I			EFFECT OF ENVIRONMENTAL-FACTORS ON RISK OF INJURY OF CHILD PEDESTRIANS BY MOTOR-VEHICLES - A CASE-CONTROL STUDY	BRITISH MEDICAL JOURNAL			English	Article							ACCIDENTS; MORTALITY	Objective-To identify and assess contribution of environmental risk factors for injury of child pedestrians by motor vehicles. Design-Community based case-control study. Environmental characteristics of sites of child pedestrian injury were compared with the environmental characteristics of selected comparison sites. Each comparison site was the same distance and direction from home of control child as was the injury site from home of relevant case child. Two control sites were selected for each injury site. Setting-Auckland region of New Zealand. Subjects-Cases were 190child pedestrians aged < 15 who were killed or hospitalised after collision with a motor vehicle on a public road during two years and two months. Controls were 380 children randomly sampled from population and frequency matched for age and sex. Main outcome measures-Traffic volume and speed and level of parking on curbs at injury sites and comparison sites. Results-Risk of injury of child pedestrians was strongly associated with traffic volume: risk of injury at sites with highest traffic volumes was 14 times greater than that at least busy sites (odds ratio 14.30; 95% confidence interval 6.98 to 29.20), and risk increased with increasing traffic volume. High density of curb parking was also associated with increased risk (odds ratio 8.12; 3.32 to 19.90). Risk was increased at sites with mean speeds over 40 km/h (odds ratio 2.68; 1.26 to 5.69), although risk did not increase further with increasing speed. Conclusion-Reducing traffic volume in urban areas could significantly reduce rates of child pedestrian injury. Restricting curb parking may also be effective.	DEPT COMMUNITY HLTH,INJURY PREVENT RES CTR,AUCKLAND,NEW ZEALAND; UNIV AUCKLAND,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND; UNIV AUCKLAND,DEPT CIVIL & RESOURCE ENGN,AUCKLAND,NEW ZEALAND; OFF COMMISSIONER CHILDREN,WELLINGTON,NEW ZEALAND	University of Auckland; University of Auckland				Jackson, Rod/0000-0001-5914-6934				ELLEY WB, 1985, NEW ZEAL J EDUC STUD, V20, P115; ENGEL U, 1992, ACCIDENT ANAL PREV, V24, P17, DOI 10.1016/0001-4575(92)90068-T; KENDRICK D, 1993, ARCH DIS CHILD, V68, P669, DOI 10.1136/adc.68.5.669; Lawson S., 1990, ACCIDENTS YOUNG PEDE; MUELLER BA, 1990, AM J EPIDEMIOL, V132, P550, DOI 10.1093/oxfordjournals.aje.a115691; PLESS IB, 1987, AM J PUBLIC HEALTH, V77, P358, DOI 10.2105/AJPH.77.3.358; Preston B., 1992, CUTTING PEDESTRIAN C; RIVARA FP, 1985, PEDIATRICS, V76, P375; RIVARA FP, 1990, AM J DIS CHILD, V144, P692, DOI 10.1001/archpedi.1990.02150300090023; ROBERTS I, 1992, BRIT MED J, V305, P283, DOI 10.1136/bmj.305.6848.283; ROBERTS I, 1993, J PAEDIATR CHILD H, V29, P233, DOI 10.1111/j.1440-1754.1993.tb00494.x; ROBERTS I, 1992, NEW ZEAL MED J, V105, P51; ROBERTS I, 1993, BRIT MED J, V306, P1737, DOI 10.1136/bmj.306.6894.1737; ROBERTS I, 1991, NEW ZEAL MED J, V104, P247; ROBERTS I, 1994, SOC SCI MED, V38, P749, DOI 10.1016/0277-9536(94)90465-0; ROBERTS I, 1993, EPIDEMIOLOGY, V4, P477, DOI 10.1097/00001648-199309000-00015; ROBERTS I, 1994, AUST J PUBLIC HEALTH, V18, P43; ROBERTS I, IN PRESS PEDIATRICS; ROBERTS IG, 1993, ARCH DIS CHILD, V68, P190, DOI 10.1136/adc.68.2.190; 1991, CENSUS POPULATION DW; 1983, ROAD TRANSPORT RES T	21	161	164	1	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 14	1995	310	6972					91	94		10.1136/bmj.310.6972.91	http://dx.doi.org/10.1136/bmj.310.6972.91			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QC223	7833733	Green Published			2022-12-28	WOS:A1995QC22300019
J	JAMES, DK				JAMES, DK			CONTROVERSIES IN MANAGEMENT - SHOULD OBSTETRICIANS SEE WOMEN WITH NORMAL PREGNANCIES - OBSTETRICIANS SHOULD FOCUS ON PROBLEMS	BRITISH MEDICAL JOURNAL			English	Article							DELIVERY				JAMES, DK (corresponding author), QUEENS MED CTR,NOTTINGHAM NG7 2UH,ENGLAND.							HAVERCAMP A, 1982, PERINATOLOGY NEONATO, V6, P75; INCH S, 1985, J ROY SOC MED, V78, P683, DOI 10.1177/014107688507800821; JAMES D, 1991, HOSPITAL UPDATE, V18, P885; KLEIN M, 1983, BRIT J OBSTET GYNAEC, V90, P118, DOI 10.1111/j.1471-0528.1983.tb08894.x; MACVICAR J, 1993, BRIT J OBSTET GYNAEC, V100, P316, DOI 10.1111/j.1471-0528.1993.tb12972.x; PARSBOOSINGH J, 1990, EFFECTIVE CARE PREGN, V1, P192; REID M, 1990, EFFECTIVE CARE PREGN, V1, P131; REID M, 1986, PERINATAL CARE DELIV, P486; 1993, CHANGING CHILDBIRTH; 1992, 2ND HOUS COMM SEL CO	10	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 7	1995	310	6971					37	38		10.1136/bmj.310.6971.37	http://dx.doi.org/10.1136/bmj.310.6971.37			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB060	7827555	Green Published			2022-12-28	WOS:A1995QB06000032
J	MURPHY, EA; BELL, AL; WOJTULEWSKI, J; BRZESKI, M; MADHOK, R; CAPELL, HA				MURPHY, EA; BELL, AL; WOJTULEWSKI, J; BRZESKI, M; MADHOK, R; CAPELL, HA			STUDY OF ERYTHROPOIETIN IN TREATMENT OF ANEMIA IN PATIENTS WITH RHEUMATOID-ARTHRITIS	BRITISH MEDICAL JOURNAL			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; ANEMIA		UNIV GLASGOW,GLASGOW ROYAL INFIRM,DEPT MED,GLASGOW G31 2ER,LANARK,SCOTLAND; QUEENS UNIV BELFAST,MUSGRAVE PK HOSP,BELFAST BT9 7JB,ANTRIM,NORTH IRELAND; EASTBOURNE DIST GEN HOSP,EASTBOURNE BN21 2UD,E SUSSEX,ENGLAND; GLASGOW ROYAL INFIRM,CTR RHEUMAT DIS,GLASGOW G4 0SF,LANARK,SCOTLAND	University of Glasgow; Queens University Belfast; University of Glasgow								ANDONOPOULOS AP, 1992, CLIN RHEUMATOL, V11, P138; GUDBJORNSSON B, 1992, ANN RHEUM DIS, V51, P747, DOI 10.1136/ard.51.6.747; PINCUS T, 1990, AM J MED, V89, P161, DOI 10.1016/0002-9343(90)90294-N; SMITH MA, 1992, ANN RHEUM DIS, V51, P753, DOI 10.1136/ard.51.6.753; TAKASHINA N, 1990, J RHEUMATOL, V17, P885	5	18	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 19	1994	309	6965					1337	1338		10.1136/bmj.309.6965.1337	http://dx.doi.org/10.1136/bmj.309.6965.1337			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT625	7866082	Green Published			2022-12-28	WOS:A1994PT62500022
J	OLIVER, MF; DEFEYTER, PJ; LUBSEN, J; POCOCK, S; SIMOONS, M; BACHMANN, K; DELAYE, J; EMANUELSSON, H; KALTENBACH, M; KINGMA, JH; LEGRAND, V; RAFFLENBEUL, W; RUTSCH, W; SIMOONS, ML; STOEL, I; THOMPSON, GR; SAELMAN, JPM; DECKERS, JW; QUERE, M; SIX, AJ; VERMEERS, PHMJ; SELIN, K; WIKLUND, O; DAVIES, G; MAHER, V; REYNEN, K; MARTINEZ, C; SCHMUTZLER, H; BOTT, J; SCHNEIDER, W; WINKELMANN, BR; TENKATE, J; NIKUTTA, P; DELAY, J; MATHIEUMULIN, MP; VOS, J; BOERMA, GJM; MEYER, J; VOGEL, RA; AMO, D; PAMEIJER, J; RODENBURG, L; SEED, P; DUMONT, JM; JONKERS, P; SUCKOW, XF; VANDALEN, FJ				OLIVER, MF; DEFEYTER, PJ; LUBSEN, J; POCOCK, S; SIMOONS, M; BACHMANN, K; DELAYE, J; EMANUELSSON, H; KALTENBACH, M; KINGMA, JH; LEGRAND, V; RAFFLENBEUL, W; RUTSCH, W; SIMOONS, ML; STOEL, I; THOMPSON, GR; SAELMAN, JPM; DECKERS, JW; QUERE, M; SIX, AJ; VERMEERS, PHMJ; SELIN, K; WIKLUND, O; DAVIES, G; MAHER, V; REYNEN, K; MARTINEZ, C; SCHMUTZLER, H; BOTT, J; SCHNEIDER, W; WINKELMANN, BR; TENKATE, J; NIKUTTA, P; DELAY, J; MATHIEUMULIN, MP; VOS, J; BOERMA, GJM; MEYER, J; VOGEL, RA; AMO, D; PAMEIJER, J; RODENBURG, L; SEED, P; DUMONT, JM; JONKERS, P; SUCKOW, XF; VANDALEN, FJ			EFFECT OF SIMVASTATIN ON CORONARY ATHEROMA - THE MULTICENTER ANTI-ATHEROMA STUDY (MAAS)	LANCET			English	Article							DENSITY LIPOPROTEIN CHOLESTEROL; ARTERY DISEASE; HEART-DISEASE; ATHEROSCLEROSIS-REGRESSION; CLINICAL-TRIALS; PROGRESSION; THERAPY; DIET; HYPERCHOLESTEROLEMIA; CHOLESTYRAMINE	It has yet to be established whether substantial reduction of plasma lipids will lead to retardation, and to what extent and how quickly, of diffuse and focal coronary atheroma. The Multicentre Anti-Atheroma Study (MAAS) is randomised double-blind clinical trial of 381 patients with coronary heart disease assigned to treatment with diet and either simvastatin 20 mg daily or placebo for 4 years. Patients on simvastatin had a 23% reduction in serum cholesterol, a 31% reduction in low-density lipoprotein cholesterol, and a 9% increase in high-density lipoprotein cholesterol compared with placebo over 4 years. Quantitative coronary angiography was done at baseline, and after 2 and 4 years. 167 patients (89%) on placebo and 178 (92%) on simvastatin had baseline and follow-up angiograms. In the placebo group there were reductions in mean lumen diameter (-0.08 mm) and in minimum lumen diameter (-0.13 mm). Treatment effects were + 0.06 (95% Cl 0.02 to 0.10) and + 0.08 mm (0.03 to 0.14) for mean and minimum lumen diameter, respectively (combined p = 0.006). Patients on placebo had an increase in mean diameter stenosis of 3.6% and the treatment effect of simvastatin was - 2.6% (- 4.4 to - 0.8). Treatment effects were observed regardless of diameter stenosis at baseline. On a per-patient basis, angiographic progression occurred less often in the simvastatin group, 41 versus 54 patients; and regression was more frequent, 33 versus 20 patients (combined p = 0.02). Significantly more new lesions and new tote I occlusions developed in the placebo group, 48 versus 28, and 18 versus 8, respectively. There was no difference in clinical outcome. The numbers of patients who died or had a myocardial infarction were 16 and 14 in the placebo and simvastatin groups, respectively. In the placebo group more patients underwent coronary angioplasty or re-vascularisation, 34 versus 23 on simvastatin. The trial showed that 20 mg simvastatin daily over 4 years reduces hyperlipidaemia and slows progression of diffuse and focal coronary atherosclerosis.	ERASMUS UNIV ROTTERDAM, THORAXCTR, 3000 DR ROTTERDAM, NETHERLANDS; ST ANTONIUS HOSP, NIEUWEGEIN, NETHERLANDS; SAHLGRENS UNIV HOSP, GOTHENBURG, SWEDEN; HAMMERSMITH HOSP, LONDON, ENGLAND; UNIV ERLANGEN NURNBERG, W-8520 ERLANGEN, GERMANY; FREE UNIV BERLIN, KLINIKUM RUDOLF VIRCHOW, STANDORT CHARLOTTENBURG, W-1000 BERLIN, GERMANY; UNIV FRANKFURT, KARDIOL ABT, W-6000 FRANKFURT, GERMANY; DRECHTSTEDEN ZIEKENHUIS, DORDRECHT, NETHERLANDS; MED HSCH HANNOVER KLINIKUM, KARDIOL ABT, HANNOVER, GERMANY; HOP CARDIOVASC & PNEUMOL LOUIS PRADEL, LYON, FRANCE; CARDIALYSIS BV, ROTTERDAM, NETHERLANDS; ERASMUS UNIV ROTTERDAM, HOSP DIJKZIGT, DEPT CLIN CHEM, 3015 GD ROTTERDAM, NETHERLANDS; SOCAR SA, GIVRINS, SWITZERLAND; CHU SART TILMAN, LIEGE, BELGIUM	Erasmus University Rotterdam; St. Antonius Hospital Utrecht; Sahlgrenska University Hospital; Imperial College London; University of Erlangen Nuremberg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Goethe University Frankfurt; Hannover Medical School; CHU Lyon; Cardialysis; Erasmus University Rotterdam; Erasmus MC; University of Liege	OLIVER, MF (corresponding author), NATL HEART & LUNG INST, LONDON SW3 6LY, ENGLAND.		Seed, Paul T/C-4435-2008; Jonkers, Peter/X-6360-2019	Seed, Paul T/0000-0001-7904-7933; Jonkers, Peter/0000-0002-5996-2891				BLANKENHORN DH, 1993, ANN INTERN MED, V119, P969, DOI 10.7326/0003-4819-119-10-199311150-00002; BLANKENHORN DH, 1994, ARTERIOSCLER THROMB, V14, P177, DOI 10.1161/01.ATV.14.2.177; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BLANKENHORN DH, 1990, JAMA-J AM MED ASSOC, V263, P1646, DOI 10.1001/jama.263.12.1646; BOERMA GJM, 1986, CLIN CHEM, V32, P943; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BRUSCHKE AVG, 1992, EUR HEART J, V13, P70, DOI 10.1093/eurheartj/13.suppl_H.70; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; BUCHWALD H, 1994, J AM COLL CARDIOL, pA389; BUCOLO G, 1973, CLIN CHEM, V19, P476; DAVIES MJ, 1990, CIRCULATION, V82, P38; DEFEYTER PJ, 1991, CIRCULATION, V84, P412, DOI 10.1161/01.CIR.84.1.412; DUMONT JM, 1993, CONTROL CLIN TRIALS, V14, P209, DOI 10.1016/0197-2456(93)90004-W; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FUSTER V, 1992, CIRCULATION, V86, P1; HOLME I, 1993, BRIT HEART J, V69, pS42; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; KATTERMANN R, 1984, J CLIN CHEM CLIN BIO, V22, P245; LEVY RI, 1984, CIRCULATION, V69, P325, DOI 10.1161/01.CIR.69.2.325; MYERS GL, 1989, CLIN LAB MED, V9, P105, DOI 10.1016/S0272-2712(18)30645-0; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; OLIVER MF, 1992, LANCET, V339, P1241, DOI 10.1016/0140-6736(92)91189-F; OLIVER MF, 1992, CARDIOVASCULAR RISK, V2, P234; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; POCOCK SJ, 1987, BIOMETRICS, V43, P487, DOI 10.2307/2531989; PROSSER R, 1991, ML 3 SOFTWARE 3 LEVE; REIBER JHC, 1985, CIRCULATION, V71, P280, DOI 10.1161/01.CIR.71.2.280; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; VOS J, 1993, PROG CARDIOVASC DIS, V35, P435, DOI 10.1016/0033-0620(93)90028-C; WARNICK GR, 1985, CLIN CHEM, V31, P217; WATERS D, 1994, CIRCULATION, V89, P959, DOI 10.1161/01.CIR.89.3.959; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X	33	560	568	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 3	1994	344	8923					633	638						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7864934				2022-12-28	WOS:A1994PE38600007
J	ANNAS, GJ				ANNAS, GJ			REFRAMING THE DEBATE ON HEALTH-CARE REFORM BY REPLACING OUR METAPHORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									BOSTON UNIV,SCH MED,SCH PUBL HLTH,BOSTON,MA 02118	Boston University	ANNAS, GJ (corresponding author), BOSTON UNIV,SCH MED,BOSTON,MA 02118, USA.			Annas, George/0000-0001-5836-7831				Beisecker A.E., 1993, HEALTH COMMUN, V5, P41; CHILDRESS JF, 1982, WHO SHOULD DECIDE, P7; DUBOS R, 1959, MIRAGE HLTH, P233; ECKHOLM E, 1994, NY TIMES        1218, P34; Friedman E, 1991, Healthc Forum J, V34, P11; Fussell P., 2013, GREAT WAR MODERN MEM; GAYLIN W, 1993, HARPERS          OCT, P57; Horwitz W. A., 1994, ETHICS BEHAV, V4, P345; KEEGAN J, 1994, HIST WARFARE, P56; Lakof G., 1980, METAPHORS WE LIVE; MCKINLAY JB, 1974, P AM HEART ASS C APP, P7; Potter VR, 1971, BIOETHICS BRIDGE FUT; RELMAN AS, 1991, NEW ENGL J MED, V325, P854, DOI 10.1056/NEJM199109193251205; RELMAN AS, 1992, ATLANTIC MONTHLY MAR, P99; SESSIONS G, 1995, DEEP ECOLOGY 21ST CE; SONTAG S, 1990, ILLNESS AS METAPHOR; Thomas L, 1974, LIVES CELL NOTES BIO; 1994, LANCET, V343, P429	18	98	99	1	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 16	1995	332	11					744	747						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL788	7854386				2022-12-28	WOS:A1995QL78800012
J	EXNER, DV; MUZYKA, T; GILLIS, AM				EXNER, DV; MUZYKA, T; GILLIS, AM			PROARRHYTHMIA IN PATIENTS WITH THE WOLFF-PARKINSON-WHITE SYNDROME AFTER STANDARD DOSES OF INTRAVENOUS ADENOSINE	ANNALS OF INTERNAL MEDICINE			English	Note							SUPRAVENTRICULAR TACHYCARDIA; ATRIAL-FLUTTER		UNIV CALGARY, HLTH SCI CTR, DEPT MED, CALGARY, AB T2N 4N1, CANADA; FOOTHILLS PROV GEN HOSP, DIV CARDIOL, CALGARY, AB T2N 2T9, CANADA; MISERICORDIA HOSP, EDMONTON, AB T5R 4H5, CANADA	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba			E, D/AAH-1638-2020					AFRIDI I, 1992, OBSTET GYNECOL, V80, P481; BELARDINELLI L, 1989, PROG CARDIOVASC DIS, V32, P73, DOI 10.1016/0033-0620(89)90015-7; BOTTERON GW, 1994, J CARDIOVASC ELECTR, V5, P477, DOI 10.1111/j.1540-8167.1994.tb01288.x; BRODSKY MA, 1994, NEW ENGL J MED, V330, P288, DOI 10.1056/NEJM199401273300413; CAMM AJ, 1991, NEW ENGL J MED, V325, P1621, DOI 10.1056/NEJM199112053252306; GARRATT CJ, 1991, CIRCULATION, V84, P1962, DOI 10.1161/01.CIR.84.5.1962; MANZ M, 1993, EUR HEART J, V14, P91, DOI 10.1093/eurheartj/14.suppl_E.91; RANKIN AC, 1993, BRIT HEART J, V69, P263; SHARMA AD, 1990, AM J MED, V88, P337, DOI 10.1016/0002-9343(90)90486-W; SLADE AKB, 1993, BRIT HEART J, V70, P91	10	28	28	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1995	122	5					351	352		10.7326/0003-4819-122-5-199503010-00005	http://dx.doi.org/10.7326/0003-4819-122-5-199503010-00005			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ085	7847646				2022-12-28	WOS:A1995QJ08500005
J	GRAYSON, ML; GIBBONS, GW; BALOGH, K; LEVIN, E; KARCHMER, AW				GRAYSON, ML; GIBBONS, GW; BALOGH, K; LEVIN, E; KARCHMER, AW			PROBING TO BONE IN INFECTED PEDAL ULCERS - A CLINICAL SIGN OF UNDERLYING OSTEOMYELITIS IN DIABETIC-PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							THERAPEUTIC CONSIDERATIONS; UNSUSPECTED OSTEOMYELITIS; DIAGNOSIS; FOOT; FEATURES; IN-111; SCINTIGRAPHY; DISEASE	Objective.-To assess a bedside technique for diagnosing osteomyelitis. Design.-We prospectively assessed infected pedal ulcers for detectable bone by probing with a sterile, blunt, stainless steel probe. We then examined the relationship between detection of bone and the presence or absence of osteomyelitis that was defined histopathologically and/or clinically. Setting.-A tertiary care center. Patients.-Seventy-five hospitalized diabetic patients with a total of 76 infected foot ulcers were studied. Results.-Osteomyelitis was diagnosed in 50 instances (66%) and was excluded in 26 instances. Bone was detected by probing in 33 of 50 ulcers with contiguous osteomyelitis; in contrast, bone was probed in only four of 26 ulcers without contiguous osteomyelitis (P<.001). Bone detected on probing was visible in only three instances. Palpating bone on probing the pedal ulcer had a sensitivity of 66% for osteomyelitis, a specificity of 85%, a positive predictive value of 89%, and a negative predictive value of 56%. Conclusions.-Palpation of bone in the depths of infected pedal ulcers in patients with diabetes is strongly correlated with the presence of underlying osteomyelitis. If bone is palpated on probing, specialized roentgenographic and radionuclide tests to diagnose osteomyelitis are unnecessary. Probing for bone should be included in the initial assessment of all diabetic patients with infected pedal ulcers.	NEW ENGLAND DEACONESS HOSP,DEPT MED,DIV INFECT DIS,BOSTON,MA 02215; NEW ENGLAND DEACONESS HOSP,DEPT SURG,DIV VASC SURG,BOSTON,MA 02215; NEW ENGLAND DEACONESS HOSP,DEPT PATHOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard Medical School								BAMBERGER DM, 1987, AM J MED, V83, P653, DOI 10.1016/0002-9343(87)90894-1; BELTRAN J, 1990, SKELETAL RADIOL, V19, P37; CAPUTO GM, 1994, NEW ENGL J MED, V331, P854, DOI 10.1056/NEJM199409293311307; GIBBONS GW, 1984, MANAGEMENT DIABETIC, P97; GRAYSON ML, 1994, CLIN INFECT DIS, V18, P683, DOI 10.1093/clinids/18.5.683; Karchmer A W, 1994, Curr Clin Top Infect Dis, V14, P1; KEENAN AM, 1989, ARCH INTERN MED, V149, P2262, DOI 10.1001/archinte.149.10.2262; Lipsky B A, 1990, Infect Dis Clin North Am, V4, P409; MAURER AH, 1986, RADIOLOGY, V161, P221, DOI 10.1148/radiology.161.1.3763871; MOST RS, 1983, DIABETES CARE, V6, P87, DOI 10.2337/diacare.6.1.87; NEWMAN LG, 1991, JAMA-J AM MED ASSOC, V266, P1246, DOI 10.1001/jama.266.9.1246; NEWMAN LG, 1992, DIABETES CARE, V15, P1527, DOI 10.2337/diacare.15.11.1527; PARK HM, 1982, J NUCL MED, V23, P569; PETERSON LR, 1989, AM J MED, V86, P801, DOI 10.1016/0002-9343(89)90476-2; ROSAI J, 1989, ACKERMANS SURGICAL P, P1463; SCHAUWECKER DS, 1988, J NUCL MED, V29, P1651; SELDIN DW, 1985, J NUCL MED, V26, P988; WALDVOGEL FA, 1970, NEW ENGL J MED, V282, P198, DOI 10.1056/NEJM197001222820406; WALDVOGEL FA, 1970, NEW ENGL J MED, V282, P316, DOI 10.1056/NEJM197002052820606; WALDVOGEL FA, 1970, NEW ENGL J MED, V282, P260, DOI 10.1056/NEJM197001292820507; WILLIAMSON MR, 1991, MAGN RESON IMAGING, V9, P945, DOI 10.1016/0730-725X(91)90540-3; YUH WTC, 1989, AM J ROENTGENOL, V152, P795, DOI 10.2214/ajr.152.4.795	22	342	353	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	1995	273	9					721	723		10.1001/jama.273.9.721	http://dx.doi.org/10.1001/jama.273.9.721			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH814	7853630				2022-12-28	WOS:A1995QH81400031
J	WU, AW; DAMIANO, AM; LYNN, J; ALZOLA, C; TENO, J; LANDEFELD, CS; DESBIENS, N; TSEVAT, J; MAYEROAKES, A; HARRELL, FE; KNAUS, WA				WU, AW; DAMIANO, AM; LYNN, J; ALZOLA, C; TENO, J; LANDEFELD, CS; DESBIENS, N; TSEVAT, J; MAYEROAKES, A; HARRELL, FE; KNAUS, WA			PREDICTING FUTURE FUNCTIONAL STATUS FOR SERIOUSLY ILL HOSPITALIZED ADULTS - THE SUPPORT PROGNOSTIC MODEL	ANNALS OF INTERNAL MEDICINE			English	Article							SICKNESS IMPACT PROFILE; MEDICAL INTENSIVE-CARE; CRITICALLY ILL; HEALTH-STATUS; CLASSIFICATION-SYSTEM; ACUTE PHYSIOLOGY; ICU PATIENTS; SHORT-TERM; MORTALITY; QUALITY	Objective: To develop a model estimating the probability of an adult patient having severe functional limitations 2 months after being hospitalized with one of nine serious illnesses. Design: Prospective cohort study. Setting: Five teaching hospitals in the United States. Participants: 1746 patients (model development) who survived 2 months and completed an interview, selected from 4301 patients in the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT); independent validation sample of 2478 patients. Measurements and Main Outcomes: Patient function 2 months after admission categorized as absence or presence of severe functional limitations (defined as Sickness Impact Profile scores greater than or equal to 30 or as activities of daily living scores greater than or equal to 4 [levels that require near-constant personal assistance]). A logistic regression model was constructed to predict severe functional limitation. Results: One third (n = 590) of patients who were interviewed at 2 months had severe functional limitations. Changes in functional status were common: Of those with no baseline dependencies (not dependent on personal assistance), 21% were severely limited at 2 months; of those with 4 or more baseline limitations, 30% had improved. The patient's ability to do activities of daily living was the most important predictor of functional status. Physiologic abnormalities, diagnosis, days in hospital, age, quality of life, and previous exercise capacity also contributed substantially. Model performance, assessed using receiver-operating characteristic curves, was 0.79 for the development sample and 0.75 for the validation sample. The model was well calibrated for the entire risk range. Conclusions: Functional outcome varied substantially after hospitalization for a serious illness. A small amount of readily available clinical information can estimate the probability of severe functional limitations.	DARTMOUTH COLL, SCH MED, DARTMOUTH HITCHCOCK MED CTR, CTR EVALUAT CLIN SCI, HANOVER, NH 03755 USA; DUKE UNIV, MED CTR, DIV BIOMETRY, DURHAM, NC 27705 USA; DUKE UNIV, MED CTR, CTR HEART, DURHAM, NC 27705 USA; CASE WESTERN RESERVE UNIV, SCH MED, CLEVELAND, OH USA; MARSHFIELD MED RES FDN, MARSHFIELD CLIN, DEPT GEN INTERNAL MED, MARSHFIELD, WI 54449 USA; BETH ISRAEL HOSP, DEPT MED, DIV CLIN EPIDEMIOL, BOSTON, MA 02215 USA; UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA USA; GEORGE WASHINGTON UNIV, MED CTR, WASHINGTON, DC USA	Dartmouth College; Duke University; Duke University; Case Western Reserve University; Marshfield Clinic; Harvard University; Beth Israel Deaconess Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; George Washington University	WU, AW (corresponding author), JOHNS HOPKINS UNIV, CTR HLTH SERV RES & DEV, 624 N BROADWAY, BALTIMORE, MD 21205 USA.		Wu, Albert/AAJ-4780-2021; Knaus, William/AAX-2138-2020					ATKINSON AC, 1980, BIOMETRIKA, V67, P413, DOI 10.1093/biomet/67.2.413; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; CHARLSON ME, 1987, J CHRON DIS, V40, P705, DOI 10.1016/0021-9681(87)90107-X; CHELLURI L, 1993, JAMA-J AM MED ASSOC, V269, P3119, DOI 10.1001/jama.269.24.3119; DAVERAT P, 1991, STROKE, V22, P1, DOI 10.1161/01.STR.22.1.1; DEBRUIN AF, 1992, SOC SCI MED, V35, P1003, DOI 10.1016/0277-9536(92)90240-Q; DEYO RA, 1989, MED CARE, V27, pS254, DOI 10.1097/00005650-198903001-00020; DEYO RA, 1988, J RHEUMATOL, V15, P1557; GOLDSTEIN RL, 1986, CRIT CARE MED, V14, P783, DOI 10.1097/00003246-198609000-00005; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; INOUYE SK, 1993, J GEN INTERN MED, V8, P645, DOI 10.1007/BF02598279; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KNAUS WA, 1991, SCIENCE, V254, P389, DOI 10.1126/science.1925596; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KNAUS WA, 1993, ANN INTERN MED, V118, P753, DOI 10.7326/0003-4819-118-10-199305150-00001; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LEGALL JR, 1982, CRIT CARE MED, V10, P575; LEGALL JR, 1984, CRIT CARE MED, V12, P975; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; LEMESHOW S, 1985, CRIT CARE MED, V13, P519, DOI 10.1097/00003246-198507000-00001; MAHUL P, 1991, INTENS CARE MED, V17, P7, DOI 10.1007/BF01708401; MAYEROAKES SA, 1991, J AM GERIATR SOC, V39, P862, DOI 10.1111/j.1532-5415.1991.tb04452.x; MOR V, 1989, J CLIN EPIDEMIOL, V42, P895, DOI 10.1016/0895-4356(89)90103-0; MUNDT DJ, 1989, ARCH INTERN MED, V149, P68, DOI 10.1001/archinte.149.1.68; MURPHY DJ, 1990, J CLIN EPIDEMIOL, V43, pR5, DOI 10.1016/0895-4356(90)90210-G; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; PATRICK DL, 1989, MED CARE, V27, pS217, DOI 10.1097/00005650-198903001-00018; RUBENSTEIN LZ, 1984, J AM GERIATR SOC, V32, P503, DOI 10.1111/j.1532-5415.1984.tb02235.x; SAGE WM, 1986, CRIT CARE MED, V14, P777, DOI 10.1097/00003246-198609000-00004; TEASDALE G, 1974, LANCET, V2, P81; TSEVAT J, 1990, J CLIN EPIDEMIOL, V43, pS73, DOI 10.1016/0895-4356(90)90224-D; ZAREN B, 1987, CRIT CARE MED, V15, P743, DOI 10.1097/00003246-198708000-00006; [No title captured]	37	114	114	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1995	122	5					342	350		10.7326/0003-4819-122-5-199503010-00004	http://dx.doi.org/10.7326/0003-4819-122-5-199503010-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ085	7847645				2022-12-28	WOS:A1995QJ08500004
J	CHENG, RH; KUHN, RJ; OLSON, NH; ROSSMANN, MG; CHOI, HK; SMITH, TJ; BAKER, TS				CHENG, RH; KUHN, RJ; OLSON, NH; ROSSMANN, MG; CHOI, HK; SMITH, TJ; BAKER, TS			NUCLEOCAPSID AND GLYCOPROTEIN ORGANIZATION IN AN ENVELOPED VIRUS	CELL			English	Article							SEMLIKI-FOREST VIRUS; ROSS RIVER VIRUS; SINDBIS VIRUS; CORE PROTEIN; NUCLEOTIDE-SEQUENCE; 3-DIMENSIONAL STRUCTURE; ELECTRON MICROGRAPHS; SERINE PROTEINASE; SPHERICAL VIRUSES; DEDUCED SEQUENCE	Alphaviruses are a group of icosahedral, positive-strand RNA, enveloped viruses. The membrane bilayer, which surrounds the similar to 400 Angstrom diameter nucleocapsid, is penetrated by 80 spikes arranged in a T = 4 lattice. Each spike is a trimer of heterodimers consisting of glycoproteins E1 and E2. Cryoelectron microscopy and image reconstruction of Ross River virus showed that the T = 4 quaternary structure of the nucleocapsid consists of pentamer and hexamer clusters of the capsid protein, but not dimers, as have been observed in several crystallographic studies. The E1-E2 heterodimers form one-to-one associations with the nucleocapsid monomers across the lipid bilayer. Knowledge of the atomic structure of the capsid protein and our reconstruction allows us to identify capsid-protein residues that interact with the RNA, the glycoproteins, and adjacent capsid-proteins.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus			Cheng, Holland/A-8973-2008; Smith, Thomas J/K-9086-2013; Kuhn, Richard/AAR-2722-2021	Smith, Thomas J/0000-0003-3528-6793; Kuhn, Richard/0000-0003-4148-1026; , Timothy/0000-0001-6543-8968	NIAID NIH HHS [AI11217, AI33982, P01 AI035212] Funding Source: Medline; NIGMS NIH HHS [R37 GM033050, GM33050, R01 GM033050] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035212, R29AI033982, R01AI011217] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033050, R37GM033050] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDROUBI A, 1992, ULTRAMICROSCOPY, V46, P175, DOI 10.1016/0304-3991(92)90013-A; ALIPERTI G, 1978, VIROLOGY, V90, P366, DOI 10.1016/0042-6822(78)90321-5; ANTHONY RP, 1991, J VIROL, V65, P1187, DOI 10.1128/JVI.65.3.1187-1194.1991; BAKER TS, 1991, BIOPHYS J, V60, P1445, DOI 10.1016/S0006-3495(91)82181-6; BAKER TS, 1988, P NATL ACAD SCI USA, V85, P422, DOI 10.1073/pnas.85.2.422; BARTH BU, 1992, J VIROL, V66, P7560, DOI 10.1128/JVI.66.12.7560-7564.1992; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; CHENG RH, 1992, VIROLOGY, V186, P655, DOI 10.1016/0042-6822(92)90032-K; CHENG RH, 1994, STRUCTURE, V2, P271; CHOI HK, 1991, NATURE, V354, P37, DOI 10.1038/354037a0; COOMBS K, 1987, J MOL BIOL, V195, P359, DOI 10.1016/0022-2836(87)90657-7; COOMBS K, 1987, VIRUS RES, V7, P131, DOI 10.1016/0168-1702(87)90075-X; CROWTHER RA, 1971, PHILOS T R SOC B, V261, P221, DOI 10.1098/rstb.1971.0054; DALGARNO L, 1983, VIROLOGY, V129, P170, DOI 10.1016/0042-6822(83)90404-X; DALRYMPLE JM, 1976, VIROLOGY, V69, P93, DOI 10.1016/0042-6822(76)90197-5; DOHERTY R. L., 1963, AUSTRALIAN J SCI, V26, P183; FARAGHER SG, 1988, VIROLOGY, V163, P509, DOI 10.1016/0042-6822(88)90292-9; FULLER SD, 1987, CELL, V48, P923, DOI 10.1016/0092-8674(87)90701-X; GAROFF H, 1974, VIROLOGY, V61, P493, DOI 10.1016/0042-6822(74)90285-2; GAROFF H, 1974, P NATL ACAD SCI USA, V71, P3988, DOI 10.1073/pnas.71.10.3988; GAROFF H, 1980, NATURE, V288, P236, DOI 10.1038/288236a0; GEIGENMULLERGNI.U, 1993, J VIROL, V7, P1620; HAHN CS, 1988, P NATL ACAD SCI USA, V85, P5997, DOI 10.1073/pnas.85.16.5997; HARRISON S C, 1974, Journal of Supramolecular Structure, V2, P486, DOI 10.1002/jss.400020233; HARRISON SC, 1992, J MOL BIOL, V226, P277, DOI 10.1016/0022-2836(92)90141-6; HARRISON SC, 1984, TRENDS BIOCHEM SCI, V9, P345, DOI 10.1016/0968-0004(84)90057-4; HARRISON SC, 1971, J MOL BIOL, V60, P523, DOI 10.1016/0022-2836(71)90186-0; HELENIUS A, 1980, EUR J BIOCHEM, V106, P613, DOI 10.1111/j.1432-1033.1980.tb04609.x; HOLMES KC, 1994, STRUCTURE, V2, P589, DOI 10.1016/S0969-2126(00)00061-7; HORZINEK M, 1969, J VIROL, V4, P514, DOI 10.1128/JVI.4.4.514-520.1969; JACROT B, 1987, ANIMAL VIRUS STRUCTU, P89; KAARIAINEN L, 1971, VIROLOGY, V43, P291, DOI 10.1016/0042-6822(71)90246-7; Kay B. H., 1989, The arboviruses: epidemiology and ecology. Volume IV., P93; KENNEY JM, 1994, STRUCTURE, V2, P823, DOI 10.1016/S0969-2126(94)00083-2; KUHN RJ, 1991, VIROLOGY, V182, P430, DOI 10.1016/0042-6822(91)90584-X; LEE HR, 1994, VIROLOGY, V202, P390, DOI 10.1006/viro.1994.1355; LOPEZ S, 1994, J VIROL, V68, P1316, DOI 10.1128/JVI.68.3.1316-1323.1994; MARSHALL ID, 1984, CURRENT TOPICS VECTO, P31; MAYNE JT, 1984, VIROLOGY, V134, P338, DOI 10.1016/0042-6822(84)90302-7; METSIKKO K, 1990, J VIROL, V64, P4678; OLSON NH, 1989, ULTRAMICROSCOPY, V30, P281, DOI 10.1016/0304-3991(89)90057-0; PAREDES AM, 1993, P NATL ACAD SCI USA, V90, P9095, DOI 10.1073/pnas.90.19.9095; PAREDES AM, 1993, VIROLOGY, V187, P329; RICE CM, 1982, J MOL BIOL, V154, P325, DOI 10.1016/0022-2836(82)90067-5; RICE CM, 1981, P NATL ACAD SCI-BIOL, V78, P2062, DOI 10.1073/pnas.78.4.2062; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROST B, 1993, TRENDS BIOCHEM SCI, V18, P120, DOI 10.1016/0968-0004(93)90017-H; SIMMONS DT, 1974, J MOL BIOL, V86, P397, DOI 10.1016/0022-2836(74)90027-8; STRAUSS EG, 1978, J VIROL, V28, P466, DOI 10.1128/JVI.28.2.466-474.1978; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; STUBBS MJ, 1991, J MOL BIOL, V221, P39, DOI 10.1016/0022-2836(91)80200-E; TONG L, 1992, ACTA CRYSTALLOGR A, V48, P430, DOI 10.1107/S0108767391014630; TONG L, 1993, J MOL BIOL, V230, P228, DOI 10.1006/jmbi.1993.1139; UBOL S, 1991, J VIROL, V65, P6913, DOI 10.1128/JVI.65.12.6913-6921.1991; VENIENBRYAN C, 1994, J MOL BIOL, V236, P572, DOI 10.1006/jmbi.1994.1166; VOGEL RH, 1986, NATURE, V320, P533, DOI 10.1038/320533a0; VRATI S, 1986, VIROLOGY, V151, P222, DOI 10.1016/0042-6822(86)90044-9; WAHLBERG JM, 1992, J VIROL, V66, P7309, DOI 10.1128/JVI.66.12.7309-7318.1992; WANG KS, 1991, VIROLOGY, V181, P694, DOI 10.1016/0042-6822(91)90903-O; WEISS B, 1994, NUCLEIC ACIDS RES, V22, P780, DOI 10.1093/nar/22.5.780; WENGLER G, 1992, VIROLOGY, V191, P880, DOI 10.1016/0042-6822(92)90263-O; ZIEMIECKI A, 1978, J MOL BIOL, V122, P259, DOI 10.1016/0022-2836(78)90189-4	64	276	279	1	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					621	630						10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867069				2022-12-28	WOS:A1995QJ60200014
J	BRECKENRIDGE, A				BRECKENRIDGE, A			RECENT ADVANCES - CLINICAL-PHARMACOLOGY AND THERAPEUTICS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MYOCARDIAL-INFARCTION; NITRIC-OXIDE; MORTALITY; SURVIVAL; TRIAL				BRECKENRIDGE, A (corresponding author), UNIV LIVERPOOL, DEPT THERAPEUT & PHARMACOL, LIVERPOOL L69 3BX, MERSEYSIDE, ENGLAND.							BALL SG, 1994, EUR HEART J, V15, P20, DOI 10.1093/eurheartj/15.suppl_B.20; BENNETT BM, 1994, TOP PHARM SCI, V179, P245; BURKE WJ, 1993, J AM GERIATR SOC, V41, P1219, DOI 10.1111/j.1532-5415.1993.tb07306.x; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; COOKSON C, 1994, FINANCIAL TIMES 1112; COOPER DA, 1993, NEW ENGL J MED, V329, P297, DOI 10.1056/NEJM199307293290501; DEVITA C, 1994, LANCET, V343, P1115; HENNEKENS CH, 1994, ARCH INTERN MED, V154, P37, DOI 10.1001/archinte.154.1.37; KIRK SJ, 1990, BIOCHEM BIOPH RES CO, V173, P660, DOI 10.1016/S0006-291X(05)80086-5; LAUBE BL, 1993, JAMA-J AM MED ASSOC, V269, P2106, DOI 10.1001/jama.269.16.2106; LEES C, 1994, LANCET, V343, P1325, DOI 10.1016/S0140-6736(94)92468-6; MARRE M, 1994, DIABETES, V43, P384, DOI 10.2337/diabetes.43.3.384; MCMURRAY J, 1994, BRIT MED J, V309, P1631, DOI 10.1136/bmj.309.6969.1631; MCMURRAY J, 1994, BMJ-BRIT MED J, V309, P1343, DOI 10.1136/bmj.309.6965.1343; MULDER JW, 1994, AIDS, V8, P313, DOI 10.1097/00002030-199403000-00004; NEWHOUSE PA, 1994, NEUROPSYCHOPHARMACOL, V10, P93, DOI 10.1038/npp.1994.11; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; ROGERS J, 1994, CNS DRUGS, V1, P241, DOI 10.2165/00023210-199401040-00001; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; RUTHER E, 1994, PHARMACOPSYCHIATRY, V27, P32, DOI 10.1055/s-2007-1014271; SELIGMANN M, 1994, LANCET, V343, P871; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SWEDBERG K, 1992, NEW ENGL J MED, V327, P678, DOI 10.1056/NEJM199209033271002; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; VALLANCE P, 1994, BRIT MED J, V309, P453, DOI 10.1136/bmj.309.6952.453; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275; 1994, PRESCRIPTION IMPROVE; 1994, PRIORITY SETTING NHS; 1994, 6TH AM HEART ASS M	34	5	5	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 11	1995	310	6976					377	380		10.1136/bmj.310.6976.377	http://dx.doi.org/10.1136/bmj.310.6976.377			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG721	7866217	Green Published			2022-12-28	WOS:A1995QG72100024
J	YARMOLINSKY, MB				YARMOLINSKY, MB			PROGRAMMED CELL-DEATH IN BACTERIAL-POPULATIONS	SCIENCE			English	Editorial Material							ESCHERICHIA-COLI; STABLE MAINTENANCE; SELFISH GENES; PLASMID R100; F-PLASMID; PROTEIN; GROWTH; SYSTEM; CCD; PEM				YARMOLINSKY, MB (corresponding author), NCI,BIOCHEM LAB,BLDG 37,ROOM 4D-15,BETHESDA,MD 20892, USA.							BEEMAN RW, 1992, SCIENCE, V256, P89, DOI 10.1126/science.1566060; BENZER S, 1955, P NATL ACAD SCI USA, V41, P344, DOI 10.1073/pnas.41.6.344; Benzer S., 1957, Proceedings of the International Genetics Symposia, 1956. Tokyo & Kyoto, September 1956, pp; BERNARD P, 1992, J MOL BIOL, V226, P735, DOI 10.1016/0022-2836(92)90629-X; BOE L, 1991, MOL MICROBIOL, V5, P2541, DOI 10.1111/j.1365-2958.1991.tb02100.x; BULL JJ, 1992, SCIENCE, V256, P65, DOI 10.1126/science.1566058; Chater K. F., 1984, MICROBIAL DEV, P89; CRICK FH, 1961, NATURE, V192, P1227, DOI 10.1038/1921227a0; GERDES K, 1986, EMBO J, V5, P2023, DOI 10.1002/j.1460-2075.1986.tb04459.x; GERDES K, 1990, New Biologist, V2, P946; HALL BG, 1990, GENETICS, V126, P5; HARSHEY RM, 1994, MOL MICROBIOL, V13, P389, DOI 10.1111/j.1365-2958.1994.tb00433.x; HENGGEARONIS R, 1993, CELL, V72, P165, DOI 10.1016/0092-8674(93)90655-A; HURST LD, 1993, CELL, V75, P407, DOI 10.1016/0092-8674(93)90375-Z; JAFFE A, 1985, J BACTERIOL, V163, P841; KAISER D, 1984, MICROBIAL DEV, P197; KOCH AL, 1987, CELLULAR MOL BIOL, V2, pCH11; LEHNHERR H, 1993, J MOL BIOL, V233, P414, DOI 10.1006/jmbi.1993.1521; LENSKI RE, 1994, J BACTERIOL, V176, P3140, DOI 10.1128/jb.176.11.3140-3147.1994; LIU J, 1994, P NATL ACAD SCI USA, V91, P4618, DOI 10.1073/pnas.91.11.4618; LOSICK R, 1992, NATURE, V355, P601, DOI 10.1038/355601a0; LURIA SE, 1987, CELLULAR MOL BIOL, V2, pCH102; MASUDA YJ, 1993, J BACTERIOL, V175, P6850, DOI 10.1128/jb.175.21.6850-6856.1993; MOLINEUX IJ, 1991, NEW BIOL, V3, P230; NAITO T, 1995, SCIENCE, V267, P897, DOI 10.1126/science.7846533; PETERS LL, 1993, CELL, V74, P135, DOI 10.1016/0092-8674(93)90301-6; RILEY MA, 1993, MOL BIOL EVOL, V10, P1380; ROBERTS RC, 1994, J MOL BIOL, V237, P35, DOI 10.1006/jmbi.1994.1207; ROBERTSON BD, 1992, TRENDS GENET, V8, P422, DOI 10.1016/0168-9525(92)90325-X; ROSENBERG SM, 1994, GENOME, V37, P893, DOI 10.1139/g94-127; RUIZECHEVARRIA MJ, 1991, MOL GEN GENET, V225, P355, DOI 10.1007/BF00261674; SELANDER RK, 1987, CELLULAR MOL BIOL, V2, pCH103; Shapiro J. A., 1988, SCI AM, V258, P62; SNYDER L, 1994, MOL BIOL BACTERIOP T, V4, pCH39; SUMMERS DK, 1993, MOL MICROBIOL, V8, P1031, DOI 10.1111/j.1365-2958.1993.tb01648.x; THISTED T, 1994, EMBO J, V13, P1950, DOI 10.1002/j.1460-2075.1994.tb06464.x; TSUCHIMOTO S, 1992, J BACTERIOL, V174, P4205, DOI 10.1128/JB.174.13.4205-4211.1992; YORGEY P, 1994, P NATL ACAD SCI USA, V91, P4519, DOI 10.1073/pnas.91.10.4519	38	283	301	3	29	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 10	1995	267	5199					836	837		10.1126/science.7846528	http://dx.doi.org/10.1126/science.7846528			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG207	7846528				2022-12-28	WOS:A1995QG20700044
J	GORDON, DW; ROSENTHAL, G; HART, J; SIROTA, R; BAKER, AL				GORDON, DW; ROSENTHAL, G; HART, J; SIROTA, R; BAKER, AL			CHAPARRAL INGESTION - THE BROADENING SPECTRUM OF LIVER-INJURY CAUSED BY HERBAL MEDICATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							NORDIHYDROGUAIARETIC ACID; GRANULOMATOUS HEPATITIS; ARACHIDONIC-ACID; METABOLISM; LEUKOCYTES; DILTIAZEM; FAILURE	Unconventional medical practices, including the use of herbal remedies, are prevalent in the United States. Chaparral is an herbal preparation made from a desert shrub and used for its antioxidant properties. We report the case of a 60-year-old woman who took chaparral for 10 months and developed severe hepatitis for which no other cause could be found. Despite aggressive supportive therapy, the patient deteriorated and required orthotopic liver transplantation. She is now well, more than 1 year after her transplant. This case suggests that chaparral can cause serious liver injury and fulminant hepatic failure. Herbal medications should be considered as potential causes of liver toxicity.	UNIV CHICAGO HOSP,DEPT MED,LIVER STUDY UNIT,CHICAGO,IL 60637; UNIV CHICAGO HOSP,DEPT PATHOL,CHICAGO,IL; W SUBURBAN HOSP,DEPT MED,OAK PK,IL; W SUBURBAN HOSP,DEPT PATHOL,OAK PK,IL	University of Chicago; University of Illinois System; University of Chicago; University of Illinois System								AGARWAL R, 1991, DRUG METAB DISPOS, V19, P620; BOKOCH GM, 1981, J BIOL CHEM, V256, P4156; CAPDEVILA J, 1988, ARCH BIOCHEM BIOPHYS, V261, P257, DOI 10.1016/0003-9861(88)90340-2; Clark F., 1992, Morbidity and Mortality Weekly Report, V41, P812; EMOND JC, 1989, GASTROENTEROLOGY, V96, P1583, DOI 10.1016/0016-5085(89)90530-1; KATZ M, 1990, J CLIN GASTROENTEROL, V12, P203, DOI 10.1097/00004836-199004000-00021; LEE WM, 1993, NEW ENGL J MED, V329, P1862, DOI 10.1056/NEJM199312163292508; SALARI H, 1984, PROSTA LEUKOTR MED, V13, P53, DOI 10.1016/0262-1746(84)90102-1; SARACHEK NS, 1985, GASTROENTEROLOGY, V88, P1260, DOI 10.1016/S0016-5085(85)80089-5; TOFT E, 1991, HISTOPATHOLOGY, V18, P474, DOI 10.1111/j.1365-2559.1991.tb00882.x	10	111	114	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	1995	273	6					489	490		10.1001/jama.273.6.489	http://dx.doi.org/10.1001/jama.273.6.489			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE498	7837368				2022-12-28	WOS:A1995QE49800033
J	MIYASHITA, T; REED, JC				MIYASHITA, T; REED, JC			TUMOR-SUPPRESSOR P53 IS A DIRECT TRANSCRIPTIONAL ACTIVATOR OF THE HUMAN BAX GENE	CELL			English	Article							WILD-TYPE P53; CELL-LINE; C-MYC; APOPTOSIS; PROTEIN; BCL-2; INDUCTION; MAX; ACCUMULATION; EXPRESSION	The bax gene promoter region contains four motifs with homology to consensus p53-binding sites. In cotransfection assays using p53-deficient tumor cell lines, wild-type but not mutant p53 expression plasmids transactivated a reporter gene plasmid that utilized the bax gene promoter to drive transcription of chloramphenicol acetyltransferase. In addition, wildtype p53 transactivated reporter gene constructs containing a heterologous minimal promoter and a 39-bp region from the bax gene promoter in which the p53-binding site consensus sequences reside. Introduction of mutations into the consensus p53-binding site sequences abolished p53 responsiveness of reporter gene plasmids. Wild-type but not mutant p53 protein bound to oligonucleotides corresponding to this region of the bax promoter, based on gel retardation assays. Taken together, the results suggest that bax is a p53 primary-response gene, presumably involved in a p53-regulated pathway for induction of apoptosis.	LA JOLLA CANC RES FDN, LA JOLLA, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [CA60181] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060181] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRISTOW RG, 1994, ONCOGENE, V9, P1527; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HARPER JW, 1993, CELL, V75, P805; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KITADA S, 1994, ANTISENSE RES DEV, V4, P71, DOI 10.1089/ard.1994.4.71; Kitada S, 1993, Antisense Res Dev, V3, P157; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SPALHOLZ BA, 1987, J VIROL, V61, P2128, DOI 10.1128/JVI.61.7.2128-2137.1987; SUN XF, 1992, LANCET, V340, P1369, DOI 10.1016/0140-6736(92)92558-W; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VISAKORPI T, 1992, J NATL CANCER I, V84, P883, DOI 10.1093/jnci/84.11.883; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG YS, 1993, ONCOGENE, V8, P3427; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	48	3789	3876	2	146	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 27	1995	80	2					293	299						7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7834749				2022-12-28	WOS:A1995QD92400012
J	MULLER, CW; REY, FA; SODEOKA, M; VERDINE, GL; HARRISON, SC				MULLER, CW; REY, FA; SODEOKA, M; VERDINE, GL; HARRISON, SC			STRUCTURE OF THE NF-KAPPA-B P50 HOMODIMER BOUND TO DNA	NATURE			English	Article							CRYSTAL-STRUCTURE; BINDING SUBUNIT; TRANSCRIPTIONAL ACTIVATION; 3-DIMENSIONAL STRUCTURE; CYTOPLASMIC RETENTION; NUCLEIC-ACIDS; P65 SUBUNIT; PROTEIN; REL; GENE	The structure of a large fragment of the p50 subunit of the human transcription factor NF-kappa B, bound as a homodimer to DNA, reveals that the Rel-homology region has two beta-barrel domains that grip DNA in the major groove. Both domains contact the DNA backbone. The amino-terminal specificity domain contains a recognition loop that interacts with DNA bases; the carboxy-terminal dimerization domain bears the site of I-kappa B interaction. The folds of these domains are related to immunoglobulin-like modules. The amino-terminal domain also resembles the core domain of p53.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN	Harvard University; Harvard University; University of Tokyo	MULLER, CW (corresponding author), HOWARD HUGHES MED INST,7 DIVINITY AVE,CAMBRIDGE,MA 02138, USA.		Rey, Felix/B-6497-2012; Müller, Christoph W/I-7420-2012; Sodeoka, Mikiko/A-9952-2008	Müller, Christoph W/0000-0003-2176-8337; Sodeoka, Mikiko/0000-0002-1344-364X				BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, X PLOR VERSION 3 1; BURKE PA, 1989, J EXP MED, V169, P1309, DOI 10.1084/jem.169.4.1309; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; EPP O, 1975, BIOCHEMISTRY-US, V14, P4943, DOI 10.1021/bi00693a025; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1988, PROTEINS, V4, P77, DOI 10.1002/prot.340040202; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUY M, 1992, NATURE, V357, P89, DOI 10.1038/357089a0; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KIDD S, 1992, CELL, V1, P623; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LEHMING N, UNPUB EMBO J; LIU J, 1994, P NATL ACAD SCI USA, V91, P908, DOI 10.1073/pnas.91.3.908; Liu J, 1994, CHEM BIOL, V1, P47, DOI 10.1016/1074-5521(94)90040-X; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; NEKLUDOVA L, 1994, P NATL ACAD SCI USA, V91, P6948, DOI 10.1073/pnas.91.15.6948; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SODEOKA M, 1993, BIOORG MED CHEM LETT, V3, P1095, DOI 10.1016/S0960-894X(00)80294-2; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x	48	471	495	1	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					311	317		10.1038/373311a0	http://dx.doi.org/10.1038/373311a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830764				2022-12-28	WOS:A1995QD40400049
J	OAKLEY, A; FULLERTON, D; HOLLAND, J; ARNOLD, S; FRANCEDAWSON, M; KELLEY, P; MCGRELLIS, S				OAKLEY, A; FULLERTON, D; HOLLAND, J; ARNOLD, S; FRANCEDAWSON, M; KELLEY, P; MCGRELLIS, S			SEXUAL HEALTH-EDUCATION INTERVENTIONS FOR YOUNG-PEOPLE - A METHODOLOGICAL REVIEW	BRITISH MEDICAL JOURNAL			English	Article							HIGH-SCHOOL-STUDENTS; AIDS EDUCATION; RISK; INFORMATION; WORK	Objectives-To locate reports of sexual health education interventions for young people, assess the methodological quality of evaluations, identify the subgroup with a methodologically sound design, and assess the evidence with respect to the effectiveness of different approaches to promoting young people's sexual health. Design-Survey of reports in English by means of electronic databases and hand searches for relevant studies conducted in the developed world since 1982. Papers were reviewed for eight methodological qualities. The evidence on effectiveness generated by studies meeting four core criteria was assessed. Judgments on effectiveness by reviewers and authors were compared. Papers-270 papers reporting sexual health interventions. Main outcome measure-The methodological quality of evaluations. Results-73 reports of evaluations of sexual health interventions examining the effectiveness of these interventions in changing knowledge, attitudes, or behavioural outcomes were identified, of which 65 were separate outcome evaluations. Of these studies, 45 (69%) lacked random control groups, 44 (68%) failed to present preintervention and 38 (59%) postintervention data, and 26 (40%) omitted to discuss the relevance of loss of data caused by drop outs. Only 12 (18%) of the 65 outcome evaluations were judged to be methodologically sound. Academic reviewers were more likely than authors to judge studies as unclear because of design faults. Only two of the sound evaluations recorded interventions which were effective in showing an impact on young people's sexual behaviour. Conclusions-The design of evaluations in sexual health intervention needs to be improved so that reliable evidence of the effectiveness of different approaches to promoting young people's sexual health may be generated.			OAKLEY, A (corresponding author), UNIV LONDON,INST EDUC,SOCIAL SCI RES UNIT,LONDON WC1H 0NS,ENGLAND.							ABRAHAM C, 1991, HEALTH EDUC RES, V6, P19, DOI 10.1093/her/6.1.19; ABRAMSON PR, 1989, EVALUATION REV, V13, P516, DOI 10.1177/0193841X8901300504; ALTMAN DG, 1994, BRIT MED J, V308, P283, DOI 10.1136/bmj.308.6924.283; ASHWORTH CS, 1992, J ADOLESCENT HEALTH, V13, P582, DOI 10.1016/1054-139X(92)90372-I; Barth R P, 1992, J Adolesc Res, V7, P208, DOI 10.1177/074355489272006; CHALMERS TC, 1977, NEW ENGL J MED, V297, P1091, DOI 10.1056/NEJM197711172972004; CHRISTOPHER FS, 1991, FAM RELAT, V39, P68; DICLEMENTE RJ, 1989, J SEX RES, V26, P188, DOI 10.1080/00224498909551505; EISEN M, 1992, PREVENTING ADOLESCEN, P220; Hamalainen S., 1992, Health Education Journal, V51, P135, DOI 10.1177/001789699205100308; HERZ EJ, 1986, HEALTH EDUC QUART, V13, P201, DOI 10.1177/109019818601300301; HOFFERTH SL, 1991, EVAL PROGRAM PLANN, V14, P13; Kirby D, 1980, J Sch Health, V50, P559; LEWIS C, 1990, NEW DIR CHILD ADOLES, V50, P35; LOEVINSOHN BP, 1990, INT J EPIDEMIOL, V4, P788; MACDONALD G, 1992, BRIT J SOC WORK, V22, P615; MASSEY DE, 1990, HLTH ED J, V49, P134; MELLANBY A, 1992, GENITOURIN MED, V68, P241; OAKLEY A, 1994, SSRU DATABASE PROJEC; Prendergast S., 1994, THIS IS TIME GROW GI; Reader E. G., 1988, Health Education Journal, V47, P125, DOI 10.1177/001789698804700406; ROTHERAMBORUS MJ, 1991, JAMA-J AM MED ASSOC, V266, P1237, DOI 10.1001/jama.266.9.1237; SHELDON TA, 1994, BRIT MED J, V309, P142, DOI 10.1136/bmj.309.6948.142; SMITH R, 1993, BRIT MED J, V307, P1403; STAHLER GJ, 1989, FAM PLANN PERSPECT, V21, P123, DOI 10.2307/2135663; STOUT JW, 1989, PEDIATRICS, V83, P375; THOMAS BH, 1992, PREVENTING ADOLESCEN, P28; THOMAS LL, 1985, J SCHOOL HEALTH, V55, P274, DOI 10.1111/j.1746-1561.1985.tb04141.x; TONES K, 1991, HLTH ED EFFECTIVENES; WANLASS RL, 1983, ARCH SEX BEHAV, V12, P487, DOI 10.1007/BF01542211; WEINMAN ML, 1992, J ADOLESCENCE, V15, P19, DOI 10.1016/0140-1971(92)90062-A; WELLINGS K, 1994, SEXUAL BEHAVIOUR BRI; WENGER NS, 1992, ANN INTERN MED, V117, P905, DOI 10.7326/0003-4819-117-11-905; WIGHT D, 1992, AIDS CARE, V4, P11, DOI 10.1080/09540129208251616; WOODCOCK C, 1993, CHILDREN TEENAGERS H; 1992, HLTH NATION STRATEGY; 1988, SURVEY PERRSONAL SOC; 1993, SURVEY HLTH ED POLIC; 1994, REPORT COCHRANE COLL	39	139	141	1	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 21	1995	310	6973					158	162		10.1136/bmj.310.6973.158	http://dx.doi.org/10.1136/bmj.310.6973.158			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QD201	7833754	Green Published			2022-12-28	WOS:A1995QD20100020
J	DELTURCO, MR; PALLI, D; CARIDDI, A; CIATTO, S; PACINI, P; DISTANTE, V; AZZINI, V; BELSANTI, V; BARTOLUCCI, R; DICOSTANZO, F; BERTUSI, M; DANESE, S; GIARDINA, G; DAIUTO, G; UCCELLO, V; DELEO, G; PUNZO, C; GOSSO, P; GRISO, C; LOCATELLI, E; MANSUTTI, M; SANDRI, P; MOLINO, AM; SCHINCAGLIA, P; TIENGHI, A				DELTURCO, MR; PALLI, D; CARIDDI, A; CIATTO, S; PACINI, P; DISTANTE, V; AZZINI, V; BELSANTI, V; BARTOLUCCI, R; DICOSTANZO, F; BERTUSI, M; DANESE, S; GIARDINA, G; DAIUTO, G; UCCELLO, V; DELEO, G; PUNZO, C; GOSSO, P; GRISO, C; LOCATELLI, E; MANSUTTI, M; SANDRI, P; MOLINO, AM; SCHINCAGLIA, P; TIENGHI, A			INTENSIVE DIAGNOSTIC FOLLOW-UP AFTER TREATMENT OF PRIMARY BREAST-CANCER - A RANDOMIZED TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHEST-X-RAY; BONE; SCINTIGRAPHY; RECURRENCES; METASTASES	Objective.-To evaluate the effectiveness of early detection of intrathoracic a Design.-Randomized clinical trial allocating breast cancer patients to two alternative follow-up protocols (intensive vs clinical) for at least 5 years. Setting.-Twelve breast clinics (referral centers) in different areas in Italy. Patients.-A total of 1243 consecutive patients (either premenopausal or postmenopausal) surgically treated for unilateral invasive breast carcinoma with no evidence of metastases. The two study groups were well balanced in terms of clinical and prognostic characteristics. Intervention.-Patients in both treatment groups had physical examination and mammography, while patients of the intensive follow-up group had, in addition, chest roentgenography and bone scan every 6 months. Main Outcome Measures.-Vital status at 5 years was the main outcome; information was available for all except five patients (0.4%). Relapse-free survival was also analyzed. Results.-Overall, 393 recurrences (104 local and 289 distant) were observed during the study. Increased detection of isolated intrathoracic and bone metastases was evident in the intensive follow-up group compared with the clinical follow-up group (112 vs 71 cases), while no difference was observed for other sites and for local and/or regional recurrences. The 5-year relapse-free survival rate was significantly higher for the clinical follow-up group, with patients in the intensive follow-up group showing earlier detection of recurrences. No difference in 5-year overall mortality (18.6% vs 19.5%) was observed between the two follow-up groups. Conclusions.-Periodic chest roentgenography and bone scan allow earlier detection of distant metastases, but anticipated diagnosis appears to be the only effect of intensive follow-up, and no impact on prognosis is evident after 5 years. Periodic intensive follow-up with chest roentgenography and bone scan should not be recommended as a routine policy.	CTR STUDIO & PREVENZ ONCOL, EPIDEMIOL UNIT, FLORENCE, ITALY; UNIV FLORENCE, UNITA SANITARIA LOCALE 10D, RADIOTHERAPY UNIT, FLORENCE, ITALY; UNIV FLORENCE, DEPT SURG, FLORENCE, ITALY; UNIV VERONA, GINECOL CLIN, VERONA, ITALY; OSPED MONTELUCE, DIV ONCOL, PERUGIA, ITALY; OSPED S MARIA, SERV ONCOL, TERNI, ITALY; OSPED S ANNA FERRARA, DIV ONCOL, FERRARA, ITALY; UNIV TURIN, CATTEDRA OSTET & GINECOL A, TURIN, ITALY; FDN PASCALE, IST TUMORI, NAPLES, ITALY; UNIV BARI, IST SEMEIOT CHIRURG, BARI, ITALY; OSPED ALBA, DIV CHIRURG, ALBA, ITALY; UNIV VERONA, POLICLIN BORGO TRENTO, DIV RADIOTERAPIA, VERONA, ITALY; OSPED VITTORE BRUZZI, MILAN, ITALY; CTR DIAGNOSI & CURA TUMORI, TRIESTE, ITALY; UNIV VERONA, DIV MED ONCOL, VERONA, ITALY; OSPED S MARIA CROCI, DIV ONCOL, RAVENNA, ITALY	University of Florence; University of Florence; University of Verona; University of Ferrara; Arcispedale Sant'Anna; University of Turin; IRCCS Fondazione Pascale; Universita degli Studi di Bari Aldo Moro; University of Verona; University of Verona	DELTURCO, MR (corresponding author), CTR STUDIO & PREVENZ ONCOL, BREAST UNIT, VIALE A VOLTA 171, I-50131 FLORENCE, ITALY.		Danese, Silvio/ABH-9571-2020	Danese, Silvio/0000-0001-7341-1351; PALLI, Domenico/0000-0002-5558-2437; tumino, rosario/0000-0003-2666-414X				ANDREOLI C, 1987, TUMORI, V73, P463, DOI 10.1177/030089168707300506; CAPOCACCIA R, 1990, CANCER CAUSE CONTROL, V1, P23, DOI 10.1007/BF00053180; CHAUDARY MA, 1983, BRIT J SURG, V70, P517, DOI 10.1002/bjs.1800700903; CIATTO S, 1989, BRIT J CANCER, V60, P102, DOI 10.1038/bjc.1989.229; CIATTO S, 1984, TUMORI, V70, P179, DOI 10.1177/030089168407000212; CIATTO S, 1983, TUMORI, V69, P151, DOI 10.1177/030089168306900211; Coleman R E, 1990, Clin Oncol (R Coll Radiol), V2, P328, DOI 10.1016/S0936-6555(05)80995-1; HIETANEN P, 1986, ACTA ONCOL, V25, P15, DOI 10.3109/02841868609136370; HORTON J, 1984, CANCER, V53, P790, DOI 10.1002/1097-0142(19840201)53:3+<790::AID-CNCR2820531330>3.0.CO;2-F; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LOGAGER VB, 1990, EUR J CANCER, V26, P553, DOI 10.1016/0277-5379(90)90073-3; PEREZ DJ, 1983, LANCET, V2, P613; RUTGERS EJT, 1989, BRIT J SURG, V76, P187, DOI 10.1002/bjs.1800760227; SCANLON EF, 1980, CANCER, V46, P977, DOI 10.1002/1097-0142(19800815)46:4+<977::AID-CNCR2820461320>3.0.CO;2-0; SCHAPIRA DV, 1991, JAMA-J AM MED ASSOC, V265, P380, DOI 10.1001/jama.265.3.380; THOMSEN HS, 1987, EUR J CANCER CLIN ON, V23, P779, DOI 10.1016/0277-5379(87)90278-1; TOMIN R, 1987, J CLIN ONCOL, V5, P62, DOI 10.1200/JCO.1987.5.1.62; WERTHEIMER MD, 1991, JAMA-J AM MED ASSOC, V265, P396, DOI 10.1001/jama.265.3.396; WINCHESTER DP, 1979, CANCER, V43, P956, DOI 10.1002/1097-0142(197903)43:3<956::AID-CNCR2820430326>3.0.CO;2-L; ZELEN M, 1968, CANCER RES, V28, P207; ZWAVELING A, 1987, J SURG ONCOL, V34, P194, DOI 10.1002/jso.2930340314; 1985, TUMORI MAMMELLA PROT	22	466	469	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	1994	271	20					1593	1597		10.1001/jama.1994.03510440053032	http://dx.doi.org/10.1001/jama.1994.03510440053032			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL758	7848404				2022-12-28	WOS:A1994NL75800027
J	LINDPAINTNER, K; PFEFFER, MA; KREUTZ, R; STAMPFER, MJ; GRODSTEIN, F; LAMOTTE, F; BURING, J; HENNEKENS, CH				LINDPAINTNER, K; PFEFFER, MA; KREUTZ, R; STAMPFER, MJ; GRODSTEIN, F; LAMOTTE, F; BURING, J; HENNEKENS, CH			A PROSPECTIVE EVALUATION OF AN ANGIOTENSIN-CONVERTING-ENZYME GENE POLYMORPHISM AND THE RISK OF ISCHEMIC-HEART-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INSERTION DELETION POLYMORPHISM; MYOCARDIAL-INFARCTION; CARDIOMYOPATHY; CHOLESTEROL; EXPRESSION	Background. In a previous study, men with a history of myocardial infarction were found to have an increased prevalence of homozygosity for the deletional allele (D) of the angiotensin-converting-enzyme (ACE) gene, The D allele is associated with higher levels of ACE, which may predispose a person to ischemic heart disease. We investigated the association between the ACE genotype and the incidence of myocardial infarction, as well as other manifestations of ischemic heart disease, in a large, prospective cohort of U.S. male physicians, Methods. In the Physicians' Health Study, ischemic heart disease as defined by angina, coronary revascularization, or myocardial infarction developed in 1250 men by 1992, They were matched with 2340 controls according to age and smoking history. Zygosity for the deletion-insertion (D-I) polymorphism of the ACE gene was determined by an assay based on the polymerase chain reaction, Data were analyzed for both matched pairs and unmatched samples, with adjustment for the effects of known or suspected risk factors by conditional and non-conditional logistic regression, respectively. Results. The ACE genotype was not associated with the occurrence of either ischemic heart disease or myocardial infarction, The adjusted relative risk associated with the D allele was 1.07 (95 percent confidence interval, 0.96 to 1.19; P = 0.24) for ischemic heart disease and 1.05 (95 percent confidence interval, 0.89 to 1.25; P = 0.56) for myocardial infarction, if an additive mode of inheritance is assumed, Additional analyses assuming dominant and recessive effects of the D allele also failed to show any association, as did the examination of low-risk subgroups, Conclusions. In a large, prospectively followed population of U.S. male physicians, the presence of the D allele of the ACE gene conferred no appreciable increase in the risk of ischemic heart disease or myocardial infarction.	BRIGHAM & WOMENS HOSP,DIV CARDIOVASC DIS,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV PREVENT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,CHANNING LAB,BOSTON,MA 02115; CHILDRENS HOSP,DEPT CARDIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health			Kreutz, Reinhold/AEV-0507-2022	Kreutz, Reinhold/0000-0002-4818-211X	NCI NIH HHS [CA42182, CA40360] Funding Source: Medline; NHLBI NIH HHS [K04-HL03138-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040360, R01CA042182] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL003138] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1988, NEW ENGL J MED; [Anonymous], 1989, NEW ENGL J MED, V321, P129; BOHN M, 1993, CLIN GENET, V44, P298; BOHN M, 1993, CLIN GENET, V44, P292; BRITTON S, 1973, AM J PHYSIOL, V225, P1226, DOI 10.1152/ajplegacy.1973.225.5.1226; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; COSTEROUSSE O, 1993, BIOCHEM J, V290, P33, DOI 10.1042/bj2900033; EVANS AE, 1994, Q J MED, V87, P211; FABRIS B, 1990, CLIN EXP PHARMACOL P, V17, P309, DOI 10.1111/j.1440-1681.1990.tb01326.x; HERBERT PN, 1985, J CLIN INVEST, V76, P403, DOI 10.1172/JCI111986; HERMAN B, 1983, AM J EPIDEMIOL, V118, P514, DOI 10.1093/oxfordjournals.aje.a113657; HIRSCH AT, 1991, CIRC RES, V59, P475; HOIT BD, 1986, CIRCULATION, V74, P712, DOI 10.1161/01.CIR.74.4.712; HUBERT C, 1991, J BIOL CHEM, V266, P15377; JORDE LB, 1988, AM J CARDIOL, V62, P708, DOI 10.1016/0002-9149(88)91207-6; LINDPAINTNER K, 1993, J MOL CELL CARDIOL, V25, P133, DOI 10.1006/jmcc.1993.1017; LINDPAINTNER K, 1993, CLIN RES, V41, pA216; Magrini F, 1988, Am J Med, V84, P55, DOI 10.1016/0002-9343(88)90205-7; MARIAN AJ, 1993, LANCET, V342, P1085, DOI 10.1016/0140-6736(93)92064-Z; MOCHIZUKI T, 1992, J CLIN INVEST, V89, P490, DOI 10.1172/JCI115611; OHISHI M, 1993, NAT GENET, V5, P324, DOI 10.1038/ng1293-324; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; RAYNOLDS MV, 1993, LANCET, V342, P1073, DOI 10.1016/0140-6736(93)92061-W; RIDKER PM, 1993, CIRCULATION, V87, P1969, DOI 10.1161/01.CIR.87.6.1969; RIGAT B, 1992, NUCLEIC ACIDS RES, V20, P1433, DOI 10.1093/nar/20.6.1433-a; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; ROSNER B, 1978, INT J EPIDEMIOL, V7, P367, DOI 10.1093/ije/7.4.367; RUIZ J, 1994, P NATL ACAD SCI USA, V91, P3662, DOI 10.1073/pnas.91.9.3662; RUTHERFORD JD, 1994, CIRCULATION, V90, P1731, DOI 10.1161/01.CIR.90.4.1731; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; SCHUNKERT H, 1994, NEW ENGL J MED, V330, P1634, DOI 10.1056/NEJM199406093302302; SHANMUGAM V, 1993, PCR METH APPL, V3, P120; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; TIRET L, 1992, AM J HUM GENET, V51, P197; TIRET L, 1993, LANCET, V341, P991, DOI 10.1016/0140-6736(93)91075-W; UNDERWOOD DA, 1985, AM J CARDIOL, V55, P631, DOI 10.1016/0002-9149(85)90126-2; YUSUF S, 1992, LANCET, V340, P1173, DOI 10.1016/0140-6736(92)92889-N	39	861	893	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 16	1995	332	11					706	711		10.1056/NEJM199503163321103	http://dx.doi.org/10.1056/NEJM199503163321103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL788	7854377				2022-12-28	WOS:A1995QL78800003
J	WOLOSHIN, S; BICKELL, NA; SCHWARTZ, LM; GANY, F; WELCH, HG				WOLOSHIN, S; BICKELL, NA; SCHWARTZ, LM; GANY, F; WELCH, HG			LANGUAGE BARRIERS IN MEDICINE IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPEAKING PATIENTS; HEALTH-CARE; INTERPRETERS; COMMUNICATION; INTERVIEW; HISPANICS; EMERGENCY; HISTORY		NYU,SCH MED,DIV PRIMARY CARE,NEW YORK,NY; DARTMOUTH COLL,SCH MED,CTR EVALUAT CLIN SCI,HANOVER,NH 03755	New York University; Dartmouth College	WOLOSHIN, S (corresponding author), DEPT VET AFFAIRS MED CTR,VET AFFAIRS OUTCOMES GRP 111B,WHITE RIVER JCT,VT 05009, USA.							ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; CARR R, 1994, LTD ENGLISH PROFIC B; CRIVELLA BJ, 1982, POLICY GUIDANCE APPL; DAY TW, 1992, MINN MED, V75, P15; DIEHL AK, 1993, AM J MED SCI, V4305, P383; DOWNING BT, 1991, NATIONAL C HLTH MENT; DOWNING BT, 1992, PROFESSIONAL TRAININ; EBDEN P, 1988, LANCET, V13, P347; FOX SA, 1991, MED CARE, V29, P1065, DOI 10.1097/00005650-199111000-00001; GAVIRIA M, 1982, J NATL MED ASSOC, V74, P983; HAMPTON JR, 1975, BRIT MED J, V2, P486, DOI 10.1136/bmj.2.5969.486; KIRKMANLIFF B, 1991, AM J PUBLIC HEALTH, V81, P1399, DOI 10.2105/AJPH.81.11.1399; KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251; LAUNER J, 1978, BRIT MED J, V2, P934, DOI 10.1136/bmj.2.6142.934; LIPKIN M, 1984, ANN INTERN MED, V100, P277, DOI 10.7326/0003-4819-100-2-277; LIPKIN M, 1994, OFFICE PRACTICE MED, P1287; MANSON A, 1988, MED CARE, V26, P1119, DOI 10.1097/00005650-198812000-00003; MARCOS LR, 1979, AM J PSYCHIAT, V136, P171; MARCOS LR, 1973, ARCH GEN PSYCHIAT, V29, P655; PEGALIS SE, 1992, AM LAW MED MALPRACTI; PUTSCH RW, 1985, JAMA-J AM MED ASSOC, V254, P3344, DOI 10.1001/jama.254.23.3344; RICHMAN R, 1993, CHICAGO REPORTER, V22, P1; RIDDICK S, 1992, P LANGUAGE RIGHTS C; RIDDICK S, 1991, AM PUBLIC HLTH ASS A; ROSEN K, 1991, ANN EMERG MED, V20, P466; SANDLER G, 1980, AM HEART J, V100, P928, DOI 10.1016/0002-8703(80)90076-9; Siegler M, 1990, J Clin Ethics, V1, P5; SOLIS JM, 1990, AM J PUBLIC HEALTH, V80, P11, DOI 10.2105/AJPH.80.Suppl.11; SUCHMAN AL, 1988, ANN INTERN MED, V108, P125, DOI 10.7326/0003-4819-108-1-125; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; TUMULTY PA, 1970, NEW ENGL J MED, V283, P20, DOI 10.1056/NEJM197007022830105; VASQUEZ C, 1991, HOSP COMMUNITY PSYCH, V42, P163; WATT IS, 1993, J PUBLIC HEALTH MED, V15, P129; 1971, TITLE 6 COMPENDIUM, V1, P19; 1992, ASTHO BILINGUAL HLTH; 1993, REPORT HHS CIVIL RIG; 1993, ESTABLISH EFFECTIVE; 1993, INTERPRETER SERVICES; 1993, STATISTICAL ABSTRACT; 1992, ENSURING ACCESS HLTH; 1986, LANGUAGE SERVICES AD; 1990, SIMULTANEOUS INTER 2; 1989, HLTH PEOPLE 2000 NAT; 1985, REPORT SECRETARYS TA; 1990, SIMULTANEOUS INTER 1; 1993, REGION 5 NEWSLETTER; 1980, TITLE 6 COMPENDIUM, V1, P72; 1982, MAKING HLTH CARE DEC, P3; 1980, TITLE 6 COMPENDIUM, V1, P66; 1992, PROJECT 3000 2000; 1979, MEDICARE PROVIDER RE; 1994, CLASSIFICATION PLAN; 1990, AM J PUBLIC HLTH S, V80, P11; 1986, AD HOC INTERPRETATIO; 1993, OUTLINE INTERPRETER	55	231	231	1	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	1995	273	9					724	728		10.1001/jama.273.9.724	http://dx.doi.org/10.1001/jama.273.9.724			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QH814	7853631				2022-12-28	WOS:A1995QH81400032
J	D'SOUZA-SCHOREY, C; LI, GP; COLOMBO, MI; STAHL, PD				D'SOUZA-SCHOREY, C; LI, GP; COLOMBO, MI; STAHL, PD			A REGULATORY ROLE FOR ARF6 IN RECEPTOR-MEDIATED ENDOCYTOSIS	SCIENCE			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING-PROTEIN; GOLGI MEMBRANES; MUTAGENESIS; EXPRESSION; COATOMER; CELLS	Adenosine diphosphate-ribosylation factor 6 (ARF6), ARF6 mutants, and ARF1 were transiently expressed in Chinese hamster ovary cells, and the effects on receptor-mediated endocytosis were assessed. Overexpressed ARF6 localized to the cell periphery and led to a redistribution of transferrin receptors to the cell surface and a decrease in the rate of uptake of transferrin. Similar results were obtained when a mutant defective in guanosine triphosphate hydrolysis was expressed. Expression of a dominant negative mutant, ARF6(T27N), resulted in an intracellular distribution of transferrin receptors and an inhibition of transferrin recycling to the cell surface. In contrast, overexpression of ARF1 had little or no effect on these parameters of endocytosis.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)			Li, Guangpu/GRS-5397-2022; Stahl, Philip/D-6315-2012					BALCH WE, 1992, J BIOL CHEM, V267, P13053; BERON W, UNPUB; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DSOUZASCHOREY C, UNPUB; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LI GP, 1993, J BIOL CHEM, V268, P24475; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Sambrook J, 1989, MOL CLONING LABORATO; SCHURMANN A, 1994, J BIOL CHEM, V269, P15683; STAHL P, 1980, CELL, V19, P207, DOI 10.1016/0092-8674(80)90402-X; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; TEAL SB, 1994, J BIOL CHEM, V269, P3135; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; WAGNER P, 1992, METHOD ENZYMOL, V219, P369; Whitney J. A., 1993, Molecular Biology of the Cell, V4, p445A; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289	25	365	369	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 24	1995	267	5201					1175	1178		10.1126/science.7855600	http://dx.doi.org/10.1126/science.7855600			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855600				2022-12-28	WOS:A1995QJ23700040
J	MILLER, RH; LUFT, HS				MILLER, RH; LUFT, HS			ESTIMATING HEALTH EXPENDITURE GROWTH UNDER MANAGED COMPETITION - SCIENCE, SIMULATIONS, AND SCENARIOS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COST-CONTAINMENT; CARE REFORM; INSURANCE; PHYSICIANS; SYSTEMS	The estimated impact of health system reform proposals on health expenditures influences the health system reform debate. Health expenditure growth rate (HEGR) estimates are particularly critical because small differences in rates over time create large differences in health expenditures. There currently is no hard scientific basis for estimating the impact of managed care/managed competition legislation and market developments on the HEGR. For the 1994 health system reform debate, the two leading nonpartisan modelers developed qualitative scenarios about future health system developments in which managed care/managed competition would have little or no impact on the HEGR. We conclude that there are alternative plausible scenarios, based on current health system changes interacting with potential legislation, in which managed care/managed competition will substantially lower the HEGR. We recommend that simulation models should provide a range of estimates that better reflect both market trends and the profound uncertainty about the effects of health system reform.	UNIV CALIF SAN FRANCISCO, INST HLTH & AGING, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	MILLER, RH (corresponding author), UNIV CALIF SAN FRANCISCO, INST HLTH POLICY STUDIES, 1388 SUTTER ST, 11TH FLOOR, SAN FRANCISCO, CA 94109 USA.							Ackerman F K 3rd, 1992, Health Care Manage Rev, V17, P81; ANDERSON HJ, 1992, HOSPITALS, V66, P26; BARER ML, 1988, MILBANK Q, V66, P1, DOI 10.2307/3349985; CERNE F, 1994, HOSP HEALTH NETWORK, V68, P32; Davidson R J, 1992, J Am Health Policy, V2, P12; EDLIN M, 1993, MANAGED HEALTHCA JUL, V3, P45; ENTHOVEN AC, 1994, HEALTH AFFAIR, V13, P81, DOI 10.1377/hlthaff.13.1.81; ENTHOVEN AC, 1993, HEALTH AFFAIR, V12, P27, DOI 10.1377/hlthaff.12.3.27; EVANS RG, 1990, J HEALTH POLIT POLIC, V15, P101, DOI 10.1215/03616878-15-1-101; EVANS RG, 1989, NEW ENGL J MED, V320, P571, DOI 10.1056/NEJM198903023200906; FINDLAY S, 1993, BUS HEALTH, V11, P28; FINDLAY S, 1993, BUS HEALTH, V11, P27; FISCUS JW, 1993, MANAGED HLTH CARE NE, V2, P34; FISCUS JW, 1993, MANAGED HLTH CARE NE, V2, P1; GABEL J, 1991, HEALTH AFFAIR, V10, P48, DOI 10.1377/hlthaff.10.4.48; GABEL J, 1990, HEALTH AFFAIR, V9, P161, DOI 10.1377/hlthaff.9.3.161; GABEL JR, 1992, HEALTH AFFAIR, V11, P186, DOI 10.1377/hlthaff.11.4.186; Getzen T E, 1990, Adv Health Econ Health Serv Res, V11, P27; GILLIES RR, 1993, HOSP HEALTH SERV ADM, V38, P467; GINZBERG E, 1990, JAMA-J AM MED ASSOC, V263, P1820, DOI 10.1001/jama.263.13.1820; GINZBERG E, 1992, JAMA-J AM MED ASSOC, V268, P3115, DOI 10.1001/jama.268.21.3115; GOLDSMITH J, 1993, HEALTH AFFAIR, V12, P160, DOI 10.1377/hlthaff.12.3.160; GRANT PN, 1991, CALIFORNIA PHYSI SEP, P32; GRANT PN, 1992, CALIFORNIA HOSP  MAR, P12; GRUMBACH K, 1991, JAMA-J AM MED ASSOC, V265, P2369; HOY EW, 1991, HEALTH AFFAIR, V10, P18, DOI 10.1377/hlthaff.10.4.18; KRAUS N, MANAGED CARE DECADE; KRONICK R, 1993, NEW ENGL J MED, V328, P148, DOI 10.1056/NEJM199301143280225; MADISON DL, 1988, MILBANK Q, V66, P240, DOI 10.2307/3350032; MALLORY JS, 1990, BESTS REV        APR, P40; MALLORY JS, 1990, BESTS REV        APR, P42; MALLORY JS, 1990, BESTS REV        APR, P111; MALLORY JS, 1990, BESTS REV        APR, P36; MALLORY JS, 1990, BESTS REV        APR, P38; MEYER H, 1993, AM MED NEWS     0308, P1; MEYER H, 1993, AM MED NEWS     0412, P8; MEYER H, 1993, AM MED NEWS     0412, P6; MILLER RH, 1994, ANNU REV PUBL HEALTH, V15, P437; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; MILLER RH, 1994, ASSESSING ASSUMPTION; MILLER RH, 1994, RES COST EFFECTIVENE; NEWHOUSE JP, 1993, HEALTH AFFAIR, V12, P152, DOI 10.1377/hlthaff.12.suppl_1.152; PACKERTURSMAN J, 1992, HMO MAGAZINE     NOV, P39; PALSBO SE, 1993, HMO IND PROFILE; PARINGER LC, 1994, ASSESSING DEFINITION; PEAR R, 1994, NY TIMES        0509, pA7; PETERSEN C, 1993, MANAGED HEALTHCARE, V3, P32; PINE D, 1994, BUSINESS HLTH SA, V12, P58; RICE T, 1993, JAMA-J AM MED ASSOC, V270, P1357, DOI 10.1001/jama.270.11.1357; SCHWARTZ WB, 1994, HEALTH AFFAIR, V13, P224, DOI 10.1377/hlthaff.13.1.224; SCHWARTZ WB, 1987, JAMA-J AM MED ASSOC, V257, P220, DOI 10.1001/jama.257.2.220; SHORTELL SM, 1993, HOSP HEALTH SERV ADM, V38, P447; Starr B, 1993, Bus Health, V11, ppassim; Starr P, 1982, SOCIAL TRANSFORMATIO; SULLIVAN CB, 1992, HEALTH AFFAIR, V11, P172, DOI 10.1377/hlthaff.11.4.172; Tweed V, 1994, Bus Health, V12, P27; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WEISBROD BA, 1991, J ECON LIT, V29, P523; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906; 1992, PROJECTIONS NATIONAL; 1994, EFFECTS MANAGED CARE; 1993, MANAGED COMPETITION; 1992, POTENTIAL IMPACT CER; 1994, INTERSTUDY COMPETITI; 1993, MANAGED HLTH CARE EF; 1993, OTAH522 OFF TECHN AS; 1993, HLTH BENEFITS 1993	67	12	12	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	1995	273	8					656	662		10.1001/jama.273.8.656	http://dx.doi.org/10.1001/jama.273.8.656			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QG748	7844877				2022-12-28	WOS:A1995QG74800032
J	FITZGERALD, JM				FITZGERALD, JM			THE DOWNSIDE OF ISONIAZID CHEMOPROPHYLAXIS	LANCET			English	Editorial Material							PULMONARY TUBERCULOSIS; COST-EFFECTIVENESS; PROPHYLAXIS		UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER,BC,CANADA	University of British Columbia	FITZGERALD, JM (corresponding author), UNIV BRITISH COLUMBIA,CTR DIS CONTROL,DIV TB CONTROL,VANCOUVER,BC,CANADA.							FITZGERALD JM, 1990, AM REV RESPIR DIS, V142, P848, DOI 10.1164/ajrccm/142.4.848; FITZGERALD JM, 1993, CLIN INVEST MED S4, V16, P764; FITZGERALD JM, 1993, CAN J PUBLIC HLTH, V84, P249; FITZGERALD JM, IN PRESS CAN COMMUN; GODFREYFAUSSETT P, 1994, BRIT MED J, V309, P1230; MANALO F, 1990, AM REV RESPIR DIS, V142, P1301, DOI 10.1164/ajrccm/142.6_Pt_1.1301; MURRAY CJL, 1991, LANCET, V338, P1305, DOI 10.1016/0140-6736(91)92600-7; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; SCHULZER M, 1994, INT J EPIDEMIOL, V23, P400, DOI 10.1093/ije/23.2.400; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; WOBESER W, 1989, CLIN INVEST MED, V12, P149; 1993, TUBERCULOSIS GUIDE H	12	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					404	404		10.1016/S0140-6736(95)90397-6	http://dx.doi.org/10.1016/S0140-6736(95)90397-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853947				2022-12-28	WOS:A1995QG90400005
J	PAPHASSARANG, C; TOMSON, G; CHOPRAPAWON, C; WEERASURIYA, K				PAPHASSARANG, C; TOMSON, G; CHOPRAPAWON, C; WEERASURIYA, K			THE LAO NATIONAL DRUG POLICY - LESSONS ALONG THE JOURNEY	LANCET			English	Article									KAROLINSKA INST,DEPT INT HLTH & SOCIAL MED,INT HLTH CARE RES UNIT,S-17177 STOCKHOLM,SWEDEN; THAILAND HLTH RES INST,BANGKOK,THAILAND; UNIV COLOMBO,FAC MED,DEPT PHARMACOL,COLOMBO,SRI LANKA; MINIST PUBL HLTH,DEPT FOOD & DRUG,VIANGCHAN,LAOS	Karolinska Institutet; University of Colombo								CHETLEY A, 1994, LANCET, V343, P967; DUMOULIN J, 1994, LAO DRUG DATA BASE; FUNCK B, 1993, CHALLENGE EC REFORMM, P123; Hall P, 1975, CHANGE CHOICE CONFLI; HOGERZEIL HV, 1993, LANCET, V343, P1408; KINTANAR QL, 1992, PRESCRIPTION CHANGE, P32; MANGLA B, 1993, LANCET, V342, P608, DOI 10.1016/0140-6736(93)91424-K; PAPHASSARANG C, 1992, NATIONAL DRUG POLICY; PONGPRADITH S, 1993, DIARRHOEAL DISEASE C; REICH MR, 1994, HLTH POLICY PLANN, V9, P1; ROBLES A, 1992, PRESCRIPTION CHANGE; TOMSON G, 1986, LANCET, V2, P620; TOMSON G, 1992, NAIONAL DRUG POLICY; 1988, GUIDELINES DEV NATIO; 1994, REPORT BIENNIUM 1992; 1993, INVESTING HLTH WORLD; 1993, NATIONAL DRUG POLICY; 1994, LAO SOCIAL INDICATOR; 1992, ETHICAL CRITERIA MED	19	23	23	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					433	435		10.1016/S0140-6736(95)90408-5	http://dx.doi.org/10.1016/S0140-6736(95)90408-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853957				2022-12-28	WOS:A1995QG90400016
J	MAST, EE; GOODMAN, RA; BOND, WW; FAVERO, MS; DROTMAN, DP				MAST, EE; GOODMAN, RA; BOND, WW; FAVERO, MS; DROTMAN, DP			TRANSMISSION OF BLOOD-BORNE PATHOGENS DURING SPORTS - RISK AND PREVENTION	ANNALS OF INTERNAL MEDICINE			English	Article							HIV-1 INFECTION	Publicity about human immunodeficiency virus (HIV) infection in athletes has focused attention on the potential for transmission of blood-borne pathogens during sports and athletic competitions. Existing information suggests that the potential risk for such transmission is extremely low and that the principal risks athletes have for acquiring HIV and hepatitis B virus are related to off-the-field activities. Therefore, efforts to prevent transmission of blood-borne pathogens among athletes should emphasize prevention in off-the-field settings. We summarize technical and other information about this issue, and provide recommendations for the education of sports participants, for infection control in athletic settings, and for training of coaches and officials.			MAST, EE (corresponding author), CTR DIS CONTROL & PREVENT, HEPATITIS BRANCH, MAILSTOP G37, 1600 CLIFTON RD, ATLANTA, GA 30333 USA.							[Anonymous], 1991, MMWR Recomm Rep, V40, P1; BROWN LS, 1995, ANN INTERN MED, V122, P271, DOI 10.7326/0003-4819-122-4-199502150-00005; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; GOODMAN RA, 1994, JAMA-J AM MED ASSOC, V271, P862, DOI 10.1001/jama.271.11.862; IPPOLITO G, 1994, JAMA-J AM MED ASSOC, V272, P433, DOI 10.1001/jama.272.6.433; KASHIWAGI S, 1982, JAMA-J AM MED ASSOC, V248, P213, DOI 10.1001/jama.248.2.213; OFARRELL N, 1992, LANCET, V339, P246, DOI 10.1016/0140-6736(92)90048-8; TORRE D, 1990, LANCET, V335, P1105, DOI 10.1016/0140-6736(90)92684-A; 1991, FED REGISTER, V56, P64005; 1993, BLOODBORNE PATHOGENS; 1991, PEDIATRICS, V88, P640; 1994, MMWR-MORBID MORTAL W, V43, P353; 1992, HIV AIDS RELATED POL; 1989, GLOBAL PROGRAMME AID; 1994, MMWR-MORBID MORTAL W, V43, P347	15	31	32	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1995	122	4					283	285		10.7326/0003-4819-122-4-199502150-00008	http://dx.doi.org/10.7326/0003-4819-122-4-199502150-00008			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF769	7825765				2022-12-28	WOS:A1995QF76900008
J	ASHBY, M; WAKEFIELD, M; BEILBY, J				ASHBY, M; WAKEFIELD, M; BEILBY, J			GENERAL-PRACTITIONERS KNOWLEDGE AND USE OF LIVING WILLS	BRITISH MEDICAL JOURNAL			English	Article									ROYAL ADELAIDE HOSP,ADELAIDE,SA 5000,AUSTRALIA; MARY POTTER HOSPICE,ADELAIDE,SA 5000,AUSTRALIA; S AUSTRALIAN HLTH COMMISS,BEHAV EPIDEMIOL UNIT,ADELAIDE,SA 5000,AUSTRALIA; ROYAL AUSTRALASIAN COLL GEN PRACTITIONERS,S AUSTRALIA FAC,RES & HLTH PROMOT UNIT,PAYNEHAM,SA 5069,AUSTRALIA	Royal Adelaide Hospital								Ashby M, 1993, Palliat Med, V7, P273, DOI 10.1177/026921639300700403; DYER C, 1993, BRIT MED J, V307, P1023; Stern K, 1993, Palliat Med, V7, P283, DOI 10.1177/026921639300700404; Wakefield Melanie A., 1993, Palliative Medicine, V7, P117, DOI 10.1177/026921639300700205; 1992, LANCET, V340, P1321	5	19	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 28	1995	310	6974					230	230		10.1136/bmj.310.6974.230	http://dx.doi.org/10.1136/bmj.310.6974.230			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE496	7866128	Green Published			2022-12-28	WOS:A1995QE49600027
J	CARTLIDGE, PHT; DAWSON, AT; STEWART, JH; VUJANIC, GM				CARTLIDGE, PHT; DAWSON, AT; STEWART, JH; VUJANIC, GM			VALUE AND QUALITY OF PERINATAL AND INFANT POSTMORTEM EXAMINATIONS - COHORT ANALYSIS OF 400 CONSECUTIVE DEATHS	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; AUDIT; FETAL	Objectives-To evaluate the contribution that perinatal and infant necropsy makes to clinical practice and to see how this might be influenced by the quality of the investigation. Design-Cohort analysis, with data from the all Wales perinatal survey, of perinatal and infant deaths during 1993 of babies born to mothers usually resident in Wales. The clinicopathological classification of death based on clinical details was compared with the classification after necropsy. Similarly, cases in which necropsy yielded new information were identified. The quality of the necropsy was assessed by scoring six aspects of the examination. Subjects-400 consecutive deaths at 20 weeks of gestation to 1 year of age. Main outcome measures-Necropsy rate, effect of necropsy on clinicopathological classification, new information disclosed by necropsy, quality of necropsies, and the link between new information and quality of the necropsy. Results-Necropsy was performed in 232 cases (58%). The clinicopathological classification was altered by necropsy in 29 cases (13%). New information was obtained in 60 cases (26%), and in 42 (18%) it disclosed the cause of death. The quality of necropsy was substantially higher when the main cause of death was detected than when nothing new was found. Conclusion-Necropsy is underused. Clinicians should be more positive about necropsies and realise how much clinically relevant information can be obtained from a good quality examination.			CARTLIDGE, PHT (corresponding author), UNIV WALES COLL MED,DEPT CHILD HLTH,CARDIFF CF4 4XN,S GLAM,WALES.		Vujanic, Gordan M./AAW-4712-2020; Vujanic, Gordan M./AFS-3176-2022	Vujanic, Gordan M./0000-0003-0726-6939; Vujanic, Gordan M./0000-0003-0726-6939				BRITTON M, 1974, ACTA MED SCAND, V196, P203; CLAYTONSMITH J, 1990, BRIT MED J, V300, P295, DOI 10.1136/bmj.300.6720.295; DULEY LMM, 1986, BRIT J OBSTET GYNAEC, V93, P1233, DOI 10.1111/j.1471-0528.1986.tb07856.x; GAU G, 1977, BRIT MED J, V1, P1580, DOI 10.1136/bmj.1.6076.1580; HEY EN, 1986, BRIT J OBSTET GYNAEC, V93, P1213, DOI 10.1111/j.1471-0528.1986.tb07854.x; KEELING JW, 1989, ARCH DIS CHILD, V64, P1345, DOI 10.1136/adc.64.10_Spec_No.1345; PORTER HJ, 1987, J CLIN PATHOL, V40, P180, DOI 10.1136/jcp.40.2.180; RUSHTON DI, 1991, BRIT J OBSTET GYNAEC, V98, P624, DOI 10.1111/j.1471-0528.1991.tb13446.x; SHEN-SCHWARZ S, 1989, Pediatric Pathology, V9, P1; WIGGLESWORTH JS, 1980, LANCET, V2, P684; 1993, REPORT NATIONAL CONF; 1980, 1979 80 SOC SERV COM; 1993, CONFIDENTIAL ENQUIRY; 1993, GUIDELINES POST MORT; 1990, B ROYAL COLLEGE PATH, V69, P10; 1988, REPORT FETAL PERINAT	16	114	119	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 21	1995	310	6973					155	158		10.1136/bmj.310.6973.155	http://dx.doi.org/10.1136/bmj.310.6973.155			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD201	7833753	Green Published			2022-12-28	WOS:A1995QD20100019
J	SUMMERTON, N				SUMMERTON, N			POSITIVE AND NEGATIVE FACTORS IN DEFENSIVE MEDICINE - A QUESTIONNAIRE STUDY OF GENERAL-PRACTITIONERS	BRITISH MEDICAL JOURNAL			English	Article								Objectives-(a) To investigate defensive medical practices among general practitioners; (b) to compare any such practices with general practitioners' understanding of certain aspects of the terms of service and medical negligence and practitioners' concerns about the risk of being sued or having a complaint lodged. Design-Postal questionnaire survey. Each questionnaire was followed by a reminder. Subjects-500 systematically selected general practitioners on the membership list of the Medical Defence Union. Main outcome measures-Answers to questions on defensive medical practices, understanding of certain aspects of the terms of service and medical negligence, and concerns about the risk of being sued or having a complaint lodged. Results-300 general practitioners returned the questionnaire (response rate 60%). 294 (98%) claimed to have made some practice changes as a result of the possibility of a patient complaining. Of the defensive medical practices adopted, the most common (over half of doctors stating likely or very likely) seemed to be increased diagnostic testing, increased referrals, increased follow up, and more detailed patient explanations and note taking. Respondents practised defensive medicine as a possible consequence of concerns about the risks of being sued or having a complaint lodged. This association was particularly strong for negative defensive practices. Defensive medical practice did not correlate with any misunderstanding about the law of negligence or the general practitioners' terms of service. Conclusions-General practitioners are practising defensive medicine. Some defensive practices such as increased patient explanations or more detailed note taking are clearly beneficial. However, implementing the findings of the Wilson report may increase negative defensive medical practices.			SUMMERTON, N (corresponding author), BRADFORD HLTH AUTHOR,DEPT PUBL HLTH MED,SHIPLEY BD18 3LD,W YORKSHIRE,ENGLAND.							BLACK N, 1990, LANCET, V335, P35, DOI 10.1016/0140-6736(90)90151-T; DINGWALL R, IN PRESS MED LAW REV; FLEISS JL, 1973, STATISTICAL METHODS; FRY J, 1993, GENERAL PRACTICE FAC; HERSHEY N, 1973, POLITICS LAW HLTH CA; MCQUADE JS, 1991, J ROY SOC MED, V84, P408, DOI 10.1177/014107689108400710; SIBBALD B, 1994, BRIT J GEN PRACT, V44, P297; TANCREDI LR, 1978, SCIENCE, V200, P879, DOI 10.1126/science.644329; 1994, BEING HEARD REPORT R; 1990, EPIINFO VERSION 5 0; 1992, COMPLAINTS FAMILY HL	11	121	122	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 7	1995	310	6971					27	29		10.1136/bmj.310.6971.27	http://dx.doi.org/10.1136/bmj.310.6971.27			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB060	7827550	Green Published			2022-12-28	WOS:A1995QB06000027
J	DUFFY, TP				DUFFY, TP			AN ANATOMY LESSON	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							RETROPERITONEAL FIBROSIS; TAMOXIFEN				DUFFY, TP (corresponding author), YALE UNIV,SCH MED,NEW HAVEN,CT 06510, USA.							BABAYAN RK, 1985, HOSP PRACT, V20, P51; CLARK CP, 1991, SURGERY, V109, P502; COMINGS DE, 1967, ANN INTERN MED, V66, P884, DOI 10.7326/0003-4819-66-5-884; DENT RG, 1983, THORAX, V38, P955, DOI 10.1136/thx.38.12.955; DUFF HJ, 1982, AM J CARDIOL, V50, P305, DOI 10.1016/0002-9149(82)90181-3; GLEESON MH, 1970, P ROY SOC MED, V63, P1309, DOI 10.1177/003591577006301240; HUGHES D, 1993, AM J SURG PATHOL, V17, P482, DOI 10.1097/00000478-199305000-00007; KINZBRUNNER B, 1983, CANCER-AM CANCER SOC, V52, P2201, DOI 10.1002/1097-0142(19831215)52:12<2201::AID-CNCR2820521204>3.0.CO;2-#; KOEP L, 1977, SURGERY, V81, P250; KUWANA M, 1992, ARTHRITIS RHEUM, V35, P1245, DOI 10.1002/art.1780351020; LEVINE MR, 1993, ARCH OPHTHALMOL-CHIC, V111, P841, DOI 10.1001/archopht.1993.01090060129037; LIEBMAN RM, 1983, AM J ROENTGENOL, V141, P949, DOI 10.2214/ajr.141.5.949; ORMOND JK, 1948, J UROLOGY, V59, P1072, DOI 10.1016/S0022-5347(17)69482-5; ROCKEY DC, 1993, NEW ENGL J MED, V329, P1691, DOI 10.1056/NEJM199312023292303	14	7	8	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 4	1994	331	5					318	320		10.1056/NEJM199408043310509	http://dx.doi.org/10.1056/NEJM199408043310509			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ227	7832838				2022-12-28	WOS:A1994NZ22700009
J	ARANETA, MRG; MASCOLA, L; ELLER, A; ONEIL, L; GINSBERG, MM; BURSAW, M; MARIK, J; FRIEDMAN, S; SIMS, CA; REKART, ML; COLLIE, F				ARANETA, MRG; MASCOLA, L; ELLER, A; ONEIL, L; GINSBERG, MM; BURSAW, M; MARIK, J; FRIEDMAN, S; SIMS, CA; REKART, ML; COLLIE, F			HIV TRANSMISSION THROUGH DONOR ARTIFICIAL-INSEMINATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SEXUALLY-TRANSMITTED DISEASES; INFECTION; WOMEN; RISK; SEMEN	Objective.-To investigate and report cases of human immunodeficiency virus (HIV) transmission through donor artificial insemination (AI) before 1986 at five infertility clinics. Design.-Two types of look-back studies were performed: (1) identification of an HIV-infected woman who reported previous AI, followed by identification of the infected donor(s) and contact tracing of women who were inseminated with his semen, and (2) identification of an HIV-infected donor and subsequent examination of women receiving AI procedures using his semen. Setting.-Five infertility clinics in Los Angeles County, California; San Diego County, California; Arizona; and Vancouver, British Columbia. Patients.-A total of 230 women were inseminated with semen from any one of the five identified HIV-infected donors; 199 (87%) consented to HIV testing. Main Outcome Measure.-Seropositivity for HIV among AI recipients. Results.-Seven (3.52%) of the 199 women (95% confidence interval, 1.55% to 7.41%) who were artificially inseminated with semen from any of five HIV-infected donors and consented to HIV testing tested HIV-seropositive. Information on HIV risk was available for three of the five donors; all three reported a history of having sex with men. Four HIV-infected women were identified through uncommon circumstances, rather than through routine look-back studies of donors. Conclusion.-Infection with HIV through donor AI performed before routine HIV screening of semen donors represents a potentially serious threat to women who underwent AI procedures. Public health policies requiring retrospective identification of HIV-infected semen donors and patients receiving AI before 1986, especially in acquired immunodeficiency syndrome (AIDS)-prevalent areas, should be considered routine. Women diagnosed with AIDS or HIV infection, in whom no identified risk of HIV acquisition is established, should be questioned about previous AI procedures.	LOS ANGELES CTY DEPT HLTH SERV,LOS ANGELES,CA; SAN DIEGO CTY DEPT HLTH SERV,SAN DIEGO,CA; BRITISH COLUMBIA CTR DIS CONTROL,VANCOUVER,BC,CANADA									BERRY WR, 1987, JAMA-J AM MED ASSOC, V257, P1079, DOI 10.1001/jama.257.8.1079; CHIASSON MA, 1990, J ACQ IMMUN DEF SYND, V3, P69; CHONG AP, 1975, FERTIL STERIL, V26, P791; CURIECOHEN M, 1979, NEW ENGL J MED, V300, P585, DOI 10.1056/NEJM197903153001103; ESKENAZI B, 1989, J ACQ IMMUN DEF SYND, V2, P187; FIUMARA NJ, 1972, BRIT J VENER DIS, V48, P308; HOLMBERG SD, 1989, J INFECT DIS, V160, P116, DOI 10.1093/infdis/160.1.116; INSLER V, 1986, INFERTILITY MALE FEM, P612; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; MASCOLA L, 1987, JAMA-J AM MED ASSOC, V257, P1093, DOI 10.1001/jama.257.8.1093; MASCOLA L, 1983, NEW ENGL J MED, V309, P1058; MASCOLA L, 1986, NEW ENGL J MED, V21, P1354; MOORE DE, 1989, JAMA-J AM MED ASSOC, V261, P3441, DOI 10.1001/jama.261.23.3441; NAGEL TC, 1986, FERTIL STERIL, V46, P959; PADIAN NS, 1990, J INFECT DIS, V161, P883, DOI 10.1093/infdis/161.5.883; PETERMAN TA, 1988, JAMA-J AM MED ASSOC, V259, P55, DOI 10.1001/jama.259.1.55; PETERMAN TA, 1987, TRANSFUSION, V27, P371, DOI 10.1046/j.1537-2995.1987.27587320525.x; PIOT P, 1989, BRIT MED J, V298, P623, DOI 10.1136/bmj.298.6674.623; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; REKART ML, 1988, 4TH INT C AIDS STOCK; SEMPRINI AE, 1992, LANCET, V340, P1317, DOI 10.1016/0140-6736(92)92495-2; STEINBERGER E, 1978, JAMA-J AM MED ASSOC, V223, P778; STEWART GJ, 1985, LANCET, V2, P581; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; 1990, FERTIL STERIL S1, V53, pS1; 1990, MMWR-MORBID MORTAL W, V39, P255; 1994, MMWR-MORBID MORTAL W, V43, P1; 1985, MMWR-MORBID MORTAL W, V34, P294; 1987, MMWR-MORBID MORTAL W, V36, P137; 1990, MMWR-MORBID MORTAL W, V39, P249	31	48	48	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	1995	273	11					854	858		10.1001/jama.273.11.854	http://dx.doi.org/10.1001/jama.273.11.854			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL402	7869555				2022-12-28	WOS:A1995QL40200022
J	DAQUILA, RT; JOHNSON, VA; WELLES, SL; JAPOUR, AJ; KURITZKES, DR; DEGRUTTOLA, V; REICHELDERFER, PS; COOMBS, RW; CRUMPACKER, CS; KAHN, JO; RICHMAN, DD				DAQUILA, RT; JOHNSON, VA; WELLES, SL; JAPOUR, AJ; KURITZKES, DR; DEGRUTTOLA, V; REICHELDERFER, PS; COOMBS, RW; CRUMPACKER, CS; KAHN, JO; RICHMAN, DD			ZIDOVUDINE RESISTANCE AND HIV-1 DISEASE PROGRESSION DURING ANTIRETROVIRAL THERAPY	ANNALS OF INTERNAL MEDICINE			English	Article						ZIDOVUDINE; DRUG RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS-1; ANTIVIRAL AGENTS; DIDANOSINE	HUMAN-IMMUNODEFICIENCY-VIRUS; SYNCYTIUM-INDUCING PHENOTYPE; REVERSE-TRANSCRIPTASE; SENSITIVITY; CAPACITY; CHILDREN; MUTATION; INVITRO; AIDS	Objective: To evaluate the association between resistance of human immunodeficiency virus type 1 (HIV-1) to zidovudine and clinical progression. Design: Retrospective analysis of specimens from patients in the AIDS Clinical Trials Group (ACTG) protocol 116B/117, a randomized comparison of didanosine with continued zidovudine therapy in patients with advanced HIV-1 disease who had received 16 weeks or more of previous zidovudine therapy. Setting: Participating ACTG virology laboratories. Patients: 187 patients with baseline HIV-1 isolates. Measurements: Zidovudine susceptibility testing and assays for syncytium-inducing phenotype were done on baseline HIV-1 isolates. Relative hazards for clinical progression or death associated with baseline clinical, virologic, and immunologic factors were determined from Cox proportional hazards regression models. Results: Compared with other patients, 15% (26 of 170) with isolates showing high-level zidovudine resistance (50% inhibitory zidovudine concentration greater than or equal to 1.0 mu M) had 1.74 times the risk for progressing to a new AIDS-defining event or death (95% CI, 1.00 to 3.03) and 2.78 times the risk for death (CI, 1.21 to 6.39) in analyses that controlled for baseline CD4(+) T-lymphocyte count, syncytium-inducing HIV-1 phenotype, disease stage, and randomized treatment assignment. The clinical benefit of didanosine was not limited to patients with highly zidovudine-resistant baseline HIV-1 isolates. Conclusions: High-level resistance of HIV-1 to zidovudine predicted more rapid clinical progression and death when adjusted for other factors. However, patients with advanced HIV-1 disease may benefit from a change in monotherapy from zidovudine to didanosine whether high-level HIV-1 resistance to zidovudine is present or absent, and laboratory assessment of zidovudine resistance is not necessary for deciding when to switch monotherapy from zidovudine to didanosine.	HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; UNIV ALABAMA,SCH MED,BIRMINGHAM,AL; VET AFFAIRS MED CTR,BIRMINGHAM,AL; UNIV COLORADO,HLTH SCI CTR,DENVER,CO; VET AFFAIRS MED CTR,DENVER,CO; NIAID,BETHESDA,MD 20892; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,AIDS PROGRAM,SAN FRANCISCO,CA; UNIV CALIF SAN DIEGO,SAN DIEGO,CA 92103; VET AFFAIRS MED CTR,LA JOLLA,CA; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,BOSTON,MA	Harvard University; Harvard T.H. Chan School of Public Health; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School					NIAID NIH HHS [AI 29193, AI 32775, AI 27659] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029193, U01AI032775, U01AI027659] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASJO B, 1986, LANCET, V2, P660; BOUCHER CAB, 1992, AIDS, V6, P1259, DOI 10.1097/00002030-199211000-00003; BOZZETTE SA, 1993, J INFECT DIS, V168, P1374, DOI 10.1093/infdis/168.6.1374; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; Chou TC, 1991, SYNERGISM ANTAGONISM, P61; COX DR, 1972, J R STAT SOC B, V34, P187; ERON JJ, 1993, ANTIMICROB AGENTS CH, V37, P1480, DOI 10.1128/AAC.37.7.1480; GAO WY, 1993, J CLIN INVEST, V91, P2326, DOI 10.1172/JCI116463; HEAGY W, 1991, J CLIN INVEST, V87, P1916, DOI 10.1172/JCI115217; HOLLINGER FB, 1992, J CLIN MICROBIOL, V30, P1787, DOI 10.1128/JCM.30.7.1787-1794.1992; HOOPER C, 1994, 3RD INT WORKSH HIV D, P67; JAPOUR AJ, 1994, J CLIN MICROBIOL, V32, P2291, DOI 10.1128/JCM.32.9.2291-2294.1994; JAPOUR AJ, 1993, ANTIMICROB AGENTS CH, V37, P1095, DOI 10.1128/AAC.37.5.1095; JAPOUR AJ, 1995, IN PRESS J INFECT DI; JOHNSON VA, 1992, J INFECT DIS, V166, P1143, DOI 10.1093/infdis/166.5.1143; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KATZENSTEIN DA, 1994, J INFECT DIS, V169, P416, DOI 10.1093/infdis/169.2.416; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; KOOT M, 1992, AIDS, V6, P49, DOI 10.1097/00002030-199201000-00006; KOZAL MJ, 1993, J INFECT DIS, V167, P526, DOI 10.1093/infdis/167.3.526; KOZAL MJ, 1994, ANN INTERN MED, V121, P263, DOI 10.7326/0003-4819-121-4-199408150-00005; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1991, AIDS, V5, P137, DOI 10.1097/00002030-199102000-00002; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MAYERS DL, 1993, ANTIMICROB AGENTS CH, V38, P307; MONTANER JSG, 1993, AIDS, V7, P189, DOI 10.1097/00002030-199302000-00006; OGINO MT, 1993, J PEDIATR-US, V123, P1, DOI 10.1016/S0022-3476(05)81529-X; RICHMAN DD, 1991, J INFECT DIS, V164, P1075, DOI 10.1093/infdis/164.6.1075; RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; SPRUANCE SL, 1994, ANN INTERN MED, V120, P360, DOI 10.7326/0003-4819-120-5-199403010-00002; STCLAIR MH, 1993, J ACQ IMMUN DEF SYND, V6, P891; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; TUDORWILLIAMS G, 1992, LANCET, V339, P15, DOI 10.1016/0140-6736(92)90140-X; TUDORWILLIAMS G, 1992, LANCET, V339, P627; VONBRIESEN H, 1987, J MED VIROL, V23, P51, DOI 10.1002/jmv.1890230107; 1987, MMWR MORB MORTAL S1, V36, pS1	38	235	239	2	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	MAR 15	1995	122	6					401	408		10.7326/0003-4819-122-6-199503150-00001	http://dx.doi.org/10.7326/0003-4819-122-6-199503150-00001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM266	7856987				2022-12-28	WOS:A1995QM26600001
J	PEABODY, JW; YU, JCI; WANG, YR; BICKEL, SR				PEABODY, JW; YU, JCI; WANG, YR; BICKEL, SR			HEALTH SYSTEM REFORM IN THE REPUBLIC-OF-CHINA - FORMULATING POLICY IN A MARKET-BASED HEALTH SYSTEM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									DEPT VET AFFAIRS,DEPT MED,LOS ANGELES,CA; NATL HLTH INSURANCE TASK FORCE,TAIPEI,TAIWAN; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	PEABODY, JW (corresponding author), RAND CORP,1700 MAIN ST,SANTA MONICA,CA 90407, USA.				AHRQ HHS [1 T32 HS 00046-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BAUM WC, 1985, INVESTING DEV LESSON, P5; BLENDON RJ, 1993, JAMA-J AM MED ASSOC, V269, P2573, DOI 10.1001/jama.269.19.2573; CHEN CL, 1988, ACTA PAEDIATR SIN SB, V29, pB23; CHEN CW, 1987, KAO HSIUNG I HSUEH K, V3, P446; CHIANG TL, 1987, HLTH CARE DELIVERY T; HAMMOND KR, 1985, APPLIED SOCIAL PSYCH, V6, P233; HSIAO WCL, 1989, CURRENT SYSTEM HLTH; LIN S, 1994, NATIONAL HLTH EXPEND; MEIER GM, 1989, LEADING ISSUES EC DE, P62; PEABODY JW, 1995, HEALTH POLICY, V31, P29, DOI 10.1016/0168-8510(94)00669-6; Schieber G J, 1992, Health Care Financ Rev, V13, P1; Tsai S P, 1989, Asia Pac J Public Health, V3, P41, DOI 10.1177/101053958900300107; TSAI WH, 1988, MODERN TRADITIONAL H, P35; WEN CP, 1974, MED CARE, V12, P85, DOI 10.1097/00005650-197401000-00008; YAUNG CL, 1989, DEC INT S HLTH CAR S; YEH C, 1994, CHINA POST      0719, P1; YEH C, 1994, CHINA POST      0719, P16; 1990, HUMAN DEV REPORT, P17; 1993, HLTH POLICY STUDIES, V3; 1993, STATISTICAL DATA TAI, P256; 1987, HLTH STATISTICS TAIW; 1993, WORLD FIGURES; 1993, PROGR PLANNING IMPLE; 1993, WORLD DEV REPORT INV, P238; 1994, HLTH VITAL STATISTIC, P62; 1990, W PACIFIC REGION DAT; 1993, HLTH CARE EXPENDITUR; 1993, STATISTICS MED FACIL	28	38	39	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	1995	273	10					777	781		10.1001/jama.273.10.777	http://dx.doi.org/10.1001/jama.273.10.777			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QJ750	7861571				2022-12-28	WOS:A1995QJ75000028
J	JANSEN, A; VANHAGEN, M; DREXHAGE, HA				JANSEN, A; VANHAGEN, M; DREXHAGE, HA			DEFECTIVE MATURATION AND FUNCTION OF ANTIGEN-PRESENTING CELLS IN TYPE-1 DIABETES	LANCET			English	Note							MICE	Macrophages and dendritic cells are important as antigen-presenting cells in the islet autoimmune response. We report decreased maturation of dendritic cells from blood monocytes of 61 patients with type 1 diabetes compared with 31 healthy controls (medians 26 and 35%, respectively, p=0.0005). The dendritic cells also had reduced ability to cluster (96 and 124 clusters, respectively, p=0.0005), and to stimulate autologous and allogeneic T cells. Because optimum antigen presentation is primarily required for tolerance induction rather than for immunisation, the defective maturation and function of diabetic dendritic cells might be the basis for disturbed activation of regulatory (suppressor) T cells.	ERASMUS UNIV ROTTERDAM,DEPT IMMUNOL,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam								CLARESALZLER MJ, 1992, J CLIN INVEST, V90, P741, DOI 10.1172/JCI115946; FAUSTMAN D, 1991, SCIENCE, V254, P1756, DOI 10.1126/science.1763324; INABA K, 1986, J EXP MED, V163, P247, DOI 10.1084/jem.163.2.247; JANSEN A, 1994, DIABETES, V43, P667, DOI 10.2337/diabetes.43.5.667; KNIGHT SC, 1985, P NATL ACAD SCI USA, V82, P4495, DOI 10.1073/pnas.82.13.4495; LANGMUIR PB, 1993, INT IMMUNOL, V5, P169, DOI 10.1093/intimm/5.2.169; LETY MA, 1992, CLIN IMMUNOL IMMUNOP, V64, P188, DOI 10.1016/0090-1229(92)90199-X; MOOIJ P, 1993, J ENDOCRINOL, V140, P503; SERREZE DV, 1988, J IMMUNOL, V140, P3801; SERREZE DV, 1993, J IMMUNOL, V150, P2534	10	119	119	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 25	1995	345	8948					491	492		10.1016/S0140-6736(95)90586-3	http://dx.doi.org/10.1016/S0140-6736(95)90586-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7861877				2022-12-28	WOS:A1995QH92900013
J	THOMPSON, JE; PHILLIPS, RJ; ERDJUMENTBROMAGE, H; TEMPST, P; GHOSH, S				THOMPSON, JE; PHILLIPS, RJ; ERDJUMENTBROMAGE, H; TEMPST, P; GHOSH, S			I-KAPPA-B-BETA REGULATES THE PERSISTENT RESPONSE IN A BIPHASIC ACTIVATION OF NF-KAPPA-B	CELL			English	Article							CANDIDATE PROTOONCOGENE BCL-3; REL-ASSOCIATED PP40; TRANSCRIPTION FACTOR; PRECURSOR P105; DNA-BINDING; INHIBITOR; ALPHA; FAMILY; PHOSPHORYLATION; PROTEINS	We have cloned the cDNA encoding I kappa B-beta, one of the two major I kappa B isoforms in mammalian cells. The recombinant I kappa B-beta protein interacts with equal affinity to p65 and c-Rel and does not exhibit a preference between these Rel proteins. Instead the primary difference between I kappa B-alpha and I kappa B-beta is in their response to different inducers of NF-kappa B activity. One class of inducers causes rapid but transient activation of NF-kappa B by primarily affecting I kappa B-alpha complexes, whereas another class of inducers causes persistent activation of NF-kappa B by affecting both I kappa B-alpha and I kappa B-beta complexes. Therefore, the overall activation of NF-kappa B consists of two overlapping phases, a transient phase mediated through I kappa B-alpha and a persistent phase mediated through I kappa B-beta.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOL SECT,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; MEM SLOAN KETTERING CANC CTR,MOLEC BIOL PROGRAM,NEW YORK,NY 10021	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University; Memorial Sloan Kettering Cancer Center				Erdjument-Bromage, Hediye/0000-0003-0224-3594	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033443] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI33443] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1993, NATURE, V365, P82; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KOPP E, 1994, ADV IMMUNOL, V58, P1; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LINK E, 1992, J BIOL CHEM, V267, P239; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; WASSERMAN SA, 1993, MOL BIOL CELL, V4, P767, DOI 10.1091/mbc.4.8.767; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	33	695	719	1	15	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					573	582		10.1016/0092-8674(95)90511-1	http://dx.doi.org/10.1016/0092-8674(95)90511-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867065	hybrid			2022-12-28	WOS:A1995QJ60200009
J	XU, WG; ROULD, MA; JUN, S; DESPLAN, C; PABO, CO				XU, WG; ROULD, MA; JUN, S; DESPLAN, C; PABO, CO			CRYSTAL-STRUCTURE OF A PAIRED DOMAIN-DNA COMPLEX AT 2.5-ANGSTROM RESOLUTION REVEALS STRUCTURAL BASIS FOR PAX DEVELOPMENTAL MUTATIONS	CELL			English	Article							TUMOR ALVEOLAR RHABDOMYOSARCOMA; HOMEOBOX-CONTAINING GENE; WAARDENBURG SYNDROME; 2.8-A RESOLUTION; POINT MUTATION; NUCLEIC-ACIDS; BOX GENE; HOMEODOMAIN; PROTEIN; RECOGNITION	The 2.5 Angstrom resolution structure of a cocrystal containing the paired domain from the Drosophila paired (prd) protein and a 15 bp site shows structually independent N-terminal and C-terminal subdomains. Each of these domains contains a helical region resembling the homeodomain and the Hin recombinase. The N-terminal domain makes extensive DNA contacts, using a novel beta turn motif that binds in the minor groove and a helix-turn-helix unit with a docking arrangement surprisingly similar to that of the lambda repressor. The C-terminal domain is not essential for prd binding and does not contact the optimized site. All known developmental missense mutations in the paired box of mammalian Pax genes map to the N-terminal subdomain, and most of them are found at the protein-DNA interface.	MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA; ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Rockefeller University	XU, WG (corresponding author), MIT, DEPT BIOL, 77 MASSACHUSETTS AVE, CAMBRIDGE, MA 02139 USA.			Xu, Wenqing/0000-0002-2884-3101; Desplan, Claude/0000-0002-6914-1413	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031471] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-31471] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BRENNAN RG, 1993, CELL, V74, P773, DOI 10.1016/0092-8674(93)90456-Z; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; CAI JX, 1994, MECH DEVELOP, V47, P139, DOI 10.1016/0925-4773(94)90086-8; CHALEPAKIS G, 1994, NUCLEIC ACIDS RES, V22, P3131, DOI 10.1093/nar/22.15.3131; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; FENG JA, 1994, SCIENCE, V263, P348, DOI 10.1126/science.8278807; FINNEY M, 1990, CELL, V60, P5, DOI 10.1016/0092-8674(90)90708-M; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HANSON IM, 1994, NAT GENET, V6, P168, DOI 10.1038/ng0294-168; HILL RE, 1992, NATURE, V355, P750, DOI 10.1038/355750a0; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HOTH CF, 1993, AM J HUM GENET, V52, P455; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; QIAN YQ, 1994, J MOL BIOL, V238, P333, DOI 10.1006/jmbi.1994.1296; RAVISHANKER G, 1989, J BIOMOL STRUCT DYN, V6, P669, DOI 10.1080/07391102.1989.10507729; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1992, ACTA CRYSTALLOGR A, V48, P751, DOI 10.1107/S0108767392003404; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STAPLETON P, 1993, NAT GENET, V3, P292, DOI 10.1038/ng0493-292; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TASSABEHJI M, 1993, NAT GENET, V3, P26, DOI 10.1038/ng0193-26; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; VOGAN KJ, 1993, GENOMICS, V17, P364, DOI 10.1006/geno.1993.1333; WALLIN J, 1993, MAMM GENOME, V4, P354, DOI 10.1007/BF00360584; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5	51	304	313	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 24	1995	80	4					639	650		10.1016/0092-8674(95)90518-9	http://dx.doi.org/10.1016/0092-8674(95)90518-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867071	Bronze			2022-12-28	WOS:A1995QJ60200016
J	KAUFMANN, Y; MANY, A; RECHAVI, G; MOR, O; BINIAMINOV, M; ROSENTHAL, E; LEVANON, M; DAVIDSOHN, J; AIZMAN, I; MARK, Z; BROKSIMONI, F; RAMOT, B				KAUFMANN, Y; MANY, A; RECHAVI, G; MOR, O; BINIAMINOV, M; ROSENTHAL, E; LEVANON, M; DAVIDSOHN, J; AIZMAN, I; MARK, Z; BROKSIMONI, F; RAMOT, B			LYMPHOMA WITH RECURRENT CYCLES OF SPONTANEOUS REMISSION AND RELAPSE - POSSIBLE ROLE OF APOPTOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							PROGRAMMED CELL-DEATH; LYMPHOCYTIC LYMPHOMA; T-CELL; LEUKEMIA; INDUCTION		TEL AVIV UNIV,SACKLER SCH MED,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine	KAUFMANN, Y (corresponding author), CHAIM SHEBA MED CTR,INST HEMATOL,IL-52621 TEL HASHOMER,ISRAEL.							BOOKMAN MA, 1990, J NATL CANCER I, V82, P742, DOI 10.1093/jnci/82.9.742; BUCCHERI V, 1993, LEUKEMIA, V7, P919; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; FRIEDMAN DF, 1991, J EXP MED, V174, P525, DOI 10.1084/jem.174.3.525; HAKIM I, 1993, BRIT J HAEMATOL, V84, P436, DOI 10.1111/j.1365-2141.1993.tb03098.x; KAUFMANN Y, 1987, J IMMUNOL, V139, P977; KON S, 1987, P NATL ACAD SCI USA, V84, P5053, DOI 10.1073/pnas.84.14.5053; KORSMEYER SJ, 1983, J CLIN INVEST, V71, P301, DOI 10.1172/JCI110770; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MOR O, 1994, MOL BIOL LIFE SCI AD, V13, P53; SELLINS KS, 1987, J IMMUNOL, V139, P3199; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; VANENDERT PM, 1992, BLOOD, V79, P129; WEISENBURGER DD, 1987, BLOOD, V69, P1617	15	35	35	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 23	1995	332	8					507	510		10.1056/NEJM199502233320805	http://dx.doi.org/10.1056/NEJM199502233320805			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH288	7830732				2022-12-28	WOS:A1995QH28800005
J	MARSHALL, M; LOCKWOOD, A; GATH, D				MARSHALL, M; LOCKWOOD, A; GATH, D			SOCIAL-SERVICES CASE-MANAGEMENT FOR LONG-TERM MENTAL-DISORDERS - A RANDOMIZED CONTROLLED TRIAL	LANCET			English	Article							NEEDS; CARE; ILL	Case management arose in the USA as a solution to the difficulties of providing community care to people with severe mental disorders. The basic principle of the approach is that a case manager takes responsibility for a client; arranges an assessment of need, a comprehensive service plan, delivery of suitable services, and monitoring and assessment of services delivered. The case-management approach has been widely accepted, to the extent that recent legislation has made case-management the cornerstone of community care in the UK. We did a randomised controlled trial to evaluate a social services case-management team for people with long-term mental disorders. Subjects were referred from hostels for the homeless, night shelters, a general-practitioner clinic for the homeless, the Oxford City Council homelessness unit, and local voluntary-sector group homes. Of 103 subjects referred, 80 consented to be randomised to treatment or control groups. At 14-month follow-up, as assessed by standardised interviews, there were no significant differences between groups in number of needs, quality of life, employment status, quality of accommodation, social behaviour, or severity of psychiatric symptoms. In the case-management group there was a significant reduction in deviant behaviour on a standardised behaviour rating scale (REHAB) (mean=0.79; 95% CI 0.26-1.32). It is unfortunate, in view of the limited effectiveness we have shown, that social services case-management was not evaluated in randomised controlled trials before its implementation in the UK.			MARSHALL, M (corresponding author), UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7JX,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Baker R., 1983, USERS MANUAL REHABIL; BREWIN CR, 1988, PSYCHOL MED, V18, P457, DOI 10.1017/S0033291700007996; BREWIN CR, 1987, PSYCHOL MED, V17, P971, DOI 10.1017/S0033291700000787; FORD R, 1993, IMPLEMENTING CASE MA; FRANKLIN JL, 1987, AM J PUBLIC HEALTH, V77, P674, DOI 10.2105/AJPH.77.6.674; Griffiths R, 1988, COMMUNITY CARE AGEND; Holloway F, 1991, Int J Soc Psychiatry, V37, P2, DOI 10.1177/002076409103700102; HOLLOWAY F, 1991, BRIT J PSYCHIAT, V159, P142, DOI 10.1192/bjp.159.1.142; KRAWIECKA M, 1977, ACTA PSYCHIAT SCAND, V55, P299, DOI 10.1111/j.1600-0447.1977.tb00174.x; Lear G, 1993, Nurs Times, V89, P26; LEHMAN AF, 1983, ARCH GEN PSYCHIAT, V40, P369; Marshall M., 1994, PHILOS PSYCHOL PSYCH, V1, P27; MARSHALL M, 1994, IN PRESS PSYCHOL MED; ROSSLER W, 1992, ACTA PSYCHIAT SCAND, V86, P445, DOI 10.1111/j.1600-0447.1992.tb03295.x; SEGAL S, 1977, COMMUNITY BASED SHEL; Shepherd G, 1990, Health Trends, V22, P59; THORNICROFT G, 1991, International Review of Psychiatry, V3, P125, DOI 10.3109/09540269109067527; 1986, MAKING REALITY COMMU	18	67	68	1	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					409	412		10.1016/S0140-6736(95)90399-2	http://dx.doi.org/10.1016/S0140-6736(95)90399-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QG904	7853949				2022-12-28	WOS:A1995QG90400007
J	ELLRODT, AG; CONNER, L; RIEDINGER, M; WEINGARTEN, S				ELLRODT, AG; CONNER, L; RIEDINGER, M; WEINGARTEN, S			MEASURING AND IMPROVING PHYSICIAN COMPLIANCE WITH CLINICAL-PRACTICE GUIDELINES - A CONTROLLED INTERVENTIONAL TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article							CARE; APPROPRIATENESS; DELAYS; TOOL	Objective: To determine factors that may lead physicians not to comply with clinical practice guidelines. Design: Retrospective analysis of patients whose physicians were not compliant with discharge recommendations from a prospective, controlled interventional trial of a guideline to reduce hospital length of stay for patients admitted for chest pain. Setting: A large community teaching hospital. Participants: Patients admitted with chest pain who were not discharged according to a practice guideline. Results: 79 (34%) of 230 patients with chest pain classified as being at low risk by concurrent or retrospective review were not discharged by day 3 (the guideline recommendation). Of these 79 patients, 33 (42%) were misclassified at concurrent review (10 were falsely classified as being at high risk and 23 were falsely classified as being at low risk). Of 46 correctly classified patients, 11 (14%) were classified as having noncompliant physicians because of health care system inefficiencies. The status of 7 (9%) patients was changed to high risk between initial classification and potential discharge. For 15 patients (19%), no obvious reason for delayed discharge was found, but they had a higher severity of illness than did low-risk patients discharged according to the guideline as measured by mean time-insensitive predictive instrument scores (41.3% +/- [SD] 14.1% compared with 31.5% +/- 14.3%; P = 0.017). In 13 patients (16%), physicians refused to follow the guideline recommendations. Conclusions: In measuring and attempting to improve physician compliance with a length-of-stay guideline, physician refusal accounts for a small percentage (16%) of noncompliance. Implementation issues, health care system inefficiency, and severity of illness were the predominant reasons why physicians did not comply with guidelines. Our study further supports the principle that clinical practice guidelines should complement rather than be a substitute for physician judgment.			ELLRODT, AG (corresponding author), CEDARS SINAI MED CTR, DEPT MED, 8700 BEVERLY BLVD, BECKER 113, LOS ANGELES, CA 90048 USA.							CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Ellrodt A G, 1992, QRB Qual Rev Bull, V18, P456; FRIEDMAN P, 1991, GB STAT VERSION 3 0; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; KASSIRER JP, 1993, NEW ENGL J MED, V329, P1263, DOI 10.1056/NEJM199310213291710; LAFFEL G, 1993, TXB TOTAL QUALITY HE, P40; PHELPS CE, 1993, NEW ENGL J MED, V329, P1241, DOI 10.1056/NEJM199310213291707; RELMAN AS, 1991, NEW ENGL J MED, V324, P922; SALEMSCHATZ S, 1994, JAMA-J AM MED ASSOC, V272, P871, DOI 10.1001/jama.272.11.871; SELKER HP, 1991, MED CARE, V29, P610, DOI 10.1097/00005650-199107000-00002; SELKER HP, 1989, MED CARE, V27, P112, DOI 10.1097/00005650-198902000-00003; SHENG A, 1993, J GEN INTERN MED, V8, P573, DOI 10.1007/BF02599642; TANENBAUM SJ, 1993, NEW ENGL J MED, V329, P1268, DOI 10.1056/NEJM199310213291713; WEINGARTEN S, 1993, AM J CARDIOL, V71, P259, DOI 10.1016/0002-9149(93)90787-D; WEINGARTEN SR, 1994, ANN INTERN MED, V120, P257, DOI 10.7326/0003-4819-120-4-199402150-00001; WILSON MC, 1991, MED DECIS MAKING, V11, P334; 1992, TRUE EPISTAT STATIST	17	137	138	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1995	122	4					277	282		10.7326/0003-4819-122-4-199502150-00007	http://dx.doi.org/10.7326/0003-4819-122-4-199502150-00007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF769	7825764				2022-12-28	WOS:A1995QF76900007
J	SHATTUCKEIDENS, D; MCCLURE, M; SIMARD, J; LABRIE, F; NAROD, S; COUCH, F; HOSKINS, K; WEBER, B; CASTILLA, L; ERDOS, M; BRODY, L; FRIEDMAN, L; OSTERMEYER, E; SZABO, C; KING, MC; JHANWAR, S; OFFIT, K; NORTON, L; GILEWSKI, T; LUBIN, M; OSBORNE, M; BLACK, D; BOYD, M; STEEL, M; INGLES, S; HAILE, R; LINDBLOM, A; OLSSON, H; BORG, A; BISHOP, DT; SOLOMON, E; RADICE, P; SPATTI, G; GAYTHER, S; PONDER, B; WARREN, W; STRATTON, M; LIU, QY; FUJIMURA, F; LEWIS, C; SKOLNICK, MH; GOLDGAR, DE				SHATTUCKEIDENS, D; MCCLURE, M; SIMARD, J; LABRIE, F; NAROD, S; COUCH, F; HOSKINS, K; WEBER, B; CASTILLA, L; ERDOS, M; BRODY, L; FRIEDMAN, L; OSTERMEYER, E; SZABO, C; KING, MC; JHANWAR, S; OFFIT, K; NORTON, L; GILEWSKI, T; LUBIN, M; OSBORNE, M; BLACK, D; BOYD, M; STEEL, M; INGLES, S; HAILE, R; LINDBLOM, A; OLSSON, H; BORG, A; BISHOP, DT; SOLOMON, E; RADICE, P; SPATTI, G; GAYTHER, S; PONDER, B; WARREN, W; STRATTON, M; LIU, QY; FUJIMURA, F; LEWIS, C; SKOLNICK, MH; GOLDGAR, DE			A COLLABORATIVE SURVEY OF 80 MUTATIONS IN THE BRCA1 BREAST-CANCER AND OVARIAN-CANCER SUSCEPTIBILITY GENE - IMPLICATIONS FOR PRESYMPTOMATIC TESTING AND SCREENING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FAMILIAL BREAST; RAPID DETECTION; IDENTIFICATION; POLYMORPHISMS; LINKAGE; ONSET	Objectives.-To report the initial experience of an international group of investigators in identifying mutations in the BRCA1 breast and ovarian cancer susceptibility gene, to assess the spectrum of such mutations in samples from patients with different family histories of cancer, and to determine the frequency of recurrent mutations. Design.-Nine laboratories in North America and the United Kingdom tested for BRCA1 mutations in DNA samples obtained from a total of 372 unrelated patients with breast or ovarian cancer largely chosen from high-risk families. Three of these laboratories also analyzed a total of 714 additional samples from breast or ovarian cancer cases, including 557 unselected for family history, for two specific mutations that had been found to recur in familial samples. Participants.-A total of 1086 women with either breast or ovarian cancer. Main Outcome Measure.-The detection of sequence Variation in patients' DNA samples that is not found in sets of control samples. Results.-BRCA1 mutations have now been identified in a total of 80 patient samples. Thirty-eight distinct mutations were found among 63 mutations identified through a complete screen of the BRCA1 gene. Three specific mutations appeared relatively common, occurring eight, seven, and five times, respectively. When specific tests for the two most common mutations were performed in larger sets of samples, they were found in 17 additional patients, Mutations predicted to result in a truncated protein accounted for 86% of the mutations detected by complete screening. Conclusions.-The high frequency of protein-terminating mutations and the observation of many recurrent mutations found in a diverse set of samples could lead to a relatively simple diagnostic test for BRCA1 mutations. More data must be accumulated to address specifically the sensitivity and specificity of such a diagnostic testing procedure and to better estimate the age-specific risk for breast and ovarian cancer associated with such mutations.	UNIV UTAH,SCH MED,DEPT MED INFORMAT,SALT LAKE CITY,UT 84108; MYRIAD GENET,SALT LAKE CITY,UT; CHU LAVAL,RES CTR,DEPT MOLEC ENDOCRINOL,QUEBEC CITY,PQ,CANADA; UNIV LAVAL,QUEBEC CITY,PQ,CANADA; MCGILL UNIV,DEPT MED GENET,MONTREAL,PQ,CANADA; UNIV PENN,DEPT HEMATOL ONCOL,PHILADELPHIA,PA; NATL CTR HUMAN GENOME RES,BETHESDA,MD; UNIV CALIF BERKELEY,DEPT MOLEC BIOL,BERKELEY,CA; UNIV CALIF BERKELEY,DEPT CELL BIOL,BERKELEY,CA; UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA; MEM SLOAN KETTERING CANC CTR,DEPT HUMAN GENET,NEW YORK,NY; MEM SLOAN KETTERING CANC CTR,DEPT ONCOL,NEW YORK,NY; STRANG CANC PREVENT CTR,NEW YORK,NY; BEATSON INST CANC RES,GLASGOW,LANARK,SCOTLAND; UNIV ST ANDREWS,ST ANDREWS,FIFE,SCOTLAND; UNIV SO CALIF,DEPT EPIDEMIOL,LOS ANGELES,CA; KAROLINSKA INST,DEPT CLIN GENET,STOCKHOLM,SWEDEN; LUND UNIV,INST ONCOL,LUND,SWEDEN; IMPERIAL CANC RES FUND,SOMAT CELL GENET LABS,LONDON,ENGLAND; IST NAZL TUMORI,DIV EXPTL ONCOL,MILAN,ITALY; IST NAZL TUMORI,DIV SURG GYNECOL ONCOL,MILAN,ITALY; UNIV CAMBRIDGE,DEPT PATHOL,CRC,HUMAN CANC GENET RES GRP,CAMBRIDGE,ENGLAND; INST CANC RES,MOLEC CARCINOGENESIS SECT,SUTTON,SURREY,ENGLAND; UNIV UTAH,SCH MED,DEPT MED INFORMAT,GENET EPIDEMIOL GRP,SALT LAKE CITY,UT	Utah System of Higher Education; University of Utah; Myriad Genetics, Inc; Laval University; Laval University; McGill University; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Beatson Institute; University of St Andrews; University of Southern California; Karolinska Institutet; Lund University; Cancer Research UK; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Cambridge; University of London; Institute of Cancer Research - UK; Utah System of Higher Education; University of Utah			Radice, Paolo/O-3119-2013; Lewis, Cathryn/M-8766-2019; Lewis, Cathryn M/A-5225-2010; Narod, Steven A/AAA-6112-2022	Radice, Paolo/0000-0001-6298-4111; Lewis, Cathryn/0000-0002-8249-8476; Lewis, Cathryn M/0000-0002-8249-8476; Olsson, Hakan/0000-0002-8794-9635; Boyd, Marie/0000-0003-4120-2218; Bishop, Tim/0000-0002-8752-8785; Simard, Jacques/0000-0001-6906-3390; King, Mary-Claire/0000-0001-9426-1743	NCI NIH HHS [CA-27632, CA-55914] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055914, R01CA027632] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CLAUS EB, 1991, AM J HUM GENET, V48, P232; CLAUS EB, 1990, AM J EPIDEMIOL, V131, P961, DOI 10.1093/oxfordjournals.aje.a115616; EASTON DF, 1995, AM J HUM GENET, V56, P265; EASTON DF, 1994, LANCET, V344, P761, DOI 10.1016/S0140-6736(94)92256-X; EASTON DF, 1993, AM J HUM GENET, V52, P678; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GROMPE M, 1993, NAT GENET, V5, P111, DOI 10.1038/ng1093-111; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HOSKINS KF, 1995, JAMA-J AM MED ASSOC, V273, P577, DOI 10.1001/jama.273.7.577; KELSEY JL, 1991, CA-CANCER J CLIN, V41, P147; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OFFIT K, 1994, J CLIN ONCOL, V12, P1724, DOI 10.1200/JCO.1994.12.8.1724; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; ROEST PAM, 1993, HUM MOL GENET, V2, P1719, DOI 10.1093/hmg/2.10.1719; SHEFFIELD VC, 1991, AM J HUM GENET, V49, P699; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; VANDERLUIJT R, 1994, GENOMICS, V20, P1, DOI 10.1006/geno.1994.1119; WHITE MB, 1992, GENOMICS, V12, P301, DOI 10.1016/0888-7543(92)90377-5; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231	23	390	408	0	23	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	1995	273	7					535	541		10.1001/jama.273.7.535	http://dx.doi.org/10.1001/jama.273.7.535			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF686	7837387				2022-12-28	WOS:A1995QF68600022
J	STRITTMATTER, SM; FANKHAUSER, C; HUANG, PL; MASHIMO, H; FISHMAN, MC				STRITTMATTER, SM; FANKHAUSER, C; HUANG, PL; MASHIMO, H; FISHMAN, MC			NEURONAL PATHFINDING IS ABNORMAL IN MICE LACKING THE NEURONAL GROWTH CONE PROTEIN GAP-43	CELL			English	Article							IMMUNO-CYTOCHEMICAL LOCALIZATION; CALMODULIN-BINDING-PROTEIN; CENTRAL NERVOUS-SYSTEM; PRENATAL RAT-BRAIN; NEURITE OUTGROWTH; TYROSINE-HYDROXYLASE; OPTIC CHIASM; PC12 CELLS; MOUSE; GUIDANCE	GAP-43 has been termed a ''growth'' or ''plasticity'' protein because it is expressed at high levels in neuronal growth cones during development and during axonal regeneration. By homologous recombination, we generated mice lacking GAP-43. The mice die in the early postnatal period. GAP-43-deficient retinal axons remain trapped in the chiasm for 6 days, unable to navigate past this midline decision point. Over the subsequent weeks of life, most GAP-43-deficient axons do enter the appropriate tracts, and the adult CNS is grossly normal. There is no evidence for interference with nerve growth rate, and cultured neurons extend neurites and growth cones in a fashion indistinguishable from controls. Thus, the GAP-43 protein is not essential for axonal outgrowth or growth cone formation pet se, but is required at certain decision points, such as the optic chiasm. This is compatible with the hypothesis that GAP-43 serves to amplify pathfinding signals from the growth cone.	HARVARD UNIV, MASSACHUSETTS GEN HOSP E, SCH MED, CARDIOVASC RES CTR, BOSTON, MA 02129 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP E, SCH MED, DEPT MED, BOSTON, MA 02129 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP E, SCH MED, DEPT NEUROL, BOSTON, MA 02129 USA; YALE UNIV, SCH MED, DEPT NEUROL, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT NEUROBIOL, NEW HAVEN, CT 06520 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Yale University; Yale University	STRITTMATTER, SM (corresponding author), HARVARD UNIV, MASSACHUSETTS GEN HOSP E, SCH MED, DEV BIOL LAB, BOSTON, MA 02129 USA.		Strittmatter, Stephen/F-5739-2011	Strittmatter, Stephen/0000-0001-8188-3092				AIGNER L, 1993, J CELL BIOL, V123, P417, DOI 10.1083/jcb.123.2.417; ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; ARGIRO V, 1982, J NEUROSCI, V2, P503; BAETGE EE, 1991, NEURON, V6, P21, DOI 10.1016/0896-6273(91)90118-J; BENOWITZ LI, 1987, TRENDS NEUROSCI, V10, P527, DOI 10.1016/0166-2236(87)90135-4; BENOWITZ LI, 1988, J NEUROSCI, V8, P339; BOVOLENTA P, 1991, DEVELOPMENT, V113, P625; BOVOLENTA P, 1987, J NEUROSCI, V7, P1447; COLELLO RJ, 1992, J COMP NEUROL, V317, P357, DOI 10.1002/cne.903170404; DAVIES A, 1984, J COMP NEUROL, V223, P124, DOI 10.1002/cne.902230110; DELAMONTE SM, 1989, DEV BRAIN RES, V46, P161, DOI 10.1016/0165-3806(89)90279-4; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; GODEMENT P, 1990, NEURON, V5, P173, DOI 10.1016/0896-6273(90)90307-2; GRABCZYK E, 1990, EUR J NEUROSCI, V2, P822, DOI 10.1111/j.1460-9568.1990.tb00393.x; HONIG MG, 1993, DEV BIOL, V156, P454, DOI 10.1006/dbio.1993.1092; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; IGARASHI M, 1993, SCIENCE, V259, P77, DOI 10.1126/science.8418498; KARNS LR, 1987, SCIENCE, V236, P597, DOI 10.1126/science.2437653; KROGER S, 1990, J NEUROSCI, V10, P3118; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LOVINGER DM, 1985, BRAIN RES, V343, P137, DOI 10.1016/0006-8993(85)91167-9; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Robertson E. J., 1987, TERATOCARCINOMAS EMB; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; SHEA TB, 1991, J NEUROSCI, V11, P1685; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SPECHT LA, 1981, J COMP NEUROL, V199, P255, DOI 10.1002/cne.901990208; SPECHT LA, 1981, J COMP NEUROL, V199, P233, DOI 10.1002/cne.901990207; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; SRETAVAN DW, 1994, NEURON, V12, P957, DOI 10.1016/0896-6273(94)90307-7; SRETAVAN DW, 1993, NEURON, V10, P761, DOI 10.1016/0896-6273(93)90176-R; STITTMATTER SM, 1994, J NEUROSCI, V14, P2327; STRITTMATTER SM, 1991, J BIOL CHEM, V266, P22465; STRITTMATTER SM, 1991, BIOESSAYS, V13, P127, DOI 10.1002/bies.950130306; STRITTMATTER SM, 1994, J NEUROSCI, V14, P5503; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STRITTMATTER SM, 1992, J NEUROBIOL, V23, P507, DOI 10.1002/neu.480230506; STRITTMATTER SM, 1994, J CELL SCI, V107, P195; STRITTMATTER SM, 1993, P NATL ACAD SCI USA, V90, P5327, DOI 10.1073/pnas.90.11.5327; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WIDMER F, 1993, J CELL BIOL, V120, P503, DOI 10.1083/jcb.120.2.503; WIZENMANN A, 1993, DEVELOPMENT, V117, P725; YANKNER BA, 1990, MOL BRAIN RES, V7, P39, DOI 10.1016/0169-328X(90)90071-K; ZUBER MX, 1989, SCIENCE, V244, P1193, DOI 10.1126/science.2658062	47	342	348	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	1995	80	3					445	452		10.1016/0092-8674(95)90495-6	http://dx.doi.org/10.1016/0092-8674(95)90495-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859286	hybrid			2022-12-28	WOS:A1995QG47000011
J	CROFTS, N; STEWART, T; HEARNE, P; PING, XY; BRESCHKIN, AM; LOCARNINI, SA				CROFTS, N; STEWART, T; HEARNE, P; PING, XY; BRESCHKIN, AM; LOCARNINI, SA			SPREAD OF BLOODBORNE VIRUSES AMONG AUSTRALIAN PRISON ENTRANTS	BRITISH MEDICAL JOURNAL			English	Article							HEPATITIS-C VIRUS; INTRAVENOUS-DRUG-USERS; HIV TRANSMISSION; UNITED-STATES; PREVALENCE; INFECTION; VACCINATION; ANTIBODIES; HEROIN; JAIL	Objectives-To assess spread of bloodborne viruses among prison entrants in Victoria, Australia. Design-Voluntary confidential testing of all prison entrants for markers of exposure to bloodborne viruses with collection of minimal data on demography and risk factors over 12 months. Setting-Her Majesty's Prisons, Pentridge and Fairlea, Victoria, Australia. Subjects-3429 male and 198 female prison entrants (> 99% of all prison entrants); 344 entered prison and were tested more than once. Main outcome measures-Prevalence and incidence of antibodies to HIV, hepatitis B, and hepatitis C viruses, and minimal data on risk factors. Results-1562 (46%) gave a history of use of injected drugs, 1171 (33%) had antibody to hepatitis B core antigen, 1418 (39%) were anti-hepatitis C positive including 914 (64%) of the men who injected drugs, 91 (2.5%) were positive for hepatitis B surface antigen, and 17 (0.47%) were positive for antibody to HIV. Incidence rates for infection with hepatitis B and C virus were 12.6 and 18.3 per 100 person years, respectively; in men who injected drugs and were aged less than 30 years (29% of all prison entrants) these were 21 and 41 per 100 person years. Seroconversion to hepatitis B or C was associated with young age and shorter stay in prison. Only 5% of those who were not immune to hepatitis B reported hepatitis B immunisation. Conclusions-Hepatitis B and C are spreading rapidly through some populations of injecting drug users in Victoria, particularly among men aged less than 30 years at risk of imprisonment in whom rates of spread are extreme; this group constitutes a sizeable at risk population for spread of HIV. This spread is occurring in a context of integrated harm reduction measures outside prisons for prevention of viral spread but few programmes within or on transition from prisons; it poses an urgent challenge to these programmes.	PENTRIDGE HOSP,HER MAJESTYS PRISON,COBURG,VIC 3058,AUSTRALIA; FAIRFIELD HOSP,DEPT VIROL,VICTORIAN INFECT DIS REFERENCE LAB,FAIRFIELD,VIC 3078,AUSTRALIA	Victorian Infectious Diseases Reference Laboratory	CROFTS, N (corresponding author), MACFARLANE BURNET CTR MED RES,EPIDEMIOL & INT HLTH UNIT,POB 65,FAIRFIELD,VIC 3078,AUSTRALIA.							BAYAS JM, 1993, VACCINE, V11, P1441, DOI 10.1016/0264-410X(93)90174-V; BELL J, 1990, MED J AUSTRALIA, V152, P361, DOI 10.5694/j.1326-5377.1990.tb125185.x; BIRD AG, 1992, AIDS, V6, P725, DOI 10.1097/00002030-199207000-00017; BIRD AG, 1991, AIDS, V8, P1345; BRESLOW NE, 1980, STATISTICAL METHODS; CHRISTIE B, 1993, BRIT MED J, V307, P151; CLAYTON D, 1993, STAT MODELS EPIDEMIO, P81; CROFTS N, 1993, MED J AUSTRALIA, V159, P237, DOI 10.5694/j.1326-5377.1993.tb137822.x; DECKER MD, 1985, J INFECT DIS, V152, P214, DOI 10.1093/infdis/152.1.214; DOBINSON I, 1986, J DRUG ISSUES, V16, P249, DOI 10.1177/002204268601600211; DONOGHOE M C, 1989, AIDS Care, V1, P51, DOI 10.1080/09540128908260235; GAUGHWIN MD, 1991, AIDS, V5, P845, DOI 10.1097/00002030-199107000-00008; GAUGHWIN MD, 1992, HIV AIDS AUSTR PRISO; GORE SM, 1993, BRIT MED J, V307, P147, DOI 10.1136/bmj.307.6897.147; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HAHN RA, 1989, JAMA-J AM MED ASSOC, V261, P2677, DOI 10.1001/jama.261.18.2677; HOLSEN DS, 1993, EUR J CLIN MICROBIOL, V12, P673, DOI 10.1007/BF02009378; INDERMAUER D, 1988, AUSTR NZ J CRIMINOLO, V3, P144; INDERMAUER D, 1990, SUBSTANCE ABUSE HIST; Kaldor J, 1993, Drug Alcohol Rev, V12, P175, DOI 10.1080/09595239300185611; OKAMOTO H, 1990, JPN J EXP MED, V60, P223; SKIDMORE CA, 1990, BRIT MED J, V300, P219, DOI 10.1136/bmj.300.6719.219; SUGITANI M, 1992, LANCET, V339, P1018, DOI 10.1016/0140-6736(92)90538-E; THOMPSON SC, 1993, MED J AUSTRALIA, V159, P562, DOI 10.5694/j.1326-5377.1993.tb138023.x; VLAHOV D, 1991, JAMA-J AM MED ASSOC, V265, P1129, DOI 10.1001/jama.265.9.1129; WATSON PG, 1973, MED J AUSTRALIA, V2, P421, DOI 10.5694/j.1326-5377.1973.tb115203.x; WOLK J, 1990, MED J AUSTRALIA, V152, P453, DOI 10.5694/j.1326-5377.1990.tb125302.x; 1993, NATIONAL HIV AIDS ST; 1990, NATIONAL HIV SEROPRE	29	132	134	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 4	1995	310	6975					285	288		10.1136/bmj.310.6975.285	http://dx.doi.org/10.1136/bmj.310.6975.285			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF717	7866168	Green Published			2022-12-28	WOS:A1995QF71700022
J	FLETCHER, JC; SPENCER, EM				FLETCHER, JC; SPENCER, EM			INCOMPETENT PATIENT ON THE SLIPPERY SLOPE	LANCET			English	Editorial Material							ADVANCE DIRECTIVES				FLETCHER, JC (corresponding author), UNIV VIRGINIA,SCH MED,CTR BIOMED ETH,CHARLOTTESVILLE,VA 22908, USA.							Beauchamp T. L., 1994, PRINCIPLES BIOMEDICA, P178; BROCK DW, 1994, J CLIN ETHIC, V5, P57; DRESSER R, 1994, HASTINGS CENT REP, V24, P6, DOI 10.2307/3562836; EMANUEL L, 1993, J CLIN ETHIC, V4, P8; FAGAN J, 1992, J CLIN EXP NEUROPSYC, V14, P36; MENIKOFF JA, 1992, NEW ENGL J MED, V327, P1165, DOI 10.1056/NEJM199210153271612; NIEMIRA D, 1993, HASTINGS CENT REP, V23, P14, DOI 10.2307/3563361; TENO JM, 1994, J CLIN ETHIC, V5, P23	8	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					271	272		10.1016/S0140-6736(95)90271-6	http://dx.doi.org/10.1016/S0140-6736(95)90271-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QE731	7837859				2022-12-28	WOS:A1995QE73100005
J	SHIPLEY, M				SHIPLEY, M			ABC OF RHEUMATOLOGY - PAIN IN THE HAND AND WRIST	BRITISH MEDICAL JOURNAL			English	Article											SHIPLEY, M (corresponding author), UCL HOSP, LONDON, ENGLAND.							1993, WOLFE COLOURED ATLAS	1	4	4	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 28	1995	310	6974					239	243		10.1136/bmj.310.6974.239	http://dx.doi.org/10.1136/bmj.310.6974.239			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE496	7866131	Green Published			2022-12-28	WOS:A1995QE49600031
J	SIMPSON, N; LENTON, S; RANDALL, R				SIMPSON, N; LENTON, S; RANDALL, R			PARENTAL REFUSAL TO HAVE CHILDREN IMMUNIZED - EXTENT AND REASONS	BRITISH MEDICAL JOURNAL			English	Article											SIMPSON, N (corresponding author), COMMUNITY CHILD HLTH,BATH BA1 3QE,AVON,ENGLAND.							BEGG NT, 1985, BRIT MED J, V291, P1370, DOI 10.1136/bmj.291.6506.1370; MOSKOWITZ R, 1984, HOMOEOPATH, V4; TALBOT NA, 1983, NEW ENGL J MED, V309, P1641, DOI 10.1056/NEJM198312293092611	3	41	41	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 28	1995	310	6974					227	227						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QE496	7866125				2022-12-28	WOS:A1995QE49600023
J	MARSHALL, CJ				MARSHALL, CJ			SPECIFICITY OF RECEPTOR TYROSINE KINASE SIGNALING - TRANSIENT VERSUS SUSTAINED EXTRACELLULAR SIGNAL-REGULATED KINASE ACTIVATION	CELL			English	Review							EPIDERMAL GROWTH-FACTOR; PC12 CELLS; PROTEIN-KINASE; PHEOCHROMOCYTOMA CELLS; TRANSDUCTION PATHWAY; NEUROTROPHIC FACTOR; DIFFERENTIATION; RAF; DOWNSTREAM; BETA	A number of different intracellular signaling pathways have been shown to be activated by receptor tyrosine kinases. These activation events include the phosphoinositide 3-kinase, 70 kDa S6 kinase, mitogen-activated protein kinase (MAPK), phospholipase C-gamma, and the Jak/STAT pathways. The precise role of each of these pathways in cell signaling remains to be resolved, but studies on the differentiation of mammalian PC12 cells in tissue culture and the genetics of cell fate determination in Drosophila and Caenorhabiditis suggest that the extracellular signal-regulated kinase (ERK-regulated) MAPK pathway may be sufficient for these cellular responses. Experiments with PC12 cells also suggest that the duration of ERK activation is critical for cell signaling decisions.			MARSHALL, CJ (corresponding author), INST CANC RES,CHESTER BEATTY LABS,237 FULHAM RD,LONDON SW3 6JB,ENGLAND.		Agena, Fabiana A/C-5819-2015	Agena, Fabiana A/0000-0002-4526-4857				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; AMMERER G, 1994, CURR OPIN GENET DEV, V4, P90, DOI 10.1016/0959-437X(94)90096-5; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BANUETT F, 1994, GENE DEV, V8, P1367, DOI 10.1101/gad.8.12.1367; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COUNTAWAY JL, 1992, J BIOL CHEM, V265, P3407; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MELOCHE S, 1992, MOL ENDOCRINOL, V658, P845; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORRIS JDH, 1989, ONCOGENE, V4, P21; MUROYA K, 1992, ONCOGENE, V7, P277; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OHMICHI M, 1993, ENDOCRINOLOGY, V133, P46, DOI 10.1210/en.133.1.46; PERRIMON N, 1993, CELL, V74, P219, DOI 10.1016/0092-8674(93)90412-J; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHLESSINGER J, 1995, IN PRESS S QUANTITAT; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; YAN M, 1994, NATURE, V320, P798; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	79	4193	4280	9	234	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 27	1995	80	2					179	185		10.1016/0092-8674(95)90401-8	http://dx.doi.org/10.1016/0092-8674(95)90401-8			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7834738	Bronze			2022-12-28	WOS:A1995QD92400001
J	LLOYD, DCEF; HARRIS, CM; CLUCAS, DW				LLOYD, DCEF; HARRIS, CM; CLUCAS, DW			LOW-INCOME SCHEME INDEX - A NEW DEPRIVATION SCALE BASED ON PRESCRIBING IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							UNDERPRIVILEGED AREAS	Objectives-To describe and validate a new deprivation index, based on the percentage of prescribed items exempt from the prescription charge under the low income scheme, at both family health services authority and practice level. Design-Comparison of the index with three other deprivation indices and correlation of index values with the use of drugs given for conditions with known social class gradients. Setting-All 90 family health services authorities and 7619/9289 practices in England. Results-The ranking of family health services authorities on the new index correlated highly with rankings on the other indices. Values in relation to the use of drugs given for conditions with known social class gradients were in the predicted direction at both family health services authority level and practice level; correlation was highly significant at the authority level, but less significant at practice level. Conclusions-The new index provides a good measure of deprivation at family health services authority level, and at practice level the results are sufficiently encouraging to warrant further research. It provides the best available instrument for relating deprivation to the use of drugs in any population that can be defined by prescribing data, but an attempt to use it in determining allocation of resources would at this stage be premature.	UNIV LEEDS,RES SCH MED,PRESCRIBING RES UNIT,LEEDS LS2 9NZ,W YORKSHIRE,ENGLAND	University of Leeds								CARRHILL RA, 1991, BRIT MED J, V302, P393, DOI 10.1136/bmj.302.6773.393; HUNT K, 1990, BRIT J OBSTET GYNAEC, V97, P1080, DOI 10.1111/j.1471-0528.1990.tb02494.x; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; MORRIS R, 1991, J PUBLIC HEALTH MED, V13, P318; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; SMITH GD, 1991, BRIT MED J, V302, P359, DOI 10.1136/bmj.302.6773.359; TALBOT RJ, 1991, BRIT MED J, V302, P383, DOI 10.1136/bmj.302.6773.383; Townsend PP., 1988, HLTH DEPRIVATION INE; 1993, 19938 DEP HLTH STAT; 1991, HLTH WARNING LOW INC; 1992, INCOME SUPPORT STATI; 1993, PRESCRIPTION COST AN	12	29	29	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 21	1995	310	6973					165	169		10.1136/bmj.310.6973.165	http://dx.doi.org/10.1136/bmj.310.6973.165			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD201	7833758	Green Published			2022-12-28	WOS:A1995QD20100025
J	SOUTAR, RL; KING, DJ				SOUTAR, RL; KING, DJ			FORTNIGHTLY REVIEW - BONE-MARROW TRANSPLANTATION	BRITISH MEDICAL JOURNAL			English	Article							LEUKEMIA; AUTOTRANSPLANTATION; CHEMOTHERAPY; THALASSEMIA; SURVIVORS; PROGRESS; ADULTS				SOUTAR, RL (corresponding author), ABERDEEN ROYAL HOSP NHS TRUST,DEPT HAEMATOL,ABERDEEN AB9 2ZD,SCOTLAND.							ANDRYKOWSKI MA, 1989, BONE MARROW TRANSPL, V4, P505; APPELBAUM FR, 1988, BLOOD, V72, P179; BALL ED, 1993, HEMATOL ONCOL CLIN N, V7, P201, DOI 10.1016/S0889-8588(18)30264-8; BARRETT J, 1992, BONE MARROW TRANSPL, P33; BIERMAN PJ, 1994, BLOOD, V85, P1161; Borgan-Pignatti C, 1992, BONE MARROW TRANSPL, P151; CHRISTIANSEN NP, 1993, HEMATOL ONCOL CLIN N, V7, P177, DOI 10.1016/S0889-8588(18)30263-6; CLEAVER S, 1992, BONE MARROW TRANSPL, P361; CUST MP, 1989, BRIT MED J, V299, P1494, DOI 10.1136/bmj.299.6714.1494; DAVIDSON NE, 1992, J CLIN ONCOL, V10, P517, DOI 10.1200/JCO.1992.10.4.517; DEEG HJ, 1984, BRIT J HAEMATOL, V57, P185, DOI 10.1111/j.1365-2141.1984.tb08521.x; GELLER RB, 1993, HEMATOL ONCOL CLIN N, V7, P547, DOI 10.1016/S0889-8588(18)30231-4; GOLDMAN JM, 1994, BLOOD REV, V8, P21, DOI 10.1016/0268-960X(94)90004-3; GORDONSMITH E, 1991, HEMATOLOGY BASIC PRI, P161; HENGEVELD MW, 1988, BONE MARROW TRANSPL, V3, P69; HOEZLER DF, 1993, HEMATOL ONCOL CLIN N, V7, P139; HOROWITZ MM, 1991, ANN INTERN MED, V115, P13, DOI 10.7326/0003-4819-115-1-13; HOROWITZ MM, 1992, BONE MARROW TRANSPL, P367; JOHNSON FL, 1993, HEMATOL ONCOL CLIN N, V7, P647, DOI 10.1016/S0889-8588(18)30236-3; JONES R, 1992, J CLIN PATHOL, V45, P1053, DOI 10.1136/jcp.45.12.1053; KESSINGER A, 1993, HEMATOL ONCOL CLIN N, V7, P535, DOI 10.1016/S0889-8588(18)30230-2; LUCARELLI G, 1991, BRIT J HAEMATOL, V78, P300, DOI 10.1111/j.1365-2141.1991.tb04440.x; MACKIE MJ, 1990, CLIN HAEMATOL, P203; MORGAN G, 1992, BONE MARROW TRANSPL, P119; MORSY MA, 1993, JAMA-J AM MED ASSOC, V270, P2338, DOI 10.1001/jama.270.19.2338; MYERS SE, 1993, HEMATOL ONCOL CLIN N, V7, P631, DOI 10.1016/S0889-8588(18)30235-1; NICOL AJ, 1994, BRIT J HAEMATOL, V87, P1, DOI 10.1111/j.1365-2141.1994.tb04862.x; SCHUSTER JJ, 1991, J CLIN ONCOL, V9, P1045; SHPALL EJ, 1993, HEMATOL ONCOL CLIN N, V7, P663, DOI 10.1016/S0889-8588(18)30237-5; SULLIVAN KM, 1991, HEMATOLOGY BASIC PRI, P242; TILEY C, 1992, BONE MARROW TRANSPL, P11; VELLODI A, 1992, BONE MARROW TRANSPL, P161; VOSE JM, 1993, HEMATOL ONCOL CLIN N, V7, P577, DOI 10.1016/S0889-8588(18)30232-6; WEATHERALL DJ, 1993, NEW ENGL J MED, V329, P877, DOI 10.1056/NEJM199309163291212	34	24	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 7	1995	310	6971					31	36		10.1136/bmj.310.6971.31	http://dx.doi.org/10.1136/bmj.310.6971.31			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB060	7827553	Green Published			2022-12-28	WOS:A1995QB06000030
J	YOUNG, J				YOUNG, J			CONTROVERSIES IN MANAGEMENT - IS STROKE BETTER MANAGED IN THE COMMUNITY .10. COMMUNITY CARE ALLOWS PATIENTS TO REACH THEIR FULL-POTENTIAL	BRITISH MEDICAL JOURNAL			English	Article							TRIAL				YOUNG, J (corresponding author), ST LUKES HOSP,DEPT HLTH CARE ELDERLY,BRADFORD BD5 0NA,W YORKSHIRE,ENGLAND.			young, john/0000-0003-4085-9306				ANDERSON R, 1992, AFTERMATH STROKE; ANDREWS K, 1979, RHEUMATOL REHABIL, V18, P43, DOI 10.1093/rheumatology/18.1.43; BAMFORD J, 1986, BRIT MED J, V292, P1369, DOI 10.1136/bmj.292.6532.1369; BLAXTER M, 1980, MEANING DISABILITY; FORSTER A, 1992, BRIT MED J, V305, P1446, DOI 10.1136/bmj.305.6867.1446; GARRAWAY WM, 1980, BRIT MED J, V281, P827, DOI 10.1136/bmj.281.6244.827; HOLBROOK M, 1982, J ROY COLL PHYS LOND, V16, P100; KETTLE M, 1989, CLIN REHABIL, V3, P131; YOUNG JB, 1992, BRIT MED J, V304, P1085, DOI 10.1136/bmj.304.6834.1085	9	27	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 19	1994	309	6965					1356	1357		10.1136/bmj.309.6965.1356	http://dx.doi.org/10.1136/bmj.309.6965.1356			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT625	7866086	Green Published			2022-12-28	WOS:A1994PT62500031
J	SAPER, CB; BREDER, CD				SAPER, CB; BREDER, CD			SEMINARS IN MEDICINE OF THE BETH-ISRAEL-HOSPITAL, BOSTON - THE NEUROLOGIC BASIS OF FEVER	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CORTICOTROPIN-RELEASING FACTOR; CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; NEUROLEPTIC MALIGNANT SYNDROME; ANTEROVENTRAL 3RD VENTRICLE; SUBFORNICAL ORGAN; ANGIOTENSIN-II; PARABRACHIAL NUCLEUS; ENDOGENOUS PYROGEN; FEBRILE RESPONSE		BETH ISRAEL HOSP, PROGRAM NEUROSCI, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; UNIV CHICAGO, COMM NEUROBIOL, CHICAGO, IL 60637 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Chicago	SAPER, CB (corresponding author), BETH ISRAEL HOSP, DEPT NEUROL, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.		Saper, Clifford/L-3815-2019		NINDS NIH HHS [NS22835] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022835] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALIN BJ, 1986, J COMP NEUROL, V251, P260, DOI 10.1002/cne.902510209; BANKS WA, 1989, BRAIN RES BULL, V23, P433, DOI 10.1016/0361-9230(89)90185-8; BENNETT IL, 1953, J EXP MED, V98, P493, DOI 10.1084/jem.98.5.493; BERKENBOSCH F, 1987, SCIENCE, V238, P524, DOI 10.1126/science.2443979; BERNHEIM HA, 1979, ANN INTERN MED, V91, P261, DOI 10.7326/0003-4819-91-2-261; BLATTEIS CM, 1983, BRAIN RES BULL, V11, P519, DOI 10.1016/0361-9230(83)90124-7; BLATTEIS CM, 1987, CAN J PHYSIOL PHARM, V65, P1255, DOI 10.1139/y87-200; BREDER CD, 1993, J COMP NEUROL, V337, P543, DOI 10.1002/cne.903370403; BREDER CD, 1988, SCIENCE, V240, P321, DOI 10.1126/science.3258444; BREDER CD, 1992, J COMP NEUROL, V322, P409, DOI 10.1002/cne.903220309; BREDER CD, 1993, THESIS U CHICAGO CHI; COLLINS RC, 1989, ANN INTERN MED, V110, P992, DOI 10.7326/0003-4819-110-12-992; CRAWLEY JN, 1984, BRAIN RES, V295, P289, DOI 10.1016/0006-8993(84)90978-8; DEMPSEY EW, 1968, EXP NEUROL, V22, P568, DOI 10.1016/0014-4886(68)90150-7; DINARELLO CA, 1988, METHOD ENZYMOL, V163, P495; DINARELLO CA, 1984, NEW ENGL J MED, V311, P1413; DINARELLO CA, 1984, J CLIN INVEST, V74, P906, DOI 10.1172/JCI111508; DINARELLO CA, 1986, J EXP MED, V163, P1433, DOI 10.1084/jem.163.6.1433; DINARELLO CA, 1978, NEW ENGL J MED, V298, P607, DOI 10.1056/NEJM197803162981107; DINARELLO CA, 1991, FEVER BASIC MECHANIS, P23; DUFF GW, 1986, YALE J BIOL MED, V59, P125; FONTANA A, 1982, J IMMUNOL, V129, P2413; GARRISON FH, 1929, INTRO HIST MED MED C, P738; Goodman E. L, 1991, FEVER BASIC MECHANIS, P267; GOULON M, 1983, NEUROLOGY, V33, P516; GRANATO JE, 1983, ANN NEUROL, V14, P89, DOI 10.1002/ana.410140117; HANSON DF, 1984, INFECT IMMUN, V45, P483, DOI 10.1128/IAI.45.2.483-490.1984; HEIMANPATTERSON TD, 1993, MED CLIN N AM, V77, P477, DOI 10.1016/S0025-7125(16)30265-6; HERBERT H, 1990, J COMP NEUROL, V293, P581, DOI 10.1002/cne.902930405; HERBERT H, 1990, J COMP NEUROL, V293, P540, DOI 10.1002/cne.902930404; HORI T, 1988, BRAIN RES BULL, V20, P75, DOI 10.1016/0361-9230(88)90010-X; KATSUURA G, 1990, AM J PHYSIOL, V258, pE163, DOI 10.1152/ajpendo.1990.258.1.E163; Kluger MJ., 1991, FEVER BASIC MECH MAN, P105; KURIYAMA K, 1990, BRAIN RES BULL, V24, P803, DOI 10.1016/0361-9230(90)90143-N; LASZLO A, 1993, INT J RADIAT BIOL, V63, P569, DOI 10.1080/09553009314450751; LECHAN RM, 1990, BRAIN RES, V514, P135, DOI 10.1016/0006-8993(90)90445-H; LIND RW, 1982, J COMP NEUROL, V210, P265, DOI 10.1002/cne.902100306; LIND RW, 1984, CLIN EXP HYPERTENS A, V6, P1915, DOI 10.3109/10641968409046101; LIND RW, 1984, BRAIN RES, V321, P209, DOI 10.1016/0006-8993(84)90174-4; Mackowiak PA, 1991, FEVER BASIC MECH MAN, P255; MATSUMURA K, 1990, BRAIN RES, V533, P147, DOI 10.1016/0006-8993(90)91808-T; MENKIN V, 1945, ARCH PATHOL, V39, P28; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; MURAKAMI N, 1990, J PHYSIOL-LONDON, V428, P299, DOI 10.1113/jphysiol.1990.sp018213; PHILLIPS MI, 1987, CIRCUMVENTRICULAR OR, P157; PLATASALAMAN CR, 1988, BRAIN RES, V448, P106, DOI 10.1016/0006-8993(88)91106-7; Plum F, 1978, Res Publ Assoc Res Nerv Ment Dis, V56, P415; SAPER CB, 1992, PROG BRAIN RES, V93, P419; SAPHIER D, 1990, NEUROSCI LETT, V114, P283, DOI 10.1016/0304-3940(90)90577-V; SAPOLSKY R, 1987, SCIENCE, V238, P522, DOI 10.1126/science.2821621; SCARBOROUGH DE, 1990, ANN NY ACAD SCI, V594, P169; SHAPIRO RE, 1985, J COMP NEUROL, V234, P344, DOI 10.1002/cne.902340306; SHIBATA M, 1990, YALE J BIOL MED, V63, P147; SHIBATA M, 1991, BRAIN RES, V562, P323, DOI 10.1016/0006-8993(91)90639-D; SIMON HB, 1993, NEW ENGL J MED, V329, P483; STITT JT, 1986, YALE J BIOL MED, V59, P137; STITT JT, 1991, J PHYSIOL-LONDON, V432, P99, DOI 10.1113/jphysiol.1991.sp018378; TANAKA J, 1993, EXP NEUROL, V119, P235, DOI 10.1006/exnr.1993.1025; VANDERKOOY D, 1984, BRAIN RES, V295, P345, DOI 10.1016/0006-8993(84)90982-X; YATVIN MB, 1993, INT J HYPERTHER, V9, P165, DOI 10.3109/02656739309022533; YI PN, 1979, BIOCHEM BIOPH RES CO, V91, P177, DOI 10.1016/0006-291X(79)90600-4	61	249	260	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 30	1994	330	26					1880	1886						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT530	7832832				2022-12-28	WOS:A1994NT53000009
J	SCHNEIDER, DL; BARRETTCONNOR, EL; MORTON, DJ				SCHNEIDER, DL; BARRETTCONNOR, EL; MORTON, DJ			THYROID-HORMONE USE AND BONE-MINERAL DENSITY IN ELDERLY WOMEN - EFFECTS OF ESTROGEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							L-THYROXINE THERAPY; PREMENOPAUSAL WOMEN; LEVOTHYROXINE; HYPOTHYROIDISM; METABOLISM	Objective.-To determine the effect of long-term use of thyroid hormone on bone mineral density (BMD) in elderly women and the potential mitigating effects of estrogen replacement therapy. Design.-Cross-sectional, community-based study. Setting.-Rancho Bernardo, Calif. Participants.-A total of 991 white women aged 50 to 98 years who participated in a study of osteoporosis. Main Outcome Measures.-Bone mineral density at the ultradistal radius and midshaft radius using single-photon absorptiometry and at the hip and lumbar spine using dual-energy x-ray absorptiometry. Results.-A total of 196 women taking thyroid hormone for a mean duration of 20.4 years were compared with 795 women who were not using thyroid hormone. Women taking daily thyroxine-equivalent doses of 200 mu g or more had significantly lower BMD levels at the midshaft radius and hip compared with those taking less than 200 mu g. Daily doses of 1.6 mu g/kg and greater were associated with lower bone mass at ail four sites compared with nonuse, whereas doses less than 1.6 mu g/kg were not associated with lower BMD levels. These associations were independent of age, body mass index, smoking status, and use of thiazides, corticosteroids, and estrogen. Women taking both estrogen and a thyroid hormone dose of 1.6 mu g/kg or greater had significantly higher BMD levels at all four sites than women taking the same thyroid hormone dose alone. Women taking both thyroid hormone and estrogen had BMD levels comparable with those observed in women taking only estrogen. Conclusions.-Long-term thyroid hormone use at thyroxine-equivalent doses of 1.6 mu g/kg or greater was associated with significant osteopenia at the ultradistal radius, midshaft radius, hip, and lumbar spine. Estrogen use appears to negate thyroid hormone-associated loss of bone density in postmenopausal women,	UNIV CALIF SAN DIEGO,DEPT FAMILY & PREVENT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE ON AGING [R37AG007181, R01AG007181] Funding Source: NIH RePORTER; NIA NIH HHS [AG 07181] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADLIN EV, 1991, AM J MED, V90, P360, DOI 10.1016/0002-9343(91)90577-K; AUWERX J, 1986, Q J MED, V60, P737; BAUER DC, 1993, ANN INTERN MED, V118, P657, DOI 10.7326/0003-4819-118-9-199305010-00001; CHRISTIANSEN C, 1991, OSTEOPOROSIS INT, V1, P7; CIVITELLI R, 1988, CALCIFIED TISSUE INT, V42, P77, DOI 10.1007/BF02556338; COLSTON KW, 1989, J BONE MINER RES, V4, P625; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DIAMOND T, 1990, J CLIN ENDOCR METAB, V72, P1184; FISH LH, 1987, NEW ENGL J MED, V316, P764, DOI 10.1056/NEJM198703263161302; FRANKLYN JA, 1992, LANCET, V340, P9, DOI 10.1016/0140-6736(92)92423-D; GILMAN AG, 1980, GOODMAN GILMANS PHAR, P1406; GREENSPAN SL, 1991, AM J MED, V91, P5, DOI 10.1016/0002-9343(91)90066-7; KUNG AWC, 1991, JAMA-J AM MED ASSOC, V265, P2688, DOI 10.1001/jama.265.20.2688; MUNDY GR, 1976, J CLIN INVEST, V58, P529, DOI 10.1172/JCI108497; PAUL TL, 1988, JAMA-J AM MED ASSOC, V259, P3137, DOI 10.1001/jama.259.21.3137; RIBOT C, 1990, CLIN ENDOCRINOL, V33, P143, DOI 10.1111/j.1365-2265.1990.tb00477.x; ROSENBAUM RL, 1982, ANN INTERN MED, V96, P53, DOI 10.7326/0003-4819-96-1-53; ROSS DS, 1987, AM J MED, V82, P1167, DOI 10.1016/0002-9343(87)90219-1; SIMONSEN LLP, 1993, PHARM TIMES, V59, P29; STALL GM, 1990, ANN INTERN MED, V113, P265, DOI 10.7326/0003-4819-113-4-265; TAELMAN P, 1990, CLIN ENDOCRINOL, V33, P107, DOI 10.1111/j.1365-2265.1990.tb00471.x; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; 1988, SAS STAT USERS GUIDE	23	135	137	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 27	1994	271	16					1245	1249		10.1001/jama.271.16.1245	http://dx.doi.org/10.1001/jama.271.16.1245			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG362	7848399				2022-12-28	WOS:A1994NG36200023
J	SEIDENFELD, J; HANOLD, LS; LOEB, JM				SEIDENFELD, J; HANOLD, LS; LOEB, JM			A NEW TOOL - REQUEST FOR INDICATORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									JOINT COMMISS ACCREDITAT HLTHCARE ORG,RES & EVALUAT,OAKBROOK TERRACE,IL 60181		SEIDENFELD, J (corresponding author), JOINT COMMISS ACCREDITAT HLTHCARE ORG,RES & DEV,OAKBROOK TERRACE,IL 60181, USA.							1995, JAMA-J AM MED ASSOC, V273, P99; AGENDA CHANGE	2	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	1995	273	9					691	691						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH814	7853612				2022-12-28	WOS:A1995QH81400006
J	AKERLEY, BJ; COTTER, PA; MILLER, JF				AKERLEY, BJ; COTTER, PA; MILLER, JF			ECTOPIC EXPRESSION OF THE FLAGELLAR REGULON ALTERS DEVELOPMENT OF THE BORDETELLA HOST INTERACTION	CELL			English	Article							VIRULENCE FACTORS; SALMONELLA-TYPHIMURIUM; SENSORY TRANSDUCTION; REPRESSED GENE; BVG-LOCUS; PERTUSSIS; SEQUENCES; PROTEINS; BRONCHISEPTICA; IDENTIFICATION	Signal transduction molecules within the two-component family represent a conserved adaptation for the control of genes involved in pathogenesis. The Bordetella virulence control locus, bvgAS, activates and represses gene expression in response to environmental signals. While infection requires virulence gene activation, the role of gene repression during infection is not understood. By altering regulatory genes and reversing regulatory connections, we found evidence that the BvgAS-repressed genes responsible for motility are neither required nor expressed during colonization of the host. Expression of this Bvg(-) phase-specific phenotype in the Bvg(+) growth phase resulted in a defect in tracheal colonization. Therefore, BvgAS promotes virulence both by activating genes required for colonization and by repressing genes that inhibit the development of infection.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles			Akerley, Brian/AAD-6668-2020; Akerley, Brian/B-7343-2008; Akerley, Brian/ABH-6977-2020	Akerley, Brian/0000-0002-8142-7035; Akerley, Brian/0000-0002-8142-7035; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008747] Funding Source: NIH RePORTER; NIAID NIH HHS [AI08747, AI07323] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKERLEY BJ, 1993, J BACTERIOL, V175, P3468, DOI 10.1128/jb.175.11.3468-3479.1993; AKERLEY BJ, 1992, J BACTERIOL, V174, P980, DOI 10.1128/jb.174.3.980-990.1992; ARICO B, 1989, P NATL ACAD SCI USA, V86, P6671, DOI 10.1073/pnas.86.17.6671; ARICO B, 1991, MOL MICROBIOL, V5, P2481, DOI 10.1111/j.1365-2958.1991.tb02093.x; BARTLETT DH, 1988, J BACTERIOL, V170, P1575, DOI 10.1128/jb.170.4.1575-1581.1988; BEATTIE DT, 1992, INFECT IMMUN, V60, P571, DOI 10.1128/IAI.60.2.571-577.1992; BEATTIE DT, 1990, J BACTERIOL, V172, P6997, DOI 10.1128/jb.172.12.6997-7004.1990; BEHLAU I, 1993, J BACTERIOL, V175, P4475, DOI 10.1128/JB.175.14.4475-4484.1993; BOUCHER PE, 1994, J MOL BIOL, V241, P363, DOI 10.1006/jmbi.1994.1513; COTTER PA, 1994, INFECT IMMUN, V62, P3381, DOI 10.1128/IAI.62.8.3381-3390.1994; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FENG P, 1990, J GEN MICROBIOL, V136, P337, DOI 10.1099/00221287-136-2-337; GRAF J, 1994, J BACTERIOL, V176, P6986, DOI 10.1128/JB.176.22.6986-6991.1994; HARLOW E, 1988, ANTIBODIES LABORATOR; JONES BD, 1992, INFECT IMMUN, V60, P2475, DOI 10.1128/IAI.60.6.2475-2480.1992; KOMEDA Y, 1982, J BACTERIOL, V150, P16, DOI 10.1128/JB.150.1.16-26.1982; LACEY B. W., 1960, JOUR HYG, V58, P57; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU XY, 1994, J BACTERIOL, V176, P7345, DOI 10.1128/JB.176.23.7345-7351.1994; MACNAB RM, 1992, ANNU REV GENET, V26, P131, DOI 10.1146/annurev.ge.26.120192.001023; MILLER JF, 1992, J BACTERIOL, V174, P970, DOI 10.1128/jb.174.3.970-979.1992; MILLER JF, 1989, SCIENCE, V243, P916, DOI 10.1126/science.2537530; MULLER M, 1993, NUCLEIC ACIDS RES, V21, P3320, DOI 10.1093/nar/21.14.3320; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; REID JL, 1987, GENE, V57, P239; ROY CR, 1991, J BACTERIOL, V173, P2385, DOI 10.1128/JB.173.7.2385-2392.1991; ROY CR, 1990, P NATL ACAD SCI USA, V87, P3763, DOI 10.1073/pnas.87.10.3763; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARLATO V, 1990, P NATL ACAD SCI USA, V87, P6753, DOI 10.1073/pnas.87.17.6753; SCHMITT CK, 1994, J BACTERIOL, V176, P368, DOI 10.1128/JB.176.2.368-377.1994; SILVERMAN M, 1977, J BACTERIOL, V120, P1196; STAINER DW, 1971, J GEN MICROBIOL, V63, P211; STIBITZ S, 1989, NATURE, V338, P266, DOI 10.1038/338266a0; STIBITZ S, 1991, J BACTERIOL, V173, P4288, DOI 10.1128/JB.173.14.4288-4296.1991; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; UHL MA, 1994, P NATL ACAD SCI USA, V91, P1163, DOI 10.1073/pnas.91.3.1163; WEISS AA, 1983, INFECT IMMUN, V42, P33, DOI 10.1128/IAI.42.1.33-41.1983	39	211	219	2	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					611	620		10.1016/0092-8674(95)90515-4	http://dx.doi.org/10.1016/0092-8674(95)90515-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867068	Bronze			2022-12-28	WOS:A1995QJ60200013
J	GILBERT, SP; WEBB, MR; BRUNE, M; JOHNSON, KA				GILBERT, SP; WEBB, MR; BRUNE, M; JOHNSON, KA			PATHWAY OF PROCESSIVE ATP HYDROLYSIS BY KINESIN	NATURE			English	Article							ADP RELEASE; MICROTUBULES; MOVEMENT; MYOSIN; MOTOR; IDENTIFICATION; SUBFRAGMENT-1; ACTOMYOSIN; MOLECULES; MOTILITY	Direct measurement of the kinetics of kinesin dissociation from microtubules, the release of phosphate and ADP from kinesin, and rebinding of kinesin to the microtubule have defined the mechanism for the kinesin ATPase cycle. The processivity of ATP hydrolysis is ten molecules per site at low salt concentration but is reduced to one ATP per site at higher salt concentration. Kinesin dissociates from the microtubule after ATP hydrolysis. This step is rate-limiting. The subsequent rebinding of kinesin ADP to the microtubule is fast, so kinesin spends only a small fraction of its duty cycle in the dissociated state. These results provide an explanation for the motility differences between skeletal myosin and kinesin.	PENN STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,UNIVERSITY PK,PA 16802; NATL INST MED RES,LONDON NW7 1AA,ENGLAND	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; MRC National Institute for Medical Research				Webb, Martin/0000-0002-0134-9621	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026726] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM026726] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; GILBERT SP, 1994, BIOCHEMISTRY-US, V33, P1951, DOI 10.1021/bi00173a044; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; GREENE LE, 1980, J BIOL CHEM, V255, P543; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HARRISON BC, 1993, NATURE, V362, P73, DOI 10.1038/362073a0; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HOLZBAUR ELF, 1989, BIOCHEMISTRY-US, V28, P7010, DOI 10.1021/bi00443a034; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; JOHNSON KA, 1985, ANNU REV BIOPHYS BIO, V14, P161, DOI 10.1146/annurev.bb.14.060185.001113; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LASEK RJ, 1985, NATURE, V316, P645, DOI 10.1038/316645a0; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; SADHU A, 1992, J BIOL CHEM, V267, P11352; SCHOLEY JM, 1985, NATURE, V318, P483, DOI 10.1038/318483a0; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; TAYLOR EW, 1992, HEART CARDIOVASCULAR, P1281; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017	24	256	257	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					671	676		10.1038/373671a0	http://dx.doi.org/10.1038/373671a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854446	Green Accepted			2022-12-28	WOS:A1995QH92800045
J	LELLOUCH, E; PAUBERT, G; MORENO, R; FESTOU, MC; BEZARD, B; BOCKELEEMORVAN, D; COLOM, P; CROVISIER, J; ENCRENAZ, T; GAUTIER, D; MARTEN, A; DESPOIS, D; STROBEL, DF; SIEVERS, A				LELLOUCH, E; PAUBERT, G; MORENO, R; FESTOU, MC; BEZARD, B; BOCKELEEMORVAN, D; COLOM, P; CROVISIER, J; ENCRENAZ, T; GAUTIER, D; MARTEN, A; DESPOIS, D; STROBEL, DF; SIEVERS, A			CHEMICAL AND THERMAL RESPONSE OF JUPITER ATMOSPHERE FOLLOWING THE IMPACT OF COMET SHOEMAKER-LEVY-9	NATURE			English	Article							MILLIMETER	July 1994, the collisions of the fragments of comet Shoemaker-Levy 9 with Jupiter resulted in dramatic changes in the planet's atmosphere. Observations of the events suggest that the composition and thermal properties of the atmosphere were considerably modified at the impact sites, with the changes persisting for times lasting from minutes to weeks (see, for example, refs 1-4). Here we report observations of the impact sites at millimetre wavelengths, which reveal strong emission lines associated with carbon monoxide, carbonyl sulphide and carbon monosulphide. The abundance of carbon monoxide in the jovian atmosphere is normally very low(5); carbonyl sulphide and carbon monosulphide, on the other hand, have not hitherto been detected, We find that the largest fragments (G and K) each produced approximately 10(14) g of carbon monoxide, 3 x 10(12) g of carbonyl sulphide and 3 x 10(11) g of carbon monosulphide, most probably by shock-induced chemical reactions(6). Our observations also place firm constraints on the thermal response of Jupiter's stratosphere to the impacts.	IRAM, E-18012 GRANADA, SPAIN; OBSERV MIDI PYRENEES, F-31400 TOULOUSE, FRANCE; OBSERV BORDEAUX, F-33270 FLOIRAC, FRANCE; JOHNS HOPKINS UNIV, BALTIMORE, MD 21218 USA	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Johns Hopkins University	LELLOUCH, E (corresponding author), OBSERV PARIS, F-92195 MEUDON, FRANCE.		Strobel, Darrell5/AAO-6643-2021	Strobel, Darrell5/0000-0002-0944-8675; Bezard, Bruno/0000-0002-5433-5661; Gorski, Andrzej/0000-0002-0863-6041				ALLEN M, 1992, ICARUS, V100, P527, DOI 10.1016/0019-1035(92)90115-N; BJORAKER GL, IN PRESS B AM ASTR S; BOCKELEEMORVAN D, IN PRESS B AM ASTR S; BROOKE T, IN PRESS B AM ASTR S; BROSSMAN AW, IN PRESS B AM ASTR S; ENCRENAZ T, IN PRESS B AM ASTR S; GLADSTONE GR, 1987, SP494 NASA, P221; GRIFFIN MJ, 1986, ICARUS, V65, P244, DOI 10.1016/0019-1035(86)90137-5; GRIFFITH CA, IN PRESS B AM ASTR S; JESSBERGER EK, 1991, COMETS POST HALLEY E, V2, P1075; LELLOUCH E, 1984, ASTRON ASTROPHYS, V135, P365; MAILLARD JP, IN PRESS GEOPHYS RES; MARTIN TZ, IN PRESS B AM ASTR S; MEADOWS V, IN PRESS B AM ASTR S; MOSES JI, IN PRESS B AM ASTR S; NOLL KS, 1988, ASTROPHYS J, V324, P1210, DOI 10.1086/165975; NOLL KS, IN PRESS SCIENCE; ORTON GS, IN PRESS SCIENCE; WEST R, IN PRESS B AM ASTR S; ZAHNLE K, IN PRESS B AM ASTR S	21	66	67	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 16	1995	373	6515					592	595		10.1038/373592a0	http://dx.doi.org/10.1038/373592a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854414				2022-12-28	WOS:A1995QG99700047
J	WHITTINGTON, MA; TRAUB, RD; JEFFERYS, JGR				WHITTINGTON, MA; TRAUB, RD; JEFFERYS, JGR			SYNCHRONIZED OSCILLATIONS IN INTERNEURON NETWORKS DRIVEN BY METABOTROPIC GLUTAMATE-RECEPTOR ACTIVATION	NATURE			English	Article							CAT VISUAL-CORTEX; RAT HIPPOCAMPUS; PYRAMIDAL NEURONS; INHIBITORY NEURONS; OLFACTORY SYSTEM; RESPONSES; FREQUENCY; INVITRO; HUMANS; EEG	PARTIALLY synchronous 40-Hz oscillations of cortical neurons have been implicated in cognitive function. Specifically, coherence of these oscillations between different parts of the cortex may provide conjunctive properties(1,2) to solve the 'binding problem': associating features detected by the cortex into unified perceived objects. Here we report an emergent 40-Hz oscillation in networks of inhibitory neurons connected by synapses using GABA(A) (gamma-aminobutyric acid) receptors in slices of rat hippocampus and neocortex. These network inhibitory postsynaptic potential oscillations occur in response to the activation of metabotropic glutamate receptors. The oscillations can entrain pyramidal cell discharges. The oscillation frequency is determined both by the net excitation of interneurons and by the kinetics of the inhibitory postsynaptic potentials between them. We propose that interneuron network oscillations, in conjunction with intrinsic membrane resonances and long-loop (such as thalamocortical) interactions, contribute to 40-Hz rhythms in vivo.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,DEPT PHYSIOL & BIOPHYS,LONDON W2 1PG,ENGLAND; IBM CORP,DIV RES,TJ WATSON RES CTR,YORKTOWN HTS,NY 10598; COLUMBIA UNIV,DEPT NEUROL,NEW YORK,NY 10032	Imperial College London; International Business Machines (IBM); Columbia University			Jefferys, John/E-6132-2012; Jefferys, John G R/AAF-1164-2021	Jefferys, John/0000-0003-0106-4412; Jefferys, John G R/0000-0003-0106-4412; Whittington, Miles Adrian/0000-0002-0247-1362	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADRIAN ED, 1950, ELECTROEN CLIN NEURO, V2, P377, DOI 10.1016/0013-4694(50)90075-7; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BRESSLER SL, 1980, ELECTROEN CLIN NEURO, V50, P19, DOI 10.1016/0013-4694(80)90319-3; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; DAVIES CH, 1990, J PHYSIOL-LONDON, V424, P513, DOI 10.1113/jphysiol.1990.sp018080; DAVIES SN, 1989, PROC R SOC SER B-BIO, V236, P373, DOI 10.1098/rspb.1989.0028; EECKMAN FH, 1990, BRAIN RES, V528, P238, DOI 10.1016/0006-8993(90)91663-2; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P6048, DOI 10.1073/pnas.88.14.6048; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; ENGEL AK, 1990, EUR J NEUROSCI, V2, P588, DOI 10.1111/j.1460-9568.1990.tb00449.x; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P9136, DOI 10.1073/pnas.88.20.9136; Gray C M, 1994, J Comput Neurosci, V1, P11, DOI 10.1007/BF00962716; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; GULYAS AI, 1993, NATURE, V366, P683, DOI 10.1038/366683a0; KATSUMARU H, 1988, EXP BRAIN RES, V72, P363; LLINAS R, 1993, P NATL ACAD SCI USA, V90, P2078, DOI 10.1073/pnas.90.5.2078; LLINAS RR, 1991, P NATL ACAD SCI USA, V88, P897, DOI 10.1073/pnas.88.3.897; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059, DOI 10.1152/jn.1991.66.3.1059; MCBAIN CJ, 1994, J NEUROSCI, V14, P4433; MICHELSON HB, 1994, J PHYSIOL-LONDON, V477, P35, DOI 10.1113/jphysiol.1994.sp020169; MILES R, 1993, J PHYSIOL-LONDON, V463, P461, DOI 10.1113/jphysiol.1993.sp019605; NUNEZ A, 1992, NEUROSCIENCE, V51, P7, DOI 10.1016/0306-4522(92)90464-D; RIBARY U, 1991, P NATL ACAD SCI USA, V88, P11037, DOI 10.1073/pnas.88.24.11037; ROPERT N, 1990, J PHYSIOL-LONDON, V428, P707, DOI 10.1113/jphysiol.1990.sp018236; SOLTESZ I, 1993, J NEUROPHYSIOL, V70, P97, DOI 10.1152/jn.1993.70.1.97; STERIADE M, 1993, NEUROSCIENCE, V56, P1, DOI 10.1016/0306-4522(93)90556-U; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P501, DOI 10.1152/jn.1989.61.3.501	28	1222	1238	2	53	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					612	615		10.1038/373612a0	http://dx.doi.org/10.1038/373612a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854418				2022-12-28	WOS:A1995QG99700054
J	JANSEN, RWMM; LIPSITZ, LA				JANSEN, RWMM; LIPSITZ, LA			POSTPRANDIAL HYPOTENSION - EPIDEMIOLOGY, PATHOPHYSIOLOGY, AND CLINICAL MANAGEMENT	ANNALS OF INTERNAL MEDICINE			English	Review							BLOOD-PRESSURE REDUCTION; CHRONIC AUTONOMIC FAILURE; SOMATOSTATIN ANALOG SMS-201-995; VASOACTIVE INTESTINAL PEPTIDE; HYPERTENSIVE ELDERLY SUBJECTS; HEMODYNAMIC-CHANGES; ORAL GLUCOSE; HEART-RATE; CARDIOVASCULAR-RESPONSES; HIGH-CARBOHYDRATE	Objective: To show the clinical relevance of postprandial hypotension and to review its pathophysiology and management. Data Sources: Articles on postprandial hypotension were identified through MEDLINE and bibliographies of relevant articles. Study Selection: All articles and case reports describing meal-related hypotension in the elderly and in patients with autonomic failure. Data. Synthesis: Postprandial hypotension, defined as a decrease in systolic blood pressure of 20 mm Hg or more, may result in syncope, falls, dizziness, weakness, angina pectoris, and stroke. Postprandial hypotension is distinct from and probably more common than orthostatic hypotension. Because meal-related hypotension is particularly common in older hypertensive patients, it has important implications for the evaluation and management of hypertension. The mechanism of postprandial hypotension is not fully understood. Possible contributors include inadequate sympathetic nervous system compensation for meal-induced splanchnic blood pooling; impairments in baroreflex function; inadequate postprandial increases in cardiac output; and impaired peripheral vasoconstriction, insulin-induced vasodilation, and release of vasodilatory gastrointestinal peptides. Although caffeine is often recommended as treatment for postprandial hypotension, available data do not support its use. Octreotide, a somatostatin analog, has been shown to be effective, but it is expensive and must be given parenterally. Conclusion: All physicians caring for elderly patients should be aware of the hypotensive effects of food intake and should consider postprandial hypotension in the evaluation of syncope, falls, dizziness, and other cerebral ischemic symptoms.	BETH ISRAEL HOSP, HEBREW REHABIL CTR AGED, BOSTON, MA 02131 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School					NIA NIH HHS [AG09538, AG08812, AG04390] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG008812, P01AG004390, R01AG009538, P60AG008812] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON EA, 1993, HYPERTENSION, V21, P136, DOI 10.1161/01.HYP.21.2.136; ANDERSON EA, 1991, J CLIN INVEST, V87, P2246, DOI 10.1172/JCI115260; APPENZELLER O, 1970, ARCH NEUROL-CHICAGO, V23, P137, DOI 10.1001/archneur.1970.00480260043006; ARMSTRONG E, 1990, J AUTONOM NERV SYST, V31, P174; ARONOW WS, 1994, AM J GERIATR SOC, V42, P930; BAGATELL CJ, 1984, AM J CLIN NUTR, V39, P421, DOI 10.1093/ajcn/39.3.421; BANNISTER R, 1993, AUTONOMIC FAILURE TX, P622; BANNISTER R, 1993, AUTONOMIC FAILURE TX, P531; BELLOMO G, 1988, GERONTOLOGY, V34, P311, DOI 10.1159/000212972; BERNE C, 1989, J CLIN INVEST, V84, P1403, DOI 10.1172/JCI114313; BROWN RT, 1986, NEUROLOGY, V36, P1402, DOI 10.1212/WNL.36.10.1402; CATZ A, 1992, PARAPLEGIA, V30, P582, DOI 10.1038/sc.1992.118; CONNELLY CM, 1994, IN PRESS AM J CARDIO; CORNYN JW, 1986, AM J CARDIOL, V57, P238, DOI 10.1016/0002-9149(86)90898-2; CREAGER MA, 1985, J PHARMACOL EXP THER, V235, P709; DEMEY C, 1989, CLIN PHYSIOL, V9, P77; DEMEY C, 1993, BRIT J CLIN PHARMACO, V36, P427; DEMEY C, 1987, EUR J CLIN PHARMACOL, V32, P471, DOI 10.1007/BF00637672; DOMSCHKE S, 1978, GUT, V19, P1049, DOI 10.1136/gut.19.11.1049; FAGAN TC, 1990, CARDIOVASC DRUG THER, V4, P493, DOI 10.1007/BF01857759; FAGAN TC, 1986, CLIN PHARMACOL THER, V39, P255, DOI 10.1038/clpt.1986.35; FAGAN TC, 1986, AM J CARDIOL, V58, P636, DOI 10.1016/0002-9149(86)90291-2; FAGIUS J, 1994, CLIN SCI, V86, P159, DOI 10.1042/cs0860159; FRASE LL, 1987, AM J CARDIOL, V60, P1356, DOI 10.1016/0002-9149(87)90619-9; Gladstone SA, 1935, ARCH INTERN MED, V55, P533, DOI 10.1001/archinte.1935.00160220003001; GRIBBIN B, 1971, CIRC RES, V29, P424, DOI 10.1161/01.RES.29.4.424; Grollman A, 1929, AM J PHYSIOL, V89, P366, DOI 10.1152/ajplegacy.1929.89.2.366; HAIGH RA, 1991, J HUM HYPERTENS, V5, P83; HAKUSUI S, 1991, NEUROLOGY, V41, P712, DOI 10.1212/WNL.41.5.712; HESELTINE D, 1990, CLIN SCI, V79, P517, DOI 10.1042/cs0790517; HESELTINE D, 1991, J AM GERIATR SOC, V39, P160, DOI 10.1111/j.1532-5415.1991.tb01619.x; HESELTINE D, 1991, POSTGRAD MED J, V67, P543, DOI 10.1136/pgmj.67.788.543; HIRAYAMA M, 1993, J AUTONOM NERV SYST, V45, P149, DOI 10.1016/0165-1838(93)90126-F; HIRAYAMA M, 1993, J AUTONOM NERV SYST, V43, P1, DOI 10.1016/0165-1838(93)90315-L; HOELDTKE RD, 1985, ANN INTERN MED, V103, P889, DOI 10.7326/0003-4819-103-6-889; HOELDTKE RD, 1986, LANCET, V2, P602, DOI 10.1016/S0140-6736(86)92428-1; HOELDTKE RD, 1987, J AM GERIATR SOC, V35, P354, DOI 10.1111/j.1532-5415.1987.tb04643.x; HOELDTKE RD, 1989, AM J MED, V86, P673, DOI 10.1016/0002-9343(89)90442-7; HOELDTKE RD, 1991, CIRCULATION, V84, P168, DOI 10.1161/01.CIR.84.1.168; JANSEN RW, 1995, IN PRESS ARCH INTERN; JANSEN RWMM, 1987, GERONTOLOGY, V33, P363, DOI 10.1159/000212904; JANSEN RWMM, 1988, J CARDIOVASC PHARM, V12, pS59, DOI 10.1097/00005344-198806124-00011; JANSEN RWMM, 1989, J AM GERIATR SOC, V37, P1135, DOI 10.1111/j.1532-5415.1989.tb06677.x; JANSEN RWMM, 1989, J AM GERIATR SOC, V37, P1017, DOI 10.1111/j.1532-5415.1989.tb06914.x; JANSEN RWMM, 1987, AM J CARDIOL, V60, P1087, DOI 10.1016/0002-9149(87)90358-4; JANSEN RWMM, 1991, J AM GERIATR SOC, V39, P1201, DOI 10.1111/j.1532-5415.1991.tb03575.x; JANSEN RWMM, 1989, J CLIN ENDOCR METAB, V68, P752, DOI 10.1210/jcem-68-4-752; JANSEN RWMM, 1990, EUR J CLIN INVEST, V20, P192, DOI 10.1111/j.1365-2362.1990.tb02268.x; JANSEN RWMM, 1988, J HYPERTENS, V6, pS669; Jansen RWMM, 1987, J HYPERTENS       S5, V5, pS501; JONSSON PV, 1990, ARCH INTERN MED, V150, P1518, DOI 10.1001/archinte.150.7.1518; KAMATA T, 1994, STROKE, V25, P511, DOI 10.1161/01.STR.25.2.511; KELBAEK H, 1989, ARCH INTERN MED, V149, P363, DOI 10.1001/archinte.149.2.363; KELBAEK H, 1987, J APPL PHYSIOL, V63, P1862, DOI 10.1152/jappl.1987.63.5.1862; KOONER JS, 1989, J HYPERTENS, V7, pS40, DOI 10.1097/00004872-198900076-00017; KRAJEWSKI A, 1993, J AM GERIATR SOC, V41, P19, DOI 10.1111/j.1532-5415.1993.tb05942.x; KUIPERS HMM, 1991, J AM GERIATR SOC, V39, P181, DOI 10.1111/j.1532-5415.1991.tb01623.x; LEENDERS KL, 1990, BRAIN, V113, P27, DOI 10.1093/brain/113.1.27; LEMBO G, 1993, HYPERTENSION, V21, P1015, DOI 10.1161/01.HYP.21.6.1015; LENDERS JWM, 1988, AGE AGEING, V17, P236, DOI 10.1093/ageing/17.4.236; LIANG CS, 1982, J CLIN INVEST, V69, P1321, DOI 10.1172/JCI110572; LIPSITZ LA, 1985, CLIN SCI, V69, P337, DOI 10.1042/cs0690337; LIPSITZ LA, 1986, J AM GERIATR SOC, V34, P267, DOI 10.1111/j.1532-5415.1986.tb04222.x; LIPSITZ LA, 1986, AM J CARDIOL, V58, P810, DOI 10.1016/0002-9149(86)90359-0; LIPSITZ LA, 1993, CIRCULATION, V87, P391, DOI 10.1161/01.CIR.87.2.391; LIPSITZ LA, 1983, ANN INTERN MED, V99, P92, DOI 10.7326/0003-4819-99-1-92; LIPSITZ LA, 1990, CIRCULATION, V81, P1803, DOI 10.1161/01.CIR.81.6.1803; LIPSITZ LA, 1983, NEW ENGL J MED, V309, P81, DOI 10.1056/NEJM198307143090205; LIPSITZ LA, 1994, CLIN SCI, V87, P259, DOI 10.1042/cs0870259; LIPSITZ LA, 1986, J CHRON DIS, V39, P619, DOI 10.1016/0021-9681(86)90187-6; LOW PA, 1993, CLIN AUTONOMIC DISOR, P157; MADER SL, 1989, ARCH INTERN MED, V149, P2757, DOI 10.1001/archinte.149.12.2757; MASUO K, 1991, CLIN EXP PHARMACOL P, V18, P155, DOI 10.1111/j.1440-1681.1991.tb01426.x; MATHIAS CJ, 1989, CLIN SCI, V77, P85, DOI 10.1042/cs0770085; MATHIAS CJ, 1989, J NEUROL SCI, V94, P255, DOI 10.1016/0022-510X(89)90235-9; MATHIAS CJ, 1991, J NEUROL NEUROSUR PS, V54, P726, DOI 10.1136/jnnp.54.8.726; MATHIAS CJ, 1987, BRIT MED J, V295, P161, DOI 10.1136/bmj.295.6591.161; MATHIAS CJ, 1993, AUTONOMIC FAILURE TX, P489; MCGARRY K, 1983, HYPERTENSION, V5, P763, DOI 10.1161/01.HYP.5.5.763; MEYER JS, 1994, CLIN NEUROLOGY AGING, P214; MICIELI G, 1987, NEUROLOGY, V37, P386, DOI 10.1212/WNL.37.3.386; MILES DW, 1968, CLIN SCI, V34, P419; MONETA GL, 1988, GASTROENTEROLOGY, V95, P1294, DOI 10.1016/0016-5085(88)90364-2; NAKAJIMA S, 1992, AM HEART J, V124, P1669, DOI 10.1016/0002-8703(92)90118-F; NATALI A, 1990, DIABETES, V39, P490, DOI 10.2337/diabetes.39.4.490; Nozaki S, 1993, Rinsho Shinkeigaku, V33, P1135; ONROT J, 1985, NEW ENGL J MED, V313, P549, DOI 10.1056/NEJM198508293130905; PAGE MM, 1976, DIABETES, V25, P90, DOI 10.2337/diabetes.25.2.90; PEITZMAN SJ, 1989, ARCH INTERN MED, V149, P286, DOI 10.1001/archinte.149.2.286; POTTER JF, 1989, CLIN SCI, V77, P265, DOI 10.1042/cs0770265; QAMAR MI, 1988, SCAND J GASTROENTERO, V23, P26, DOI 10.3109/00365528809093842; RAIMBACH SJ, 1989, CLIN SCI, V77, P623, DOI 10.1042/cs0770623; REED G, 1985, AM J MED SCI, V289, P37, DOI 10.1097/00000441-198501000-00007; ROBERTSON D, 1981, AM J CARDIOL, V48, P1048, DOI 10.1016/0002-9149(81)90319-2; ROWE JW, 1981, DIABETES, V30, P219, DOI 10.2337/diab.30.3.219; RYAN SM, 1992, AM J CARDIOL, V69, P201, DOI 10.1016/0002-9149(92)91305-N; SASAKI E, 1992, DIABETES RES CLIN PR, V18, P113, DOI 10.1016/0168-8227(92)90007-E; SEYERHANSEN K, 1977, BRIT MED J, V2, P1262, DOI 10.1136/bmj.2.6097.1262; SHANNON RP, 1986, HYPERTENSION, V8, P438, DOI 10.1161/01.HYP.8.5.438; SHERMAN RA, 1988, AM J KIDNEY DIS, V12, P37, DOI 10.1016/S0272-6386(88)80069-6; SHIMADA K, 1986, CLIN SCI, V70, P489, DOI 10.1042/cs0700489; SIDERY MB, 1991, AM J PHYSIOL, V261, pH1430, DOI 10.1152/ajpheart.1991.261.5.H1430; SIDERY MB, 1993, CLIN SCI, V84, P263, DOI 10.1042/cs0840263; SMIRK FH, 1953, LANCET, V264, P457; TAKATA S, 1985, ANGIOLOGY, V36, P110, DOI 10.1177/000331978503600207; VAITKEVICIUS PV, 1991, ANN INTERN MED, V115, P865, DOI 10.7326/0003-4819-115-11-865; VESTAL RE, 1979, CLIN PHARMACOL THER, V26, P181; VOLLENWEIDER P, 1993, J CLIN INVEST, V92, P147, DOI 10.1172/JCI116542; WAALER BA, 1992, ACTA PHYSIOL SCAND, V146, P321, DOI 10.1111/j.1748-1716.1992.tb09426.x; WAALER BA, 1991, ACTA PHYSIOL SCAND, V142, P33, DOI 10.1111/j.1748-1716.1991.tb09125.x; WEI JY, 1992, NEW ENGL J MED, V327, P1735, DOI 10.1056/NEJM199212103272408; WESTENEND M, 1985, J HYPERTENS, V3, pS417; YI JJ, 1990, BRIT HEART J, V63, P22, DOI 10.1136/hrt.63.1.22; ZOCCALI C, 1989, CLIN NEPHROL, V31, P323	114	301	318	0	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1995	122	4					286	295		10.7326/0003-4819-122-4-199502150-00009	http://dx.doi.org/10.7326/0003-4819-122-4-199502150-00009			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF769	7825766	Green Submitted			2022-12-28	WOS:A1995QF76900009
J	SCHICHMAN, SA; CANAANI, E; CROCE, CM				SCHICHMAN, SA; CANAANI, E; CROCE, CM			SELF-FUSION OF THE ALL1 GENE - A NEW GENETIC MECHANISM FOR ACUTE-LEUKEMIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYELOID-LEUKEMIA; 11Q23 CHROMOSOMAL TRANSLOCATIONS; ACUTE LYMPHOBLASTIC-LEUKEMIA; ALU-ALU RECOMBINATION; MLL GENE; FAMILIAL HYPERCHOLESTEROLEMIA; HOMOLOGOUS RECOMBINATION; DROSOPHILA-TRITHORAX; TOPOISOMERASE-II; LIMITED REGION		THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,REHOVOT,ISRAEL	Jefferson University; Weizmann Institute of Science	SCHICHMAN, SA (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,BLUEMLE LIFE SCI BLDG,ROOM 1035,233 S 10TH ST,PHILADELPHIA,PA 19107, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647	NCI NIH HHS [CA39860] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039860] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNARD OA, 1994, ONCOGENE, V9, P1039; BIONDI A, 1993, BLOOD, V82, P29443; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CALIGIURI MA, 1994, CANCER RES, V54, P370; CHEN CS, 1993, BLOOD, V81, P2386; CIMINO G, 1993, BLOOD, V82, P544; CIMINO G, 1991, CANCER RES, V51, P6712; CORRAL J, 1993, P NATL ACAD SCI USA, V90, P8538, DOI 10.1073/pnas.90.18.8538; CROCE CM, 1987, CELL, V49, P155, DOI 10.1016/0092-8674(87)90552-6; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DEVLIN RH, 1990, AM J HUM GENET, V46, P112; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; DOWNING JR, 1994, BLOOD, V83, P330, DOI 10.1182/blood.V83.2.330.bloodjournal832330; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1994, CANCER RES, V54, P2327; GU Y, 1992, P NATL ACAD SCI USA, V89, P10464, DOI 10.1073/pnas.89.21.10464; HEIM S, 1987, CANCER CYTOGENETICS; HILDEN JM, 1993, CANCER RES, V53, P3853; HUANG LS, 1989, J BIOL CHEM, V264, P11394; HUNGER SP, 1993, BLOOD, V81, P3197; IIDA S, 1993, ONCOGENE, V8, P3083; KENNISON JA, 1993, TRENDS GENET, V9, P75, DOI 10.1016/0168-9525(93)90227-9; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KOBAYASHI H, 1993, BLOOD, V82, P547; LEHRMAN MA, 1986, P NATL ACAD SCI USA, V83, P3679, DOI 10.1073/pnas.83.11.3679; LEHRMAN MA, 1987, CELL, V48, P827, DOI 10.1016/0092-8674(87)90079-1; LI L, 1993, AM J HUM GENET, V53, P140; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MARKERT ML, 1988, J CLIN INVEST, V81, P1323, DOI 10.1172/JCI113458; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; MITELMAN F, 1993, CHROMOSOME COORDINAT, V1, P700; MITELMAN F, 1981, GENES CHROMOSOMES NE, P335; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MORRISSEY J, 1993, BLOOD, V81, P1124; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; NEGRINI M, 1993, CANCER RES, V53, P4489; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; NOWELL PC, 1960, SCIENCE, V132, P1497; NOWELL PC, 1990, AM J CLIN PATHOL, V94, P229, DOI 10.1093/ajcp/94.2.229; NOWELL PC, 1994, FASEB J, V8, P408, DOI 10.1096/fasebj.8.6.8168690; PRASAD R, 1993, CANCER RES, V53, P5624; RAIMONDI SC, 1993, BLOOD, V81, P2237; REEVES R, 1990, J BIOL CHEM, V265, P8573; ROWLEY JD, 1992, GENE CHROMOSOME CANC, V5, P264, DOI 10.1002/gcc.2870050316; RUBNITZ JE, 1994, BLOOD, V84, P570; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA; SCHICHMAN SA, 1994, CANCER RES, V54, P4277; SCHICHMAN SA, 1994, P NATL ACAD SCI USA, V91, P6236, DOI 10.1073/pnas.91.13.6236; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; SUPER HJG, 1993, BLOOD, V82, P3705; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; YAMAMOTO K, 1994, BLOOD, V83, P2912, DOI 10.1182/blood.V83.10.2912.2912; ZIEMINVANDERPOE.S, 1991, P NATL ACAD SCI USA, V88, P10835	57	69	69	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	1995	273	7					571	576		10.1001/jama.273.7.571	http://dx.doi.org/10.1001/jama.273.7.571			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF686	7837391				2022-12-28	WOS:A1995QF68600028
J	FREED, GL; CLARK, SJ; SORENSON, J; LOHR, JA; CEFALO, R; CURTIS, P				FREED, GL; CLARK, SJ; SORENSON, J; LOHR, JA; CEFALO, R; CURTIS, P			NATIONAL ASSESSMENT OF PHYSICIANS BREAST-FEEDING KNOWLEDGE, ATTITUDES, TRAINING, AND EXPERIENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EDUCATION; MANAGEMENT; HEALTH; CARE	Objective.-Previous reports have demonstrated that physician counseling can improve rates of breast-feeding initiation and duration but suggest that physicians are ill-prepared for this role. It is unclear whether residency training for pediatricians, obstetrician/gynecologists, and family physicians provides the knowledge and skills necessary for effective breast-feeding promotion. Design.-Survey. Participants.-A national random sample of 3115 residents and 1920 practicing physicians in pediatrics, obstetrics/gynecology, and family medicine. Outcomes.-Assessment of breast-feeding knowledge, attitudes, training, and experience. Results.-Overall response rate was 68%. All groups demonstrated significant deficits in knowledge of breast-feeding benefits and clinical management; for example, less than 50% of residents chose appropriate clinical management for a breast-fed jaundiced infant or a breast abscess. Practicing physicians performed slightly better, but still more than 30% chose incorrect advice for mothers with low milk supply. Residents reported that their breast-feeding instruction consisted mainly of didactic lecture, not patient experience. Only 55% of senior residents recalled even one instance of precepting related to breast-feeding, and less than 20% had demonstrated breast-feeding techniques at least five times during residency. Regarding preparation for breast-feeding counseling, more than 50% of all practicing physicians rated their residency training as inadequate. Overall, physician involvement in breast-feeding promotion was endorsed by 90% of respondents, yet only half rated themselves as effective in counseling breast-feeding patients. The greatest predictor of physician self-confidence was previous personal or spousal breast-feeding experience. Conclusions.-In this national sample of residents and practicing physicians in three specialties, physicians were ill-prepared to counsel breast-feeding mothers. Deliberate efforts must be made to incorporate clinically based breast-feeding training into residency programs and continuing education workshops to better prepare physicians for their role in breast-feeding promotion.	UNIV N CAROLINA,DEPT HLTH BEHAV & HLTH EDUC,CHAPEL HILL,NC; UNIV N CAROLINA,DEPT OBSTET & GYNECOL,CHAPEL HILL,NC; UNIV N CAROLINA,DEPT FAMILY MED,CHAPEL HILL,NC	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	FREED, GL (corresponding author), UNIV N CAROLINA,CECIL G SHEPS CTR HLTH SERV RES,DIV COMMUNITY PEDIAT,CB 7590,CHAPEL HILL,NC 27599, USA.				NICHD NIH HHS [1-R29-HD-29555-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD029555] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anderson E, 1991, J Obstet Gynecol Neonatal Nurs, V20, P58, DOI 10.1111/j.1552-6909.1991.tb01677.x; APPLEBAUM RM, 1975, REPROD MED, V14, P93; BENTLEY JD, 1989, NEW ENGL J MED, V320, P1531, DOI 10.1056/NEJM198906083202306; CUNNINGHAM AS, 1991, J PEDIATR-US, V118, P659, DOI 10.1016/S0022-3476(05)80023-X; FREED GL, 1993, JAMA-J AM MED ASSOC, V269, P243, DOI 10.1001/jama.269.2.243; FREED GL, 1992, SOUTHERN MED J, V85, P483, DOI 10.1097/00007611-199205000-00006; FREED GL, 1991, AM J DIS CHILD, V145, P917, DOI 10.1001/archpedi.1991.02160080095027; GOLDSTEIN AO, 1993, FAM MED, V25, P254; HAYES B, 1981, J OBSTET GYNECOL NEO, V10, P480; HELLIKER K, 1994, WALL STREET J   0822, pA1; HOLLEN B K, 1976, Journal of Tropical Pediatrics and Environmental Child Health, V22, P288; KISTIN N, 1990, PEDIATRICS, V86, P741; Lawrence R A, 1989, Pediatr Rev, V11, P163, DOI 10.1542/pir.11-6-163; LAWRENCE RA, 1982, PEDIATRICS, V70, P912; LAWRENCE RA, 1989, BREASTFEEDING GUIDE; Lewinski C A, 1992, J Hum Lact, V8, P143, DOI 10.1177/089033449200800319; MITCHELMAN DF, 1990, AM J HEALTH PROMOT, V4, P181; NEIFERT MR, 1986, PEDIATR CLIN N AM, V33, P743; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1074, DOI 10.1001/jama.270.9.1074; Simon J L, 1988, Fam Med, V20, P224; 1978, PEDIATRICS, V62, P591; 1993, GRADUATE MED ED DIRE; 1994, AM FAM PHYSICIAN, V50, P457; 1993, HLTH US 1992; 1990, HLTH PEOPLE 2000; 1992, GUIDELINES PERINATAL	26	200	204	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	1995	273	6					472	476		10.1001/jama.273.6.472	http://dx.doi.org/10.1001/jama.273.6.472			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE498	7837365				2022-12-28	WOS:A1995QE49800030
J	DOWLING, CJ; KUMAR, S; BOULTON, AJM				DOWLING, CJ; KUMAR, S; BOULTON, AJM			A DIFFICULT CASE - SEVERE GASTROPARESIS DIABETICORUM IN A YOUNG PATIENT WITH INSULIN-DEPENDENT DIABETES - A CASE-REPORT	BRITISH MEDICAL JOURNAL			English	Note											DOWLING, CJ (corresponding author), MANCHESTER ROYAL INFIRM,DEPT MED,MANCHESTER M13 9WL,LANCS,ENGLAND.		kumar, sudhesh/D-6945-2013	kumar, sudhesh/0000-0003-4326-5941				HOROWITZ M, 1994, DIABETOLOGIA, V37, P543, DOI 10.1007/BF00403371; KASSANDER P, 1958, ANN INTERN MED, V48, P797, DOI 10.7326/0003-4819-48-4-797	2	10	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 4	1995	310	6975					308	309		10.1136/bmj.310.6975.308	http://dx.doi.org/10.1136/bmj.310.6975.308			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF717	7866175	Green Published			2022-12-28	WOS:A1995QF71700031
J	SCHLAUG, G; JANCKE, L; HUANG, YX; STEINMETZ, H				SCHLAUG, G; JANCKE, L; HUANG, YX; STEINMETZ, H			IN-VIVO EVIDENCE OF STRUCTURAL BRAIN ASYMMETRY IN MUSICIANS	SCIENCE			English	Article							CEREBRAL LATERALIZATION; BIOLOGICAL MECHANISMS; LANGUAGE; SPECIALIZATION; ORGANIZATION; ASSOCIATIONS; HYPOTHESIS; DOMINANCE; PATHOLOGY; ABILITIES	Certain human talents, such as musical ability, have been associated with left-right differences in brain structure and function. In vivo magnetic resonance morphometry of the brain in musicians was used to measure the anatomical asymmetry of the planum temporale, a brain area containing auditory association cortex and previously shown to be a marker of structural and functional asymmetry. Musicians with perfect pitch revealed stronger leftward planum temporale asymmetry than nonmusicians or musicians without perfect pitch. The results indicate that outstanding musical ability is associated with increased leftward asymmetry of cortex subserving music-related functions.	UNIV DUSSELDORF, DEPT NEUROL, D-40225 DUSSELDORF, GERMANY; UNIV DUSSELDORF, INST GEN PSYCHOL, CYBERNET PSYCHOL & PSYCHOBIOL SECT, D-40225 DUSSELDORF, GERMANY	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf			Jäncke, Lutz/C-3792-2009; Jäncke, Lutz/D-2910-2013	Jäncke, Lutz/0000-0002-8115-4890; Jäncke, Lutz/0000-0003-2110-9067				ALAJOUANINE T, 1948, BRAIN, V71, P229, DOI 10.1093/brain/71.3.229; ALTENMULLER E, 1986, EUR ARCH PSY CLIN N, V235, P342, DOI 10.1007/BF00381003; ANNETT M, 1970, BRIT J PSYCHOL, V61, P303, DOI 10.1111/j.2044-8295.1970.tb01248.x; BACHEM A, 1955, J ACOUST SOC AM, V27, P1180, DOI 10.1121/1.1908155; BESSON M, 1994, NEUROSCI LETT, V168, P101, DOI 10.1016/0304-3940(94)90426-X; BEVER TG, 1974, SCIENCE, V185, P537, DOI 10.1126/science.185.4150.537; CHI JG, 1977, ARCH NEUROL-CHICAGO, V34, P346, DOI 10.1001/archneur.1977.00500180040008; DAMASIO AR, 1977, MUSIC BRAIN, P141; Demonet J. F., 1993, Human Brain Mapping, V1, P39, DOI 10.1002/hbm.460010105; GALABURDA AM, 1978, SCIENCE, V199, P852, DOI 10.1126/science.341314; GALABURDA AM, 1987, NEUROPSYCHOLOGIA, V25, P853, DOI 10.1016/0028-3932(87)90091-1; GALABURDA AM, 1978, ARCH NEUROL-CHICAGO, V35, P812, DOI 10.1001/archneur.1978.00500360036007; GESCHWIN.N, 1970, SCIENCE, V170, P940, DOI 10.1126/science.170.3961.940; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P428, DOI 10.1001/archneur.1985.04060050026008; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P521, DOI 10.1001/archneur.1985.04060060019009; GESCHWIND N, 1968, SCIENCE, V161, P186, DOI 10.1126/science.161.3837.186; HASSLER M, 1988, DEV NEUROPSYCHOL, V4, P129, DOI 10.1080/87565648809540399; HASSLER M, 1990, BRAIN COGNITION, V13, P1, DOI 10.1016/0278-2626(90)90036-N; HASSLER M, 1993, INT J NEUROSCI, V68, P145, DOI 10.3109/00207459308994270; HIRSHKOWITZ M, 1978, NEUROPSYCHOLOGIA, V16, P125, DOI 10.1016/0028-3932(78)90052-0; JANCKE L, 1994, NEUROREPORT, V5, P1161; KIRK RE, 1968, EXPT DESIGN PROCEDUR, P69; KLEIN M, 1984, SCIENCE, V223, P1306, DOI 10.1126/science.223.4642.1306; KLEIST K, 1959, SENSORISCHE APHASIEN, P32; KRUMHANSL CL, 1991, ANNU REV PSYCHOL, V42, P277; Luria A R, 1965, J Neurol Sci, V2, P288, DOI 10.1016/0022-510X(65)90113-9; MAZZIOTTA JC, 1982, NEUROLOGY, V32, P921, DOI 10.1212/WNL.32.9.921; Meyer A., 1977, MUSIC BRAIN, P255; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; Rasmussen T, 1977, Ann N Y Acad Sci, V299, P355, DOI 10.1111/j.1749-6632.1977.tb41921.x; RINGO JL, 1994, CEREB CORTEX, V4, P331, DOI 10.1093/cercor/4.4.331; SATZ P, 1979, SCIENCE, V203, P1131, DOI 10.1126/science.424744; SERGEANT D, 1969, J RES MUSIC EDUC, V17, P135, DOI 10.2307/3344200; SERGENT J, 1993, TRENDS NEUROSCI, V16, P168, DOI 10.1016/0166-2236(93)90142-9; STEINMETZ H, 1991, READ WRIT, V3, P331, DOI 10.1007/BF00354966; STEINMETZ H, 1991, ANN NEUROL, V29, P315, DOI 10.1002/ana.410290314; STEINMETZ H, 1990, BRAIN LANG, V39, P357, DOI 10.1016/0093-934X(90)90145-7; STEINMETZ H, IN PRESS CORTEX; von Economo C, 1930, Z GESAMTE NEUROL PSY, V130, P678; WADA JA, 1975, ARCH NEUROL-CHICAGO, V32, P239, DOI 10.1001/archneur.1975.00490460055007; Welker W., 1990, Cerebral Cortex, V8B, P3; Wertheim N, 1969, HDB CLIN NEUROLOGY, V4, P195; WISE R, 1991, BRAIN, V114, P1803, DOI 10.1093/brain/114.4.1803; WITELSON SF, 1973, BRAIN, V96, P641, DOI 10.1093/brain/96.3.641; Yakovlev P. I., 1967, REGIONAL DEV BRAIN E, P3; YENIKOMSHIAN GH, 1976, SCIENCE, V192, P387, DOI 10.1126/science.816005; ZATORRE RJ, 1994, J NEUROSCI, V14, P1908, DOI 10.1523/jneurosci.14-04-01908.1994; ZATORRE RJ, 1992, SCIENCE, V256, P846, DOI 10.1126/science.1589767; ZATORRE RJ, 1979, NEUROPSYCHOLOGIA, V17, P607, DOI 10.1016/0028-3932(79)90035-6; 1987, CEREBRAL LATERALIZAT	50	544	559	1	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	1995	267	5198					699	701		10.1126/science.7839149	http://dx.doi.org/10.1126/science.7839149			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QE733	7839149				2022-12-28	WOS:A1995QE73300044
J	AKCICEK, F; YALNIZ, T; BASCI, A; OK, E; MEES, EJD				AKCICEK, F; YALNIZ, T; BASCI, A; OK, E; MEES, EJD			DIURETIC EFFECT OF FRUSEMIDE IN PATIENTS WITH NEPHROTIC SYNDROME - IS IT POTENTIATED BY INTRAVENOUS ALBUMIN	BRITISH MEDICAL JOURNAL			English	Article							FUROSEMIDE				AKCICEK, F (corresponding author), EGE UNIV,SCH MED,DEPT INTERNAL MED,DIV NEPHROL,BORNOVA 35100,TURKEY.							DAVISON AM, 1974, BRIT MED J, V1, P481, DOI 10.1136/bmj.1.5906.481; KIRCHNER KA, 1990, J PHARMACOL EXP THER, V252, P1097; RABELINK TJ, 1993, CLIN SCI, V84, P1; WEISS RA, 1984, NEW YORK STATE J MED, V84, P384	4	44	47	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 21	1995	310	6973					162	163		10.1136/bmj.310.6973.162	http://dx.doi.org/10.1136/bmj.310.6973.162			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD201	7833755	Green Published			2022-12-28	WOS:A1995QD20100021
J	LEE, TH; PEARSON, SD; JOHNSON, PA; GARCIA, TB; WEISBERG, MC; GUADAGNOLI, E; COOK, F; GOLDMAN, L				LEE, TH; PEARSON, SD; JOHNSON, PA; GARCIA, TB; WEISBERG, MC; GUADAGNOLI, E; COOK, F; GOLDMAN, L			FAILURE OF INFORMATION AS AN INTERVENTION TO MODIFY CLINICAL MANAGEMENT - A TIME-SERIES TRIAL IN PATIENTS WITH ACUTE CHEST PAIN	ANNALS OF INTERNAL MEDICINE			English	Article							LOW-RISK PATIENTS; ACUTE MYOCARDIAL-INFARCTION; EMERGENCY ROOM PATIENTS; ISCHEMIC-HEART-DISEASE; PREDICTIVE INSTRUMENT; PRACTICE GUIDELINES; INTENSIVE-CARE; MULTICENTER; IDENTIFICATION; COMPLICATIONS	Objective: To test whether a low-intensity, nonintrusive intervention improved the efficiency of management of patients with acute chest pain. Design: Time-series trial with six 14-week cycles, each including a 5-week intervention period and a 5-week control period separated by a-week ''washout'' periods. Setting: Urban teaching hospital. Patients: 1921 patients aged 30 years or older with acute chest pain unexplained by local trauma or chest radiograph. Intervention: Risk estimates and triage recommendations were made available to physicians at the time of emergency department evaluation and, for hospitalized patients, on a daily basis before morning rounds. Flowsheets and stickers, but no direct human contact, were used to transmit this information. at Measurements: Rates of admission to the hospital and coronary care unit, inpatient costs, and lengths of stay. Results: Rates of admission during intervention and control periods were similar in both the hospital (52% and 51 %, respectively) and the coronary care unit (10% and 10%, respectively). Total lengths of stay in the hospital were similar (4.9 +/- 5.9 days and 4.9 +/- 5.7 days, respectively), as were average total costs ($7822 +/- $13 217 and $7955 +/- $13 400, respectively). No differences in management were detected for the subgroup of patients with low clinical risk for acute myocardial infarction. Conclusions: The use of information alone without direct human contact-did not affect management of patients with acute chest pain at this hospital. Although this low-intensity intervention might be more effective for other conditions and in other settings, our data support the use of other strategies to affect physician decision making.	HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Harvard Medical School	LEE, TH (corresponding author), BRIGHAM & WOMENS HOSP, 75 FRANCIS ST, BOSTON, MA 02115 USA.				AHRQ HHS [R01 HS06452] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006452] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BRUSH JE, 1985, NEW ENGL J MED, V312, P1137, DOI 10.1056/NEJM198505023121801; Coffey R J, 1992, Qual Manag Health Care, V1, P45; COREY GA, 1987, J FAM PRACTICE, V25, P127; GASPOZ JM, 1994, J AM COLL CARDIOL, V24, P1249, DOI 10.1016/0735-1097(94)90106-6; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; GOLDMAN L, 1989, CLIN RES, V37, pA524; GRAFF L, 1992, ANN EMERG MED, V21, P967, DOI 10.1016/S0196-0644(05)82937-3; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; LEE TH, 1985, ARCH INTERN MED, V145, P65, DOI 10.1001/archinte.145.1.65; LEE TH, 1991, NEW ENGL J MED, V324, P1239, DOI 10.1056/NEJM199105023241803; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MULLEY AG, 1980, NEW ENGL J MED, V302, P943, DOI 10.1056/NEJM198004243021704; PEARSON SD, 1994, J GEN INTERN MED, V9, P241, DOI 10.1007/BF02599648; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; SELKER HP, 1991, MED CARE, V29, P610, DOI 10.1097/00005650-199107000-00002; TIERNEY WM, 1985, CRIT CARE MED, V13, P526, DOI 10.1097/00003246-198507000-00002; WEINGARTEN S, 1993, AM J CARDIOL, V71, P259, DOI 10.1016/0002-9149(93)90787-D; WEINGARTEN S, 1990, ANN INTERN MED, V113, P283, DOI 10.7326/0003-4819-113-4-283; WEINGARTEN SR, 1994, ANN INTERN MED, V120, P257, DOI 10.7326/0003-4819-120-4-199402150-00001; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	20	94	96	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1995	122	6					434	437		10.7326/0003-4819-122-6-199503150-00006	http://dx.doi.org/10.7326/0003-4819-122-6-199503150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM266	7856992				2022-12-28	WOS:A1995QM26600006
J	KLONOFFCOHEN, HS; EDELSTEIN, SL				KLONOFFCOHEN, HS; EDELSTEIN, SL			A CASE-CONTROL STUDY OF ROUTINE AND DEATH SCENE SLEEP POSITION AND SUDDEN-INFANT-DEATH-SYNDROME IN SOUTHERN CALIFORNIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COT DEATH; PRONE; RISK; EPIDEMIOLOGY	Objective.-To investigate whether infants who died of sudden infant death syndrome (SIDS) were routinely placed in different sleep positions compared with healthy infants in a multiethnic diverse population in the United States. Design.-A population-based case-control study. Setting.-Five counties in Southern California including Los Angeles, Orange, San Bernardino, Riverside, and San Diego. Participants.-Parents of 200 white, African-American, Hispanic, and Asian infants who died of SIDS between January 1989 and December 1992 and parents of 200 healthy, living infants matched on the basis of birth hospital, birth date, race, and gender. Information was obtained from detailed telephone interviews with the parents and validated with obstetric and pediatric records. Main Outcome Measures.-Routine sleep position, type of bedding, and objects in bed were determined for both case and control infants, while the last-placed and found sleep and face positions at death were reported for SIDS infants. Results.-Approximately 66% of SIDS infants and 64% of comparison infants routinely slept on their abdomens (P=.91). At the time of death, 80% of cases were found sleeping on their abdomens. There was no difference in routine sleep position for SIDS infants and comparison infants (odds ratio=0.76; 95% confidence interval, 0.42 to 1.38), while simultaneously adjusting for birth weight (in grams), medical conditions at birth, breast-feeding, passive smoking, maternal recreational drug use, prenatal care, and infant vomiting. Hispanic parents routinely placed their infants on their abdomens less frequently than white parents (P<.01). However, the prone sleep position (face down) was the most commonly found sleep position at death in both Hispanic and non-Hispanic infants. Conclusions.-Routine prone sleep position was not associated with an increased risk of SIDS in this study population. The results need to be confirmed with other parents of SIDS infants interviewed before the height of publicity regarding prone sleep position in the United States.			KLONOFFCOHEN, HS (corresponding author), UNIV CALIF SAN DIEGO, DEPT FAMILY & PREVENT MED, DIV EPIDEMIOL, 9500 GILMAN DR, 0607, LA JOLLA, CA 92037 USA.							BEAL S, 1991, MED J AUSTRALIA, V155, P507, DOI 10.5694/j.1326-5377.1991.tb93882.x; BEAL SM, 1991, J PAEDIATR CHILD H, V27, P334, DOI 10.1111/j.1440-1754.1991.tb00414.x; BEAL SM, 1986, AUST PAEDIATR J, V22, P13; BECKWITH J, 1988, SUDDEN INFANT DEATH; CAMERON MH, 1986, AUST PAEDIATR J, V22, P37; DAVIES DP, 1985, LANCET, V2, P1346; DEJONGE GA, 1989, BRIT MED J, V298, P722, DOI 10.1136/bmj.298.6675.722; DREWS CD, 1990, INT J EPIDEMIOL, V19, P405, DOI 10.1093/ije/19.2.405; DWYER T, 1992, J EPIDEMIOL COMMUN H, V46, P98, DOI 10.1136/jech.46.2.98; DWYER T, 1991, LANCET, V337, P1244, DOI 10.1016/0140-6736(91)92917-Q; ENGELBERTS AC, 1990, ARCH DIS CHILD, V65, P462, DOI 10.1136/adc.65.4.462; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; GIBBONS LE, 1993, AM J EPIDEMIOL, V137, P654, DOI 10.1093/oxfordjournals.aje.a116723; GOULD JB, 1988, ANN NY ACAD SCI, V533, P62, DOI 10.1111/j.1749-6632.1988.tb37234.x; GUNTHEROTH WG, 1992, JAMA-J AM MED ASSOC, V267, P2359, DOI 10.1001/jama.267.17.2359; HOFFMAN HJ, 1992, CLIN PERINATOL, V19, P717, DOI 10.1016/S0095-5108(18)30427-5; KATTWINKEL J, 1992, PEDIATRICS, V89, P1120; KEMP JS, 1991, NEW ENGL J MED, V324, P1858, DOI 10.1056/NEJM199106273242605; KLEINBAUM D, 1982, OBSERVATIONAL RES; KROUS H F, 1988, Pediatrician, V15, P231; MCGLASHAN ND, 1988, LANCET, V2, P106; MITCHELL EA, 1992, J PAEDIATR CHILD H, V28, pS3, DOI 10.1111/j.1440-1754.1992.tb02729.x; MITCHELL EA, 1992, J PAEDIATR CHILD H, V28, pS9, DOI 10.1111/j.1440-1754.1992.tb02732.x; NELSON EAS, 1989, AUST PAEDIATR J, V25, P202; NICHOLL JP, 1989, J EPIDEMIOL COMMUN H, V43, P133, DOI 10.1136/jech.43.2.133; PETERSON D R, 1988, Pediatrician, V15, P198; PONSONBY AL, 1992, BRIT MED J, V304, P277, DOI 10.1136/bmj.304.6822.277; PONSONBY AL, 1993, NEW ENGL J MED, V329, P377, DOI 10.1056/NEJM199308053290601; SENECAL J, 1987, ARCH FR PEDIATR, V44, P131; STEELE R, 1966, CAN MED ASSOC J, V94, P1165; WIGFIELD RE, 1992, BRIT MED J, V304, P282, DOI 10.1136/bmj.304.6822.282; 1991, CALIFORNIA MORBIDITY	32	35	35	1	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	1995	273	10					790	794		10.1001/jama.273.10.790	http://dx.doi.org/10.1001/jama.273.10.790			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ750	7861573				2022-12-28	WOS:A1995QJ75000030
J	ECKMAN, MH; GREENFIELD, S; MACKEY, WC; WONG, JB; KAPLAN, S; SULLIVAN, L; DUKES, K; PAUKER, SG				ECKMAN, MH; GREENFIELD, S; MACKEY, WC; WONG, JB; KAPLAN, S; SULLIVAN, L; DUKES, K; PAUKER, SG			FOOT INFECTIONS IN DIABETIC-PATIENTS - DECISION AND COST-EFFECTIVENESS ANALYSES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOWER-EXTREMITY AMPUTATIONS; ORAL ANTIMICROBIAL THERAPY; PEDAL OSTEOMYELITIS; CONVENIENT APPROXIMATION; PERSONAL-COMPUTER; BONE-SCINTIGRAPHY; LIFE EXPECTANCY; SOFT-TISSUE; CIPROFLOXACIN; DIAGNOSIS	Objective.-To examine the cost-effectiveness of approaches to the diagnosis and treatment of patients with type II (non-insulin-dependent) diabetes mellitus (NIDDM) who have foot infections and suspected osteomyelitis. Design.-Decision and cost-effectiveness analyses were performed using a Markov model. We examined the prevalence of osteomyelitis, the major complications and efficacies of long-term antibiotic therapy and surgery, and the performance characteristics of four diagnostic tests (roentgenography, technetium Tc 99m bone scanning, indium In 111-labeled white blood cell scanning, and magnetic resonance imaging). Data were drawn from the English-language literature using MEDLINE searches and bibliographies from selected articles. Setting.-Primary care. Patients.-Patients with NIDDM who had foot infections and suspected osteomyelitis but no signs of systemic toxicity. Interventions.-following hospitalization for surgical debridement and intravenous antibiotic therapy: (1) treatment for presumed soft-tissue infection, (2) culture-guided empiric treatment for presumed osteomyelitis, (3) 71 combinations of diagnostic tests preceding antibiotic therapy for osteomyelitis, (4) 71 combinations of tests preceding amputation, and (5) immediate amputation. Main Outcome Measures.-Quality-adjusted life expectancy, average costs. Results.-Culture-guided empiric treatment for osteomyelitis with 10 weeks of oral antibiotic therapy has similar effectiveness to testing followed by a long course of antibiotic therapy if any test result is positive. However, empiric treatment is the least expensive strategy. Conclusions.-Noninvasive testing adds significant expense to the treatment of patients with NIDDM in whom pedal osteomyelitis is suspected, and such testing may result in little improvement in health outcomes. In patients without systemic toxicity, a 10-week course of culture-guided oral antibiotic therapy following surgical debridement may be as effective as and less costly than other approaches.	TUFTS UNIV NEW ENGLAND MED CTR, DEPT MED, PRIMARY CARE OUTCOMES RES INST, BOSTON, MA 02111 USA; TUFTS UNIV NEW ENGLAND MED CTR, DEPT SURG, DIV VASC SURG, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts Medical Center; Tufts University	ECKMAN, MH (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, DEPT MED, DIV CLIN DECIS MAKING, BOX 302, 750 WASHINGTON AVE, BOSTON, MA 02111 USA.			Greenfield, Sheldon/0000-0003-4628-1998; Kaplan, Sherrie/0000-0002-8644-5849; Wong, John/0000-0003-4203-9010; Eckman, Mark/0000-0001-8253-269X; Sullivan, Lisa/0000-0003-0726-7149	AHRQ HHS [HS-06665] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		APELQVIST J, 1989, DIABETIC MED, V6, P526, DOI 10.1111/j.1464-5491.1989.tb01221.x; BAMBERGER DM, 1987, AM J MED, V83, P653, DOI 10.1016/0002-9343(87)90894-1; BECK JR, 1982, AM J MED, V73, P883, DOI 10.1016/0002-9343(82)90786-0; BECK JR, 1982, AM J MED, V73, P889, DOI 10.1016/0002-9343(82)90787-2; BELTRAN J, 1990, SKELETAL RADIOL, V19, P37; BENTON GS, 1985, SURG GYNECOL OBSTET, V161, P523; BILD DE, 1989, DIABETES CARE, V12, P24, DOI 10.2337/diacare.12.1.24; BLACK J, 1987, J INFECT DIS, V155, P968, DOI 10.1093/infdis/155.5.968; CAPUTO GM, 1994, NEW ENGL J MED, V331, P854, DOI 10.1056/NEJM199409293311307; CHRISTENSEN S, 1976, ACTA ORTHOP SCAND, V47, P329, DOI 10.3109/17453677608992001; CONNELL FA, 1991, MMWR-MORBID MORTAL W, V40, P737; DAVIS H, 1989, ANN INTERN MED, V111, P1041, DOI 10.7326/0003-4819-111-12-1041; De Frang R D, 1991, Ann Vasc Surg, V5, P202, DOI 10.1007/BF02016758; DESAI Y, 1986, BRIT J SURG, V73, P392, DOI 10.1002/bjs.1800730527; DURHAM JR, 1989, AM J SURG, V158, P127, DOI 10.1016/0002-9610(89)90360-7; EDMONDS ME, 1986, Q J MED, V60, P763; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; Geiss Linda S., 1993, Morbidity and Mortality Weekly Report, V42, P1; Gentry L O, 1990, Infect Dis Clin North Am, V4, P485; GENTRY LO, 1991, ANN INTERN MED, V114, P986, DOI 10.7326/0003-4819-114-11-986; GENTRY LO, 1988, J ANTIMICROB CHEMOTH, V21, P115, DOI 10.1093/jac/21.suppl_C.115; GENTRY LO, 1990, ANTIMICROB AGENTS CH, V34, P40, DOI 10.1128/AAC.34.1.40; Geroulakos G, 1991, Eur J Vasc Surg, V5, P655, DOI 10.1016/S0950-821X(05)80901-6; GREENFIELD S, 1994, DIABETES CARE, V17, P32; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; HARRIS MI, 1985, NIH851468 US DEP HLT; Hobson M I, 1990, J R Coll Surg Edinb, V35, P113; HUGHES C E, 1987, Clinical Therapeutics, V10, P36; JONES EW, 1987, DIABETIC MED, V4, P475, DOI 10.1111/j.1464-5491.1987.tb00912.x; KAHN KL, 1986, J CLIN GASTROENTEROL, V8, P346, DOI 10.1097/00004836-198606002-00005; KEENAN AM, 1989, ARCH INTERN MED, V149, P2262, DOI 10.1001/archinte.149.10.2262; LAU J, 1983, MED DECIS MAKING, V3, P39, DOI 10.1177/0272989X8300300110; LEVEY AS, 1987, ANN INTERN MED, V107, P697, DOI 10.7326/0003-4819-107-5-697; LIPSKY B, 1989, 29TH INT C ANT AG CH; Lipsky B A, 1990, Clin Geriatr Med, V6, P747; Lipsky B A, 1990, Infect Dis Clin North Am, V4, P409; LIPSKY BA, 1990, ARCH INTERN MED, V150, P790, DOI 10.1001/archinte.150.4.790; LITZELMAN DK, 1993, ANN INTERN MED, V119, P36, DOI 10.7326/0003-4819-119-1-199307010-00006; LOUIE TJ, 1976, ANN INTERN MED, V85, P461, DOI 10.7326/0003-4819-85-4-461; LUSK RH, 1977, J INFECT DIS, V135, pS111, DOI 10.1093/infdis/135.Supplement.S111; MALONE JM, 1989, AM J SURG, V158, P520, DOI 10.1016/0002-9610(89)90183-9; MALONE JM, 1981, ARCH SURG-CHICAGO, V116, P93; MAURER AH, 1986, RADIOLOGY, V161, P221, DOI 10.1148/radiology.161.1.3763871; MOSKOWITZ AJ, 1988, ANN INTERN MED, V108, P435, DOI 10.7326/0003-4819-108-3-435; MOSKOWITZ AJ, 1986, MED DECIS MAKING, V6, P267; MOST RS, 1983, DIABETES CARE, V6, P87, DOI 10.2337/diacare.6.1.87; MUSHLIN AI, 1994, J GEN INTERN MED, V9, P1, DOI 10.1007/BF02599133; NAGLIE IG, 1992, MED DECIS MAKING, V12, P239, DOI 10.1177/0272989X9201200401; NEWMAN LG, 1991, JAMA-J AM MED ASSOC, V266, P1246, DOI 10.1001/jama.266.9.1246; NIX DE, 1987, AM J MED, V82, P146; OCONNOR GT, 1993, MED DECIS MAKING, V13, P87, DOI 10.1177/0272989X9301300201; PARK HM, 1982, J NUCL MED, V23, P569; PAUKER SG, 1981, ARCH INTERN MED, V141, P1831, DOI 10.1001/archinte.141.13.1831; PETERSON LR, 1989, AM J MED, V86, P801, DOI 10.1016/0002-9343(89)90476-2; POTTS JR, 1979, AM J SURG, V138, P924, DOI 10.1016/0002-9610(79)90323-4; ROSENBERG JM, 1984, AM J SURG, V147, P486, DOI 10.1016/0002-9610(84)90010-2; SANFORD JP, 1994, ANTIMICROBIAL THERAP; SAPICO FL, 1980, J CLIN MICROBIOL, V12, P413, DOI 10.1128/JCM.12.3.413-420.1980; SCHAUWECKER DS, 1988, J NUCL MED, V29, P1651; SEGALL GM, 1989, CLIN NUCL MED, V14, P255, DOI 10.1097/00003072-198904000-00003; SELDIN DW, 1985, J NUCL MED, V26, P988; SINGER RB, 1976, MED RISKS, pCH9; STIEFELD SM, 1991, ORTHOP CLIN N AM, V22, P439; STIRNEMANN P, 1987, J CARDIOVASC SURG, V28, P152; TU JV, 1993, AM REV RESPIR DIS, V148, P370, DOI 10.1164/ajrccm/148.2.370; Wagner F W Jr, 1981, Foot Ankle, V2, P64; WAGNER FW, 1986, SURGERY FOOT, P423; WALKER RC, 1991, MAYO CLIN PROC, V66, P1249, DOI 10.1016/S0025-6196(12)62477-X; WANG A, 1990, MAGN RESON IMAGING, V8, P805, DOI 10.1016/0730-725X(90)90017-V; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WASSERMAN Y, 1993, PHYSICIANS FEE REFER, P62; WEINSTEIN D, 1993, FOOT ANKLE, V14, P18, DOI 10.1177/107110079301400104; WENNBERG JE, 1990, NEW ENGL J MED, V323, P1202, DOI 10.1056/NEJM199010253231710; WHEAT J, 1985, AM J MED, V78, P218, DOI 10.1016/0002-9343(85)90388-2; WHEAT LJ, 1986, ARCH INTERN MED, V146, P1935, DOI 10.1001/archinte.146.10.1935; WILSON KH, 1985, SOUTHERN MED J, V78, P223, DOI 10.1097/00007611-198502000-00035; YAMAMOTO F, 1980, PROGNOSIS SURGICAL D, P88; YUH WTC, 1989, AM J ROENTGENOL, V152, P795, DOI 10.2214/ajr.152.4.795; ZIMMERMAN J, 1980, SCAND J INFECT DIS, V12, P79, DOI 10.3109/inf.1980.12.issue-1.15; ZLATKIN MB, 1987, RADIOL CLIN N AM, V25, P1095; [No title captured]; 1990, PHS901101 US DEP HLT, P10	82	188	191	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	1995	273	9					712	720		10.1001/jama.273.9.712	http://dx.doi.org/10.1001/jama.273.9.712			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH814	7853629				2022-12-28	WOS:A1995QH81400030
J	MATTSON, RH				MATTSON, RH			COMPARING ANTIEPILEPTIC DRUGS	LANCET			English	Editorial Material											MATTSON, RH (corresponding author), YALE UNIV,SCH MED,DEPT NEUROL,NEW HAVEN,CT, USA.							LEBER PD, 1989, EPILEPSIA, V30, P557; MATTSON RH, 1992, NEW ENGL J MED, V327, P765, DOI 10.1056/NEJM199209103271104; ROTHMAN KJ, 1994, NEW ENGL J MED, V333, P394	3	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 25	1995	345	8948					467	468		10.1016/S0140-6736(95)90576-6	http://dx.doi.org/10.1016/S0140-6736(95)90576-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7861870	hybrid			2022-12-28	WOS:A1995QH92900003
J	THANOS, D; MANIATIS, T				THANOS, D; MANIATIS, T			NF-KAPPA-B - A LESSON IN FAMILY VALUES	CELL			English	Review							TRANSCRIPTION FACTOR; ACTIVATION; PROTEINS; ALPHA		HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA	Harvard University			Thanos, Dimitris/AAE-5720-2019					BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; IP YT, 1994, CURR OPIN GENET DEV, V4, P672, DOI 10.1016/0959-437X(94)90133-N; LAI JH, 1994, J BIOL CHEM, V269, P30077; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MEACOCK S, 1994, J BIOL CHEM, V269, P31756; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TONY Y, 1995, CURR BIOL, V5, P1; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; WASSERMAN SA, 1993, MOL BIOL CELL, V4, P767, DOI 10.1091/mbc.4.8.767; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	29	1215	1299	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 24	1995	80	4					529	532		10.1016/0092-8674(95)90506-5	http://dx.doi.org/10.1016/0092-8674(95)90506-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867060	Bronze			2022-12-28	WOS:A1995QJ60200004
J	ECKHARDT, M; MUHLENHOFF, M; BETHE, A; KOOPMAN, J; FROSCH, M; GERARDYSCHAHN, R				ECKHARDT, M; MUHLENHOFF, M; BETHE, A; KOOPMAN, J; FROSCH, M; GERARDYSCHAHN, R			MOLECULAR CHARACTERIZATION OF EUKARYOTIC POLYSIALYLTRANSFERASE-1	NATURE			English	Article							CELL-ADHESION MOLECULE; POLYSIALIC ACID; N-CAM; NERVE; NCAM; POLYSACCHARIDE; EXPRESSION; ANTIBODY; BINDING; CLONING	POLYSIALIC acid (PSA) is a dynamically regulated product of posttranslational modification of the neural cell adhesion molecule, NCAM(1,2). Presence of the large anionic carbohydrate modulates NCAM binding properties and, by increasing the intercellular space, influences interactions between other cell surface molecules(1-5). PSA expression underlies cell type- and developmental-specific alterations(6) and correlates with stages of cellular motility(6-8), In the adult, PSA becomes restricted to regions of permanent neural plasticity and regenerating neural and muscle tissues(6,9,10). Recent data implicate its important function in spatial learning and memory(11,12), and in tumour biology(13-16). Here we describe the molecular characterization of polysialyltransferase-1, the key enzyme of eukaryotic PSA synthesis. In reconstitution experiments, the newly cloned enzyme induces PSA synthesis in all NCAM-expressing cell lines. Our data therefore represent convincing evidence that the polycondensation of alpha-2,8-linked sialic acids in mammals is the result of a single enzymatic activity and provide a new basis for studying the functional role of PSA in neuro- and tumour biology.	HANNOVER MED SCH,INST MED MIKROBIOL,D-30625 HANNOVER,GERMANY; NETHERLANDS CANC INST,DEPT TUMOR BIOL,1006 CX AMSTERDAM,NETHERLANDS	Hannover Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf; Netherlands Cancer Institute			Frosch, Matthias/H-2411-2013					ACHESON A, 1991, J CELL BIOL, V114, P143, DOI 10.1083/jcb.114.1.143; BLERHUIZEN MFA, 1993, GENE DEV, V7, P468; BLOCH RJ, 1992, J CELL BIOL, V116, P449, DOI 10.1083/jcb.116.2.449; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; DANILOFF JK, 1986, J CELL BIOL, V103, P929, DOI 10.1083/jcb.103.3.929; DOHERTY P, 1990, NEURON, V5, P209, DOI 10.1016/0896-6273(90)90310-C; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; GERARDYSCHAHN R, 1994, INT J CANCER S, V8, P38; HAYRINEN J, 1989, MOL IMMUNOL, V26, P523, DOI 10.1016/0161-5890(89)90003-5; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; KERN WF, 1993, LEUKEMIA LYMPHOMA, V12, P1, DOI 10.3109/10428199309059565; KITAZUME S, 1994, J BIOL CHEM, V269, P10330; KOMMINOTH P, 1991, AM J PATHOL, V139, P297; LANDMESSER L, 1992, J NEUROBIOL, V23, P1131, DOI 10.1002/neu.480230906; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; MARTINI R, 1988, J CELL BIOL, V106, P1735, DOI 10.1083/jcb.106.5.1735; MCCOY RD, 1984, J BIOL CHEM, V260, P12659; MOOLENAAR CECK, 1990, CANCER RES, V50, P1102; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SASAKI K, 1994, J BIOL CHEM, V269, P15950; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; TAKAMATSU K, 1994, CANCER RES, V54, P2598; TANG J, 1992, NEURON, V8, P1031, DOI 10.1016/0896-6273(92)90125-W; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; TOMLINSON S, 1985, J VIROL, V55, P374, DOI 10.1128/JVI.55.2.374-378.1985; YANG PF, 1992, J CELL BIOL, V116, P1487, DOI 10.1083/jcb.116.6.1487	31	269	278	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					715	718		10.1038/373715a0	http://dx.doi.org/10.1038/373715a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854457				2022-12-28	WOS:A1995QH92800059
J	BRIDGES, SH; SARVER, N				BRIDGES, SH; SARVER, N			GENE-THERAPY AND IMMUNE RESTORATION FOR HIV DISEASE	LANCET			English	Review							IMMUNODEFICIENCY-VIRUS TYPE-1; RETROVIRAL VECTORS; T-LYMPHOCYTES; CD4+ CELLS; EXPRESSION; INFECTION; RIBOZYMES; PROTEIN; INVIVO; MOUSE		NIAID,DIV AIDS,TARGETED INTERVENT BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ALDROVANDI GM, 1993, NATURE, V363, P732, DOI 10.1038/363732a0; BAHNER I, 1993, J VIROL, V67, P3199, DOI 10.1128/JVI.67.6.3199-3207.1993; BEVEC D, 1994, HUM GENE THER, V5, P193, DOI 10.1089/hum.1994.5.2-193; BONYHADI ML, 1993, NATURE, V363, P728, DOI 10.1038/363728a0; BRADY HJM, 1994, P NATL ACAD SCI USA, V91, P365, DOI 10.1073/pnas.91.1.365; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; CARROLL R, 1994, J VIROL, V68, P6047, DOI 10.1128/JVI.68.9.6047-6051.1994; CARUSO M, 1992, P NATL ACAD SCI USA, V89, P182, DOI 10.1073/pnas.89.1.182; CHU THT, IN PRESS J VIROL; CURIEL TJ, 1993, HUM GENE THER, V4, P741, DOI 10.1089/hum.1993.4.6-741; DUAN LX, 1994, P NATL ACAD SCI USA, V91, P5075, DOI 10.1073/pnas.91.11.5075; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; IRWIN MJ, 1994, J VIROL, V68, P5036, DOI 10.1128/JVI.68.8.5036-5044.1994; KANESHIMA H, 1994, CURR OPIN IMMUNOL, V6, P327, DOI 10.1016/0952-7915(94)90109-0; KASSAHARA N, 1994, SCIENCE, V266, P1373; KOLLMANN TR, 1994, P NATL ACAD SCI USA, V91, P8032, DOI 10.1073/pnas.91.17.8032; KOLLMANN TR, 1994, J EXP MED, V179, P513, DOI 10.1084/jem.179.2.513; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LEE SW, 1994, J VIROL, V68, P8254, DOI 10.1128/JVI.68.12.8254-8264.1994; LEVY JA, 1993, MICROBIOL REV, V56, P183; MALIM MH, 1992, J EXP MED, V176, P1197, DOI 10.1084/jem.176.4.1197; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; MUZYCZKA N, 1992, CURR TOP MICROBIOL, V158, P97; NABEL GJ, 1994, HUM GENE THER, V5, P79, DOI 10.1089/hum.1994.5.1-79; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PAROLIN C, 1994, J VIROL, V68, P3888, DOI 10.1128/JVI.68.6.3888-3895.1994; RIDDELL SR, 1992, HUM GENE THER, V3, P319, DOI 10.1089/hum.1992.3.3-319; ROBERTS MR, 1994, BLOOD, V84, P2787; ROSSI JJ, 1992, ADV EXP MED BIOL, V312, P95; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SARVER N, 1993, J NIH RES, V5, P63; SHIMADA T, 1991, J CLIN INVEST, V88, P1043, DOI 10.1172/JCI115365; SMITH C, 1993, UCLA UCI AIDS S GEN, P25; SULLENGER BA, 1991, J VIROL, V65, P6811, DOI 10.1128/JVI.65.12.6811-6816.1991; SULLENGER BA, 1993, SCIENCE, V262, P1566, DOI 10.1126/science.8248806; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; VORMOOR J, 1994, BLOOD, V83, P2489; WALKER BD, 1994, J ACQ IMMUN DEF SYND, V7, pS6; WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156; WOFFENDIN C, 1994, P NATL ACAD SCI USA, V91, P11581, DOI 10.1073/pnas.91.24.11581; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; YAMADA O, 1994, GENE THER, V1, P38; YU M, 1994, GENE THER, V1, P13; YU M, 1993, P NATL ACAD SCI USA, V90, P6340, DOI 10.1073/pnas.90.13.6340; ZHOU SZ, 1993, EXP HEMATOL, V21, P928	47	55	55	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					427	432						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853956				2022-12-28	WOS:A1995QG90400015
J	FERRARI, S; RIZZOLI, R; CHEVALLEY, T; SLOSMAN, D; EISMAN, JA; BONJOUR, JP				FERRARI, S; RIZZOLI, R; CHEVALLEY, T; SLOSMAN, D; EISMAN, JA; BONJOUR, JP			VITAMIN-D-RECEPTOR-GENE POLYMORPHISMS AND CHANGE IN LUMBAR-SPINE BONE-MINERAL DENSITY	LANCET			English	Note							WOMEN; MASS; DETERMINANTS; CALCIUM; TWIN	Common vitamin-D-receptor (VDR) gene allelic variants predict bone mineral density. We analysed VDR alleles and rate of change of lumbar-spine bone mineral density over 18 months in 72 elderly subjects. 9 BB homozygotes lost bone mineral density but 26 homozygotes for the alternative genotype (bb) did not (mean change -2.3 [SE 1.0] vs 0.9 [0.7]% per year, p<0.05), irrespective of calcium intake. Among 37 heterozygotes (Bb), however, change in bone mineral density correlated with calcium intake (r=035, p<0.03). This association between a marker and rate of bone loss in the elderly suggests that the effect of calcium intake on maintenance of bone mass could relate to VDR gene polymorphisms.	WHO,COLLABORATING CTR OSTEOPOROSIS & BONE DIS,DEPT MED,DIV CLIN PATHOPHYSIOL,GENEVA,SWITZERLAND; UNIV HOSP GENEVA,DEPT RADIOL,DIV NUCL MED,CH-1211 GENEVA,SWITZERLAND	World Health Organization; University of Geneva			Eisman, John A/C-2886-2014; Chevalley, Thierry/AAQ-1412-2021; Ferrari, Serge/ABD-2730-2020	Chevalley, Thierry/0000-0003-3338-1148; Ferrari, Serge/0000-0002-1372-4417				CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; CHEVALLEY T, 1994, OSTEOPOROSIS INT, V4, P245, DOI 10.1007/BF01623348; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; DEQUEKER J, 1987, BONE, V8, P207, DOI 10.1016/8756-3282(87)90166-9; Kelly P J, 1990, Osteoporos Int, V1, P56, DOI 10.1007/BF01880417; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; MORRISON NA, 1992, P NATL ACAD SCI USA, V89, P6665, DOI 10.1073/pnas.89.15.6665; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; SEEMAN E, 1989, NEW ENGL J MED, V320, P554, DOI 10.1056/NEJM198903023200903; SMITH DM, 1973, J CLIN INVEST, V52, P2800, DOI 10.1172/JCI107476	10	235	240	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					423	424		10.1016/S0140-6736(95)90404-2	http://dx.doi.org/10.1016/S0140-6736(95)90404-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853953				2022-12-28	WOS:A1995QG90400012
J	ELTON, A; HONIG, P; BENTOVIM, A; SIMONS, J				ELTON, A; HONIG, P; BENTOVIM, A; SIMONS, J			WITHHOLDING CONSENT TO LIFESAVING TREATMENT - 3 CASES	BRITISH MEDICAL JOURNAL			English	Article								The refusal of children or their parents to consent to treatment that professionals regard as essential always results in a dilemma. Responding to such refusals demands careful and sensitive clinical and ethicolegal intervention and close cooperation among professionals, in particular doctors and social workers. Since the introduction of the Children Act 1989 the number of cases in which children have withheld consent to Lifesaving treatment has risen, and it is now increasingly recognised that children have a right to have their views legally represented if a local authority or health authority seeks a court's leave to carry out treatment. Professionals have to consider which legal route, under either the Children Act or the Mental Health Act, is likely to be best for the individual child.	HOSP SICK CHILDREN,DEPT SOCIAL WORK,LONDON WC1N 3JH,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	ELTON, A (corresponding author), HOSP SICK CHILDREN,DEPT PSYCHOL MED,GREAT ORMOND ST,LONDON WC1N 3JH,ENGLAND.							DEVEREUX JA, 1993, BRIT MED J, V306, P1459, DOI 10.1136/bmj.306.6890.1459; FREEMAN M, 1992, ADOPTION FOSTERING, V17, P14; LEWIS C, 1992, LAW SOC GAZETTE, V89, P27	3	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 11	1995	310	6976					373	377		10.1136/bmj.310.6976.373	http://dx.doi.org/10.1136/bmj.310.6976.373			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG721	7866216	Green Published			2022-12-28	WOS:A1995QG72100023
J	SPATARO, JA; VANHORN, L				SPATARO, JA; VANHORN, L			EXERCISE TO REDUCE POTBELLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							BODY-COMPOSITION				SPATARO, JA (corresponding author), NORTHWESTERN UNIV, SCH MED, CHICAGO, IL USA.							FOSTER WR, 1985, ANN INTERN MED, V103, P981; FRONTERA WR, 1988, J APPL PHYSIOL, V64, P1038, DOI 10.1152/jappl.1988.64.3.1038; MOREY MC, 1989, J AM GERIATR SOC, V37, P348, DOI 10.1111/j.1532-5415.1989.tb05503.x; NIEMAN DC, 1990, ANN SPORTS MED, V3, P2; POLLOCK ML, 1987, J APPL PHYSIOL, V62, P725, DOI 10.1152/jappl.1987.62.2.725; SIDNEY KH, 1977, AM J CLIN NUTR, V30, P326, DOI 10.1093/ajcn/30.3.326; Stamford B A, 1988, Exerc Sport Sci Rev, V16, P341	7	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	1995	273	6					503	503		10.1001/jama.273.6.503	http://dx.doi.org/10.1001/jama.273.6.503			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE498	7837371				2022-12-28	WOS:A1995QE49800037
J	STROBEL, SA; CECH, TR				STROBEL, SA; CECH, TR			MINOR-GROOVE RECOGNITION OF THE CONSERVED G-CENTER-DOT-U PAIR AT THE TETRAHYMENA RIBOZYME REACTION SITE	SCIENCE			English	Article							5' SPLICE-SITE; GROUP-I INTRON; RNA SUBSTRATE; 2'-HYDROXYL GROUPS; ACTIVE-SITE; TERTIARY INTERACTIONS; THERMOPHILA RIBOZYME; KINETIC DESCRIPTION; CHEMICAL SYNTHESIS; CATALYTIC INTRONS	The guanine uracil (G.U) base pair that helps to define the 5'-splice site of group I introns is phylogenetically highly conserved. In such a wobble base pair, G makes two hydrogen bonds with U in a geometry shifted from that of a canonical Watson-Crick pair. The contribution made by individual functional groups of the G.U pair in the context of the Tetrahymena ribozyme was examined by replacement of the G.U pair with synthetic base pairs that maintain a wobble configuration, but that systematically alter functional groups in the major and minor grooves of the duplex. The substitutions demonstrate that the exocyclic amine of G, when presented on the minor groove surface by the wobble base pair conformation, contributes substantially (2 kilocalories.mole(-1)) to binding by making a tertiary interaction with the ribozyme active site. It contributes additionally to transition state stabilization. The ribozyme active site also makes tertiary contacts with a tripod of 2'-hydroxyls on the minor groove surface of the splice site helix. This suggests that the ribozyme binds the duplex primarily in the minor groove. The alanyl aminoacyl transfer RNA (tRNA) synthetase recognizes the exocyclic amine of an invariant G.U pair and contacts a similar array of 2'-hydroxyls when binding the tRNA(Ala) acceptor stem, providing an unanticipated parallel between protein-RNA and RNA-RNA interactions,	UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder								BARFOD ET, 1989, MOL CELL BIOL, V9, P3657, DOI 10.1128/MCB.9.9.3657; BEEN MD, 1994, TRENDS BIOCHEM SCI, V19, P251, DOI 10.1016/0968-0004(94)90151-1; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BEVILACQUA PC, 1993, P NATL ACAD SCI USA, V90, P8357, DOI 10.1073/pnas.90.18.8357; BEVILACQUA PC, 1991, BIOCHEMISTRY-US, V30, P10632, DOI 10.1021/bi00108a005; BEVILACQUA PC, 1992, SCIENCE, V258, P1355, DOI 10.1126/science.1455230; CECH TR, 1994, NAT STRUCT BIOL, V1, P273, DOI 10.1038/nsb0594-273; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; CECH TR, 1992, J BIOL CHEM, V267, P17479; CHOWRIRA BM, 1991, NATURE, V354, P320, DOI 10.1038/354320a0; DOUDNA JA, 1989, P NATL ACAD SCI USA, V86, P7402, DOI 10.1073/pnas.86.19.7402; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; FU DJ, 1993, BIOCHEMISTRY-US, V32, P10629, DOI 10.1021/bi00091a013; GREEN R, 1991, NUCLEIC ACIDS RES, V19, P4161, DOI 10.1093/nar/19.15.4161; GUTELL RR, 1994, MICROBIOL REV, V58, P10, DOI 10.1128/MMBR.58.1.10-26.1994; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; HERSCHLAG D, 1992, BIOCHEMISTRY-US, V31, P1386, DOI 10.1021/bi00120a015; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1993, BIOCHEMISTRY-US, V32, P8299, DOI 10.1021/bi00083a034; HERSCHLAG D, 1993, BIOCHEMISTRY-US, V32, P8312, DOI 10.1021/bi00083a035; HICKEY DR, 1985, BIOCHEMISTRY-US, V24, P3987, DOI 10.1021/bi00336a028; HOLBROOK SR, 1978, J MOL BIOL, V123, P631, DOI 10.1016/0022-2836(78)90210-3; HOLBROOK SR, 1991, NATURE, V353, P579, DOI 10.1038/353579a0; KNITT S, 1994, BIOCHEMISTRY-US, V33, P13864; MAJERFELD I, 1994, NAT STRUCT BIOL, V1, P287, DOI 10.1038/nsb0594-287; MCCONNELL TS, 1993, P NATL ACAD SCI USA, V90, P8362, DOI 10.1073/pnas.90.18.8362; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOHR G, 1994, NATURE, V370, P147, DOI 10.1038/370147a0; Moore M., 1993, RNA WORLD, P303; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; MURPHY FL, 1989, P NATL ACAD SCI USA, V86, P9218, DOI 10.1073/pnas.86.23.9218; MUSIERFORSYTH K, 1992, NATURE, V357, P513, DOI 10.1038/357513a0; MUSIERFORSYTH K, 1991, SCIENCE, V253, P784, DOI 10.1126/science.1876835; PYLE AM, 1994, BIOCHEMISTRY-US, V33, P13856, DOI 10.1021/bi00250a040; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; SALDANHA R, 1993, FASEB J, V7, P15, DOI 10.1096/fasebj.7.1.8422962; SALVO JL, 1992, J BIOL CHEM, V267, P2845; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; STROBEL SA, 1993, BIOCHEMISTRY-US, V32, P13593, DOI 10.1021/bi00212a027; STROBEL SA, 1994, BIOCHEMISTRY-US, V33, P13824, DOI 10.1021/bi00250a037; STROBEL SM, UNPUB; USMAN N, 1987, J AM CHEM SOC, V109, P7845, DOI 10.1021/ja00259a037; WANG JF, 1993, SCIENCE, V260, P504, DOI 10.1126/science.7682726; WARING RB, 1986, NATURE, V321, P133, DOI 10.1038/321133a0; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	50	154	167	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 3	1995	267	5198					675	679		10.1126/science.7839142	http://dx.doi.org/10.1126/science.7839142			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839142				2022-12-28	WOS:A1995QE73300037
J	DAR, K; WILLIAMS, T; AITKEN, R; WOODS, KL; FLETCHER, S				DAR, K; WILLIAMS, T; AITKEN, R; WOODS, KL; FLETCHER, S			ARTERIAL VERSUS CAPILLARY SAMPLING FOR ANALYZING BLOOD-GAS PRESSURES	BRITISH MEDICAL JOURNAL			English	Article									KETTERING GEN HOSP NHS TRUST,DEPT MED & CLIN BIOCHEM,KETTERING NN16 8UZ,NORTHANTS,ENGLAND; UNIV LEICESTER,DEPT MED & THERAPEUT,LEICESTER,LEICS,ENGLAND	University of Leicester								British Thoracic Association, 1982, BR MED J CLIN RES ED, V285, P1251; JOHNSON AJ, 1984, BRIT MED J, V288, P1870, DOI 10.1136/bmj.288.6434.1870; LANGLANDS JH, 1965, LANCET, V2, P315; MORTENSEN JD, 1967, CIRCULATION, V35, P1118, DOI 10.1161/01.CIR.35.6.1118; TURNER JS, 1990, CRIT CARE MED, V18, P966, DOI 10.1097/00003246-199009000-00012	5	55	57	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 7	1995	310	6971					24	25		10.1136/bmj.310.6971.24	http://dx.doi.org/10.1136/bmj.310.6971.24			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB060	7827548	Green Published			2022-12-28	WOS:A1995QB06000023
J	LINCOLN, NB				LINCOLN, NB			CONTROVERSIES IN MANAGEMENT - IS STROKE BETTER MANAGED IN THE COMMUNITY - ONLY HOSPITALS CAN PROVIDE THE REQUIRED SKILLS	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; REHABILITATION; CARE				LINCOLN, NB (corresponding author), CITY HOSP NOTTINGHAM,STRUCT RES UNIT,HUCKNALL RD,NOTTINGHAM NG5 1PB,ENGLAND.		Lincoln, Nadina B/B-9149-2009					BAMFORD J, 1986, BRIT MED J, V292, P1369, DOI 10.1136/bmj.292.6532.1369; CLARKE PA, IN PRESS CLIN REHABI; GLADMAN JRF, 1993, J NEUROL NEUROSUR PS, V56, P960, DOI 10.1136/jnnp.56.9.960; HANGER HC, 1993, STROKE, V24, P536, DOI 10.1161/01.STR.24.4.536; INDREDAVIK B, 1991, STROKE, V22, P1026, DOI 10.1161/01.STR.22.8.1026; KALRA L, 1993, STROKE, V24, P1462, DOI 10.1161/01.STR.24.10.1462; LANGHORNE P, 1993, LANCET, V342, P395, DOI 10.1016/0140-6736(93)92813-9; SANDERCOCK P, 1992, LANCET, V339, P537, DOI 10.1016/0140-6736(92)90348-7; WADE DT, 1985, LANCET, V1, P323; WOLFE CDA, 1993, J EPIDEMIOL COMMUN H, V47, P144, DOI 10.1136/jech.47.2.144	10	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 19	1994	309	6965					1357	1358		10.1136/bmj.309.6965.1357	http://dx.doi.org/10.1136/bmj.309.6965.1357			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT625	7866087	Green Published			2022-12-28	WOS:A1994PT62500032
J	MALLINSON, RH; GOLDSMITH, DJA; HIGGINS, RM; VENNING, MC; ACKRILL, P				MALLINSON, RH; GOLDSMITH, DJA; HIGGINS, RM; VENNING, MC; ACKRILL, P			LESSON OF THE WEEK - ACUTE SWOLLEN LEGS DUE TO RHABDOMYOLYSIS - INITIAL MANAGEMENT AS DEEP-VEIN THROMBOSIS MAY LEAD TO ACUTE-RENAL-FAILURE	BMJ-BRITISH MEDICAL JOURNAL			English	Article									WITHINGTON HOSP, ATRIFICIAL KIDNEY UNIT, MANCHESTER M20 8LR, LANCS, ENGLAND				Goldsmith, David J A/H-6965-2018	Goldsmith, David J A/0000-0002-4349-9193				ANDERSON RJ, 1992, DISEASES KIDNEY; BETTER OS, 1990, NEPHRON, V55, P97, DOI 10.1159/000185934; Bywaters EGL, 1941, BRIT MED J, V1941, P427, DOI 10.1136/bmj.1.4185.427; GROSSMAN RA, 1974, NEW ENGL J MED, V291, P807, DOI 10.1056/NEJM197410172911601; HAY SM, 1992, BRIT MED J, V305, P1474, DOI 10.1136/bmj.305.6867.1474; HOU SH, 1983, AM J MED, V74, P243, DOI 10.1016/0002-9343(83)90618-6; RON D, 1984, ARCH INTERN MED, V144, P277, DOI 10.1001/archinte.144.2.277; WARD MM, 1988, ARCH INTERN MED, V148, P1553, DOI 10.1001/archinte.148.7.1553	8	3	6	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 19	1994	309	6965					1361	1362		10.1136/bmj.309.6965.1361	http://dx.doi.org/10.1136/bmj.309.6965.1361			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT625	7866089	Green Published			2022-12-28	WOS:A1994PT62500035
J	THOMPSON, SG				THOMPSON, SG			SYSTEMATIC REVIEW - WHY SOURCES OF HETEROGENEITY IN METAANALYSIS SHOULD BE INVESTIGATED	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CLINICAL-TRIALS; CORONARY HEART-DISEASE; METAANALYSIS; CHOLESTEROL; OVERVIEWS; MORTALITY; BIAS; RISK	Although meta-analysis is now well established as a method of reviewing evidence, an uncritical use of the technique can be very misleading. One common problem is the failure to investigate appropriately the sources of heterogeneity, in particular the clinical differences between the studies included. This paper distinguishes between the concepts of clinical and statistical heterogeneity and exemplifies the importance of investigating heterogeneity by using published-meta-analyses of epidemiological studies of serum cholesterol concentration and clinical trials of its reduction. Although not without some dangers of speculative conclusions, prompted by overzealous inspection of the data to hand, a sensible investigation of sources of heterogeneity should increase both the scientific and the clinical relevance of the results of meta-analyses.,			THOMPSON, SG (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, MED STAT UNIT, KEPPEL ST, LONDON WC1E 7HT, ENGLAND.							ABE O, 1992, LANCET, V339, P71; Altman DG, 1991, PRACTICAL STAT MED R, P167; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1992, Lancet, V339, P1; BAILEY KR, 1987, STAT MED, V6, P351, DOI 10.1002/sim.4780060327; BRAND R, 1992, STAT MED, V11, P2077, DOI 10.1002/sim.4780111605; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DICKERSIN K, 1992, EPIDEMIOL REV, V14, P154, DOI 10.1093/oxfordjournals.epirev.a036084; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; GALBRAITH RF, 1988, STAT MED, V7, P889, DOI 10.1002/sim.4780070807; HUGHES MD, 1992, BIOMETRICS, V48, P41, DOI 10.2307/2532737; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LAW MR, 1991, CANCER CAUSE CONTROL, V2, P253, DOI 10.1007/BF00052142; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; Manolio T A, 1992, Ann Epidemiol, V2, P161, DOI 10.1016/1047-2797(92)90051-Q; MEIER P, 1987, STAT MED, V6, P329, DOI 10.1002/sim.4780060322; OXMAN A, 1994, COCHRANE COLLABORA 6; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; PAGLIARO L, 1992, ANN INTERN MED, V117, P59, DOI 10.7326/0003-4819-117-1-59; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; RAVNSKOV U, 1992, BMJ-BRIT MED J, V305, P15, DOI 10.1136/bmj.305.6844.15; SCHULZ KF, IN PRESS JAMA; SENN S, 1994, STAT MED, V13, P293, DOI 10.1002/sim.4780130310; SHIPLEY MJ, 1991, BRIT MED J, V303, P89, DOI 10.1136/bmj.303.6794.89; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; Thompson S G, 1993, Stat Methods Med Res, V2, P173, DOI 10.1177/096228029300200205; THOMPSON SG, 1991, LANCET, V338, P1127, DOI 10.1016/0140-6736(91)91975-Z; WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	30	717	731	1	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 19	1994	309	6965					1351	1355		10.1136/bmj.309.6965.1351	http://dx.doi.org/10.1136/bmj.309.6965.1351			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT625	7866085	Green Published			2022-12-28	WOS:A1994PT62500029
J	GARG, A; BANTLE, JP; HENRY, RR; COULSTON, AM; GRIVER, KA; RAATZ, SK; BRINKLEY, L; CHEN, YDI; GRUNDY, SM; HUET, BA; REAVEN, GM				GARG, A; BANTLE, JP; HENRY, RR; COULSTON, AM; GRIVER, KA; RAATZ, SK; BRINKLEY, L; CHEN, YDI; GRUNDY, SM; HUET, BA; REAVEN, GM			EFFECTS OF VARYING CARBOHYDRATE CONTENT OF DIET IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MONOUNSATURATED FATTY-ACIDS; CORONARY HEART-DISEASE; LOW-DENSITY LIPOPROTEINS; PLASMA-LIPOPROTEINS; GLUCOSE-TOLERANCE; ENERGY-INTAKE; BODY-WEIGHT; 7 COUNTRIES; MEN; CHOLESTEROL	Objective.-To study effects of variation in carbohydrate content of diet on glycemia and plasma lipoproteins in patients with non-insulin-dependent diabetes mellitus (NIDDM). Design.-A four-center randomized crossover trial. Setting.-Outpatient and inpatient evaluation in metabolic units. Patients.-Forty-two NIDDM patients receiving glipizide therapy. Interventions.-A high-carbohydrate diet containing 55% of the total energy as carbohydrates and 30% as fats was compared with a high-monounsaturated-fat diet containing 40% carbohydrates and 45% fats. The amounts of saturated fats, polyunsaturated fats, cholesterol, sucrose, and protein were similar. The study diets, prepared in metabolic kitchens, were provided as the sole nutrients to subjects for 6 weeks each. To assess longer-term effects, a subgroup of 21 patients continued the diet they received second for an additional 8 weeks. Main outcome Measures.-Fasting plasma glucose, insulin, lipoproteins, and glycosylated hemoglobin concentrations. Twenty-four-hour profiles of glucose, insulin, and triglyceride levels. Results.-The site of study as well as the diet order did not affect the results. Compared with the high-monounsaturated-fat diet, the high-carbohydrate diet increased fasting plasma triglyceride levels and very low-density lipoprotein cholesterol levels by 24% (P<.0001) and 23% (P=.0001), respectively, and increased daylong plasma triglyceride, glucose, and insulin values by 10% (P=.03), 12% (P<.0001), and 9% (P=.02), respectively. Plasma total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol levels remained unchanged. The effects of both diets on plasma glucose, insulin, and triglyceride levels persisted for 14 weeks. Conclusions.-ln NIDDM patients, high-carbohydrate diets compared with high-monounsaturated-fat diets caused persistent deterioration of glycemic control and accentuation of hyperinsulinemia, as well as increased plasma triglyceride and very-low-density lipoprotein cholesterol levels, which may not be desirable.	UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX USA; UNIV TEXAS, SW MED CTR, GEN CLIN RES CTR, DALLAS, TX USA; STANFORD UNIV, SCH MED, DEPT INTERNAL MED, STANFORD, CA USA; UNIV MINNESOTA, DEPT MED, MINNEAPOLIS, MN USA; UNIV CALIF SAN DIEGO, DEPT MED, SAN DIEGO, CA 92103 USA; VET AFFAIRS MED CTR, SAN DIEGO, CA USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Stanford University; University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	GARG, A (corresponding author), UNIV TEXAS, SW MED CTR, CTR HUMAN NUTR, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000827, M01RR000400, M01RR000633] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR-00400, M01-RR-00827, M01-RR00633] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABBOTT WGH, 1989, DIABETES CARE, V12, P102, DOI 10.2337/diacare.12.2.102; ANDERSON JW, 1973, AM J CLIN NUTR, V26, P600, DOI 10.1093/ajcn/26.6.600; ANDERSON JW, 1977, AM J CLIN NUTR, V30, P402, DOI 10.1093/ajcn/30.3.402; [Anonymous], 1987, DIABETES CARE, V10, P126; ANTONIS A, 1961, LANCET, V1, P3; BERRY EM, 1992, AM J CLIN NUTR, V56, P394, DOI 10.1093/ajcn/56.2.394; BERTRAND E, 1993, ANN CARDIOL ANGEIOL, V42, P193; BJORNTORP P, 1978, METABOLISM, V27, P1853, DOI 10.1016/S0026-0495(78)80004-3; BONANOME A, 1991, AM J CLIN NUTR, V54, P586, DOI 10.1093/ajcn/54.3.586; BRUNZELL JD, 1974, DIABETES, V23, P138, DOI 10.2337/diab.23.2.138; BRUNZELL JD, 1971, NEW ENGL J MED, V284, P521, DOI 10.1056/NEJM197103112841004; BRUSSAARD JH, 1982, ATHEROSCLEROSIS, V42, P205, DOI 10.1016/0021-9150(82)90151-4; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; COULSTON AM, 1987, AM J MED, V82, P213, DOI 10.1016/0002-9343(87)90058-1; COULSTON AM, 1989, DIABETES CARE, V12, P94, DOI 10.2337/diacare.12.2.94; DREON DM, 1988, AM J CLIN NUTR, V47, P995, DOI 10.1093/ajcn/47.6.995; FLATT JP, 1987, ANN NY ACAD SCI, V499, P104, DOI 10.1111/j.1749-6632.1987.tb36202.x; FOLTIN RW, 1990, AM J CLIN NUTR, V52, P969, DOI 10.1093/ajcn/52.6.969; FONTBONNE A, 1989, DIABETOLOGIA, V32, P300, DOI 10.1007/BF00265546; FONTBONNE AM, 1991, DIABETES CARE, V14, P461, DOI 10.2337/diacare.14.6.461; GARG A, 1992, DIABETES, V41, P1278, DOI 10.2337/diabetes.41.10.1278; GARG A, 1992, DIABETES CARE, V15, P1572, DOI 10.2337/diacare.15.11.1572; GARG A, 1988, NEW ENGL J MED, V319, P829, DOI 10.1056/NEJM198809293191304; GRUNDY SM, 1986, NEW ENGL J MED, V314, P745, DOI 10.1056/NEJM198603203141204; HALES CN, 1963, BIOCHEM J, V88, P137, DOI 10.1042/bj0880137; Hanefeld M, 1991, NUTR METAB CARDIOVAS, V1, P135; HARRIS JA, 1919, CARNEGIE I WASHINGTO, V279; Himsworth HP, 1935, CLIN SCI, V2, P67; Himsworth HP, 1935, CLIN SCI, V2, P117; JONES DY, 1987, AM J CLIN NUTR, V45, P1451, DOI 10.1093/ajcn/45.6.1451; KEYS A, 1986, AM J EPIDEMIOL, V124, P903, DOI 10.1093/oxfordjournals.aje.a114480; KEYS A, 1970, CIRCULATION, V41, pI1; KLEIN RL, 1990, DIABETOLOGIA, V33, P299, DOI 10.1007/BF00403324; LEIBEL RL, 1992, AM J CLIN NUTR, V55, P350, DOI 10.1093/ajcn/55.2.350; LISSNER L, 1987, AM J CLIN NUTR, V46, P886, DOI 10.1093/ajcn/46.6.886; MATTSON FH, 1985, J LIPID RES, V26, P194; MENOTTI A, 1989, ANN MED, V21, P175, DOI 10.3109/07853898909149929; MENSINK RP, 1989, NEW ENGL J MED, V321, P436, DOI 10.1056/NEJM198908173210705; NETER J, 1985, APPLIED LINEAR STATI, P1021; PARILLO M, 1992, METABOLISM, V41, P1373, DOI 10.1016/0026-0495(92)90111-M; REAVEN GM, 1988, NEW ENGL J MED, V319, P862, DOI 10.1056/NEJM198809293191310; REAVEN GM, 1992, METABOLISM, V41, P16, DOI 10.1016/0026-0495(92)90088-R; RICCARDI G, 1984, DIABETOLOGIA, V26, P116, DOI 10.1007/BF00281117; RIVELLESE AA, 1990, DIABETES CARE, V13, P446, DOI 10.2337/diacare.13.4.446; ROMIEU I, 1988, AM J CLIN NUTR, V47, P406, DOI 10.1093/ajcn/47.3.406; SHEPHERD J, 1980, J LIPID RES, V21, P91; SIMPSON HCR, 1981, LANCET, V1, P1; STERN MP, 1992, DIABETES, V41, P484, DOI 10.2337/diabetes.41.4.484; STOUT RW, 1990, DIABETES CARE, V13, P631, DOI 10.2337/diacare.13.6.631; TUCKER LA, 1992, AM J CLIN NUTR, V56, P616, DOI 10.1093/ajcn/56.4.616; VEGA GL, 1982, J LIPID RES, V23, P811; WEST CE, 1990, AM J EPIDEMIOL, V131, P271, DOI 10.1093/oxfordjournals.aje.a115497; WEST KM, 1983, DIABETES CARE, V6, P361, DOI 10.2337/diacare.6.4.361; WOLF RN, 1983, J NUTR, V113, P1521, DOI 10.1093/jn/113.8.1521; 1988, DIABETES NUTR METAB, V1, P145; 1981, J CANN DIET ASS, V42, P110; 1982, MANUAL LABORATORY OP; 1987, DIABETES CARE, V10, P639	59	287	292	1	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 11	1994	271	18					1421	1428		10.1001/jama.271.18.1421	http://dx.doi.org/10.1001/jama.271.18.1421			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ693	7848401				2022-12-28	WOS:A1994NJ69300030
J	BELLINGER, DC; JONAS, RA; RAPPAPORT, LA; WYPIJ, D; WERNOVSKY, G; KUBAN, KCK; BARNES, PD; HOLMES, GL; HICKEY, PR; STRAND, RD; WALSH, AZ; HELMERS, SL; CONSTANTINOU, JE; CARRAZANA, EJ; MAYER, JE; HANLEY, FL; CASTANEDA, AR; WARE, JH; NEWBURGER, JW				BELLINGER, DC; JONAS, RA; RAPPAPORT, LA; WYPIJ, D; WERNOVSKY, G; KUBAN, KCK; BARNES, PD; HOLMES, GL; HICKEY, PR; STRAND, RD; WALSH, AZ; HELMERS, SL; CONSTANTINOU, JE; CARRAZANA, EJ; MAYER, JE; HANLEY, FL; CASTANEDA, AR; WARE, JH; NEWBURGER, JW			DEVELOPMENTAL AND NEUROLOGIC STATUS OF CHILDREN AFTER HEART-SURGERY WITH HYPOTHERMIC CIRCULATORY ARREST OR LOW-FLOW CARDIOPULMONARY BYPASS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TERM SEIZURE SUSCEPTIBILITY; CARDIAC-SURGERY; PROFOUND HYPOTHERMIA; BRAIN-DAMAGE; INFANTS; HYPOXIA; PERFORMANCE; MORPHOLOGY	Background. Deep hypothermia with either total circulatory arrest or low-flow cardiopulmonary bypass is used to support vital organs during heart surgery in infants. We compared the developmental and neurologic sequelae of these two strategies one year after surgery. Methods. Infants with D-transposition of the great arteries who underwent an arterial-switch operation were randomly assigned to a method of support consisting predominantly of circulatory arrest or a method consisting predominantly of low-flow bypass. Developmental and neurologic evaluations and magnetic resonance imaging (MRI) were performed at one year of age. Results. Of the 171 patients enrolled in the study, 155 were evaluated. After adjustment for the presence or absence of a ventricular septal defect, the infants assigned to circulatory arrest, as compared with those assigned to low-flow bypass, had a lower mean score on the Psychomotor Development Index of the Bayley Scales of Infant Development (a 6.5-point deficit, P=0.01) and a higher proportion had scores less than or equal to 80 (i.e., 2 SD or more below the population mean) (27 percent vs. 12 percent, P=0.02). The score on the Psychomotor Development Index was inversely related to the duration of circulatory arrest (P=0.02). The risk of neurologic abnormalities increased with the duration of circulatory arrest (P=0.04). The method of support was not associated with the prevalence of abnormalities on MRI scans of the brain, scores on the Mental Development Index of the Bayley Scale, or scores on a test of visual-recognition memory. Perioperative electroencephalographic seizure activity was associated with lower scores on the Psychomotor Development Index (P=0.002) and an increased likelihood of abnormalities on MRI scans of the brain (P<0.001). Conclusions. Heart surgery performed with circulatory arrest as the predominant support strategy is associated with a higher risk of delayed motor development and neurologic abnormalities at the age of one year than is surgery with low-flow bypass as the predominant support strategy.	CHILDRENS HOSP,DEPT CARDIOL,BOSTON,MA 02115; CHILDRENS HOSP,DEPT CARDIOVASC SURG,BOSTON,MA; CHILDRENS HOSP,DEPT NEUROL,BOSTON,MA; CHILDRENS HOSP,DEPT MED,BOSTON,MA; CHILDRENS HOSP,DEPT ANESTHESIA,BOSTON,MA; CHILDRENS HOSP,DEPT RADIOL,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT RADIOL,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health			Rappaport, Leonard/HGD-6175-2022; Carvalho, Lidiane/P-8446-2019; Hickey, Paul/GYV-3947-2022	Carvalho, Lidiane/0000-0002-2290-329X; Wypij, David/0000-0001-8367-8711; Kuban, Karl/0000-0001-5299-3567	NCRR NIH HHS [RR02172] Funding Source: Medline; NHLBI NIH HHS [HL41786] Funding Source: Medline; NICHD NIH HHS [P30-HD18655] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002172] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041786] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bayley N., 1969, BAYLEY SCALES INFANT; CLARKSON PM, 1980, CIRCULATION, V62, P855, DOI 10.1161/01.CIR.62.4.855; DICKINSON DF, 1979, ARCH DIS CHILD, V54, P1, DOI 10.1136/adc.54.1.1; Dubowitz LMS, 1981, CLIN DEV MED, V79; Dunn L.M., 2007, PEABODY PICTURE VOCA; FAGAN JF, 1986, PEDIATRICS, V78, P1021; Folkerth T L, 1975, Recent Adv Stud Cardiac Struct Metab, V10, P411; GILLES FH, 1973, J NEUROPATH EXP NEUR, V32, P179; GLAUSER TA, 1990, PEDIATRICS, V85, P991; GROSS SJ, 1992, PEDIATRICS, V90, P681; HAKAIKSE K, 1978, DEV MED CHILD NEUROL, V20, P62; Hollingshead A.B., 1975, 4 FACTOR INDEX SOCIA; HOLMES GL, 1991, EPILEPSIA, V32, pS14; JENSEN FE, 1991, ANN NEUROL, V29, P629, DOI 10.1002/ana.410290610; JENSEN FE, 1992, EPILEPSIA, V33, P971, DOI 10.1111/j.1528-1157.1992.tb01746.x; JENSEN FE, 1991, LIFE SCI, V49, P399, DOI 10.1016/0024-3205(91)90448-K; JONAS RA, 1993, ANN THORAC SURG, V56, P1467, DOI 10.1016/0003-4975(93)90732-W; KIRKLIN JW, 1993, CARDIAC SURGERY MORP, V1; LOMBROSO CT, 1993, J EPILEPSY, V6, P39, DOI 10.1016/S0896-6974(05)80010-6; MCCONNELL JR, 1990, AM J DIS CHILD, V144, P374, DOI 10.1001/archpedi.1990.02150270124041; MESSMER BJ, 1976, J THORAC CARDIOV SUR, V72, P495; MOLINA JE, 1984, J THORAC CARDIOV SUR, V87, P596; MURAOKA R, 1981, J THORAC CARDIOV SUR, V81, P364; NEWBURGER JW, 1993, NEW ENGL J MED, V329, P1057, DOI 10.1056/NEJM199310073291501; ODOHERTY N, 1986, NEUROLOGICAL EXAMINA; Paine R.S., 1966, CLIN DEV MED, V20-21; Prechtl HFR, 1977, CLIN DEV MED, V63; ROSS G, 1989, J DEV BEHAV PEDIATR, V10, P44; ROSS G, 1985, PEDIATRICS, V76, P885; STEVENSON JG, 1974, CIRCULATION, V50, P54; SUBRAMANIAN S, 1976, CHILD CONGENITAL HEA, P421; TERPLAN KL, 1976, J NEUROL, V212, P225, DOI 10.1007/BF00314525; TERPLAN KL, 1973, AM J DIS CHILD, V125, P176; TREASURE T, 1983, J THORAC CARDIOV SUR, V86, P761; ULVUND SE, 1984, HUM DEV, V27, P76, DOI 10.1159/000272905; Volpe J., 1995, NEUROLOGY NEWBORN, P279; WELLS FC, 1983, J THORAC CARDIOV SUR, V86, P823; WRIGHT JS, 1979, J THORAC CARDIOV SUR, V77, P466; Yi S.H., 1993, MANUAL BAYLEY SCALES; 1992, STATXACT TURBO STATI	40	522	536	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 2	1995	332	9					549	555		10.1056/NEJM199503023320901	http://dx.doi.org/10.1056/NEJM199503023320901			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ090	7838188				2022-12-28	WOS:A1995QJ09000001
J	DALESSANDRO, U; OLALEYE, BO; MCGUIRE, W; LANGEROCK, P; BENNETT, S; AIKINS, MK; THOMSON, MC; CHAM, MK; CHAM, BA; GREENWOOD, BM				DALESSANDRO, U; OLALEYE, BO; MCGUIRE, W; LANGEROCK, P; BENNETT, S; AIKINS, MK; THOMSON, MC; CHAM, MK; CHAM, BA; GREENWOOD, BM			MORTALITY AND MORBIDITY FROM MALARIA IN GAMBIAN CHILDREN AFTER INTRODUCTION OF AN IMPREGNATED BEDNET PROGRAM	LANCET			English	Article							AFRICA; NETS; STRATEGY; TRIAL	After the success of a controlled trial of insecticide-treated bednets in lowering child mortality, The Gambia initiated a National Insecticide Impregnated Bednet Programme (NlBP) in 1992 with the objective of introducing this form of malaria control into all large villages in The Gambia. Five areas (population 115 895) were chosen as sentinel sites for evaluation of the NlBP. During the first year of intervention a 25% reduction was achieved in ail-cause mortality in children 1-9 years old living in treated villages (rate ratio 0.75 [95% CI 0.57-0.98], p=0.04). If one area where the programme was ineffective was excluded, the was 38% (0.62 [0.46-0.83), p=0.001). A in rates of parasitaemia and high-density parasitaemia, an increase in mean packed-cell volume (rate ratio 0.75 [95% Cl 0.59-0.98], p=0.04) and an improvement in the nutritional status of children living in treated villages were also detected. In a country such as The Gambia, where nets were widely used and which has a good primary health care system, it is possible to achieve insecticide-treatment of bednets at a national level with a significant reduction in child mortality; but at a cost which the country cannot afford.	MRC LABS,BANJUL,GAMBIA; JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC INFECT DIS GRP,OXFORD,ENGLAND; LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON,ENGLAND; MINIST HLTH & SOCIAL WELF,BANJUL,GAMBIA	MRC Laboratory Molecular Biology; University of Oxford; University of London; London School of Hygiene & Tropical Medicine			D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009; McGuire, William/0000-0001-8572-3467				ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E; ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P37, DOI 10.1016/0035-9203(93)90174-O; ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P31, DOI 10.1016/0035-9203(93)90173-N; ALONSO PL, 1987, ANN TROP PAEDIATR, V7, P187, DOI 10.1080/02724936.1987.11748504; Bryan J.H., 1987, Parassitologia (Rome), V29, P221; DALESSANDRO U, 1994, B WORLD HEALTH ORGAN, V72, P391; EWBANK DC, 1993, INT J EPIDEMIOL, V22, pS8, DOI 10.1093/ije/22.Supplement_1.S8; GIGLIOLI G, 1972, B WORLD HEALTH ORGAN, V46, P181; GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q; GREENWOOD BM, 1983, T R SOC TROP MED S2, V87, P3; MAURITSEN RH, 1984, THESIS U WASHINGTON; SNOW RW, 1987, T ROY SOC TROP MED H, V81, P563, DOI 10.1016/0035-9203(87)90408-1; SNOW RW, 1988, T ROY SOC TROP MED H, V82, P212, DOI 10.1016/0035-9203(88)90414-2; SNOW RW, 1992, LANCET, V340, P351, DOI 10.1016/0140-6736(92)91414-4; THOMPSON BH, 1993, CIRCULATION, V88, P638; WATERLOW JC, 1977, B WORLD HEALTH ORGAN, V55, P489; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	17	326	330	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 25	1995	345	8948					479	483		10.1016/S0140-6736(95)90582-0	http://dx.doi.org/10.1016/S0140-6736(95)90582-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7861874				2022-12-28	WOS:A1995QH92900009
J	WHITE, MA; NICOLETTE, C; MINDEN, A; POLVERINO, A; VANAELST, L; KARIN, M; WIGLER, MH				WHITE, MA; NICOLETTE, C; MINDEN, A; POLVERINO, A; VANAELST, L; KARIN, M; WIGLER, MH			MULTIPLE RAS FUNCTIONS CAN CONTRIBUTE TO MAMMALIAN-CELL TRANSFORMATION	CELL			English	Article							ACTIVATED PROTEIN-KINASE; NIH 3T3 CELLS; MAP KINASE; GROWTH-FACTOR; HA-RAS; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; IN-VITRO; RAF-1; YEAST	We have developed a generalized approach, using two hybrid interactions, to isolate Ha-Ras effector loop mutations that separate the ability of Ha-Ras to interact with different downstream effecters. These mutations attenuate or eliminate Ha-ras(G12V) transformation of mammalian cells, but retain complementary activity, as demonstrated by synergistic induction of foci of growth-transformed cells, and by the ability to activate different downstream components. The transformation defect of Ha-ras(G12V, E37G) is rescued by a mutant, raf1, that restores interaction. These results indicate that multiple cellular components, including Raf1, are activated by Ha-Ras and contribute to Ha-Ras-induced mammalian cell transformation.	UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,PROGRAM BIOMED SCI,LA JOLLA,CA 92093	University of California System; University of California San Diego	WHITE, MA (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.			Wigler, Michael/0000-0003-4396-1971				BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARTEL PL, 1994, IN PRESS METH ENZYMO; BOLLAG G, 1994, ANN REV CELL BIOL, V7, P601; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CUADRADO A, 1993, ONCOGENE, V8, P2443; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE G, 1994, MOL CELL BIOL, V14, P4579, DOI 10.1128/MCB.14.7.4579; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1990, CANCER CELL-MON REV, V2, P377; NADINDAVIS SA, 1986, EMBO J, V5, P2963, DOI 10.1002/j.1460-2075.1986.tb04593.x; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; PORRAS A, 1994, J BIOL CHEM, V269, P12741; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; QURESHI SA, 1992, J BIOL CHEM, V267, P17635; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; Sambrook J, 1989, MOL CLONING LABORATO; Sherman F., 1986, METHODS YEAST GENETI; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SHIROUZU M, 1994, ONCOGENE, V9, P2153; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VANHEUSDEN GPH, 1992, FEBS LETT, V302, P145, DOI 10.1016/0014-5793(92)80426-H; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WIGLER M, 1988, COLD SPRING HARB SYM, V53, P649, DOI 10.1101/SQB.1988.053.01.074; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WOTTON D, 1993, J BIOL CHEM, V268, P17975; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052	58	632	638	0	7	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					533	541		10.1016/0092-8674(95)90507-3	http://dx.doi.org/10.1016/0092-8674(95)90507-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867061	Bronze			2022-12-28	WOS:A1995QJ60200005
J	STEBBINS, CE; BORUKHOV, S; ORLOVA, M; POLYAKOV, A; GOLDFARB, A; DARST, SA				STEBBINS, CE; BORUKHOV, S; ORLOVA, M; POLYAKOV, A; GOLDFARB, A; DARST, SA			CRYSTAL-STRUCTURE OF THE GREA TRANSCRIPT CLEAVAGE FACTOR FROM ESCHERICHIA-COLI	NATURE			English	Article							RNA-POLYMERASE; ELONGATION-FACTOR; PROTEIN; ERRORS; MAPS	TRANSCRIPTION elongation factors stimulate the activity of DNA-dependent RNA polymerases by increasing the overall elongation rate and the completion of RNA chains. One group of such factors, which includes Escherichia coli GreA, GreB and eukaryotic SII (TFIIS), acts by inducing hydrolytic cleavage of the transcript within the RNA polymerase, followed by relase of the 3'-terminal fragment(1-5). Here we report the crystal structure of GreA at 2.2 Angstrom resolution. The structure contains an amino-terminal domain consisting of an antiparallel alpha-helical coiled-coil dimer which extends into solution, reminiscent of the coiled coil in seryl-tRNA synthetases(6). A site near the tip of the coiled-coil 'finger' plays a direct role in the transcript cleavage reaction by contacting the 3'-end of the transcript. The structure exhibits an unusual asymmetric charge distribution which indicates the manner in which GreA interacts with the RNA polymerase elongation complex.	ROCKEFELLER UNIV,NEW YORK,NY 10021; PUBL HLTH RES INST CITY NEW YORK INC,NEW YORK,NY 10016	Rockefeller University			Borukhov, Sergei/AAF-3195-2019; Stebbins, Erec/N-2565-2018	Borukhov, Sergei/0000-0002-3517-3003; Stebbins, Erec/0000-0001-6229-5308				BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BORUKHOV S, 1991, J BIOL CHEM, V266, P23932; Brunger A.T., 1992, X PLOR VERSION 3 1 M; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DARST SA, 1994, J MOL BIOL, V242, P582, DOI 10.1006/jmbi.1994.1603; DRAPEAU GR, 1980, J BIOL CHEM, V255, P839; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; JACOBSON GR, 1973, J BIOL CHEM, V248, P6583; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; MARKS GL, 1992, NUCLEIC ACIDS RES, V20, P3785, DOI 10.1093/nar/20.14.3785; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REIONES D, 1992, J BIOL CHEM, V26, P3795; RICHARDSON JS, 1985, METHOD ENZYMOL, V115, P359; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SPARKOWSKI J, 1990, NUCLEIC ACIDS RES, V16, P6443; WOODY AYM, 1984, BIOCHEMISTRY-US, V23, P2843, DOI 10.1021/bi00308a001; Zhang K. Y. J., 1990, ACTA CRYST A, VA46, P41	26	116	121	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					636	640		10.1038/373636a0	http://dx.doi.org/10.1038/373636a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854424				2022-12-28	WOS:A1995QG99700061
J	GARDULF, A; ANDERSEN, V; BJORKANDER, J; ERICSON, D; FROLAND, SS; GUSTAFSON, R; HAMMARSTROM, L; JACOBSEN, MB; JONSSON, E; MOLLER, G; NYSTROM, T; SOEBERG, B; SMITH, CIE				GARDULF, A; ANDERSEN, V; BJORKANDER, J; ERICSON, D; FROLAND, SS; GUSTAFSON, R; HAMMARSTROM, L; JACOBSEN, MB; JONSSON, E; MOLLER, G; NYSTROM, T; SOEBERG, B; SMITH, CIE			SUBCUTANEOUS IMMUNOGLOBULIN REPLACEMENT IN PATIENTS WITH PRIMARY ANTIBODY DEFICIENCIES - SAFETY AND COSTS	LANCET			English	Article							INTRAVENOUS IMMUNOGLOBULIN; GAMMA-GLOBULIN; HOME TREATMENT; SELF-INFUSION; THERAPY	Immunoglobulins (IgG) as replacement therapy in primary antibody deficiencies can be given as intramuscular injections, or as intravenous or subcutaneous infusions. Our aims were to obtain information on the frequency of adverse systemic reactions during subcutaneous therapy, the occurrence and intensity of tissue reactions at the infusion sites, and serum IgG changes. Furthermore, we compared costs between the different replacement regimes. Our study included 165 patients (69 women, 96 men, aged 13-76 years) with primary hypogammaglobulinaemia or IgG-subclass deficiencies. Data were compiled from questionnaires filled in by the patients and from their medical records. 33168 subcutaneous infusions (27 030 in home therapy) had been given, 106 (of which 16 were at home) adverse systemic reactions (100 mild, 6 moderate) were recorded in 28 patients (17%). No severe or anaphylactoid reactions occurred. Despite large immunoglobulin volumes given during 434 patient years (28 480 infusions), no signs have been found that indicate the transmission of hepatitis virus. Transient tissue reactions occurred at the infusion sites but were not troublesome to most patients and we found significant increases in mean serum IgG. The use of subcutaneous instead of intravenous infusions at home would reduce the yearly cost per patient for the health-care sector by US $10 100 in Sweden alone. We conclude that subcutaneous administration of IgG is a safe and convenient method of providing immunoglobulins. We were able to reach serum IgG concentrations similar to those by the intravenous therapy and we found that the method could also be used successfully in patients with previous severe or anaphylactoid reactions to intramuscular injections, Lancet1995;345:365-69	HUDDINGE UNIV HOSP,KAROLINSKA INST,DEPT INTERNAL MED,HUDDINGE,SWEDEN; KAROLINSKA HOSP,KAROLINSKA INST,S-10401 STOCKHOLM,SWEDEN; SWEDISH COUNCIL TECHNOL ASSESSMENT HLTH CARE,STOCKHOLM,SWEDEN; KAROLINSKA INST,DEPT PHYS THERAPY,STOCKHOLM,SWEDEN; SAHLGRENS UNIV HOSP,ASTHMA & ALLERGY RES CTR,S-41345 GOTHENBURG,SWEDEN; RIGSHOSP,DEPT INTERNAL MED TTA,DK-2100 COPENHAGEN,DENMARK; NATL HOSP NORWAY,DEPT MED A,CLIN IMMUNOL & INFECT DIS SECT,OSLO,NORWAY	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Sahlgrenska University Hospital; Rigshospitalet; University of Copenhagen; University of Oslo; National Hospital Norway	GARDULF, A (corresponding author), HUDDINGE UNIV HOSP,KAROLINSKA INST,DEPT CLIN IMMUNOL,F71,S-14186 HUDDINGE,SWEDEN.			SMITH, C. I. Edvard/0000-0003-1907-3392				ASHIDA ER, 1986, J CLIN IMMUNOL, V6, P306, DOI 10.1007/BF00917331; BAYSTON K, 1985, NZ MED J, P652; BERGER M, 1980, ANN INTERN MED, V93, P55, DOI 10.7326/0003-4819-93-1-55; Bjorkander J, 1986, Monogr Allergy, V20, P157; BJORKANDER J, 1985, INFECTION, V13, P102, DOI 10.1007/BF01642867; CASTEELSVANDAELE M, 1990, NEW ENGL J MED, V323, P614; CHAPEL H, 1988, CLIN EXP IMMUNOL, V73, P160; DALAKAS MC, 1994, NEUROLOGY, V44, P223, DOI 10.1212/WNL.44.2.223; GARDULF A, 1993, CLIN EXP IMMUNOL, V92, P200; GARDULF A, 1991, LANCET, V338, P162; GARDULF A, IN PRESS J ADV NURS; LEAHY MF, 1986, LANCET, V1, P48; MARODI L, 1986, ORVOSI HETILAP, V27, P1621; MCMAHON SB, 1992, TRENDS NEUROSCI, V15, P497, DOI 10.1016/0166-2236(92)90102-E; OCHS HD, 1987, J INFECT DIS, V156, P652, DOI 10.1093/infdis/156.4.652; PAY PL, 1994, J HEPATOL, V21, P455; REMVIG L, 1991, J INTERN MED, V229, P73, DOI 10.1111/j.1365-2796.1991.tb00309.x; ROORD JJ, 1982, LANCET, V1, P689; ROSEN FS, 1992, IMMUNODEFIC REV, V3, P195; THOMAS MJ, 1993, LANCET, V342, P1432, DOI 10.1016/0140-6736(93)92798-X; UGAZIO AG, 1982, LANCET, V1, P226; UGAZIO AG, 1984, PROGR IMMUNODEFICIEN, V1, P441; VANDERMEER JMW, 1988, IMMUNOGLOBULINS, P71; WANIEWSKI J, 1994, J CLIN IMMUNOL, V14, P90, DOI 10.1007/BF01541341; WELCH MJ, 1983, J CLIN IMMUNOL, V3, P285, DOI 10.1007/BF00915353	25	223	227	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 11	1995	345	8946					365	369						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF722	7845120				2022-12-28	WOS:A1995QF72200014
J	KHAW, KT				KHAW, KT			TEMPERATURE AND CARDIOVASCULAR MORTALITY	LANCET			English	Editorial Material											KHAW, KT (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,CLIN GERONTOL UNIT,CAMBRIDGE,ENGLAND.							BOARDMAN B, 1991, FUEL POVERTY, P144; Curwen M., 1988, Population Trends, P17; Curwen M., 1991, HLTH TRENDS, V22, P169; GORDON DJ, 1989, J CLIN EPIDEMIOL, V41, P679; KUNST AE, 1993, AM J EPIDEMIOL, V137, P331, DOI 10.1093/oxfordjournals.aje.a116680; NEILD PJ, 1994, CLIN SCI, V86, P43, DOI 10.1042/cs0860043; ROGOT E, 1976, AM J EPIDEMIOL, V103, P565, DOI 10.1093/oxfordjournals.aje.a112261; WOODHOUSE PR, 1993, J HYPERTENS, V11, P1267; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1; WYNDHAM CH, 1978, S AFR MED J, V53, P1051; 1995, LANCET, V345, P353	11	60	63	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 11	1995	345	8946					337	338		10.1016/S0140-6736(95)90336-4	http://dx.doi.org/10.1016/S0140-6736(95)90336-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF722	7845112				2022-12-28	WOS:A1995QF72200004
J	DANGL, JL				DANGL, JL			PIECE DE RESISTANCE - NOVEL CLASSES OF PLANT-DISEASE RESISTANCE GENES	CELL			English	Review							INSTABILITY; TOMATO; MAIZE				DANGL, JL (corresponding author), MAX DELBRUCK LAB,CARL LINNE WEG 10,D-50829 COLOGNE,GERMANY.							BENNETZEN JL, 1988, NATURE, V332, P369, DOI 10.1038/332369a0; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; DANGL JL, 1992, PLANT J, V2, P3, DOI 10.1111/j.1365-313X.1992.00003.x; DELORENZO G, 1994, BIOCHEM SOC T, V22, P394, DOI 10.1042/bst0220394; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; ELLIS JG, 1995, IN PRESS P NATL ACAD; FREIALDENHOVEN A, 1994, PLANT CELL, V6, P983; GODIARD L, 1994, CURR OPIN GENET DEV, V4, P662, DOI 10.1016/0959-437X(94)90132-M; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; HAMMONDKOSACK KE, 1994, PLANT CELL, V6, P361, DOI 10.2307/3869756; HAMMONDKOSACK KE, 1994, P NATL ACAD SCI USA, V91, P10445, DOI 10.1073/pnas.91.22.10445; JONES DA, 1993, MOL PLANT MICROBE IN, V6, P348, DOI 10.1094/MPMI-6-348; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; LAMB CJ, 1994, CELL, V76, P419, DOI 10.1016/0092-8674(94)90106-6; LAWRENCE G, 1993, PLANT J, V4, P659, DOI 10.1046/j.1365-313X.1993.04040659.x; LAWRENCE GJ, 1994, TRENDS MICROBIOL, V2, P363; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MARTIN GB, 1994, PLANT CELL, V6, P1543, DOI 10.1105/tpc.6.11.1543; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; NASRALLAH JB, 1994, SCIENCE, V266, P1505, DOI 10.1126/science.266.5190.1505; SALMERON JM, 1994, PLANT CELL, V6, P511, DOI 10.1105/tpc.6.4.511; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SUDUPAK MA, 1993, GENETICS, V133, P119; TRAUT TW, 1994, EUR J BIOCHEM, V229, P9; WALKER JC, 1993, PLANT J, V3, P451, DOI 10.1046/j.1365-313X.1993.t01-23-00999.x; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6	30	94	103	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					363	366		10.1016/0092-8674(95)90485-9	http://dx.doi.org/10.1016/0092-8674(95)90485-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859277	Bronze			2022-12-28	WOS:A1995QG47000001
J	SPITAL, A				SPITAL, A			MANDATED CHOICE - A PLAN TO INCREASE PUBLIC COMMITMENT TO ORGAN DONATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRESUMED CONSENT; PROCUREMENT; DONORS; SHORTAGE	Objectives.-To estimate the impact of mandated choice-a system that requires competent adults to decide prospectively whether or not they wish to be organ donors when they die-on public commitment to organ donation; and to explore who is best suited to provide consent-the family or the individual? Design.-A national, random-digit telephone survey conducted by the Gallup Organization in July 1993. Participants.-A representative sample (n=1002) of adults (aged 18 years and older) living in homes with telephones in the continental United States. Results.-Although the majority of respondents had given at least some thought to organ donation, only 25% had carefully considered this issue. Overall, 30% had decided to donate, but 58% were undecided and only 38% had made their wishes known to a family member. Yet the vast majority (82%) believes that the best way to obtain consent is for each adult to decide for himself or herself, rather than leaving this decision for the family. Under mandated choice, which is designed to encourage such self-determination, 63% would sign up to donate, 24% would not, and 13% were unsure. Conclusions.-Only a small fraction of the US public is currently committed to organ donation and relatively few people have carefully considered and communicated their wishes regarding this important issue. Therefore, the difficult question of consent is often left for the family. Yet most people believe that ideally all adults should answer this question for themselves, in contrast to our present family-oriented approach, but consistent with the design of mandated choice. If mandated choice became law, it appears that most adults would sign up to donate, thereby increasing the pool of desperately needed committed donors.	UNIV ROCHESTER,SCH MED,ROCHESTER,NY	University of Rochester								COHEN C, 1992, TRANSPLANT P, V24, P2168; CUTLER JA, 1993, TRANSPLANTATION, V56, P225; Dennis J Michael, 1994, UNOS Update, V10, P16; EVANS RW, 1992, JAMA-J AM MED ASSOC, V267, P239, DOI 10.1001/jama.267.2.239; GARRISON RN, 1991, SURG GYNECOL OBSTET, V173, P391; ISERSON KV, 1993, JAMA-J AM MED ASSOC, V270, P1930, DOI 10.1001/jama.1993.03510160048014; KATZ BJ, 1984, BEVERLY HILLS BAR J, V18, P152; KENNEDY AP, 1992, J TRAUMA, V33, P516, DOI 10.1097/00005373-199210000-00005; KOKKEDEE W, 1992, SOC SCI MED, V35, P177, DOI 10.1016/0277-9536(92)90164-L; LEE PP, 1992, CORNEA, V11, P102, DOI 10.1097/00003226-199203000-00002; LEE PP, 1986, SURGERY, V100, P867; MACKERSIE RC, 1991, ANN SURG, V213, P143, DOI 10.1097/00000658-199102000-00009; MANNINEN DL, 1985, JAMA-J AM MED ASSOC, V253, P3111, DOI 10.1001/jama.253.21.3111; OVERCAST TD, 1984, JAMA-J AM MED ASSOC, V251, P1559, DOI 10.1001/jama.251.12.1559; PROTTAS JM, 1991, J HEALTH POLIT POLIC, V16, P121, DOI 10.1215/03616878-16-1-121; SPITAL A, 1993, CLIN TRANSPLANT, V7, P525; SPITAL A, 1992, ARCH INTERN MED, V152, P2421, DOI 10.1001/archinte.152.12.2421; SPITAL A, 1991, N ENGL JMED, V25, P1243; VEATCH RM, 1991, NEW ENGL J MED, V325, P1246, DOI 10.1056/NEJM199110243251711; 1990, HARVARD LAW REV, V103, P1614; 1994, UNOS UPDATE, V10, P34; 1991, SOLVING ORGAN SHORTA; 1994, JAMA-J AM MED ASSOC, V272, P809	23	53	53	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	1995	273	6					504	506		10.1001/jama.273.6.504	http://dx.doi.org/10.1001/jama.273.6.504			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE498	7837372				2022-12-28	WOS:A1995QE49800040
J	HERSKOWITZ, I				HERSKOWITZ, I			MAP KINASE PATHWAYS IN YEAST - FOR MATING AND MORE	CELL			English	Review							SIGNAL-TRANSDUCTION PATHWAY; PHEROMONE RESPONSE PATHWAY; PUTATIVE PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; FILAMENTOUS GROWTH; USTILAGO-MAYDIS; GENE; HOMOLOG				HERSKOWITZ, I (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; AMMERER G, 1994, CURR OPIN GENET DEV, V4, P90, DOI 10.1016/0959-437X(94)90096-5; ANTONSSON B, 1994, J BIOL CHEM, V269, P16821; BANNO H, 1993, MOL CELL BIOL, V13, P4745, DOI 10.1128/MCB.13.8.4745; BANUETT F, 1994, GENE DEV, V8, P1367, DOI 10.1101/gad.8.12.1367; BANUETT F, 1992, TRENDS GENET, V8, P174, DOI 10.1016/0168-9525(92)90091-H; BANUETT F, 1989, P NATL ACAD SCI USA, V86, P5878, DOI 10.1073/pnas.86.15.5878; BANUETT F, 1994, EXP MYCOL, V18, P247, DOI 10.1006/emyc.1994.1024; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOLKER M, 1992, CELL, V68, P441, DOI 10.1016/0092-8674(92)90182-C; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CHOI KY, 1994, CELL, V78, P499; COSTIGAN C, 1994, MOL CELL BIOL, V14, P2391, DOI 10.1128/MCB.14.4.2391; COSTIGAN C, 1992, MOL CELL BIOL, V12, P1162, DOI 10.1128/MCB.12.3.1162; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; ELION EA, 1991, COLD SPRING HARB SYM, V56, P41; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; ERREDE B, 1993, NATURE, V362, P261, DOI 10.1038/362261a0; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FIELDS S, 1987, MOL CELL BIOL, V7, P3818, DOI 10.1128/MCB.7.10.3818; FIELDS S, 1989, NATURE, V15, P270; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; HASSON MS, 1994, MOL CELL BIOL, V14, P1054, DOI 10.1128/MCB.14.2.1054; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; KRISAK L, 1994, GENE DEV, V8, P2151, DOI 10.1101/gad.8.18.2151; KRON SJ, 1994, MOL BIOL CELL, V5, P1003, DOI 10.1091/mbc.5.9.1003; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEBERER E, 1993, MOL GEN GENET, V241, P241, DOI 10.1007/BF00284675; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEE KS, 1992, MOL CELL BIOL, V12, P172, DOI 10.1128/MCB.12.1.172; LEVIN DE, 1994, CELL MOL BIOL RES, V40, P229; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LEVIN DE, 1994, CURR BIOL, V4, P990, DOI 10.1016/S0960-9822(00)00223-2; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; MACKAY V, 1974, GENETICS, V76, P255; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTIN H, 1993, MOL GEN GENET, V241, P177, DOI 10.1007/BF00280215; MAZZONI C, 1993, J CELL BIOL, V123, P1821, DOI 10.1083/jcb.123.6.1821; MITCHELL AP, 1994, MICROBIOL REV, V58, P56, DOI 10.1128/MMBR.58.1.56-70.1994; MUKAI Y, 1993, MOL CELL BIOL, V13, P2050, DOI 10.1128/MCB.13.4.2050; NEIMAN AM, 1993, TRENDS GENET, V9, P390, DOI 10.1016/0168-9525(93)90139-9; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; NEIMAN AM, 1994, P NATL ACAD SCI USA, V91, P3398, DOI 10.1073/pnas.91.8.3398; OBARA T, 1991, P NATL ACAD SCI USA, V88, P5877, DOI 10.1073/pnas.88.13.5877; OGITA K, 1990, P NATL ACAD SCI USA, V87, P5011, DOI 10.1073/pnas.87.13.5011; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PARAVICINI G, 1992, MOL CELL BIOL, V12, P4896, DOI 10.1128/MCB.12.11.4896; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PRINTEN JA, 1994, GENETICS, V138, P609; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SNETSELAAR KM, 1993, EXP MYCOL, V17, P345, DOI 10.1006/emyc.1993.1033; SPELLIG T, 1994, EMBO J, V13, P1620, DOI 10.1002/j.1460-2075.1994.tb06425.x; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; TORRES L, 1991, MOL MICROBIOL, V5, P2845, DOI 10.1111/j.1365-2958.1991.tb01993.x; TRUEHEART J, 1992, J BACTERIOL, V174, P7831, DOI 10.1128/JB.174.23.7831-7833.1992; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VANAELST L, 1995, IN PRESS COLD SPRING, V59; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WATANABE M, 1994, J BIOL CHEM, V269, P16829; XU HP, 1994, MOL CELL BIOL, V14, P50, DOI 10.1128/MCB.14.1.50; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166; ZHOU Z, 1993, MOL CELL BIOL, V13, P1069	85	881	915	0	39	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 27	1995	80	2					187	197		10.1016/0092-8674(95)90402-6	http://dx.doi.org/10.1016/0092-8674(95)90402-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7834739	Bronze			2022-12-28	WOS:A1995QD92400002
J	WARREN, RW; NAGY, L; SELEGUE, J; GATES, J; CARROLL, S				WARREN, RW; NAGY, L; SELEGUE, J; GATES, J; CARROLL, S			EVOLUTION OF HOMEOTIC GENE-REGULATION AND FUNCTION IN FLIES AND BUTTERFLIES	NATURE			English	Article							BITHORAX-COMPLEX; DROSOPHILA; EXPRESSION	IT has been proposed that the evolution of homeotic genes parallels, and to some degree directs, the evolution of segment diversity in the myriapod-insect lineage(1-3). But the discovery of discrete Antennapedia complex (ANT-C) and bithorax complex (BX-C) gene members in crustacea(4) chelicerates(5), annelids(6-8) and various insects(9-11), as well as in vertebrates(12), indicates that the expansion and diversification of homeotic genes preceded the diversification of arthropods and insects. How, then, have these genes influenced the evolution of body plans? To address this question, we now examine homeotic gene expression and regulation in butterflies (Lepidoptera), which, unlike flies, possess larval abdominal limbs and two pairs of wings. We show that the difference in larval limb number between these insects results from striking changes in BX-C gene regulation in the butterfly abdomen, and we deduce that the wing-patterning genes regulated by Ultrabithorax have diverged in the course of butterfly and fly evolution. These findings have general implications for the role of homeotic genes in animal evolution.	UNIV WISCONSIN, HOWARD HUGHES MED INST, MADISON, WI 53706 USA; UNIV WISCONSIN, MOLEC BIOL LAB, MADISON, WI 53706 USA	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								AKAM M, 1988, DEVELOPMENT, V104, P123; AKAM M, IN PRESS DEVELOPMENT; AVEROF M, 1993, CURR BIOL, V3, P73, DOI 10.1016/0960-9822(93)90158-K; Bateson W., 1894, MAT STUDY VARIATION, DOI [10.5962/bhl.title.1348, DOI 10.5962/BHL.TITLE.1348]; BEACHY PA, 1985, NATURE, V313, P545, DOI 10.1038/313545a0; BEEMAN RW, 1989, DEV BIOL, V133, P196, DOI 10.1016/0012-1606(89)90311-4; BIRKETSMITH SJR, 1984, PROLEGS LEGS WINGS I; CARTWRIGHT P, 1993, MOL PHYLOGENET EVOL, V2, P185, DOI 10.1006/mpev.1993.1019; DICK MH, 1994, MOL PHYLOGENET EVOL, V3, P146, DOI 10.1006/mpev.1994.1017; GARCIABELLIDO A, 1977, AM ZOOL, V17, P613; GARCIAFERNANDEZ J, 1994, NATURE, V370, P563, DOI 10.1038/370563a0; GOLDSCHMIDT RB, 1940, MATERIAL BASIS EVOLU; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KARCH F, 1985, CELL, V43, P81, DOI 10.1016/0092-8674(85)90014-5; KELSH R, 1994, DEV GENET, V15, P19, DOI 10.1002/dvg.1020150104; KELSH R, 1993, DEVELOPMENT, V117, P293; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LEWIS EB, 1963, AM ZOOL, V3, P33; MACIAS A, 1990, DEVELOPMENT, V110, P1197; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MORATA G, 1976, ROUX ARCH DEV BIOL, V179, P125, DOI 10.1007/BF00848298; PANGANIBAN G, 1994, CURR BIOL, V4, P671, DOI 10.1016/S0960-9822(00)00151-2; Raff R.A., 1983, EMBRYOS GENES EVOLUT; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHANKLAND M, 1991, DEVELOPMENT, P29; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; STUART JJ, 1993, DEVELOPMENT, V117, P233; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; WHITE RAH, 1984, CELL, V39, P163, DOI 10.1016/0092-8674(84)90202-2; WYSOCKADILLER JW, 1989, NATURE, V341, P760, DOI 10.1038/341760a0	31	162	168	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 1	1994	372	6505					458	461		10.1038/372458a0	http://dx.doi.org/10.1038/372458a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7840822				2022-12-28	WOS:A1994PV01200055
J	MACKOWIAK, PA				MACKOWIAK, PA			FEVER - BLESSING OR CURSE - A UNIFYING HYPOTHESIS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; IFN-GAMMA; MONOCLONAL-ANTIBODIES; BORRELIA-BURGDORFERI; ESCHERICHIA-COLI; INFECTION; INTERLEUKIN-1; CYTOKINES; SURVIVAL	Considerable data indicate that fever and its mediators have the capacity both to potentiate and to inhibit resistance to infection. It is difficult to reconcile these apparently contradictory observations if they are viewed solely from the standpoint of the individual. However, when viewed from the perspective of the species, both fever's salutary effects on mild to moderately severe infections and its pernicious influence on fulminating infections become teleologically plausible. If one accepts preservation of the species, rather than survival of the individual, as the essence of evolution, fever and its mediators might have evolved as mechanisms both for accelerating recovery of individuals from localized or mild to moderately severe systemic infections in the interest of continued propagation of the species and for hastening the elimination of fulminantly infected individuals who pose a threat of epidemic disease to the species.	UNIV MARYLAND, SCH MED, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	MACKOWIAK, PA (corresponding author), DEPT VET AFFAIRS, MED CTR, 10 N GREENE ST, ROOM 5D145, BALTIMORE, MD 21201 USA.							ALEXANDER HR, 1991, J CLIN INVEST, V88, P34, DOI 10.1172/JCI115298; BELL JF, 1974, INFECT IMMUN, V10, P510, DOI 10.1128/IAI.10.3.510-515.1974; BERNHEIM HA, 1976, SCIENCE, V193, P237, DOI 10.1126/science.935867; BERNHEIM HA, 1978, BRIT J EXP PATHOL, V59, P76; BIRX DL, 1990, BLOOD, V76, P2303; BRYANT RE, 1971, ARCH INTERN MED, V127, P120, DOI 10.1001/archinte.127.1.120; CARMICHAEL LE, 1969, J INFECT DIS, V120, P664, DOI 10.1093/infdis/120.6.664; COVERT JB, 1977, NATURE, V267, P43, DOI 10.1038/267043a0; CURFS JHAJ, 1990, J EXP MED, V172, P1287, DOI 10.1084/jem.172.5.1287; DINARELLO CA, 1991, J INFECT DIS, V163, P1177, DOI 10.1093/infdis/163.6.1177; DINARELLO CA, 1991, FEVER BASIC MECHANIS, P23; DORAN TF, 1989, J PEDIATR-US, V114, P1045, DOI 10.1016/S0022-3476(89)80461-5; FEDUCHI E, 1991, VIROLOGY, V180, P822, DOI 10.1016/0042-6822(91)90100-P; FREUDENBERG MA, 1991, INFECT IMMUN, V59, P2110, DOI 10.1128/IAI.59.6.2110-2115.1991; FURUUCHI S, 1976, INFECT IMMUN, V13, P990, DOI 10.1128/IAI.13.3.990-992.1976; GIBSON RL, 1991, AM REV RESPIR DIS, V143, P598, DOI 10.1164/ajrccm/143.3.598; GRAHAM NMH, 1990, J INFECT DIS, V162, P1277, DOI 10.1093/infdis/162.6.1277; GREISMAN SE, 1991, FEVER BASIC MECH MAN, P143; HABICHT GS, 1991, J INFECT DIS, V164, P568, DOI 10.1093/infdis/164.3.568; HEDGES S, 1991, INFECT IMMUN, V59, P421, DOI 10.1128/IAI.59.1.421-427.1991; HEINZEL FP, 1990, J IMMUNOL, V145, P2920; HENRICSON BE, 1991, INFECT IMMUN, V59, P1188, DOI 10.1128/IAI.59.3.1188-1191.1991; JACOBS RF, 1990, SCAND J INFECT DIS, P7; JENKINS JK, 1991, AM REV RESPIR DIS, V143, P155, DOI 10.1164/ajrccm/143.1.155; JOHNSON J, 1991, AM REV RESPIR DIS, V144, P179, DOI 10.1164/ajrccm/144.1.179; KLUGER MJ, 1975, SCIENCE, V188, P166, DOI 10.1126/science.1114347; Kluger MJ., 1991, FEVER BASIC MECH MAN, P105; KUHN LR, 1949, P SOC EXP BIOL MED, V71, P341, DOI 10.3181/00379727-71-17185; Kuhn LR, 1939, P SOC EXP BIOL MED, V41, P573; LIEW FY, 1990, J IMMUNOL, V145, P4306; LWOFF A, 1959, BACTERIOL REV, V23, P109, DOI 10.1128/MMBR.23.3.109-124.1959; MACKOWIAK PA, 1980, AM J MED SCI, V280, P73, DOI 10.1097/00000441-198009000-00002; MELLOUK S, 1991, J IMMUNOL, V146, P3971; NAOTUNNE TD, 1991, J EXP MED, V173, P523, DOI 10.1084/jem.173.3.523; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; OPAL SM, 1991, J CLIN INVEST, V88, P885, DOI 10.1172/JCI115390; OVERBEEK BP, 1991, REV INFECT DIS, V13, P751; RADOLF JD, 1991, J IMMUNOL, V147, P1968; Rich AR, 1936, B JOHNS HOPKINS HOSP, V59, P171; RISEMAN B, 1956, J CLIN INVEST, V35, P940; ROOK GAW, 1991, TUBERCLE, V72, P13, DOI 10.1016/0041-3879(91)90019-O; SAEZLLORENS X, 1991, J INFECT DIS, V163, P1267, DOI 10.1093/infdis/163.6.1267; SAMBHI SK, 1991, P NATL ACAD SCI USA, V88, P4025, DOI 10.1073/pnas.88.9.4025; SCHMIDT JR, 1960, J INFECT DIS, V107, P356, DOI 10.1093/infdis/107.3.356; STANLEY ED, 1975, JAMA-J AM MED ASSOC, V231, P1248, DOI 10.1001/jama.231.12.1248; STARNES HF, 1990, J IMMUNOL, V145, P4185; STRIJP HAG, 1991, IMMUNOLOGY, V73, P77; TOMS GL, 1977, BRIT J EXP PATHOL, V58, P444; TORRICO F, 1991, J IMMUNOL, V146, P3626; UNGAR BLP, 1991, J IMMUNOL, V147, P1014; VOGELS MTE, 1992, ANTIMICROB AGENTS CH, V36, P1; WAKABAYASHI G, 1991, J CLIN INVEST, V87, P1925, DOI 10.1172/JCI115218; WALKER DL, 1958, J IMMUNOL, V80, P39; WEINSTEIN MP, 1978, AM J MED, V64, P592, DOI 10.1016/0002-9343(78)90578-8; WOODMAN JP, 1991, J IMMUNOL, V147, P2019	55	69	72	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1994	120	12					1037	1040		10.7326/0003-4819-120-12-199406150-00010	http://dx.doi.org/10.7326/0003-4819-120-12-199406150-00010			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ964	7832829				2022-12-28	WOS:A1994NQ96400010
J	SALLER, DN; LESSER, KB; HARREL, U; ROGERS, BB; OYER, CE				SALLER, DN; LESSER, KB; HARREL, U; ROGERS, BB; OYER, CE			THE CLINICAL UTILITY OF THE PERINATAL AUTOPSY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To evaluate the clinical utility of the perinatal autopsy in determining the cause of a perinatal death. Design.-Retrospective observational survey. Setting.-University-affiliated, private, tertiary care hospital, limited to obstetrics, gynecology, and neonatology. Subjects.-All fetal deaths and neonatal deaths from 1990 and 1991 at Women and Infants Hospital, Providence, RI, were reviewed. Fetal deaths with a gestational age of less than 20 weeks and neonatal deaths occurring more than 48 hours after birth were excluded. Main Outcome Measures.-A clinical medical record review assessed the clinical diagnosis. Pathology records were reviewed independently. The clinical and autopsy diagnoses were compared and categorized as follows: (1) confirm (clinical and autopsy diagnoses concordant); (2) change (clinical and autopsy diagnoses discordant); (3) add (significant unexpected findings noted on the autopsy although the clinical diagnosis was not altered); (4) autopsy inconclusive; (5) autopsy not done or not available. Results.-Of 168 perinatal deaths, an autopsy was not obtained in 26.2% and was inconclusive in 24.2% of cases with an autopsy. Of 94 patients with conclusive autopsies, in 55.3%, the pathologic diagnosis confirmed the clinical diagnosis, and in 44.7%, it changed or significantly added to the clinical diagnosis. Conclusions.-These findings support the clinical relevance of the perinatal autopsy. As few published reports directly address the specific yield of the autopsy among fetal and neonatal deaths, these results may be useful in counseling patients who are considering a perinatal autopsy.	UNIV ROCHESTER,STRONG MEM HOSP,SCH MED,DEPT PEDIAT,ROCHESTER,NY 14642; BROWN UNIV,WOMEN & INFANTS HOSP,SCH MED,DEPT OBSTET & GYNECOL,PROVIDENCE,RI; BROWN UNIV,WOMEN & INFANTS HOSP,SCH MED,DEPT PATHOL,PROVIDENCE,RI; UNIV ARIZONA,DEPT OBSTET & GYNECOL,TUCSON,AZ; CHILDRENS MED CTR,DEPT PATHOL,DALLAS,TX 75235	University of Rochester; Brown University; Women & Infants Hospital Rhode Island; Brown University; Women & Infants Hospital Rhode Island; University of Arizona	SALLER, DN (corresponding author), UNIV ROCHESTER,STRONG MEM HOSP,SCH MED,DEPT OBSTET & GYNECOL,DIV MATERNAL FETAL MED,BOX 8668,ROCHESTER,NY 14642, USA.							CUNNINGHAM FG, 1993, WILLIAMS OBSTETRICS, P5; FRETTS RC, 1992, OBSTET GYNECOL, V79, P35; GOLDMAN L, 1983, NEW ENGL J MED, V308, P1000, DOI 10.1056/NEJM198304283081704; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; LUNDBERG GD, 1994, JAMA-J AM MED ASSOC, V271, P317, DOI 10.1001/jama.1994.03510280079038; MCKUSICK VA, 1992, MENDELIAN INHERITANC, pR21; MEIER PR, 1986, OBSTET GYNECOL, V67, P349; RAO MG, 1990, AM J CLIN PATHOL, V93, P486, DOI 10.1093/ajcp/93.4.486; SHEN-SCHWARZ S, 1989, Pediatric Pathology, V9, P1	9	83	86	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	1995	273	8					663	665		10.1001/jama.273.8.663	http://dx.doi.org/10.1001/jama.273.8.663			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG748	7844878				2022-12-28	WOS:A1995QG74800033
J	MADICO, G; GILMAN, RH; CHECKLEY, W; CABRERA, L; KOHLSTADT, I; KACENA, K; DIAZ, JF; BLACK, R				MADICO, G; GILMAN, RH; CHECKLEY, W; CABRERA, L; KOHLSTADT, I; KACENA, K; DIAZ, JF; BLACK, R			COMMUNITY INFECTION RATIO AS AN INDICATOR FOR TUBERCULOSIS-CONTROL	LANCET			English	Article								The epidemiology of tuberculosis remains poorly understood. We investigated the relative importance of within-household and community transmission of infection among children aged 6 months to 14 years living in a Peruvian shanty-town. The prevalence of Mycobacterium tuberculosis exposure among 175 contact children (sharing a household with a person who had confirmed pulmonary tuberculosis) and 382 control children (living in nearby households free of active tuberculosis) was defined as the proportion of children with a positive purified protein derivative (PPD) skin-test. 97 (55%) contact children and 129 (34%) controls were PPD positive. Living in a contact household (odds ratio 1.74, 95% CI 1.11-2.73) and age (1.11, 1.06-1.18) were significant risk factors for PPD positivity. We calculated the community infection ratio (CIR) as the odds ratio of PPD-positive controls to PPD-positive contacts: [GRAPHICS] A low CIR therefore suggests mainly household spread of infection, whereas a high value suggests frequent transmission outside the household. The adjusted odds ratio (for age, sex, within-household correlation, and household size) was 0.40 (95% CI 0.26-0.64), compared with values of 0.18-0.37 in studies elsewhere. Currently recommended tuberculosis control strategies are suitable for areas with low CIRs. Different strategies may be needed for areas, such as that we studied, with high values.	AB PRISMA,LIMA,PERU; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INT HLTH & BIOSTAT,BALTIMORE,MD 21205	Johns Hopkins University				Madico, Guillermo/0000-0002-8323-8262; Black, Robert/0000-0001-9926-7984; Checkley, William/0000-0003-1106-8812				ASPIN J, 1953, Tubercle, V34, P20, DOI 10.1016/S0041-3879(53)80042-5; Brown K. H., 1981, Nutrition Research, V1, P33, DOI 10.1016/S0271-5317(81)80006-1; CAREY V, 1993, BIOMETRIKA, V80, P517, DOI 10.2307/2337173; COMSTOCK GW, 1967, AM REV RESPIR DIS, V95, P935; DESPREZ R, 1990, PRINCIPLES PRACTICE, P1880; FLEISS JL, 1991, STATISTICAL METHODS, P76; GETCHELL WS, 1992, AM J TROP MED HYG, V47, P721, DOI 10.4269/ajtmh.1992.47.721; GLASSROTH J, 1980, NEW ENGL J MED, V302, P1441, DOI 10.1056/NEJM198006263022603; GRYZBOWSKI S, 1975, B INT UNION TUBERC, V50, P90; LIANG KY, 1993, ANNU REV PUBL HEALTH, V14, P43, DOI 10.1146/annurev.pu.14.050193.000355; MENZIES R, 1992, AM REV RESPIR DIS, V145, P621, DOI 10.1164/ajrccm/145.3.621; NARAIN SR, 1966, B WORLD HEALTH ORGAN, V34, P639; QAQISH BF, 1992, BIOMETRICS, V48, P939, DOI 10.2307/2532359; ROSE CE, 1979, AM REV RESPIR DIS, V119, P603; SHAW JB, 1954, AM REV TUBERC PULM, V69, P724; STYBLO K, 1989, REV INF DIS S2, V2, pS339; SUDRE P, 1992, B WORLD HEALTH ORGAN, V70, P149; WATERLOW JC, 1977, B WORLD HEALTH ORGAN, V55, P489	18	44	44	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					416	419		10.1016/S0140-6736(95)90401-8	http://dx.doi.org/10.1016/S0140-6736(95)90401-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853950				2022-12-28	WOS:A1995QG90400009
J	KURZROCK, R; COHEN, PR				KURZROCK, R; COHEN, PR			ERYTHEMA-GYRATUM-REPENS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note									UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MED SPECIALTIES,DERMATOL SECT,HOUSTON,TX; UNIV TEXAS,SCH MED,DEPT DERMATOL,HOUSTON,TX; UNIV TEXAS,SCH MED,DEPT PATHOL,HOUSTON,TX	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas System	KURZROCK, R (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CLIN INVEST,BOX 302,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.		Kurzrock, Razelle/AAU-9782-2020					BARBER PV, 1978, BRIT J DERMATOL, V98, P465; BARRIERE H, 1978, ANN DERMATOL VENER, V105, P319; BOYD AS, 1992, J AM ACAD DERMATOL, V26, P757, DOI 10.1016/0190-9622(92)70107-Q; CHEESBROUGH MJ, 1985, CLIN EXP DERMATOL, V10, P466, DOI 10.1111/j.1365-2230.1985.tb00606.x; GAMMEL JA, 1952, AMA ARCH DERM SYPH, V66, P494, DOI 10.1001/archderm.1952.01530290070010; HOLT PJA, 1977, BRIT J DERMATOL, V96, P343, DOI 10.1111/j.1365-2133.1977.tb07127.x; INGBER A, 1983, Z HAUTKRANKHEITEN, V58, P1298; OLSEN TG, 1984, CUTIS, V34, P351; TYRING SK, 1993, CLIN DERMATOL, V11, P135, DOI 10.1016/0738-081X(93)90110-X	9	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	1995	273	7					594	594		10.1001/jama.273.7.594	http://dx.doi.org/10.1001/jama.273.7.594			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF686	7837395				2022-12-28	WOS:A1995QF68600032
J	GABUNIA, L; VEKUA, A				GABUNIA, L; VEKUA, A			A PLIOPLEISTOCENE HOMINID FROM DMANISI, EAST GEORGIA, CAUCASUS	NATURE			English	Article								ARCHAEOLOGICAL excavations at the mediaeval site of Dmanisi (East Georgia) revealed that the town was built on a series of deposits yielding Late Villafranchian mammalian fossils and led to the discovery in late 1991 of a well preserved early human mandible. Dmanisi, where excavations are being carried out by a joint expedition of the Archaeological Research Centre of the Georgian Academy of Sciences and the Romisch-Germanisches Zentralmuseum (Mainz, Germany), is located southwest of Tbilisi, at about 44 degrees 20' N, 41 degrees 20' E (Fig. 1). The fossils date Ifo the latest Pliocene (or perhaps to the earliest Pleistocene), probably between 1.8 and 1.6 million years ago (Myr). Here we identify the mandible as belonging to the species Home erectus, of which it is the earliest known representative in western Eurasia. It shows a number of similarities to the African and Chinese representatives of this species.			GABUNIA, L (corresponding author), GEORGIAN ACAD SCI, INST PALEOBIOL, 9 SULKHAN SABA, TBILISI 380007, GEORGIA.							AN ZH, 1989, QUATERNARY RES, V32, P213, DOI 10.1016/0033-5894(89)90077-X; BOSINSKI G, 1991, JB ROMISCH GERMAN ZE, V36, P76; BOSINSKI G, 1991, JB ROMISCH GERMANISC, V36, P93; Brown Barbara, 1993, P161; GABUNIA L, 1993, DMANISI MAN ACCOMPAN, P1; MAJSURADZE G, 1991, JB ROMISCH GERMAN ZE, V36, P74; MUSKHELISHVITI A, IN PRESS JB ROMISCH; Rightmire G. P., 1990, EVOLUTION HOMO ERECT; ROEBROEKS W, 1994, CURR ANTHROPOL, V35, P301, DOI 10.1086/204279; SOLOGASHVILI D, IN PRESS JB ROMISCH; SWISHER CC, 1994, SCIENCE, V263, P1118, DOI 10.1126/science.8108729; VEROSUB KL, 1991, 1 EUROPEENS, P237; Walker Alan, 1993, P63; WEIDENREICH F, 1937, PALAEONTOL SINICA D, V1, P1; Wood B., 1991, HOMINID CRANIAL REMA, V4	15	230	239	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	1995	373	6514					509	512		10.1038/373509a0	http://dx.doi.org/10.1038/373509a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7845461				2022-12-28	WOS:A1995QF72400055
J	BUCKLEY, NA; DAWSON, AH; WHYTE, IM; OCONNELL, DL				BUCKLEY, NA; DAWSON, AH; WHYTE, IM; OCONNELL, DL			RELATIVE TOXICITY OF BENZODIAZEPINES IN OVERDOSE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TEMAZEPAM	Objective-To assess the sedative effects in overdose of temazepam and oxazepam compared with other benzodiazepines to determine if this explains reported differences in fatal toxicity. Design-Cohort study of patients admitted with benzodiazepine poisoning. Setting-Newcastle, Australia. Subjects-303 patients who had ingested benzodiazepine alone or in combination with alcohol and presented to a general hospital which served a well defined geographical area. Main outcome measures-Degree of sedation: Glasgow coma score, McCarron Score, and whether patients were stuporose or comatose. Results-Oxazepam produced less and temazepam more sedation than other benzodiazepines. Unadjusted odds ratios for coma with oxazepam and temazepam compared with other benzodiazepines were 0.0 (95% confidence interval 0.0 to 0.85) and 1.86 (0.68 to 4.77) respectively, chi(2) = 7.08, 2df, P = 0.03. After adjustment for potentially confounding effects of age, dose ingested, and coingestion of alcohol, the odds ratios were 0.22 (0.0 to 1.43) for oxazepam and 1.94 (0.57 to 6.23) for temazepam. Similar results were obtained for other measures of sedation. Conclusions-These results were in accordance with fatal toxicity indices derived from coroners' data on mortality and rates of prescription. The relative safety of benzodiazepines in overdose should be a consideration when they are prescribed.	UNIV NEWCASTLE, DEPT PHARMACOL, NEWCASTLE, NSW 2298, AUSTRALIA; NEWCASTLE MATER MISERICORDIAE HOSP, NEWCASTLE, NSW 2298, AUSTRALIA; UNIV NEWCASTLE, CTR CLIN EPIDEMIOL & BIOSTAT, NEWCASTLE, NSW, AUSTRALIA	University of Newcastle; Calvary Mater Newcastle Hospital; University of Newcastle	BUCKLEY, NA (corresponding author), UNIV NEWCASTLE, DEPT CLIN TOXICOL, NEWCASTLE, NSW 2298, AUSTRALIA.		Dawson, Andrew/D-5085-2012; Dawson, Andrew H/U-8041-2019; Whyte, Ian/A-1621-2010; Buckley, Nicholas A/D-4030-2012	Dawson, Andrew/0000-0002-8047-397X; Dawson, Andrew H/0000-0002-8047-397X; Whyte, Ian/0000-0001-7693-3948; Buckley, Nicholas A/0000-0002-6326-4711				ALEXANDER B, 1991, J SUBST ABUSE TREAT, V8, P9, DOI 10.1016/0740-5472(91)90022-3; BUCKLEY NA, IN PRESS MED J AUST; BUSTO U, 1980, AM J PSYCHIAT, V137, P224; CASSIDY S, 1987, BRIT MED J, V295, P1021, DOI 10.1136/bmj.295.6605.1021; CROME P, 1993, ACTA PSYCHIAT SCAND, V87, P33, DOI 10.1111/j.1600-0447.1993.tb05371.x; Dwyer P S, 1984, Hum Toxicol, V3 Suppl, p145S; FORREST ARW, 1986, LANCET, V2, P226; FUCCELLA LM, 1977, EUR J CLIN PHARMACOL, V12, P383, DOI 10.1007/BF00562455; GAUDREAULT P, 1991, DRUG SAFETY, V6, P247, DOI 10.2165/00002018-199106040-00003; GREENBLATT DJ, 1989, ARCH GEN PSYCHIAT, V46, P326; HOJER J, 1989, J INTERN MED, V226, P117; JOHNS MW, 1977, BRIT MED J, V1, P1128, DOI 10.1136/bmj.1.6069.1128; MARTIN CD, 1986, J ANAL TOXICOL, V10, P77, DOI 10.1093/jat/10.2.77; MCCARRON MM, 1982, JAMA-J AM MED ASSOC, V248, P55, DOI 10.1001/jama.248.1.55; MEHTA C, 1993, LOGXACT VERSION 1 1; MITLER MM, 1981, PHARMACOTHERAPY, V1, P3; SERFATY M, 1993, BRIT J PSYCHIAT, V163, P386, DOI 10.1192/bjp.163.3.386; 1994, DATA AUSTR DRUG UTIL	18	52	55	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 28	1995	310	6974					219	221		10.1136/bmj.310.6974.219	http://dx.doi.org/10.1136/bmj.310.6974.219			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE496	7866122	Green Published			2022-12-28	WOS:A1995QE49600020
J	MEAD, GM				MEAD, GM			CONTROVERSIES IN MANAGEMENT - CHEMOTHERAPY FOR SOLID TUMORS - ROUTINE TREATMENT NOT YET JUSTIFIED .18.	BRITISH MEDICAL JOURNAL			English	Article							CELL LUNG-CANCER; DOXORUBICIN; MITOMYCIN				MEAD, GM (corresponding author), ROYAL S HANTS HOSP,DEPT MED ONCOL,SOUTHAMPTON SO9 4PE,HANTS,ENGLAND.							BYRNE M, 1992, BRIT MED J, V304, P1523, DOI 10.1136/bmj.304.6841.1523; COATES A, 1993, LANCET, V342, P4, DOI 10.1016/0140-6736(93)91876-N; CULLINAN SA, 1985, JAMA-J AM MED ASSOC, V253, P2061, DOI 10.1001/jama.253.14.2061; GRILLI R, 1993, J CLIN ONCOL, V11, P1866, DOI 10.1200/JCO.1993.11.10.1866; KIM NK, 1993, CANCER, V71, P3813, DOI 10.1002/1097-0142(19930615)71:12<3813::AID-CNCR2820711205>3.0.CO;2-5; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; SOUQUET PJ, 1993, LANCET, V342, P19; 1993, DRUG THER B, V31, P29; 1992, J CLIN ONCOL, V10, P896; 1993, DRUG THER B, V31, P77	10	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 28	1995	310	6974					246	247		10.1136/bmj.310.6974.246	http://dx.doi.org/10.1136/bmj.310.6974.246			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE496	7866133	Green Published			2022-12-28	WOS:A1995QE49600033
J	HUNTER, T				HUNTER, T			PROTEIN-KINASES AND PHOSPHATASES - THE YIN AND YANG OF PROTEIN-PHOSPHORYLATION AND SIGNALING	CELL			English	Review							CYCLIN-DEPENDENT KINASES; EMBRYONIC-CELL CYCLE; MAP KINASE; TYROSINE KINASE; FISSION YEAST; NEGATIVE REGULATION; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; MITOTIC INHIBITOR; MULTIPLE ROLES				HUNTER, T (corresponding author), SALK INST BIOL STUDIES, MOLEC BIOL & VIROL LAB, LA JOLLA, CA 92037 USA.							ALBERTS AS, 1994, J BIOL CHEM, V269, P7623; ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, IN PRESS CURR BIOL; AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; BARBET NC, 1993, NATURE, V364, P824, DOI 10.1038/364824a0; BEULLENS M, 1992, J BIOL CHEM, V267, P16538; BOOHER R, 1989, CELL, V57, P1009, DOI 10.1016/0092-8674(89)90339-5; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; CHOCK PB, 1977, P NATL ACAD SCI USA, V74, P2766, DOI 10.1073/pnas.74.7.2766; CHOI KY, 1994, CELL, V78, P499; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CLARKE PR, 1994, CURR BIOL, V4, P647, DOI 10.1016/S0960-9822(00)00144-5; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1989, J BIOL CHEM, V264, P21435; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; EDGAR BA, 1994, GENE DEV, V8, P440, DOI 10.1101/gad.8.4.440; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; GINTY DD, 1991, J BIOL CHEM, V266, P17454; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; HUNTER T, 1994, IN PRESS CELL BIOL; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KINOSHITA N, 1993, GENE DEV, V7, P1059, DOI 10.1101/gad.7.6.1059; KORNBLUTH S, 1994, MOL BIOL CELL, V5, P273, DOI 10.1091/mbc.5.3.273; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LABBE JC, 1994, EMBO J, V13, P5155, DOI 10.1002/j.1460-2075.1994.tb06845.x; LALLI E, 1994, J BIOL CHEM, V269, P17359; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEE RM, 1992, J BIOL CHEM, V267, P1088; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LEE TH, 1994, MOL BIOL CELL, V5, P323, DOI 10.1091/mbc.5.3.323; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MILLAR JBA, 1992, EMBO J, V11, P4943, DOI 10.1002/j.1460-2075.1992.tb05601.x; MILLAR JBA, 1992, EMBO J, V11, P4933, DOI 10.1002/j.1460-2075.1992.tb05600.x; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; NAKIELNY S, 1992, FEBS LETT, V308, P183, DOI 10.1016/0014-5793(92)81271-M; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PARKER LL, 1993, NATURE, V363, P736, DOI 10.1038/363736a0; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PICARD A, 1989, J CELL BIOL, V109, P3347, DOI 10.1083/jcb.109.6.3347; PICKHAM KM, 1992, MOL CELL BIOL, V12, P3192, DOI 10.1128/MCB.12.7.3192; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1994, J CELL SCI, V107, P2789; POSNER BI, 1994, J BIOL CHEM, V269, P4596; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SELVA E, 1993, J BIOL CHEM, V268, P2250; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SOLOMON MJ, 1994, TRENDS BIOCHEM SCI, V19, P496, DOI 10.1016/0968-0004(94)90137-6; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; TANG ZH, 1993, EMBO J, V12, P3427, DOI 10.1002/j.1460-2075.1993.tb06017.x; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VAN EYNDE A, 1994, BIOCHEM J, V297, P447, DOI 10.1042/bj2970447; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANZYL W, 1992, MOL CELL BIOL, V12, P4946, DOI 10.1128/MCB.12.11.4946; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; WALKER DH, 1992, MOL BIOL CELL, V3, P687, DOI 10.1091/mbc.3.6.687; WARBRICK E, 1991, EMBO J, V10, P4291, DOI 10.1002/j.1460-2075.1991.tb05007.x; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WHEAT WH, 1994, MOL CELL BIOL, V14, P5881, DOI 10.1128/MCB.14.9.5881; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; WU L, 1993, NATURE, V363, P738, DOI 10.1038/363738a0; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	127	2530	2624	11	237	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	1995	80	2					225	236		10.1016/0092-8674(95)90405-0	http://dx.doi.org/10.1016/0092-8674(95)90405-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7834742	Bronze			2022-12-28	WOS:A1995QD92400005
J	ANTIA, NH				ANTIA, NH			KEYHOLE SURGERY	LANCET			English	Editorial Material											ANTIA, NH (corresponding author), FDN MED RES,84-A,RG THADANI MARG,BOMBAY 400018,MAHARASHTRA,INDIA.								0	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					596	597		10.1016/S0140-6736(94)91972-0	http://dx.doi.org/10.1016/S0140-6736(94)91972-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7848413				2022-12-28	WOS:A1994PD42400016
J	THOMPSON, SG; KIENAST, J; PYKE, SDM; HAVERKATE, F; VANDELOO, JCW				THOMPSON, SG; KIENAST, J; PYKE, SDM; HAVERKATE, F; VANDELOO, JCW			HEMOSTATIC FACTORS AND THE RISK OF MYOCARDIAL-INFARCTION OR SUDDEN-DEATH IN PATIENTS WITH ANGINA-PECTORIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY DISEASE; C-REACTIVE PROTEIN; TISSUE PLASMINOGEN-ACTIVATOR; EUROPEAN-CONCERTED-ACTION; ISCHEMIC-HEART-DISEASE; UNSTABLE ANGINA; QUALITY ASSESSMENT; DISABILITIES ECAT; FIBRINOGEN; PLASMA	Background. Increased levels of certain hemostatic factors may play a part in the development of acute coronary syndromes and may be associated with an increased risk of coronary events in patients with angina pectoris. Methods. We conducted a prospective multicenter study of 3043 patients with angina pectoris who underwent coronary angiography and were followed for two years, Base-line measurements included the concentrations of selected hemostatic factors indicative of a thrombophilic state or endothelial injury, The results were analyzed in relation to the subsequent incidence of myocardial infarction or sudden coronary death. Results. After adjustment for the extent of coronary artery disease and other risk factors, an increased incidence of myocardial infarction or sudden death was associated with higher base-line concentrations of fibrinogen (mean +/-SD, 3,28+/-0.74 g per liter in patients who subsequently had coronary events, as compared with 3.00+/-0.71 g per liter in those who did not; P=0.01), von Willebrand factor antigen (138+/-49 percent vs, 125+/-49 percent, P=0.05), and tissue plasminogen activator (t-PA) antigen (11.9+/-4.7 ng per milliliter vs. 10.0+/-4.2 ng per milliliter, P=0.02). The concentration of C-reactive protein was also directly correlated with the incidence of coronary events (P=0.05), except when we adjusted for the fibrinogen concentration, In patients with high serum cholesterol levels, the risk of coronary events rose with increasing levels of fibrinogen and C-reactive protein, but the risk remained low even given high serum cholesterol levels in the presence of low fibrinogen concentrations. Conclusions. In patients with angina pectoris, the levels of fibrinogen, von Willebrand factor antigen, and t-PA antigen are independent predictors of subsequent acute coronary syndromes. In addition, low fibrinogen concentrations characterize patients at low risk for coronary events despite increased serum cholesterol levels. Our data are consistent with a pathogenetic role of impaired fibrinolysis, endothelial-cell injury, and inflammatory activity in the progression of coronary artery disease.	UNIV MUNSTER, DEPT INTERNAL MED, D-48129 MUNSTER, GERMANY; UNIV LONDON LONDON SCH HYG & TROP MED, MED STAT UNIT, LONDON WC1E 7HT, ENGLAND; GAUBIUS LAB, LEIDEN, NETHERLANDS	University of Munster; University of London; London School of Hygiene & Tropical Medicine								BERK BC, 1990, AM J CARDIOL, V65, P168, DOI 10.1016/0002-9149(90)90079-G; BOWIE EJW, 1993, THROMBOSIS AND ITS MANAGEMENT, P134; CHANDLER WL, 1990, BLOOD, V76, P930; COOPER J, 1991, FIBRINOLYSIS, V5, P105, DOI 10.1016/0268-9499(91)90051-5; CORTELLARO M, 1992, ARTERIOSCLER THROMB, V12, P1063, DOI 10.1161/01.ATV.12.9.1063; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; DEBEER FC, 1982, BRIT HEART J, V47, P239; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; FISHER L, 1984, NEW ENGL J MED, V310, P750; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; Green F, 1989, Baillieres Clin Haematol, V2, P945, DOI 10.1016/S0950-3536(89)80053-8; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; Grossman W., 1986, CARDIAC CATHETERIZAT; HAMSTEN A, 1987, LANCET, V2, P3; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P54, DOI 10.1161/01.ATV.14.1.54; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P1392; HURLIMANN J, 1966, J EXP MED, V123, P365, DOI 10.1084/jem.123.2.365; JANSSON JH, 1991, BRIT HEART J, V66, P351; JANSSON JH, 1991, EUR HEART J, V12, P157, DOI 10.1093/oxfordjournals.eurheartj.a059862; Jespersen J, 1992, ECAT ASSAY PROCEDURE; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; KOSTIS JB, 1982, CHEST, V81, P571, DOI 10.1378/chest.81.5.571; KRUSKAL JB, 1987, NEW ENGL J MED, V317, P1361, DOI 10.1056/NEJM198711263172201; KUSHNER I, 1978, J CLIN INVEST, V61, P235, DOI 10.1172/JCI108932; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MICHALOPOULOS CD, 1993, EUR HEART J, V14, P8; PEPYS MB, 1981, LANCET, V1, P653; RIDKER PM, 1993, LANCET, V341, P1165, DOI 10.1016/0140-6736(93)90998-V; STONE MC, 1985, J ROY COLL GEN PRACT, V35, P565; THAULOW E, 1991, CIRCULATION, V84, P613, DOI 10.1161/01.CIR.84.2.613; THEROUX P, 1987, CIRCULATION, V75, P156, DOI 10.1161/01.CIR.75.1.156; THOMPSON SG, 1989, THROMB HAEMOSTASIS, V61, P301; THOMPSON SG, 1991, THROMB HAEMOSTASIS, V65, P149; TRIP MD, 1990, NEW ENGL J MED, V322, P1549, DOI 10.1056/NEJM199005313222201; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WIMAN B, 1990, AM J CARDIOL, V66, pG54, DOI 10.1016/0002-9149(90)90397-J; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836; ZACK PM, 1984, AM HEART J, V108, P1408, DOI 10.1016/0002-8703(84)90684-7; ZALEWSKI A, 1991, CIRCULATION, V83, P1685, DOI 10.1161/01.CIR.83.5.1685	41	1470	1529	1	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 9	1995	332	10					635	641		10.1056/NEJM199503093321003	http://dx.doi.org/10.1056/NEJM199503093321003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK066	7845427				2022-12-28	WOS:A1995QK06600003
J	MOERTEL, CG; FLEMING, TR; MACDONALD, JS; HALLER, DG; LAURIE, JA; TANGEN, CM; UNGERLEIDER, JS; EMERSON, WA; TORMEY, DC; GLICK, JH; VEEDER, MH; MAILLIARD, JA				MOERTEL, CG; FLEMING, TR; MACDONALD, JS; HALLER, DG; LAURIE, JA; TANGEN, CM; UNGERLEIDER, JS; EMERSON, WA; TORMEY, DC; GLICK, JH; VEEDER, MH; MAILLIARD, JA			FLUOROURACIL PLUS LEVAMISOLE AS EFFECTIVE ADJUVANT THERAPY AFTER RESECTION OF STAGE-III COLON-CARCINOMA - A FINAL REPORT	ANNALS OF INTERNAL MEDICINE			English	Article							CANCER	Objective: To determine the effectiveness of two adjuvant therapy regimens in improving surgical cure rates in stage III (Dukes stage C) colon cancer. Design: Randomized, concurrently controlled clinical trial. Setting: Major cancer centers, universities, and community clinics affiliated with the North Cancer Treatment Group, the Southwest Oncology Group, and the Eastern Cooperative Oncology Group. Patients: Those who had had curative-intent resections of stage III colon cancer in the previous 1 to 5 weeks. Intervention: Patients were assigned to observation only, to levamisole alone (50 mg orally three times/d far 3 days, repeated every 2 weeks for 1 year), or to this regimen of levamisole plus fluorouracil (450 mg/m(2) body surface area intravenously daily for 5 days and then, beginning at 28 days, weekly for 48 weeks). Measurements: Rates of cancer recurrence and death. Early- and late-treatment side effects. Results: With all 929 eligible patients able to be followed for 5 years or more (median follow-up, 6.5 years), fluorouracil plus levamisole reduced the recurrence rate by 40% (P < 0.0001) and the death rate by 33% (P = 0.0007). Levamisole reduced the recurrence rate by only 2% and the death rate by only 6%. With few exceptions, toxicity was mild and patient compliance was excellent. No evidence of late side effects was seen. Conclusion: Fluorouracil plus levamisole is tolerable adjuvant therapy to surgery; it has been confirmed to substantially increase cure rates for patients with highrisk (stage III) colon cancer. It should be considered standard treatment for all such patients not entered into clinical trials.	MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA; FRED HUTCHINSON CANC RES CTR, SEATTLE, WA USA; TEMPLE UNIV, CTR CANC, PHILADELPHIA, PA 19140 USA; UNIV PENN, CTR CANC, PHILADELPHIA, PA 19104 USA; GRAND FORKS CLIN LTD, GRAND FORKS, ND 58201 USA; OHIO STATE UNIV, COLUMBUS, OH USA; ST LOUIS COMMUNITY CLIN ONCOL PROGRAM, ST LOUIS, MO USA; AMC, CANC RES CTR, DENVER, CO 80214 USA; ONCOL HEMATOL ASSOCIATES, PEORIA, IL 61602 USA; CREIGHTON UNIV, CTR CANC, MED ONCOL SERV, OMAHA, NE 68131 USA; ST JOSEPH HOSP, OMAHA, NE USA	Mayo Clinic; Fred Hutchinson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania; University System of Ohio; Ohio State University; AMC Cancer Research Center; Creighton University					NATIONAL CANCER INSTITUTE [U10CA037404, U10CA025224, P01CA031224] Funding Source: NIH RePORTER; NCI NIH HHS [CA-31224, CA-37404, CA-25224] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNAUD JP, 1989, BRIT J SURG, V76, P284, DOI 10.1002/bjs.1800760322; BUYSE M, 1988, JAMA-J AM MED ASSOC, V259, P3571; COX DR, 1972, J R STAT SOC B, V34, P187; GREM JL, 1989, J NATL CANCER I, V81, P1413, DOI 10.1093/jnci/81.18.1413; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444; HOOK CC, 1992, ANN NEUROL, V31, P262, DOI 10.1002/ana.410310306; JANIK J, 1993, J CLIN ONCOL, V11, P125, DOI 10.1200/JCO.1993.11.1.125; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOVACH JS, 1992, J NATL CANCER I, V84, P515, DOI 10.1093/jnci/84.7.515; LAURIE JA, 1989, J CLIN ONCOL, V7, P1447, DOI 10.1200/JCO.1989.7.10.1447; MANTEL N, 1959, J NATL CANCER I, V22, P719; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; MOERTEL CG, 1993, J CLIN ONCOL, V11, P2386, DOI 10.1200/JCO.1993.11.12.2386; OCONNELL M, 1993, P AN M AM SOC CLIN, V12, P190; PIEDBOIS P, 1992, J CLIN ONCOL, V10, P896; WOLMARK N, 1993, P AN M AM SOC CLIN, V12, P197; ZANIBONI A, 1993, P AN M AM SOC CLIN, V12, P191; 1992, SAS P229 I INC TECHN, P433	18	762	776	0	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1995	122	5					321	326		10.7326/0003-4819-122-5-199503010-00001	http://dx.doi.org/10.7326/0003-4819-122-5-199503010-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ085	7847642				2022-12-28	WOS:A1995QJ08500001
J	WALDMANN, TA				WALDMANN, TA			HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-I ASSOCIATED ADULT T-CELL LEUKEMIA - THE JOSEPH-GOLDBERGER-CLINICAL-INVESTIGATOR-LECTURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							RECEPTOR GAMMA-CHAIN; ANTI-TAC-H; INTERLEUKIN-2 RECEPTOR; MONOCLONAL-ANTIBODY; PSEUDOMONAS EXOTOXIN; RADIOIMMUNOTHERAPY; LYMPHOMA; FEATURES; SURVIVAL; DOMAINS				WALDMANN, TA (corresponding author), NCI,METAB BRANCH,BLDG 10,ROOM 4N115,BETHESDA,MD 20892, USA.		Waldmann, Thomas/AAT-5972-2021	Waldmann, Thomas/0000-0003-4500-6660				BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; BAZAN JF, 1990, P NATL ACAD SCI USA, V18, P6934; BROWN PS, 1991, P NATL ACAD SCI USA, V88, P2663, DOI 10.1073/pnas.88.7.2663; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; JUNGHANS RP, 1990, CANCER RES, V50, P1495; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOZAK RW, 1986, P NATL ACAD SCI USA, V83, P474, DOI 10.1073/pnas.83.2.474; KOZAK RW, 1989, CANCER RES, V49, P2639; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; QUEEN C, 1989, P NATL ACAD SCI USA, V86, P10029, DOI 10.1073/pnas.86.24.10029; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; UCHIYAMA T, 1981, J IMMUNOL, V126, P1393; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WALDMANN TA, 1993, BLOOD, V82, P1701; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WALDMANN TA, 1993, LEUKEMIA, V7, pS151; YAMAGUCI K, 1994, LANCET, V243, P213	24	5	6	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	1995	273	9					735	737		10.1001/jama.273.9.735	http://dx.doi.org/10.1001/jama.273.9.735			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH814	7853633				2022-12-28	WOS:A1995QH81400034
J	WINKENS, RAG; POP, P; BUGTERMAESSEN, AMA; GROL, RPTM; KESTER, ADM; BEUSMANS, GHMI; KNOTTNERUS, JA				WINKENS, RAG; POP, P; BUGTERMAESSEN, AMA; GROL, RPTM; KESTER, ADM; BEUSMANS, GHMI; KNOTTNERUS, JA			RANDOMIZED CONTROLLED TRIAL OF ROUTINE INDIVIDUAL FEEDBACK TO IMPROVE RATIONALITY AND REDUCE NUMBERS OF TEST REQUESTS	LANCET			English	Article							TEST-ORDERING BEHAVIOR; GENERAL-PRACTITIONERS; LABORATORY TESTS; PHYSICIANS; STRATEGIES; RESIDENTS; EDUCATION; CARE	Feedback can be described as a way to provide information on doctors' performance to enable changes in future behaviour. Feedback is used with the aim of changing test-ordering behaviour. It can lead to reductions in test usage and cost savings. It is not sufficiently clear, however, whether feedback leads to more appropriate test use. Since 1985, the Diagnostic Coordinating Center Maastricht has been giving feedback on diagnostic tests as a routine health care activity to all family doctors in its region. Both quantity and quality of requests are discussed. In a randomised, controlled trial over 2.5 years, discussion of tests not included previously was added to the existing routine feedback. One group of family doctors (n=39) received feedback on test-group A (electrocardiography, endoscopy, cervical smears, and allergy tests), the other (n=40) on test-group B (radiographic and ultrasonographic tests). Thus, each group of doctors acted as a control group for the other. Changes in volume and rationality of requests were analysed. The number of requests decreased during the trial (p=0.036). Request numbers decreased particularly for test-group A (p=0.04); The proportion of requests that were non-rational decreased more in the intervention than in the control groups (p=0.009). Rationality improved predominantly for test-group B (p=0.043). Thus, routine feedback can change the quantity and quality of requests.	UNIV NIJMEGEN,CTR RES QUAL FAMILY PRACTICE,NIJMEGEN,NETHERLANDS; UNIV MAASTRICHT,CTR RES QUAL FAMILY PRACTICE,MAASTRICHT,NETHERLANDS; UNIV LIMBURG,DEPT METHODOL & STAT,MAASTRICHT,NETHERLANDS; UNIV LIMBURG,DEPT FAMILY PRACTICE,MAASTRICHT,NETHERLANDS	Radboud University Nijmegen; Maastricht University; Hasselt University; Hasselt University	WINKENS, RAG (corresponding author), DIAGNOST CORDINATING CTR MAASTRICHT,POB 5800,6202 AZ MAASTRICHT,NETHERLANDS.		Knottnerus, Andre/F-4866-2013; Knottnerus, Johannes A/A-3829-2009; Grol, Richard/C-8523-2013					ARMITAGE P, 1987, STATISTICAL METHODS; AXTADAM P, 1993, MED CARE, V31, P784, DOI 10.1097/00005650-199309000-00003; BERWICK DM, 1986, JAMA-J AM MED ASSOC, V255, P1450, DOI 10.1001/jama.255.11.1450; BEUSMANS GHM, 1988, HUISAARTS WET, V31, P154; BUNTINX F, 1993, FAM PRACT, V10, P219, DOI 10.1093/fampra/10.2.219; DOWLING PT, 1989, ACAD MED, V64, P410, DOI 10.1097/00001888-198907000-00017; EISENBERG JM, 1985, MED CARE, V23, P461, DOI 10.1097/00005650-198505000-00010; FOWKES FGR, 1986, LANCET, V1, P367; JENNRICH RI, 1986, BIOMETRICS, V42, P805, DOI 10.2307/2530695; MARTIN AR, 1980, NEW ENGL J MED, V303, P1330, DOI 10.1056/NEJM198012043032304; MARTON KI, 1985, ARCH INTERN MED, V145, P816, DOI 10.1001/archinte.145.5.816; MUGFORD M, 1991, BRIT MED J, V303, P398, DOI 10.1136/bmj.303.6799.398; POP P, 1989, J ROY COLL GEN PRACT, V39, P507; RUTTEN GEH, 1993, NHG STANDAARDEN HUIS; SCHECTMAN JM, 1991, ARCH INTERN MED, V151, P2163, DOI 10.1001/archinte.151.11.2163; TIERNEY WM, 1987, ANN INTERN MED, V107, P569, DOI 10.7326/0003-4819-107-4-569; TIERNEY WM, 1990, NEW ENGL J MED, V322, P1499, DOI 10.1056/NEJM199005243222105; WINKENS RAG, 1992, BRIT MED J, V304, P1093, DOI 10.1136/bmj.304.6834.1093	18	58	58	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 25	1995	345	8948					498	502		10.1016/S0140-6736(95)90588-X	http://dx.doi.org/10.1016/S0140-6736(95)90588-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7861879				2022-12-28	WOS:A1995QH92900015
J	MILLAR, AJ; STRAUME, M; CHORY, J; CHUA, NH; KAY, SA				MILLAR, AJ; STRAUME, M; CHORY, J; CHUA, NH; KAY, SA			THE REGULATION OF CIRCADIAN PERIOD BY PHOTOTRANSDUCTION PATHWAYS IN ARABIDOPSIS	SCIENCE			English	Article							PLANTS; PHYTOCHROME; EXPRESSION; MUTANTS; CLOCK	Transgenic Arabidopsis plants expressing a luciferase gene fused to a circadian-regulated promoter exhibited robust rhythms in bioluminescence. The cyclic luminescence has a 24.7-hour period in white light but 30- to 36-hour periods under constant darkness. Either red or blue light shortened the period of the wild type to 25 hours. A phytochrome-deficient mutation lengthened the period in continuous red light but had little effect in continuous blue fight, whereas seedlings carrying mutations that activate light-dependent pathways in darkness maintained shorter periods in constant darkness. These results suggest that both phytochrome- and blue light-responsive photoreceptor pathways control the period of the circadian clock.	UNIV VIRGINIA,DEPT BIOL,NSF,CTR BIOL TIMING,CHARLOTTESVILLE,VA 22903; SALK INST,PLANT BIOL LAB,SAN DIEGO,CA 92186; ROCKEFELLER UNIV,PLANT MOLEC BIOL LAB,NEW YORK,NY 10021	National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia; Salk Institute; Rockefeller University			Kay, Steve A/F-6025-2011; Millar, Andrew J/G-2423-2012	Kay, Steve A/0000-0002-0402-2878; Millar, Andrew J/0000-0003-1756-3654	NIGMS NIH HHS [GM44640] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044640, R56GM044640] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNIER G, 1993, PLANT CELL, V5, P1147, DOI 10.1105/tpc.5.10.1147; Bevington PR, 1969, DATA REDUCTION ERROR, P73; CHORY J, 1993, TRENDS GENET, V9, P167, DOI 10.1016/0168-9525(93)90163-C; CHORY J, 1989, PLANT CELL, V1, P867, DOI 10.1105/tpc.1.9.867; CHORY J, 1991, PLANT CELL, V3, P445, DOI 10.1105/tpc.3.5.445; DENG XW, 1994, CELL, V76, P423, DOI 10.1016/0092-8674(94)90107-4; DENG XW, 1991, GENE DEV, V5, P1172, DOI 10.1101/gad.5.7.1172; Edmunds LN, 1988, CELLULAR MOL BASES B; HARRIS PJC, 1976, PLANTA, V129, P253, DOI 10.1007/BF00398267; HORWITZ BA, 1978, PLANT SCI LETT, V13, P9, DOI 10.1016/0304-4211(78)90058-5; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; MCCLUNG CR, 1994, ARABIDOPSIS THALIANA; MCNELLIS TW, 1994, PLANT CELL, V6, P487, DOI 10.1105/tpc.6.4.487; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; MILLAR AJ, 1994, THESIS ROCKEFELLER U; MILLAR AJ, UNPUB; Millar AJ, 1992, PLANT MOL BIOL REP, V10, P324, DOI 10.1007/BF02668909; PEPPER A, 1994, CELL, V78, P109, DOI 10.1016/0092-8674(94)90577-0; ROENNEBERG T, 1988, NATURWISSENSCHAFTEN, V75, P206, DOI 10.1007/BF00735584; SIMON E, 1976, PLANT PHYSIOL, V58, P421, DOI 10.1104/pp.58.3.421; Sweeney BM., 1987, RHYTHMIC PHENOMENA P	21	223	228	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1163	1166		10.1126/science.7855596	http://dx.doi.org/10.1126/science.7855596			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855596				2022-12-28	WOS:A1995QJ23700036
J	GOTTLIEB, BR				GOTTLIEB, BR			ABORTION - 1995	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											GOTTLIEB, BR (corresponding author), BROOKSIDE COMMUNITY HLTH CTR,BOSTON,MA 02130, USA.							COOPER H, 1993, WALL STREET J   0316, pB1; COOPER H, 1993, WALL STREET J   0312, pB6; Forrest J D, 1993, Womens Health Issues, V3, P152, DOI 10.1016/S1049-3867(05)80249-X; Hern W M, 1994, Womens Health Issues, V4, P48, DOI 10.1016/S1049-3867(05)80109-4; KIELICH AM, 1993, PATIENT CARE, V27, P10; McKeegan M, 1993, Womens Health Issues, V3, P127, DOI 10.1016/S1049-3867(05)80245-2; MEIER KJ, 1994, AM J PUBLIC HEALTH, V84, P1468, DOI 10.2105/AJPH.84.9.1468; Radford B, 1993, Womens Health Issues, V3, P144, DOI 10.1016/S1049-3867(05)80248-8; WESTHOFF C, 1993, OBSTET GYNECOL, V81, P311; 1984, UNINTENDED PREGNANCY, P130; 1992, JAMA-J AM MED ASSOC, V268, P3231; 1994, FACTS BELIEF ABORTIO	12	9	9	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 23	1995	332	8					532	533		10.1056/NEJM199502233320811	http://dx.doi.org/10.1056/NEJM199502233320811			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH288	7830737				2022-12-28	WOS:A1995QH28800010
J	HALEVY, O; NOVITCH, BG; SPICER, DB; SKAPEK, SX; RHEE, J; HANNON, GJ; BEACH, D; LASSAR, AB				HALEVY, O; NOVITCH, BG; SPICER, DB; SKAPEK, SX; RHEE, J; HANNON, GJ; BEACH, D; LASSAR, AB			CORRELATION OF TERMINAL CELL-CYCLE ARREST OF SKELETAL-MUSCLE WITH INDUCTION OF P21 BY MYOD	SCIENCE			English	Article							RETINOBLASTOMA GENE-PRODUCT; MYOGENIC DIFFERENTIATION; DEPENDENT KINASES; PROTEIN; EXPRESSION; E2F; P53; SUPPRESSION; ASSOCIATION; INHIBITION	Skeletal muscle differentiation entails the coordination of muscle-specific gene expression and terminal withdrawal from the cell cycle. This cell cycle arrest in the G(0) phase requires the retinoblastoma tumor suppressor protein (Rb). The function of Rb is negatively regulated by cyclin-dependent kinases (Cdks), which are controlled by Cdk inhibitors. Expression of MyoD, a skeletal muscle-specific transcriptional regulator, activated the expression of the Cdk inhibitor p21 during differentiation of murine myocytes and in nonmyogenic cells. MyoD-mediated induction of p21 did not require the tumor suppressor protein p53 and correlated with cell cycle withdrawal. Thus, MyoD may induce terminal cell cycle arrest during skeletal muscle differentiation by increasing the expression of p21.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; CHILDRENS HOSP,DEPT PEDIAT HEMATOL ONCOL,BOSTON,MA 02115; COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724; DANA FARBER CANC INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute			Hannon, Gregory/AAB-3568-2019; Rhee, James/V-9973-2019	Novitch, Bennett/0000-0002-2696-3708	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD062915] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR008214] Funding Source: NIH RePORTER; NIAMS NIH HHS [F32ARO8214-01A1] Funding Source: Medline; NICHD NIH HHS [N01-HD-6-2915] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CLEGG CH, 1987, J CELL BIOL, V105, P937, DOI 10.1083/jcb.105.2.937; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COPPOLA JA, 1990, ONCOGENE, V5, P1731; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DOTTO P, COMMUNICATION; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EMERSON CP, 1993, CURR OPIN GENET DEV, V3, P265, DOI 10.1016/0959-437X(93)90033-L; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P427, DOI 10.1093/oxfordjournals.jbchem.a123916; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALEVY O, 1993, BIOCHEM BIOPH RES CO, V192, P714, DOI 10.1006/bbrc.1993.1473; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; NEVINS JR, 1992, SCIENCE, V258, P424; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOVITCH BG, UNPUB; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; SASSOON DA, 1993, DEV BIOL, V156, P11, DOI 10.1006/dbio.1993.1055; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; THORBURN AM, 1993, MOL BIOL CELL, V4, P705, DOI 10.1091/mbc.4.7.705; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VOGELSTEIN B, COMMUNICATION; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	49	1090	1102	0	22	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 17	1995	267	5200					1018	1021		10.1126/science.7863327	http://dx.doi.org/10.1126/science.7863327			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG990	7863327				2022-12-28	WOS:A1995QG99000037
J	LINTON, MF; ATKINSON, JB; FAZIO, S				LINTON, MF; ATKINSON, JB; FAZIO, S			PREVENTION OF ATHEROSCLEROSIS IN APOLIPOPROTEIN E-DEFICIENT MICE BY BONE-MARROW TRANSPLANTATION	SCIENCE			English	Article							HERITABLE HYPERLIPIDEMIC RABBITS; III HYPERLIPOPROTEINEMIA; LIVER-TRANSPLANTATION; DENSITY-LIPOPROTEIN; PLASMA-LIPOPROTEINS; MOUSE MACROPHAGES; APOPROTEIN-E; CELLS; HYPERCHOLESTEROLEMIA; CHOLESTEROL	Apolipoprotein E (apoE) deficiency causes severe hyperlipidemia and atherosclerosis in humans and in gene-targeted mice. Although the majority of apoE in plasma is of hepatic origin, apoE is synthesized by a variety of cell types, including macrophages. Because macrophages derive from hematopoietic cells, bone marrow transplantation was used to examine the potential of apoE synthesized by bone marrow-derived cells to correct the hyperlipidemia and atherosclerosis caused by apoE deficiency. After transplantation of bone marrow from mice with the normal apoE gene into apoE-deficient mice, apoE was detected in serum and promoted clearance of lipoproteins and normalization of serum cholesterol levels. ApoE-deficient mice given transplants of normal bone marrow showed virtually complete protection from diet-induced atherosclerosis.	VANDERBILT UNIV,MED CTR N,SCH MED,DEPT PATHOL,NASHVILLE,TN 37232	Vanderbilt University	LINTON, MF (corresponding author), VANDERBILT UNIV,MED CTR N,SCH MED,DEPT MED,DIV ENDOCRINOL,ROOM AA 4206,NASHVILLE,TN 37232, USA.				NHLBI NIH HHS [HL-02925] Funding Source: Medline; NIDDK NIH HHS [DK-26657-15] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026657] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASU SK, 1981, P NATL ACAD SCI-BIOL, V78, P7545, DOI 10.1073/pnas.78.12.7545; BASU SK, 1983, SCIENCE, V219, P871, DOI 10.1126/science.6823554; BASU SK, 1982, J BIOL CHEM, V257, P9788; BLUE ML, 1983, P NATL ACAD SCI-BIOL, V80, P283, DOI 10.1073/pnas.80.1.283; BRUNSTETTER MA, 1971, ARCH INTERN MED, V127, P1064, DOI 10.1001/archinte.127.6.1064; DRISCOLL DM, 1984, J LIPID RES, V25, P1368; FAZIO S, 1993, TRENDS CARDIOVAS MED, V3, P191, DOI 10.1016/1050-1738(93)90005-Q; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GHISELLI G, 1981, SCIENCE, V214, P1239, DOI 10.1126/science.6795720; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; ISHIBASHI S, 1990, J BIOL CHEM, V265, P3040; KERR WJ, COMMUNICATION; KLEIN J, 1983, IMMUNOGENETICS, V17, P553, DOI 10.1007/BF00366126; KRAFT HG, 1989, J CLIN INVEST, V83, P137, DOI 10.1172/JCI113849; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; LINTON MF, 1994, CIRCULATION, V90, P133; LINTON MF, UNPUB; LONGO DL, 1980, J EXP MED, V151, P1452, DOI 10.1084/jem.151.6.1452; LONGO DL, 1983, J IMMUNOL, V130, P2525; MABUCHI H, 1989, METABOLISM, V38, P115, DOI 10.1016/0026-0495(89)90249-7; MAHLEY RW, 1989, J CLIN INVEST, V83, P2125, DOI 10.1172/JCI114126; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PARADIS K, 1990, J PEDIATR GASTR NUTR, V11, P525, DOI 10.1097/00005176-199011000-00014; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; ROSENFELD ME, 1993, ARTERIOSCLER THROMB, V13, P1382, DOI 10.1161/01.ATV.13.9.1382; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SHIMANO H, 1992, P NATL ACAD SCI USA, V89, P1750, DOI 10.1073/pnas.89.5.1750; THIELE DL, 1989, J CLIN INVEST, V84, P1947, DOI 10.1172/JCI114383; WILLIAMS DL, 1985, J BIOL CHEM, V260, P2444; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; YAMADA N, 1992, J CLIN INVEST, V89, P706, DOI 10.1172/JCI115639; YAMADA N, 1989, P NATL ACAD SCI USA, V86, P665, DOI 10.1073/pnas.86.2.665; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	37	399	418	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 17	1995	267	5200					1034	1037		10.1126/science.7863332	http://dx.doi.org/10.1126/science.7863332			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG990	7863332				2022-12-28	WOS:A1995QG99000042
J	PARKER, SB; EICHELE, G; ZHANG, PM; RAWLS, A; SANDS, AT; BRADLEY, A; OLSON, EN; HARPER, JW; ELLEDGE, SJ				PARKER, SB; EICHELE, G; ZHANG, PM; RAWLS, A; SANDS, AT; BRADLEY, A; OLSON, EN; HARPER, JW; ELLEDGE, SJ			P53-INDEPENDENT EXPRESSION OF P21(CIP)1 IN MUSCLE AND OTHER TERMINALLY DIFFERENTIATING CELLS	SCIENCE			English	Article							CYCLIN-DEPENDENT KINASES; GENE MYF-5; PROTEIN; MYOD; MICE; FIBROBLASTS; P53; PROLIFERATION; NEUROGENESIS; INACTIVATION	Terminal differentiation is coupled to withdrawal from the cell cycle. The cyclin-dependent kinase inhibitor (CKI) p21(Cip1) is transcriptionally regulated by p53 and can induce growth arrest. CKIs are therefore potential mediators of developmental control of cell proliferation. The expression pattern of mouse p21 correlated with terminal differentiation of multiple cell lineages including skeletal muscle, cartilage, skin, and nasal epithelium in a p53-independent manner. Although the muscle-specific transcription factor MyoD is sufficient to activate p21 expression in 10T1/2 cells, p21 was expressed in myogenic cells of mice lacking the genes encoding MyoD and myogenin, demonstrating that p21 expression does not require these transcription factors. The p21 protein may function during development as an inducible growth inhibitor that contributes to cell cycle exit and differentiation.	BAYLOR COLL MED,HOWARD HUGHES MED INST,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,DEPT HUMAN & MOLEC GENET,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Howard Hughes Medical Institute; University of Texas System; UTMD Anderson Cancer Center				Bradley, Allan/0000-0002-2349-8839; Harper, Jeffrey/0000-0002-6944-7236	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040339, R01AR039849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40339, AR39849] Funding Source: Medline; NIA NIH HHS [AG-11085] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRENNAN T, 1990, J CELL BIOL, V11, P929; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; CHRIST B, 1983, ANAT EMBRYOL, V166, P87, DOI 10.1007/BF00317946; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EDMONDSON D, 1989, GENE DEV, V3, P28; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDIERY WS, 1994, CANCER RES, V54, P1169; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P874; EMERSON CP, 1993, CURR OPIN GENET DEV, V3, P265, DOI 10.1016/0959-437X(93)90033-L; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRAZIADEI PPC, 1979, J NEUROCYTOL, V8, P1, DOI 10.1007/BF01206454; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HUITFELDT HS, 1991, CARCINOGENESIS, V12, P2063, DOI 10.1093/carcin/12.11.2063; KAEHN K, 1988, ANAT EMBRYOL, V177, P191, DOI 10.1007/BF00321131; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LI Y, 1994, ONCOGENE, V9, P2261; LUTZ B, 1994, DEVELOPMENT, V120, P25, DOI 10.1242/dev.120.1.25; MICHIELI P, 1994, CANCER RES, V54, P3391; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAWLS A, UNPUB; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SASSOON D, 1989, NATURE, V344, P303; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; THORBURN AM, 1993, MOL BIOL CELL, V4, P705, DOI 10.1091/mbc.4.7.705; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhang P. X., UNPUB	53	1052	1067	0	25	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 17	1995	267	5200					1024	1027		10.1126/science.7863329	http://dx.doi.org/10.1126/science.7863329			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG990	7863329				2022-12-28	WOS:A1995QG99000039
J	BEGOVICH, AB; ERLICH, HA				BEGOVICH, AB; ERLICH, HA			HLA TYPING FOR BONE-MARROW TRANSPLANTATION - NEW POLYMERASE CHAIN REACTION-BASED METHODS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STRAND CONFORMATION POLYMORPHISM; OLIGONUCLEOTIDE PROBES; AMPLIFIED DNA; HOST-DISEASE; HISTOCOMPATIBILITY ANTIGENS; 3-DIMENSIONAL STRUCTURE; NUCLEOTIDE-SEQUENCES; CHRONIC GRAFT; RAPID METHOD; SURVIVAL				BEGOVICH, AB (corresponding author), ROCHE MOLEC SYST INC,DEPT HUMAN GENET,1145 ATLANTIC AVE,ALAMEDA,CA 94501, USA.							AMOS DB, 1969, TRANSPLANTATION, V7, P220, DOI 10.1097/00007890-196903000-00023; BACH FH, 1966, SCIENCE, V153, P545, DOI 10.1126/science.153.3735.545; BARNES DWH, 1955, 1954 RAD S, P134; BEATTY PG, 1993, BLOOD, V81, P249; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BODMER JG, 1994, TISSUE ANTIGENS, V44, P1, DOI 10.1111/j.1399-0039.1994.tb02351.x; BORTIN MM, 1973, NATURE, V179, P811; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BUGAWAN TL, 1990, IMMUNOGENETICS, V32, P231; BUGAWAN TL, 1994, TISSUE ANTIGENS, V44, P137, DOI 10.1111/j.1399-0039.1994.tb02371.x; BUGAWAN TL, 1994, HUM IMMUNOL S1, V40, P67; BUYSE I, 1909, TISSUE ANTIGENS, V41, P1; CARRINGTON M, 1992, HUM IMMUNOL, V33, P208, DOI 10.1016/0198-8859(92)90073-V; CLIFT RA, 1987, ANNU REV IMMUNOL, V5, P43, DOI 10.1146/annurev.iy.05.040187.000355; DAUSSET J., 1958, ACTA HAEMATOL, V20, P156; DOHERTY PC, 1975, LANCET, V1, P1406, DOI 10.1016/S0140-6736(75)92610-0; DUPONT B, 1980, CANCER ACHIEVEMENTS, P683; ERLICH H, 1991, EUR J IMMUNOGENET, V18, P333; ERLICH HA, 1986, BIO-TECHNOL, V4, P975, DOI 10.1038/nbt1186-975; FLOMENBERG N, 1989, IMMUNOBIOLOGY HLA, V1, P532; FORMAN SJ, 1994, BONE MARROW TRANSPLA; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HOSHINO S, 1992, HUM IMMUNOL, V33, P98, DOI 10.1016/0198-8859(92)90059-V; KAWAI S, 1994, HUM IMMUNOL, V41, P121, DOI 10.1016/0198-8859(94)90004-3; LONGO MC, 1990, GENE, V93, P125, DOI 10.1016/0378-1119(90)90145-H; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MAEDA M, 1989, TISSUE ANTIGENS, V34, P290, DOI 10.1111/j.1399-0039.1989.tb01745.x; MARSH SGE, 1992, TISSUE ANTIGENS, V40, P229, DOI 10.1111/j.1399-0039.1992.tb02050.x; McCullough J, 1989, BONE MARROW TRANSPL, P641; MICKELSON EM, 1993, TISSUE ANTIGENS, V42, P465, DOI 10.1111/j.1399-0039.1993.tb02190.x; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2508; NG J, 1993, TISSUE ANTIGENS, V42, P478; OH SH, 1993, TISSUE ANTIGENS, V41, P135, DOI 10.1111/j.1399-0039.1993.tb01992.x; OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x; PETERSDORF EW, 1994, HUMAN IMMUNOL S1, V40, P3; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SAIKI RK, 1989, P NATL ACAD SCI USA, V86, P6230, DOI 10.1073/pnas.86.16.6230; SAIKI RK, 1988, SCIENCE, V289, P487; SCHARF SJ, 1991, HUM IMMUNOL, V30, P190, DOI 10.1016/0198-8859(91)90034-7; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; SULLIVAN KM, 1989, BLOOD, V73, P1720; TERASAKI PI, 1964, ANN NY ACAD SCI, V120, P322, DOI 10.1111/j.1749-6632.1964.tb34731.x; TROWSDALE J, 1985, IMMUNOL REV, V85, P5, DOI 10.1111/j.1600-065X.1985.tb01129.x; UPHOFF DE, 1957, J NATL CANCER I, V19, P123; UPHOFF DE, 1958, J NATL CANCER I, V20, P617; WEIDEN PL, 1981, NEW ENGL J MED, V304, P1529, DOI 10.1056/NEJM198106183042507; WETTSTEIN PJ, 1989, HUMAN IMMUNOGENETICS, P339; YOSHIDA M, 1992, HUM IMMUNOL, V34, P257, DOI 10.1016/0198-8859(92)90025-I; ZEMMOUR J, 1992, TISSUE ANTIGENS, V40, P221, DOI 10.1111/j.1399-0039.1992.tb02049.x; ZIMMERMAN PA, 1993, NUCLEIC ACIDS RES, V21, P4541, DOI 10.1093/nar/21.19.4541	53	39	39	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	1995	273	7					586	591		10.1001/jama.273.7.586	http://dx.doi.org/10.1001/jama.273.7.586			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF686	7837393				2022-12-28	WOS:A1995QF68600030
J	LI, Y; LACERDA, DA; WARMAN, ML; BEIER, DR; YOSHIOKA, H; NINOMIYA, Y; OXFORD, JT; MORRIS, NP; ANDRIKOPOULOS, K; RAMIREZ, F; WARDELL, BB; LIFFERTH, GD; TEUSCHER, C; WOODWARD, SR; TAYLOR, BA; SEEGMILLER, RE; OLSEN, BR				LI, Y; LACERDA, DA; WARMAN, ML; BEIER, DR; YOSHIOKA, H; NINOMIYA, Y; OXFORD, JT; MORRIS, NP; ANDRIKOPOULOS, K; RAMIREZ, F; WARDELL, BB; LIFFERTH, GD; TEUSCHER, C; WOODWARD, SR; TAYLOR, BA; SEEGMILLER, RE; OLSEN, BR			A FIBRILLAR COLLAGEN GENE, COL11A1, IS ESSENTIAL FOR SKELETAL MORPHOGENESIS	CELL			English	Article							XI COLLAGEN; II COLLAGEN; V COLLAGEN; CARTILAGE; MICE; ORGANIZATION; EXPRESSION; CLONING; REVEALS; TISSUE	Mice that are homozygous for the autosomal recessive chondrodysplasia (cho) mutation die at birth with abnormalities in cartilage of limbs, ribs, mandible, and trachea. Limb bones of newborn cho/cho mice are wider at the metaphyses than normal bones and only about half the normal length. By linkage analysis, the cho gene and the gene encoding the alpha 1(XI) chain of cartilage collagen XI were mapped to the same region of chromosome 3. Deletion of a cytidine residue about 570 nt downstream of the translation initiation codon in cho alpha 1(XI) mRNA causes a reading frame shift and introduces a premature stop codon. The data demonstrate that collagen XI is essential for normal formation of cartilage collagen fibrils and the cohesive properties of cartilage. The results also suggest that the normal differentiation and spatial organization of growth plate chondrocytes is critially dependent on the presence of type XI collagen in cartilage extracellular matrix.	BRIGHAM & WOMENS HOSP,DIV GENET,BOSTON,MA 02115; OKAYAMA UNIV,SCH MED,DEPT MOLEC BIOL & BIOCHEM,OKAYAMA 700,JAPAN; SHRINERS HOSP CRIPPLED CHILDRENS,RES DEPT,PORTLAND,OR 97201; MT SINAI MED CTR,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; BRIGHAM YOUNG UNIV,DEPT MICROBIOL,PROVO,UT 84602; BRIGHAM YOUNG UNIV,DEPT ZOOL,PROVO,UT 84602; JACKSON LAB,BAR HARBOR,ME 04609	Harvard University; Brigham & Women's Hospital; Okayama University; Icahn School of Medicine at Mount Sinai; Brigham Young University; Brigham Young University; Jackson Laboratory	LI, Y (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.		Oxford, Julia Thom/AAH-2842-2019	Oxford, Julia Thom/0000-0002-4850-3569	NIAMS NIH HHS [AR36820, AR36819] Funding Source: Medline; NIGMS NIH HHS [GM38862] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036819, R37AR036819, R37AR036820, R01AR036820] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BEIER DR, 1993, MAMM GENOME, V4, P627, DOI 10.1007/BF00360898; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BERNARD M, 1988, J BIOL CHEM, V263, P17159; BROEK DL, 1985, J BIOL CHEM, V260, P555; BRUNNER HG, 1994, HUM MOL GENET, V3, P1561, DOI 10.1093/hmg/3.9.1561; BURTON BK, 1986, J PEDIATR-US, V109, P642, DOI 10.1016/S0022-3476(86)80228-1; DIETRICH W, 1992, GENETICS, V131, P423; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; Eyre D, 1987, STRUCTURE FUNCTION C, P261; GAROFALO S, 1993, P NATL ACAD SCI USA, V90, P3825, DOI 10.1073/pnas.90.9.3825; GREENSPAN DS, 1991, J BIOL CHEM, V266, P24727; HAUSSER I, 1994, HUM GENET, V93, P394; HENRY I, 1988, Genomics, V3, P87, DOI 10.1016/0888-7543(88)90165-6; HEPWORTH W B, 1990, Pediatric Pathology, V10, P919; JACENKO O, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P327; KIMURA T, 1989, J BIOL CHEM, V264, P13910; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; MAYNE R, 1993, J BIOL CHEM, V268, P9381; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MONSON CB, 1981, J BONE JOINT SURG AM, V63, P637, DOI 10.2106/00004623-198163040-00015; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; OXFORD JT, 1994, EXP CELL RES, V213, P28, DOI 10.1006/excr.1994.1169; SEEGMILL.R, 1972, J ULTRA MOL STRUCT R, V38, P288, DOI 10.1016/S0022-5320(72)90006-8; SEEGMILLER R, 1971, J CELL BIOL, V48, P580, DOI 10.1083/jcb.48.3.580; SEEGMILLER RE, 1981, CONNECT TISSUE RES, V9, P69, DOI 10.3109/03008208109160242; SEEGMILLER RE, 1986, TERATOLOGY, V33, P339, DOI 10.1002/tera.1420330313; SELDIN MF, 1993, GENOME, V4, pS47; SHAW LM, 1990, TRENDS BIOCHEM SCI, V16, P191; SHEREN SB, 1986, COMP BIOCHEM PHYS B, V85, P5, DOI 10.1016/0305-0491(86)90214-2; SMITH GN, 1985, J BIOL CHEM, V260, P761; SPRANGER J, 1990, ADV HUM GENET, P1; STEPHENS TD, 1976, TERATOLOGY, V13, P317, DOI 10.1002/tera.1420130312; TAYLOR BA, 1989, GENOMICS, V5, P221, DOI 10.1016/0888-7543(89)90050-5; VIKKULA M, 1995, CELL, V80, P431, DOI 10.1016/0092-8674(95)90493-X	36	281	290	0	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					423	430		10.1016/0092-8674(95)90492-1	http://dx.doi.org/10.1016/0092-8674(95)90492-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859283	Bronze			2022-12-28	WOS:A1995QG47000008
J	VIKKULA, M; MARIMAN, ECM; LUI, VCH; ZHIDKOVA, NI; TILLER, GE; GOLDRING, MB; VANBEERSUM, SEC; MALEFIJT, MCD; VANDENHOOGEN, FHJ; ROPERS, HH; MAYNE, R; CHEAH, KSE; OLSEN, BR; WARMAN, ML; BRUNNER, HG				VIKKULA, M; MARIMAN, ECM; LUI, VCH; ZHIDKOVA, NI; TILLER, GE; GOLDRING, MB; VANBEERSUM, SEC; MALEFIJT, MCD; VANDENHOOGEN, FHJ; ROPERS, HH; MAYNE, R; CHEAH, KSE; OLSEN, BR; WARMAN, ML; BRUNNER, HG			AUTOSOMAL-DOMINANT AND RECESSIVE OSTEOCHONDRODYSPLASIAS ASSOCIATED WITH THE COL11A2 LOCUS	CELL			English	Article							COLLAGEN; MUTATIONS; HUMANS	Identifying mutations that cause specific osteochondrodysplasias will provide novel insights into the function of genes that are essential for skeletal morphogenesis. We report here that an autosomal dominant form of Stickler syndrome, characterized by mild spondyloepiphyseal dysplasia, osteoarthritis, and sensorineural hearing loss, but no eye involvement, is caused by a splice donor site mutation resulting in ''in-frame'' exon skipping within the COL11A2 gene, encoding the alpha 2(XI) chain of the quantitatively minor fibrillar collagen XI. We also show that an autosomal recessive disorder with similar, but more severe, characteristics is linked to the COL11A2 locus and is caused by a glycine to arginine substitution In alpha 2(XI) collagen. The results suggest that mutations in collagen XI genes are associated with a spectrum of abnormalities in human skeletal development and support the conclusion of others, based on studies of murine chondrodysplasia, that collagen XI is essential for skeletal morphogenesis.	UNIV NIJMEGEN HOSP,DEPT HUMAN GENET,6500 HB NIJMEGEN,NETHERLANDS; UNIV HONG KONG,DEPT BIOCHEM,HONG KONG,HONG KONG; UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294; VANDERBILT UNIV,MED CTR,DIV GENET,NASHVILLE,TN 37232; MASSACHUSETTS GEN HOSP E,ARTHRITIS RES MED SERV,BOSTON,MA; HARVARD UNIV,SCH MED,BOSTON,MA 02129; UNIV NIJMEGEN HOSP,DEPT ORTHOPED SURG,6500 HB NIJMEGEN,NETHERLANDS; UNIV NIJMEGEN HOSP,DEPT RHEUMATOL,6500 HB NIJMEGEN,NETHERLANDS	Radboud University Nijmegen; University of Hong Kong; University of Alabama System; University of Alabama Birmingham; Vanderbilt University; Harvard University; Harvard Medical School; Radboud University Nijmegen; Radboud University Nijmegen	VIKKULA, M (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.		van Beersum, Sylvia E.C./P-8653-2015; Brunner, Han/C-9928-2013; Vikkula, Miikka/Q-1038-2018; Cheah, Kathryn/C-4222-2009; /C-4359-2009	van Beersum, Sylvia E.C./0000-0002-4552-2908; Vikkula, Miikka/0000-0002-6236-338X; /0000-0002-1758-8854	NIAMS NIH HHS [AR03564, AR30481, ARO1925] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030481, K08AR001925, P01AR003564, R37AR030481] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRUNNER HG, 1994, HUM MOL GENET, V3, P1561, DOI 10.1093/hmg/3.9.1561; DOLZ R, 1990, ANN NY ACAD SCI, V580, P421, DOI 10.1111/j.1749-6632.1990.tb17948.x; Eyre D, 1987, STRUCTURE FUNCTION C, P261; GIEDION A, 1982, HELV PAEDIATR ACTA, V37, P361; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; KIMURA T, 1989, J BIOL CHEM, V264, P13910; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; MAYNE R, 1993, J BIOL CHEM, V268, P9381; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; SNEAD MP, 1994, IN PRESS EYE, V6; SPRANGER J, 1985, ENDOCRINE GENETICS G, P315; STICKLER GB, 1965, MAYO CLIN PROC, V40, P433; TALERICO M, 1990, MOL CELL BIOL, V10, P6299, DOI 10.1128/MCB.10.12.6299; VIKKULA M, 1994, ANN MED, V26, P107; VOLZ A, 1994, GENOMICS, V21, P464, DOI 10.1006/geno.1994.1302; WARMAN ML, 1993, NAT GENET, V5, P79, DOI 10.1038/ng0993-79	20	282	290	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					431	437		10.1016/0092-8674(95)90493-X	http://dx.doi.org/10.1016/0092-8674(95)90493-X			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859284	Green Published, Bronze			2022-12-28	WOS:A1995QG47000009
J	KARLAWISH, JHT				KARLAWISH, JHT			THE NIGHT DOCTOR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	1995	273	6					454	454		10.1001/jama.273.6.454	http://dx.doi.org/10.1001/jama.273.6.454			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE498	7837351				2022-12-28	WOS:A1995QE49800010
J	RICHTER, W; LEE, SH; WARREN, WS; HE, QH				RICHTER, W; LEE, SH; WARREN, WS; HE, QH			IMAGING WITH INTERMOLECULAR MULTIPLE-QUANTUM COHERENCES IN SOLUTION NUCLEAR-MAGNETIC-RESONANCE	SCIENCE			English	Article							SPIN ECHOES; LIQUIDS; WATER; FIELD; NMR	A magnetic resonance imaging technique based on intermolecular multiple-quantum coherences in solution (the correlated spectroscopy revamped by asymmetric z gradient echo detection or CRAZED experiment) is described here. Correlations between spins in different molecules were detected by magnetic-field gradient pulses, In order for a correlation to yield an observable signal, the separation between the two spins must be within a narrow band that depends on the area of the gradient pulses. The separation can be tuned from less than 10 micrometers to more than 1 millimeter, a convenient range for many applications.	PRINCETON UNIV,DEPT CHEM,PRINCETON,NJ 08544; JOHNS HOPKINS UNIV,SCH MED,DIV NMR RES,BALTIMORE,MD 21205	Princeton University; Johns Hopkins University					NIGMS NIH HHS [GM35253] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035253] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAGAM A, 1961, PRINCIPLES NUCLEAR M; BEDFORD AS, 1991, J MAGN RESON, V93, P516, DOI 10.1016/0022-2364(91)90080-D; BLOEMBERGEN N, 1948, PHYS REV, V73, P679, DOI 10.1103/PhysRev.73.679; BOWTELL R, 1990, J MAGN RESON, V88, P643, DOI 10.1016/0022-2364(90)90297-M; BOWTELL R, 1992, J MAGN RESON, V100, P1, DOI 10.1016/0022-2364(92)90361-A; Bushong S.C., 1988, MAGNETIC RESONANCE I; CALLAGHAN PT, 1991, PRINCIPLES NUCLEAR M; Chakeres DW, 1992, FUNDAMENTALS MAGNETI; CHINGAS GC, 1992, MAGNETIC RESONANCE M, P373; DEVILLE G, 1979, PHYS REV B, V19, P5666, DOI 10.1103/PhysRevB.19.5666; EINZEL D, 1984, PHYS REV LETT, V53, P2312, DOI 10.1103/PhysRevLett.53.2312; Ernst R. R., 1987, PRINCIPLES NUCL MAGN; HE QH, 1993, J CHEM PHYS, V98, P6779, DOI 10.1063/1.464770; KORBER H, 1991, J MAGN RESON, V93, P589, DOI 10.1016/0022-2364(91)90085-8; WARREN WS, 1993, SCIENCE, V262, P2005, DOI 10.1126/science.8266096	15	130	136	0	13	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 3	1995	267	5198					654	657		10.1126/science.7839140	http://dx.doi.org/10.1126/science.7839140			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839140				2022-12-28	WOS:A1995QE73300031
J	ROSE, S				ROSE, S			THE RISE OF NEUROGENETIC DETERMINISM	NATURE			English	Editorial Material											ROSE, S (corresponding author), OPEN UNIV, DEPT BIOL, MILTON KEYNES MK7 6AA, BUCKS, ENGLAND.							BIGNAMI G, 1982, BIOL DETERMINISM, P94; BREGGIN PR, 1993, INT J PSYCHOL PSYCHO, V11, P59; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; CHIPKIN RE, 1994, TRENDS NEUROSCI, V17, P50, DOI 10.1016/0166-2236(94)90070-1; COHEN D, 1994, OUT BLUE DEPRESSION; Dawkins Richard, 1976, SELFISH GENE; DELGADO JMW, 1971, PHYSICAL CONTROL MIN; GALANTER M, 1993, RECENT DEV ALCOHOLIS; Hamer D., 1994, SCI DESIRE SEARCH GA; HAMER DH, 1993, SCIENCE, V261, P321, DOI 10.1126/science.8332896; HARRISON G, 1990, SCHIZOPHRENIA BULL, V16, P663, DOI 10.1093/schbul/16.4.663; Herrnstein R., 1994, BELL CURVE INTELLIGE; Kitcher P, 1985, VALUING AMBITION; Kramer PD, 1994, LISTENING PROZAC; LeVay Simon, 1993, SEXUAL BRAIN; MANN CC, 1994, SCIENCE, V264, P1686, DOI 10.1126/science.8209246; Mark V., 1970, VIOLENCE BRAIN; Nelkin D, 1987, SELLING SCI; PERUTZ MF, 1988, TRENDS BIOCHEM SCI, V13, P206, DOI 10.1016/0968-0004(88)90083-7; Reiss A., 1993, UNDERSTANDING PREVEN; ROSE S, 1987, TRENDS NEUROSCI, V10, P152; Rose S, 1984, NOT IN OUR GENES; SWAAB DF, 1994, EUR J NEUROSCI, V7, P126; UHL G, 1993, TRENDS NEUROSCI, V16, P83, DOI 10.1016/0166-2236(93)90128-9; Wilson E.O., 1975, P1	25	76	76	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 2	1995	373	6513					380	382		10.1038/373380a0	http://dx.doi.org/10.1038/373380a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7830787				2022-12-28	WOS:A1995QE67000026
J	YANG, E; ZHA, JP; JOCKEL, J; BOISE, LH; THOMPSON, CB; KORSMEYER, SJ				YANG, E; ZHA, JP; JOCKEL, J; BOISE, LH; THOMPSON, CB; KORSMEYER, SJ			BAD, A HETERODIMERIC PARTNER FOR BCL-X(L) AND BCL-2, DISPLACES BAX AND PROMOTES CELL-DEATH	CELL			English	Article							SEQUENCE SIMILARITY; INTERACTION CLONING; C-MYC; PROTEIN; GENE; IDENTIFICATION; PREVENTION; MEMBRANE; SURVIVAL; ZIPPER	To extend the mammalian cell death pathway, we screened for further Bcl-2 interacting proteins. Both yeast two-hybrid screening and lambda expression cloning identified a novel interacting protein, Bad, whose homology to Bcl-2 is limited to the BH1 and BH2 domains. Bad selectively dimerized with Bcl-X(L) as well as Bcl-2, but not with Bax, Bcl-X(S), Mcl-1, A1, or itself, Bad binds more strongly to Bcl-X(L) than Bcl-2 in mammalian cells, and it reversed the death repressor activity of Bcl-X(L), but not that of Bcl-2. When Bad dimerized with Bcl-X(L), Bax was displaced and apoptosis was restored, When approximately half of Bax was heterodimerized, death was inhibited. The susceptibility of a cell to a death signal is determined by these competing dimerizations in which levels of Bad influence the effectiveness of Bcl-2 versus Bcl-X(L) in repressing death.	WASHINGTON UNIV, SCH MED,HOWARD HUGHES MED INST,DEPT MED, DIV MOLEC ONCOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED,HOWARD HUGHES MED INST,DEPT PATHOL, DIV MOLEC ONCOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED,HOWARD HUGHES MED INST,DEPT PEDIAT, DIV MOLEC ONCOL, ST LOUIS, MO 63110 USA; UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MOLEC BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT CELL BIOL, CHICAGO, IL 60637 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); University of Chicago; University of Chicago; University of Chicago			Boise, Lawrence/AAD-2314-2019; Roszak, Joanna/F-4003-2010	Boise, Lawrence/0000-0001-9436-8815	NATIONAL CANCER INSTITUTE [R01CA050239, R37CA050239] Funding Source: NIH RePORTER; NCI NIH HHS [CA50239] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; DEJONG D, 1994, CANCER RES, V54, P256; FULBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; LIN EY, 1993, J IMMUNOL, V151, P1979; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	25	1864	1977	3	49	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 27	1995	80	2					285	291		10.1016/0092-8674(95)90411-5	http://dx.doi.org/10.1016/0092-8674(95)90411-5			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7834748	Bronze			2022-12-28	WOS:A1995QD92400011
J	MCMURRAY, J; RANKIN, A				MCMURRAY, J; RANKIN, A			RECENT ADVANCES - CARDIOLOGY .1. TREATMENT OF MYOCARDIAL-INFARCTION, UNSTABLE ANGINA, AND ANGINA-PECTORIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							THROMBOLYTIC THERAPY; DIRECTIONAL ATHERECTOMY; IMMEDIATE ANGIOPLASTY; CORONARY-ARTERY; PREVENTION; ASPIRIN		UNIV GLASGOW, ROYAL INFIRM, DEPT MED, GLASGOW G31 2ER, LANARK, SCOTLAND	Royal Infirmary of Edinburgh; University of Glasgow	MCMURRAY, J (corresponding author), WESTERN GEN HOSP, DEPT CARDIOL, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.		mcmurray, John/B-2467-2013	mcmurray, John/0000-0002-6317-3975				ADELMAN AG, 1993, NEW ENGL J MED, V329, P228, DOI 10.1056/NEJM199307223290402; [Anonymous], 1994, Circulation, V89, P1545; [Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1993, Lancet, V342, P767; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BALL SG, 1993, LANCET, V342, P821; BRAUNWALD E, 1994, US DHHS PHS940602 AG; CAIRNS JA, 1994, LANCET, V343, P497, DOI 10.1016/S0140-6736(94)91457-5; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; COHEN M, 1994, CIRCULATION, V89, P81, DOI 10.1161/01.CIR.89.1.81; DEBOER MJ, 1994, J AM COLL CARDIOL, V23, P1004, DOI 10.1016/0735-1097(94)90582-7; DEBONO DP, 1994, MANAGEMENT STABLE AN; DEVITA C, 1994, LANCET, V343, P1115; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; GOLDBOURT U, 1993, ARCH INTERN MED, V153, P345, DOI 10.1001/archinte.153.3.345; GOY JJ, 1994, LANCET, V343, P1449, DOI 10.1016/S0140-6736(94)92579-8; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; HAMPTON J, 1993, LANCET, V342, P759; HAMPTON JR, 1993, LANCET, V341, P573; HELD PH, 1993, EUR HEART J, V14, P18, DOI 10.1093/eurheartj/14.suppl_F.18; HUNT D, 1992, LANCET, V339, P753; KENFORD SL, 1994, JAMA-J AM MED ASSOC, V271, P589, DOI 10.1001/jama.271.8.589; LANGE RA, 1993, NEW ENGL J MED, V328, P726, DOI 10.1056/NEJM199303113281010; LEIZOROVICZ A, 1993, NEW ENGL J MED, V329, P383; LEON MB, 1994, CIRCULATION, V89, P1323, DOI 10.1161/01.CIR.89.3.1323; MEIJER A, 1993, CIRCULATION, V87, P1524, DOI 10.1161/01.CIR.87.5.1524; RAWLES J, 1994, J AM COLL CARDIOL, V23, P1, DOI 10.1016/0735-1097(94)90494-4; RENNARD S, 1994, ARCH INTERN MED, V154, P989; Ribeiro EE, 1993, J AM COLL CARDIOL, V22, P376, DOI 10.1016/0735-1097(93)90040-8; RODRIGUEZ A, 1993, J AM COLL CARDIOL, V22, P1060, DOI 10.1016/0735-1097(93)90416-X; SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4; SIMOONS ML, 1994, LANCET, V344, P279, DOI 10.1016/S0140-6736(94)91333-1; TANG JL, 1994, BRIT MED J, V308, P21, DOI 10.1136/bmj.308.6920.21; THEROUX P, 1993, CIRCULATION, V88, P2045, DOI 10.1161/01.CIR.88.5.2045; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8; TOPOL EJ, 1993, NEW ENGL J MED, V329, P221, DOI 10.1056/NEJM199307223290401; VANDEWERF F, 1990, LANCET, V336, P71; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; WESTON CFM, 1994, BMJ-BRIT MED J, V308, P767, DOI 10.1136/bmj.308.6931.767	40	39	39	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 19	1994	309	6965					1343	1350		10.1136/bmj.309.6965.1343	http://dx.doi.org/10.1136/bmj.309.6965.1343			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT625	7866084	Green Published			2022-12-28	WOS:A1994PT62500027
J	PERRIENS, JH; STLOUIS, ME; MUKADI, YB; BROWN, C; PRIGNOT, J; POUTHIER, F; PORTAELS, F; WILLAME, JC; MANDALA, JK; KABOTO, M; RYDER, RW; ROSCIGNO, G; PIOT, P				PERRIENS, JH; STLOUIS, ME; MUKADI, YB; BROWN, C; PRIGNOT, J; POUTHIER, F; PORTAELS, F; WILLAME, JC; MANDALA, JK; KABOTO, M; RYDER, RW; ROSCIGNO, G; PIOT, P			PULMONARY TUBERCULOSIS IN HIV-INFECTED PATIENTS IN ZAIRE - A CONTROLLED TRIAL OF TREATMENT FOR EITHER 6 OR 12 MONTHS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; HIV-1-INFECTED PATIENTS; CHEMOTHERAPY; MORTALITY; KINSHASA; KENYA	Background. We studied the efficacy of a short-course regimen of chemotherapy for pulmonary tuberculosis in Kinshasa, Zaire. We also assessed whether, among patients with human immunodeficiency virus (HIV) infection, treatment should be extended from 6 to 12 months. Methods. HIV-seropositive and HIV-seronegative outpatients with pulmonary tuberculosis were treated with rifampin, isoniazid, pyrazinamide, and ethambutol daily for two months, followed by rifampin plus isoniazid twice weekly for four months. The HIV-positive patients who had no evidence of tuberculosis were then randomly assigned to receive either rifampin plus isoniazid or placebo twice weekly for a further six months. We also followed a comparison group of HIV-seronegative patients who received no further treatment for tuberculosis after six months. Results. After six months, 260 of 335 HIV-seropositive and 186 of 188 HIV-seronegative participants could be evaluated, and their rates of treatment failure were similar: 3.8 and 2.7 percent, respectively. At 24 months, the HIV-seropositive patients who received extended treatment had a relapse rate of 1.9 percent, as compared with 9 percent among the HIV-seropositive patients who received placebo for the second 6 months (P<0.01). Extended treatment did not improve survival, however. Among the HIV-seronegative patients, 5.3 percent relapsed. Conclusions. Among HIV-seropositive patients with pulmonary tuberculosis, extending treatment from 6 to 12 months reduces the rate of relapse but does not improve survival. The six-month program of partly intermittent antituberculous treatment may be an acceptable alternative when resources are limited.	PROJET SIDA, KINSHASA, DEM REP CONGO; INST TROP MED, B-2000 ANTWERP, BELGIUM; BELGIAN AGCY DEV & COOPERAT, BRUSSELS, BELGIUM; CTR DIS CONTROL & PREVENT, DIV HIV & AIDS, ATLANTA, GA 30341 USA; NIAID, BETHESDA, MD 20892 USA; UNIV CATHOLIQUE LOUVAIN, MT GODINNE, BELGIUM; BUR NATL TB, KINSHASA, DEM REP CONGO; CTR DEPISTAGE TB, KINSHASA, DEM REP CONGO	Institute of Tropical Medicine (ITM); Centers for Disease Control & Prevention - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Universite Catholique Louvain								[Anonymous], 1991, Am Rev Respir Dis, V143, P700; [Anonymous], 1987, Am Rev Respir Dis, V136, P1339; CANETTI G, 1963, B WORLD HEALTH ORGAN, V29, P565; CANUETO J, 1992, 8TH INT C AIDS 3RD S, V2, pB103; CARTON JA, 1989, 5TH P INT C AIDS MON, P594; CASTELO A, 1989, LANCET, V2, P1173; COHN DL, 1990, ANN INTERN MED, V112, P407, DOI 10.7326/0003-4819-76-3-112-6-407; COLEBUNDERS R, 1987, AIDS, V1, P117; COMBS DL, 1990, ANN INTERN MED, V112, P397, DOI 10.7326/0003-4819-76-3-112-6-397; GIRLING DJ, 1988, AM REV RESPIR DIS, V137, P1147; HAWKEN M, 1993, LANCET, V342, P332, DOI 10.1016/0140-6736(93)91474-Z; HOPEWELL P, 1992, CLIN INFECT DIS, V15, pS282, DOI 10.1093/clind/15.Supplement_1.S282; JENKINS PA, 1982, BIOL MYCOBACTERIA, V1, P441; KASSIM S, 1992, 8TH INT C AIDS 3RD S, V2, pB101; KLAUSNER JD, 1993, J INFECT DIS, V168, P802; KLAUSNER JD, 1993, J INFECT DIS, V168, P106, DOI 10.1093/infdis/168.1.106; LAHART CJ, 1992, 32ND INT C ANT AG CH, P157; MONTANER LJG, 1992, AM REV RESPIR DIS S, V145, pA107; MUKADI Y, 1993, LANCET, V342, P143, DOI 10.1016/0140-6736(93)91346-N; MUKADI Y, 1990, 6TH INT C AIDS SAN F, V2, P233; NUNN P, 1992, AM REV RESPIR DIS, V146, P849, DOI 10.1164/ajrccm/146.4.849; OKWERA A, 1994, LANCET, V344, P1323, DOI 10.1016/S0140-6736(94)90693-9; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; PIOT P, 1990, J ACQ IMMUN DEF SYND, V3, P403; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; SNIDER DE, 1984, AM REV RESPIR DIS, V130, P1091; SNIDER DE, 1982, AM REV RESPIR DIS, V125, P265; ZAMORA L, 1990, 6TH INT C AIDS SAN F, V1, P249; 1986, MMWR-MORBID MORTAL W, V35, P448; 1993, 9TH INT C AIDS 4TH S, P339	30	242	247	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 23	1995	332	12					779	784		10.1056/NEJM199503233321204	http://dx.doi.org/10.1056/NEJM199503233321204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN442	7862181				2022-12-28	WOS:A1995QN44200004
J	DONOWITZ, M; KOKKE, FT; SAIDI, R				DONOWITZ, M; KOKKE, FT; SAIDI, R			EVALUATION OF PATIENTS WITH CHRONIC DIARRHEA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FECAL OSMOTIC GAP; LAXATIVE ABUSE; AIDS ENTEROPATHY; DIAGNOSIS; MECHANISMS; ORIGIN; COLON		JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21205 USA	Johns Hopkins University	DONOWITZ, M (corresponding author), JOHNS HOPKINS UNIV, SCH MED,DEPT MED,DIV GASTROENTEROL, 918 ROSS RES BLDG, 720 RUTLAND AVE, BALTIMORE, MD 21205 USA.							AFZALPURKAR RG, 1992, NEW ENGL J MED, V327, P1849, DOI 10.1056/NEJM199212243272605; ARRAMBIDE KA, 1989, DIGEST DIS SCI, V34, P193, DOI 10.1007/BF01536050; AVERY ME, 1990, NEW ENGL J MED, V323, P891, DOI 10.1056/NEJM199009273231307; BARTLETT JG, 1992, CLIN INFECT DIS, V15, P726, DOI 10.1093/clind/15.4.726; BERTOMEU A, 1991, J CLIN GASTROENTEROL, V13, P531, DOI 10.1097/00004836-199110000-00011; BINDER HJ, 1992, GASTROENTEROLOGY, V103, P702, DOI 10.1016/0016-5085(92)90870-5; BOND JH, 1976, J CLIN INVEST, V57, P1158, DOI 10.1172/JCI108383; BYTZER P, 1990, SCAND J GASTROENTERO, V25, P572, DOI 10.3109/00365529009095532; BYTZER P, 1989, GUT, V30, P1379, DOI 10.1136/gut.30.10.1379; CHAUDHARY NA, 1962, Q J MED, V31, P307; CHERNER JA, 1988, GASTROENTEROLOGY, V95, P657, DOI 10.1016/S0016-5085(88)80012-X; CROWE SE, 1992, GASTROENTEROLOGY, V103, P1075, DOI 10.1016/0016-5085(92)90047-3; DEWOLFF FA, 1983, HUM TOXICOL, V2, P385, DOI 10.1177/096032718300200235; DUNCAN A, 1991, ANN CLIN BIOCHEM, V28, P568, DOI 10.1177/000456329102800605; DUNCAN A, 1992, J ROY SOC MED, V85, P203; DUNCAN A, 1992, J LAB CLIN MED, V119, P359; EHERER AJ, 1992, GASTROENTEROLOGY, V103, P545, DOI 10.1016/0016-5085(92)90845-P; FINE KD, 1992, GASTROENTEROLOGY, V102, P1936, DOI 10.1016/0016-5085(92)90316-Q; FINE KD, 1993, GASTROINTESTINAL DIS, V2, P1043; FORDTRAN JS, 1967, FED PROC, V26, P1405; FROMM H, 1986, CLIN GASTROENTEROL, V15, P567; GERAEDTS AAM, 1988, SCAND J GASTROENTERO, V23, P46, DOI 10.3109/00365528809095950; GREENSON JK, 1991, ANN INTERN MED, V114, P366, DOI 10.7326/0003-4819-114-5-366; ISAACRENTON JL, 1991, CLIN LAB MED, V11, P811, DOI 10.1016/S0272-2712(18)30522-5; JAIN NK, 1985, AM J GASTROENTEROL, V80, P678; JANDA RC, 1991, GASTROENTEROLOGY, V100, P458, DOI 10.1016/0016-5085(91)90216-8; LEVITT MD, 1972, NEW ENGL J MED, V286, P973, DOI 10.1056/NEJM197205042861804; LYNN RB, 1993, NEW ENGL J MED, V329, P1940, DOI 10.1056/NEJM199312233292608; MADOFF RD, 1992, NEW ENGL J MED, V326, P1002; MAGLINTE DDT, 1992, RADIOLOGY, V184, P541, DOI 10.1148/radiology.184.2.1620862; OSTERHOLM MT, 1986, JAMA-J AM MED ASSOC, V256, P484, DOI 10.1001/jama.256.4.484; PARSONNET J, 1989, ANN INTERN MED, V110, P985, DOI 10.7326/0003-4819-110-12-985; PERKINS SL, 1993, CLIN BIOCHEM, V26, P179, DOI 10.1016/0009-9120(93)90023-Y; POWELL DW, 1991, TXB GASTROENTEROLOGY, P732; READ NW, 1980, GASTROENTEROLOGY, V78, P264; ROOD RP, 1991, DIARRHEAL DISEASES, P397; Schiller LA, 1991, DIARRHEAL DISEASES, P219; SMELT AHM, 1992, PROSTAGLANDINS, V43, P567, DOI 10.1016/0090-6980(92)90116-B; TALLEY NJ, 1992, AM J EPIDEMIOL, V136, P165, DOI 10.1093/oxfordjournals.aje.a116483; UNGAR BLP, 1984, J INFECT DIS, V149, P90, DOI 10.1093/infdis/149.1.90; VALDOVINOS MA, 1993, MAYO CLIN PROC, V68, P691, DOI 10.1016/S0025-6196(12)60606-5; YEOH E, 1993, AM J MED, V95, P397, DOI 10.1016/0002-9343(93)90309-D	42	64	66	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 16	1995	332	11					725	729		10.1056/NEJM199503163321107	http://dx.doi.org/10.1056/NEJM199503163321107			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL788	7854381				2022-12-28	WOS:A1995QL78800007
J	DWYER, T; PONSONBY, AL; BLIZZARD, L; NEWMAN, NM; COCHRANE, JA				DWYER, T; PONSONBY, AL; BLIZZARD, L; NEWMAN, NM; COCHRANE, JA			THE CONTRIBUTION OF CHANGES IN THE PREVALENCE OF PRONE SLEEPING POSITION TO THE DECLINE IN SUDDEN-INFANT-DEATH-SYNDROME IN TASMANIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COT DEATHS; RISK; AUSTRALIA	Objective.-To determine the independent contribution of changes in infant sleep position to the recent decline in sudden infant death syndrome (SIDS) rate in Tasmania. Design.-(1) A comparison of the whole population incidence of SIDS before and after an intervention to reduce the prevalence of prone sleeping position. (2) A within-cohort analysis of the contribution of sleep position and other exposures to the decline in SIDS after the intervention. Setting.-Tasmania, Australia. Participants.-(1) All SIDS cases from 1975 through 1992. (2) A sample of one in five infants born in Tasmania who at perinatal assessment were scored to be at higher risk for SIDS since January 1988. Of 5534 infants included in the study, 39 later died of SIDS. Interventions.-Multiple public health activities to reduce the prevalence of the prone infant sleeping position in Tasmania and verbal information on the association between prone position and SIDS to cohort participants from May 1, 1991. Main Outcome Measure.-Sudden infant death syndrome incidence. Results.-The Tasmanian SIDS rate decreased (P<.01) from 3.8 (95% confidence interval [CI], 3.5 to 4.2) deaths per 1000 live births from 1975 through 1990 to a rate of 1.5 (95% CI, 0.9 to 2.2) deaths per 1000 live births in 1991 through 1992. The SIDS mortality rate in the cohort by period of birth was 7.6 (95% CI, 4.9 to 10.3) deaths per 1000 live births for those born from May 1, 1988, through April 30, 1991, and 4.1 (95% CI, 1.3 to 7.0) deaths per 1000 infants for those born from May 1, 1998, through October 31, 1992. The prevalence of usual prone sleeping position at 1 month of age was 29.9% and 4.3% in these two cohorts, respectively (adjusted odds ratio, 0.11; 95% CI, 0.08 to 0.13). Logistic regression demonstrated that 70% of the SIDS rate reduction in the cohort could be accounted for by the decreased prevalence of the prone sleeping position. Other factors examined individually contributed to less than 10% of the SIDS rate reduction. Conclusions.-The major contributing factor to the recent SIDS rate decline in Tasmania has been the reduction in the proportion of infants usually sleeping prone.			DWYER, T (corresponding author), UNIV TASMANIA,MENZIES CRR POPULAT HLTH RES,GPO BOX 252C,HOBART,TAS 7000,AUSTRALIA.		Ponsonby, Anne-Louise/AAE-4351-2019	Ponsonby, Anne-Louise/0000-0002-6581-3657	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028979] Funding Source: NIH RePORTER; NICHD NIH HHS [001 HD28979-01A1] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEAL S, 1991, MED J AUSTRALIA, V155, P507, DOI 10.5694/j.1326-5377.1991.tb93882.x; BEAL SM, 1991, J PAEDIATR CHILD H, V27, P334, DOI 10.1111/j.1440-1754.1991.tb00414.x; BEAL SM, 1986, AUST PAEDIATR J, V22, P13; BRESLOW NE, 1993, STATISTICAL METHODS, V2, P109; d'Espaignet E T, 1990, Paediatr Perinat Epidemiol, V4, P422, DOI 10.1111/j.1365-3016.1990.tb00670.x; DWYER T, 1991, LANCET, V337, P1244, DOI 10.1016/0140-6736(91)92917-Q; EMERY JL, 1986, MED J AUSTRALIA, V144, P469, DOI 10.5694/j.1326-5377.1986.tb101052.x; ENGELBERTS AC, 1990, ARCH DIS CHILD, V65, P462, DOI 10.1136/adc.65.4.462; GIBBONS LE, 1993, AM J EPIDEMIOL, V137, P654, DOI 10.1093/oxfordjournals.aje.a116723; GUNTHEROTH WG, 1992, JAMA-J AM MED ASSOC, V267, P2359, DOI 10.1001/jama.267.17.2359; HOFFMAN HJ, 1992, CLIN PERINATOL, V19, P717, DOI 10.1016/S0095-5108(18)30427-5; HOLBOROW P, 1991, NEW ZEAL MED J, V104, P296; JONES ME, 1994, EPIDEMIOLOGY, V5, P332, DOI 10.1097/00001648-199405000-00012; LEE NNY, 1989, BRIT MED J, V298, P721, DOI 10.1136/bmj.298.6675.721; LEWIS J, 1993, LANCET, V341, P51, DOI 10.1016/0140-6736(93)92525-X; MITCHELL EA, 1991, J PAEDIATR CHILD H, V27, P319, DOI 10.1111/j.1440-1754.1991.tb00409.x; MITCHELL EA, 1992, J PAEDIATR CHILD H, V28, pS9, DOI 10.1111/j.1440-1754.1992.tb02732.x; MITCHELL EA, 1992, J PAEDIATR CHILD H S; PONSONBY AL, 1994, PREV MED, V23, P402, DOI 10.1006/pmed.1994.1055; PONSONBY AL, 1992, BRIT MED J, V304, P277, DOI 10.1136/bmj.304.6822.277; PONSONBY AL, 1994, NEW ENGL J MED, V330, P64; PONSONBY AL, 1993, NEW ENGL J MED, V329, P377, DOI 10.1056/NEJM199308053290601; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P146; SALONEN JT, 1989, INT J EPIDEMIOL, V18, P595, DOI 10.1093/ije/18.3.595; SPIERS PS, 1994, ARCH PEDIAT ADOL MED, V148, P141, DOI 10.1001/archpedi.1994.02170020027004; WILLIAMS AL, 1990, AUST NZ J OBSTET GYN, V30, P98, DOI 10.1111/j.1479-828X.1990.tb03235.x; 1993, STATISTICAL METHODS, V2, P131; 1992, SURVEY INFANT SLEEPI; 1993, BIRTHS 1988 1992 AUS; 1993, FETAL INFANT DEATHS; 1993, DEATHS 1988 1992 AUS; 1991, 112TH SESS NHMRC COU; [No title captured]; 1990, SAS STAT USERS GUIDE, V2; 1994, FETAL INFANT DEATHS; 1991, J PAEDIATR CHILD HLT, V27, P323; 1990, SAS STAT USERS GUIDE, V1	38	129	130	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	1995	273	10					783	789		10.1001/jama.273.10.783	http://dx.doi.org/10.1001/jama.273.10.783			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ750	7861572				2022-12-28	WOS:A1995QJ75000029
J	QUILL, TE; CASSEL, CK				QUILL, TE; CASSEL, CK			NONABANDONMENT - A CENTRAL OBLIGATION FOR PHYSICIANS	ANNALS OF INTERNAL MEDICINE			English	Article							INFORMED CONSENT; CARE; MODELS; ILL	Nonabandonment is one of a physician's central ethical obligations; it reflects a longitudinal commitment both to care about patients and to jointly seek solutions to problems with patients throughout their illnesses. The depth of this commitment may vary depending on the physician's and the patient's values and personalities, their shared experiences, and the patient's clinical circumstances. Traditional principled ethical analyses must balance the personal histories, values, motivations, and intentions of the participants with more general considerations. Such analyses often focus on a particular act, isolated in time, and yet the consequences of one decision immediately lead to a new set of choices. Nonabandonment places the physician's open-ended, long-term, caring commitment to joint problem solving at the core of medical ethics and clinical medicine. There is a world of difference between facing an uncertain future alone and facing it with a committed, caring, knowledgeable partner who will not shy away from difficult decisions when the path is unclear.	UNIV ROCHESTER, SCH MED, ROCHESTER, NY USA; UNIV CHICAGO, SCH MED, GEN INTERNAL MED SECT, CHICAGO, IL 60637 USA	University of Rochester; University of Chicago								[Anonymous], 2014, MANS SEARCH MEANING; BARON RJ, 1985, ANN INTERN MED, V103, P606, DOI 10.7326/0003-4819-103-4-606; Beauchamp TL, 2009, PRINCIPLES BIOMEDICA; BENSON JA, 1983, ANN INTERN MED, V99, P720, DOI 10.7326/0003-4819-99-5-720; BERNAT JL, 1993, ARCH INTERN MED, V153, P2723, DOI 10.1001/archinte.153.24.2723; Brody H., 1987, STORIES SICKNESS; Cassel, 1991, NATURE SUFFERING GOA; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; EMANUEL EJ, 1993, NEW ENGL J MED, V329, P879, DOI 10.1056/NEJM199309163291213; FOX RC, IN PRESS ENTRY US BI; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; Gilligan C., 1982, DIFFERENT VOICE; GUSTAFSON JM, 1990, J MED PHILOS, V15, P125, DOI 10.1093/jmp/15.2.125; Jonsen A. R., 1988, ABUSE CASUISTRY HIST; Jonsen Albert R., 1998, CLIN ETHICS, V4th; KATZ J, 1992, HUM MED, V8, P187; KRAUT AM, 1990, JAMA-J AM MED ASSOC, V263, P1807, DOI 10.1001/jama.263.13.1807; LIDZ CW, 1988, ARCH INTERN MED, V148, P1385, DOI 10.1001/archinte.148.6.1385; MacIntyre A., 1984, AFTER VIRTUE; MATTHEWS DA, 1993, ANN INTERN MED, V118, P973, DOI 10.7326/0003-4819-118-12-199306150-00010; MAY WF, 1983, PHYSICIANS COVENANT; Montgomery Hunter K, 1991, DOCTORS STORIES NARR; NOBLE J, 1987, TXB GENERAL MED PRIM, P3; NOVACK DH, 1987, J GEN INTERN MED, V2, P346, DOI 10.1007/BF02596174; Peabody FW, 1927, J AMER MED ASSOC, V88, P0877, DOI 10.1001/jama.1927.02680380001001; PELLEGRINO ED, 1993, JAMA-J AM MED ASSOC, V270, P874, DOI 10.1001/jama.270.7.874; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; QUILL TE, 1983, ANN INTERN MED, V98, P228, DOI 10.7326/0003-4819-98-2-228; QUILL TE, 1991, ARCH INTERN MED, V151, P463; QUILL TE, 1990, ARCH INTERN MED, V150, P1857, DOI 10.1001/archinte.150.9.1857; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; QUILL TE, 1993, NEW ENGL J MED, V329, P1039, DOI 10.1056/NEJM199309303291414; Quill TE, 1993, DEATH DIGNITY MAKING; Ramsey Paul, 1970, PATIENT PERSON; Rogers C.A., 1961, BECOMING PERSON; SEDLER RA, 1993, HASTINGS CENT REP, V23, P20, DOI 10.2307/3562062; Sherwin S., 1992, NO LONGER PATIENT FE; SHOWSTACK J, 1992, JAMA-J AM MED ASSOC, V267, P2497, DOI 10.1001/jama.267.18.2497; SINGER GR, 1975, NEW ENGL J MED, V293, P780; TOULMIN S, 1981, HASTINGS CENT REP, V11, P31, DOI 10.2307/3560542; TRUOG RD, 1992, NEW ENGL J MED, V327, P1678, DOI 10.1056/NEJM199212033272311; ZANER RM, 1970, WAY PHENOMENOLOGY; ZINN W, 1993, ARCH INTERN MED, V153, P306, DOI 10.1001/archinte.153.3.306; 1992, ANN INTERN MED, V117, P947; 1986, CURRENT OPINIONS 198, P8; 1992, JAMA-J AM MED ASSOC, V276, P2229	48	185	185	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1995	122	5					368	374		10.7326/0003-4819-122-5-199503010-00008	http://dx.doi.org/10.7326/0003-4819-122-5-199503010-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ085	7847649				2022-12-28	WOS:A1995QJ08500008
J	PERRIMON, N				PERRIMON, N			HEDGEHOG AND BEYOND	CELL			English	Review							GENE				PERRIMON, N (corresponding author), HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115, USA.			Perrimon, Norbert/0000-0001-7542-472X				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; BUMCROT DA, 1995, IN PRESS MOL CELL BI; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CHANG DT, 1994, DEVELOPMENT, V120, P3339; DEVREOTES PN, 1994, NEURON, V12, P235, DOI 10.1016/0896-6273(94)90267-4; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; FORBES AJ, 1993, DEVELOPMENT S, V119, P115; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HOOPER JE, 1994, NATURE, V372, P461, DOI 10.1038/372461a0; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEPAGE T, 1995, IN PRESS NATURE; LI W, 1994, NATURE, V371, P609; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SMITH JC, 1994, CELL, V76, P193, DOI 10.1016/0092-8674(94)90325-5; STRUTT DI, 1995, IN PRESS NATURE; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9	25	152	175	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					517	520		10.1016/0092-8674(95)90503-0	http://dx.doi.org/10.1016/0092-8674(95)90503-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867057	Bronze			2022-12-28	WOS:A1995QJ60200001
J	ADAMOPOULOS, S; PIEPOLI, M; QIANG, FX; PISSIMISSIS, E; DAVIES, M; BERNARDI, L; FORFAR, C; SLEIGHT, P; COATS, A				ADAMOPOULOS, S; PIEPOLI, M; QIANG, FX; PISSIMISSIS, E; DAVIES, M; BERNARDI, L; FORFAR, C; SLEIGHT, P; COATS, A			EFFECTS OF PULSED BETA-STIMULANT THERAPY ON BETA-ADRENOCEPTORS AND CHRONOTROPIC RESPONSIVENESS IN CHRONIC HEART-FAILURE	LANCET			English	Article							ADRENERGIC-RECEPTOR DENSITY; AUTONOMIC FUNCTION; DOBUTAMINE; EXERCISE; INFUSION; NOREPINEPHRINE; IMPROVEMENT; MORTALITY; TOLERANCE; HUMANS	In animals, intermittent sympathomimetic stimulation with dobutamine produces benefits analogous to those of physical conditioning. Longer intermittent or continuous beta-stimulant therapies have not, however, been successful in managing patients with chronic heart failure. We have investigated the role of beta-receptor stimulants in patients with severe chronic heart failure by changing the method of administration to intermittent, very short-duration pulsed intrope therapy (PIT). We studied 10 patients (mean age 64 [SE 2] years) with stable moderate to severe chronic heart failure (ejection fraction 23 [3]%) who received PIT, and 10 control patients matched for age and severity. We infused sufficient dobutamine to raise heart rate to 70-80% maximum for 30 min per day, 4 days per week for 3 weeks. PIT increased exercise tolerance (from 10.4 [1.2] min at baseline to 13.0 [1.5] min at 3 weeks; p<0.001, 95% CI for difference 1.6 to 3.9) and lowered peripheral vascular resistance (19.8 [3.1] to 17.7 [2.4] mm Hg.min.L(-1); p<0.05, -4.1 to -0.1). PIT produced significant increases in lymphocyte beta-receptor density (502 [110] to 1200 [219] per cell, p<0.02, 258 to 1138) and chronotropic responsiveness to exercise (change in heart rest to peak exercise 51.0 [3.2] to 57.5 [3.9] beats per min; p<0.01, 2.9-10.1), Plasma noradrenaline concentrations (2.39 [0.28] to 1.65 [0.19] nmol/L, p<0.05) were reduced. The patients' symptoms were also improved. By contrast, no change in autonomic function or exercise capacity was seen in the control group. Short-duration PIT induces pharmacological conditioning with improved symptoms, autonomic balance, exercise tolerance, beta-receptor up-regulation, and enhanced chronotropic responsiveness in chronic heart failure.	NATL HEART & LUNG INST, DEPT CARDIAC MED, LONDON SW3 6LY, ENGLAND; JOHN RADCLIFFE HOSP, DEPT CARDIOVASC MED, OXFORD OX3 9DU, ENGLAND; UNIV BIRMINGHAM, QUEEN ELIZABETH HOSP, DEPT CARDIOVASC MED, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND; UNIV PAVIA, I-27100 PAVIA, ITALY	Imperial College London; University of Oxford; University of Birmingham; University of Pavia			Piepoli, Massimo/HHC-3488-2022; Piepoli, Massimo F/J-9437-2016; Stewart Coats, Andrew/E-4451-2012	Piepoli, Massimo/0000-0003-1124-234X; Piepoli, Massimo F/0000-0003-1124-234X; Stewart Coats, Andrew/0000-0002-2771-4260				BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; BRODDE OE, 1986, SCIENCE, V231, P1584, DOI 10.1126/science.3006250; BUTLER J, 1983, J PHYSIOL-LONDON, V344, P113, DOI 10.1113/jphysiol.1983.sp014927; COATS AJS, 1992, CIRCULATION, V85, P2119, DOI 10.1161/01.CIR.85.6.2119; COATS AJS, 1990, LANCET, V335, P63, DOI 10.1016/0140-6736(90)90536-E; COATS AJS, 1992, BRIT HEART J, V68, P223; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; COLUCCI WS, 1989, CIRCULATION, V80, P314, DOI 10.1161/01.CIR.80.2.314; COLUCCI WS, 1981, NEW ENGL J MED, V305, P185, DOI 10.1056/NEJM198107233050402; DIES F, 1986, CIRCULATION, V74, P38; ECKBERG DL, 1971, NEW ENGL J MED, V285, P877, DOI 10.1056/NEJM197110142851602; ERLEMEIER HH, 1992, CARDIOVASC DRUG THER, V6, P391, DOI 10.1007/BF00054187; ESLER M, 1979, LIFE SCI, V25, P1461, DOI 10.1016/0024-3205(79)90371-0; FOWLER MB, 1986, CIRCULATION, V74, P1290, DOI 10.1161/01.CIR.74.6.1290; FOWLER MB, 1985, J AM COLL CARDIOL, V5, P535; HORN EM, 1988, CIRCULATION, V78, P1373, DOI 10.1161/01.CIR.78.6.1373; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; LIANG CS, 1979, J CLIN INVEST, V64, P613, DOI 10.1172/JCI109501; LIANG CS, 1984, CIRCULATION, V69, P113, DOI 10.1161/01.CIR.69.1.113; MAKI T, 1989, ACTA PHYSIOL SCAND, V136, P569, DOI 10.1111/j.1748-1716.1989.tb08703.x; MICHEL MC, 1988, BRIT J PHARMACOL, V94, P685, DOI 10.1111/j.1476-5381.1988.tb11576.x; OLIVARI MT, 1983, J AM COLL CARDIOL, V2, P411, DOI 10.1016/S0735-1097(83)80266-6; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; POMERANZ B, 1985, AM J PHYSIOL, V248, pH151, DOI 10.1152/ajpheart.1985.248.1.H151; TOHMEH JF, 1980, J CLIN INVEST, V65, P836, DOI 10.1172/JCI109735; TOWNEND JN, 1993, EUR HEART J, V14, P243, DOI 10.1093/eurheartj/14.2.243; UNVERFERTH DV, 1980, J PHARMACOL EXP THER, V215, P527; VONLEIER C, 1982, CIRCULATION, V65, P1382, DOI 10.1161/01.CIR.65.7.1382	29	31	42	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 11	1995	345	8946					344	349		10.1016/S0140-6736(95)90339-9	http://dx.doi.org/10.1016/S0140-6736(95)90339-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF722	7845114				2022-12-28	WOS:A1995QF72200007
J	SINGER, MI; ANGLIN, TM; SONG, LY; LUNGHOFER, L				SINGER, MI; ANGLIN, TM; SONG, LY; LUNGHOFER, L			ADOLESCENTS EXPOSURE TO VIOLENCE AND ASSOCIATED SYMPTOMS OF PSYCHOLOGICAL TRAUMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTTRAUMATIC-STRESS-DISORDER; CHILD-ABUSE; SCHOOL; YOUTH; MALTREATMENT; CONSEQUENCES; COMMUNITY; IMPACT; EVENTS; AGE	Objective.-To examine the extent to which adolescents are exposed to various types of violence as either victims or witnesses, and the association of such exposure with trauma symptoms; specifically, the hypotheses that exposure to violence will have a positive and significant association with depression, anger, anxiety, dissociation, posttraumatic stress, and total trauma symptoms. Design and Setting.-The study employed a survey design using an anonymous self-report questionnaire administered to students (grades 9 through 12) in six public high schools during the 1992-1993 school year. Participants.-Sixty-eight percent of the students attending the participating schools during the survey participated in the study (N=3735). Ages ranged from 14 to 19 years; 52% were female; and 35% were African American, 33% white, and 23% Hispanic. Results.-All hypotheses were supported. Multiple regression analyses of the total sample revealed that violence exposure variables (and to a lesser extent, demographic variables) explained a significant portion of variance in all trauma symptom scores, including depression (R(2)=.31), anger (R(2)=.30), anxiety (R(2)=.30), dissociation (R(2)=.23), posttraumatic stress (R(2)=.31), and total trauma (R(2)=.37). Conclusions.-A significant and consistent association was demonstrated linking violence exposure to trauma symptoms within a diverse sample of high school students. Our findings give evidence of the need to identify and provide trauma-related services for adolescents who have been exposed to violence.	UNIV COLORADO,SCH MED,DEPT PEDIAT,DENVER,CO; CHILDRENS HOSP,ADOLESCENT MED SECT,DENVER,CO	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Children's Hospital Colorado	SINGER, MI (corresponding author), CASE WESTERN RESERVE UNIV,MANDEL SCH APPL SOCIAL SCI,10900 EUCLID AVE,CLEVELAND,OH 44106, USA.							ACHENBACH TM, 1991, MANUAL CHILD BEHAVIO; BAKER AM, 1990, AM J ORTHOPSYCHIAT, V60, P496, DOI 10.1037/h0079207; Bell C C, 1991, J Health Care Poor Underserved, V2, P175; BERMAN AL, 1991, ADOLESCENT SUICIDE A; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; BRIERE J, IN PRESS PROFESSIONA; BROUNSTEIN PJ, 1989, PATTERNS SUBSTANCE U; BROWNE A, 1986, PSYCHOL BULL, V99, P66, DOI 10.1037/0033-2909.99.1.66; DAWES A, 1989, INT J MENT HEALTH, V18, P16, DOI 10.1080/00207411.1989.11449122; DODGE KA, 1990, SCIENCE, V250, P1678, DOI 10.1126/science.2270481; Dryfoos JG., 1990, ADOLESCENTS RISK PRE; DURANT DH, 1994, AM J PUBLIC HEALTH, V84, P612; ELLIOTT DM, 1994, BEHAV SCI LAW, V12, P261, DOI 10.1002/bsl.2370120306; EVANS JJ, 1994, JAN C CHILD MALTR SA; FAMULARO R, 1993, AM J DIS CHILD, V147, P755, DOI 10.1001/archpedi.1993.02160310057018; FINGERHUT LA, 1992, JAMA-J AM MED ASSOC, V267, P3048, DOI 10.1001/jama.267.22.3048; FITZPATRICK KM, 1993, J AM ACAD CHILD PSY, V32, P424, DOI 10.1097/00004583-199303000-00026; FREEMAN LN, 1993, J AM ACAD CHILD PSY, V32, P419, DOI 10.1097/00004583-199303000-00025; Garbarino J., 1992, CHILDREN DANGER COPI; GARBARINO J, 1989, NOTE CHILDREN YOUGH; GREENE MB, 1993, CRIME DELINQUENCY, V39, P106, DOI 10.1177/0011128793039001007; HIBBARD RA, 1990, PEDIATRICS, V86, P896; JOHNSON SB, 1988, BEHAV ASSESSMENT CHI, P491; JOHNSTON LD, 1992, NIH933480 NAT I DRUG, P1; KAISER HF, 1970, PSYCHOMETRIKA, V35, P401, DOI 10.1007/BF02291817; KOOP CE, 1992, JAMA-J AM MED ASSOC, V267, P3075, DOI 10.1001/jama.267.22.3075; KOOP CE, 1994, JAMA-J AM MED ASSOC, V271, P1404; KOOP CE, 1992, JAMA-J AM MED ASSOC, V268, P3074; KOVACS M, 1977, DEPRESSION CHILDHOOD, P43; LANKTREE CB, 1993, 101 ANN M AM PSYCH A; LANKTREE CB, 1991, 99TH ANN M AM PSYCH; LEWIS DO, 1992, J AM ACAD CHILD PSY, V31, P383, DOI 10.1097/00004583-199205000-00001; MALMQUIST CP, 1986, J AM ACAD CHILD PSY, V25, P320, DOI 10.1016/S0002-7138(09)60253-3; MARTINEZ P, 1993, PSYCHIATRY, V56, P22; Pynoos R.S., 1988, J TRAUMA STRESS, V1, P445, DOI [DOI 10.1002/JTS.2490010406, https://doi.org/10.1002/jts.2490010406]; PYNOOS RS, 1987, ARCH GEN PSYCHIAT, V44, P1057; PYNOOS RS, 1985, POSTTRAUMATIC STRESS, P17; SACK WH, 1986, J AM ACAD CHILD PSY, V25, P377, DOI 10.1016/S0002-7138(09)60260-0; SCHUBINER H, 1993, J ADOLESCENT HEALTH, V14, P214, DOI 10.1016/1054-139X(93)90008-D; SHAKOOR BH, 1991, J NATL MED ASSOC, V83, P233; SHELEY JF, 1992, AM J DIS CHILD, V146, P677, DOI 10.1001/archpedi.1992.02160180035012; STRAKER G, 1988, CHILD ABUSE NEGLECT, V12, P383, DOI 10.1016/0145-2134(88)90051-8; TAL A, 1976, PSYCHOSOM MED, V38, P190, DOI 10.1097/00006842-197605000-00005; TERR LC, 1985, PSYCHIAT CLIN N AM, V8, P815; WOLFE DA, 1992, AGGRESSION AND VIOLENCE THROUGHOUT THE LIFE SPAN, P31; ZIV A, 1974, J PERS SOC PSYCHOL, V30, P24, DOI 10.1037/h0036611; 1989, NATIONAL ADOLESCENT; 1993, JAMA-J AM MED ASSOC, V270, P1850; 1991, NCJ131645 US DEP JUS; 1993, NCJ144776 US DEP JUS; 1993, MMWR-MORBID MORTAL W, V42, P773	51	529	535	0	58	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	1995	273	6					477	482		10.1001/jama.273.6.477	http://dx.doi.org/10.1001/jama.273.6.477			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QE498	7837366				2022-12-28	WOS:A1995QE49800031
J	ROBERTS, TL; WOOD, DA; RIEMERSMA, RA; GALLAGHER, PJ; LAMPE, FC				ROBERTS, TL; WOOD, DA; RIEMERSMA, RA; GALLAGHER, PJ; LAMPE, FC			TRANS ISOMERS OF OLEIC AND LINOLEIC ACIDS IN ADIPOSE-TISSUE AND SUDDEN CARDIAC DEATH	LANCET			English	Article							CORONARY HEART-DISEASE; TRANSUNSATURATED FATTY-ACIDS; BODY TISSUE; LIPIDS; WOMEN; RISK; OILS; MEN	Trans isomers of unsaturated fatty acids are formed by biological or industrial hydrogenation. A population case-control study of sudden cardiac death in men was done to test the hypothesis that trans isomers of oleic acid and linoleic acid increase the risk of sudden cardiac death due to coronary artery disease. In adipose tissue obtained at necropsy from 66 cases of sudden cardiac death and taken from 286 healthy age and sex matched controls, the proportions of trans isomers of oleic and linoleic acid were measured by gas-liquid chromatography. In cases, the mean (SE) percentage of total trans fatty acids (C18:1 plus C18:2), expressed as a proportion of all fatty acids, was significantly lower (2.68 [0.08]%) than in healthy controls (2.86 [0.04]%; p<0.05). Trans C18:1 was 2.1 (0.7)% in cases compared with 2.27 (0.04)% (p<0.05) in controls. The proportion of all trans isomers of linoleic acid was 0.58 (0.02)% in cases compared with 0.59 (0.01)% in controls (p=0.98). The estimated relative risk for sudden cardiac death of trans C18:1 and C18:2 fatty acids combined did not differ significantly from 1.0 in relation to the distribution of these trans isomers by quintile in the control population. The relative risk (95% CI) of sudden cardiac death in the top quintile was 0.40 (0.15-1.02) for C18:1 and 1.08 (0.48-2.74) for C18:2 compared with the bottom quintiles of their respective control distributions. When these univariate relations for irans fatty acids were adjusted for coronary risk factors, smoking was the only factor that remained independently associated with risk of sudden cardiac death (2.27 [1.23-4.17]). Overall, there was no evidence of a relation between trans isomers of oleic and linoleic acids combined and sudden cardiac death. However, trans oleic acid was negatively associated with risk of sudden cardiac death, whereas no association with trans forms of linoleic acid was seen. This study does not support the hypothesis that trans isomers increase the risk of sudden cardiac death.	ROYAL BROMPTON HOSP,NATL HEART & LUNG INST,DEPT CLIN EPIDEMIOL,LONDON SW3 6LY,ENGLAND; UNIV EDINBURGH,CARDIOVASC RES UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND; SOUTHAMPTON UNIV HOSP,SOUTHAMPTON GEN HOSP,DEPT PATHOL,SOUTHAMPTON,HANTS,ENGLAND; SOUTHAMPTON UNIV HOSP,SOUTHAMPTON GEN HOSP,DEPT MED STAT & COMP,SOUTHAMPTON,HANTS,ENGLAND	Imperial College London; Royal Brompton Hospital; University of Edinburgh; University of Southampton; University of Southampton			Robles-Sardin, Alma E/M-7714-2015; Lampe, Fiona/I-5826-2019	Robles-Sardin, Alma E/0000-0003-2044-7793; Lampe, Fiona/0000-0001-6851-5471	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		HOLMAN RT, 1956, P SOC EXP BIOL MED, V93, P175, DOI 10.3181/00379727-93-22699; LONDON SJ, 1991, AM J CLIN NUTR, V54, P340, DOI 10.1093/ajcn/54.2.340; MACINTYRE DE, 1984, BLOOD, V63, P848; MANN GV, 1994, LANCET, V343, P1268, DOI 10.1016/S0140-6736(94)92157-1; MCLENNAN PL, 1988, AM HEART J, V116, P709, DOI 10.1016/0002-8703(88)90328-6; MCLENNAN PL, 1985, CAN J PHYSIOL PHARM, V63, P1411, DOI 10.1139/y85-232; MENSINK RP, 1990, NEW ENGL J MED, V323, P439, DOI 10.1056/NEJM199008163230703; MENSINK RP, 1991, EUR J CLIN NUTR, V45, P375; PRIVETT OS, 1955, ARCH BIOCHEM BIOPHYS, V57, P156, DOI 10.1016/0003-9861(55)90188-0; ROBERTS TL, 1993, BRIT HEART J, V70, P524; SARGENT CA, 1990, BIOCHEM SOC T, V18, P1077, DOI 10.1042/bst0181077; THOMAS LH, 1983, J EPIDEMIOL COMMUN H, V37, P22, DOI 10.1136/jech.37.1.22; THOMAS LH, 1992, J EPIDEMIOL COMMUN H, V46, P78, DOI 10.1136/jech.46.1.78; THOMAS LH, 1981, AM J CLIN NUTR, V34, P877, DOI 10.1093/ajcn/34.5.877; THOMAS LH, 1983, J EPIDEMIOL COMMUN H, V37, P16, DOI 10.1136/jech.37.1.16; THOMAS LH, 1981, J EPIDEMIOL COMMUNIT, V35, P252; VESTER I, 1991, P SCAND FORUM LIP RE, V1, P39; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; WOOD DA, 1987, LANCET, V1, P177; WOOD DA, 1984, LANCET, V2, P117, DOI 10.1016/S0140-6736(84)91044-4; WOOD R, 1993, J LIPID RES, V34, P1; 1987, REPORT BRIT NUTRITIO	22	122	127	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					278	282		10.1016/S0140-6736(95)90274-0	http://dx.doi.org/10.1016/S0140-6736(95)90274-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE731	7837861				2022-12-28	WOS:A1995QE73100008
J	GILBERT, RE; WIGFIELD, RE; FLEMING, PJ; BERRY, PJ; RUDD, PT				GILBERT, RE; WIGFIELD, RE; FLEMING, PJ; BERRY, PJ; RUDD, PT			BOTTLE-FEEDING AND THE SUDDEN-INFANT-DEATH-SYNDROME	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SLEEPING POSITION; UNEXPECTED DEATH; RISK-FACTORS; BREAST-MILK; COT DEATH; EPIDEMIOLOGY; CHILDREN; PRETERM	Objective-To determine whether the risk of the sudden infant death syndrome is increased in bottle fed babies. Design-Population based case-control study matching for age and time. Subjects-All babies aged 1 week to 1 year dying of sudden infant death syndrome during November 1987 to April 1989 or February 1990 to June 1991 and two live controls. Setting-Avon and north Somerset. Main outcome measures-Breast or bottle feeding, sleeping position, maternal smoking, parental employment, and length of gestation. Results-Compared with being fully breast fed, the crude odds ratio for sudden infant death in fully bottle fed babies was 3.1 and for mixed breast and bottle fed babies 1.5. These odds ratios fell to 1.8 (95% confidence interval 0.7 to 4.8) and 1.2 (0.5 to 2.7) respectively after maternal smoking, parental employment, preterm gestation, and sleeping position had been adjusted for. Sleeping position partly masked the effect of being bottle fed on sudden infant death as breast fed babies were more likely to have slept prone than bottle fed babies. Conclusions-Bottle feeding is not a significant independent risk factor for the sudden infant death syndrome. Patterns of maternal smoking, preterm gestation, and parental employment status account for most of the apparent association with bottle feeding.	ST MICHAELS HOSP, DEPT CHILD HLTH, BRISTOL BS2 8EG, AVON, ENGLAND; ROYAL UNITED HOSP, BATH UNIT RES PAEDIAT, BATH BA1 3NG, AVON, ENGLAND; ST MICHAELS HOSP, DEPT PAEDIAT PATHOL, BRISTOL BS2 8EG, AVON, ENGLAND		GILBERT, RE (corresponding author), INST CHILD HLTH, DEPT EPIDEMIOL & BIOSTAT, LONDON WC1N 1EH, ENGLAND.		Fleming, Peter J/A-9081-2010; Fleming, Peter/O-3231-2019	Fleming, Peter J/0000-0003-2521-5764; Fleming, Peter/0000-0003-2521-5764; Gilbert, Ruth/0000-0001-9347-2709	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEAL SM, 1986, AUST PAEDIATR J, V22, P13; BIERINGSORENSEN F, 1978, ACTA PAEDIATR SCAND, V67, P129, DOI 10.1111/j.1651-2227.1978.tb16292.x; BROOKS JG, 1994, PEDIATRICS, V94, P456; CARPENTE.RG, 1965, BRIT J PREV SOC MED, V19, P1; DWYER T, 1991, LANCET, V337, P1244, DOI 10.1016/0140-6736(91)92917-Q; ENGELBERTS AC, 1991, THESIS; FEDRICK J, 1974, BRIT J PREV SOC MED, V28, P164; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; FORD RPK, 1993, INT J EPIDEMIOL, V22, P885, DOI 10.1093/ije/22.5.885; FROGART P, 1971, BR J PREV SOC MED, V49, P119; HARRIS JDC, 1982, J EPIDEMIOL COMMUN H, V36, P162, DOI 10.1136/jech.36.3.162; HOFFMAN HJ, 1988, ANN NY ACAD SCI, V533, P13, DOI 10.1111/j.1749-6632.1988.tb37230.x; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; KNOWELDEN J, 1984, MULTICENTRE STUDY PO; KRAUS AS, 1971, C J PUBLIC HEALTH, V62, P210; KRAUS JF, 1989, INT J EPIDEMIOL, V18, P113, DOI 10.1093/ije/18.1.113; LUCAS A, 1990, LANCET, V336, P1519, DOI 10.1016/0140-6736(90)93304-8; LUCAS A, 1992, LANCET, V339, P261, DOI 10.1016/0140-6736(92)91329-7; LUCAS A, 1990, BRIT MED J, V300, P837, DOI 10.1136/bmj.300.6728.837; MCGLASHAN ND, 1989, SOC SCI MED, V29, P1015, DOI 10.1016/0277-9536(89)90059-2; MITCHELL EA, 1992, AUST J PUBLIC HEALTH, V16, P158; MURPHY JF, 1982, J EPIDEMIOL COMMUN H, V36, P17, DOI 10.1136/jech.36.1.17; POLLOCK JI, 1992, EFFECTS SMOKING FETU, P108; PROTESTOS CD, 1973, ARCH DIS CHILD, V48, P835, DOI 10.1136/adc.48.11.835; RHEAD WJ, 1973, BMJ-BRIT MED J, V4, P548, DOI 10.1136/bmj.4.5891.548-d; SAVAGE F, 1992, MIDIRS MIDWIFERY DIG, V2, P3; WATSON E, 1981, MED SCI LAW, V21, P78, DOI 10.1177/002580248102100202; WHITE AS, 1992, INFANT FEEDING 1990; WIGFIELD RE, 1992, BRIT MED J, V304, P282, DOI 10.1136/bmj.304.6822.282; WILLIAMS AF, 1994, ARCH DIS CHILD, V71, P376; 1993, REPORT CHIEF MED OFF	31	47	48	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 14	1995	310	6972					88	90		10.1136/bmj.310.6972.88	http://dx.doi.org/10.1136/bmj.310.6972.88			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC223	7833732	Green Published			2022-12-28	WOS:A1995QC22300018
J	PAGE, DL; STEEL, CM; DIXON, JM				PAGE, DL; STEEL, CM; DIXON, JM			ABC OF BREAST DISEASES - CARCINOMA IN-SITU AND PATIENTS AT HIGH-RISK OF BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article									UNIV ST ANDREWS,ST ANDREWS,FIFE,SCOTLAND; ROYAL INFIRM,EDINBURGH,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of St Andrews; Royal Infirmary of Edinburgh; University of Edinburgh	PAGE, DL (corresponding author), VANDERBILT UNIV,MED CTR,NASHVILLE,TN 37232, USA.								0	32	33	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 7	1995	310	6971					39	42		10.1136/bmj.310.6971.39	http://dx.doi.org/10.1136/bmj.310.6971.39			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB060	7827556	Green Published			2022-12-28	WOS:A1995QB06000035
J	KALRA, D				KALRA, D			MEDICINE IN EUROPE .11. ELECTRONIC HEALTH RECORDS - THE EUROPEAN SCENE	BRITISH MEDICAL JOURNAL			English	Article								Caring for patients' health problems relies increasingly on sharing information between clinical departments and disciplines and with managers. The medical record of the future will need to provide a flexible and shareable framework for recording and analysing the consultation process. The advanced informatics in medicine (AIM) programme seeks to encourage research and development in telemedicine in areas that are beyond the scope of any one country. It includes many European projects attempting to define the best storage and transmission formats for such diverse data types as laboratory results, biosignals, x ray images, and photographs, and in clinical specialties varying from intensive care to medicine for elderly people. One example, the good European health record project, is developing a model architecture for computerised health records across Europe that is capable of operating on a wide variety of computer hardwares and will also be able to communicate with many different information systems. The ultimate European health record will be comprehensive and medicolegally acceptable across clinical domains, hold all data types, and be automatically translated between languages.			KALRA, D (corresponding author), UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,CLIN RECORDS RES UNIT,LONDON EC1M 6BQ,ENGLAND.		Kalra, D/H-6661-2019	Kalra, D/0000-0001-5254-4067					0	19	19	0	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 19	1994	309	6965					1358	1361		10.1136/bmj.309.6965.1358	http://dx.doi.org/10.1136/bmj.309.6965.1358			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT625	7866088	Green Published			2022-12-28	WOS:A1994PT62500034
J	LINDPAINTNER, K				LINDPAINTNER, K			FINDING AN OBESITY GENE - A TALE OF MICE AND MAN	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											LINDPAINTNER, K (corresponding author), BRIGHAM & WOMENS HOSP,75 FRANCIS ST,BOSTON,MA 02115, USA.							ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	1	35	39	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 9	1995	332	10					679	680		10.1056/NEJM199503093321012	http://dx.doi.org/10.1056/NEJM199503093321012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK066	7845436				2022-12-28	WOS:A1995QK06600012
J	WUTHRICH, DA; LEBOWITZ, AL				WUTHRICH, DA; LEBOWITZ, AL			TOPHACEOUS GOUT	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									BOSTON UNIV,MED CTR,BOSTON,MA 02118	Boston University	WUTHRICH, DA (corresponding author), UNIV WASHINGTON,SEATTLE,WA 98195, USA.								0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 9	1995	332	10					646	646		10.1056/NEJM199503093321005	http://dx.doi.org/10.1056/NEJM199503093321005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK066	7845429				2022-12-28	WOS:A1995QK06600005
J	SCHIEVINK, WI; MICHELS, VV; MOKRI, B; PIEPGRAS, DG; PERRY, HO				SCHIEVINK, WI; MICHELS, VV; MOKRI, B; PIEPGRAS, DG; PERRY, HO			A FAMILIAL SYNDROME OF ARTERIAL DISSECTIONS WITH LENTIGINOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							INTERNAL CAROTID-ARTERY; AORTIC DISSECTION; CUSHINGS-SYNDROME; ATRIAL-MYXOMA; NEURAL CREST; DISEASE; DYSPLASIA; NECROPSY; ANEURYSM; COMPLEX		MAYO CLIN & MAYO FDN, DEPT MED GENET, ROCHESTER, MN USA; MAYO CLIN & MAYO FDN, DEPT NEUROL, ROCHESTER, MN USA; MAYO CLIN & MAYO FDN, DEPT DERMATOL, ROCHESTER, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	SCHIEVINK, WI (corresponding author), MAYO CLIN & MAYO FDN, DEPT NEUROL SURG, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							ATHERTON DJ, 1980, BRIT J DERMATOL, V103, P421, DOI 10.1111/j.1365-2133.1980.tb07266.x; BAIN J, 1986, MAYO CLIN PROC, V61, P508, DOI 10.1016/S0025-6196(12)61989-2; BEIGHTON P, 1993, MCKUSICKS HERITABLE, P189; CARNEY JA, 1985, MEDICINE, V64, P270, DOI 10.1097/00005792-198507000-00007; CARNEY JA, 1990, AM J SURG PATHOL, V14, P206, DOI 10.1097/00000478-199003000-00002; EDWARDS BS, 1982, MAYO CLIN PROC, V57, P564; FOX B, 1990, CAUSE MANAGEMENT ANE, P79; GORLIN RJ, 1969, AM J DIS CHILD, V117, P652, DOI 10.1001/archpedi.1969.02100030654006; GUTHRIE W, 1972, J PATHOL, V108, P219, DOI 10.1002/path.1711080308; KAPPETEIN AP, 1991, J THORAC CARDIOV SUR, V102, P830, DOI 10.1016/S0022-5223(19)33931-5; KUIVANIEMI H, 1993, NEUROLOGY, V43, P2652, DOI 10.1212/WNL.43.12.2652; LARSON EW, 1984, AM J CARDIOL, V53, P849, DOI 10.1016/0002-9149(84)90418-1; Le Lievre C S, 1975, J Embryol Exp Morphol, V34, P125; LEDOUARIN N, 1982, DEV CELL BIOL, V12; LEVER WF, 1990, HISTOPATHOLOGY SKIN, P772; MACKIE RM, 1992, TXB DERMATOLOGY, V2, P1525; MOKRI B, 1987, STROKE, V18, P246, DOI 10.1161/01.STR.18.1.246; MOKRI B, 1994, SUNDTS OCCLUSIVE CER, P45; NICOD P, 1989, J AM COLL CARDIOL, V13, P811, DOI 10.1016/0735-1097(89)90221-0; PETIT H, 1983, J NEURORADIOLOGY, V10, P15; REES JR, 1973, BRIT HEART J, V35, P874; RHODES AR, 1984, J AM ACAD DERMATOL, V10, P72, DOI 10.1016/S0190-9622(84)80047-X; ROBERTS WC, 1982, AM HEART J, V104, P115, DOI 10.1016/0002-8703(82)90650-0; ROSENQUIST TH, 1990, ANAT RECORD, V226, P347, DOI 10.1002/ar.1092260312; RUBINSTEIN M, 1964, NEUROLOGY, V14, P125, DOI 10.1212/WNL.14.2.125; SCHIEVINK WI, 1994, NEW ENGL J MED, V330, P393, DOI 10.1056/NEJM199402103300604; SCHIEVINK WI, 1994, LANCET, V343, P452, DOI 10.1016/S0140-6736(94)92693-X; SCHIEVINK WI, 1994, NEUROLOGY, V44, P1607, DOI 10.1212/WNL.44.9.1607; SCHIEVINK WI, 1994, STROKE, V25, P889, DOI 10.1161/01.STR.25.4.889; SCHIEVINK WI, 1993, STROKE, V24, P1678, DOI 10.1161/01.STR.24.11.1678; SCHWEIZERCAGIANUT M, 1982, VIRCHOWS ARCH A, V397, P183, DOI 10.1007/BF00442388; SEUANEZ H, 1976, CLIN GENET, V9, P266; SOMIO S, 1993, J AM SOC NEPHROL, V4, P1371; VARANI E, 1988, MED-RIV ENC MED ITAL, V8, P293; WALTHER RJ, 1966, NEW ENGL J MED, V275, P1220, DOI 10.1056/NEJM196612012752203; WARNES CA, 1985, AM J CARDIOL, V55, P236, DOI 10.1016/0002-9149(85)90342-X; YOUNG WF, 1989, NEW ENGL J MED, V321, P1659, DOI 10.1056/NEJM198912143212407	37	40	42	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 2	1995	332	9					576	579		10.1056/NEJM199503023320905	http://dx.doi.org/10.1056/NEJM199503023320905			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ090	7838191				2022-12-28	WOS:A1995QJ09000005
J	MACARTHUR, C; SAUNDERS, N; FELDMAN, W				MACARTHUR, C; SAUNDERS, N; FELDMAN, W			HELICOBACTER-PYLORI, GASTRODUODENAL DISEASE, AND RECURRENT ABDOMINAL-PAIN IN CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							DUODENAL-ULCER DISEASE; GASTRIC-ACID SECRETION; CAMPYLOBACTER-PYLORI; PEPTIC-ULCER; FOLLOW-UP; ANTRAL GASTRITIS; PEPSINOGEN-I; INFECTION; ASSOCIATION; PREVALENCE	Objective.-To assess the evidence for a cause-and-effect relationship between Helicobacter pylori infection and antral gastritis, peptic ulcer disease, and recurrent abdominal pain in children. Data Sources.-A MEDLINE search from January 1983 through July 1994 was used to identify pertinent English-language publications. Current Contents and selected specialty journals were searched manually. Editorials, reviews, case reports, abstracts, and letters to the editor were excluded. Study Selection.-All studies in children (ie, 0 to 18 years) were included. Data Extraction.-Hill's criteria for causal inference were used to determine the strength of the evidence for a causal relationship. Data Synthesis.-In total, 45 studies (case series, cross-sectional surveys, and treatment trials) were retrieved. The rate ratio of antral gastritis in children with H pylori infection (compared with uninfected children) ranged from 1.9 to 71.0 (median, 4.6). The prevalence of H pylori infection in children with duodenal ulcer was high (range, 33% to 100%; median, 92%) compared with children with gastric ulcer (range, 11% to 75%; median, 25%). Prevalence rates of infection in children with recurrent abdominal pain were inconsistent (range, 0% to 81%, median, 22%), with lower rates in children meeting Apley's criteria (range, 0% to 9%; median, 6%). Conclusions.-There is strong evidence for an association between H pylori infection and antral gastritis and duodenal ulcer disease in children; however, data from randomized, double-blind, placebo-controlled treatment trials are required. There is weak evidence for an association with gastric ulcer and weak or no evidence for an association with recurrent abdominal pain.	UNIV TORONTO,TORONTO,ON,CANADA	University of Toronto	MACARTHUR, C (corresponding author), HOSP SICK CHILDREN,DIV GEN PAEDIAT,PAEDIAT OUTCOMES RES TEAM,555 UNIV AVE,TORONTO,ON M5G 1X8,CANADA.							APLEY J, 1957, ARCH DIS CHILD, V33, P165; ARMITAGE P, 1987, STATISTICAL METHODS, P115; ASHORN M, 1993, J PEDIATR GASTR NUTR, V16, P273, DOI 10.1097/00005176-199304000-00009; BLASER MJ, 1990, J INFECT DIS, V161, P626, DOI 10.1093/infdis/161.4.626; BUJANOVER Y, 1990, J PEDIATR GASTR NUTR, V11, P41, DOI 10.1097/00005176-199007000-00008; CARVALHO AST, 1991, BRAZ J MED BIOL RES, V24, P163; CELINSKA-CEDRO D, 1989, Materia Medica Polona, V21, P259; CHAMBERLAIN CE, 1990, ARCH INTERN MED, V150, P951, DOI 10.1001/archinte.150.5.951; CONTINIBALI S, 1990, AM J GASTROENTEROL, V85, P1573; CRABTREE JE, 1991, J CLIN PATHOL, V44, P768, DOI 10.1136/jcp.44.9.768; CZINN SJ, 1987, J PEDIATR-US, V110, P569, DOI 10.1016/S0022-3476(87)80551-6; CZINN SJ, 1986, J PEDIATR-US, V109, P80, DOI 10.1016/S0022-3476(86)80579-0; DEGIACOMA C, 1991, J PEDIATR-US, V119, P205, DOI 10.1016/S0022-3476(05)80728-0; DEGIACOMO C, 1990, J PEDIATR GASTR NUTR, V11, P310; DOOLEY CP, 1988, ANN INTERN MED, V108, P70, DOI 10.7326/0003-4819-108-1-70; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; DRUMM B, 1987, PEDIATRICS, V80, P192; DRUMM B, 1987, NEW ENGL J MED, V316, P1557, DOI 10.1056/NEJM198706183162501; DRUMM B, 1993, GASTROENTEROL CLIN N, V22, P169; DRUMM B, 1990, ARCH DIS CHILD, V65, P1278, DOI 10.1136/adc.65.11.1278; DRUMM B, 1990, NEW ENGL J MED, V322, P359, DOI 10.1056/NEJM199002083220603; DRUMM B, 1988, J PEDIATR-US, V113, P908, DOI 10.1016/S0022-3476(88)80030-1; FALCHETTI D, 1988, Z KINDERCHIR, V1, P50; FARRELL MK, 1993, J PEDIATR GASTR NUTR, V16, P118, DOI 10.1097/00005176-199302000-00003; FICH A, 1991, DIGEST DIS SCI, V36, P10, DOI 10.1007/BF01300079; FIEDOREK SC, 1992, AM J GASTROENTEROL, V87, P347; GLASSMAN MS, 1989, DIGEST DIS SCI, V34, P1501, DOI 10.1007/BF01537100; GLASSMAN MS, 1992, CLIN PEDIATR, V31, P481, DOI 10.1177/000992289203100807; GLASSMAN MS, 1990, DIGEST DIS SCI, V35, P993, DOI 10.1007/BF01537248; GOODWIN CS, 1988, LANCET, V2, P1467; GORMALLY S, 1994, ARCH DIS CHILD, V70, P165, DOI 10.1136/adc.70.3.165; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1495, DOI 10.1016/0016-5085(91)90644-Z; HARDIKAR W, 1991, J GASTROEN HEPATOL, V6, P450, DOI 10.1111/j.1440-1746.1991.tb00886.x; HASSALL E, 1991, DIGEST DIS SCI, V36, P417, DOI 10.1007/BF01298868; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; ISRAEL DM, 1993, J PEDIATR-US, V123, P53, DOI 10.1016/S0022-3476(05)81536-7; Judd R H, 1992, Adv Pediatr, V39, P283; KILBRIDGE PM, 1988, AM J DIS CHILD, V142, P1149, DOI 10.1001/archpedi.1988.02150110027012; KOOP H, 1991, DIGESTION, V48, P230, DOI 10.1159/000200698; KRAMER MS, 1988, CLIN EPIDEMIOLOGY BI, P58; LEE A, 1993, INFECT IMMUN, V61, P1601, DOI 10.1128/IAI.61.5.1601-1610.1993; MAAROOS HI, 1991, SCAND J GASTROENTERO, V26, P95, DOI 10.3109/00365529109103994; MAHONY MJ, 1988, ARCH DIS CHILD, V63, P654, DOI 10.1136/adc.63.6.654; MAHONY MJ, 1992, ARCH DIS CHILD, V67, P940, DOI 10.1136/adc.67.7.940; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MAVROMICHALIS I, 1992, EUR J PEDIATR, V151, P560, DOI 10.1007/BF01957720; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MITCHELL HM, 1993, J PEDIATR GASTR NUTR, V16, P120, DOI 10.1097/00005176-199302000-00004; MORRIS A, 1987, AM J GASTROENTEROL, V82, P192; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; ODERDA G, 1989, ARCH DIS CHILD, V64, P326, DOI 10.1136/adc.64.3.326; ODERDA G, 1991, DIGEST DIS SCI, V36, P572, DOI 10.1007/BF01297021; ODERDA G, 1992, GUT, V33, P1328, DOI 10.1136/gut.33.10.1328; ODERDA G, 1989, LANCET, V1, P690; ODERDA G, 1990, J CLIN PATHOL, V43, P762, DOI 10.1136/jcp.43.9.762; ORMAND JE, 1991, DIGEST DIS SCI, V36, P142, DOI 10.1007/BF01300747; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PETERSON WL, 1991, NEW ENGL J MED, V324, P1043, DOI 10.1056/NEJM199104113241507; PRIETO G, 1992, J PEDIATR GASTR NUTR, V14, P420, DOI 10.1097/00005176-199205000-00008; QUEIROZ DMM, 1991, GUT, V32, P464, DOI 10.1136/gut.32.5.464; QUEIROZ DMM, 1991, J PEDIATR GASTR NUTR, V12, P178, DOI 10.1097/00005176-199102000-00007; RADHAKRISHNAN S, 1993, J PEDIATR GASTR NUTR, V16, P126, DOI 10.1097/00005176-199302000-00005; ROCHA GA, 1993, J PEDIATR GASTR NUTR, V16, P247, DOI 10.1097/00005176-199304000-00004; SIPPONEN P, 1990, SCAND J GASTROENTERO, V25, P966, DOI 10.3109/00365529008997621; SULLIVAN PB, 1991, POSTGRAD MED J, V67, P330, DOI 10.1136/pgmj.67.786.330; TAYLOR DN, 1991, EPIDEMIOL REV, V13, P42, DOI 10.1093/oxfordjournals.epirev.a036078; THOMAS JE, 1990, J CLIN MICROBIOL, V28, P2641, DOI 10.1128/JCM.28.12.2641-2646.1990; TROUT KS, 1981, CAN MED ASSOC J, V124, P985; VANDENPLAS Y, 1992, PEDIATRICS, V90, P608; VANDERMEER SB, 1992, EUR J PEDIATR, V151, P799, DOI 10.1007/BF01957927; VANZANTEN SJOV, 1994, CAN MED ASSOC J, V150, P177; VANZANTEN SJOV, 1994, CAN MED ASSOC J, V150, P189; VEEREMANWAUTERS G, 1989, WESTERN J MED, V151, P406; WYATT JI, 1990, J CLIN PATHOL, V43, P981, DOI 10.1136/jcp.43.12.981; YAHAV J, 1992, GUT, V33, P1162, DOI 10.1136/gut.33.9.1162; YEUNG CK, 1990, ARCH DIS CHILD, V65, P1212, DOI 10.1136/adc.65.11.1212; YEUNG CK, 1990, J PEDIATR GASTR NUTR, V10, P357, DOI 10.1097/00005176-199004000-00016; 1994, JAMA-J AM MED ASSOC, V272, P65; 1993, LANCET, V341, P1359	79	183	185	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	1995	273	9					729	734		10.1001/jama.273.9.729	http://dx.doi.org/10.1001/jama.273.9.729			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH814	7853632				2022-12-28	WOS:A1995QH81400033
J	DAVIES, AE; KIDD, D; STONE, SP; MACMAHON, J				DAVIES, AE; KIDD, D; STONE, SP; MACMAHON, J			PHARYNGEAL SENSATION AND GAG REFLEX IN HEALTHY-SUBJECTS	LANCET			English	Note							ACUTE STROKE; ASPIRATION	The gag reflex is often used in the assessment of swallowing, yet its absence does not predict aspiration in acute stroke. Disordered pharyngeal sensation has been found to be a sensitive predictor. The occurrence of gag reflex and pharyngeal sensation in healthy people is unknown. We studied these tests in 140 healthy subjects (half elderly and half young). Gag reflex was absent in 37% of subjects whereas pharyngeal sensation was absent in only 1. The results largely explain the low predictive value of gag reflex in the assessment of aspiration in acute stroke. Testing pharyngeal sensation would be more likely to be useful in these circumstances.	UNIV LONDON,ROYAL FREE HOSP,SCH MED,DEPT GERIATR MED,LONDON,ENGLAND; UNIV LONDON,NATL HOSP NEUROL & NEUROSURG,DEPT CLIN NEUROL,LONDON,ENGLAND; BELFAST CITY HOSP,DEPT RESP MED,BELFAST,ANTRIM,NORTH IRELAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Belfast City Hospital								GORDON C, 1987, BRIT MED J, V295, P411, DOI 10.1136/bmj.295.6595.411; HORNER J, 1990, NEUROLOGY, V40, P1686, DOI 10.1212/WNL.40.11.1686; HORNER J, 1988, NEUROLOGY, V38, P1359; JENKYN LR, 1985, ARCH NEUROL-CHICAGO, V42, P1154, DOI 10.1001/archneur.1985.04060110036012; KIDD D, 1993, Q J MED, V86, P825; SCHMIDT R, 1993, NEUROLOGY, V43, P2490, DOI 10.1212/WNL.43.12.2490; SPLAINGARD ML, 1988, ARCH PHYS MED REHAB, V69, P637; STANNERS AJ, 1993, AGE AGEING S2, V22, pP17; TOMLINSON BE, 1992, GREENFIELDS NEUROPAT, P1297	9	79	80	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 25	1995	345	8948					487	488		10.1016/S0140-6736(95)90584-7	http://dx.doi.org/10.1016/S0140-6736(95)90584-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7861875				2022-12-28	WOS:A1995QH92900011
J	HALL, DT; STROBEL, DF; FELDMAN, PD; MCGRATH, MA; WEAVER, HA				HALL, DT; STROBEL, DF; FELDMAN, PD; MCGRATH, MA; WEAVER, HA			DETECTION OF AN OXYGEN ATMOSPHERE ON JUPITER MOON EUROPA	NATURE			English	Article							IO PLASMA TORUS; FREQUENCY REDISTRIBUTION; GALILEAN SATELLITES; ELECTRON-IMPACT; CROSS-SECTIONS; SPECTROSCOPY; EXCITATION; MOLECULES; UV	EUROPA, the second large satellite out from Jupiter, is roughly the size of Earth's Moon, but unlike the Moon, it has water ice on its surface(1), There have been Suggestions that an oxygen atmosphere should accumulate around such a body, through reactions which break up the water molecules and form molecular hydrogen and oxygen(2,3), The lighter H-2 molecules would escape from Europa relatively easily, leaving behind an atmosphere rich in oxygen, Here we report the detection of atomic oxygen emission from Europa, which we interpret as being produced by the simultaneous dissociation and excitation of atmospheric O-2 by electrons from Jupiter's magnetosphere, Europa's molecular oxygen atmosphere is very tenuous, with a surface pressure about 10(-11) that of the Earth's atmosphere at sea level.	SPACE TELESCOPE SCI INST,BALTIMORE,MD 21218	Space Telescope Science Institute	HALL, DT (corresponding author), JOHNS HOPKINS UNIV,CTR ASTROPHYS SCI,34TH & CHARLES ST,BALTIMORE,MD 21218, USA.		Strobel, Darrell5/AAO-6643-2021; Weaver, Harold A/D-9188-2016	Strobel, Darrell5/0000-0002-0944-8675; Weaver, Harold A/0000-0003-0951-7762				BAGENAL F, 1994, J GEOPHYS RES-SPACE, V99, P11043, DOI 10.1029/93JA02908; Cheng A.F., 1986, SATELLITES, P403, DOI [10.2307/j.ctv1v3gr3r.13, DOI 10.2307/J.CTV1V3GR3R.13]; CLARK RN, 1980, ICARUS, V44, P388, DOI 10.1016/0019-1035(80)90033-0; GLADSTONE GR, 1992, J GEOPHYS RES-SPACE, V97, P19519, DOI 10.1029/92JA00991; HAPKE B, 1981, ICARUS, V47, P361, DOI 10.1016/0019-1035(81)90184-6; ITIKAWA Y, 1989, J PHYS CHEM REF DATA, V18, P23, DOI 10.1063/1.555841; JOHNSON RE, 1983, GEOPHYS RES LETT, V10, P892, DOI 10.1029/GL010i009p00892; LAHER RR, 1990, J PHYS CHEM REF DATA, V19, P277, DOI 10.1063/1.555872; LANE AL, 1981, NATURE, V292, P38, DOI 10.1038/292038a0; LEE JS, 1980, ASTROPHYS J, V240, P185, DOI 10.1086/158222; MALIN MC, 1986, SATELLITES, P689; MEIER RR, 1991, SPACE SCI REV, V58, P1, DOI 10.1007/BF01206000; MEIER RR, 1982, PLANET SPACE SCI, V30, P439, DOI 10.1016/0032-0633(82)90053-8; NELSON RM, 1987, ICARUS, V72, P358, DOI 10.1016/0019-1035(87)90180-1; SHEMANSKY DE, 1988, J GEOPHYS RES, V93, P1773, DOI 10.1029/JA093iA03p01773; SITTLER EC, 1987, J GEOPHYS RES, V92, P5741, DOI 10.1029/JA092iA06p05741; VANHOOSIER ME, 1988, ASTROPHYS LETT COMM, V27, P163; YUNG YL, 1977, ICARUS, V20, P97; ZIPF EC, 1986, J PHYS B-AT MOL OPT, V19, P2199, DOI 10.1088/0022-3700/19/14/014; [No title captured]	20	278	280	0	55	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					677	679		10.1038/373677a0	http://dx.doi.org/10.1038/373677a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854447				2022-12-28	WOS:A1995QH92800046
J	OTT, M; SCHAEFFEL, F				OTT, M; SCHAEFFEL, F			A NEGATIVELY POWERED LENS IN THE CHAMELEON	NATURE			English	Article							ACCOMMODATION	CHAMELEONS are arboral Lizards that spot their prey visually and catch it by highly precise shots with their long sticky tongue, They scan their environment by large-amplitude independent saccadic eye movements; once an insect is detected, the head axis is aligned towards the target ('head tracking'(1), both eyes come forward to fixate the insect and, in a phase called 'initial protrusion'(2), the sticky tongue is loaded with tension by a special hyoid apparatus(3) and subsequently shot out of the mouth with great precision, Lenses placed in front of the eyes produce predictable errors in distance estimation(4), suggesting that chameleons rely on accommodation cues when measuring the distance to their prey, but focusing has never been measured directly, Using a new technique to measure accommodation(5), we now show that accommodation is precise enough to serve as the major distance cue. Because accurate focusing requires large retinal images, we have tested image magnification and find that it is higher than in any other vertebrate eye scaled to the same size, This is a result of a unique optical design: unlike other vertebrate eyes, the crystalline lens of the chameleon has negative refractive power, Although there is a trend among vertebrates to increase corneal power and to decrease lens power with higher visual acuity, only in the chameleon eye has this tendency led to a reversal of the sign of the power of the lens.	UNIV TUBINGEN,HOSP EYE,DEPT EXPTL OPHTHALMOL,D-72076 TUBINGEN,GERMANY	Eberhard Karls University of Tubingen								ALTEVOGT R, 1954, Z VERGL PHYSIOL, V36, P66, DOI 10.1007/BF00297854; [Anonymous], 1977, VISUAL SYSTEM VERTEB, DOI [DOI 10.1007/978-3-642-66468-7, 10.1007/978-3-642-66468-7_11, DOI 10.1007/978-3-642-66468-7_11]; CITRON MC, 1973, VISION RES, V13, P873, DOI 10.1016/0042-6989(73)90050-3; FLANDERS M, 1985, VISION RES, V25, P935, DOI 10.1016/0042-6989(85)90204-4; GLICKSTEIN M, 1970, SCIENCE, V192, P605; HARKNESS L, 1977, NATURE, V267, P346, DOI 10.1038/267346a0; Martin G.R., 1994, P5; Miller W.H., 1979, HDB SENSORY PHYSL, V7 / 6 / 6 A, P69, DOI [10.1007/978-3-642-66999-6_3, DOI 10.1007/978-3-642-66999-6]; OKEEFE LP, 1988, OPHTHAL PHYSL OPT, V8, P97, DOI 10.1111/j.1475-1313.1988.tb01086.x; SCHAEFFEL F, 1987, J COMP PHYSIOL A, V160, P375, DOI 10.1007/BF00613027; SCHAEFFEL F, 1988, VISION RES, V28, P639, DOI 10.1016/0042-6989(88)90113-7; SCHAEFFEL F, 1994, J OPT SOC AM A, V11, P487, DOI 10.1364/JOSAA.11.000487; SCHAEFFEL F, 1988, CLIN VISION SCI, V3, P83; WAGNER H, 1992, J COMP PHYSIOL A, V169, P515; WAINWRIGHT PC, 1992, J EXP BIOL, V168, P1; YOUNG T, 1801, PHILOS T R SOC LONDO, V19, P23	16	58	59	2	44	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					692	694		10.1038/373692a0	http://dx.doi.org/10.1038/373692a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854450				2022-12-28	WOS:A1995QH92800052
J	SCHMIDT, C; BLADT, F; GOEDECKE, S; BRINKMANN, V; ZSCHIESCHE, W; SHARPE, M; GHERARDI, E; BIRCHMEIER, C				SCHMIDT, C; BLADT, F; GOEDECKE, S; BRINKMANN, V; ZSCHIESCHE, W; SHARPE, M; GHERARDI, E; BIRCHMEIER, C			SCATTER FACTOR/HEPATOCYTE GROWTH-FACTOR IS ESSENTIAL FOR LIVER DEVELOPMENT	NATURE			English	Article							MET RECEPTOR; EPITHELIAL INTERACTIONS; MOLECULAR-CLONING; TYROSINE KINASE; HEPATOCYTE; IDENTIFICATION; CELLS; MOTILITY; GENE	POLYPEPTIDE growth factors are important effecters of cell growth and differentiation in vitro and are thought to be critical for processes such as specification of cell fate, tissue growth and organogenesis in vivo, Scatter factor(1-3)/hepatocyte growth factor(4,5) (SF/HGF) is the prototype of an emerging family of growth factors that resemble in their domain structure and mechanism of activation the blood proteinase plasminogen(6,7). The cellular responses of SF/HGF are mediated by the c-Met tyrosine kinase receptor(8-10). Here we report that mice lacking SF/HGF fail to complete development and die in utero. The mutation affects the embryonic liver, which is reduced in size and shows extensive loss of parenchymal cells, In addition, development of the placenta, particularly of trophoblast cells, is impaired. Thus, SF/HGF is essential for the development of several epithelial organs.	MAX PLANCK GESELL,MAX DELBRUCK LAB,D-50829 COLOGNE,GERMANY; MAX DELBRUCK CTR MOLEC MED,D-13122 BERLIN,GERMANY; UNIV CAMBRIDGE,SCH MED,MRC CTR,ICRF,CELL INTERACT LAB,CAMBRIDGE CB2 2QH,ENGLAND	Max Planck Society; Helmholtz Association; Max Delbruck Center for Molecular Medicine; MRC Laboratory Molecular Biology; University of Cambridge			Gherardi, Ermanno/AAB-9608-2022; Brinkmann, Volker/A-6015-2009	GHERARDI, ERMANNO/0000-0002-0016-2945				BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLAYTON DF, 1985, MOL CELL BIOL, V5, P2623, DOI 10.1128/MCB.5.10.2623; DENK H, 1985, EXP CELL RES, V161, P161, DOI 10.1016/0014-4827(85)90500-2; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HILBERG F, 1993, NATURE, V385, P179; KUEHN R, 1991, Science (Washington D C), V254, P707; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V181, P691, DOI 10.1016/0006-291X(91)91246-9; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; SHIOTA G, 1994, HEPATOLOGY, V19, P962, DOI 10.1016/0270-9139(94)90297-6; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STERN CD, 1990, DEVELOPMENT, V110, P1271; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145	29	1179	1248	2	42	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					699	702		10.1038/373699a0	http://dx.doi.org/10.1038/373699a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854452				2022-12-28	WOS:A1995QH92800054
J	BLENDON, RJ; ALTMAN, DE; BENSON, J; BRODIE, M; JAMES, M; CHERVINSKY, G				BLENDON, RJ; ALTMAN, DE; BENSON, J; BRODIE, M; JAMES, M; CHERVINSKY, G			HEALTH-CARE POLICY IMPLICATIONS OF THE 1994 CONGRESSIONAL ELECTIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									HARVARD UNIV,SCH PUBL HLTH,HARVARD PROGRAM PUBL OPIN & HLTH CARE,BOSTON,MA 02115; HENRY J KAISER FAMILY FDN,MENLO PK,CA; KRC COMMUN RES,NEWTON,MA	Harvard University; Harvard T.H. Chan School of Public Health	BLENDON, RJ (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	1995	273	8					671	674		10.1001/jama.273.8.671	http://dx.doi.org/10.1001/jama.273.8.671			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QG748	7844881				2022-12-28	WOS:A1995QG74800037
J	LEBIHAN, D; JEZZARD, P; HAXBY, J; SADATO, N; RUECKERT, L; MATTAY, V				LEBIHAN, D; JEZZARD, P; HAXBY, J; SADATO, N; RUECKERT, L; MATTAY, V			FUNCTIONAL MAGNETIC-RESONANCE-IMAGING OF THE BRAIN	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							POSITRON-EMISSION TOMOGRAPHY; CEREBRAL BLOOD-FLOW; HUMAN VISUAL-CORTEX; SUPPLEMENTARY MOTOR AREA; SENSORY STIMULATION; CORTICAL AREAS; ACTIVATION; MOVEMENTS; ORGANIZATION; OXYGENATION	This conference reviewed the potential scope of application for recently developed techniques for functional magnetic resonance imaging (fMRI) of the brain. The most successful technique is based on the sensitivity of magnetic resonance imaging (MRI) to magnetic effects caused by the modulation of the oxygenation state of hemoglobin, which is induced by local variations in blood flow during task activation. Typically, the MRI signal increases by a few percentage points during brain activation because blood flow and oxygen supply sharply increase. Brain activation images with excellent combined spatial and temporal resolution have been obtained noninvasively using visual, sensorimotor, or auditory stimuli, or during higher-order cognitive processes such as language or mental imagery. Although sensitive to misregistration artifacts and macroscopic vessels, MRI permits both the direct correlation of function with underlying anatomy and repeated studies on the same person. It may become the method of choice for studies of mental and cognitive processes, presurgical mapping, monitoring recovery from stroke or head injuries, exploration of seizure disorders, or monitoring the effects of neuropharmaceuticals.	NIH,WARREN GRANT MAGNUSON CLIN CTR,DEPT DIAGNOST RADIOL,BETHESDA,MD; NHLBI,CARDIAC ENERGET LAB,BETHESDA,MD 20892; NIMH,PSYCHOL & PSYCHOPATHOL & PATHOL LAB,FUNCT BRAIN IMAGING SECT,BETHESDA,MD; NINCDS,HUMAN MOTOR CONTROL SECT,MED NEUROL BRANCH,BETHESDA,MD; NINCDS,COGNIT NEUROSCI SECT,MED NEUROL BRANCH,BETHESDA,MD; NIMH,DIAGNOST RADIOL RES LAB,OFF INTRAURAL RES,BETHESDA,MD; NIMH,CLIN BRAIN DISORDERS BRANCH,BETHESDA,MD	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	LEBIHAN, D (corresponding author), CEA,SERV HOSP FREDERIC JOLIOT,DRIPP,4 PL GEN LECLERC,F-91401 ORSAY,FRANCE.			Jezzard, Peter/0000-0001-7912-2251; Sadato, Norihiro/0000-0002-9786-3907				BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; BELLIVEAU JW, 1991, SCIENCE, V254, P716, DOI 10.1126/science.1948051; BENSON RR, 1993, 12TH ANN M SOC MAGN, P1398; BERMAN KF, 1991, J CEREB BLOOD FLOW M, V11, pS851; BINDER JR, 1993, 45TH ANN M AM AC NEU, pA189; BOURGEOIS BF, 1993, CURR OPIN NEUROL NEU, V6, P223; BREITER HC, 1993, 12TH ANN M SOC MAGN, P58; Casey B. J., 1993, Society for Neuroscience Abstracts, V19, P1285; Cohen J. D., 1993, Society for Neuroscience Abstracts, V19, P1285; COLEBATCH JG, 1991, J NEUROPHYSIOL, V65, P1392, DOI 10.1152/jn.1991.65.6.1392; CORBETTA M, 1991, J NEUROSCI, V11, P2383; CORBETTA M, 1993, J NEUROSCI, V13, P1202; Cuenod C. A., 1993, Society for Neuroscience Abstracts, V19, P843; CUENOD CA, 1993, 12TH ANN M SOC MAGN, P1387; DEIBER MP, 1991, EXP BRAIN RES, V84, P393; Denis M, 1985, Can J Appl Sport Sci, V10, p4S; DESIMONE R, 1989, HDB NEUROPSYCHOLOGY, P267; ENGEL J, 1993, CURR OPIN NEUROL NEU, V6, P240; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FELTZ DL, 1983, J SPORT PSYCHOL, V5, P25, DOI 10.1123/jsp.5.1.25; Fieldman J. B., 1993, 12TH ANN M SOC MAGN, P1416; FOX PT, 1985, J NEUROPHYSIOL, V54, P348, DOI 10.1152/jn.1985.54.2.348; FOX PT, 1986, P NATL ACAD SCI USA, V83, P1140, DOI 10.1073/pnas.83.4.1140; FOX PT, 1987, J NEUROSCI, V7, P913; Friston K.J., 1994, HUM BRAIN MAPP, V1, P153, DOI DOI 10.1002/HBM.460010207; GHEZ C, 1985, PRINCIPLES NEURAL SC, P488; GRAFTON ST, 1991, J NEUROPHYSIOL, V66, P735, DOI 10.1152/jn.1991.66.3.735; GRAFTON ST, 1993, EXP BRAIN RES, V95, P172; HAALAND KY, 1989, NEUROPSYCHOLOGIA, V27, P961, DOI 10.1016/0028-3932(89)90071-7; HALSBAND U, 1993, BRAIN, V116, P243, DOI 10.1093/brain/116.1.243; HAXBY JV, 1991, P NATL ACAD SCI USA, V88, P1621, DOI 10.1073/pnas.88.5.1621; HAXBY JV, 1994, J NEUROSCI, V14, P6336; HERTZPANNIER L, 1994, 12TH ANN M SOC MAGN, P326; HINKE RM, 1993, NEUROREPORT, V4, P675, DOI 10.1097/00001756-199306000-00018; JACK CR, 1994, RADIOLOGY, V190, P85, DOI 10.1148/radiology.190.1.8259434; JONES RD, 1989, BRAIN, V112, P113, DOI 10.1093/brain/112.1.113; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; KIM SG, 1993, SCIENCE, V261, P615, DOI 10.1126/science.8342027; KIMURA D, 1977, BRAIN, V100, P527, DOI 10.1093/brain/100.3.527; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LAUTERBUR PC, 1973, NATURE, V242, P190, DOI 10.1038/242190a0; LEBIHAN D, 1993, P NATL ACAD SCI USA, V90, P11802, DOI 10.1073/pnas.90.24.11802; LEBIHAN D, 1993, 1993 ANN M SOC MAGN, P11; MANSFIELD P, 1977, J PHYS C SOLID STATE, V10, pL55, DOI 10.1088/0022-3719/10/3/004; MCCARTHY G, 1993, P NATL ACAD SCI USA, V90, P4952, DOI 10.1073/pnas.90.11.4952; McCarthy G., 1993, Society for Neuroscience Abstracts, V19, P790; Nobre A. C., 1993, Society for Neuroscience Abstracts, V19, P1808; NYBERGHANSEN R, 1963, ACTA NEUROL SCAND, V39, P1, DOI 10.1111/j.1600-0404.1963.tb05384.x; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; OJEMANN GA, 1991, J NEUROSCI, V11, P2281; PARKS RW, 1988, J CLIN EXP NEUROPSYC, V10, P565, DOI 10.1080/01688638808402795; Pauling L, 1936, P NATL ACAD SCI USA, V22, P210, DOI 10.1073/pnas.22.4.210; Penfield W, 1937, BRAIN, V60, P389, DOI 10.1093/brain/60.4.389; Petersen S E, 1989, J Cogn Neurosci, V1, P153, DOI 10.1162/jocn.1989.1.2.153; RAO SM, 1993, NEUROLOGY, V43, P2311, DOI 10.1212/WNL.43.11.2311; RAO SM, 1992, 11TH ANN M SOC MAGN, P1827; ROLAND PE, 1980, J NEUROPHYSIOL, V43, P118, DOI 10.1152/jn.1980.43.1.118; ROY C, 1896, J PHYSIOL-LONDON, V11, P85; Rueckert L, 1994, J Neuroimaging, V4, P67; SCHNEIDER W, 1993, NATURE, V365, P150, DOI 10.1038/365150a0; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; Sexton R. S., 1993, Society for Neuroscience Abstracts, V19, P1224; SHIBASAKI H, 1993, BRAIN, V116, P1387, DOI 10.1093/brain/116.6.1387; THULBORN KR, 1982, BIOCHIM BIOPHYS ACTA, V714, P265, DOI 10.1016/0304-4165(82)90333-6; TOOTELL RB, 1995, IN PRESS J NEUROSCI; TURNER R, 1991, MAGNET RESON MED, V22, P159, DOI 10.1002/mrm.1910220117; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549; WASSERMANN EM, 1993, ELECTROEN CLIN NEURO, V89, P424, DOI 10.1016/0168-5597(93)90116-7; WASSERMANN EM, 1992, ELECTROEN CLIN NEURO, V85, P1, DOI 10.1016/0168-5597(92)90094-R; WATSON JDG, 1993, CEREB CORTEX, V3, P79, DOI 10.1093/cercor/3.2.79; WEILLER C, 1992, ANN NEUROL, V31, P463, DOI 10.1002/ana.410310502; Weinberger D. R., 1993, Society for Neuroscience Abstracts, V19, P7; WISE R, 1991, BRAIN, V114, P1803, DOI 10.1093/brain/114.4.1803; ZEKI S, 1991, J NEUROSCI, V11, P641	75	50	50	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	FEB 15	1995	122	4					296	303		10.7326/0003-4819-122-4-199502150-00010	http://dx.doi.org/10.7326/0003-4819-122-4-199502150-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF769	7825767				2022-12-28	WOS:A1995QF76900010
J	ASSAD, JA; MAUNSELL, JHR				ASSAD, JA; MAUNSELL, JHR			NEURONAL CORRELATES OF INFERRED MOTION IN PRIMATE POSTERIOR PARIETAL CARTER	NATURE			English	Article							SACCADE-RELATED ACTIVITY; LATERAL INTRAPARIETAL AREA; ASSOCIATION CORTEX; EYE POSITION; 7A	FOR many types of behaviours, it is necessary to monitor the position or movement of objects that are temporarily occluded. The primate posterior parietal cortex contains neurons that are active during visual guidance tasks: in some cases, even if the visual target disappears transiently(1,2). It has been proposed that activity of this sort could be related to current or planned eye movements(1,2), but it might also provide a more generalized abstract representation of the spatial disposition of targets, even when they are not visible. We have recorded from monkey posterior parietal cortex while the animal viewed a visual stimulus that disappeared, and then, depending on experimental context, could be inferred to be either moving or stationary. During this temporary absence of the stimulus, about half of the neurons were found to be significantly more active on those trials in which the stimulus could be presumed to be moving rather than stationary. The activity was thus present in the absence of either sensory input or motor output, suggesting that it may indeed constitute a generalized representation of target motion.			ASSAD, JA (corresponding author), BAYLOR COLL MED,DIV NEUROSCI S603,HOUSTON,TX 77030, USA.		Maunsell, John/G-5702-2010	Maunsell, John/0000-0003-0018-4439	NEI NIH HHS [R01 EY005911] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSEN RA, 1990, J NEUROSCI, V10, P1176; BARASH S, 1991, J NEUROPHYSIOL, V66, P1109, DOI 10.1152/jn.1991.66.3.1109; BARASH S, 1991, J NEUROPHYSIOL, V66, P1095, DOI 10.1152/jn.1991.66.3.1095; CRIST CF, 1988, J NEUROSCI METH, V26, P117, DOI 10.1016/0165-0270(88)90160-4; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; MOUNTCASTLE VB, 1975, J NEUROPHYSIOL, V38, P871, DOI 10.1152/jn.1975.38.4.871; NEWSOME WT, 1988, J NEUROPHYSIOL, V60, P604, DOI 10.1152/jn.1988.60.2.604; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; ROBINSON DL, 1978, J NEUROPHYSIOL, V41, P910, DOI 10.1152/jn.1978.41.4.910	9	173	174	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 9	1995	373	6514					518	521		10.1038/373518a0	http://dx.doi.org/10.1038/373518a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7845463				2022-12-28	WOS:A1995QF72400058
J	LAMBERT, M				LAMBERT, M			CONTROVERSIES IN MANAGEMENT - SHOULD CAROTID ENDARTERECTOMY BE PURCHASED - PURCHASERS NEED A BROADER PERSPECTIVE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CEREBROVASCULAR-DISEASE; STROKE; ANGIOGRAPHY; OXFORDSHIRE				LAMBERT, M (corresponding author), WAKEFIELD HLTH AUTHOR, WHITE ROSE HOUSE, WAKEFIELD WF1 1LT, W YORKSHIRE, ENGLAND.			Lambert, Mark/0000-0003-3528-9070				ASPLUND K, 1993, CEREBROVASC DIS, V3, P34, DOI 10.1159/000108747; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BROWN MM, 1992, BMJ-BRIT MED J, V305, P1071, DOI 10.1136/bmj.305.6861.1071; CAMPLING EA, 1992, REPORT NATIONAL CONF; DENNIS M, 1991, BRIT MED J, V303, P636, DOI 10.1136/bmj.303.6803.636; DENNIS MS, 1989, STROKE, V20, P333, DOI 10.1161/01.STR.20.3.333; HANKEY GJ, 1990, BMJ-BRIT MED J, V300, P1485, DOI 10.1136/bmj.300.6738.1485; HANKEY GJ, 1990, STROKE, V21, P209, DOI 10.1161/01.STR.21.2.209; HOWARD G, 1991, J STROKE CEREBROVASC, V40, P166; MURIE JA, 1991, BRIT J SURG, V78, P397, DOI 10.1002/bjs.1800780406; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; TURNIPSEED WD, 1993, SURGERY, V114, P643; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; 1991, CM1523; 1990, CM555	15	10	10	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 4	1995	310	6975					317	318		10.1136/bmj.310.6975.317	http://dx.doi.org/10.1136/bmj.310.6975.317			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF717	7866178	Green Published			2022-12-28	WOS:A1995QF71700041
J	TAYLOR, A; GOLDBERG, D; EMSLIE, J; WRENCH, J; GRUER, L; CAMERON, S; BLACK, J; DAVIS, B; MCGREGOR, J; FOLLETT, E; HARVEY, J; BASSON, J; MCGAVIGAN, J				TAYLOR, A; GOLDBERG, D; EMSLIE, J; WRENCH, J; GRUER, L; CAMERON, S; BLACK, J; DAVIS, B; MCGREGOR, J; FOLLETT, E; HARVEY, J; BASSON, J; MCGAVIGAN, J			OUTBREAK OF HIV-INFECTION IN A SCOTTISH PRISON	BRITISH MEDICAL JOURNAL			English	Article							INJECTING DRUG-USERS; HUMAN-IMMUNODEFICIENCY-VIRUS; RISK-FACTORS; INMATES; AIDS; SEROPOSITIVITY; SURVEILLANCE	Objectives-To investigate the possible spread of HIV infection and its route of transmission among prison inmates. Design-In response to an outbreak of acute clinical hepatitis B and two seroconversions to HIV infection, counselling and testing for HIV were offered to all inmates over a two week period in July 1993. Information was sought about drug injecting, sexual behaviour, and previous HIV testing. Setting-HM Prison Glenochil in Scotland. Subjects-Adult male prisoners. Main outcome measures-Uptake of HIV counselling and testing; occurrence and mode of HIV transmission within the prison. Results-Of a total 378 inmates, 227 (60%) were counselled and 162 (43%) tested for HIV. Twelve (7%) of those tested were positive for antibody to HIV. One third (76) of those counselled had injected drugs at some time, of whom 33 (43%) had injected in Glenochil; all 12 seropositive men belonged to this latter group. Thirty two of these 33 had shared needles and syringes in the prison. A further two inmates who injected in the prison were diagnosed as positive for HIV two months previously. Evidence based on sequential results and time of entry into prison indicated that eight transmissions definitely occurred within prison in the first half of 1993. Conclusion-This is the first report of an outbreak of HIV infection occurring within a prison. Restricted access to injecting equipment resulted in random sharing and placed injectors at high risk of becoming infected with HIV. Measures to prevent further spread of infection among prison injectors are urgently required.	FORTH VALLEY HLTH BOARD,STIRLING FK8 1DX,SCOTLAND; RUCHILL HOSP,HIV & ADDICT RESOURCE CTR,GLASGOW,LANARK,SCOTLAND; RUCHILL HOSP,REG VIRUS LAB,GLASGOW G20 9NB,LANARK,SCOTLAND; RUCHILL HOSP,HIV & ADDICT CLIN DIRECTORATE,HIV COUNSELING CLIN,GLASGOW,LANARK,SCOTLAND; HLTH CTR,ALLOA FK10 1AB,CLACK,SCOTLAND; FALKIRK & DIST ROYAL INFIRM,FORTH VALLEY HLTH BOARD,FALKIRK FK1 5QE,SCOTLAND; ROYAL INFIRM,STIRLING FK8 2AU,SCOTLAND; SCOTTISH HOME & HLTH DEPT,EDINBURGH EH1 3DE,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh	TAYLOR, A (corresponding author), RUCHILL HOSP,SCOTTISH CTR INFECT & ENVIRONM HLTH,GLASGOW G20 9NB,LANARK,SCOTLAND.			Gruer, Laurence/0000-0002-1089-2896				BIRD AG, 1993, BRIT MED J, V307, P228, DOI 10.1136/bmj.307.6898.228; BIRD AG, 1992, AIDS, V6, P725, DOI 10.1097/00002030-199207000-00017; CARVELL ALM, 1990, BRIT MED J, V300, P1383, DOI 10.1136/bmj.300.6736.1383; CASTRO K, 1991, 7 INT C AIDS FLOR 16, P314; CHOOPANYA K, 1991, AIDS, V5, P1509, DOI 10.1097/00002030-199112000-00014; CONTORREGI C, 1993, 9TH INT C AIDS BERL; COVELL RG, 1993, DRUG ALCOHOL DEPEN, V32, P9, DOI 10.1016/0376-8716(93)90017-K; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DESJARLAIS DC, 1992, AIDS, V6, P1053, DOI 10.1097/00002030-199210000-00001; DOLAN K, 1994, 5TH P INT C RED DRUG; DOLAN K, 1992, 8TH INT C AIDS AMST; DYE S, 1991, BRIT MED J, V302, P1506, DOI 10.1136/bmj.302.6791.1506; FRERICHS RR, 1992, LANCET, V340, P1496, DOI 10.1016/0140-6736(92)92755-5; GELLERT GA, 1993, AM J PUBLIC HEALTH, V83, P1454, DOI 10.2105/AJPH.83.10.1454; GREEN ST, 1991, ANSWER SCOTTISH CTR; Hankins C, 1991, Can Dis Wkly Rep, V17, P233; HARDING TW, 1987, LANCET, V2, P1260; HORSBURGH CR, 1990, AM J PUBLIC HEALTH, V80, P209, DOI 10.2105/AJPH.80.2.209; KALL KI, 1990, AIDS, V4, P153, DOI 10.1097/00002030-199002000-00009; KENNEDY D, 1991, BRIT MED J, V312, P1507; MARTIN V, 1990, AIDS, V4, P1023, DOI 10.1097/00002030-199010000-00013; MCKEE KJ, 1992, SCOT MED J, V37, P132, DOI 10.1177/003693309203700502; NAIK TN, 1991, AIDS, V5, P117, DOI 10.1097/00002030-199101000-00026; POWER KG, 1992, BRIT J ADDICT, V87, P35; RICHARDSON C, 1993, AIDS, V7, P1485, DOI 10.1097/00002030-199311000-00013; TAYLOR A, 1994, INT J STD AIDS, V5, P105, DOI 10.1177/095646249400500205; TAYLOR A, 1993, BRIT MED J, V307, P623, DOI 10.1136/bmj.307.6904.623; Turnbull P. J., 1991, PRISON HIV AIDS RISK; VLAHOV D, 1991, JAMA-J AM MED ASSOC, V265, P1129, DOI 10.1001/jama.265.9.1129; 1989, MMWR-MORBID MORTAL W, V38, P1	30	172	174	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 4	1995	310	6975					289	292		10.1136/bmj.310.6975.289	http://dx.doi.org/10.1136/bmj.310.6975.289			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QF717	7866169	Green Published			2022-12-28	WOS:A1995QF71700023
J	FRAGNETO, G; THOMAS, RK; RENNIE, AR; PENFOLD, J				FRAGNETO, G; THOMAS, RK; RENNIE, AR; PENFOLD, J			NEUTRON REFLECTION STUDY OF BOVINE BETA-CASEIN ADSORBED ON OTS SELF-ASSEMBLED MONOLAYERS	SCIENCE			English	Article							AQUEOUS PERMANGANATE INTERACTION; PENETRATION-CONTROLLED REACTIONS; LANGMUIR-BLODGETT MONOLAYERS; SILICA WATER INTERFACE; LONG-CHAIN SURFACTANTS; PROTEIN ADSORPTION; POLYSTYRENE LATEX; SPECULAR REFLECTION; ORGANIC MONOLAYERS; SERUM-ALBUMIN	Specular neutron reflection has been used to determine the structure and composition of bovine beta-casein adsorbed on a solid surface from an aqueous phosphate-buffered solution at pH 7. The protein was adsorbed on a hydrophobic monolayer self-assembled from deuterated octadecyltrichlorosilane solution on a silicon (111) surface. A two-layer structure formed consisting of one dense layer of thickness 23 +/- 1 angstroms and a surface coverage of 1.9 milligrams per square meter adjacent to the surface and an external layer protruding into the solution of thickness 35 +/- 1 angstroms and 12 percent protein volume fraction. The structure of the (beta-casein) layer is explained in terms of the charge distribution in the protein.	UNIV CAMBRIDGE,CAVENDISH LAB,CAMBRIDGE CB3 OHE,ENGLAND; UNIV OXFORD,PHYS CHEM LAB,OXFORD OX1 3QZ,ENGLAND; RUTHERFORD APPLETON LAB,DIDCOT OX11 0QX,OXON,ENGLAND	University of Cambridge; University of Oxford; UK Research & Innovation (UKRI); Science & Technology Facilities Council (STFC); STFC Rutherford Appleton Laboratory								BENJAMINS J, 1975, FARADAY DISCUSS, V59, P218, DOI 10.1039/dc9755900218; BORETOS JW, 1980, SYNTHETIC BIOMEDICAL, P187; BRASH JL, 1985, MAKROMOL CHEM S, V9, P69; BROOKSBANK DV, 1993, J CHEM SOC FARADAY T, V89, P3419, DOI 10.1039/ft9938903419; CALDWELL KD, 1992, J CHROMATOGR, V604, P63, DOI 10.1016/0021-9673(92)85529-3; CARLES C, 1988, FEBS LETT, V229, P265, DOI 10.1016/0014-5793(88)81138-4; CUYPERS PA, 1978, ANAL BIOCHEM, V84, P56, DOI 10.1016/0003-2697(78)90483-9; DICKINSON E, 1993, LANGMUIR, V9, P242, DOI 10.1021/la00025a046; DILLMAN WJ, 1973, J COLLOID INTERF SCI, V44, P221, DOI 10.1016/0021-9797(73)90215-4; FAIR BD, 1980, J COLLOID INTERF SCI, V77, P525, DOI 10.1016/0021-9797(80)90325-2; Feijter J. A. D., 1978, BIOPOLYMERS, V17, P1759; FRAGNETO G, UNPUB; GAN CS, 1994, J COLLOID INTERF SCI, V162, P214; GRAHAM DE, 1979, J COLLOID INTERF SCI, V70, P415, DOI 10.1016/0021-9797(79)90049-3; GUN J, 1984, J COLLOID INTERF SCI, V101, P201, DOI 10.1016/0021-9797(84)90020-1; Heavens O.S, 1991, OPTICAL PROPERTIES T; HENCKEVORT HJ, 1984, J COLLOID INTERF SCI, V98, P138; Horbett T. A., 2019, HYDROGELS MED PHARM, P127; IVARSSON B, 1986, CRIT REV BIOCOMPAT, V2, P1; JENNISSEN HP, 1989, BER BUNSEN PHYS CHEM, V93, P948, DOI 10.1002/bbpc.19890930905; JONSSON U, 1985, J COLLOID INTERF SCI, V103, P60; KERN W, 1990, J ELECTROCHEM SOC, V137, P1887, DOI 10.1149/1.2086825; LEE EM, 1989, CHEM PHYS LETT, V162, P196, DOI 10.1016/0009-2614(89)85124-3; LEE EM, 1990, EUROPHYS LETT, V13, P135, DOI 10.1209/0295-5075/13/2/007; MACKIE AR, 1991, J CHEM SOC FARADAY T, V87, P3043, DOI 10.1039/ft9918703043; MAOZ R, 1987, LANGMUIR, V3, P1045, DOI 10.1021/la00078a028; MAOZ R, 1987, LANGMUIR, V3, P1034, DOI 10.1021/la00078a027; MAOZ R, 1984, J COLLOID INTERF SCI, V100, P465, DOI 10.1016/0021-9797(84)90452-1; MATRITCHIE F, 1972, J COLLOID INTERF SCI, V38, P484; MCDERMOTT DB, UNPUB; MCDERMOTT DC, 1994, J COLLOID INTERF SCI, V162, P304, DOI 10.1006/jcis.1994.1043; MCDERMOTT DC, 1992, LANGMUIR, V8, P1204, DOI 10.1021/la00040a031; MIZUTANI T, 1985, J LIQ CHROMATOGR, V8, P925, DOI 10.1080/01483918508067122; NETZER L, 1983, J AM CHEM SOC, V105, P674, DOI 10.1021/ja00341a087; NETZER L, 1983, THIN SOLID FILMS, V99, P235, DOI 10.1016/0040-6090(83)90386-3; NETZER L, 1983, THIN SOLID FILMS, V100, P67, DOI 10.1016/0040-6090(83)90230-4; NORDE W, 1978, J COLLOID INTERF SCI, V66, P257, DOI 10.1016/0021-9797(78)90303-X; NYLANDER T, 1994, J COLLOID INTERF SCI, V162, P151, DOI 10.1006/jcis.1994.1020; PENFOLD J, 1990, J PHYS-CONDENS MAT, V2, P1369, DOI 10.1088/0953-8984/2/6/001; PORATH J, 1987, BIOTECHNOL PROGR, V3, P14, DOI 10.1002/btpr.5420030104; PRIME KL, 1993, J AM CHEM SOC, V115, P10714, DOI 10.1021/ja00076a032; PRIME KL, 1991, SCIENCE, V252, P1164, DOI 10.1126/science.252.5009.1164; RENNIE AR, 1990, LANGMUIR, V6, P1031, DOI 10.1021/la00095a025; SAGIV J, 1980, J AM CHEM SOC, V102, P92, DOI 10.1021/ja00521a016; SCHMIDT DG, 1972, J COLLOID INTERF SCI, V39, P655, DOI 10.1016/0021-9797(72)90073-2; SEARS VF, 1993, NEUTRON NEWS, V3, P26; SEVASTIANOV VI, 1988, CRIT REV BIOCOMPAT, V4, P109; SODERQUIST ME, 1980, J COLLOID INTERF SCI, V75, P386, DOI 10.1016/0021-9797(80)90463-4; SUZAWA T, 1982, J COLLOID INTERF SCI, V86, P144, DOI 10.1016/0021-9797(82)90049-2; TIDSWELL IM, 1990, PHYS REV B, V41, P1111, DOI 10.1103/PhysRevB.41.1111; WATANABE N, 1986, COLLOID POLYM SCI, V264, P903, DOI 10.1007/BF01410642; WEAST RC, 1973, HDB CHEM PHYSICS B; WEAST RC, 1973, HDB CHEM PHYSICS C; WU XZ, 1993, PHYS REV LETT, V70, P958, DOI 10.1103/PhysRevLett.70.958	54	136	137	0	26	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 3	1995	267	5198					657	660		10.1126/science.7839141	http://dx.doi.org/10.1126/science.7839141			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839141				2022-12-28	WOS:A1995QE73300032
J	TOMAC, A; LINDQVIST, E; LIN, LFH; OGREN, SO; YOUNG, D; HOFFER, BJ; OLSON, L				TOMAC, A; LINDQVIST, E; LIN, LFH; OGREN, SO; YOUNG, D; HOFFER, BJ; OLSON, L			PROTECTION AND REPAIR OF THE NIGROSTRIATAL DOPAMINERGIC SYSTEM BY GDNF IN-VIVO	NATURE			English	Article							CENTRAL CATECHOLAMINE NEURONS; FIBROBLAST GROWTH-FACTOR; NEUROTROPHIC FACTOR; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE MPTP; SUBSTANTIA-NIGRA; MICE; CULTURE; RAT	GLIAL-CELL-LINE-DERIVED neurotrophic factor (GDNF), a recently cloned new member of the transforming growth factor-beta superfamily, promotes survival of cultured fetal mesencephalic dopamine neurons(1) and is expressed in the developing striatum(2,3). There have, however, been no reports about effects of GDNF in situ. We have used the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which produces parkinsonian symptoms in man, to determine whether GDNF might exert protective or regenerative effects in vivo in the adult nigrostriatal dopamine system in C57/Bl mice. GDNF injected over the substantia nigra or in striatum before MPTP potently protects the dopamine system, as shown by numbers of mesencephalic dopamine nerve cell bodies, dopamine nerve terminal densities and dopamine levels. When GDNF is given after MPTP, dopamine levels and fibre densities are significantly restored. In both cases, motor behaviour is increased above,normal levels. We conclude that intracerebral GDNF administration exerts both protective and reparative effects on the nigrostriatal dopamine system, which may have implications for the development of new treatment strategies for Parkinson's disease.	SYNERGEN INC,BOULDER,CO 80301; UNIV COLORADO,DEPT PREVENT MED & BIOSTAT,DENVER,CO 80217	University of Colorado System; University of Colorado Denver	TOMAC, A (corresponding author), KAROLINSKA INST,DEPT NEUROSCI,S-17177 STOCKHOLM,SWEDEN.			Ogren, Sven Ove/0000-0003-2573-5276				BECK KD, 1993, NEUROSCIENCE, V52, P855, DOI 10.1016/0306-4522(93)90534-M; DAHLSTROM A, 1964, ACTA PHYSIOL SCAND, V62, P1; FERRARI G, 1991, J NEUROSCI RES, V30, P493, DOI 10.1002/jnr.490300306; HEIKKILA RE, 1984, SCIENCE, V224, P1451, DOI 10.1126/science.6610213; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; Hudson J., 1993, Society for Neuroscience Abstracts, V19, P652; HUMPEL C, 1994, NEUROSCIENCE, V59, P791, DOI 10.1016/0306-4522(94)90284-4; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; JONSSON G, 1985, N-S ARCH PHARMACOL, V331, P1, DOI 10.1007/BF00498844; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; MAGAL E, 1993, NEUROSCIENCE, V52, P867, DOI 10.1016/0306-4522(93)90535-N; NIKKHAH G, 1993, EXP BRAIN RES, V92, P516; OGREN SO, 1979, DOPAMINERGIC ERGOT D, P187; OTTO D, 1990, J NEUROSCI, V10, P1912; SCHAAR DG, 1993, EXP NEUROL, V124, P368, DOI 10.1006/exnr.1993.1207; SCHMIDTKASTNER R, 1994, MOL BRAIN RES, V26, P325, DOI 10.1016/0169-328X(94)90106-6; SPINA MB, 1992, J NEUROCHEM, V59, P99, DOI 10.1111/j.1471-4159.1992.tb08880.x; STROMBERG I, 1993, EXP NEUROL, V124, P401, DOI 10.1006/exnr.1993.1214; SUNDSTROM E, 1987, BRAIN RES, V405, P26; SUNDSTROM E, 1990, BRAIN RES, V528, P181, DOI 10.1016/0006-8993(90)91656-2	21	1002	1079	0	29	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					335	339		10.1038/373335a0	http://dx.doi.org/10.1038/373335a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830766	Bronze			2022-12-28	WOS:A1995QD40400057
J	HALL, PA; PAYNE, JF; STACK, CG; STOKES, MA				HALL, PA; PAYNE, JF; STACK, CG; STOKES, MA			PARENTS IN THE RECOVERY ROOM - SURVEY OF PARENTAL AND STAFF ATTITUDES	BRITISH MEDICAL JOURNAL			English	Article							ANESTHESIA		CHILDRENS HOSP,DEPT ANAESTHESIA,BIRMINGHAM B16 8ET,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT ANAESTHESIA,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham								BEVAN JC, 1990, CAN J ANAESTH, V37, P177, DOI 10.1007/BF03005466; PARNASS SM, 1993, ANESTHESIOLOGY, V79, pA1156; SCHULMAN JL, 1967, PEDIATRICS, V39, P111; 1991, WELFARE CHILDREN YOU; 1959, CHARTER CHILDREN HOS	5	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 21	1995	310	6973					163	164		10.1136/bmj.310.6973.163	http://dx.doi.org/10.1136/bmj.310.6973.163			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD201	7833756	Green Published			2022-12-28	WOS:A1995QD20100022
J	MURRAY, SA; GRAHAM, LJC; DLUGOLECKA, MJ				MURRAY, SA; GRAHAM, LJC; DLUGOLECKA, MJ			HOW MANY GENERAL-PRACTITIONERS FOR 1433 PATIENTS	BRITISH MEDICAL JOURNAL			English	Article									LOTHIAN HLTH,EDINBURGH EH8 9RS,MIDLOTHIAN,SCOTLAND		MURRAY, SA (corresponding author), UNIV EDINBURGH,MACKENZIE MED CTR,EDINBURGH EH8 9DX,MIDLOTHIAN,SCOTLAND.							BILLINGHURST B, 1993, BRIT J GEN PRACT, V43, P336; SALISBURY CJ, 1989, BRIT MED J, V229, P608; TOLLMAN S, 1991, SOC SCI MED, V32, P633, DOI 10.1016/0277-9536(91)90142-Y	3	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 14	1995	310	6972					100	100		10.1136/bmj.310.6972.100	http://dx.doi.org/10.1136/bmj.310.6972.100			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QC223	7833697	Green Published			2022-12-28	WOS:A1995QC22300024
J	COWAN, FM; JOHNSON, AM; ASHLEY, R; COREY, L; MINDEL, A				COWAN, FM; JOHNSON, AM; ASHLEY, R; COREY, L; MINDEL, A			ANTIBODY TO HERPES-SIMPLEX VIRUS TYPE-2 AS SEROLOGICAL MARKER OF SEXUAL LIFE-STYLE IN POPULATIONS	BRITISH MEDICAL JOURNAL			English	Article							GENITAL HERPES; INFECTIONS; TRANSMISSION; PREVALENCE; FREQUENCY; RISK	Objectives-To examine the epidemiology of antibody to herpes simplex virus type 2 and to assess its suitability as a serological marker of sexual behaviour in populations with high and low prevalences. Design-Cross sectional survey. Setting-Department of genitourinary medicine and blood donation centre in central London. Subjects-Representative sample of 869 patients attending department between November 1990 and December 1991, and 1494 consecutive blood donors attending for donation between February and April 1992. Method-Participants had a blood sample taken for antibody testing with a novel type specific assay and completed a questionnaire. Results-Prevalence of antibody differed significantly between the two groups (188/833 (22.7%) clinic attenders; 102/1347 (7.6%) blood donors). In both populations antibody was strongly associated with sex, sexual orientation, years of sexual activity, number of lifetime sexual partners, and past infection with sexually transmitted diseases after other factors were controlled for. Only 130 (45%) of all those with antibody had symptoms suggestive of genital herpes, and 79 (27.4%) had had genital herpes diagnosed. Of those:without antibody to herpes simplex viruses type 1 and 2, 8.0% reported genital blisters or sores and 1.1% had had genital herpes diagnosed by a doctor. Conclusions-The strong relation between herpes simplex virus type 2 and sexual lifestyle suggests that the presence of antibody to the virus may be suitable for use as an objective, serological marker of patterns of sexual behaviour in different populations. These data show that only a minority of those infected with herpes simplex virus type 2 have a diagnosis of genital herpes or express clinical symptoms, making serological determinants of infection essential for epidemiological studies.	CHILDRENS HOSP & MED CTR, DEPT LAB MED, DIV VIROL, SEATTLE, WA 98105 USA	Seattle Children's Hospital	COWAN, FM (corresponding author), UCL, SCH MED, ACAD DEPT GENITOURINARY MED, MORTIMER ST, LONDON WC1E 6AV, ENGLAND.		Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436; Johnson, Anne/0000-0003-1330-7100; Mindel, Adrian/0000-0002-8780-9982; Cowan, Frances/0000-0003-3087-4422	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASHLEY R, 1991, ANN INTERN MED, V115, P520, DOI 10.7326/0003-4819-115-7-520; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BARTON IG, 1982, BRIT J VENER DIS, V58, P44; BREINIG MK, 1990, J INFECT DIS, V162, P299, DOI 10.1093/infdis/162.2.299; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; COWAN FM, 1993, GENITOURIN MED, V69, P141; GIBSON JJ, 1990, J INFECT DIS, V162, P306, DOI 10.1093/infdis/162.2.306; JOHNSON AM, 1992, NATURE, V360, P410, DOI 10.1038/360410a0; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; KOUTSKY LA, 1990, SEX TRANSM DIS, V17, P90, DOI 10.1097/00007435-199004000-00009; LEE RM, 1990, AM BEHAV SCI, V33, P510, DOI 10.1177/0002764290033005002; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; Nahmias A J, 1990, Scand J Infect Dis Suppl, V69, P19; SCOULAR A, 1990, GENITOURIN MED, V66, P226; SIEGEL D, 1992, JAMA-J AM MED ASSOC, V268, P1702, DOI 10.1001/jama.268.13.1702; 1992, CMND1986; 1988, EGRET EPIDEMIOLOGICA; 1985, STATISTICAL PACKAGE	20	220	223	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 19	1994	309	6965					1325	1329		10.1136/bmj.309.6965.1325	http://dx.doi.org/10.1136/bmj.309.6965.1325			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT625	7866079	Green Published			2022-12-28	WOS:A1994PT62500018
J	ETCHASON, J; PETZ, L; KEELER, E; CALHOUN, L; KLEINMAN, S; SNIDER, C; FINK, A; BROOK, R				ETCHASON, J; PETZ, L; KEELER, E; CALHOUN, L; KLEINMAN, S; SNIDER, C; FINK, A; BROOK, R			THE COST-EFFECTIVENESS OF PREOPERATIVE AUTOLOGOUS BLOOD DONATIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSFUSION-INDUCED IMMUNOMODULATION; QUALITY-OF-LIFE; NON-A-HEPATITIS; NON-B-HEPATITIS; INFECTION; HEALTH; REPLACEMENT; COLLECTION; COMPONENTS	Background. Since the recognition that human immunodeficiency virus is transmissible by blood transfusion there has been increasing public and professional support for autologous blood donations before elective surgery. Autologous blood donation is, however, a more expensive process than the donation of allogeneic blood by community volunteers, Furthermore, there have been recent improvements in the safety of the volunteer blood supply, Methods. We used a decision-analysis model to assess the cost effectiveness of donating autologous blood for four surgical procedures, Cost data were collected from the observation of transfusion practice at the University of California, Los Angeles, in 1992, Estimates of the risks of transfusion-associated diseases and the costs of treating them came from the medical literature. Cost effectiveness was expressed in dollars per quality-adjusted year of life saved. We performed sensitivity analyses of the variables in our model and examined the effect of strategies suggested to reduce costs. Results. Substituting autologous for allogeneic blood resulted in little expected health benefit (0.0002 to 0.00044 quality-adjusted year of life saved) at considerable additional cost ($68 to $4,783 per unit of blood). The additional cost of autologous blood was primarily a function of the discarding of units that were donated but not transfused and of a more labor-intensive donation process, The cost-effectiveness values ranged from $235,000 to over $23 million per quality-adjusted year of life saved. Conclusions. Given the improved safety of allogeneic transfusions today, the increased protection afforded by donating autologous blood is limited and may not justify the increased cost.	UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA USA; UNIV CALIF LOS ANGELES, CTR HLTH SCI, DEPT PATHOL & LAB MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, CTR HLTH SCI, DEPT MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, CTR HLTH SCI, DEPT HLTH SERV, LOS ANGELES, CA 90024 USA; RAND CORP, SANTA MONICA, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; RAND Corporation	ETCHASON, J (corresponding author), W LOS ANGELES VET AFFAIRS MED CTR, DIV GEN INTERNAL MED, 11301 WILSHIRE BLVD, LOS ANGELES, CA 90073 USA.		Brugnara, Carlo/A-8041-2010	Brugnara, Carlo/0000-0001-8192-8713	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K07HL002151] Funding Source: NIH RePORTER; NHLBI NIH HHS [K07 HL02151] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER JW, 1991, TRANSFUSION, V31, P195, DOI 10.1046/j.1537-2995.1991.31391165165.x; AXELROD FB, 1989, TRANSFUSION, V29, P677, DOI 10.1046/j.1537-2995.1989.29890020438.x; BIRKMEYER JD, 1993, TRANSFUSION, V33, P544, DOI 10.1046/j.1537-2995.1993.33793325048.x; BIRKMEYER JD, 1994, ANN THORAC SURG, V57, P161, DOI 10.1016/0003-4975(94)90386-7; BLOOM BS, 1993, ANN INTERN MED, V118, P298, DOI 10.7326/0003-4819-118-4-199302150-00009; BLUMBERG N, 1990, YALE J BIOL MED, V63, P429; CARSON JL, 1992, AM J MED, V92, P45, DOI 10.1016/0002-9343(92)90014-3; CLEARY PD, 1993, MED CARE, V31, P569, DOI 10.1097/00005650-199307000-00001; CUMMING PD, 1989, NEW ENGL J MED, V321, P941, DOI 10.1056/NEJM198910053211405; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; GIORDANO GF, 1991, TRANSFUSION, V31, P509, DOI 10.1046/j.1537-2995.1991.31691306247.x; GOODNOUGH LT, 1994, ARCH PATHOL LAB MED, V118, P333; GROSSMAN BJ, 1988, TRANSFUSION, V28, P283, DOI 10.1046/j.1537-2995.1988.28388219162.x; HEISS MM, 1993, LANCET, V342, P1328, DOI 10.1016/0140-6736(93)92247-Q; HEISS MM, 1994, LANCET, V343, P64; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; KAPLAN RM, 1989, MED CARE, V27, pS27, DOI 10.1097/00005650-198903001-00003; KEELER E, 1992, MED DECIS MAKING, V12, P307, DOI 10.1177/0272989X9201200410; KEELER EB, 1983, MANAGE SCI, V29, P300, DOI 10.1287/mnsc.29.3.300; KHABBAZ RF, 1993, ANN INTERN MED, V118, P448; KRUSKALL MS, 1994, TRANSFUSION, V34, P259, DOI 10.1046/j.1537-2995.1994.34394196627.x; KRUSKALL MS, 1986, TRANSFUSION, V26, P335, DOI 10.1046/j.1537-2995.1986.26486262740.x; MEZROW CK, 1992, TRANSFUSION, V32, P27, DOI 10.1046/j.1537-2995.1992.32192116427.x; MURPHY P, 1991, TRANSFUSION, V31, P212, DOI 10.1046/j.1537-2995.1991.31391165169.x; MURPHY PJ, 1992, J THORAC CARDIOV SUR, V104, P1092; NELSON KE, 1992, ANN INTERN MED, V117, P554, DOI 10.7326/0003-4819-117-7-554; NEWMAN RJ, 1994, US NEWS WORLD R 0627, P68; POPOVSKY MA, 1992, AM J CLIN PATHOL, V97, P297, DOI 10.1093/ajcp/97.3.297; RENNER SW, 1992, ARCH PATHOL LAB MED, V116, P613; SACKETT DL, 1978, J CHRON DIS, V31, P697, DOI 10.1016/0021-9681(78)90072-3; SAZAMA K, 1990, TRANSFUSION, V30, P583, DOI 10.1046/j.1537-2995.1990.30790385515.x; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SIMON TL, 1989, HUM PATHOL, V20, P3, DOI 10.1016/0046-8177(89)90196-2; SMITH DM, 1992, CLIN LAB MED, V12, P723, DOI 10.1016/S0272-2712(18)30484-0; STARKEY JM, 1989, JAMA-J AM MED ASSOC, V262, P3452, DOI 10.1001/jama.262.24.3452; TASWELL HF, 1981, SEMINAR IMMUNE MEDIA, P71; TOY PTCY, 1992, ARCH PATHOL LAB MED, V116, P611; TRIULZI DJ, 1990, TRANSFUSION MEDICINE IN THE 1990S, P1; WACHTEL T, 1992, ANN INTERN MED, V116, P129, DOI 10.7326/0003-4819-116-2-129; WALLACE EL, 1993, TRANSFUSION, V33, P139, DOI 10.1046/j.1537-2995.1993.33293158046.x; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; YOMTOVIAN R, 1992, J BONE JOINT SURG AM, V74A, P1265, DOI 10.2106/00004623-199274080-00021; 1992, DHHS PHS931104 PUBL; 1986, JAMA-J AM MED ASSOC, V256, P2378	46	389	393	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 16	1995	332	11					719	724		10.1056/NEJM199503163321106	http://dx.doi.org/10.1056/NEJM199503163321106			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL788	7854380				2022-12-28	WOS:A1995QL78800006
J	ASHTON, CM; KUYKENDALL, DH; JOHNSON, ML; WRAY, NP; WU, L				ASHTON, CM; KUYKENDALL, DH; JOHNSON, ML; WRAY, NP; WU, L			THE ASSOCIATION BETWEEN THE QUALITY OF INPATIENT CARE AND EARLY READMISSION	ANNALS OF INTERNAL MEDICINE			English	Article						PATIENT READMISSION; QUALITY OF HEALTH CARE; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); HOSPITALIZATION	DISEASE	Objective: To determine whether the quality of care during a hospital stay is associated with unplanned readmission within 14 days. Design: Case-control study. Setting: 12 Veterans Affairs hospitals. Patients: Men discharged after a hospitalization for diabetes (n = 593), chronic obstructive lung disease (n = 1172), or heart failure (n = 748). The ratio of controls (men without an unplanned readmission within 14 days to any Veterans Affairs hospital) to cases (men with such a readmission) was 3:1. Main Outcome Measures: Unplanned readmission to any of the 159 Veterans Affairs hospitals within 14 days of discharge. Quality of care during the index stay was assessed by chart review using disease-specific explicit criteria for the process of inpatient care, which were developed by panels composed of expert physicians. Adherence scores (the percentage of applicable criteria that were met) were calculated for the admission workup, evaluation and treatment, and readiness for discharge. Results: After adjustment was made for demographic characteristics, severity of illness, and need for care, adherence scores correlated with early unplanned readmission (P < 0.05). For patients with diabetes and heart failure, decreased readiness-for-discharge adherence scores correlated with increased risk for readmission (P = 0.001 and P = 0.016, respectively). In patients with obstructive lung disease, decreased admission-workup scores correlated with increased risk for readmission (P = 0.013). One of 7 readmissions in patients with diabetes, 1 of 5 readmissions in patients with heart failure, and 1 of 12 readmissions in patients with obstructive lung disease were attributable to substandard care. Conclusions: Lower quality of inpatient care increases the risk for unplanned early readmission in patients with heart failure, diabetes, or obstructive lung disease. Under certain circumstances, readmission is associated with remediable deficiencies in the process of inpatient care.	BAYLOR COLL MED, HOUSTON, TX 77030 USA	Baylor College of Medicine	ASHTON, CM (corresponding author), VET AFFAIRS MED CTR, 2002 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.							ANDERSON GF, 1984, NEW ENGL J MED, V311, P1349, DOI 10.1056/NEJM198411223112105; ASHTON CM, 1994, J GEN INTERN MED, V9, P208, DOI 10.1007/BF02600126; ASHTON CM, 1994, MED CARE, V32, P755, DOI 10.1097/00005650-199408000-00001; ASHTON CM, 1987, MED CARE, V25, P1184, DOI 10.1097/00005650-198712000-00008; CAPLAN RA, 1991, JAMA-J AM MED ASSOC, V265, P1957, DOI 10.1001/jama.265.15.1957; FEINGLASS J, 1991, HEALTH SERV RES, V26, P183; Fleiss J. L., 1981, STAT METHODS RATES P, V2nd, P211, DOI DOI 10.2307/2530193; FLEMING C, 1992, MED CARE, V30, P377, DOI 10.1097/00005650-199205000-00001; HAYWARD RA, 1993, MED CARE, V31, P394, DOI 10.1097/00005650-199305000-00002; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P162; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LUDKE RL, 1993, INQUIRY-J HEALTH CAR, V30, P95; MANHEIM LM, 1990, MED CARE, V28, P29, DOI 10.1097/00005650-199001000-00005; REED RL, 1991, J GEN INTERN MED, V6, P223, DOI 10.1007/BF02598964; SANAZARO PJ, 1991, JAMA-J AM MED ASSOC, V265, P1977, DOI 10.1001/jama.265.15.1977; SIMMER TL, 1991, MED CARE, V29, pJS31; THOMAS JW, 1991, MED CARE, V29, P377, DOI 10.1097/00005650-199104000-00006; TOPOL EJ, 1988, NEW ENGL J MED, V318, P1083, DOI 10.1056/NEJM198804283181702; WILLIAMS EI, 1988, BRIT MED J, V297, P784, DOI 10.1136/bmj.297.6651.784; WRAY NP, 1995, MED CARE, V33, P75, DOI 10.1097/00005650-199501000-00007; 1989, ANAL READMISSIONS US; 1989, SAS UNIX 607	23	280	289	1	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1995	122	6					415	421		10.7326/0003-4819-122-6-199503150-00003	http://dx.doi.org/10.7326/0003-4819-122-6-199503150-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QM266	7856989				2022-12-28	WOS:A1995QM26600003
J	VLADECK, BC				VLADECK, BC			MEDICARE, MEDICAID FRAUD AND ABUSE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											VLADECK, BC (corresponding author), US HLTH CARE FINANCING ADM, BALTIMORE, MD 21207 USA.								0	4	5	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	1995	273	10					766	766		10.1001/jama.273.10.766	http://dx.doi.org/10.1001/jama.273.10.766			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QJ750	7861557				2022-12-28	WOS:A1995QJ75000004
J	BUONOMANO, DV; MERZENICH, MM				BUONOMANO, DV; MERZENICH, MM			TEMPORAL INFORMATION TRANSFORMED INTO A SPATIAL CODE BY A NEURAL-NETWORK WITH REALISTIC PROPERTIES	SCIENCE			English	Article							RAT HIPPOCAMPUS; PAIRED-PULSE; DISCRIMINATION; FACILITATION; COMPUTATION; INVITRO; CORTEX; TIME; CA1	Neurons exhibit a wide range of properties in addition to postsynaptic potential (PSP) summation and spike generation. Although other neuronal properties such as paired-pulse facilitation (PPF) and slow PSPs are well characterized, their role in information processing remains unclear. It is possible that these properties contribute to temporal processing in the range of hundreds of milliseconds, a range relevant to most complex sensory processing. A continuous-time neural network model based on integrate-and-fire elements that incorporate PPF and slow inhibitory postsynaptic potentials (IPSPs) was developed here. The time constants of the PPF and IPSPs were estimated from empirical data and were identical and constant for all elements in the circuit. When these elements were incorporated into a circuit inspired by neocortical connectivity, the network was able to discriminate different temporal patterns. Generalization emerged spontaneously. These results demonstrate that known time-dependent neuronal properties enable a network to transform temporal information into a spatial code in a self-organizing manner-that is, with no need to assume a spectrum of time delays or to custom-design the circuit.			BUONOMANO, DV (corresponding author), UNIV CALIF SAN FRANCISCO, KECK CTR INTEGRAT NEUROSCI, SAN FRANCISCO, CA 94143 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH010431] Funding Source: NIH RePORTER; NIMH NIH HHS [F32 MH10431] Funding Source: Medline; NINDS NIH HHS [NS-10414] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson J.A., 1988, NEUROCOMPUTING; ANDERSON JA, 1990, NEUROCOMPUTING, V2; ANTON PS, 1991, BIOL CYBERN, V65, P407, DOI 10.1007/BF00216975; Braitenberg V, 1967, Prog Brain Res, V25, P334; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; BUONOMANO DV, 1994, NEURAL COMPUT, V6, P38, DOI 10.1162/neco.1994.6.1.38; CARR CE, 1993, ANNU REV NEUROSCI, V16, P223, DOI 10.1146/annurev.ne.16.030193.001255; CREAGER R, 1980, J PHYSIOL-LONDON, V299, P409, DOI 10.1113/jphysiol.1980.sp013133; DOUGLAS RJ, 1990, J PHYSIOL-LONDON, V40, P735; GIBBON J, 1984, ANN NY ACAD SCI, V423, P52, DOI 10.1111/j.1749-6632.1984.tb23417.x; GROSSBERG S, 1989, NEURAL NETWORKS, V2, P79, DOI 10.1016/0893-6080(89)90026-9; Margoliash D., 1983, J NEUROSCI, V3, P133; MASON A, 1991, J NEUROSCI, V11, P72; MCCORMICK DA, 1989, J NEUROPHYSIOL, V62, P1018, DOI 10.1152/jn.1989.62.5.1018; MCCORMICK DA, 1990, SYNAPTIC ORG BRAIN, P33; MOORE JW, 1989, BIOL CYBERN, V62, P17, DOI 10.1007/BF00217657; NATHAN T, 1991, J NEUROPHYSIOL, V66, P1704, DOI 10.1152/jn.1991.66.5.1704; OGDEN G, 1978, PSYCHOL REV, V85, P172; Rumelhart D., 1986, PARALLEL DISTRIBUTED; SULLIVAN WE, 1982, J NEUROPHYSIOL, V48, P1033, DOI 10.1152/jn.1982.48.4.1033; Swadlow H. A., 1993, Society for Neuroscience Abstracts, V19, P1704; TALLAL P, 1993, ANN NY ACAD SCI, V682; TANK DW, 1987, P NATL ACAD SCI USA, V84, P1896, DOI 10.1073/pnas.84.7.1896; WELKER E, 1993, EUR J NEUROSCI, V5, P691, DOI 10.1111/j.1460-9568.1993.tb00534.x; WOOD CC, 1976, J ACOUST SOC AM, V60, P1381, DOI 10.1121/1.381231; WORGOTTER F, 1991, J NEUROSCI, V11, P1959; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	27	321	323	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 17	1995	267	5200					1028	1030		10.1126/science.7863330	http://dx.doi.org/10.1126/science.7863330			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG990	7863330				2022-12-28	WOS:A1995QG99000040
J	ICHIDA, T; MATSUNAMI, H; KAWASAKI, S; MAKUUCHI, M; HARADA, T; ITOH, S; ASAKURA, H				ICHIDA, T; MATSUNAMI, H; KAWASAKI, S; MAKUUCHI, M; HARADA, T; ITOH, S; ASAKURA, H			LIVING RELATED-DONOR LIVER-TRANSPLANTATION FROM ADULT TO ADULT FOR PRIMARY BILIARY-CIRRHOSIS	ANNALS OF INTERNAL MEDICINE			English	Note									SHINSHU UNIV, SCH MED, DEPT SURG 1, NAGANO, JAPAN	Shinshu University	ICHIDA, T (corresponding author), NIIGATA UNIV, SCH MED, DEPT INTERNAL MED 3, 754 ASAHIMACHI DORI 1, NIIGATA 951, JAPAN.		幕内, 雅敏 m/A-2140-2012					BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007; DELAND FH, 1968, RADIOLOGY, V91, P1195, DOI 10.1148/91.6.1195; DICKSON ER, 1989, HEPATOLOGY, V10, P1, DOI 10.1002/hep.1840100102; KAWASAKI S, 1993, HEPATOLOGY, V18, P1115; MAKUUCHI M, 1993, SURGERY, V113, P395; NAGASUE N, 1987, ANN SURG, V206, P30, DOI 10.1097/00000658-198707000-00005; Platt J L, 1992, ASAIO J, V38, P8, DOI 10.1097/00002480-199201000-00005; SALLIE R, 1991, J GASTROEN HEPATOL, V6, P558, DOI 10.1111/j.1440-1746.1991.tb00909.x; STARZL TE, 1993, LANCET, V341, P65, DOI 10.1016/0140-6736(93)92553-6; STRONG RW, 1990, NEW ENGL J MED, V322, P1505, DOI 10.1056/NEJM199005243222106	10	51	59	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1995	122	4					275	276		10.7326/0003-4819-122-4-199502150-00006	http://dx.doi.org/10.7326/0003-4819-122-4-199502150-00006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF769	7825763				2022-12-28	WOS:A1995QF76900006
J	HAVARD, J				HAVARD, J			WORLD SUMMIT ON SOCIAL-DEVELOPMENT	LANCET			English	Editorial Material											HAVARD, J (corresponding author), COMMONWEALTH MED ASSOC,LONDON,ENGLAND.							1994, LANCET, V344, P1377	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 11	1995	345	8946					335	336		10.1016/S0140-6736(95)90334-8	http://dx.doi.org/10.1016/S0140-6736(95)90334-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QF722	7845110	Green Submitted, Bronze			2022-12-28	WOS:A1995QF72200002
J	PUOLIJOKI, H; REKIARO, M				PUOLIJOKI, H; REKIARO, M			LACK OF EFFECT OF NEDOCROMIL SODIUM IN ACE-INHIBITOR-INDUCED COUGH	LANCET			English	Letter							DIABETIC NEPHROPATHY				PUOLIJOKI, H (corresponding author), ETELA POHJANMAA CENT HOSP,DEPT MED,SF-60220 SEINAJOKI,FINLAND.							BJORCK S, 1992, BMJ-BRIT MED J, V304, P339, DOI 10.1136/bmj.304.6823.339; HARGREAVES, 1995, LANCET, V345, P13; JACKSON DM, 1988, BRIT J PHARMACOL, V93, P609, DOI 10.1111/j.1476-5381.1988.tb10317.x; KELLEHER CC, 1990, DRUGS, V39, P639, DOI 10.2165/00003495-199039050-00001	4	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 11	1995	345	8946					394	394		10.1016/S0140-6736(95)90385-2	http://dx.doi.org/10.1016/S0140-6736(95)90385-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF722	7845148				2022-12-28	WOS:A1995QF72200062
J	VAADIA, E; HAALMAN, I; ABELES, M; BERGMAN, H; PRUT, Y; SLOVIN, H; AERTSEN, A				VAADIA, E; HAALMAN, I; ABELES, M; BERGMAN, H; PRUT, Y; SLOVIN, H; AERTSEN, A			DYNAMICS OF NEURONAL INTERACTIONS IN MONKEY CORTEX IN RELATION TO BEHAVIORAL EVENTS	NATURE			English	Article							CROSS-CORRELATION ANALYSIS; CAT STRIATE CORTEX; VISUAL-CORTEX; SYNCHRONIZATION; CONNECTIVITY; NETWORK	IT is possible that brain cortical function is mediated by dynamic modulation of coherent firing in groups of neurons. Indeed, a correlation of firing between cortical neurons, seen following sensory stimuli or during motor behaviour, has been described(1-5). However, the time course of modifications of correlation in relation to behaviour was not evaluated systematically. Here we show that correlated firing between single neurons, recorded simultaneously in the frontal cortex of monkeys performing a behavioural task, evolves within a fraction of a second, and in systematic relation to behavioural events. Moreover, the dynamic patterns of correlation depend on the distance between neurons, and can emerge even without modulation of the firing rates. These findings support the notion that neurons can associate rapidly into a functional group in order to perform a computational task, at the same time becoming dissociated from concurrently activated competing groups. Thus, they call for a revision of prevailing models of neural coding that rely solely on single neuron firing rates(6-8).	HEBREW UNIV JERUSALEM,CTR NEURAL COMPUTAT,IL-91010 JERUSALEM,ISRAEL; WEIZMANN INST SCI,CTR RES HIGHER BRAIN FUNCT,IL-76100 REHOVOT,ISRAEL	Hebrew University of Jerusalem; Weizmann Institute of Science	VAADIA, E (corresponding author), HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT PHYSIOL,IL-91010 JERUSALEM,ISRAEL.		Vaadia, Eilon/E-9347-2011					ABELES M, 1993, BRAIN THEORY, P149; ABELES M, 1982, J NEUROSCI METH, V5, P317, DOI 10.1016/0165-0270(82)90002-4; AERTSEN A, 1994, PHYSICA D, V75, P103, DOI 10.1016/0167-2789(94)90278-X; AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900, DOI 10.1152/jn.1989.61.5.900; AHISSAR E, 1992, SCIENCE, V257, P1412, DOI 10.1126/science.1529342; Barlow H B, 1972, Perception, V1, P371, DOI 10.1068/p010371; Barlow H.B., 1992, INFORMATION PROCESSI, P169; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; FETZ E, 1991, CEREB CORTEX, V9, P1; GRA CM, 1992, VIS NEUROSCI, V8, P37; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; HANSEL D, 1992, PHYS REV LETT, V68, P718, DOI 10.1103/PhysRevLett.68.718; KANEKO K, 1990, PHYSICA D, V41, P137, DOI 10.1016/0167-2789(90)90119-A; KRUGER J, 1990, VISUAL NEUROSCI, V5, P135, DOI 10.1017/S0952523800000171; MICHALSKI A, 1983, EXP BRAIN RES, V51, P97; MURTHY VN, IN PRESS OSCILLATORY; NELSON JI, 1992, VISUAL NEUROSCI, V9, P21, DOI 10.1017/S0952523800006349; NEWSOME WT, 1989, NATURE, V341, P52, DOI 10.1038/341052a0; PALM G, 1988, BIOL CYBERN, V59, P1, DOI 10.1007/BF00336885; SELEMON LD, 1990, J COMP NEUROL, V297, P359, DOI 10.1002/cne.902970304; THOMSON AM, 1994, TRENDS NEUROSCI, V17, P119, DOI 10.1016/0166-2236(94)90121-X; TOYAMA K, 1981, J NEUROPHYSIOL, V46, P191, DOI 10.1152/jn.1981.46.2.191; TSO DY, 1986, J NEUROSCI, V6, P1160; Vaadia E, 1992, INFORMATION PROCESSI, P81	24	603	613	0	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 9	1995	373	6514					515	518		10.1038/373515a0	http://dx.doi.org/10.1038/373515a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7845462				2022-12-28	WOS:A1995QF72400057
J	GORE, SM; BIRD, AG; BURNS, SM; GOLDBERG, DJ; ROSS, AJ; MACGREGOR, J				GORE, SM; BIRD, AG; BURNS, SM; GOLDBERG, DJ; ROSS, AJ; MACGREGOR, J			DRUG INJECTION AND HIV PREVALENCE IN INMATES OF GLENOCHIL PRISON	BRITISH MEDICAL JOURNAL			English	Article							SAUGHTON-PRISON; SURVEILLANCE; EDINBURGH; JAIL	Objective-To determine prevalence of HIV infection and drug injecting behaviour among inmates of Glenochil Prison on a specified date a year after an outbreak of hepatitis B and HIV infection. Design-Cross sectional: voluntary, anonymous HIV salivary antibody surveillance and Linked self completion questionnaire on risk factors. Setting-Glenochil prison, Scotland, a year after an outbreak of hepatitis B and HIV transmission related to drug injection. Subjects-352 prisoners, of whom 295 (84%) took part; 284 questionnaires (96%) passed logical checks. Main outcome measures-HIV prevalence; proportion of all inmates who had ever injected drugs, had ever injected inside prison, had started injecting drugs while inside prison. Results-More than half (150/284) the current inmates were also in Glenochil Prison during the critical period of January to June 1993, when hepatitis B and HIV were transmitted. Similar proportions of current inmates and men who were also in Glenochil during the critical period were drug users (27% (75/278) v 30% (44/149)). A quarter of injecting drug users (18/72) had first injected inside prison, irrespective of whether they were in Glenochil in January to June 1993 and regardless of the calendar period when they first injected. Significantly more inmates from Glasgow (41%; 56/138) than from Edinburgh (21%; 7/34) or elsewhere (11%; 12/106) were injecting drug users. On testing for HIV, seven saliva samples out of 293 gave positive results-four were presumed to be from inmates known to be infected with HIV, and the others from injecting drug users from Glasgow, all of whom had been in Glenochil during January to June 1993, when two of the three had injected drugs and had been tested for HIV, with negative results. The ratio of overall (2.4%) to disclosed (1.4%) HIV prevalence was 1.7. For men who had injected drugs in Glenochil during January to June 1993, HIV prevalence was estimated at 29%. Conclusion-Between a quarter and a third of prisoners who injected drugs in Glenochil in January to June 1993 were infected with HIV. There is widespread ongoing risk of bloodborne virus infection within prisons, which is probably long standing but demands urgent attention.	CHURCHILL HOSP,DEPT IMMUNOL,OXFORD OX3 7LJ,ENGLAND; CITY HOSP EDINBURGH,REG VIRUS LAB,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND; RUCHILL HOSP,SCOTTISH CTR INFECT & ENVIRONM HLTH,GLASGOW G20 9NB,LANARK,SCOTLAND; CTR HIV RES,MRC,BIOSTAT INITIAT AIDS & HIV SCOTLAND,EDINBURGH EH9 3JN,MIDLOTHIAN,SCOTLAND; HM PRISON & YOUNG OFFENDERS INST,ALLOA FK10 3AD,CLACK,SCOTLAND	University of Oxford	GORE, SM (corresponding author), INST PUBL HLTH,MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2SR,ENGLAND.							BIRD AG, 1993, AIDS, V7, P1277, DOI 10.1097/00002030-199309000-00025; BIRD AG, 1993, BRIT MED J, V307, P228, DOI 10.1136/bmj.307.6898.228; BIRD AG, 1992, AIDS, V6, P725, DOI 10.1097/00002030-199207000-00017; BIRD AG, 1994, AIDS, V8, P1345, DOI 10.1097/00002030-199409000-00021; CARRELL S, 1994, SCOTSMAN        0808, P2; CHRISTIE B, 1993, BRIT MED J, V307, P151; GORE SM, 1993, BRIT MED J, V307, P147, DOI 10.1136/bmj.307.6897.147; GORE SM, IN PRESS DEATHS CUST, V2; TAYLOR A, 1995, BRIT MED J, V310, P289, DOI 10.1136/bmj.310.6975.289	9	84	88	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 4	1995	310	6975					293	296		10.1136/bmj.310.6975.293	http://dx.doi.org/10.1136/bmj.310.6975.293			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QF717	7866170	Green Published			2022-12-28	WOS:A1995QF71700024
J	MCLEAN, AR				MCLEAN, AR			AFTER THE HONEYMOON IN MEASLES CONTROL	LANCET			English	Editorial Material							VACCINATION				MCLEAN, AR (corresponding author), INST PASTEUR,UNITE IMMUNOBIOL,PARIS,FRANCE.							ANDERSON RM, 1982, SCIENCE, V215, P1053, DOI 10.1126/science.7063839; ARYA SC, 1993, VACCINE, V11, P391, DOI 10.1016/0264-410X(93)90213-H; BABAD HR, IN PRESS EPIDEMIOL I; CHEN RT, 1994, INT J EPIDEMIOL, V23, P185, DOI 10.1093/ije/23.1.185; Clements C. John, 1992, World Health Statistics Quarterly, V45, P285; CUTTS FT, 1994, J INFECT DIS, V170, pS32, DOI 10.1093/infdis/170.Supplement_1.S32; JOHN TJ, 1980, INDIAN J MED RES, V72, P153; LENNON JL, 1986, J PEDIATR-US, V108, P671, DOI 10.1016/S0022-3476(86)81039-3; MARKOWITZ LE, 1992, J INFECT DIS, V166, P205, DOI 10.1093/infdis/166.1.205; MCLEAN AR, 1988, EPIDEMIOL INFECT, V100, P419, DOI 10.1017/S0950268800067170; MILLER E, 1994, BRIT MED J, V309, P1102, DOI 10.1136/bmj.309.6962.1102; MULHOLLAND K, 1995, LANCET, V345, P305, DOI 10.1016/S0140-6736(95)90282-1; ROUDERFER V, 1994, MATH BIOSCI, V124, P59, DOI 10.1016/0025-5564(94)90024-8	13	31	31	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					272	272		10.1016/S0140-6736(95)90272-4	http://dx.doi.org/10.1016/S0140-6736(95)90272-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE731	7837860				2022-12-28	WOS:A1995QE73100006
J	VANDERMEER, ALH; VANDERWEEL, FR; LEE, DN				VANDERMEER, ALH; VANDERWEEL, FR; LEE, DN			THE FUNCTIONAL-SIGNIFICANCE OF ARM MOVEMENTS IN NEONATES	SCIENCE			English	Article							VISUAL GUIDANCE; AFFORDANCES	Arm movements made by newborn babies are usually dismissed as unintentional, purposeless, or reflexive, Spontaneous arm-waving movements were recorded while newborns lay supine facing to one side. They were allowed to see only the arm they were facing, only the opposite arm on a video monitor, or neither arm. Small forces pulled on their wrists in the direction of the toes. The babies opposed the perturbing force so as to keep an arm up and moving normally, but only when they could see the arm, either directly or on the video monitor. The findings indicate that newborns can purposely control their arm movements in the face of external forces and that development of visual control of arm movement is underway soon after birth.			VANDERMEER, ALH (corresponding author), UNIV EDINBURGH,DEPT PSYCHOL,PERCEPT ACT LABS,7 GEORGE SQ,EDINBURGH EH8 9JZ,MIDLOTHIAN,SCOTLAND.							Bernstein N, 1967, COORDINATION REGULAT; BOWER TGR, 1970, NATURE, V228, P679, DOI 10.1038/228679a0; BUTTERWORTH G, 1988, BRIT J DEV PSYCHOL, V6, P303, DOI 10.1111/j.2044-835X.1988.tb01103.x; Fraiberg S., 1977, INSIGHTS BLIND; Gesell A., 1947, DEV DIAGNOSIS; GIBSON EJ, 1988, ANNU REV PSYCHOL, V39, P1, DOI 10.1146/annurev.ps.39.020188.000245; Gibson J.J., 1986, ECOLOGICAL APPROACH; LEE DN, 1974, PERCEPT PSYCHOPHYS, V15, P529, DOI 10.3758/BF03199297; Piaget J., 1952, ORIGINS INTELLIGENCE; THELEN E, 1990, SENSORY MOTOR ORG DE, V1, P39; TREVARTHEN C, 1974, Neurosciences Research Program Bulletin, V12, P570; VONHOFSTEN C, 1982, DEV PSYCHOL, V18, P450, DOI 10.1037/0012-1649.18.3.450; WARREN WH, 1984, J EXP PSYCHOL HUMAN, V10, P683, DOI 10.1037/0096-1523.10.5.683; WARREN WH, 1987, J EXP PSYCHOL HUMAN, V13, P371, DOI 10.1037/0096-1523.13.3.371; WHITE BL, 1964, CHILD DEV, V35, P349, DOI 10.1111/j.1467-8624.1964.tb05944.x; Winter DA, 1979, BIOMECHANICS HUMAN M	16	151	153	0	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 3	1995	267	5198					693	695		10.1126/science.7839147	http://dx.doi.org/10.1126/science.7839147			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QE733	7839147				2022-12-28	WOS:A1995QE73300042
J	HILL, CS; TREISMAN, R				HILL, CS; TREISMAN, R			TRANSCRIPTIONAL REGULATION BY EXTRACELLULAR SIGNALS - MECHANISMS AND SPECIFICITY	CELL			English	Review							NF-KAPPA-B; SERUM RESPONSE ELEMENT; DNA-BINDING ACTIVITY; HEAT-SHOCK FACTOR; PROTEIN-KINASE-A; GROWTH-FACTOR; C-FOS; TYROSINE PHOSPHORYLATION; MAP KINASE; GENE-TRANSCRIPTION				HILL, CS (corresponding author), IMPERIAL CANC RES FUND,TRANSCRIPT LAB,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.			Treisman, Richard/0000-0002-9658-0067; Hill, Caroline/0000-0002-8632-0480				ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ALBERTS AS, 1994, J BIOL CHEM, V269, P7623; ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; ALESSI DR, 1993, ONCOGENE, V8, P2015; AMMERER G, 1994, CURR OPIN GENET DEV, V4, P90, DOI 10.1016/0959-437X(94)90096-5; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; BENDER A, 1986, CELL, V47, P929, DOI 10.1016/0092-8674(86)90808-1; BEULLENS M, 1993, J BIOL CHEM, V268, P13172; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1994, CELL, V78, P973, DOI 10.1016/0092-8674(94)90273-9; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CHENG Q, 1994, J BIOL CHEM, V269, P13551; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CHOI KY, 1994, CELL, V78, P499; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COOPER JP, 1994, GENE DEV, V8, P1400, DOI 10.1101/gad.8.12.1400; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DERIJARD B, 1994, CELL, V78, P1025; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GRONEMEYER H, 1993, J RECEPTOR RES, V13, P667, DOI 10.3109/10799899309073686; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANNIGAN GE, 1992, J INTERFERON RES, V12, P355, DOI 10.1089/jir.1992.12.355; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HOJ A, 1994, EMBO J, V13, P2617; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; JIANG J, 1993, EMBO J, V12, P3201, DOI 10.1002/j.1460-2075.1993.tb05989.x; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KIROV N, 1993, EMBO J, V12, P3193, DOI 10.1002/j.1460-2075.1993.tb05988.x; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; KYRIAKIS JM, 1994, NATURE, V359, P156; LALLI E, 1994, J BIOL CHEM, V269, P17359; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LEE G, 1994, MOL CELL BIOL, V14, P4579, DOI 10.1128/MCB.14.7.4579; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MCCAFFREY PG, 1994, IN PRESS J BIOL CHEM; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUSCH J, 1994, GENE DEV, V8, P1247, DOI 10.1101/gad.8.11.1247; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHELDON LA, 1993, GENE DEV, V7, P1549, DOI 10.1101/gad.7.8.1549; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SLUSS HK, 1994, MOL CELL BIOL, V114, P8376; STJOHNSTON D, 1992, CELL, V68, P201; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; THANOS D, 1993, COLD SPRING HARB SYM, V58, P73, DOI 10.1101/SQB.1993.058.01.011; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WILLIAMS GT, 1993, MOL CELL BIOL, V13, P6124, DOI 10.1128/MCB.13.10.6124; YAN M, 1994, NATURE, V372, P398; YUAN YLO, 1993, GENE DEV, V7, P1584, DOI 10.1101/gad.7.8.1584	127	1197	1229	0	23	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 27	1995	80	2					199	211		10.1016/0092-8674(95)90403-4	http://dx.doi.org/10.1016/0092-8674(95)90403-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7834740	Bronze			2022-12-28	WOS:A1995QD92400003
J	SHA, WC; LIOU, HC; TUOMANEN, EI; BALTIMORE, D				SHA, WC; LIOU, HC; TUOMANEN, EI; BALTIMORE, D			TARGETED DISRUPTION OF THE P50 SUBUNIT OF NF-KAPPA-B LEADS TO MULTIFOCAL DEFECTS IN IMMUNE-RESPONSES	CELL			English	Article							DNA-BINDING SUBUNIT; TRANSCRIPTION FACTORS; ENHANCER; PROMOTER; GENE; REL; INHIBITION; EXPRESSION; DORSAL; INVOLVEMENT	NF-kappa B, a heterodimeric transcription factor composed of p50 and p65 subunits, can be activated in many cell types and is thought to regulate a wide variety of genes involved in immune function and development, Mice lacking the p50 subunit of NF-kappa B show no developmental abnormalities, but exhibit multifocal defects in immune responses involving B lymphocytes and nonspecific responses to infection. B cells do not proliferate in response to bacterial lipopolysaccharide and are defective in basal and specific antibody production. Mice lacking p50 are unable effectively to clear L. monocytogenes and are more susceptible to infection with S. pneumoniae, but are more resistant to infection with murine encephalomyocarditis virus. These data support the role of NF-kappa B as a vital transcription factor for both specific and nonspecific immune responses, but do not indicate a developmental role for the factor.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; CORNELL UNIV,COLL MED,DEPT CELL BIOL,DIV ALLERGY & IMMUNOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT MED,DIV ALLERGY & IMMUNOL,NEW YORK,NY 10021; ROCKEFELLER UNIV,MOLEC INFECT DIS LAB,NEW YORK,NY 10021	Massachusetts Institute of Technology (MIT); Cornell University; Cornell University; Rockefeller University			Tuomanen, Elaine I/N-3081-2018	Tuomanen, Elaine I/0000-0003-0349-8716	NIAID NIH HHS [AI08724-02] Funding Source: Medline; NIGMS NIH HHS [GM39458] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039458] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATCHISON ML, 1987, CELL, V48, P121, DOI 10.1016/0092-8674(87)90362-X; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BANCROFT GJ, 1991, IMMUNOL REV, V124, P5, DOI 10.1111/j.1600-065X.1991.tb00613.x; Coligan J.E., 1993, CURRENT PROTOCOLS IM; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOODBOURN S, 1985, CELL, V41, P509, DOI 10.1016/S0092-8674(85)80024-6; GRILLI M, 1991, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LIEBERMANN TA, 1990, MOL CELL BIOL, V10, P2327; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LIU JL, 1991, J IMMUNOL, V146, P1685; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; MANIATIS T, 1992, POSITIVE NEGATIVE RE; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PESSARA U, 1990, MOL CELL BIOL, V10, P4146, DOI 10.1128/MCB.10.8.4146; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SEN R, 1987, MOL CELL BIOL, V7, P1989, DOI 10.1128/MCB.7.5.1989; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6	38	1021	1048	1	20	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 27	1995	80	2					321	330		10.1016/0092-8674(95)90415-8	http://dx.doi.org/10.1016/0092-8674(95)90415-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7834752	hybrid			2022-12-28	WOS:A1995QD92400015
J	OPPENHEIM, RW; HOUENOU, LJ; JOHNSON, JE; LIN, LFH; LI, LX; LO, AC; NEWSOME, AL; PREVETTE, DM; WANG, SW				OPPENHEIM, RW; HOUENOU, LJ; JOHNSON, JE; LIN, LFH; LI, LX; LO, AC; NEWSOME, AL; PREVETTE, DM; WANG, SW			DEVELOPING MOTOR-NEURONS RESCUED FROM PROGRAMMED AND AXOTOMY-INDUCED CELL-DEATH BY GDNF	NATURE			English	Article							NEUROTROPHIC FACTOR; NERVOUS-SYSTEM; SURVIVAL; MUSCLE; MOTONEURONS; SUPPORT; CULTURE; INVIVO	DURING normal development of the vertebrate nervous system, large numbers of neurons in the central and peripheral nervous system undergo naturally occurring cell death(1). For example, about half of all spinal motor neurons die over a period of a few days in developing avian, rat and mouse embryos(1). Previous studies have shown that extracts from muscle and brain, secreted factors from glia, as well as several growth factors and neurotrophic agents, including muscle-derived factors, can promote the survival of developing motor neurons in vitro and in vivo(2-15). But because neurotrophins and other known trophic agents administered alone or in combination are insufficient to rescue all developing motor neurons from cell deaths(8), other neurotrophic molecules are probably essential for the survival and differentiation of motor neurons. Here we report that glial-cell-line-derived neurotrophic factor (GDNF), a potent neurotrophic factor that enhances survival of mammalian midbrain dopaminergic neurons(16,17), rescues developing avian motor neurons from natural programmed cell death in vivo and promotes the survival of enriched populations of cultured motor neurons. Furthermore, treatment with this agent in vivo also prevents the induced death and atrophy of both avian and mouse spinal motor neurons following peripheral axotomy.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,NEUROSCI PROGRAM,WINSTON SALEM,NC 27157; SYNERGEN INC,BOULDER,CO 80301	Wake Forest University; Wake Forest Baptist Medical Center	OPPENHEIM, RW (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT NEUROBIOL & ANAT,WINSTON SALEM,NC 27157, USA.							ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BLOCHGALLEGO E, 1993, DEVELOPMENT, V111, P221; DOHRMANN U, 1987, DEV BIOL, V124, P145, DOI 10.1016/0012-1606(87)90467-2; DOHRMANN U, 1986, DEV BIOL, V118, P209, DOI 10.1016/0012-1606(86)90089-8; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; HOUENOU LJ, 1994, PROG BRAIN RES, V102, P209; JOHNSON J, 1994, CURR BIOL, V4, P662, DOI 10.1016/S0960-9822(00)00149-4; KOLIATSOS VE, 1993, NEURON, V10, P359, DOI 10.1016/0896-6273(93)90326-M; KOLIATSOS VE, 1994, P NATL ACAD SCI USA, V91, P3304, DOI 10.1073/pnas.91.8.3304; LANCEJONES C, 1982, DEV BRAIN RES, V4, P473, DOI 10.1016/0165-3806(82)90192-4; LI LX, 1994, J NEUROBIOL, V25, P759, DOI 10.1002/neu.480250702; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; MILLIGAN CE, 1994, J NEUROBIOL, V25, P1005, DOI 10.1002/neu.480250809; MITSUMOTO H, 1994, SCIENCE, V265, P1107, DOI 10.1126/science.8066451; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; OPPENHEIM RW, 1993, J NEUROBIOL, V24, P1065, DOI 10.1002/neu.480240806; OPPENHEIM RW, 1988, SCIENCE, V240, P919, DOI 10.1126/science.3363373; OPPENHEIM RW, 1986, DEV BIOL, V114, P425; OPPENHEIM RW, 1991, SCIENCE, V257, P1616; RIECKE GK, 1982, PHYSIOL BEHAV, V28, P755; SCHAAR DG, 1993, EXP NEUROL, V124, P368, DOI 10.1006/exnr.1993.1207; SENDTNER M, 1992, NATURE, V360, P755; SPRINGER JE, 1994, Q EXPL NEUROL, V127, P167; STOMBERG I, 1993, EXP NEUROL, V124, P401; VONBARTHELD CS, 1994, NEURON, V12, P639, DOI 10.1016/0896-6273(94)90219-4; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0; YIN QW, 1994, J NEUROSCI, V14, P7629	30	620	674	1	32	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					344	346		10.1038/373344a0	http://dx.doi.org/10.1038/373344a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830769				2022-12-28	WOS:A1995QD40400060
J	BURGER, MPM; HOLLEMA, H; PIETERS, WJLM; QUINT, WGV				BURGER, MPM; HOLLEMA, H; PIETERS, WJLM; QUINT, WGV			PREDICTIVE VALUE OF HUMAN PAPILLOMAVIRUS TYPE FOR HISTOLOGICAL DIAGNOSIS OF WOMEN WITH CERVICAL CYTOLOGICAL ABNORMALITIES	BRITISH MEDICAL JOURNAL			English	Article									SSZOG,PATHOL LAB,9675 HJ WINSCHOTEN,NETHERLANDS; SSDZ,CTR DIAGNOST,2625 AD DELFT,NETHERLANDS		BURGER, MPM (corresponding author), UNIV GRONINGEN HOSP,DEPT OBSTET & GYNAECOL,ONCOL GYNAECOL SECT,OOSTERSINGEL 59,9713 EZ GRONINGEN,NETHERLANDS.							BURGER MPM, 1993, BRIT MED J, V306, P749, DOI 10.1136/bmj.306.6880.749; CUZICK J, 1994, BRIT J CANCER, V69, P167, DOI 10.1038/bjc.1994.28; GENEST DR, 1993, HUM PATHOL, V24, P760; LORINCZ AT, 1992, OBSTET GYNECOL, V79, P328, DOI 10.1097/00006250-199203000-00002; VANRANST M, 1992, J GEN VIROL, V73, P2653, DOI 10.1099/0022-1317-73-10-2653	5	26	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 14	1995	310	6972					94	95		10.1136/bmj.310.6972.94	http://dx.doi.org/10.1136/bmj.310.6972.94			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC223	7833734	Green Published			2022-12-28	WOS:A1995QC22300020
J	GUPTA, R; GUPTA, VP; AHLUWALIA, NS				GUPTA, R; GUPTA, VP; AHLUWALIA, NS			EDUCATIONAL STATUS, CORONARY HEART-DISEASE, AND CORONARY RISK FACTOR PREVALENCE IN A RURAL-POPULATION OF INDIA	BRITISH MEDICAL JOURNAL			English	Article							ASSOCIATION; MORTALITY; LEVEL; MEN	Objective-To define the association between educational level and prevalence of coronary heart disease and coronary risk factors in India. Design-Total community cross sectional survey with a doctor administered questionnaire, physical examination, and electrocardiography. Setting-A cluster of three villages in rural Rajasthan, western India. Subjects-3148 residents aged over 20 (1982 men, 1166 women) divided into various groups according to years of formal schooling. Results-Illiteracy and low educational levels were associated with less prestigious occupations (agricultural and farm labouring) and inferior housing. There was an inverse correlation of educational level with age (rank correlation: men -0.45, women -0.49). The prevalence of coronary heart disease (diagnosed by electrocardiography) was significantly higher among uneducated and less educated people and showed an inverse relation with education in both sexes. Among uneducated and less educated people there was a higher prevalence of the coronary risk factors smoking and hypertension. Educational level showed a significant inverse correlation with systolic and diastolic blood pressure. Logistic regression analysis with adjustment for age showed that educational level had an inverse relation with prevalence of electrocardiographically diagnosed coronary heart disease (odds ratio: men 0.82, women 0.53), hypertension (men 0.88, women 0.56), and smoking (men 0.73, women 0.65) but not with hypercholesterolaemia and obesity. The inverse relation of coronary heart disease with educational level abated after adjustment for smoking, physical activity, body mass index, and blood pressure (odds ratio: men 0.98, women 0.78). Conclusion-Uneducated and less educated people in rural India have a higher prevalence of coronary heart disease and of the coronary risk factors smoking and hypertension.	UNIV RAJASTHAN,DEPT STAT,JAIPUR 302004,RAJASTHAN,INDIA	University of Rajasthan	GUPTA, R (corresponding author), MONILEK HOSP & RES CTR,DEPT MED,JAWAHAR NAGAR,JAIPUR 302004,RAJASTHAN,INDIA.							ANGELL M, 1993, NEW ENGL J MED, V329, P126, DOI 10.1056/NEJM199307083290210; CHADHA SL, 1990, INDIAN J MED RES-B, V92, P424; Dewan B D, 1974, Indian Heart J, V26, P68; Gupta R, 1994, J Assoc Physicians India, V42, P24; Gupta S P, 1975, J Assoc Physicians India, V23, P885; GURALNIK JM, 1993, NEW ENGL J MED, V329, P110, DOI 10.1056/NEJM199307083290208; JACOBSEN BK, 1988, AM J EPIDEMIOL, V127, P923, DOI 10.1093/oxfordjournals.aje.a114895; Jajoo U N, 1988, J Assoc Physicians India, V36, P689; Joshi P P, 1993, J Assoc Physicians India, V41, P579; KAPLAN GA, 1993, CIRCULATION, V88, P1973, DOI 10.1161/01.CIR.88.4.1973; MARMOT MG, 1987, ANNU REV PUBL HEALTH, V8, P111, DOI 10.1146/annurev.pu.08.050187.000551; MCKEIGUE PM, 1993, CIRCULATION, V87, P152, DOI 10.1161/01.CIR.87.1.152; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; ROSE G, 1981, BRIT HEART J, V45, P13, DOI 10.1136/hrt.45.1.13; Rose G, 1982, CARDIOVASCULAR SURVE; SARVOTHAM SG, 1968, CIRCULATION, V37, P839; 1993, ARCH INTERN MED, V153, P154; 1993, STATUS HLTH RAJASTHA, P3; 1989, STRONG HEART STUDY M; 1992, J CLIN EPIDEMIOL, V45, P841	21	127	130	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 19	1994	309	6965					1332	1336		10.1136/bmj.309.6965.1332	http://dx.doi.org/10.1136/bmj.309.6965.1332			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT625	7866081	Green Published			2022-12-28	WOS:A1994PT62500020
J	SUTHANTHIRAN, M; STROM, TB				SUTHANTHIRAN, M; STROM, TB			MEDICAL PROGRESS - RENAL-TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							T-CELL ACTIVATION; HUMAN LYMPHOCYTES-T; HUMAN IL-2 RECEPTOR; GROWTH-FACTOR-BETA; INTERLEUKIN-2 RECEPTOR; KIDNEY-TRANSPLANTATION; MONOCLONAL-ANTIBODY; CYCLOSPORINE-A; FISH-OIL; COLLABORATIVE TRANSPLANT		BETH ISRAEL HOSP, DEPT MED, DIV IMMUNOL, BOSTON, MA 02215 USA; CORNELL UNIV, MED CTR, NEW YORK HOSP, ROGOSIN INST, DEPT MED, NEW YORK, NY 10021 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Cornell University; NewYork-Presbyterian Hospital; Harvard University; Harvard Medical School			Strom, Terry B./E-9268-2010; Suthanthiran, Manikkam/AAL-9104-2020	Strom, Terry B./0000-0002-7570-0736; 				ALMAWI WY, 1991, J IMMUNOL, V146, P3523; ARYA SK, 1984, J IMMUNOL, V133, P273; BACH JF, 1986, RES MONOGRAPHS IMMUN, V9, P105; BASADONNA G, 1993, CLIN TRANSPLANTS 199, P227; BELZER FO, 1976, KIDNEY, V2, P1796; BENOIT G, 1991, PRESSE MED, V20, P2045; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; BROWN MH, 1989, NATURE, V339, P551, DOI 10.1038/339551a0; Cecka J M, 1993, Clin Transpl, P1; Cecka J M, 1991, Clin Transpl, P1; CECKA JM, 1992, TRANSPLANTATION, V53, P59, DOI 10.1097/00007890-199201000-00011; CHATENOUD L, 1993, TRANSPLANT P, V25, P47; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Cicciarelli J, 1991, Clin Transpl, P325; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Curtis J J, 1992, Curr Opin Nephrol Hypertens, V1, P100, DOI 10.1097/00041552-199210000-00015; DANTAL J, 1994, NEW ENGL J MED, V330, P7, DOI 10.1056/NEJM199401063300102; DAWIDSON I, 1991, J AM SOC NEPHROL, V2, P983; DRUEKE TB, 1991, KIDNEY INT, V39, pS24; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EGGERS PW, 1988, NEW ENGL J MED, V318, P223, DOI 10.1056/NEJM198801283180406; ELION GB, 1967, FED PROC, V26, P898; EVANS RW, 1992, JAMA-J AM MED ASSOC, V267, P239, DOI 10.1001/jama.267.2.239; EVANS RW, 1993, TRANSPLANT P, V25, P1694; EVANS RW, 1991, NATIONAL COOPERATIVE; FARRUGIA E, 1992, MAYO CLIN PROC, V67, P879, DOI 10.1016/S0025-6196(12)60828-3; FIRST MR, 1993, TRANSPLANT P, V25, P52; FOX BC, 1990, AM J MED, V89, P255, DOI 10.1016/0002-9343(90)90337-D; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; FUNG MR, 1991, J IMMUNOL, V147, P1253; GASTON RS, 1993, JAMA-J AM MED ASSOC, V270, P1352, DOI 10.1001/jama.270.11.1352; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GJERTSON DW, 1991, NEW ENGL J MED, V324, P1032, DOI 10.1056/NEJM199104113241505; GOLDSTEIN G, 1985, NEW ENGL J MED, V313, P337; GOODMAN ER, 1993, CLIN TRANSPLANTS 199, P285; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HIBBERD PL, 1992, TRANSPLANTATION, V53, P68, DOI 10.1097/00007890-199201000-00013; HUNSICKER LG, 1992, SEMIN NEPHROL, V12, P293; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; JULIAN BA, 1991, NEW ENGL J MED, V325, P544, DOI 10.1056/NEJM199108223250804; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; KASISKE BL, 1991, AM J KIDNEY DIS, V17, P700, DOI 10.1016/S0272-6386(12)80355-6; KASISKE BL, 1991, KIDNEY INT, V40, P514, DOI 10.1038/ki.1991.240; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KELLEY VE, 1989, TRANSPLANTATION, V48, P98, DOI 10.1097/00007890-198907000-00023; KERMAN RH, 1991, TRANSPLANTATION, V51, P338, DOI 10.1097/00007890-199102000-00013; KIRKMAN RL, 1991, TRANSPL P, V23, P1066; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KNIGHT RJ, 1994, TRANSPLANTATION, V57, P1581; KNUDSEN PJ, 1987, J IMMUNOL, V139, P4129; KOKADO Y, 1990, CLIN TRANSPLANT, V4, P191; KREIS H, 1992, KIDNEY INT, V42, pS188; KRENSKY AM, 1990, NEW ENGL J MED, V322, P510, DOI 10.1056/NEJM199002223220805; KUNZENDORF U, 1991, TRANSPLANTATION, V52, P280, DOI 10.1097/00007890-199108000-00018; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; KUPIECWEGLINSKI JW, 1994, IMMUNOLOGY OF CORNEAL TRANSPLANTATION, P213; LI B, 1991, J EXP MED, V174, P1259, DOI 10.1084/jem.174.5.1259; LINDHEIMER MD, 1992, AM J KIDNEY DIS, V19, P173, DOI 10.1016/S0272-6386(12)70128-2; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; LIPMAN ML, 1992, TRANSPLANTATION, V53, P73, DOI 10.1097/00007890-199201000-00014; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LUKE RG, 1991, J AM SOC NEPHROL, V2, pS37; MAKOWKA L, 1993, IMMUNOL REV, V136, P51, DOI 10.1111/j.1600-065X.1993.tb00654.x; MASLINSKI W, 1992, J BIOL CHEM, V267, P15281; MATHEW TH, 1988, AM J KIDNEY DIS, V12, P85, DOI 10.1016/S0272-6386(88)80001-5; Miceli M C, 1991, Semin Immunol, V3, P133; MITSUISHI Y, 1993, CLIN TRANSPLANTS 199, P371; Morris R.E., 1992, TRANSPLANT REV-ORLAN, P39; MORRIS RE, 1991, TRANSPLANT P, V23, P493; MYERS BD, 1986, KIDNEY INT, V30, P964, DOI 10.1038/ki.1986.280; NADLER SG, 1992, SCIENCE, V258, P484, DOI 10.1126/science.1411548; NEUMAYER HH, 1992, KIDNEY INT, V41, pS87; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NORMAN DJ, 1993, TRANSPLANTATION, V55, P44, DOI 10.1097/00007890-199301000-00009; NORMAN DJ, 1992, SEMIN NEPHROL, V12, P315; OGURA K, 1993, TRANSPLANTATION, V56, P294; OGURA K, 1993, CLIN TRANSPLANTS 199, P357; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; OPELZ G, 1993, TRANSPLANT P, V25, P2443; OPELZ G, 1991, LANCET, V338, P461, DOI 10.1016/0140-6736(91)90540-6; OPELZ G, 1993, LANCET, V342, P1514, DOI 10.1016/S0140-6736(05)80084-4; OPELZ G, 1992, TRANSPLANT P, V24, P2342; OPELZ G, 1993, TRANSPLANT P, V25, P173; OPELZ G, 1988, NEW ENGL J MED, V318, P1289, DOI 10.1056/NEJM198805193182001; PARFREY PS, 1985, KIDNEY INT, V28, P959, DOI 10.1038/ki.1985.224; PAUL LC, 1992, TRANSPLANTATION, V53, P1169, DOI 10.1097/00007890-199206000-00001; PENN I, 1991, TRANSPLANT P, V23, P1771; PENN I, 1993, TRANSPLANTATION, V55, P742, DOI 10.1097/00007890-199304000-00011; PEREIRA BJG, 1992, NEW ENGL J MED, V327, P910, DOI 10.1056/NEJM199209243271302; PIRSCH JD, 1992, J AM SOC NEPHROL, V2, pS238; QUEEN C, 1989, P NATL ACAD SCI USA, V86, P10029, DOI 10.1073/pnas.86.24.10029; RAO KV, 1993, AM J MED, V94, P241, DOI 10.1016/0002-9343(93)90055-T; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; ROGERS TS, 1988, TRANSPLANTATION, V45, P153; RUBIN RH, 1990, REV INFECT DIS, V12, pS754; SAGALOWSKY AI, 1991, PRINCIPLES PRACTICE, P843; SANDERS CE, 1993, AM J KIDNEY DIS, V21, P9, DOI 10.1016/S0272-6386(12)80713-X; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHRIER RW, 1987, KIDNEY INT, V32, P313, DOI 10.1038/ki.1987.211; SCHWARTZ RH, 1993, SCI AM, V269, P62, DOI 10.1038/scientificamerican0893-62; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SHOSKES DA, 1994, IMMUNOL TODAY, V15, P32, DOI 10.1016/0167-5699(94)90023-X; SHOWSTACK J, 1989, NEW ENGL J MED, V321, P1086, DOI 10.1056/NEJM198910193211605; SIGAL NH, 1991, TRANSPLANT P, V23, P1; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SOLLINGER HW, 1992, TRANSPLANTATION, V53, P428, DOI 10.1097/00007890-199202010-00031; SOULILLOU JP, 1990, NEW ENGL J MED, V322, P1175, DOI 10.1056/NEJM199004263221702; SPITAL A, 1991, NEW ENGL J MED, V325, P1243, DOI 10.1056/NEJM199110243251710; STARZL TE, 1987, JAMA-J AM MED ASSOC, V258, P783; STROM TB, 1975, NEW ENGL J MED, V292, P1257, DOI 10.1056/NEJM197506122922402; SUTHANTHIRAN M, 1993, TRANSPLANTATION, V55, P1008, DOI 10.1097/00007890-199305000-00011; SUTHANTHIRAN M, 1989, AM J KIDNEY DIS, V14, P39; SUTHANTHIRAN M, 1993, KIDNEY INT, V44, pS3; SUTHANTHIRAN M, 1983, UROL CLIN N AM, V10, P315; SUTHANTHIRAN M, 1990, J EXP MED, V171, P1965, DOI 10.1084/jem.171.6.1965; SWEENEY MJ, 1972, CANCER RES, V32, P1803; TAKEMOTO S, 1992, NEW ENGL J MED, V327, P834, DOI 10.1056/NEJM199209173271202; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAKEUCHI T, 1981, J ANTIBIOT, V34, P1619, DOI 10.7164/antibiotics.34.1619; Terasaki P I, 1991, Clin Transpl, P409; TERASAKI PI, 1993, CLIN TRANSPLANTS 199, P501; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; THOMSON AW, 1993, IMMUNOL REV, V136, P71, DOI 10.1111/j.1600-065X.1993.tb00655.x; TILNEY NL, 1991, TRANSPLANTATION, V52, P389, DOI 10.1097/00007890-199109000-00001; TILNEY NL, 1978, NEW ENGL J MED, V299, P1321, DOI 10.1056/NEJM197812142992401; TURKA LA, 1991, J CLIN INVEST, V87, P940, DOI 10.1172/JCI115101; UMEDA Y, 1985, J ANTIBIOT, V38, P886, DOI 10.7164/antibiotics.38.886; UNANUE ER, 1989, FASEB J, V3, P2496, DOI 10.1096/fasebj.3.13.2572499; VACCA A, 1992, J EXP MED, V175, P637, DOI 10.1084/jem.175.3.637; VANDERHEIDE JJH, 1993, NEW ENGL J MED, V329, P769, DOI 10.1056/NEJM199309093291105; VEATCH RM, 1991, NEW ENGL J MED, V325, P1246, DOI 10.1056/NEJM199110243251711; VINCENTI FG, 1993, TRANSPLANT P, V25, P57; WAID TH, 1992, TRANSPLANTATION, V53, P80, DOI 10.1097/00007890-199201000-00015; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; Wang J. C., 1992, Journal of the American Society of Nephrology, V3, P849; WEIR MR, 1992, CALCIUM ANTAGONISTS, P391; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILLIAMS GM, 1968, NEW ENGL J MED, V279, P611, DOI 10.1056/NEJM196809192791201; WILLIAMS JM, 1985, J IMMUNOL, V135, P2249; XIAO F, 1994, IMMUNOSUPPRESSIVE DR, P203; ZANKER B, 1990, TRANSPLANTATION, V49, P183, DOI 10.1097/00007890-199001000-00040; 1990, SCI REGISTRY ORGAN T; 1986, TRANSPLANTATION, V41, P1; 1994, UNOS UPDATE, V10, P38	149	380	426	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 11	1994	331	6					365	376		10.1056/NEJM199408113310606	http://dx.doi.org/10.1056/NEJM199408113310606			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA374	7832839				2022-12-28	WOS:A1994PA37400006
J	MAY, JW				MAY, JW			TRANSFER OF A TOE TO THE HAND	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											MAY, JW (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 23	1995	332	12					785	785		10.1056/NEJM199503233321205	http://dx.doi.org/10.1056/NEJM199503233321205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN442	7862182				2022-12-28	WOS:A1995QN44200005
J	MRAK, RE				MRAK, RE			TRIPOLAR MITOTIC FIGURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											MRAK, RE (corresponding author), VET AFFAIRS MED CTR,LITTLE ROCK,AR 72205, USA.								0	2	2	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 16	1995	332	11					718	718		10.1056/NEJM199503163321105	http://dx.doi.org/10.1056/NEJM199503163321105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL788	7854379				2022-12-28	WOS:A1995QL78800005
J	PAN, DJ; RUBIN, GM				PAN, DJ; RUBIN, GM			CAMP-DEPENDENT PROTEIN-KINASE AND HEDGEHOG ACT ANTAGONISTICALLY IN REGULATING DECAPENTAPLEGIC TRANSCRIPTION IN DROSOPHILA IMAGINAL DISKS	CELL			English	Article							POLARITY GENE HEDGEHOG; EXPRESSION; WINGLESS; DISKS; COMPARTMENTS; DIRECTS; CELLS; EYE	Localized expression of decapentaplegic (dpp) is required for proper development of the Drosophila imaginal discs. Using genetic mosaics, we show that in the anterior compartment of appendage discs and anterior to the morphogenetic furrow in the eye disc, cells that lack cAMP-dependent protein kinase (PKA) activity ectopically express dpp. Pka(-) cells can influence the fate of neighboring cells to reorganize anterior patterns in appendages and trigger ectopic morphogenetic furrows in the developing retina. This organizing activity of Pka mutant cells depends on dpp activity. Our findings suggest that PKA is a component of a signaling pathway that represses dpp expression and that hh antagonizes this pathway to maintain dpp expression at the anterior-posterior compartment border and in the morphogenetic furrow.	UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley				Rubin, Gerald/0000-0001-8762-8703				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BROWN NL, 1991, DEVELOPMENT, V113, P1245; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; DEVREOTES PN, 1994, NEURON, V12, P235, DOI 10.1016/0896-6273(94)90267-4; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; EATON S, 1990, GENE DEV, V4, P1068, DOI 10.1101/gad.4.6.1068; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1994, CURR BIOL, V4, P347, DOI 10.1016/S0960-9822(00)00076-2; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; LANE ME, 1993, GENE DEV, V7, P1229, DOI 10.1101/gad.7.7a.1229; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Lee KAW, 1991, CURR OPIN CELL BIOL, V3, P953, DOI 10.1016/0955-0674(91)90113-D; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MEINHARDT H, 1983, DEV BIOL, V96, P375, DOI 10.1016/0012-1606(83)90175-6; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; RAFTERY LA, 1991, DEVELOPMENT, V113, P27; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; VINCENT JP, 1994, DEV BIOL, V164, P328, DOI 10.1006/dbio.1994.1203; Wolff Tanya, 1993, P1277; XU T, 1993, DEVELOPMENT, V117, P1223	38	222	225	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					543	552		10.1016/0092-8674(95)90508-1	http://dx.doi.org/10.1016/0092-8674(95)90508-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867062	Bronze			2022-12-28	WOS:A1995QJ60200006
J	SHAPIRO, L				SHAPIRO, L			THE BACTERIAL FLAGELLUM - FROM GENETIC NETWORK TO COMPLEX ARCHITECTURE	CELL			English	Review							SALMONELLA-TYPHIMURIUM				SHAPIRO, L (corresponding author), STANFORD UNIV,SCH MED,BECKMAN CTR,DEPT DEV BIOL,STANFORD,CA 94305, USA.							AKERLEY BJ, 1995, CELL, V80, P611, DOI 10.1016/0092-8674(95)90515-4; BRUN YV, 1994, ANNU REV BIOCHEM, V63, P419, DOI 10.1146/annurev.bi.63.070194.002223; EATON KA, 1992, J MED MICROBIOL, V37, P123, DOI 10.1099/00222615-37-2-123; EMERSON SU, 1970, SCIENCE, V169, P190, DOI 10.1126/science.169.3941.190; Forsberg Ake, 1994, Trends in Microbiology, V2, P14, DOI 10.1016/0966-842X(94)90339-5; FRANCIS NR, 1994, J MOL BIOL, V235, P1261, DOI 10.1006/jmbi.1994.1079; HUGHES KT, 1993, SCIENCE, V262, P1277, DOI 10.1126/science.8235660; IINO T, 1969, J GEN MICROBIOL, V56, P227, DOI 10.1099/00221287-56-2-227; KHAN IH, 1992, P NATL ACAD SCI USA, V89, P5956, DOI 10.1073/pnas.89.13.5956; KUTSUKAKE K, 1994, J BACTERIOL, V176, P7625, DOI 10.1128/JB.176.24.7625-7629.1994; KUTSUKAKE K, 1994, MOL GEN GENET, V243, P605, DOI 10.1007/BF00279569; LIU XY, 1994, J BACTERIOL, V176, P7345, DOI 10.1128/JB.176.23.7345-7351.1994; LOSICK R, 1993, SCIENCE, V262, P1227, DOI 10.1126/science.8235653; MACNAB RM, 1992, ANNU REV GENET, V26, P131, DOI 10.1146/annurev.ge.26.120192.001023; OHNISHI K, 1994, J BACTERIOL, V176, P2272, DOI 10.1128/JB.176.8.2272-2281.1994; OHNISHI K, 1992, MOL MICROBIOL, V6, P3149, DOI 10.1111/j.1365-2958.1992.tb01771.x; ROSQVIST R, 1994, EMBO J, V13, P964, DOI 10.1002/j.1460-2075.1994.tb06341.x; RUSSEL M, 1994, SCIENCE, V265, P612, DOI 10.1126/science.8036510; UENO T, 1994, J MOL BIOL, V236, P546, DOI 10.1006/jmbi.1994.1164; UENO T, 1992, J MOL BIOL, V227, P672, DOI 10.1016/0022-2836(92)90216-7	20	52	54	1	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 24	1995	80	4					525	527		10.1016/0092-8674(95)90505-7	http://dx.doi.org/10.1016/0092-8674(95)90505-7			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867059	Bronze			2022-12-28	WOS:A1995QJ60200003
J	TREASURE, CB; KLEIN, JL; WEINTRAUB, WS; TALLEY, JD; STILLABOWER, ME; KOSINSKI, AS; ZHANG, J; BOCCUZZI, SJ; CEDARHOLM, JC; ALEXANDER, RW				TREASURE, CB; KLEIN, JL; WEINTRAUB, WS; TALLEY, JD; STILLABOWER, ME; KOSINSKI, AS; ZHANG, J; BOCCUZZI, SJ; CEDARHOLM, JC; ALEXANDER, RW			BENEFICIAL-EFFECTS OF CHOLESTEROL-LOWERING THERAPY ON THE CORONARY ENDOTHELIUM IN PATIENTS WITH CORONARY-ARTERY DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUPEROXIDE ANION PRODUCTION; LOW-DENSITY LIPOPROTEIN; DEPENDENT RELAXATION; ATHEROSCLEROSIS-REGRESSION; DIETARY-TREATMENT; HYPERCHOLESTEROLEMIA; ACETYLCHOLINE; INCREASES; RABBITS	Background. Impaired endothelium-mediated relaxation contributes to vasospasm and myocardial ischemia in patients with coronary artery disease. We hypothesized that cholesterol-lowering therapy with the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin could improve endothelium-mediated responses in patients with coronary atherosclerosis. Methods. In a randomized, double-blind, placebo-controlled trial, we studied coronary endothelial responses in 23 patients randomly assigned to either lovastatin (40 mg twice daily; 11 patients) or placebo (12 patients) plus a lipid-lowering diet (American Heart Association Step 1 diet). Patients were studied 12 days after randomization and again at 5% months. These patients had total cholesterol levels ranging from 160 to 300 mg per deciliter (4.1 to 7.8 mmol per liter) and were undergoing coronary angioplasty. At the initial and follow-up studies, patients received serial intracoronary infusions (in a coronary artery not undergoing angioplasty) of acetylcholine to assess endothelium-mediated vasodilatation. The responses of the coronary vessels were analyzed with quantitative angiography. Results. The patients in the placebo and lovastatin groups had similar responses to acetylcholine at a mean of 12 days of therapy (expressed as the percentage of change in diameter in response to acetylcholine doses of 10(-9) M, 10(-8) M, 10(-7) M, and 10(-6) M). In the placebo group, the respective mean (+/-SE) changes were 1+/-2, 0+/-2, -2+/-4, and -19+/-4 percent; in the lovastatin group, they were -2+/-2, -4+/-4, -12+/-5, and -16+/-7 percent (P=0.32). (Coronary-artery constriction is reflected by negative numbers.) The responses to acetylcholine in the placebo group after a mean of 5.5 months of therapy were -3+/-3, -1+/-2, -8+/-4, and -18+/-5 percent, respectively; there was significant improvement in the lovastatin group, which had responses of 3+/-3, 3+/-3, 0+/-2, and 0+/-3 percent (P = 0.004). Conclusions. Cholesterol lowering with lovastatin significantly improved endothelium-mediated responses in the coronary arteries of patients with atherosclerosis. Such improvement in the local regulation of coronary arterial tone could potentially relieve ischemic symptoms and signal the stabilization of the atherosclerotic plaque.	UNIV LOUISVILLE, SCH MED, DEPT MED, DIV CARDIOL, LOUISVILLE, KY 40292 USA; MED CTR DELAWARE, DIV CARDIOL, NEWARK, DE USA; EMORY UNIV, SCH PUBL HLTH, DIV BIOSTAT, ATLANTA, GA 30322 USA; MERCK & CO INC, RES LABS, RAHWAY, NJ USA; SANGER CLIN PA, CHARLOTTE, NC USA	University of Louisville; Emory University; Merck & Company	TREASURE, CB (corresponding author), EMORY UNIV, SCH MED, DEPT MED, DIV CARDIOL, PO DRAWER LL, ATLANTA, GA 30322 USA.				NHLBI NIH HHS [HL48667] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048667] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLANKENHORN DH, 1993, ANN INTERN MED, V119, P969, DOI 10.7326/0003-4819-119-10-199311150-00002; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; DIGGLE PJ, 1994, OXFORD STATISTICAL S, V13; EGASHIRA K, 1994, CIRCULATION, V89, P2519, DOI 10.1161/01.CIR.89.6.2519; Fisher LD., 1997, BIOMETRICS, V53, P1182; GIBSON M, 1992, AM J CARDIOL, V69, P1286, DOI 10.1016/0002-9149(92)91222-P; GOULD KL, 1994, CIRCULATION, V89, P1530, DOI 10.1161/01.CIR.89.4.1530; HARRISON DG, 1987, J CLIN INVEST, V80, P1808, DOI 10.1172/JCI113276; KJEKSHUS J, 1993, AM J CARDIOL, V71, P393; LEUNG WH, 1993, LANCET, V341, P1496, DOI 10.1016/0140-6736(93)90634-S; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MINOR RL, 1990, J CLIN INVEST, V86, P2109, DOI 10.1172/JCI114949; MUGGE A, 1991, CIRC RES, V69, P1293, DOI 10.1161/01.RES.69.5.1293; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; OHARA Y, 1993, CIRCULATION, V88, P467; OLIVER MF, 1994, LANCET, V344, P633; OSBORNE JA, 1989, J CLIN INVEST, V83, P465, DOI 10.1172/JCI113905; REIBER JHC, 1985, CIRCULATION, V71, P280, DOI 10.1161/01.CIR.71.2.280; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SIMON BC, 1990, J CLIN INVEST, V86, P75, DOI 10.1172/JCI114718; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; VITA JA, 1990, CIRCULATION, V81, P491, DOI 10.1161/01.CIR.81.2.491; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; WEINTRAUB WS, 1992, AM J CARDIOL, V70, P293, DOI 10.1016/0002-9149(92)90607-Z; 1994, LANCET, V344, P762; 1992, P229 SAS I INC TECHN, P287	27	1096	1133	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 23	1995	332	8					481	487		10.1056/NEJM199502233320801	http://dx.doi.org/10.1056/NEJM199502233320801			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH288	7830728				2022-12-28	WOS:A1995QH28800001
J	CHAKOS, MH; LIEBERMAN, JA; ALVIR, J; BILDER, R; ASHTARI, M				CHAKOS, MH; LIEBERMAN, JA; ALVIR, J; BILDER, R; ASHTARI, M			CAUDATE NUCLEI VOLUMES IN SCHIZOPHRENIC-PATIENTS TREATED WITH TYPICAL ANTIPSYCHOTICS OR CLOZAPINE	LANCET			English	Letter									ALBERT EINSTEIN COLL MED,GLEN OAKS,NY 11004; ALBERT EINSTEIN COLL MED,LONG ISL JEWISH MED CTR,DEPT RADIOL,NEW HYDE PK,NY	Yeshiva University; Northwell Health; Yeshiva University	CHAKOS, MH (corresponding author), HILLSIDE HOSP,DEPT PSYCHIAT,DIV LONG ISL JEWISH MED CTR,GLEN OAKS,NY, USA.		Bilder, Robert M/A-8894-2008; Lieberman, Jeffrey/AAY-8239-2020	Bilder, Robert M/0000-0001-5085-7852; 	NIMH NIH HHS [MH-411646, MH32369, MH00537] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH032369, R37MH032369] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ASHTARI M, 1990, INVEST RADIOL, V25, P798, DOI 10.1097/00004424-199007000-00009; CHAKOS MH, 1994, AM J PSYCHIAT, V151, P1430; KESHAVAN MS, 1994, LANCET, V344, P1434, DOI 10.1016/S0140-6736(94)90599-1	3	205	208	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					456	457		10.1016/S0140-6736(95)90441-7	http://dx.doi.org/10.1016/S0140-6736(95)90441-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853978				2022-12-28	WOS:A1995QG90400051
J	DEBELLO, WM; OCONNOR, V; DRESBACH, T; WHITEHEART, SW; WANG, SSH; SCHWEIZER, FE; BETZ, H; ROTHMAN, JE; AUGUSTINE, GJ				DEBELLO, WM; OCONNOR, V; DRESBACH, T; WHITEHEART, SW; WANG, SSH; SCHWEIZER, FE; BETZ, H; ROTHMAN, JE; AUGUSTINE, GJ			SNAP-MEDIATED PROTEIN-PROTEIN INTERACTIONS ESSENTIAL FOR NEUROTRANSMITTER RELEASE	NATURE			English	Article							SQUID GIANT SYNAPSE; MEMBRANE-FUSION; CALCIUM; TRANSPORT; SYNAPTOTAGMIN; POTENTIATION; DOCKING; FAMILY; YEAST	The constitutive fusion of transport vesicles with intracellular membranes requires soluble proteins called SNAPs(1). Certain presynaptic proteins(2-4) implicated in synaptic vesicle exocytosis(5) also bind SNAPs, suggesting that SNAPs participate in the calcium-regulated membrane fusion events mediating neurotransmitter release(6,7). Here we show that injection of recombinant SNAPs into the giant synapse of squid enhances transmitter release. Conversely, injection of peptides designed to mimic the sites at which SNAP interacts with its binding partners inhibits transmitter release downstream of synaptic vesicle docking. A SNAP-dependent protein complex must therefore mediate transmitter release, showing that transmitter release shares a common molecular mechanism with constitutive membrane fusion.	MARINE BIOL LAB,WOODS HOLE,MA 02543; MAX PLANCK INST BRAIN RES,DEPT NEUROCHEM,D-60528 FRANKFURT,GERMANY; MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021	Marine Biological Laboratory - Woods Hole; Max Planck Society; Memorial Sloan Kettering Cancer Center	DEBELLO, WM (corresponding author), DUKE UNIV,MED CTR,DEPT NEUROBIOL,DURHAM,NC 27710, USA.		Augustine, George James/J-9228-2013	Whiteheart, Sidney/0000-0001-5577-0473				ADLER EM, 1991, J NEUROSCI, V11, P1496; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HESS SD, 1993, SCIENCE, V259, P1169, DOI 10.1126/science.8438167; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; Katz B., 1969, RELEASE NEURAL TRANS; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; OCONNOR V, 1994, CELL, V75, P785; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V363, P318; STEVENS CF, 1993, CELL, V72, P55, DOI 10.1016/S0092-8674(05)80028-5; SUDHOF TC, 1993, CELL, V75, P1; SWANDULLA D, 1991, NEURON, V7, P915, DOI 10.1016/0896-6273(91)90337-Y; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; WHITEHEART SW, 1992, J BIOL CHEM, V267, P12239; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	30	142	146	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					626	630		10.1038/373626a0	http://dx.doi.org/10.1038/373626a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854421				2022-12-28	WOS:A1995QG99700058
J	SHANN, F				SHANN, F			ANTIPYRETICS IN SEVERE SEPSIS	LANCET			English	Editorial Material							ASPIRIN; INFECTION; RABBITS				SHANN, F (corresponding author), ROYAL CHILDRENS HOSP,INTENS CARE UNIT,MELBOURNE,VIC,AUSTRALIA.		Shann, Frank/C-9510-2011					ADAM D, 1994, EUR J PEDIATR, V153, P394; Busser FJM, 1978, J VET PHARMACOL THER, V1, P69; ESPOSITO AL, 1984, AM REV RESPIR DIS, V130, P857; GRAHAM NMH, 1990, J INFECT DIS, V162, P1277, DOI 10.1093/infdis/162.6.1277; HSIA J, 1989, B NEW YORK ACAD MED, V65, P45; HUSSEINI RH, 1982, J INFECT DIS, V145, P520, DOI 10.1093/infdis/145.4.520; KUROSAWA S, 1987, J INFECT DIS, V155, P991, DOI 10.1093/infdis/155.5.991; MOGABGAB WJ, 1976, JAMA-J AM MED ASSOC, V235, P801, DOI 10.1001/jama.1976.03260340011003; STANLEY ED, 1975, JAMA-J AM MED ASSOC, V231, P1248, DOI 10.1001/jama.231.12.1248; VAUGHN LK, 1980, BRAIN RES BULL, V5, P69, DOI 10.1016/0361-9230(80)90285-3; VAUGHN LK, 1977, FED PROC, V36, P511; 1993, WHOARI9330	12	21	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 11	1995	345	8946					338	338		10.1016/S0140-6736(95)90337-2	http://dx.doi.org/10.1016/S0140-6736(95)90337-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF722	7845113				2022-12-28	WOS:A1995QF72200005
J	WILTON, J				WILTON, J			PREREGISTRATION HOUSE OFFICERS IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							PRE-REGISTRATION POSTS; REGIONS	Objectives-To obtain from house officers who had rotated through general practice in their preregistration year their views about their experience; and, separately, to compare the overall hours and type of work performed by hospital based and general practice based house officers. Design-Postal questionnaire; and self recording of working hours and duties during four consecutive weeks. Setting-Inner London teaching hospital and nearby general practice. Participants-28 preregistration house officers in general practice, 1981-91; and 12 preregistration house officers, four each in medicine, surgery, and general practice. Results-26 out of 28 questionnaires were returned (response rate 93%). Twelve respondents were following or thinking of following a career in general practice. Twenty five respondents were satisfied with the clinical and educational aspects of the general practice rotation and would recommend the rotation, and 25 thought four months was about the right length of time in general practice. With regard to hours and type of work performed, hospital based house officers worked on average 55.5 hours a week (excluding on call), with an average of 12.5 hours (22.5%) spent in clinical activities; general practice based house officers worked about 41 hours a week, of which 24 hours (58%) were in clinical activities. House officers in hospital received less than one hour's specific teaching a week; those in general practice received nearly three hours' a week. Conclusions-A preregistration rotation in general practice is a popular alternative to the hospital based rotation. Although this is a limited study, other medical schools should consider introducing general practice options for preregistration house officers.			WILTON, J (corresponding author), LISSON GROVE HLTH CTR,LONDON NW8 8EG,ENGLAND.							DENT THS, 1990, BRIT MED J, V300, P713, DOI 10.1136/bmj.300.6726.713; DOWLING S, 1991, DOCTORS MAKING EXPER; FIRTHCOZENS J, 1989, BRIT J HOSP MED, V41, P161; FIRTHCOZENS J, 1987, BRIT MED J, V295, P533, DOI 10.1136/bmj.295.6597.533; GARRUD P, 1990, BRIT MED J, V300, P445, DOI 10.1136/bmj.300.6722.445; GILLARD JH, 1993, BRIT MED J, V307, P1180, DOI 10.1136/bmj.307.6913.1180; GLEDHILL T, 1985, MED EDUC, V19, P305, DOI 10.1111/j.1365-2923.1985.tb01326.x; HARRIS CM, 1986, MED EDUC, V20, P136, DOI 10.1111/j.1365-2923.1986.tb01061.x; HARRIS CM, 1985, BRIT MED J, V290, P1797; HULL FM, 1989, BRIT MED J, V298, P406, DOI 10.1136/bmj.298.6671.406; ILLINGWORTH C, 1994, BRIT MED J, V308, P1109, DOI 10.1136/bmj.308.6936.1109; MCKEE M, 1992, MED EDUC, V26, P51, DOI 10.1111/j.1365-2923.1992.tb00123.x; OSWALD N, 1989, MED EDUC, V23, P319, DOI 10.1111/j.1365-2923.1989.tb01555.x; UPTON P, 1989, Health Bulletin (Edinburgh), V47, P179; 1987, RECOMMENDATIONS GENE; 1993, HLTH PERSONAL SOCIAL	16	31	31	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 11	1995	310	6976					369	372		10.1136/bmj.310.6976.369	http://dx.doi.org/10.1136/bmj.310.6976.369			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG721	7866215	Green Published			2022-12-28	WOS:A1995QG72100021
J	ERLEBACHER, A; FILVAROFF, EH; GITELMAN, SE; DERYNCK, R				ERLEBACHER, A; FILVAROFF, EH; GITELMAN, SE; DERYNCK, R			TOWARD A MOLECULAR UNDERSTANDING OF SKELETAL DEVELOPMENT	CELL			English	Review							OSTEOGENESIS IMPERFECTA; GROWTH-FACTORS; GENE; MOUSE; MICE; EXPRESSION; DIFFERENTIATION; OSTEOPETROSIS; FAMILY; DISRUPTION		UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PEDIAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CELL BIOL PROGRAM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, PROGRAM DEV BIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	ERLEBACHER, A (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT GROWTH & DEV, SAN FRANCISCO, CA 94143 USA.				NIAMS NIH HHS [R01-AR41126] Funding Source: Medline; NIDCR NIH HHS [P50DE10306] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010306] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; BYERS PH, 1992, ANNU REV MED, V43, P269, DOI 10.1146/annurev.med.43.1.269; CANALIS E, 1991, ANNU REV MED, V42, P17, DOI 10.1146/annurev.med.42.1.17; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; FASSLER R, 1994, P NATL ACAD SCI USA, V91, P5070, DOI 10.1073/pnas.91.11.5070; FEDERMAN DD, 1994, NEW ENGL J MED, V331, P1088, DOI 10.1056/NEJM199410203311611; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; FREISINGER P, 1994, J BIOL CHEM, V269, P13663; GENDRONMAGUIRE M, 1993, CELL, V75, P1317, DOI 10.1016/0092-8674(93)90619-2; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; JABS EW, 1994, NAT GENET, V8, P275, DOI 10.1038/ng1194-275; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; JACENKO O, 1994, AM J HUM GENET, V54, P163; JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; KAWAGUCHI N, 1992, P NATL ACAD SCI USA, V89, P4569, DOI 10.1073/pnas.89.10.4569; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LEWIS DB, 1993, P NATL ACAD SCI USA, V90, P11618, DOI 10.1073/pnas.90.24.11618; LI Y, 1995, CELL, V80, P401; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; MORGAN BA, 1993, CURR OPIN GENET DEV, V3, P668, DOI 10.1016/0959-437X(93)90105-X; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; MURRAY SS, 1992, J BONE MINER RES, V7, P1131; NAKASE T, 1994, J BONE MINER RES, V9, P651; NAKATA K, 1993, P NATL ACAD SCI USA, V90, P2870, DOI 10.1073/pnas.90.7.2870; OGATA T, 1991, BIOCHEM BIOPH RES CO, V180, P1194, DOI 10.1016/S0006-291X(05)81322-1; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RIJLI FM, 1993, CELL, V75, P1333, DOI 10.1016/0092-8674(93)90620-6; RODAN G A, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P85; ROSEN V, 1994, J BONE MINER RES, V9, P1759; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; SIDDHANTI SR, 1994, J CELL BIOCHEM, V55, P310, DOI 10.1002/jcb.240550307; SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; TILSTRA DJ, 1994, ANNU REV MED, V45, P149, DOI 10.1146/annurev.med.45.1.149; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VIKKULA M, 1994, ANN MED, V26, P107; VIKKULA M, 1995, CELL, V80, P431, DOI 10.1016/0092-8674(95)90493-X; VUKICEVIC S, 1989, P NATL ACAD SCI USA, V86, P8793, DOI 10.1073/pnas.86.22.8793; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; WILLING MC, 1993, AM J MED GENET, V45, P223, DOI 10.1002/ajmg.1320450214; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WOZNEY JM, 1992, MOL REPROD DEV, V32, P160, DOI 10.1002/mrd.1080320212; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	68	552	567	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	1995	80	3					371	378		10.1016/0092-8674(95)90487-5	http://dx.doi.org/10.1016/0092-8674(95)90487-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859279	Bronze			2022-12-28	WOS:A1995QG47000003
J	SELDIN, DC; LEDER, P				SELDIN, DC; LEDER, P			CASEIN KINASE II-ALPHA TRANSGENE-INDUCED MURINE LYMPHOMA - RELATION TO THEILERIOSIS IN CATTLE	SCIENCE			English	Article							INTRACELLULAR PROTOZOAN PARASITE; C-MYC GENE; E-MU-MYC; V-RAF; MICE BEARING; B-CELLS; N-MYC; TUMORS; TRANSFORMATION; PARVA	Infection of cattle with the protozoan parasite Theileria parva results in a fatal lymphoproliferative syndrome that is associated with the overexpression of casein kinase II. The role of this enzyme in the pathogenesis of lymphoproliferative disorders was investigated by expressing the catalytic subunit in lymphocytes of transgenic mice. Adult transgenic mice displayed a stochastic propensity to develop lymphoma; co-expression of a c-myc transgene in addition to casein kinase II resulted in neonatal leukemia. Thus, the casein kinase II gene can serve as an oncogene, and its dysregulated expression is capable of transforming lymphocytes in a two-step pathway with c-myc.	HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT GENET, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute				Seldin, David C/0000-0003-0168-2333	NHLBI NIH HHS [1-K08-HL0286-01] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALEXANDER WS, 1989, MOL CELL BIOL, V9, P67, DOI 10.1128/MCB.9.1.67; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; EARLY P, 1980, CELL, V20, P313, DOI 10.1016/0092-8674(80)90617-0; FRIEDRICH TD, 1989, BIOCHIM BIOPHYS ACTA, V992, P41, DOI 10.1016/0304-4165(89)90048-2; JOHANSSON M, 1993, BRIT J CANCER, V67, P1236, DOI 10.1038/bjc.1993.231; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; KURIE JM, 1990, ONCOGENE, V5, P577; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MEISNER H, 1989, BIOCHEMISTRY-US, V28, P4072, DOI 10.1021/bi00435a066; Mertens F., 1991, CATALOG CHROMOSOME A; MOROY T, 1991, ONCOGENE, V6, P1941; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; OLEMOIYOI OK, 1989, ANN NY ACAD SCI, V569, P174, DOI 10.1111/j.1749-6632.1989.tb27367.x; OLEMOIYOI OK, 1993, EMBO J, V12, P1621, DOI 10.1002/j.1460-2075.1993.tb05807.x; OLEMOIYOI OK, 1989, EXP PARASITOL, V69, P204, DOI 10.1016/0014-4894(89)90067-2; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PRINCIPATO M, 1990, MOL CELL BIOL, V10, P3562, DOI 10.1128/MCB.10.7.3562; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WIRKNER U, 1994, GENOMICS, V19, P257, DOI 10.1006/geno.1994.1056; YANGFENG TL, 1990, GENOMICS, V8, P741, DOI 10.1016/0888-7543(90)90266-W; YANGFENG TL, 1994, GENOMICS, V19, P173, DOI 10.1006/geno.1994.1032	32	353	372	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	1995	267	5199					894	897		10.1126/science.7846532	http://dx.doi.org/10.1126/science.7846532			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG207	7846532				2022-12-28	WOS:A1995QG20700061
J	BAIRD, RN				BAIRD, RN			CONTROVERSIES IN MANAGEMENT - SHOULD CAROTID ENDARTERECTOMY BE PURCHASED - TREATMENT AVOIDS MUCH MORBIDITY .19.	BRITISH MEDICAL JOURNAL			English	Article														Lambert, Mark/0000-0003-3528-9070				BAMFORD J, SEMINAR DISTRICT STR; BARNETT HJM, 1990, STROKE, V21, P2; BEEBE HG, 1989, STROKE, V20, P314; DENNIS M, 1990, STROKE, V21, P848, DOI 10.1161/01.STR.21.6.848; MAGEE TR, 1992, ANN ROY COLL SURG, V74, P430; MURIE JA, 1994, BRIT J SURG, V81, P827, DOI 10.1002/bjs.1800810612; PEARCE JMS, 1978, BRIT MED J, V1, P969, DOI 10.1136/bmj.1.6118.969; WINSLOW CM, 1988, NEW ENGL J MED, V318, P721, DOI 10.1056/NEJM198803243181201; 1991, LANCET, V337, P1235; 1991, NEW ENGL J MED, V325, P445	10	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 4	1995	310	6975					316	317		10.1136/bmj.310.6975.316	http://dx.doi.org/10.1136/bmj.310.6975.316			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF717	7866177	Green Published			2022-12-28	WOS:A1995QF71700040
J	DERIJKE, YB; DEMACKER, PNM; ASSEN, NA; SLOOTS, LM; KATAN, MB; STALENHOEF, AFH				DERIJKE, YB; DEMACKER, PNM; ASSEN, NA; SLOOTS, LM; KATAN, MB; STALENHOEF, AFH			RED WINE CONSUMPTION AND OXIDATION OF LOW-DENSITY LIPOPROTEINS	LANCET			English	Letter											DERIJKE, YB (corresponding author), ACAD ZIEKENHUIS NIJMEGEN,ALGEMEEN INWENDIGE GENEESKUNDE LAB,POSTBUS 9101,6500 HB NIJMEGEN,NETHERLANDS.		Stalenhoef, A.F.H./H-8094-2014; de Rijke, Yolanda/AAQ-5497-2020					FRANKEL EN, 1993, LANCET, V341, P454, DOI 10.1016/0140-6736(93)90206-V; KONDO, 1994, LANCET, V344, P1152	2	13	13	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					325	326		10.1016/S0140-6736(95)90316-X	http://dx.doi.org/10.1016/S0140-6736(95)90316-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE731	7837889	Green Submitted			2022-12-28	WOS:A1995QE73100054
J	CUTTING, WAM				CUTTING, WAM			PARTICIPATE IN AN INTERNATIONAL-CONFERENCE	BRITISH MEDICAL JOURNAL			English	Article							TRAVEL	Attending an international conference should be instructive and fun. But it can also be alarming and lonely. Although participating in scientific conferences is now almost essential to medical career development, no medical school describes how to make the most of the opportunity as part of its curriculum. Here are some hints on how to get yourself organised so that the experience can be both scientifically productive and enjoyable. In essence, you should travel, see places, meet people, make friends, and identify one or two ideas that you can apply in your own work or research.			CUTTING, WAM (corresponding author), UNIV EDINBURGH,DEPT CHILD LIFE & HLTH,EDINBURGH EH9 1UW,MIDLOTHIAN,SCOTLAND.							DOBBING J, 1978, BRIT MED J, V2, P827, DOI 10.1136/bmj.2.6140.827; ELLIS CJ, 1990, BRIT MED J, V301, P984, DOI 10.1136/bmj.301.6758.984-c; LOCK S, 1992, BRIT MED J, V305, P1303; MCINTOSH N, 1994, STRUCTURED ABSTRACTS; TAN KCB, 1989, BRIT MED J, V299, P1450, DOI 10.1136/bmj.299.6713.1450; WANNAN GJ, 1992, TROP DOCT        OCT, P151	6	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 28	1995	310	6974					249	251		10.1136/bmj.310.6974.249	http://dx.doi.org/10.1136/bmj.310.6974.249			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE496	7866135	Green Published			2022-12-28	WOS:A1995QE49600036
J	MARTINI, A; RAVELLI, A; DIFUCCIA, G; ROSTI, V; CAZZOLA, M; BAROSI, G				MARTINI, A; RAVELLI, A; DIFUCCIA, G; ROSTI, V; CAZZOLA, M; BAROSI, G			INTRAVENOUS IRON THERAPY FOR SEVERE ANEMIA IN SYSTEMIC-ONSET JUVENILE CHRONIC ARTHRITIS	LANCET			English	Note							CHRONIC DISEASE; ANEMIA; DEFICIENCY	The role of iron supplementation in treating the anaemia of systemic-onset juvenile chronic arthritis is not clear. Eight affected children with severe persistent anaemia unresponsive to oral iron therapy were treated with intravenous iron saccharate. From a median post-oral-iron value of 8.0 g/dL (range 6.5-9.5), haemoglobin rose to 11.0 g/dL (10.1-12.1) (p=0.01). The concentration of serum transferrin receptor, an indicator of iron deficiency, before intravenous therapy correlated with the increase in haemoglobin (r=0.88, p<0.01). Intravenous iron saccharate could be an effective treatment for chronic anaemia in this condition, especially with iron deficiency not responsive to oral iron.	UNIV PAVIA, IRCCS SAN MATTEO, DIPARTIMENTO MED INTERNA & TERAPIA MED, I-27100 PAVIA, ITALY	IRCCS Fondazione San Matteo; University of Pavia	MARTINI, A (corresponding author), UNIV PAVIA, IRCCS SAN MATTEO, PEDIAT CLIN, I-27100 PAVIA, ITALY.		Rosti, Vittorio/K-1743-2018; Cazzola, Mario/AAQ-8854-2021; RAVELLI, ANGELO/J-8161-2016	Rosti, Vittorio/0000-0003-4195-2289; Cazzola, Mario/0000-0001-6984-8817; RAVELLI, ANGELO/0000-0001-9658-0385				BENTLEY DP, 1982, RHEUMATOL REHABIL, V21, P88, DOI 10.1093/rheumatology/21.2.88; CAZZOLA M, 1992, BRIT J HAEMATOL, V80, P278, DOI 10.1111/j.1365-2141.1992.tb08133.x; FANTINI F, 1992, ARTHRITIS RHEUM, V35, P724, DOI 10.1002/art.1780350622; FERGUSON BJ, 1992, J LAB CLIN MED, V119, P385; GROSS S, 1964, PEDIATRICS, V34, P315; GROSS SJ, 1976, J PEDIATR-US, V88, P795, DOI 10.1016/S0022-3476(76)81117-1; HARVEY AR, 1987, SCAND J RHEUMATOL, V16, P53; MEANS RT, 1992, BLOOD, V80, P1639; VREUGDENHIL G, 1989, CLIN RHEUMATOL, V8, P352, DOI 10.1007/BF02030348	9	56	58	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1052	1054		10.1016/S0140-6736(94)91710-8	http://dx.doi.org/10.1016/S0140-6736(94)91710-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7864944				2022-12-28	WOS:A1994PL85200010
J	FREEMANTLE, N; HOUSE, A; SONG, F; MASON, JM; SHELDON, TA				FREEMANTLE, N; HOUSE, A; SONG, F; MASON, JM; SHELDON, TA			PRESCRIBING SELECTIVE SEROTONIN REUPTAKE INHIBITORS AS STRATEGY FOR PREVENTION OF SUICIDE	BRITISH MEDICAL JOURNAL			English	Article							ANTIDEPRESSANTS; OVERDOSE; TOXICITY; RATES; TRIAL; RISK; CARE	Objective-To evaluate a policy to reduce the incidence of suicide by means of changing the prescribing of antidepressants from the older tricycle antidepressants to the routine first line use of selective serotonin reuptake inhibitors or newer tricyclic and related antidepressants. Design-Cost effectiveness analysis with sensitivity analyses using observational data on costs, volume of prescribing, deaths, and toxicity. Setting-United Kingdom primary care. Interventions-Selective serotonin reuptake inhibitors or newer tricyclic and related antidepressants compared with the use of older tricyclics. Main outcome measures-Cost per life saved and cost per Life year saved. Results-The potential number of lives which may be saved from a switch to the routine first line use of selective serotonin reuptake inhibitors is between 300 and 450 each year. The cost per life year gained ranges from pound 19 000 to pound 173 000, depending on the assumptions used. The cost per life year gained through the use of the newer tricyclic and related antidepressants is considerably lower. Conclusions-The cost per life year gained through avoiding suicides by the routine first line use of serotonin reuptake inhibitors is likely to be high. The new tricyclics and related drugs are of similar toxicity to the serotonin reuptake inhibitors but are considerably cheaper and so are more cost effective for this purpose. Further research is required on such prescribing. Because of the great uncertainties the shift to considerably more expensive options must be further investigated.	UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND; LEEDS GEN INFIRM,DEPT LIASON PSYCHIAT,LEEDS,W YORKSHIRE,ENGLAND	University of York - UK; Leeds General Infirmary; University of Leeds	FREEMANTLE, N (corresponding author), UNIV YORK,NHS CTR REVIEWS & DISSEMINAT,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Mason, James M/D-9904-2011; Sheldon, Trevor/AAK-7088-2021; Song, Fujian/B-3516-2013; anand, amit/A-7222-2009	Mason, James M/0000-0001-9210-4082; Sheldon, Trevor/0000-0002-7479-5913; Freemantle, Nick/0000-0001-5807-5740; House, Allan/0000-0001-8721-8026				BEASLEY CM, 1991, BMJ-BRIT MED J, V303, P685, DOI 10.1136/bmj.303.6804.685; CASSIDY S, 1987, BRIT MED J, V295, P1021, DOI 10.1136/bmj.295.6605.1021; CLARKE PR, 1991, EC ANAL SCREENING BR; CLARKE RV, 1987, J EPIDEMIOL COMMUN H, V41, P114, DOI 10.1136/jech.41.2.114; DIEKSTRA RFW, 1989, ACTA PSYCHIAT SCAND, V79, P268, DOI 10.1111/j.1600-0447.1989.tb10257.x; EDWARDS JG, 1992, BRIT MED J, V304, P1644, DOI 10.1136/bmj.304.6843.1644; FARMER RDT, 1989, ACTA PSYCHIAT SCAND, V80, P25, DOI 10.1111/j.1600-0447.1989.tb03044.x; FAWCETT J, 1987, AM J PSYCHIAT, V144, P35; FRADD SO, 1992, BRIT MED J, V305, P366, DOI 10.1136/bmj.305.6849.366-c; GOLDACRE M, 1993, LANCET, V342, P283, DOI 10.1016/0140-6736(93)91822-4; GOLDSTEIN RB, 1991, ARCH GEN PSYCHIAT, V48, P618; HENRY J, 1989, ACTA PSYCHIAT S S354, V90, P37; Henry J A, 1992, Eur J Med, V1, P343; JAAKKIMAINEN L, 1990, J CLIN ONCOL, V8, P1301, DOI 10.1200/JCO.1990.8.8.1301; KAPUR S, 1992, JAMA-J AM MED ASSOC, V268, P3441, DOI 10.1001/jama.268.24.3441; KREITMAN N, 1976, BRIT J PREV SOC MED, V30, P86; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; LIN EHB, 1989, J GEN INTERN MED, V4, P1, DOI 10.1007/BF02596482; MILNE S, 1993, BRIT MED J, V306, P1126, DOI 10.1136/bmj.306.6885.1126-b; MONTGOMERY S, 1992, GENERAL PRACTIT 0522, P68; MONTGOMERY SA, 1988, INT CLIN PSYCHOPHARM, V3, P15; POKORNY AD, 1983, ARCH GEN PSYCHIAT, V40, P249; ROY A, 1983, ARCH GEN PSYCHIAT, V40, P971; SAINSBURY P, 1980, SUICIDE SYNDROME, P38; SONG FJ, 1993, BMJ-BRIT MED J, V306, P683, DOI 10.1136/bmj.306.6879.683; TUBMAN TRJ, 1990, BRIT MED J, V301, P842, DOI 10.1136/bmj.301.6756.842; 1992, BMA RPS24 BRIT NED A; 1993, EFFECTIVE HLTH CARE, V5; 1993, DRUG THER B, V31, P57; 1990, MORTALITY STATISTICS; 1992, GUIDELINES TREATING; 1992, HLTH NATION; 1993, ANATOMICAL THERAPEUT; 1986, BREAST CANCER SCREEN; 1993, HLTH NATION KEY AREA	35	85	84	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 23	1994	309	6949					249	253		10.1136/bmj.309.6949.249	http://dx.doi.org/10.1136/bmj.309.6949.249			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NZ180	7832842	Green Published			2022-12-28	WOS:A1994NZ18000021
J	ORTH, DN				ORTH, DN			MEDICAL PROGRESS - CUSHINGS-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CORTICOTROPIN-RELEASING-HORMONE; PROOPIOMELANOCORTIN GENE-EXPRESSION; DEXAMETHASONE SUPPRESSION TEST; ADRENAL-CORTICAL CARCINOMA; ECTOPIC ACTH SYNDROME; DIFFERENTIAL-DIAGNOSIS; STIMULATION TEST; ADRENOCORTICOTROPIN SECRETION; PITUITARY MICROADENOMAS; CORTISOL SECRETION				ORTH, DN (corresponding author), VANDERBILT UNIV, MED CTR, DEPT MED, DIV ENDOCRINOL, NASHVILLE, TN USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033334, R01DK046070] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00095] Funding Source: Medline; NIDDK NIH HHS [DK-33334, DK-46070] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMSTERDAM JD, 1988, J AFFECT DISORDERS, V14, P213, DOI 10.1016/0165-0327(88)90037-7; ARANA GW, 1988, AM J PSYCHIAT, V145, P707; ATKINSON AB, 1985, BMJ-BRIT MED J, V291, P1453, DOI 10.1136/bmj.291.6507.1453; AVGERINOS PC, 1994, ANN INTERN MED, V121, P318, DOI 10.7326/0003-4819-121-5-199409010-00002; BELSKY JL, 1985, J CLIN ENDOCR METAB, V60, P496, DOI 10.1210/jcem-60-3-496; BERGENSTAL DM, 1960, ANN INTERN MED, V53, P672, DOI 10.7326/0003-4819-53-4-672; BERTAGNA C, 1981, AM J MED, V71, P855, DOI 10.1016/0002-9343(81)90384-3; BERTAGNA X, 1986, J CLIN ENDOCR METAB, V63, P639, DOI 10.1210/jcem-63-3-639; BESSER GM, 1972, CLINICS ENDOCRINOLOG, V1, P451; BIEMOND P, 1990, ANN INTERN MED, V112, P738, DOI 10.7326/0003-4819-112-10-738; BODIE B, 1989, J UROLOGY, V141, P257, DOI 10.1016/S0022-5347(17)40734-8; BOREHERDING SM, 1992, ARCH INTERN MED, V152, P711; BURSTEIN S, 1965, J CLIN ENDOCR METAB, V25, P293, DOI 10.1210/jcem-25-2-293; BUZZETTI R, 1989, J CLIN INVEST, V83, P733, DOI 10.1172/JCI113940; CALOGERO AE, 1988, J CLIN INVEST, V82, P767, DOI 10.1172/JCI113677; CAREY RM, 1984, NEW ENGL J MED, V311, P13, DOI 10.1056/NEJM198407053110103; CARNEY JA, 1985, MEDICINE, V64, P270, DOI 10.1097/00005792-198507000-00007; CARPENTER PC, 1986, MAYO CLIN PROC, V61, P49, DOI 10.1016/S0025-6196(12)61398-6; CHROUSOS GP, 1984, NEW ENGL J MED, V310, P622, DOI 10.1056/NEJM198403083101004; CLARK AJL, 1990, J CLIN ENDOCR METAB, V70, P485, DOI 10.1210/jcem-70-2-485; Cushing H, 1932, B JOHNS HOPKINS HOSP, V50, P137; DEBOLD CR, 1989, J CLIN ENDOCR METAB, V68, P431, DOI 10.1210/jcem-68-2-431; DEBOLD CR, 1988, BIOCHEM BIOPH RES CO, V155, P895; DEBOLD CR, 1984, J CLIN INVEST, V73, P533, DOI 10.1172/JCI111240; DEBOLD CR, 1988, MOL ENDOCRINOL, V2, P862, DOI 10.1210/mend-2-9-862; DEBOLD CR, 1988, J CLIN INVEST, V155, P895; DEKEYZER Y, 1985, J CLIN INVEST, V76, P1892, DOI 10.1172/JCI112184; DICHEK HL, 1994, J CLIN ENDOCR METAB, V78, P418, DOI 10.1210/jc.78.2.418; DOPPMAN JL, 1987, SURGERY, V102, P1018; DOPPMAN JL, 1984, RADIOLOGY, V150, P99, DOI 10.1148/radiology.150.1.6316418; EBERWINE JH, 1987, DNA-J MOLEC CELL BIO, V6, P483, DOI 10.1089/dna.1987.6.483; EDWARDS OM, 1974, LANCET, V2, P549; ESTEBAN NV, 1991, J CLIN ENDOCR METAB, V72, P39, DOI 10.1210/jcem-72-1-39; FAHLBUSCH R, 1986, J ROY SOC MED, V79, P262, DOI 10.1177/014107688607900504; FINDLING JW, 1991, J CLIN ENDOCR METAB, V73, P408, DOI 10.1210/jcem-73-2-408; FINDLING JW, 1981, ANN INTERN MED, V94, P647, DOI 10.7326/0003-4819-94-5-647; FJELLESTADPAULSEN A, 1988, ACTA ENDOCRINOL-COP, V119, P506, DOI 10.1530/acta.0.1190506; FLACK MR, 1992, ANN INTERN MED, V116, P211, DOI 10.7326/0003-4819-116-3-211; FRIEDMAN WA, 1989, SURG NEUROL, V32, P334, DOI 10.1016/0090-3019(89)90135-3; FUKATA J, 1988, ENDOCRINOL JAPON, V35, P491; GABRILOVE JL, 1986, CLIN ENDOCRINOL, V25, P117, DOI 10.1111/j.1365-2265.1986.tb01672.x; GERTZ BJ, 1987, ENDOCRINOLOGY, V120, P381, DOI 10.1210/endo-120-1-381; GICQUEL C, 1992, J CLIN ENDOCR METAB, V75, P472, DOI 10.1210/jc.75.2.472; GOLD PW, 1986, NEW ENGL J MED, V314, P1329, DOI 10.1056/NEJM198605223142101; GROSSMAN AB, 1988, CLIN ENDOCRINOL, V29, P167, DOI 10.1111/j.1365-2265.1988.tb00258.x; HALBREICH U, 1985, ARCH GEN PSYCHIAT, V42, P909; HALL WA, 1994, ANN INTERN MED, V120, P817, DOI 10.7326/0003-4819-120-10-199405150-00001; HELLMAN L, 1970, J CLIN ENDOCR METAB, V30, P686, DOI 10.1210/jcem-30-5-686; HERMAN JP, 1992, MOL ENDOCRINOL, V6, P1061, DOI 10.1210/me.6.7.1061; HERMUS AR, 1988, NEW ENGL J MED, V318, P966, DOI 10.1056/NEJM198804143181506; HERMUS AR, 1986, LANCET, V2, P540, DOI 10.1016/S0140-6736(86)90113-3; HERMUS ARMM, 1986, J CLIN ENDOCR METAB, V62, P634, DOI 10.1210/jcem-62-4-634; HOEFNAGEL CA, 1994, EUR J NUCL MED, V21, P561; HOHNLOSER J, 1989, CLIN ENDOCRINOL, V31, P175, DOI 10.1111/j.1365-2265.1989.tb01240.x; HOWLETT TA, 1985, ANN CLIN BIOCHEM, V22, P550, DOI 10.1177/000456328502200602; HOWLETT TA, 1986, CLIN ENDOCRINOL, V24, P699, DOI 10.1111/j.1365-2265.1986.tb01667.x; JACKSON RV, 1984, J CLIN ENDOCR METAB, V58, P740, DOI 10.1210/jcem-58-4-740; JACKSON RV, 1990, CLIN EXP PHARMACOL P, V17, P179, DOI 10.1111/j.1440-1681.1990.tb01302.x; JEFFCOATE WJ, 1985, CLIN ENDOCRINOL, V23, P193, DOI 10.1111/j.1365-2265.1985.tb00215.x; JENKINS PJ, 1995, J CLIN ENDOCR METAB, V80, P165, DOI 10.1210/jc.80.1.165; JENNINGS AS, 1977, NEW ENGL J MED, V297, P957, DOI 10.1056/NEJM197711032971801; JESSOP DS, 1987, J ENDOCRINOL, V113, P133, DOI 10.1677/joe.0.1130133; KAISER FE, 1983, J CLIN ENDOCR METAB, V57, P649, DOI 10.1210/jcem-57-3-649; KELLERWOOD ME, 1984, ENDOCR REV, V5, P1, DOI 10.1210/edrv-5-1-1; KIRKLAND SC, 1984, J ENDOCRINOL, V103, P85, DOI 10.1677/joe.0.1030085; KIRKLAND SC, 1984, J ENDOCRINOL, V103, P91, DOI 10.1677/joe.0.1030091; KIRKMAN S, 1988, METABOLISM, V37, P390, DOI 10.1016/0026-0495(88)90141-2; KOPPESCHAAR HPF, 1986, CLIN ENDOCRINOL, V25, P661, DOI 10.1111/j.1365-2265.1986.tb03621.x; KRENNING EP, 1993, EUR J NUCL MED, V20, P716, DOI 10.1007/BF00181765; KVOLS LK, 1987, SEMIN ONCOL, V14, P343; LACROIX A, 1992, NEW ENGL J MED, V327, P974, DOI 10.1056/NEJM199210013271402; Liddle G W, 1969, Recent Prog Horm Res, V25, P283; LIDDLE GW, 1959, J CLIN ENDOCR METAB, V19, P875, DOI 10.1210/jcem-19-8-875; LIDDLE GW, 1960, J CLIN ENDOCR METAB, V20, P1539, DOI 10.1210/jcem-20-12-1539; Liddle GW, 1981, TXB ENDOCRINOLOGY, P249; LOLAIT SJ, 1986, J CLIN INVEST, V77, P1776, DOI 10.1172/JCI112501; LOOSEN PT, 1992, PHARMACOPSYCHIATRY, V25, P192, DOI 10.1055/s-2007-1014405; LUNSFORD LD, 1989, NEUROSURGERY, V24, P151; MAGIAKOU MA, 1994, NEW ENGL J MED, V331, P629, DOI 10.1056/NEJM199409083311002; MALCHOFF CD, 1989, J CLIN ENDOCR METAB, V68, P855, DOI 10.1210/jcem-68-4-855; MAMPALAM TJ, 1988, ANN INTERN MED, V109, P487, DOI 10.7326/0003-4819-109-6-487; MASON A M S, 1972, Clinical Endocrinology, V1, P3, DOI 10.1111/j.1365-2265.1972.tb00374.x; MCCANCE DR, 1989, CLIN ENDOCRINOL, V30, P157, DOI 10.1111/j.1365-2265.1989.tb03737.x; MEADOR CK, 1967, J CLIN ENDOCR METAB, V27, P1255, DOI 10.1210/jcem-27-9-1255; MEIKLE AW, 1982, CLIN ENDOCRINOL, V16, P401, DOI 10.1111/j.1365-2265.1982.tb00733.x; MILLER DL, 1992, RADIOLOGY, V185, P143, DOI 10.1148/radiology.185.1.1523298; MILLER J, 1994, ENDOCRINOLOGIST, V4, P7, DOI 10.1097/00019616-199401000-00004; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; MURPHY BEP, 1968, J CLIN ENDOCR METAB, V28, P343, DOI 10.1210/jcem-28-3-343; NAWATA H, 1990, J CLIN ENDOCR METAB, V71, P1068, DOI 10.1210/jcem-71-4-1068; NIEMAN LK, 1985, J CLIN ENDOCR METAB, V61, P536, DOI 10.1210/jcem-61-3-536; NIEMAN LK, 1986, ANN INTERN MED, V105, P862, DOI 10.7326/0003-4819-105-6-862; NUGENT CA, 1965, ARCH INTERN MED, V116, P172, DOI 10.1001/archinte.1965.03870020012006; OBRIEN T, 1992, CLIN ENDOCRINOL, V37, P460, DOI 10.1111/j.1365-2265.1992.tb02359.x; OLDFIELD EH, 1985, J CLIN ENDOCR METAB, V61, P644, DOI 10.1210/jcem-61-4-644; OLDFIELD EH, 1991, NEW ENGL J MED, V325, P897, DOI 10.1056/NEJM199109263251301; OLDFIELD EH, 1985, NEW ENGL J MED, V312, P1457; ORTH DN, 1971, NEW ENGL J MED, V285, P243, DOI 10.1056/NEJM197107292850501; ORTH DN, 1984, NEW ENGL J MED, V310, P649, DOI 10.1056/NEJM198403083101009; ORTH DN, 1982, J CLIN ENDOCR METAB, V55, P1017, DOI 10.1210/jcem-55-5-1017; ORTH DN, 1992, ENDOCR REV, V13, P164, DOI 10.1210/er.13.2.164; ORTH DN, 1987, ENDOCRINOL METAB, P1692; Orth DN, 1992, WILLIAMS TXB ENDOCRI, P489; OWENS MJ, 1991, PHARMACOL REV, V43, P425; PFOHL B, 1985, BIOL PSYCHIAT, V20, P1055, DOI 10.1016/0006-3223(85)90004-6; PHLIPPONNEAU M, 1994, J CLIN ENDOCR METAB, V78, P20, DOI 10.1210/jc.78.1.20; PIETERS GFFM, 1983, J CLIN ENDOCR METAB, V57, P513, DOI 10.1210/jcem-57-3-513; POMMIER RF, 1992, SURGERY, V112, P963; RAFF H, 1989, CLIN CHEM, V35, P596; REES LH, 1977, LANCET, V1, P726; REZNIK Y, 1992, NEW ENGL J MED, V327, P981, DOI 10.1056/NEJM199210013271403; ROBINSON BG, 1987, CLIN ENDOCRINOL, V27, P437, DOI 10.1111/j.1365-2265.1987.tb01171.x; ROSS EJ, 1982, LANCET, V2, P646; SAITO E, 1983, ENDOCRINOLOGY, V113, P1010, DOI 10.1210/endo-113-3-1010; SCHORR I, 1971, J BIOL CHEM, V246, P5806; SCHTEINGART DE, 1986, J CLIN ENDOCR METAB, V63, P770, DOI 10.1210/jcem-63-3-770; SCHTEINGART DE, 1982, ARCH SURG-CHICAGO, V117, P1142; SCHUMACHER OP, 1984, CANCER TREATMENT RES, V20, P219; SEDERBER.P, 1973, J CLIN ENDOCR METAB, V36, P906, DOI 10.1210/jcem-36-5-906; SMALS AGH, 1977, J ROY COLL PHYS LOND, V12, P36; SMALS AGH, 1984, J CLIN ENDOCR METAB, V58, P25, DOI 10.1210/jcem-58-1-25; SONINO N, 1991, CLIN ENDOCRINOL, V35, P347, DOI 10.1111/j.1365-2265.1991.tb03547.x; STENZELPOORE MP, 1992, ENDOCRINOLOGY, V130, P3378, DOI 10.1210/en.130.6.3378; STEWART PM, 1993, J CLIN ENDOCR METAB, V76, P748, DOI 10.1210/jc.76.3.748; STROTT CA, 1968, AM J MED, V44, P97, DOI 10.1016/0002-9343(68)90240-4; TABARIN A, 1991, J CLIN ENDOCR METAB, V73, P53, DOI 10.1210/jcem-73-1-53; TORPY DJ, 1993, CLIN EXP PHARMACOL P, V20, P299, DOI 10.1111/j.1440-1681.1993.tb01688.x; TRAINER PJ, 1994, CLIN ENDOCRINOLOGY; TYRRELL JB, 1986, ANN INTERN MED, V104, P180, DOI 10.7326/0003-4819-104-2-180; ULICK S, 1991, J STEROID BIOCHEM, V38, P59, DOI 10.1016/0960-0760(91)90401-P; VALE W, 1983, ENDOCRINOLOGY, V113, P1121, DOI 10.1210/endo-113-3-1121; VALE W, 1983, RECENT PROG HORM RES, V39, P245; VANCAUTER E, 1985, NEW ENGL J MED, V312, P1343, DOI 10.1056/NEJM198505233122102; VASSILOPOULOUSELLIN R, 1993, CANCER, V71, P3119, DOI 10.1002/1097-0142(19930515)71:10<3119::AID-CNCR2820711037>3.0.CO;2-8; VELDHUIS JD, 1990, J CLIN ENDOCR METAB, V71, P452, DOI 10.1210/jcem-71-2-452; VERHELST JA, 1991, CLIN ENDOCRINOL, V35, P169, DOI 10.1111/j.1365-2265.1991.tb03517.x; WEITZMAN ED, 1971, J CLIN ENDOCR METAB, V33, P14, DOI 10.1210/jcem-33-1-14; WERK EE, 1964, J CLIN INVEST, V43, P1824, DOI 10.1172/JCI105056; WOOTEN MD, 1993, CANCER, V72, P3145, DOI 10.1002/1097-0142(19931201)72:11<3145::AID-CNCR2820721105>3.0.CO;2-N; WULFFRAAT NM, 1988, J CLIN ENDOCR METAB, V66, P301, DOI 10.1210/jcem-66-2-301; YANOVSKI JA, 1993, JAMA-J AM MED ASSOC, V269, P2232, DOI 10.1001/jama.269.17.2232; ZARATE A, 1986, CLIN ENDOCRINOL, V24, P523, DOI 10.1111/j.1365-2265.1986.tb03281.x	142	400	433	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 23	1995	332	12					791	803		10.1056/NEJM199503233321207	http://dx.doi.org/10.1056/NEJM199503233321207			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN442	7862184				2022-12-28	WOS:A1995QN44200007
J	BOZZETTE, SA; FINKELSTEIN, DM; SPECTOR, SA; FRAME, P; POWDERLY, WG; HE, WL; PHILLIPS, L; CRAVEN, D; VANDERHORST, C; FEINBERG, J				BOZZETTE, SA; FINKELSTEIN, DM; SPECTOR, SA; FRAME, P; POWDERLY, WG; HE, WL; PHILLIPS, L; CRAVEN, D; VANDERHORST, C; FEINBERG, J			A RANDOMIZED TRIAL OF 3 ANTIPNEUMOCYSTIS AGENTS IN PATIENTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; AEROSOLIZED PENTAMIDINE; TRIMETHOPRIM-SULFAMETHOXAZOLE; PRIMARY PROPHYLAXIS; SECONDARY PROPHYLAXIS; DAPSONE-PYRIMETHAMINE; PRIMARY PREVENTION; AIDS; COTRIMOXAZOLE; ZIDOVUDINE	Background. We evaluated the effectiveness of three treatment strategies for the prevention of a first episode of Pneumocystis carinii pneumonia in patients infected with the human immunodeficiency virus (HIV). Methods. In an open-label trial, 843 patients with HIV infection and fewer than 200 CD4+ cells per cubic millimeter received zidovudine plus one of three randomly assigned prophylactic agents, beginning with trimethoprim-sulfamethoxazole, dapsone, or aerosolized pentamidine and followed by a defined sequence of other drugs to be used in cases of intolerance. Results. The estimated 36-month cumulative risks of P. carinii pneumonia were 18 percent, 17 percent, and 21 percent in the trimethoprim-sulfamethoxazole, dapsone, and aerosolized-pentamidine groups, respectively (P = 0.22). The difference in risk among treatment strategies was negligible in patients entering the study with 100 or more CD4+ lymphocytes per cubic millimeter. In those entering with fewer than 100 CD4+ cells per cubic millimeter, the risk was 33 percent with aerosolized pentamidine, as compared with 19 percent with trimethoprim-sulfamethoxazole and 22 percent with dapsone (P=0.04). The lowest failure rates occurred in patients receiving trimethoprim-sulfamethoxazole, acid failures were more common with 50 mg of dapsone than with 100 mg. Toxoplasmosis developed in less than 3 percent of patients. Of the patients assigned to the two systemic therapies, only 23 percent were receiving their assigned drug and dose when they completed the study. The median survival was approximately 39 months in all three groups, and the mortality attributable to P. carinii pneumonia was only 1 percent. Conclusions. In patients with advanced HIV infection, the three treatment strategies we examined have similar effectiveness in preventing P. carinii pneumonia. Strategies that start with trimethoprim-sulfamethoxazole or with high-dose dapsone, rather than aerosolized pentamidine, are superior in patients with fewer than 100 CD4+ lymphocytes per cubic millimeter.	UNIV CALIF SAN DIEGO, LA JOLLA, CA 92093 USA; RAND CORP, SANTA MONICA, CA USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; UNIV CINCINNATI, CINCINNATI, OH USA; WASHINGTON UNIV, SCH MED, ST LOUIS, MO USA; FRONTIER SCI TECHNOL & RES FDN, BUFFALO, NY USA; BOSTON UNIV, BOSTON, MA 02215 USA; UNIV N CAROLINA, CHAPEL HILL, NC USA; NIAID, BETHESDA, MD 20892 USA; JOHNS HOPKINS UNIV, BALTIMORE, MD USA	University of California System; University of California San Diego; RAND Corporation; Harvard University; Harvard T.H. Chan School of Public Health; University System of Ohio; University of Cincinnati; Washington University (WUSTL); Frontier Science Foundation; Boston University; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University	BOZZETTE, SA (corresponding author), VET AFFAIRS MED CTR, MAIL CODE 111N-1, 3350 LA JOLLA VILLAGE DR, SAN DIEGO, CA 92161 USA.			feinberg, judith/0000-0003-4206-7214; Powderly, William/0000-0001-7808-3086				BLUM RN, 1992, J ACQ IMMUN DEF SYND, V5, P341; BOZZETTE SA, IN PRESS AM J MED; CARR A, 1992, ANN INTERN MED, V117, P106, DOI 10.7326/0003-4819-117-2-106; CARR A, 1992, AIDS, V6, P165, DOI 10.1097/00002030-199202000-00004; CHAISSON RE, 1992, ARCH INTERN MED, V152, P2009, DOI 10.1001/archinte.152.10.2009; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FREEDBERG KA, 1991, J ACQ IMMUN DEF SYND, V4, P521; GIRARD PM, 1993, NEW ENGL J MED, V328, P1514, DOI 10.1056/NEJM199305273282102; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; HIRSCHEL B, 1991, NEW ENGL J MED, V324, P1079, DOI 10.1056/NEJM199104183241602; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; MALLOLAS J, 1993, AIDS, V7, P59, DOI 10.1097/00002030-199301000-00009; MASUR H, 1993, J ACQ IMMUN DEF SYND, V6, P46; MASUR H, 1992, NEW ENGL J MED, V327, P1853, DOI 10.1056/NEJM199212243272606; MAY T, 1994, J ACQ IMMUN DEF SYND, V7, P457; MOHLEBOETANI J, 1992, WESTERN J MED, V156, P303; PODZAMCZER D, 1993, AIDS, V7, P501, DOI 10.1097/00002030-199304000-00008; POWDERLY WG, 1995, NEW ENGL J MED, V332, P700, DOI 10.1056/NEJM199503163321102; RUSKIN J, 1991, LANCET, V337, P468, DOI 10.1016/0140-6736(91)93402-U; SAAH AJ, 1994, J ACQ IMMUN DEF SYND, V7, P287; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; SLAVIN MA, 1992, AIDS, V6, P1169, DOI 10.1097/00002030-199210000-00017; TORRES RA, 1993, AM J MED, V95, P573, DOI 10.1016/0002-9343(93)90352-P	24	263	269	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 16	1995	332	11					693	699		10.1056/NEJM199503163321101	http://dx.doi.org/10.1056/NEJM199503163321101			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL788	7854375				2022-12-28	WOS:A1995QL78800001
J	HYAMS, AL; BRANDENBURG, JA; LIPSITZ, SR; SHAPIRO, DW; BRENNAN, TA				HYAMS, AL; BRANDENBURG, JA; LIPSITZ, SR; SHAPIRO, DW; BRENNAN, TA			PRACTICE GUIDELINES AND MALPRACTICE LITIGATION - A 2-WAY STREET	ANNALS OF INTERNAL MEDICINE			English	Article							CARE; STANDARD; CLAIMS	Objective: To understand how practice guidelines are used in malpractice litigation. Design: Review of the open and closed malpractice claims of two medical malpractice insurance companies, and a mailed survey of attorneys who litigate malpractice claims. Setting: United States. Participants. Two insurance companies and 960 randomly selected malpractice attorneys. Measurements: Frequency and nature of the use of practice guidelines in litigation; understanding and frequency of the use of practice guidelines by attorneys in malpractice cases. Results: 259 claims opened in 1990-1992 at two insurance companies, including all obstetrics and anesthesia claims and a random sample of other claims, were reviewed. Seventeen of these claims involved practice guidelines, which were used as exculpatory evidence (exonerating the defendant physician) in 4 cases and as inculpatory evidence (implicating the defendant physician) in 12 cases. The only physician or patient factors associated with use of a guideline was a longer physician-patient relationship (P = 0.021). Nine hundred and sixty surveys were mailed and 578 were returned (response rate, 60.1%). Attorneys reported that once a suit is initiated, practice guidelines are likely to be used for inculpatory purposes (inculpatory in 54% of cases; exculpatory in 22.7% of cases). However, guidelines that seem to offer exculpatory value induce attorneys not to bring suits. The only attorney factor associated with increased use of guidelines was a practice in which more than 50% of business was in medical malpractice. Conclusions: Guidelines are used both by plaintiffs' and defendants' attorneys in malpractice cases. The emphasis in health reform proposals on guidelines as exculpatory evidence should be carefully considered.	HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; SAN FRANCISCO GEN HOSP, SAN FRANCISCO, CA 94110 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; San Francisco General Hospital Medical Center								Brennan T A, 1994, Health Care Manag, V1, P91; BRENNAN TA, 1991, J HEALTH POLIT POLIC, V16, P67, DOI 10.1215/03616878-16-1-67; Cox DR., 1970, ANAL BINARY DATA; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P877; EICHHORN JH, 1986, JAMA-J AM MED ASSOC, V256, P1017; Field M.J., 1992, GUIDELINES CLIN PRAC, P2; GARNICK DW, 1991, JAMA-J AM MED ASSOC, V266, P2856, DOI 10.1001/jama.266.20.2856; GRILLI R, 1991, MED CARE, V29, P50, DOI 10.1097/00005650-199101000-00005; GRILLI R, 1994, MED CARE, V32, P202, DOI 10.1097/00005650-199403000-00002; HAVIGHURST CC, 1991, LAW CONTEMP PROBL, V54, pA87; HIRSHFELD EB, 1991, JAMA-J AM MED ASSOC, V266, P2886, DOI 10.1001/jama.266.20.2886; HYAMS AL, 1994, PRACTICE GUIDELINES; LIANG MH, 1992, ANN RHEUM DIS, V51, P1257, DOI 10.1136/ard.51.11.1257; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCCULLAGH P, 1980, J ROY STAT SOC B MET, V42, P109; MEHTA CR, 1992, STATXACT USER MANUAL; Spearman C, 1904, AM J PSYCHOL, V15, P72, DOI 10.2307/1412159; TARAGIN MI, 1992, ANN INTERN MED, V117, P780, DOI 10.7326/0003-4819-117-9-780; Weiler PC, 1993, MEASURE MALPRACTICE; Wolff A, 1993, J Law Med Ethics, V21, P394; 1994, MED MALPRACTICE MAIN; 1990, SAS STAT USERS GUIDE, V2; 1990, SAS STAT USERS GUIDE, V1	23	136	136	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1995	122	6					450	455		10.7326/0003-4819-122-6-199503150-00008	http://dx.doi.org/10.7326/0003-4819-122-6-199503150-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QM266	7856994				2022-12-28	WOS:A1995QM26600008
J	BREZIS, M; ROSEN, S				BREZIS, M; ROSEN, S			MECHANISMS OF DISEASE - HYPOXIA OF THE RENAL MEDULLA - ITS IMPLICATIONS FOR DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							THICK ASCENDING LIMB; PERFUSED RAT-KIDNEY; INNER STRIPE INJURY; TRANSPORT ACTIVITY; TUBULAR-NECROSIS; CELL INJURY; FAILURE; NEPHROPATHY; RADIOCONTRAST; NEPHROTOXICITY		BETH ISRAEL HOSP,DEPT PATHOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	BREZIS, M (corresponding author), HADASSAH UNIV HOSP,DEPT MED,MT SCOPUS,POB 24035,IL-91240 JERUSALEM,ISRAEL.		Brezis, Mayer/A-1041-2010					AGMON Y, 1994, J CLIN INVEST, V94, P1069, DOI 10.1172/JCI117421; AGMON Y, 1993, AM J PHYSIOL, V265, pF802, DOI 10.1152/ajprenal.1993.265.6.F802; AGMON Y, 1993, EXP NEPHROL, V1, P357; BAILLY C, 1992, KIDNEY INT, V41, P269, DOI 10.1038/ki.1992.38; BALDWIN L, 1994, ANN INTERN MED, V120, P744, DOI 10.7326/0003-4819-120-9-199405010-00004; BEACH RE, 1992, AM J PHYSIOL, V263, pF482, DOI 10.1152/ajprenal.1992.263.3.F482; BONVENTRE JV, 1993, KIDNEY INT, V43, P1160, DOI 10.1038/ki.1993.163; BREZIS M, 1994, AM J PHYSIOL-RENAL, V267, pF1059, DOI 10.1152/ajprenal.1994.267.6.F1059; BREZIS M, 1985, J CLIN INVEST, V76, P1796, DOI 10.1172/JCI112171; BREZIS M, 1990, EUR J CLIN INVEST, V20, P199, DOI 10.1111/j.1365-2362.1990.tb02269.x; BREZIS M, 1991, J CLIN INVEST, V88, P390, DOI 10.1172/JCI115316; BREZIS M, 1988, KIDNEY INT, V34, P186, DOI 10.1038/ki.1988.164; BREZIS M, 1984, J CLIN INVEST, V73, P182, DOI 10.1172/JCI111189; BREZIS M, 1984, SCIENCE, V224, P66, DOI 10.1126/science.6322305; BREZIS M, 1984, KIDNEY INT, V26, P375, DOI 10.1038/ki.1984.185; BREZIS M, 1984, KIDNEY INT, V25, P65, DOI 10.1038/ki.1984.9; BREZIS M, 1994, AM J PHYSIOL-RENAL, V267, pF1063, DOI 10.1152/ajprenal.1994.267.6.F1063; BREZIS M, 1993, ANNU REV MED, V44, P27, DOI 10.1146/annurev.me.44.020193.000331; BREZIS M, 1991, ADV NEPHROL NECKER H, P2041; BREZIS M, 1991, J AM SOC NEPHROL, V2, pA644; BREZIS M, 1991, KIDNEY, P993; Brezis Mayer, 1993, P129; BRIGGS JP, 1987, ANNU REV PHYSIOL, V49, P251; CARROLL MA, 1991, J BIOL CHEM, V266, P12306; CHOU SY, 1990, KIDNEY INT, V37, P1, DOI 10.1038/ki.1990.1; CLARK EC, 1992, AM J PHYSIOL, V263, pR148, DOI 10.1152/ajpregu.1992.263.1.R148; CONGER JD, 1988, J CLIN INVEST, V82, P532, DOI 10.1172/JCI113628; CRABOS M, 1994, J CLIN INVEST, V93, P2372, DOI 10.1172/JCI117243; DECRESPIGNY PC, 1990, AM J NEPHROL, V10, P311, DOI 10.1159/000168125; DEROUFFIGNAC C, 1991, AM J PHYSIOL, V260, pR1023, DOI 10.1152/ajpregu.1991.260.6.R1023; DING H, 1993, J CLIN INVEST, V91, P2281, DOI 10.1172/JCI116456; DINOUR D, 1991, AM J PHYSIOL, V261, pF787, DOI 10.1152/ajprenal.1991.261.5.F787; DORMAN HR, 1990, MEDICINE, V69, P153, DOI 10.1097/00005792-199005000-00003; ELALOUF JM, 1993, J CLIN INVEST, V91, P264, DOI 10.1172/JCI116180; EPSTEIN FH, 1989, KIDNEY INT, V36, P768, DOI 10.1038/ki.1989.261; EPSTEIN FH, 1982, AM J PHYSIOL, V243, pF356, DOI 10.1152/ajprenal.1982.243.4.F356; ERIKSEN EF, 1987, KIDNEY INT, V32, P181, DOI 10.1038/ki.1987.190; FALANGA V, 1993, J CELL PHYSIOL, V157, P408, DOI 10.1002/jcp.1041570225; FINE LG, 1993, EUR J CLIN INVEST, V23, P259, DOI 10.1111/j.1365-2362.1993.tb00771.x; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; HEYMAN SN, 1993, J AM SOC NEPHROL, V4, P69; HEYMAN SN, 1991, KIDNEY INT, V40, P632, DOI 10.1038/ki.1991.255; HEYMAN SN, 1989, AM J KIDNEY DIS, V14, P377, DOI 10.1016/S0272-6386(89)80171-4; HEYMAN SN, 1988, J CLIN INVEST, V82, P401, DOI 10.1172/JCI113612; HOCHACHKA PW, 1986, SCIENCE, V231, P234, DOI 10.1126/science.2417316; HOWIE AJ, 1990, J PATHOL, V160, P245, DOI 10.1002/path.1711600311; KELLY KJ, 1994, P NATL ACAD SCI USA, V91, P812, DOI 10.1073/pnas.91.2.812; KOBAYASHI S, 1992, KIDNEY INT, V42, P710, DOI 10.1038/ki.1992.338; KUHAJDA FP, 1979, AM HEART J, V98, P294, DOI 10.1016/0002-8703(79)90039-5; LEAR S, 1990, AM J PHYSIOL, V258, pF1372, DOI 10.1152/ajprenal.1990.258.5.F1372; LEONHARDT KO, 1963, NEW ENGL J MED, V269, P115, DOI 10.1056/NEJM196307182690301; MACCUMBER MW, 1989, P NATL ACAD SCI USA, V86, P7285, DOI 10.1073/pnas.86.18.7285; MATSUBARA O, 1990, KIDNEY INT, V38, P830, DOI 10.1038/ki.1990.278; MEISTER B, 1989, P NATL ACAD SCI USA, V86, P8068, DOI 10.1073/pnas.86.20.8068; MORRISSEY JJ, 1994, KIDNEY INT, V45, P998, DOI 10.1038/ki.1994.135; OLSEN TS, 1990, APMIS, V98, P1139, DOI 10.1111/j.1699-0463.1990.tb05046.x; OLSSON RA, 1990, PHYSIOL REV, V70, P761, DOI 10.1152/physrev.1990.70.3.761; ROSEN S, 1990, KIDNEY INT, V37, P1067, DOI 10.1038/ki.1990.87; ROSEN S, 1990, TRANSPLANTATION, V49, P445, DOI 10.1097/00007890-199002000-00041; ROSEN S, 1994, MINER ELECTROL METAB, V20, P174; RUEGG CE, 1990, AM J PHYSIOL, V259, pF176, DOI 10.1152/ajprenal.1990.259.1.F176; SAFIRSTEIN R, 1994, J AM SOC NEPHROL, V4, P1387; SCHRIER RW, 1988, AM J KIDNEY DIS, V12, P243, DOI 10.1016/S0272-6386(88)80130-6; SCHUREK HJ, 1990, AM J PHYSIOL, V259, pF910, DOI 10.1152/ajprenal.1990.259.6.F910; SHANLEY PF, 1986, KIDNEY INT, V29, P1033, DOI 10.1038/ki.1986.103; SHANLEY PF, 1986, AM J PATHOL, V122, P462; SILVA P, 1990, J AM SOC NEPHROL, V1, P808; WEINSTEIN JM, 1992, NEPHRON, V62, P413, DOI 10.1159/000187090; ZAGER RA, 1988, AM J PHYSIOL, V254, pF574, DOI 10.1152/ajprenal.1988.254.4.F574; ZIYADEH FN, 1988, AM J PHYSIOL, V255, pC385, DOI 10.1152/ajpcell.1988.255.3.C385	70	873	912	0	21	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 9	1995	332	10					647	655		10.1056/NEJM199503093321006	http://dx.doi.org/10.1056/NEJM199503093321006			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK066	7845430				2022-12-28	WOS:A1995QK06600006
J	VANDERBURG, MEL; VANLENT, M; BUYSE, M; KOBIERSKA, A; COLOMBO, N; FAVALLI, G; LACAVE, AJ; NARDI, M; RENARD, J; PECORELLI, S				VANDERBURG, MEL; VANLENT, M; BUYSE, M; KOBIERSKA, A; COLOMBO, N; FAVALLI, G; LACAVE, AJ; NARDI, M; RENARD, J; PECORELLI, S			THE EFFECT OF DEBULKING SURGERY AFTER INDUCTION CHEMOTHERAPY ON THE PROGNOSIS IN ADVANCED EPITHELIAL OVARIAN-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMBINATION CHEMOTHERAPY; RANDOMIZED TRIAL; CYTOREDUCTIVE SURGERY; CLINICAL-TRIALS; CARCINOMA; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; SURVIVAL; INTERVAL	Background. Although the value of primary cytoreductive surgery for epithelial ovarian cancer is beyond doubt, the value of debulking surgery after induction chemotherapy has not yet been defined. In this randomized study we investigated the effect on survival of debulking surgery. Methods. Eligible patients had residual lesions measuring more than 1 cm in diameter after primary surgery. After three cycles of cyclophosphamide and cisplatin, these patients were randomly assigned to undergo either debulking surgery or no surgery, followed by further cycles of cyclophosphamide and cisplatin. The study end points were progression-free survival and overall survival. At surgery 65 percent of the patients had lesions measuring more than 1 cm. In 45 percent of this group, the lesions were reduced surgically to less than 1 cm. Results. Of the 319 patients who underwent randomization, 278 could be evaluated (140 patients who underwent surgery and 138 patients who did not). Progression-free and overall survival were both significantly longer in the group that underwent surgery (P=0.01). The difference in median survival was six months. The survival rate at two years was 56 percent for the group that underwent surgery and 46 percent for the group that did not. In the multivariate analysis, debulking surgery was an independent prognostic factor (P=0.012). Overall, after adjustment for all other prognostic factors, surgery reduced the risk of death by 33 percent (95 percent confidence interval, 10 to 50 percent; P=0.008). Surgery was not associated with death or severe morbidity. Conclusions. Debulking surgery significantly lengthened progression-free and overall survival. The risk of death was reduced by one third, after adjustment for a variety of prognostic factors.	INT INST DRUG DEV,BRUSSELS,BELGIUM; MED ACAD GDANSK,GDANSK,POLAND; OSPED SAN GERARDO,MONZA,ITALY; UNIV BRESCIA,BRESCIA,ITALY; CENT HOSP ASTURIAS,OVIEDO,SPAIN; REGINA ELENA INST CANC RES,ROME,ITALY; EUROPEAN ORG RES TREATMENT CANC,CTR DATA,BRUSSELS,BELGIUM	International Drug Development Institute; Fahrenheit Universities; Medical University Gdansk; San Gerardo Hospital; University of Brescia; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; European Organisation for Research & Treatment of Cancer	VANDERBURG, MEL (corresponding author), ROTTERDAM CANC INST,DANIEL DEN HOED KLIN,POB 5201,3008 AE ROTTERDAM,NETHERLANDS.		Buyse, Marc/J-4658-2013; Colombo, Nicoletta/AAB-8319-2019	Buyse, Marc/0000-0002-4559-0994				BUYSE M, 1993, STAT MED, V12, P509, DOI 10.1002/sim.4780120517; COX DR, 1972, J R STAT SOC B, V34, P187; EISENKOP SM, 1993, GYNECOL ONCOL, V51, P224, DOI 10.1006/gyno.1993.1277; GEORGE SL, 1974, J CHRON DIS, V27, P15, DOI 10.1016/0021-9681(74)90004-6; GOLDIE JH, 1979, CANCER TREAT REP, V63, P1727; HACKER NF, 1983, OBSTET GYNECOL, V61, P413; HOSKINS WJ, 1992, GYNECOL ONCOL, V47, P159, DOI 10.1016/0090-8258(92)90100-W; JACOB JH, 1991, GYNECOL ONCOL, V42, P146, DOI 10.1016/0090-8258(91)90335-3; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOTTMEIER H L, 1976, Gynecologic Oncology, V4, P13, DOI 10.1016/0090-8258(76)90002-0; LAWTON FG, 1989, OBSTET GYNECOL, V73, P61; NEIJT JP, 1987, J CLIN ONCOL, V5, P1157, DOI 10.1200/JCO.1987.5.8.1157; NEIJT JP, 1991, EUR J CANCER, V27, P1367, DOI 10.1016/0277-5379(91)90011-2; NEIJT JP, 1984, LANCET, V2, P594; NG LW, 1990, GYNECOL ONCOL, V38, P358, DOI 10.1016/0090-8258(90)90073-T; OMURA GA, 1989, J CLIN ONCOL, V7, P457, DOI 10.1200/JCO.1989.7.4.457; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; POTTER ME, 1991, GYNECOL ONCOL, V40, P195; SKIPPER HE, 1974, JAMA-J AM MED ASSOC, V230, P1033, DOI 10.1001/jama.230.7.1033; VARMA R, 1989, 2ND M INT GYN CANC S; VENESMAA P, 1992, OBSTET GYNECOL, V79, P168; VOGL SE, 1983, CANCER, V51, P2024, DOI 10.1002/1097-0142(19830601)51:11<2024::AID-CNCR2820511111>3.0.CO;2-I; WILS J, 1986, J CLIN ONCOL, V4, P1068, DOI 10.1200/JCO.1986.4.7.1068; 1979, WHO OFSET PUBLICATIO, V48	24	574	582	1	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 9	1995	332	10					629	634		10.1056/NEJM199503093321002	http://dx.doi.org/10.1056/NEJM199503093321002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK066	7845426				2022-12-28	WOS:A1995QK06600002
J	KLONOFFCOHEN, HS; EDELSTEIN, SL; LEFKOWITZ, ES; SRINIVASAN, IP; KAEGI, D; CHANG, JC; WILEY, KJ				KLONOFFCOHEN, HS; EDELSTEIN, SL; LEFKOWITZ, ES; SRINIVASAN, IP; KAEGI, D; CHANG, JC; WILEY, KJ			THE EFFECT OF PASSIVE SMOKING AND TOBACCO EXPOSURE THROUGH BREAST-MILK ON SUDDEN-INFANT-DEATH-SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MATERNAL SMOKING; CIGARETTE-SMOKING; BIRTH-WEIGHT; RISK-FACTORS; PREGNANCY; HYPOXIA	Objective.-To examine the relationship between sudden infant death syndrome (SIDS) and smoking during pregnancy; postnatal tobacco smoke exposure from the mother, father, live-in adults, and day care providers; and postnatal smoke exposure from breast-feeding. Design.-Case-control study. Setting.-Five counties in Southern California. Participants.-A total of 200 white, African-American, Hispanic, and Asian parents of infants who died of SIDS between 1989 and 1992 were compared with 200 control parents who delivered healthy infants. Case infants were matched to control infants on the basis of birth hospital, birth date, gender, and race. All information was obtained from a detailed telephone interview and validated with medical records. Main Outcome Measures.-Risk of SIDS associated with passive smoking by the mother, father, live-in adults, and day care providers; smoking in the same room as the infant; total number of cigarettes smoked by all adults; and maternal smoking during the time period of breast-feeding. Results.-Conditional logistic regression resulted in overall adjusted odds ratios (ORs) for SIDS associated with passive smoke from the mother of 2.28, the father of 3.46, other live-in adults of 2.18, and all sources of 3.50 (95% confidence interval, 1.81 to 6.75), while simultaneously adjusting for birth weight, sleep position, prenatal care, medical conditions at birth, breast-feeding, and maternal smoking during pregnancy. A dose-response effect was noted for SIDS associated with increasing numbers of cigarettes, as well as total number of smokers. Breast-feeding was protective for SIDS among nonsmokers (OR=0.37) but not smokers (OR=1.38), when adjusting for potential confounders. Conclusions.-Passive smoking in the same room as the infant increases the risk for SIDS. Physicians should educate new and prospective parents about the risks of tobacco smoke exposure during pregnancy and the first year of the infant's life.			KLONOFFCOHEN, HS (corresponding author), UNIV CALIF SAN DIEGO, DEPT FAMILY & PREVENT MED, DIV EPIDEMIOL, 9500 GILMAN DR, 0607, LA JOLLA, CA 92093 USA.							AVERY ME, 1983, NEW ENGL J MED, V309, P107, DOI 10.1056/NEJM198307143090211; BERGMAN AB, 1976, PEDIATRICS, V58, P665; BULTERYS MG, 1990, PEDIATRICS, V86, P535; CARPENTE.RG, 1965, BRIT J PREV SOC MED, V19, P1; GIBBONS LE, 1993, AM J EPIDEMIOL, V137, P654, DOI 10.1093/oxfordjournals.aje.a116723; Golding J., 1985, SUDDEN INFANT DEATH; HAGLUND B, 1990, AM J PUBLIC HEALTH, V80, P29, DOI 10.2105/AJPH.80.1.29; HOFFMAN HJ, 1988, ANN NY ACAD SCI, V533, P13, DOI 10.1111/j.1749-6632.1988.tb37230.x; KLONOFFCOHEN HS, 1995, JAMA-J AM MED ASSOC, V273, P790, DOI 10.1001/jama.273.10.790; KRAUS JF, 1989, INT J EPIDEMIOL, V18, P113, DOI 10.1093/ije/18.1.113; KROUS H F, 1988, Pediatrician, V15, P231; LI DK, 1991, AM J EPIDEMIOL, V134, P958, DOI 10.1093/oxfordjournals.aje.a116180; MALLOY MH, 1992, AM J PUBLIC HEALTH, V82, P1380, DOI 10.2105/AJPH.82.10.1380; MALLOY MH, 1988, AM J EPIDEMIOL, V128, P46, DOI 10.1093/oxfordjournals.aje.a114957; MCGLASHAN ND, 1989, SOC SCI MED, V29, P1015, DOI 10.1016/0277-9536(89)90059-2; MITCHELL E, 1991, NZ MED J, V106, P71; MITCHELL EA, 1987, NEW ZEAL MED J, V100, P269; MITCHELL EA, 1993, PEDIATRICS, V91, P893; MURPHY JF, 1982, J EPIDEMIOL COMMUN H, V36, P17, DOI 10.1136/jech.36.1.17; NAEYE RL, 1976, AM J DIS CHILD, V130, P1207, DOI 10.1001/archpedi.1976.02120120041005; PETERSON DR, 1981, AM J EPIDEMIOL, V113, P583, DOI 10.1093/oxfordjournals.aje.a113135; PONSONBY AL, 1992, BRIT MED J, V304, P277, DOI 10.1136/bmj.304.6822.277; PROTESTOS CD, 1973, ARCH DIS CHILD, V48, P835, DOI 10.1136/adc.48.11.835; SCHOENDORF KC, 1992, PEDIATRICS, V90, P905; SEXTON M, 1984, JAMA-J AM MED ASSOC, V251, P911, DOI 10.1001/jama.251.7.911; STEELE R, 1966, CAN MED ASSOC J, V94, P1165; VANDENBERG M, 1985, NEW ZEAL MED J, V98, P1075; 1993, STATISTICS EPIDEMIOL; 1985, SAS USERS GUIDE VERS; 1988, MMWR-MORBID MORTAL W, V37, P644; 1986, HLTH CONSEQUENCES IN, P38	31	171	177	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	1995	273	10					795	798		10.1001/jama.273.10.795	http://dx.doi.org/10.1001/jama.273.10.795			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ750	7861574				2022-12-28	WOS:A1995QJ75000031
J	LARACH, MG				LARACH, MG			ACCIDENTAL HYPOTHERMIA	LANCET			English	Article							CARDIOPULMONARY BYPASS; CARDIAC-ARREST; RESUSCITATION; EXPERIENCE; EXPOSURE				LARACH, MG (corresponding author), PENN STATE UNIV,COLL MED,DEPT ANAESTHESIA,500 UNIV DR,POB 850,HERSHEY,PA 17033, USA.							ANDERSON S, 1970, BRIT J ANAESTH, V42, P653, DOI 10.1093/bja/42.7.653; ANTRETTER H, 1993, NEW ENGL J MED, V330, P219; BAUMGARTNER FJ, 1992, CAN J SURG, V35, P184; BOLTE RG, 1988, JAMA-J AM MED ASSOC, V260, P377, DOI 10.1001/jama.260.3.377; BURTON AC, 1955, MAN COLD ENV, P200; CHINARD FP, 1979, ANN INTERN MED, V90, P990, DOI 10.7326/0003-4819-90-6-990_2; DAANEN HAM, 1992, AVIAT SPACE ENVIR MD, V63, P1070; DANZL DF, 1989, CRIT CARE MED, V17, P227, DOI 10.1097/00003246-198903000-00005; DANZL DF, 1987, ANN EMERG MED, V16, P1042, DOI 10.1016/S0196-0644(87)80757-6; DAVIES DM, 1967, LANCET, V1, P1036; DUGUID H, 1961, LANCET, V2, P1213; FELL RH, 1968, LANCET, V1, P392; FITZGERALD FT, 1982, ADV INTERNAL MED, V27, P127; GENTILELLO LM, 1992, J TRAUMA, V32, P316, DOI 10.1097/00005373-199203000-00009; GIESBRECHT GG, 1994, AVIAT SPACE ENVIR MD, V65, P803; GREGORY JS, 1991, J TRAUMA, V31, P1247, DOI 10.1097/00005373-199109000-00008; Grossheim R L, 1973, Alaska Med, V15, P53; HARNETT RM, 1983, AVIAT SPACE ENVIR MD, V54, P425; HAUTY MG, 1987, J TRAUMA, V27, P1107, DOI 10.1097/00005373-198710000-00002; HERITY B, 1991, J EPIDEMIOL COMMUN H, V45, P19, DOI 10.1136/jech.45.1.19; HILL JG, 1992, ANN THORAC SURG, V54, P699, DOI 10.1016/0003-4975(92)91014-Z; IVERSEN RJ, 1990, ANN EMERG MED, V19, P1335, DOI 10.1016/S0196-0644(05)82300-5; JOLLY B T, 1992, Emergency Medicine Clinics of North America, V10, P311; KEATINGE WR, 1969, SURVIVAL COLD WATER, P73; Kugelberg J, 1967, Scand J Thorac Cardiovasc Surg, V1, P142, DOI 10.3109/14017436709131858; LASH RF, 1967, J AMER MED ASSOC, V201, P269, DOI 10.1001/jama.201.4.269; LEDINGHAM IM, 1980, BRIT MED J, V280, P1102, DOI 10.1136/bmj.280.6222.1102; LEE HA, 1965, BMJ-BRIT MED J, V1, P1217, DOI 10.1136/bmj.1.5444.1217; LETSOU GV, 1992, ARCH SURG-CHICAGO, V127, P525; LINTON AL, 1966, LANCET, V1, P24; LLOYD EL, 1973, BRIT J ANAESTH, V45, P41, DOI 10.1093/bja/45.1.41; LLOYD EL, 1972, SCOT MED J, V17, P83, DOI 10.1177/003693307201700302; LLOYD EL, 1986, HYPOTHERMIA COLD STR, P237; LOCHER T, 1991, SCHWEIZ MED WSCHR, V121, P1020; LONNING PE, 1986, ACTA ANAESTH SCAND, V30, P601, DOI 10.1111/j.1399-6576.1986.tb02485.x; MILLER JW, 1980, ANN EMERG MED, V9, P456, DOI 10.1016/S0196-0644(80)80304-0; MYERS RAM, 1979, JACEP-J AM COLL EMER, V8, P523, DOI 10.1016/S0361-1124(79)80300-7; NIELSEN HK, 1992, DAN MED BULL, V39, P190; OSBORNE L, 1984, BRIT MED J, V289, P881, DOI 10.1136/bmj.289.6449.881-a; RANKIN AC, 1984, BRIT MED J, V289, P874, DOI 10.1136/bmj.289.6449.874; REULER JB, 1978, ANN INTERN MED, V89, P519, DOI 10.7326/0003-4819-89-4-519; ROMET TT, 1988, AVIAT SPACE ENVIR MD, V59, P630; SCHALLER MD, 1990, JAMA-J AM MED ASSOC, V264, P1842, DOI 10.1001/jama.264.14.1842; SCHISSLER P, 1981, SOUTHERN MED J, V74, P474, DOI 10.1097/00007611-198104000-00024; SCHWAB RH, 1964, AM J MED SCI, V248, P290, DOI 10.1097/00000441-196409000-00006; SESSLER DI, 1990, ANESTHESIOLOGY, V73, P218, DOI 10.1097/00000542-199008000-00005; SHIELDS CP, 1990, ANN EMERG MED, V19, P1093, DOI 10.1016/S0196-0644(05)81510-0; SPLITTGERBER FH, 1986, AM SURGEON, V52, P407; STONEHAM MD, 1992, ANAESTHESIA, V47, P784, DOI 10.1111/j.1365-2044.1992.tb03257.x; VONSEGESSER LK, 1991, ANN THORAC SURG, V52, P560, DOI 10.1016/0003-4975(91)90929-K; WEYMAN AE, 1974, AM J MED, V56, P13, DOI 10.1016/0002-9343(74)90746-3; WHITE JD, 1982, ANN EMERG MED, V11, P417; YATES DW, 1979, RESUSCITATION, V7, P59, DOI 10.1016/0300-9572(79)90016-9; ZACHARY L, 1982, ANN PLAS SURG, V9, P238, DOI 10.1097/00000637-198209000-00008; ZELL SC, 1985, ANN EMERG MED, V14, P339, DOI 10.1016/S0196-0644(85)80101-3; Zingg W, 1966, Med Serv J Can, V22, P399; 1993, MMWR-MORBID MORTAL W, V42, P917; [No title captured]	58	92	95	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 25	1995	345	8948					493	498		10.1016/S0140-6736(95)90587-1	http://dx.doi.org/10.1016/S0140-6736(95)90587-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7861878				2022-12-28	WOS:A1995QH92900014
J	HEBUTERNE, X; BROUSSARD, JF; RAMPAL, P				HEBUTERNE, X; BROUSSARD, JF; RAMPAL, P			ACUTE RENUTRITION BY CYCLIC ENTERAL NUTRITION IN ELDERLY AND YOUNGER PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROTEIN-ENERGY MALNUTRITION; TOTAL PARENTERAL-NUTRITION; MEDICAL PATIENTS; METABOLISM; DISEASE; NECK; UNDERNUTRITION; INTERMITTENT; EXPENDITURE; FEEDINGS	Objective.-To evaluate the efficacy and tolerance of cyclic enteral nutrition (CyEN) in elderly compared with younger patients. Design.-Prospective case series. Setting.-University hospital nutritional support unit. Patients.-A total of 51 patients younger than 65 years (mean age, 45 years) and 45 patients 65 years of age and older (mean age, 77 years) referred for refeeding after having lost at least 20% of their body weight or at least 10% in 3 months. All patients were severely undernourished but were ambulatory. Intervention.-Cyclic enteral nutrition was administered via a nasogastric tube during the night; in the daytime patients were allowed to eat normally. Measurements.-Ten biological and anthropometric nutritional parameters and a global nutritional deficiency (GND) were measured at day 0, at day 15, and at the end of CyEN. Results.-Total energy intakes were 288% and 282% of resting energy expenditure in groups 1 and 2, respectively, and duration of CyEN was a mean of 27 days in both groups. Tolerance was generally good, although one patient in each group discontinued refeeding because of aspiration pneumonia. In both groups, seven nutritional parameters and the GND improved significantly; six parameters improved significantly more in younger than in elderly patients: body weight, serum albumin, serum prealbumin, serum transferrin, 24-hour urinary creatinine, and the GND (44.7% vs 35.4%; P=.006). After 1 year, the probability to be alive without relapse was 62% in the elderly and 76% in the younger patients (P=.18). Conclusions.-Cyclic enteral nutrition appears to be a well-tolerated and effective treatment of undernutrition in older malnourished ambulatory patients, although their response to CyEN was somewhat less than in younger patients.			HEBUTERNE, X (corresponding author), HOP ARCHET, CTR AGREE NUTR PARENTERALE DOMICILE, SERV GASTROENTEROL & NUTR, F-06202 NICE 03, FRANCE.							ABADLACRUZ A, 1990, JPEN-PARENTER ENTER, V14, P618, DOI 10.1177/0148607190014006618; ABBASI A, 1994, HDB NUTR AGED, P135; AIGES H, 1989, GASTROENTEROLOGY, V97, P905, DOI 10.1016/0016-5085(89)91496-0; ARORA S, 1989, GASTROENTEROLOGY, V96, P1560, DOI 10.1016/0016-5085(89)90527-1; ASHWORTH N, 1962, LANCET, V2, P685; BASTOW D, 1985, CLIN NUTR, V4, P7, DOI 10.1016/0261-5614(85)90031-7; BASTOW MD, 1983, BRIT MED J, V287, P1589, DOI 10.1136/bmj.287.6405.1589; BASTOW MD, 1983, LANCET, V1, P143; CALLOWAY DH, 1980, AM J CLIN NUTR, V33, P2088; CAMPBELL IT, 1983, AM J CLIN NUTR, V38, P870, DOI 10.1093/ajcn/38.6.870; CIOCON JO, 1988, ARCH INTERN MED, V148, P429, DOI 10.1001/archinte.148.2.429; CIOCON JO, 1992, JPEN-PARENTER ENTER, V16, P525, DOI 10.1177/0148607192016006525; CONSTANS T, 1992, J AM GERIATR SOC, V40, P263, DOI 10.1111/j.1532-5415.1992.tb02080.x; COSNES J, 1983, GASTROEN CLIN BIOL, V7, P1003; GREENE HL, 1976, NEW ENGL J MED, V294, P423, DOI 10.1056/NEJM197602192940805; GUENTER PA, 1991, JPEN-PARENTER ENTER, V15, P277, DOI 10.1177/0148607191015003277; HARRIS JA, 1982, ANNU REV NUTR, V2, P179; HEBUTERNE X, 1992, GASTROEN CLIN BIOL, V16, P227; HENDERSON CT, 1992, J AM COLL NUTR, V11, P309; JACKSON AA, 1977, AM J CLIN NUTR, V30, P1514, DOI 10.1093/ajcn/30.9.1514; JALLUT D, 1990, JPEN-PARENTER ENTER, V14, P563, DOI 10.1177/0148607190014006563; JEEJEEBHOY KN, 1986, GUT               S1, V27, pS25; JELLIFFE DB, 1966, WHO MONOGR SER, V53, P238; JUST B, 1990, AM J CLIN NUTR, V51, P107, DOI 10.1093/ajcn/51.1.107; KAMINSKI MV, 1982, J AM COLL NUTR, V1, P35; KLEIBEUKER JH, 1991, JPEN-PARENTER ENTER, V15, P80, DOI 10.1177/014860719101500180; LEHMANN AB, 1989, AGE AGEING, V18, P339, DOI 10.1093/ageing/18.5.339; LIPSCHITZ DA, 1982, J AM COLL NUTR, V1, P17; MASLOW K, 1988, JPEN-PARENTER ENTER, V12, P425, DOI 10.1177/0148607188012005425; MOHS ME, 1994, HDB NUTR AGED, P145; MORGAN DB, 1986, AGE AGEING, V15, P65, DOI 10.1093/ageing/15.2.65; PECK A, 1990, J AM GERIATR SOC, V38, P1195, DOI 10.1111/j.1532-5415.1990.tb01498.x; ROMIJN JA, 1993, AM J PHYSIOL, V265, pE380, DOI 10.1152/ajpendo.1993.265.3.E380; RUSSELL RM, 1992, AM J CLIN NUTR, V55, P1203; SCHWARTZ RS, 1990, METABOLISM, V39, P733, DOI 10.1016/0026-0495(90)90109-P; SHIZGAL HM, 1992, AM J CLIN NUTR, V55, P783, DOI 10.1093/ajcn/55.4.783; SIMKO V, 1989, ARCH INTERN MED, V149, P557, DOI 10.1001/archinte.149.3.557; SOLOMON SM, 1990, JPEN-PARENTER ENTER, V14, P90, DOI 10.1177/014860719001400190; SULLIVAN DH, 1990, AM J CLIN NUTR, V51, P749, DOI 10.1093/ajcn/51.5.749; TOMAIOLO PP, 1981, JPEN-PARENTER ENTER, V5, P46, DOI 10.1177/014860718100500146; UAUY R, 1978, J GERONTOL, V33, P663, DOI 10.1093/geronj/33.5.663; VOORRIPS LE, 1993, AM J CLIN NUTR, V58, P15, DOI 10.1093/ajcn/58.1.15; WALKER J, 1979, AM J CLIN NUTR, V32, P1397, DOI 10.1093/ajcn/32.7.1396; WEINSIER RL, 1979, AM J CLIN NUTR, V32, P418, DOI 10.1093/ajcn/32.2.418	44	66	66	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	1995	273	8					638	643		10.1001/jama.273.8.638	http://dx.doi.org/10.1001/jama.273.8.638			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QG748	7844874				2022-12-28	WOS:A1995QG74800029
J	PUI, CH; BOYETT, JM; HANCOCK, ML; PRATT, CB; MEYER, WH; CRIST, WM				PUI, CH; BOYETT, JM; HANCOCK, ML; PRATT, CB; MEYER, WH; CRIST, WM			OUTCOME OF TREATMENT FOR CHILDHOOD-CANCER IN BLACK AS COMPARED WITH WHITE-CHILDREN - THE ST-JUDE-CHILDRENS-RESEARCH-HOSPITAL EXPERIENCE, 1962 THROUGH 1992	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE LYMPHOCYTIC-LEUKEMIA; BREAST-CANCER; RACIAL-DIFFERENCES; SOCIOECONOMIC-STATUS; SURVIVAL RATES; RACE; WOMEN; PLACE	Objective.-To determine whether there is a racial difference in prognosis among childhood cancers. Design.-An overall (30-year) survival analysis by race was followed by separate studies for ''early'' and ''recent'' treatment eras, defined by time points at which significantly improved outcome was demonstrated for specific tumor types, Stratified analyses were performed to adjust for recognized prognostic features. Setting.-Pediatric oncology research and treatment center. Patients.-The study included 798 black and 4507 white children with newly diagnosed malignancies treated from January 1962 through June 1992. These patients were accepted for treatment regardless of their financial status and were enrolled on disease-specific protocols. Results.-Across the 30-year study period, black children had a significantly poorer rate of survival than white children (P<.,001, log-rank test). In the early treatment era, a significant difference was seen for all forms of cancer combined (P<.001), with 10-year Kaplan-Meier estimates (+/-SE) of 37%+/-3% for black children and 50%+/-1% for white children. This difference largely reflected the poorer prognosis of black children with the most common childhood cancer, acute lymphoblastic leukemia. In the recent treatment era, there were no significant differences in treatment outcome by race for specific disease categories or for all forms of cancer combined, Ten-year survival rates were 67%+/-6% for black children and 66%+/-3% for white children, indicating a significantly greater improvement in the former group. Conclusion.-With equal access to effective contemporary treatment, black children with cancer fare as well as white children when treated with protocol-based therapy at a pediatric oncology research center.	ST JUDE CHILDRENS RES HOSP, DEPT BIOSTAT, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT PATHOL & LAB MED, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, COLL MED, MEMPHIS, TN USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	PUI, CH (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, 332 N LAUDERDALE, POB 318, MEMPHIS, TN 38101 USA.		Pui, Ching-Hon/N-8076-2018	Pui, Ching-Hon/0000-0003-0303-5658	NATIONAL CANCER INSTITUTE [P30CA021765, P01CA020180, P01CA023099] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 21765, P01 CA 23099, P01 CA 20180] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGELL M, 1993, NEW ENGL J MED, V329, P126, DOI 10.1056/NEJM199307083290210; AZIZ H, 1988, AM J CLIN ONCOL-CANC, V11, P166, DOI 10.1097/00000421-198804000-00015; BAIN RP, 1987, AM J OBSTET GYNECOL, V157, P914, DOI 10.1016/S0002-9378(87)80089-3; BAIN RP, 1986, J CHRON DIS, V39, P631, DOI 10.1016/0021-9681(86)90188-8; BASSETT MT, 1986, AM J PUBLIC HEALTH, V76, P1400, DOI 10.2105/AJPH.76.12.1400; BIRCH JM, 1988, BRIT MED J, V296, P1372, DOI 10.1136/bmj.296.6633.1372; BLATT J, 1992, AM J MED, V93, P57, DOI 10.1016/0002-9343(92)90680-A; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; BORING CC, 1992, CA-CANCER J CLIN, V42, P7, DOI 10.3322/canjclin.42.1.7; BRODER S, 1993, STEM CELLS, V1, P3; COX DR, 1968, STATISTICAL ANAL SER, P229; DANSEY RD, 1988, CANCER, V61, P1908, DOI 10.1002/1097-0142(19880501)61:9<1908::AID-CNCR2820610931>3.0.CO;2-N; DAYAL H, 1987, J CHRON DIS, V40, P857, DOI 10.1016/0021-9681(87)90185-8; DAYAL HH, 1982, J CHRON DIS, V35, P675, DOI 10.1016/0021-9681(82)90020-0; EVANS WE, 1991, SEMIN HEMATOL, V28, P15; FALLETTA JM, 1984, PROG CANCER RES THER, V27, P191; HOWARD J, 1992, CANCER, V69, P2349, DOI 10.1002/1097-0142(19920501)69:9&lt;2349::AID-CNCR2820690925&gt;3.0.CO;2-7; KALWINSKY DK, 1985, LEUKEMIA RES, V9, P817, DOI 10.1016/0145-2126(85)90300-5; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kitagawa EM, 1973, DIFFERENTIAL MORTALI; KLINGEMANN HG, 1986, BONE MARROW TRANSPL, V1, P87; KRAMER S, 1984, J CLIN ONCOL, V2, P917, DOI 10.1200/JCO.1984.2.8.917; LENNOX EL, 1979, BRIT MED J, V2, P567, DOI 10.1136/bmj.2.6190.567; LIPSHULTZ SE, 1991, NEW ENGL J MED, V324, P808, DOI 10.1056/NEJM199103213241205; MANTEL N, 1959, J NATL CANCER I, V22, P719; MEADOWS AT, 1983, CANCER INVEST, V1, P49, DOI 10.3109/07357908309040932; MILLER RW, 1989, PRINCIPLES PRACTICE, P3; NEGLIA JP, 1991, NEW ENGL J MED, V325, P1330, DOI 10.1056/NEJM199111073251902; NOVAKOVIC B, 1994, MED PEDIATR ONCOL, V23, P480, DOI 10.1002/mpo.2950230606; OWNBY HE, 1985, J NATL CANCER I, V75, P55; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PUI CH, 1993, BLOOD, V82, P343; PUI CH, 1990, BLOOD, V76, P1449; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; RAGLAND KE, 1991, AM J EPIDEMIOL, V133, P672; REAMAN GH, 1984, PROG CANCER RES THER, V27, P163; REINTGEN DS, 1982, JAMA-J AM MED ASSOC, V248, P1856, DOI 10.1001/jama.248.15.1856; RIVERA GK, 1993, NEW ENGL J MED, V329, P1289, DOI 10.1056/NEJM199310283291801; SATHER H, 1984, PROG CANCER RES THER, V27, P179; STEINHORN SC, 1986, AM J EPIDEMIOL, V124, P85, DOI 10.1093/oxfordjournals.aje.a114373; STILLER CA, 1988, ARCH DIS CHILD, V63, P23, DOI 10.1136/adc.63.1.23; WALTERS TR, 1972, CANCER, V29, P210, DOI 10.1002/1097-0142(197201)29:1<210::AID-CNCR2820290131>3.0.CO;2-U; YOUNG J L JR, 1986, Cancer, V58, P598, DOI 10.1002/1097-0142(19860715)58:2+<598::AID-CNCR2820581332>3.0.CO;2-C; 1992, PEDIATRICS, V89, P597; 1990, TREATMENT EARLY BREA, P1	46	73	74	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	1995	273	8					633	637		10.1001/jama.273.8.633	http://dx.doi.org/10.1001/jama.273.8.633			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG748	7844873				2022-12-28	WOS:A1995QG74800028
J	MYRUP, B; HANSEN, PM; JENSEN, T; KOFOEDENEVOLDSEN, A; FELDTRASMUSSEN, B; GRAM, J; KLUFT, C; JESPERSEN, J; DECKERT, T				MYRUP, B; HANSEN, PM; JENSEN, T; KOFOEDENEVOLDSEN, A; FELDTRASMUSSEN, B; GRAM, J; KLUFT, C; JESPERSEN, J; DECKERT, T			EFFECT OF LOW-DOSE HEPARIN ON URINARY ALBUMIN EXCRETION IN INSULIN-DEPENDENT DIABETES-MELLITUS	LANCET			English	Note							MESANGIAL-CELL-PROLIFERATION; MATRIX; RATS	We investigated the effect of heparin on urinary albumin excretion in patients with insulin-dependent diabetes mellitus. 39 patients with persistent urinary albumin excretion of 30-300 mg/24 h were randomly treated for 3 months with subcutaneous injections twice daily of isotonic saline, 5000 IU unfractionated heparin, or 2000 anti-Xa IU low-molecular-weight heparin. Unfractionated and low-molecular-weight heparin induced a significant reduction in urinary albumin excretion (p=0.04 and p=0.004). The mechanism and clinical relevance is unknown but deserve further attention.	NOVO NORDISK AS,BAGSVAERD,DENMARK; S JUTLAND UNIV CTR,THROMBOSIS RES INST,ESBJERG,DENMARK; GAUBIUS LAB,LEIDEN,NETHERLANDS	Novo Nordisk	MYRUP, B (corresponding author), STENO DIABET CTR,NIELS STEENSENS VEJ 2,DK-2820 GENTOFTE,DENMARK.			Feldt-Rasmussen, Bo/0000-0002-8267-3027; Jespersen, Jorgen/0000-0002-3059-2356				CASTELLOT JJ, 1985, AM J PATHOL, V120, P427; DECKERT T, 1989, DIABETOLOGIA, V32, P219, DOI 10.1007/BF00285287; DECKERT T, 1993, DIABETOLOGIA, V36, P244, DOI 10.1007/BF00399958; FLOEGE J, 1993, KIDNEY INT, V43, P369, DOI 10.1038/ki.1993.55; GAMBARO G, 1992, KIDNEY INT, V42, P285, DOI 10.1038/ki.1992.288; KITAMURA M, 1991, KIDNEY INT, V40, P653, DOI 10.1038/ki.1991.257; NADER HB, 1989, J CELL PHYSIOL, V140, P305, DOI 10.1002/jcp.1041400216; OSTERBY R, 1992, DIABETOLOGIA, V35, P805; TAMSMA JT, 1994, DIABETOLOGIA, V37, P313, DOI 10.1007/BF00398060; VANDENBORN J, 1992, KIDNEY INT, V41, P115, DOI 10.1038/ki.1992.15	10	88	89	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					421	422		10.1016/S0140-6736(95)90403-4	http://dx.doi.org/10.1016/S0140-6736(95)90403-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853952				2022-12-28	WOS:A1995QG90400011
J	WILLIAMS, B				WILLIAMS, B			WESTERNIZED ASIANS AND CARDIOVASCULAR-DISEASE - NATURE OR NURTURE	LANCET			English	Editorial Material							HEART-DISEASE; SOUTH ASIANS				WILLIAMS, B (corresponding author), UNIV LEICESTER,DEPT MED & THERAPEUT,LEICESTER,LEICS,ENGLAND.			Williams, Bryan/0000-0002-8094-1841				BALARAJAN R, 1991, BMJ-BRIT MED J, V302, P560, DOI 10.1136/bmj.302.6776.560; MCKEIGUE PM, 1989, J CLIN EPIDEMIOL, V42, P597, DOI 10.1016/0895-4356(89)90002-4; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; Shaukat N, 1994, BRIT HEART J, V71, P27; SHAUKAT N, 1995, FIBRINOLYSIS, V9, P1; WILLIAMS B, 1994, LANCET, V334, P521; 1986, LANCET, V1, P1307; 1991, LANCET, V331, P397	8	39	40	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					401	402		10.1016/S0140-6736(95)90394-1	http://dx.doi.org/10.1016/S0140-6736(95)90394-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853944				2022-12-28	WOS:A1995QG90400002
J	MIEDZYBRODZKA, ZH; HALL, MH; MOLLISON, J; TEMPLETON, A; RUSSELL, IT; DEAN, JCS; KELLY, KF; MARTEAU, TM; HAITES, NE				MIEDZYBRODZKA, ZH; HALL, MH; MOLLISON, J; TEMPLETON, A; RUSSELL, IT; DEAN, JCS; KELLY, KF; MARTEAU, TM; HAITES, NE			ANTENATAL SCREENING FOR CARRIERS OF CYSTIC-FIBROSIS - RANDOMIZED TRIAL OF STEPWISE V COUPLE SCREENING	BRITISH MEDICAL JOURNAL			English	Article							MUTATIONS; GENE; IDENTIFICATION; HEALTH; CARE	Objective-To perform a rigorous comparative evaluation of stepwise and couple Design-Pragmatic randomised trial. Setting-Hospital antenatal clinic serving a regional population. Subjects-2002 women (couples) attending for booking antenatal visit at less than 17 weeks' gestation with no family history of cystic fibrosis. Interventions-Offering counselling and carrier testing for cystic fibrosis, either to women in the first instance (stepwise) or to couples (couple screening). Main outcome measures-Uptake rates; anxiety; knowledge of cystic fibrosis and carrier status (both partners); attitudes to health, pregnancy, the baby, and screening (both partners); and uptake of carrier testing by relatives. Results-Uptake of screening was the same for both approaches (90%). After delivery most women remembered test results and their meaning, but 53/253 (21%) of those with negative results of couple testing had forgotten that repeat testing would be advisable if they had a pregnancy with a new partner. With stepwise screening women identified as carriers had high levels of anxiety when results were received (mean anxiety score 52.3). This dissipated with a reassuring partner's result (carriers' mean anxiety score 36.1) to levels similar to those receiving negative results from couple screening. Of those receiving negative results, women who had stepwise screening were significantly less anxious than those who had couple screening (mean score with result 32.1 v 35.4, 95% confidence interval for difference -4.7 to -2.1). Conclusions-Couple screening allows carriers to avoid transient high levels of anxiety, but is associated with more anxiety and false reassurance among most screenees who will test negative. Stepwise screening gives carriers and their relatives genetic information and is, in our opinion, the better method.	ABERDEEN MATERN HOSP, DEPT OBSTET & GYNAECOL, ABERDEEN AB9 2ZD, SCOTLAND; UNITED MED & DENT SCH, PSYCHOL & GENET RES GRP, LONDON SE1 9RT, ENGLAND	University of Aberdeen; University of London; King's College London	MIEDZYBRODZKA, ZH (corresponding author), UNIV ABERDEEN, HLTH SERV RES UNIT, DREW KAY WING, POLWARTH BLDG, ABERDEEN AB9 2ZD, SCOTLAND.		Russell, Ian T/H-1181-2012	Dean, John/0000-0003-3841-0841; Marteau, Theresa/0000-0003-3025-1129	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEKKER H, 1993, BRIT MED J, V306, P1584, DOI 10.1136/bmj.306.6892.1584; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; FERRIE RM, 1992, AM J HUM GENET, V51, P251; HARRIS H, 1993, BRIT MED J, V306, P1580, DOI 10.1136/bmj.306.6892.1580; HENSHAW RC, 1993, BRIT MED J, V307, P714, DOI 10.1136/bmj.307.6906.714; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LENCH N, 1988, LANCET, V1, P1356; LIVINGSTONE J, 1994, BRIT MED J, V308, P1459, DOI 10.1136/bmj.308.6942.1459; MARTEAU TM, 1992, J MED GENET, V29, P24, DOI 10.1136/jmg.29.1.24; MARTEAU TM, 1992, J PSYCHOSOM RES, V36, P395, DOI 10.1016/0022-3999(92)90076-E; MARTEAU TM, 1992, BRIT J CLIN PSYCHOL, V31, P301, DOI 10.1111/j.2044-8260.1992.tb00997.x; MENNIE ME, 1992, LANCET, V340, P214, DOI 10.1016/0140-6736(92)90476-J; Miedzybrodzka Z, 1993, Paediatr Perinat Epidemiol, V7, P368, DOI 10.1111/j.1365-3016.1993.tb00416.x; MIEDZYBRODZKA Z, 1991, LANCET, V338, P1524; MIEDZYBRODZKA ZH, 1993, J MED GENET, V30, P316, DOI 10.1136/jmg.30.4.316; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; SHRIMPTON AE, 1991, J MED GENET, V28, P317, DOI 10.1136/jmg.28.5.317; SPIELBERGER CD, 1970, MANUAL STATE TRAIT A; WALD NJ, 1991, LANCET, V338, P1318, DOI 10.1016/0140-6736(91)92605-2; WATSON EK, 1991, BRIT MED J, V303, P504, DOI 10.1136/bmj.303.6801.504; ZIELENSKI J, 1991, GENOMICS, V10, P229, DOI 10.1016/0888-7543(91)90504-8	22	66	66	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 11	1995	310	6976					353	357		10.1136/bmj.310.6976.353	http://dx.doi.org/10.1136/bmj.310.6976.353			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG721	7866213	Green Published			2022-12-28	WOS:A1995QG72100016
J	MIYAMOTO, S; AKIYAMA, SK; YAMADA, KM				MIYAMOTO, S; AKIYAMA, SK; YAMADA, KM			SYNERGISTIC ROLES FOR RECEPTOR OCCUPANCY AND AGGREGATION IN INTEGRIN TRANSMEMBRANE FUNCTION	SCIENCE			English	Article							FIBRONECTIN RECEPTOR; SIGNAL TRANSDUCTION; CELL-ADHESION; TYROSINE PHOSPHORYLATION; FIBROBLASTS; ANTIBODIES; BINDING; PROTEIN; MATRIX; GROWTH	Integrin receptors mediate cell adhesion, signal transduction, and cytoskeletal organization. How a single transmembrane receptor can fulfill multiple functions was clarified by comparing roles of receptor occupancy and aggregation. Integrin occupancy by monovalent ligand induced receptor redistribution, but minimal tyrosine phosphorylation signaling or cytoskeletal protein redistribution. Aggregation of integrins by noninhibitory monoclonal antibodies on beads induced intracellular accumulations of pp125(FAK) and tensin, as well as phosphorylation, but no accumulation of other cytoskeletal proteins such as talin. Combining antibody-mediated clustering with monovalent ligand occupancy induced accumulation of seven cytoskeletal proteins, including alpha-actinin, talin, and F-actin, thereby mimicking multivalent interactions with fibronectin or polyvalent peptides. Integrins therefore mediate a complex repertoire of functions through the distinct effects of receptor aggregation, receptor occupancy, or both together.	NIDR, DEV BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)				Yamada, Kenneth/0000-0003-1512-6805				AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; AKIYAMA SK, 1985, J BIOL CHEM, V260, P402; CHERESH DA, 1992, CLIN LAB MED, V12, P217, DOI 10.1016/S0272-2712(18)30514-6; COUCHMAN JR, 1979, J CELL SCI, V39, P149; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DEFILIPPI P, 1994, CELL ADHES COMMUN, V2, P75, DOI 10.3109/15419069409014203; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUBAND JL, 1988, J CELL BIOL, V107, P1385, DOI 10.1083/jcb.107.4.1385; Geiger B, 1989, CURR OPIN CELL BIOL, V1, P103, DOI 10.1016/S0955-0674(89)80045-6; GRINNELL F, 1986, EXP CELL RES, V162, P449, DOI 10.1016/0014-4827(86)90349-6; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Hay E.D., 1991, CELL BIOL EXTRACELLU, DOI 10.1007/978-1-4615-3770-0; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; METZGER H, 1992, J IMMUNOL, V149, P1477; MIYAMOTO S, UNPUB; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8	28	815	825	2	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	1995	267	5199					883	885		10.1126/science.7846531	http://dx.doi.org/10.1126/science.7846531			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG207	7846531				2022-12-28	WOS:A1995QG20700058
J	GAMES, D; ADAMS, D; ALESSANDRINI, R; BARBOUR, R; BERTHELETTE, P; BLACKWELL, C; CARR, T; CLEMENS, J; DONALDSON, T; GILLESPIE, F; GUIDO, T; HAGOPIAN, S; JOHNSONWOOD, K; KHAN, K; LEE, M; LEIBOWITZ, P; LIEBERBURG, I; LITTLE, S; MASLIAH, E; MCCONLOGUE, L; MONTOYAZAVALA, M; MUCKE, L; PAGANINI, L; PENNIMAN, E; POWER, M; SCHENK, D; SEUBERT, P; SNYDER, B; SORIANO, F; TAN, H; VITALE, J; WADSWORTH, S; WOLOZIN, B; ZHAO, J				GAMES, D; ADAMS, D; ALESSANDRINI, R; BARBOUR, R; BERTHELETTE, P; BLACKWELL, C; CARR, T; CLEMENS, J; DONALDSON, T; GILLESPIE, F; GUIDO, T; HAGOPIAN, S; JOHNSONWOOD, K; KHAN, K; LEE, M; LEIBOWITZ, P; LIEBERBURG, I; LITTLE, S; MASLIAH, E; MCCONLOGUE, L; MONTOYAZAVALA, M; MUCKE, L; PAGANINI, L; PENNIMAN, E; POWER, M; SCHENK, D; SEUBERT, P; SNYDER, B; SORIANO, F; TAN, H; VITALE, J; WADSWORTH, S; WOLOZIN, B; ZHAO, J			ALZHEIMER-TYPE NEUROPATHOLOGY IN TRANSGENIC MICE OVEREXPRESSING V717F BETA-AMYLOID PRECURSOR PROTEIN	NATURE			English	Article							SENILE PLAQUES; DISEASE; IDENTIFICATION; EXPRESSION; PATHOLOGY; DEPOSITS; PEPTIDE; CHAIN; BRAIN; GENE	ALZHEIMER'S disease (AD) is the most common cause of progressive intellectual failure in aged humans. AD brains contain numerous amyloid plaques surrounded by dystrophic neurites, and show profound synaptic loss, neurofibrillary tangle formation and gliosis. The amyloid plaques are composed of amyloid beta-peptide (A beta), a 40-42-amino-acid fragment of the beta-amyloid precursor protein (APP)(1). A primary pathogenic role for APP/A beta is suggested by missense mutations in APP that are tightly linked to autosomal dominant forms of AD(2,3). A major obstacle to elucidating and treating AD has been the lack of an animal model. Animals transgenic for APP have previously failed to show extensive AD-type neuropathology(4-10), but we now report the production of transgenic mice that express high levels of human mutant APP (with valine at residue 717 substituted by phenylalanine) and which progressively develop many of the pathological hallmarks of AD, including numerous extracellular thioflavin S-positive AP deposits, neuritic plaques, synaptic loss, astrocytosis and microgliosis. These mice support a primary role for APP/A beta in the genesis of AD and could provide a preclinical model for testing therapeutic drugs.	ATHENA NEUROSCI INC, San Francisco, CA 94080 USA; EXEMPLAR CORP, WORCESTER, MA 01605 USA; ELI LILLY & CO, LILLY RES LAB, INDIANAPOLIS, IN 46285 USA; SCRIPPS RES INST, RES INST, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT NEUROSCI, LA JOLLA, CA 92093 USA; NIMH, CLIN SCI LAB, BETHESDA, MD 20892 USA	Eli Lilly; Scripps Research Institute; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)				Mucke, Lennart/0000-0001-6256-9559				ARAI H, 1990, P NATL ACAD SCI USA, V87, P2249, DOI 10.1073/pnas.87.6.2249; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORK LC, 1988, J NEUROPATH EXP NEUR, V47, P629, DOI 10.1097/00005072-198811000-00006; DICKSON DW, 1990, ACTA NEUROPATHOL, V79, P486, DOI 10.1007/BF00296107; GAMES D, 1992, NEUROBIOL AGING, V13, P569, DOI 10.1016/0197-4580(92)90057-5; HARDY J, 1994, CLIN GERIATR MED, V10, P239, DOI 10.1016/S0749-0690(18)30343-4; HIGGINS LS, 1994, ANN NEUROL, V35, P598, DOI 10.1002/ana.410350514; HOGAN B, 1986, MANIPULATING MOUSE E; LAMB BT, 1993, NAT GENET, V5, P22, DOI 10.1038/ng0993-22; MAGGIO JE, 1992, P NATL ACAD SCI USA, V89, P5462, DOI 10.1073/pnas.89.12.5462; MANN DMA, 1992, NEURODEGENERATION, V1, P201; MASLIAH E, 1991, AM J PATHOL, V138, P235; MASLIAH E, 1991, ACTA NEUROPATHOL, V81, P428, DOI 10.1007/BF00293464; MASLIAH E, 1993, J NEUROPATH EXP NEUR, V52, P619, DOI 10.1097/00005072-199311000-00009; MCCONLOGUE L, 1994, NEUROBIOL AGING, V15, pS12; MUCKE L, 1994, BRAIN RES, V666, P151, DOI 10.1016/0006-8993(94)90767-6; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PEARSON BE, 1993, P NATL ACAD SCI USA, V90, P10578, DOI 10.1073/pnas.90.22.10578; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SAIDO TC, 1994, J BIOL CHEM, V269, P15253; SANHU FA, 1991, J BIOL CHEM, V266, P21331; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; SELKOE DJ, 1994, REV NEUROSCI, V17, P489; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717	29	2120	2283	1	169	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	1995	373	6514					523	527		10.1038/373523a0	http://dx.doi.org/10.1038/373523a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7845465				2022-12-28	WOS:A1995QF72400060
J	PAUL, WE				PAUL, WE			REEXAMINING AIDS RESEARCH PRIORITIES	SCIENCE			English	Editorial Material							MECHANISM; INFECTION; VACCINE; CELLS; GENE; HIV				PAUL, WE (corresponding author), NIH, OFF AIDS RES, BETHESDA, MD 20892 USA.							BABA TW, IN PRESS SCIENCE; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; CAO Y, IN PRESS N ENGL J ME; CLERICI M, 1994, JAMA-J AM MED ASSOC, V271, P42, DOI 10.1001/jama.271.1.42; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; CZERKINSKY C, 1993, CLIN INFECT DIS, V16, pS106, DOI 10.1093/clinids/16.Supplement_2.S106; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FIELDS BN, 1994, NATURE, V369, P95, DOI 10.1038/369095a0; GRAZIOSI C, 1994, SCIENCE, V265, P248, DOI 10.1126/science.8023143; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KLUGMAN KP, 1987, LANCET, V2, P1165; LAZARO I, 1994, J VIROL, V68, P6535, DOI 10.1128/JVI.68.10.6535-6546.1994; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; MERSON MH, 1994, INT C AIDS, V10, P4; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; PANTALEO G, IN PRESS N ENGL J ME; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PLUMMER FA, 1993, INT C AIDS, V9, P23; ROMAGNANI S, 1994, AIDS RES HUM RETROV, V10, pR3, DOI 10.1089/aid.1994.10.iii; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; UMLAUF SW, 1993, IMMUNOL REV, V133, P177, DOI 10.1111/j.1600-065X.1993.tb01516.x; WALKER CM, 1991, J VIROL, V65, P5921, DOI 10.1128/JVI.65.11.5921-5927.1991; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WINKELSTEIN WJ, 1993, INT C AIDS, V9, P88; 1994, HIV AIDS SURVEILLANC, V6, P1	29	31	34	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	1995	267	5198					633	636		10.1126/science.7839138	http://dx.doi.org/10.1126/science.7839138			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839138				2022-12-28	WOS:A1995QE73300025
J	WADA, A				WADA, A			A SPACE-TIME SLIDE-RULE (VOL 373, PG R39, 1995)	NATURE			English	Correction, Addition								Akiyoshi Wada retired some years ago as a professor of physics at Tokyo University, where he was for many years one of those in Japan urging the fuller use of physical techniques in molecular biology, notably in the automatic sequencing of DNA. Now he is the director of the interdisciplinary Sagami Chemical Research Center near Tokyo. The Wadarules reproduced on these pages (together with an explanatory note by Professor Wada) do not arise directly from the author's professional work but are the product of a fertile tile and ingenious imagination exercised, in part no doubt, on long aircraft journeys. They are offered without restriction to those who may have use for them. It is simply necessary to photocopy the diagrams, to separate the main rule from the reference rule and to mount each part on stiff card in such a way as to be able to slide the latter against the former. While the Wadarules may have a general heuristic value for those who have the time to play with them, they may have a particular educational value for young children and may be particularly useful for, say, science writers forever seeking graphic wars of dramatizing the large or small scale of some phenomenon (as in the phrase ''seems no bigger than a dime at a distance of 1 mile''). The rules can readily be amended to include objects with dimensions other than those shown. The annotation of the time rule leaves ample room for the addition of extra items, such as the average duration of the human heart-beat, the period of oscillation of ''middle C'' (0.00178 seconds) and the like.			WADA, A (corresponding author), SAGAMI CHEM RES CTR,4-4-1 NISHIOHNUMA,SAGAMIHARA,KANAGAWA 229,JAPAN.							WADA A, 1995, NATURE, V373, pR39	1	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 2	1995	373	6513					R35	R36						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7830774				2022-12-28	WOS:A1995QE67000065
J	NEER, EJ				NEER, EJ			HETEROTRIMERIC G-PROTEINS - ORGANIZERS OF TRANSMEMBRANE SIGNALS	CELL			English	Review							GUANINE-NUCLEOTIDE-BINDING; BETA-GAMMA-SUBUNITS; REGULATORY PROTEINS; ADENYLYL CYCLASE; PHOSPHOLIPID-VESICLES; ADRENERGIC-RECEPTOR; ALPHA-SUBUNITS; TRANSDUCIN; CELLS; SPECIFICITY		HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	NEER, EJ (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02115 USA.				NIGMS NIH HHS [GM36259, GM46370] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046370, R37GM036259, R01GM036259] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ASANO T, 1984, J BIOL CHEM, V259, P9351; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BETH AH, 1986, BIOCHEMISTRY-US, V25, P3824, DOI 10.1021/bi00361a013; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; BUBIS J, 1990, J BIOL CHEM, V265, P12995; BUXTON ILO, 1983, J BIOL CHEM, V258, P233; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CARLSON KE, 1986, MOL PHARMACOL, V30, P463; CARTY DJ, 1990, J BIOL CHEM, V265, P6268; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CERIONE RA, 1987, BIOCHEMISTRY-US, V26, P1485, DOI 10.1021/bi00379a041; CERIONE RA, 1986, J BIOL CHEM, V261, P3901; CERIONE RA, 1985, J BIOL CHEM, V260, P1493; CHABRE O, 1994, J BIOL CHEM, V269, P5730; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DANIELISSAKANI S, 1989, J BIOL CHEM, V264, P20240; DENKER BM, 1992, J BIOL CHEM, V267, P9998; DENKER BM, 1992, J BIOL CHEM, V267, P6272; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DUFAU ML, 1978, J BIOL CHEM, V253, P3721; FAURE M, 1994, J BIOL CHEM, V269, P7851; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GARRITSEN A, 1994, J BIOL CHEM, V269, P24418; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAESER D, 1993, MOL PHARMACOL, V43, P434; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; HANSEN CA, 1994, J CELL BIOL, V126, P811, DOI 10.1083/jcb.126.3.811; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; HUFF RM, 1985, J BIOL CHEM, V260, P864; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; JAHANGEER S, 1993, P NATL ACAD SCI USA, V90, P8782, DOI 10.1073/pnas.90.19.8782; KATADA T, 1987, J BIOL CHEM, V262, P11897; KATZ A, 1995, INR PESS P NATL ACAD; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KEEFER JR, 1994, J BIOL CHEM, V269, P16425; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LEE CH, 1995, IN PRESS MOL PHARM; LEE RH, 1992, J BIOL CHEM, V267, P25104; LINDER ME, 1990, J BIOL CHEM, V265, P8243; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; LUPAS AN, 1992, FEBS LETT, V314, P105, DOI 10.1016/0014-5793(92)80952-D; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MUNSHI R, 1991, J BIOL CHEM, V266, P22285; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEER EJ, 1994, PROTEIN SCI, V3, P3; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; RAHMATULLAH M, 1994, J BIOL CHEM, V269, P3574; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHLEGEL W, 1979, J BIOL CHEM, V254, P5168; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SPRING DJ, 1994, J BIOL CHEM, V269, P22882; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; THOMAS TC, 1993, P NATL ACAD SCI USA, V90, P10295, DOI 10.1073/pnas.90.21.10295; THOMAS TC, 1993, BIOCHEMISTRY-US, V32, P8628, DOI 10.1021/bi00084a034; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; WIELAND T, 1993, J BIOL CHEM, V268, P18111; WILCOX MD, 1994, J BIOL CHEM, V269, P12508; WONG SKF, 1994, J BIOL CHEM, V269, P18968; XIAO RP, 1994, J BIOL CHEM, V269, P19151	86	1264	1294	2	53	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	1995	80	2					249	257		10.1016/0092-8674(95)90407-7	http://dx.doi.org/10.1016/0092-8674(95)90407-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7834744	Bronze			2022-12-28	WOS:A1995QD92400007
J	TRAIN, JJA; YATES, RW; SURY, MRJ				TRAIN, JJA; YATES, RW; SURY, MRJ			LESSON OF THE WEEK - HYPOCALCEMIC STRIDER AND INFANTILE NUTRITIONAL RICKETS	BRITISH MEDICAL JOURNAL			English	Article									HOSP SICK CHILDREN,DEPT ANAESTHESIA,LONDON WC1 3JN,ENGLAND; QUEEN ELIZABETH HOSP CHILDREN,DEPT PAEDIAT,LONDON E2 8PS,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London								BARNESS LA, 1983, TXB PAEDIAT, P179; HARRISON HE, 1983, TXB PEDIATRICS, P249; HIDALGO HA, 1989, PEDIATR PULM, V7, P110, DOI 10.1002/ppul.1950070210; MAZE A, 1979, ANESTHESIOLOGY, V50, P132, DOI 10.1097/00000542-197902000-00011; POLNAY L, 1985, COMMUNITY PAEDIATRIC, P110; RIZEN MF, 1990, ANESTHESIA, P816; SHARIEF N, 1991, CLIN PEDIATR, V3, P51; 1988, REPORTS HLTH SOCIAL, V32; 1991, REPORTS HLTH SOCIAL, V41, P123	9	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 7	1995	310	6971					48	49		10.1136/bmj.310.6971.48	http://dx.doi.org/10.1136/bmj.310.6971.48			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB060	7827559	Green Published			2022-12-28	WOS:A1995QB06000039
J	UREN, NG; CRAKE, T; LEFROY, DC; DESILVA, R; DAVIES, GJ; MASERI, A				UREN, NG; CRAKE, T; LEFROY, DC; DESILVA, R; DAVIES, GJ; MASERI, A			REDUCED CORONARY VASODILATOR FUNCTION IN INFARCTED AND NORMAL MYOCARDIUM AFTER MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITRON EMISSION TOMOGRAPHY; NO-REFLOW PHENOMENON; BLOOD-FLOW; ENDOTHELIAL DYSFUNCTION; ARTERY DISEASE; L-ARGININE; ATHEROSCLEROSIS; OCCLUSION; MICROCIRCULATION; THROMBOLYSIS	Background. The ability of the coronary vascular bed to dilate and thus increase blood flow to the myocardium may be impaired in coronary artery disease, even regions of myocardium supplied by an angiographically normal coronary artery. If this kind of vasomotor dysfunction was present or accentuated after acute myocardial infarction, it might influence the extent of ischemia and necrosis in areas not directly injured by the infarction. Methods. We studied 13 patients (mean [+/-SD] age, 62+/-11 years) with single-vessel coronary artery disease after they had received thrombolytic therapy for myocardial infarction. Using positron-emission tomography (PET) with oxygen-15-labeled water, we measured regional myocardial blood flow under basal conditions and after the intravenous administration of dipyridamole (0.5 mg per kg of body weight over a period of four minutes) 8+/-3 days after infarction in all 13 patients (1-week study) and 6+/-2 months after infarction in 9 of the 13 (6-month study). On both occasions we measured blood flow both in the infarcted region and in a region of myocardium that was remote from the infarcted region and supplied by a normal artery. Results. At the one-week PET study, the coronary vasodilator response (the ratio of the myocardial blood flow after the administration of dipyridamole to basal blood flow) was 1.12+/-0.50 in the infarct-related artery and 1.53+/-0.36 in the remote region (P = 0.015). At the six-month study, the coronary vasodilator response was 1.42+/-0.37 in the infarcted region and 2.19+/-0.69 in the remote region (P = 0.004 for the comparison with the infarcted region; P = 0.011 for the comparison with the remote region at the one-week study). The value in remote myocardium remained lower than that in similar regions in 10 control patients, who had single-vessel coronary artery disease but no evidence of myocardial infarction (3.17+/-0.72; P = 0.009). Conclusions. After acute myocardial infarction, there is a severe vasodilator abnormality involving not only resistance vessels in infarcted myocardium, but also those in myocardium perfused by normal coronary vessels. This dysfunction may affect the extent of myocardial ischemia and necrosis after coronary occlusion.	HAMMERSMITH HOSP,DIV CARDIOL,LONDON,ENGLAND; HAMMERSMITH HOSP,MRC,CYCLOTRON UNIT,LONDON W12 0HS,ENGLAND	Imperial College London; Imperial College London								ARAUJO LI, 1991, CIRCULATION, V83, P875, DOI 10.1161/01.CIR.83.3.875; ARCHIE JP, 1978, CARDIOVASC RES, V12, P255, DOI 10.1093/cvr/12.4.255; BEANLANDS RSB, 1992, CIRCULATION, V86, P184; BRAUNWALD E, 1971, AM J CARDIOL, V27, P416, DOI 10.1016/0002-9149(71)90439-5; COLE JS, 1976, CATHET CARDIOVASC DI, V2, P1085; COX DA, 1989, CIRCULATION, V80, P458, DOI 10.1161/01.CIR.80.3.458; CREA F, 1993, AM HEART J, V125, P1547, DOI 10.1016/0002-8703(93)90739-V; DOMENECH RJ, 1978, CARDIOVASC RES, V12, P639, DOI 10.1093/cvr/12.11.639; DREXLER H, 1991, LANCET, V338, P1546, DOI 10.1016/0140-6736(91)92372-9; DREXLER H, 1992, CIRCULATION, V86, P255, DOI 10.1161/01.CIR.86.1.255; GODFREY K, 1985, NEW ENGL J MED, V313, P1450, DOI 10.1056/NEJM198512053132305; HACKETT D, 1987, NEW ENGL J MED, V317, P1055, DOI 10.1056/NEJM198710223171704; IIDA H, 1988, CIRCULATION, V78, P1078; IIDA H, 1988, CIRCULATION, V78, P1048; JAARSMA W, 1986, AM J CARDIOL, V58, P394, DOI 10.1016/0002-9149(86)90002-0; JEREMY RW, 1990, J AM COLL CARDIOL, V16, P695, DOI 10.1016/0735-1097(90)90362-S; KARAM R, 1990, CIRCULATION, V81, P238, DOI 10.1161/01.CIR.81.1.238; KARLSBERG RP, 1981, AM HEART J, V102, P24, DOI 10.1016/0002-8703(81)90408-7; KLOCKE FJ, 1987, CIRCULATION, V76, P1183, DOI 10.1161/01.CIR.76.6.1183; KLONER RA, 1974, J CLIN INVEST, V54, P1496, DOI 10.1172/JCI107898; KUO L, 1992, CIRC RES, V70, P465, DOI 10.1161/01.RES.70.3.465; MCALPINE HM, 1988, BRIT HEART J, V60, P117; MCFADDEN EP, 1991, NEW ENGL J MED, V324, P648, DOI 10.1056/NEJM199103073241002; MCKAY RG, 1986, CIRCULATION, V74, P693, DOI 10.1161/01.CIR.74.4.693; MCLENACHAN JM, 1991, CIRCULATION, V84, P1273, DOI 10.1161/01.CIR.84.3.1273; MINISI AJ, 1991, CIRCULATION, V84, P357, DOI 10.1161/01.CIR.84.1.357; NACCARELLA FF, 1984, AM J CARDIOL, V54, P869, DOI 10.1016/S0002-9149(84)80223-4; REIBER JHC, 1985, CIRCULATION, V71, P280, DOI 10.1161/01.CIR.71.2.280; SAMBUCETI G, 1993, AM J CARDIOL, V72, P538, DOI 10.1016/0002-9149(93)90348-G; SCHOFER J, 1985, J AM COLL CARDIOL, V5, P593, DOI 10.1016/S0735-1097(85)80381-8; SELLKE FW, 1990, CIRCULATION, V81, P1586, DOI 10.1161/01.CIR.81.5.1586; SERRUYS PW, 1986, J AM COLL CARDIOL, V7, P729, DOI 10.1016/S0735-1097(86)80330-8; SLAGER CJ, 1979, COMPUT CARDIOL, V6, P347; SPINKS TJ, 1988, IEEE T NUCL SCI, V35, P721, DOI 10.1109/23.12819; UREN NG, 1993, J AM COLL CARDIOL, V22, P650, DOI 10.1016/0735-1097(93)90172-W; WEISMAN HF, 1988, CIRCULATION, V78, P186, DOI 10.1161/01.CIR.78.1.186; YAMAMOTO Y, 1992, CIRCULATION, V86, P167, DOI 10.1161/01.CIR.86.1.167; ZEIHER AM, 1991, CIRCULATION, V83, P391, DOI 10.1161/01.CIR.83.2.391; 1985, NEW ENGL J MED, V312, P932	39	315	325	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 28	1994	331	4					222	227		10.1056/NEJM199407283310402	http://dx.doi.org/10.1056/NEJM199407283310402			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY335	7832835				2022-12-28	WOS:A1994NY33500002
J	DIXON, J; DINWOODIE, M; HODSON, D; DODD, S; POLTORAK, T; GARRETT, C; RICE, P; DONCASTER, I; WILLIAMS, M				DIXON, J; DINWOODIE, M; HODSON, D; DODD, S; POLTORAK, T; GARRETT, C; RICE, P; DONCASTER, I; WILLIAMS, M			DISTRIBUTION OF NHS FUNDS BETWEEN FUNDHOLDING AND NON-FUNDHOLDING PRACTICES	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To estimate the amount spent on specific hospital care by health agencies in 1993-4 and compare it with the resources allocated to patients registered with fundholding practices for the same type of care. To investigate whether fundholding practices and health agencies pay different amounts for inpatient care. Design-Examination of hospital episode statisties, 1991 census data, and family health services authority and health agency records. Setting-Health agencies and fundholding practices in the former North West Thames Regional Health Authority. Main outcome measures-Amount per capita allocated to inpatient and outpatient care for patients registered with fundholding and non-fundholding practices. Average specialty cost per finished consultant episode for health agencies and fundholding practices. Results-The ratio of per capita funding for patients in non-fundholding practices to those in fundholding practices ranged from 59% to 87% for inpatient and day case care and from 36% to 106% for outpatient care. Average specialty costs per episode were similar for fundholding practices and health agencies. Conclusions-Fundholding practices seem to have been funded more generously than non-fundholding practices in North West Thames.	KINGS HLTH CARE NHS TRUST,FINANCIAL SERV,LONDON SE5 9RS,ENGLAND	King's Health Partners	DIXON, J (corresponding author), N THAMES W REG HLTH AUTHOR,LONDON W2 3QR,ENGLAND.							DAY P, 1991, BRIT MED J, V303, P168, DOI 10.1136/bmj.303.6795.168; DIXON J, 1994, BRIT MED J, V308, P772, DOI 10.1136/bmj.308.6931.772; REID GS, 1991, BRIT MED J, V303, P447, DOI 10.1136/bmj.303.6800.447; 1993, EFFECT CAPITATION SH; IN PRESS FAIRER FUND; 1993, POPULATION TRENDS, V71, P22; 1994, COPORATE INFORMATION; 1994, GP FUNDHOLDER BUDGET	8	29	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 2	1994	309	6946					30	34		10.1136/bmj.309.6946.30	http://dx.doi.org/10.1136/bmj.309.6946.30			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV891	7832840	Green Published			2022-12-28	WOS:A1994NV89100023
J	GOLDBERG, MA; MARMOR, TR; WHITE, J				GOLDBERG, MA; MARMOR, TR; WHITE, J			THE RELATION BETWEEN UNIVERSAL HEALTH-INSURANCE AND COST CONTROL	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							UNITED-STATES; CARE; SURGERY; CANADA		BROOKINGS INST, WASHINGTON, DC 20036 USA	Brookings Institution	GOLDBERG, MA (corresponding author), YALE UNIV, NEW HAVEN, CT 06520 USA.							Ellwood P M, 1992, Health Econ, V1, P149, DOI 10.1002/hec.4730010303; ENTHOVEN AC, 1990, OECD SOCIAL POLICY S, V7, P57; EVANS RG, 1991, ANNU REV PUBL HEALTH, V12, P481, DOI 10.1146/annurev.pu.12.050191.002405; FORGET MJ, IN PRESS HLTH CARE R; FUCHS V, 1993, FUTURE HLTH POLICY; GLASER WA, 1987, PAYING HOSPITAL ORG; GLASER WA, 1994, J HLTH POLIT POLICY, V19; GRUBER J, 1992, 4190 NAT BUR EC RES; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; KELLERMANN AL, 1994, NEW ENGL J MED, V330, P1426; Klerman L V, 1992, FUTURE CHILD, V2, P171; LOMAS J, 1992, 9217 MCMAST U CTR HL; MARMOR TR, 1993, AM REV CANADIAN STUD, V23, P47; NADEL MV, 1991, GAOHRD91114 PUBL; REDELMEIER DA, 1993, NEW ENGL J MED, V328, P772, DOI 10.1056/NEJM199303183281107; RYLL A, 1993, GAMES HIERARCHIES NE; SALTMAN RB, 1994, IMPLEMENTING PLANNED; SCHROEDER SA, 1993, DOMESTIC AFFAIRS WIN, P105; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P785, DOI 10.1001/jama.257.6.785; STODDARD JJ, 1994, NEW ENGL J MED, V330, P1421, DOI 10.1056/NEJM199405193302006; SWARTZ K, 1994, JAMA-J AM MED ASSOC, V271, P64; WENNBERG J, 1982, SCI AM, V246, P120, DOI 10.1038/scientificamerican0482-120; White J, 1994, Brookings Rev, V12, P6; WHITE J, 1993, HEALTH AFFAIR, V12, P44, DOI 10.1377/hlthaff.12.3.44; WHITE J, 1993, DOMESTIC AFFAIRS WIN, P195; WINSLOW CM, 1988, JAMA-J AM MED ASSOC, V260, P505, DOI 10.1001/jama.260.4.505; YATES J, 1987, WHY ARE WE WAITING; 1994, FEE UPDATE MED VOLUM; 1994, EFFECTS MANAGED CARE; 1993, HLTH DATA ECOSANTE 1; 1994, EPRI145 EMPL BEN RES; 1994, 1994 PHYS PAYM REV C; 1994, J HHLTH POLIT POLICY, V19, P499	33	5	5	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 16	1995	332	11					742	744		10.1056/NEJM199503163321111	http://dx.doi.org/10.1056/NEJM199503163321111			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL788	7854385				2022-12-28	WOS:A1995QL78800011
J	CEBALLOS, PI; RUIZMALDONADO, R; MIHM, MC				CEBALLOS, PI; RUIZMALDONADO, R; MIHM, MC			CURRENT CONCEPTS - MELANOMA IN CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							METASTATIC MALIGNANT-MELANOMA; CONGENITAL NEVOCELLULAR NEVUS; DYSPLASTIC NEVI; MARROW TRANSPLANTATION; PREPUBERTAL CHILDREN; CUTANEOUS MELANOMA; REFRACTORY CANCER; PRONE FAMILIES; HIGH-RISK; CHILDHOOD		ALBANY MED COLL,DEPT DERMATOL & DERMATOPATHOL,ALBANY,NY 12208; NYU,MED CTR,DEPT DERMATOL,DERMATOPATHOL SECT,NEW YORK,NY; NATL INST PEDIAT,MEXICO CITY,DF,MEXICO	Albany Medical College; New York University								ALLCUTT D, 1993, NEUROSURGERY, V32, P721, DOI 10.1227/00006123-199305000-00004; ARONSSON S, 1963, ACTA PAEDIATR, V52, P123; BAAS PC, 1989, CANCER, V63, P199, DOI 10.1002/1097-0142(19890101)63:1<199::AID-CNCR2820630132>3.0.CO;2-C; BARKER JNWN, 1988, CLIN EXP DERMATOL, V13, P123, DOI 10.1111/j.1365-2230.1988.tb00676.x; BODDIE AW, 1987, CANCER, V60, P1720, DOI 10.1002/1097-0142(19871015)60:8<1720::AID-CNCR2820600805>3.0.CO;2-H; BODDIE AW, 1978, SOUTHERN MED J, V71, P1074, DOI 10.1097/00007611-197809000-00009; BRODSKY I, 1965, CANCER, V18, P1048, DOI 10.1002/1097-0142(196508)18:8<1048::AID-CNCR2820180817>3.0.CO;2-V; CASSO EM, 1992, J AM ACAD DERMATOL, V27, P901, DOI 10.1016/0190-9622(92)70286-O; CAVELL B, 1963, ACTA PAEDIATR S, V146, P37; CLARK WH, 1978, ARCH DERMATOL, V114, P732, DOI 10.1001/archderm.114.5.732; DARGEON HW, 1950, CANCER, V3, P299, DOI 10.1002/1097-0142(1950)3:2<299::AID-CNCR2820030211>3.0.CO;2-#; DUVIC M, 1989, ARCH DERMATOL, V125, P397, DOI 10.1001/archderm.125.3.397; FALKSON CI, 1991, J CLIN ONCOL, V9, P1403, DOI 10.1200/JCO.1991.9.8.1403; FISHER SR, 1988, LARYNGOSCOPE, V98, P184; FREEDMAN WL, 1960, OBSTET GYNECOL, V16, P550; GARI LM, 1988, PEDIATR DERMATOL, V5, P151, DOI 10.1111/j.1525-1470.1988.tb01161.x; GOLDENHERSH MA, 1988, J AM ACAD DERMATOL, V19, P712, DOI 10.1016/S0190-9622(88)70227-3; GREENE MH, 1985, ANN INTERN MED, V102, P458, DOI 10.7326/0003-4819-102-4-458; GREENE MH, 1984, HOSP PRACT, V19, P91; GREENE MH, 1984, HOSP  PRACT, V19, P107; HAYES FA, 1984, J CLIN ONCOL, V2, P1229, DOI 10.1200/JCO.1984.2.11.1229; HO VC, 1990, J AM ACAD DERMATOL, V22, P159, DOI 10.1016/0190-9622(90)70019-E; HOLMAN CDJ, 1984, JNCI-J NATL CANCER I, V72, P257; ISHII N, 1991, BRIT J DERMATOL, V124, P492, DOI 10.1111/j.1365-2133.1991.tb00633.x; KAPLAN EN, 1974, PLAST RECONSTR SURG, V53, P421, DOI 10.1097/00006534-197404000-00007; KIRKWOOD JM, 1985, ANN INTERN MED, V103, P32, DOI 10.7326/0003-4819-103-1-32; KOPF AW, 1979, J AM ACAD DERMATOL, V1, P123, DOI 10.1016/S0190-9622(79)70009-0; KRAEMER KH, 1987, ARCH DERMATOL, V123, P241, DOI 10.1001/archderm.123.2.241; LAZARUS HM, 1983, J CLIN ONCOL, V1, P359, DOI 10.1200/JCO.1983.1.6.359; Lerman R I, 1970, Cancer, V25, P436, DOI 10.1002/1097-0142(197002)25:2<436::AID-CNCR2820250223>3.0.CO;2-I; MARK GJ, 1973, HUM PATHOL, V4, P395, DOI 10.1016/S0046-8177(73)80101-7; MCCLAY EF, 1992, INT J CANCER, V50, P553; MEHREGAN AH, 1993, CANCER-AM CANCER SOC, V71, P4096, DOI 10.1002/1097-0142(19930615)71:12<4096::AID-CNCR2820711248>3.0.CO;2-Z; MELNIK MK, 1986, AM SURGEON, V52, P142; MOSS ALH, 1986, BRIT J PLAST SURG, V39, P537, DOI 10.1016/0007-1226(86)90131-1; PHILLIPS GL, 1983, CANCER, V52, P1792, DOI 10.1002/1097-0142(19831115)52:10<1792::AID-CNCR2820521006>3.0.CO;2-D; PRATT CB, 1981, CANCER, V47, P392, DOI 10.1002/1097-0142(19810115)47:2<392::AID-CNCR2820470229>3.0.CO;2-J; RAO BN, 1990, J PEDIATR SURG, V25, P198, DOI 10.1016/0022-3468(90)90402-U; REED WB, 1965, ARCH DERMATOL, V91, P100, DOI 10.1001/archderm.1965.01600080008002; REINTGEN DS, 1989, SURG GYNECOL OBSTET, V168, P249; REYNOLDS AG, 1955, OBSTET GYNECOL, V6, P205; RHODES AR, 1981, PLAST RECONSTR SURG, V67, P782, DOI 10.1097/00006534-198106000-00012; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; ROSENBERG SA, 1991, CANCER RES, V51, pS5074; ROSENBERG SA, 1988, IMPORTANT ADV ONCOLO, V4, P217; RUIZMALDONADO R, 1992, J PEDIATR-US, V120, P906, DOI 10.1016/S0022-3476(05)81958-4; SCHNEIDERMAN H, 1987, CANCER, V60, P1371, DOI 10.1002/1097-0142(19870915)60:6<1371::AID-CNCR2820600635>3.0.CO;2-0; SKOVJENSEN T, 1966, CANCER-AM CANCER SOC, V19, P620, DOI 10.1002/1097-0142(196605)19:5<620::AID-CNCR2820190504>3.0.CO;2-L; SMITH KJ, 1989, AM J SURG PATHOL, V13, P931, DOI 10.1097/00000478-198911000-00003; SPITZ S, 1948, AM J PATHOL, V24, P591; STROMBERG BV, 1979, J PEDIATR SURG, V14, P465, DOI 10.1016/S0022-3468(79)80017-2; TATE PS, 1993, J PEDIATR SURG, V28, P217, DOI 10.1016/S0022-3468(05)80279-9; TROZAK DJ, 1975, PEDIATRICS, V55, P191; TRUAX KF, 1953, ANN SURG, V137, P255, DOI 10.1097/00000658-195302000-00019; TUCKER MA, 1983, J PEDIATR-US, V103, P65, DOI 10.1016/S0022-3476(83)80777-X; VERONESI U, 1991, ARCH SURG-CHICAGO, V126, P438; WEST WH, 1987, NEW ENGL J MED, V316, P898, DOI 10.1056/NEJM198704093161502; WORKMAN ML, 1992, ANN PLAS SURG, V28, P381, DOI 10.1097/00000637-199204000-00016	58	126	128	0	45	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 9	1995	332	10					656	662		10.1056/NEJM199503093321007	http://dx.doi.org/10.1056/NEJM199503093321007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK066	7845431				2022-12-28	WOS:A1995QK06600007
J	ISENBERG, SJ; APT, L; WOOD, M				ISENBERG, SJ; APT, L; WOOD, M			A CONTROLLED TRIAL OF POVIDONE-IODINE AS PROPHYLAXIS AGAINST OPHTHALMIA NEONATORUM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SILVER-NITRATE; NEISSERIA-GONORRHOEAE; OCULAR PROPHYLAXIS; CONJUNCTIVITIS; ERYTHROMYCIN; TETRACYCLINE; EPIDEMIOLOGY; RESISTANCE; PREVENTION; GONOCOCCI	Background. Neonatal conjunctivitis (ophthalmia neonatorum) continues to cause blindness, because the agents used prophylactically to prevent this condition are not completely effective and are not widely available in many parts of the world. Povidone-iodine ophthalmic solution is an effective antibacterial agent with broad antibacterial and antiviral activity to which no bacteria are known to be resistant, and it is far less expensive and less toxic than the agents currently used to prevent neonatal conjunctivitis. Methods. We conducted a masked, prospective trial involving 3117 infants born over a period of 30 months in a hospital in Kenya. Shortly after birth each infant received a 2.5 percent solution of povidone-iodine (n = 1076), a 1 percent solution of silver nitrate (n = 929), or 0.5 percent erythromycin ointment (n = 1112) in both eyes. Randomization was achieved by rotating the three medications after each was used for a week. Results. Of the neonates treated with povidone-iodine, 13.1 percent had infectious conjunctivitis, as compared with 17.5 percent of those treated with silver nitrate (P<0.001) and 15.2 percent of those treated with erythromycin (P=0.01). Povidone-iodine was more effective against Chlamydia trachomatis than was silver nitrate (P<0.001) or erythromycin (P=0.008), There were 104 cases of noninfectious conjunctivitis (9.7 percent) in the povidone-iodine group, as compared with 129 in the silver nitrate group (13.9 percent, P<0.001) and 148 in the erythromycin group (13.3 percent, P=0.004). Many cases of noninfectious conjunctivitis were probably due to a toxic reaction to the treatment itself. The incidence of Neisseria gonorrhoeae and Staphylococcus aureus infections was similar in the three groups. Conclusions. A 2.5 percent ophthalmic solution of povidone-iodine as prophylaxis against ophthalmia neonatorum is more effective than treatment with silver nitrate or erythromycin, and it is less toxic and costs less.	UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,SCH MED,JULES STEIN EYE INST,TORRANCE,CA; PRESBYTERIAN CHURCH HOSP,DEPT EYE,KIKUYU,KENYA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	ISENBERG, SJ (corresponding author), UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,SCH MED,JULES STEIN EYE INST,LOS ANGELES,CA 90024, USA.							APT L, 1984, ARCH OPHTHALMOL-CHIC, V102, P728, DOI 10.1001/archopht.1984.01040030584025; ARVIN AM, 1986, NEW ENGL J MED, V315, P796, DOI 10.1056/NEJM198609253151303; BELL TA, 1993, PEDIATRICS, V92, P755; BENEVENTO WJ, 1990, AM J OPHTHALMOL, V109, P329, DOI 10.1016/S0002-9394(14)74560-X; BLACKPAYNE C, 1989, PEDIATR INFECT DIS J, V8, P491, DOI 10.1097/00006454-198908000-00003; BUISMAN NJF, 1988, DOC OPHTHALMOL, V70, P257, DOI 10.1007/BF00154463; BUTTERFIELD PM, 1978, AM J DIS CHILD, V132, P426, DOI 10.1001/archpedi.1978.02120290098023; CHEN JY, 1992, PEDIATR INFECT DIS J, V11, P1026, DOI 10.1097/00006454-199211120-00007; CHRISTIAN JR, 1960, J PEDIATR-US, V57, P55, DOI 10.1016/S0022-3476(60)80210-7; Crede CSF., 1881, ARCH GYNAEKOL, V18, P367, DOI [10.1007/BF01929523, DOI 10.1007/BF01929523]; FROST E, 1987, T ROY SOC TROP MED H, V81, P378, DOI 10.1016/0035-9203(87)90141-6; HAMMERSCHLAG MR, 1989, NEW ENGL J MED, V320, P769, DOI 10.1056/NEJM198903233201204; HARBISON MA, 1989, J ACQ IMMUN DEF SYND, V2, P16; HEDBERG K, 1990, PEDIATR INFECT DIS J, V9, P268, DOI 10.1097/00006454-199004000-00009; HOBSON D, 1983, BRIT MED BULL, V39, P128, DOI 10.1093/oxfordjournals.bmb.a071803; HOUANG ET, 1976, J CLIN PATHOL, V29, P752, DOI 10.1136/jcp.29.8.752; IJSSELMUIDEN CB, 1992, NEW ENGL J MED, V326, P830, DOI 10.1056/NEJM199203193261212; ISENBERG ST, 1994, AM J OPHTHALMOL, V118, P701, DOI 10.1016/S0002-9394(14)72547-4; ISON CA, 1988, LANCET, V1, P651; KNAPP JS, 1987, J INFECT DIS, V155, P819, DOI 10.1093/infdis/155.4.819; KROHN MA, 1993, AM J EPIDEMIOL, V138, P326, DOI 10.1093/oxfordjournals.aje.a116862; LAGA M, 1988, NEW ENGL J MED, V318, P653, DOI 10.1056/NEJM198803173181101; LAGA M, 1986, LANCET, V2, P1145; LAGA M, 1990, B WORLD HEALTH ORGAN, V68, P690; LAGA M, 1989, B WORLD HEALTH ORGAN, V67, P471; MOONEY BR, 1984, INFECT CONT HOSP EP, V5, P138, DOI 10.1017/S0195941700060008; MORDHORST CH, 1971, AM J OPHTHALMOL, V71, P861, DOI 10.1016/0002-9394(71)90256-X; NAHMIAS A J, 1976, Survey of Ophthalmology, V21, P100, DOI 10.1016/0039-6257(76)90086-2; SANDSTROM I, 1978, ACTA PAEDIATR SCAND, V76, P221; SANDSTROM I, 1986, ACTA PAEDIATR SC   S, V330, P1; SCHWACZ SK, 1990, JAMA-J AM MED ASSOC, V264, P1414; SPEAKER MG, 1991, OPHTHALMOLOGY, V98, P1769; VANKLINGEREN B, 1989, LANCET, V2, P1278; WHITCHER JP, 1990, INT OPHTHALMOL CLIN, V30, P39, DOI 10.1097/00004397-199030010-00019; ZANONI D, 1992, CLIN PEDIATR, V31, P295, DOI 10.1177/000992289203100506; [No title captured]	36	91	96	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 2	1995	332	9					562	566		10.1056/NEJM199503023320903	http://dx.doi.org/10.1056/NEJM199503023320903			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ090	7838190				2022-12-28	WOS:A1995QJ09000003
J	BLAKELEY, DD; ODDONE, EZ; HASSELBLAD, V; SIMEL, DL; MATCHAR, DB				BLAKELEY, DD; ODDONE, EZ; HASSELBLAD, V; SIMEL, DL; MATCHAR, DB			NONINVASIVE CAROTID-ARTERY TESTING - A METAANALYTIC REVIEW	ANNALS OF INTERNAL MEDICINE			English	Article							DIGITAL SUBTRACTION ANGIOGRAPHY; MAGNETIC-RESONANCE ANGIOGRAPHY; DOPPLER SPECTRUM ANALYSIS; CONTINUOUS WAVE DOPPLER; FLIGHT MR ANGIOGRAPHY; CONVENTIONAL ANGIOGRAPHY; OCCLUSIVE DISEASE; OCULAR PNEUMOPLETHYSMOGRAPHY; CEREBROVASCULAR-DISEASE; DUPLEX ULTRASONOGRAPHY	Purpose: To compare the operating characteristics of six noninvasive tests for carotid artery stenosis. Data Sources: A structured search was done using MEDLINE, reference lists from selected articles, and bibliographies from neurology textbooks that focused on the diagnosis of carotid artery stenosis in humans. The search yielded 568 articles. Study Selection: Articles were selected if the noninvasive test results they presented used carotid angiography as the reference standard for comparison, if carotid artery occlusion was considered as a separate category, and if contingency tables could be constructed. Data Extraction: At least two physicians reviewed all selected articles. Items abstracted included patient demographics, study design, sites of patient enrollment, whether the interpretation of test outcomes was blinded, and specific results. Sensitivity, specificity, receiver operating characteristic (ROC) curves, and summary measures of effectiveness for each test were calculated. Results: Carotid duplex ultrasonography, carotid Doppler ultrasonography, and magnetic resonance angiography have sensitivities between 0.82 and 0.86, specificities at 0.98, and test-effectiveness measures at or exceeding 3.0 when predicting 100% occlusion. For carotid stenosis of 70% or more, these three tests and supraorbital Doppler ultrasonography all have sensitivities of 0.83 to 0.86, specificities of 0.89 to 0.94, test-effectiveness measures approaching 3.0, and composite ROC areas of 0.91 to 0.92. Limiting analysis to studies that enrolled consecutive patients and those in which interpretation of the noninvasive tests was independent of the angiograms did not substantially change our results. Conclusions: Carotid duplex ultrasonography, carotid Doppler ultrasonography, and magnetic resonance angiography are all similarly successful at predicting 100% carotid artery occlusion and 70% stenosis. Other factors, such as cost, availability, and local experience may influence the decision to use these tests to screen for carotid artery atherosclerosis that may respond to surgery.	DUKE UNIV, CTR HLTH POLICY RES & EDUC, DURHAM, NC 27708 USA; VET AFFAIRS MED CTR, HLTH SERV RES 558-152, DURHAM, NC 27705 USA	Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Matchar, David/M-3951-2019	Matchar, David/0000-0003-3020-2108	PHS HHS [282-91-0028] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ACKROYD N, 1984, AUST NZ J SURG, V54, P509, DOI 10.1111/j.1445-2197.1984.tb05438.x; ANDERSON CM, 1992, AM J NEURORADIOL, V13, P989; BANDYK DF, 1985, ARCH SURG-CHICAGO, V120, P306; BARNES RW, 1977, AM J SURG, V134, P183, DOI 10.1016/0002-9610(77)90339-7; BARNES RW, 1982, ARCH SURG-CHICAGO, V117, P52, DOI 10.1001/archsurg.1982.01380250034008; BARRY R, 1987, S AFR MED J, V72, P851; BEGG CB, 1983, BIOMETRICS, V39, P207, DOI 10.2307/2530820; BEGG CB, 1987, STAT MED, V6, P411, DOI 10.1002/sim.4780060402; BENDICK PJ, 1983, MED INSTRUM, V17, P220; BONE G, 1988, EUR NEUROL, V28, P73, DOI 10.1159/000116233; CAES F, 1987, ANGIOLOGY, V38, P799, DOI 10.1177/000331978703801101; CASTALDO JE, 1989, ARCH NEUROL-CHICAGO, V46, P518, DOI 10.1001/archneur.1989.00520410052023; Centor R M, 1985, Med Decis Making, V5, P139, DOI 10.1177/0272989X8500500203; CHAMBERS J, 1988, INT J CARDIOL, V18, P427, DOI 10.1016/0167-5273(88)90061-7; CHIESA R, 1993, EUR J VASCULAR SURG, V7, P171, DOI 10.1016/S0950-821X(05)80758-3; DALTON JG, 1983, CAN MED ASSOC J, V129, P1184; Eddy DM., 1992, META ANAL CONFIDENCE; EIKELBOOM BC, 1983, SURGERY, V94, P821; FELL G, 1981, AM HEART J, V102, P221, DOI 10.1016/S0002-8703(81)80013-0; FEUSSNER JR, 1988, ANN INTERN MED, V109, P805, DOI 10.7326/0003-4819-109-10-805; FODE NC, 1986, STROKE, V17, P370, DOI 10.1161/01.STR.17.3.370; FUJITANI RM, 1992, J VASC SURG, V16, P459, DOI 10.1016/0741-5214(92)90382-I; FURUYA Y, 1992, NEURORADIOLOGY, V35, P42, DOI 10.1007/BF00588277; GARTH KE, 1983, RADIOLOGY, V147, P823, DOI 10.1148/radiology.147.3.6844621; GLOVER JL, 1984, ARCH SURG-CHICAGO, V119, P664; GOLDSTEIN LB, 1994, STROKE, V25, P1116, DOI 10.1161/01.STR.25.6.1116; HAMES TK, 1985, CARDIOVASC RES, V19, P631, DOI 10.1093/cvr/19.10.631; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HARWARD TRS, 1986, ANN SURG, V204, P32, DOI 10.1097/00000658-198607000-00004; HASSELBLAD V, 1995, PSYCHOL BULL, V117, P167, DOI 10.1037/0033-2909.117.1.167; HEISERMAN JE, 1992, RADIOLOGY, V182, P761, DOI 10.1148/radiology.182.3.1535891; HENNERICI M, 1984, J CLIN ULTRASOUND, V12, P155, DOI 10.1002/jcu.1870120307; HERRMANN JB, 1979, ARCH SURG-CHICAGO, V114, P1049; HUSTON J, 1993, RADIOLOGY, V186, P339, DOI 10.1148/radiology.186.2.8421731; JOHNSON NL, 1969, DISCRETE DISTRIBUTIO, P58; JOHNSTON KW, 1981, J CLIN ULTRASOUND, V9, P443, DOI 10.1002/jcu.1870090808; KARDAUN JWPF, 1990, METHOD INFORM MED, V29, P12; KENAGY JW, 1985, J VASC SURG, V2, P591, DOI 10.1067/mva.1985.avs0020591; KIDO DK, 1991, ARCH NEUROL-CHICAGO, V48, P484, DOI 10.1001/archneur.1991.00530170044019; LANGLOIS Y, 1983, ULTRASOUND MED BIOL, V9, P51, DOI 10.1016/0301-5629(83)90109-6; LASTER RE, 1993, AM J NEURORADIOL, V14, P681; LEAHY A, 1987, IRISH MED J, V80, P289; LITT AW, 1991, AM J NEURORADIOL, V12, P149; LO LY, 1986, STROKE, V17, P65, DOI 10.1161/01.STR.17.1.65; LONDREY GL, 1991, J VASC SURG, V13, P659; MARTIN KD, 1990, J VASC SURG, V11, P235, DOI 10.1067/mva.1990.16717; MASARYK AM, 1991, RADIOLOGY, V179, P797, DOI 10.1148/radiology.179.3.2027995; MAYBERG MR, 1991, JAMA-J AM MED ASSOC, V266, P3289, DOI 10.1001/jama.266.23.3289; MCCRORY DC, 1993, STROKE, V24, P1285, DOI 10.1161/01.STR.24.9.1285; MENDEL HJ, 1987, ANN RADIOL, V30, P115; MOSES LE, 1993, STAT MED, V12, P1293, DOI 10.1002/sim.4780121203; NORRVING B, 1981, ACTA NEUROL SCAND, V64, P241; PAVONE P, 1992, RADIOLOGY, V184, P401, DOI 10.1148/radiology.184.2.1620836; POINDEXTER JM, 1991, J CARDIOVASC SURG, V32, P64; POLAK JF, 1992, RADIOLOGY, V182, P35, DOI 10.1148/radiology.182.1.1727306; RATLIFF DA, 1985, ANGIOLOGY, V36, P333, DOI 10.1177/000331978503600601; RICOTTA JJ, 1987, J VASC SURG, V6, P512, DOI 10.1067/mva.1987.avs0060512; RILES TS, 1992, STROKE, V23, P341, DOI 10.1161/01.STR.23.3.341; Roussel L, 1988, J Belge Radiol, V71, P589; RUSH M, 1985, J CLIN ULTRASOUND, V13, P325, DOI 10.1002/jcu.1870130505; RUSSELL D, 1984, J NEUROL NEUROSUR PS, V47, P1307, DOI 10.1136/jnnp.47.12.1307; RUSSELL JB, 1982, BRUIT, V6, P23; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P51; SILLESEN H, 1988, STROKE, V19, P846, DOI 10.1161/01.STR.19.7.846; SITZER M, 1993, STROKE, V24, P1513, DOI 10.1161/01.STR.24.10.1513; SPARTERA C, 1993, J CARDIOVASC SURG, V34, P209; STEINKE W, 1990, AM J NEURORADIOL, V11, P259; STRIK F, 1988, CLIN NEUROL NEUROSUR, V90, P227, DOI 10.1016/0303-8467(88)90026-1; SULLIVAN ED, 1983, AM J SURG, V146, P577, DOI 10.1016/0002-9610(83)90291-X; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; TORVALDSEN S, 1985, MED J AUSTRALIA, V142, P542, DOI 10.5694/j.1326-5377.1985.tb113488.x; TURNIPSEED WD, 1993, J VASC SURG, V17, P832, DOI 10.1016/0741-5214(93)90032-H; VANMERODE T, 1989, STROKE, V20, P1336, DOI 10.1161/01.STR.20.10.1336; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WARLOW CP, 1980, J NEUROL SCI, V45, P135, DOI 10.1016/S0022-510X(80)80015-3; WASSERMAN DH, 1983, ARCH SURG-CHICAGO, V118, P1161; WESBEY GE, 1992, J VASC SURG, V16, P619, DOI 10.1016/0741-5214(92)90169-9; WISE G, 1979, NEUROLOGY, V29, P34, DOI 10.1212/WNL.29.1.34; WOLF PA, 1992, STROKE PATHOPHYSIOLO, P19; WOLVERSON MK, 1983, AM J ROENTGENOL, V140, P355, DOI 10.2214/ajr.140.2.355; ZANETTE E, 1987, ACTA NEUROCHIR, V84, P43, DOI 10.1007/BF01456350; ZBORNIKOVA V, 1982, ACTA NEUROL SCAND, V65, P335, DOI 10.1111/j.1600-0404.1982.tb03090.x; ZHORNIKOVA V, 1985, CLIN PHYSL, V5, P257; 1992, 1993 HEART STROKE FA	84	165	166	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1995	122	5					360	367		10.7326/0003-4819-122-5-199503010-00007	http://dx.doi.org/10.7326/0003-4819-122-5-199503010-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ085	7847648				2022-12-28	WOS:A1995QJ08500007
J	IRWIG, L; GLASZIOU, P; MARCH, L				IRWIG, L; GLASZIOU, P; MARCH, L			ETHICS OF N-OF-1 TRIALS	LANCET			English	Editorial Material									UNIV QUEENSLAND,SCH MED,DEPT SOCIAL & PREVENT MED,ST LUCIA,QLD 4067,AUSTRALIA; KURINGGAI HOSP,NO SYDNEY AREA HLTH SERV,PUBL HLTH UNIT,HORNSBY,NSW,AUSTRALIA	University of Queensland	IRWIG, L (corresponding author), UNIV SYDNEY,DEPT PUBL HLTH,SYDNEY,NSW,AUSTRALIA.		Mahon, Jeff/G-3324-2011; Glasziou, Paul/A-7832-2008; Feagan, Brian G/M-4283-2015	Glasziou, Paul/0000-0001-7564-073X; 				BALESTRA DJ, 1994, JAMA-J AM MED ASSOC, V271, P1159, DOI 10.1001/jama.1994.03510390029018; GUYATT G, 1988, CAN MED ASSOC J, V139, P497; GUYATT GH, 1990, ANN INTERN MED, V112, P293, DOI 10.7326/0003-4819-112-4-293; LARSON EB, 1993, JAMA-J AM MED ASSOC, V270, P2708, DOI 10.1001/jama.270.22.2708; MARCH L, 1994, BRIT MED J, V309, P1041, DOI 10.1136/bmj.309.6961.1041	5	26	26	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 25	1995	345	8948					469	469		10.1016/S0140-6736(95)90578-2	http://dx.doi.org/10.1016/S0140-6736(95)90578-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7861872				2022-12-28	WOS:A1995QH92900005
J	ANDERSON, TJ; MEREDITH, IT; YEUNG, AC; FREI, B; SELWYN, AP; GANZ, P				ANDERSON, TJ; MEREDITH, IT; YEUNG, AC; FREI, B; SELWYN, AP; GANZ, P			THE EFFECT OF CHOLESTEROL-LOWERING AND ANTIOXIDANT THERAPY ON ENDOTHELIUM-DEPENDENT CORONARY VASOMOTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-DENSITY LIPOPROTEINS; ARTERY DISEASE; SERUM-CHOLESTEROL; RABBIT AORTA; RISK-FACTORS; RELAXATION; PROBUCOL; ATHEROSCLEROSIS; ACETYLCHOLINE; HYPERCHOLESTEROLEMIA	Background. Patients with coronary artery disease and abnormalities of serum lipid levels often have endothelial vasodilator dysfunction, which may contribute to ischemic cardiac events. Whether cholesterol-lowering or antioxidant therapy can restore endothelium-dependent coronary vasodilatation is unknown. Methods. We randomly assigned 49 patients (mean [+/-SD] serum cholesterol level, 209+/-33 mg per deciliter [5.40+/-0.85 mmol per liter]) to receive one of three treatments: an American Heart Association Step 1 diet (the diet group, 11 patients); lovastatin and cholestyramine (the low-density lipoprotein [LDL]-lowering group, 21 patients); or lovastatin and probucol (the LDL-lowering-antioxidant group, 17 patients). Endothelium-dependent coronary-artery vasomotion in response to an intracoronary infusion of acetylcholine (10(-8) to 10(-6) M) was assessed at base line and after one year of therapy. Vasoconstrictor responses to these doses of acetylcholine are considered to be abnormal. Results. Treatment resulted in significant reductions in LDL cholesterol levels of 41+/-22 percent in the LDL-lowering-antioxidant group and 38+/-20 percent in the LDL-lowering group (P<0.001 vs. the diet group). The maximal changes in coronary-artery diameter with acetylcholine at base line and at follow-up were -19 and -2 percent, respectively, in the LDL-lowering-antioxidant group, -15 and -6 percent in the LDL-lowering group, and -14 and -19 percent in the diet group (P<0.01 for the LDL-lowering-antioxidant group vs. the diet group; P=0.08 for the LDL-lowering group vs. the diet group). (The negative numbers indicate vasoconstriction.) Thus, the greatest improvement in the vasoconstrictor response was seen in the LDL-lowering-antioxidant group. Conclusions. The improvement in endothelium-dependent vasomotion with cholesterol-lowering and antioxidant therapy may have important implications for the activity of myocardial ischemia and may explain in part the reduced incidence of adverse coronary events that is known to result from cholesterol-lowering therapy.	BRIGHAM & WOMENS HOSP, DIV CARDIOVASC, BOSTON, MA 02115 USA; BOSTON UNIV, SCH MED, DEPT MED & BIOCHEM, BOSTON, MA 02118 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Brigham & Women's Hospital; Boston University; Harvard University; Harvard Medical School	ANDERSON, TJ (corresponding author), FOOTHILLS PROV GEN HOSP, DIV CARDIOVASC, 8TH FLOOR, 1403 29TH ST NW, CALGARY, AB T2N 2T9, CANADA.			Ganz, Peter/0000-0002-0437-8882	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038780, R29HL049954, K08HL002787] Funding Source: NIH RePORTER; NHLBI NIH HHS [R29 HL-49954-01, R01 HL-38780-05, 1K08 HL-02787] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENZULY KH, 1994, CIRCULATION, V90, P1585; BENZULY KH, 1994, CIRCULATION, V89, P1810, DOI 10.1161/01.CIR.89.4.1810; BROWN BG, 1993, CIRCULATION, V87, P1781, DOI 10.1161/01.CIR.87.6.1781; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GAGE JE, 1986, CIRCULATION, V73, P865, DOI 10.1161/01.CIR.73.5.865; GRAHAM A, 1993, FEBS LETT, V330, P181, DOI 10.1016/0014-5793(93)80269-Z; HARRISON DG, 1987, J CLIN INVEST, V80, P1808, DOI 10.1172/JCI113276; KANNEL WB, 1971, ANN INTERN MED, V74, P1, DOI 10.7326/0003-4819-74-1-1; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; LEUNG WH, 1993, LANCET, V341, P1496, DOI 10.1016/0140-6736(93)90634-S; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MANGIN EL, 1993, CIRC RES, V72, P161, DOI 10.1161/01.RES.72.1.161; MEREDITH IT, 1993, CIRCULATION, V87, P56; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; OSBORNE JA, 1989, J CLIN INVEST, V83, P465, DOI 10.1172/JCI113905; PARTHASARATHY S, 1986, J CLIN INVEST, V77, P641, DOI 10.1172/JCI112349; PEDERSEN TR, 1994, LANCET, V344, P1383; PLANE F, 1993, ATHEROSCLEROSIS, V103, P73, DOI 10.1016/0021-9150(93)90041-R; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SEILER C, 1993, CIRCULATION, V88, P2139, DOI 10.1161/01.CIR.88.5.2139; SIMON BC, 1993, J CARDIOVASC PHARM, V21, P893, DOI 10.1097/00005344-199306000-00007; SIMON BC, 1990, J CLIN INVEST, V86, P75, DOI 10.1172/JCI114718; STEINBERG D, 1991, CIRCULATION, V84, P1420, DOI 10.1161/01.CIR.84.3.1420; URIEN S, 1984, MOL PHARMACOL, V26, P322; VITA JA, 1990, CIRCULATION, V81, P491, DOI 10.1161/01.CIR.81.2.491; YEUNG AC, 1991, NEW ENGL J MED, V325, P1551, DOI 10.1056/NEJM199111283252205	29	976	1037	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 23	1995	332	8					488	493		10.1056/NEJM199502233320802	http://dx.doi.org/10.1056/NEJM199502233320802			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH288	7830729	Bronze			2022-12-28	WOS:A1995QH28800002
J	LEPAGE, T; COHEN, SM; DIAZBENJUMEA, FJ; PARKHURST, SM				LEPAGE, T; COHEN, SM; DIAZBENJUMEA, FJ; PARKHURST, SM			SIGNAL-TRANSDUCTION BY CAMP-DEPENDENT PROTEIN-KINASE-A IN DROSOPHILA LIMB PATTERNING	NATURE			English	Article							HEDGEHOG GENE; PATCHED GENE; POLARITY; TRANSCRIPTION; ORGANIZATION; EXPRESSION; DIRECTS; CELLS	INTERACTION between distinctly specified cells in adjacent compartments establishes organizing centres that control growth and specify cell fate in the developing limbs of Drosophila(1-5). Localized expression of the secreted Hedgehog protein (Hh) by cells in the posterior compartment(6-8) induces expression of the secreted signalling molecules decapentaplegic (dpp) or wingless (wg) in nearby anterior cells(2,3). wg and dpp in turn organize spatial pattern in the wing and leg imaginal discs(2,4,9). The Hh signal is thought to act by antagonizing the ability of the patched (ptc) gene product to repress log and dpp expression(10-14). Here we present evidence that removing activity of the gene encoding cyclic AMP-dependent protein kinase A (pka) is functionally equivalent to removing ptc activity or to providing cells with the Hh signal. These findings suggest that cyclic AMP-dependent protein kinase A is a component of the signal transduction pathway through which Hh and Ptc direct localized expression of dpp (or wg) and establish the compartment boundary organizer.	EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY; FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,A1-162,SEATTLE,WA 98104	European Molecular Biology Laboratory (EMBL); Fred Hutchinson Cancer Center			Cohen, Stephen M/G-9930-2011; Lepage, Thierry/V-4208-2019; Diaz-Benjumea, Fernando/K-7667-2014; Lepage, Thierry/AAF-8925-2019	Cohen, Stephen M/0000-0003-2858-9163; Lepage, Thierry/0000-0003-2889-5064; Diaz-Benjumea, Fernando/0000-0003-3007-2489; 				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; DEVREOTES PN, 1994, NEURON, V12, P235, DOI 10.1016/0896-6273(94)90267-4; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; FORBES AJ, 1993, DEVELOPMENT, P115; GRAU Y, 1987, DEV BIOL, V122, P186, DOI 10.1016/0012-1606(87)90344-7; HARTWELL L, 1994, NATURE, V371, P286, DOI 10.1038/371286a0; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; LANE ME, 1994, GENE DEV, V8, P2986, DOI 10.1101/gad.8.24.2986; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MOHLER J, 1992, DEVELOPMENT, V115, P957; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; RAFERTY LA, 1991, DEVELOPMENT, V113, P27; SCHUSKE K, 1994, DEV BIOL, V164, P300, DOI 10.1006/dbio.1994.1200; STRADLER CD, 1994, REV BIOCH, V63, P101; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TOROK T, 1993, GENETICS, V35, P71; Watson S., 1994, G PROTEIN LINKED REC; XU T, 1993, DEVELOPMENT, V117, P1223	29	151	159	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					711	715		10.1038/373711a0	http://dx.doi.org/10.1038/373711a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854456				2022-12-28	WOS:A1995QH92800058
J	ALBEROLAILA, J; FORBUSH, KA; SEGER, R; KREBS, EG; PERLMUTTER, RM				ALBEROLAILA, J; FORBUSH, KA; SEGER, R; KREBS, EG; PERLMUTTER, RM			SELECTIVE REQUIREMENT FOR MAP KINASE ACTIVATION IN THYMOCYTE DIFFERENTIATION	NATURE			English	Article							T-CELL ACTIVATION; EXPRESSION; INVIVO; MICE	ENGAGEMENT of the T-cell receptor (TCR) with cognate ligands provokes different outcomes depending on the developmental stage of the T cell and on the properties of the ligand. In immature thymocytes TCR stimulation may result in maturation (positive selection) or death (negative selection), whereas in mature T cells it may induce proliferation, death or unresponsiveness(1-5). To investigate the different signals involved in these processes, we have analysed the role of the MAP kinase (MAPK) cascade, which is required for growth-factor-stimulated replication and for differentiation in other cell types(6-9), by expressing a catalytically inactive form of MAPK kinase (MEK-1) in thymocytes, thereby blocking MAPK activation, We find that positive selection of these cells is inhibited but that negative selection and TCR-induced proliferation are unaffected. Our results indicate that the intracellular signals regulating lineage commitment in T cells parallel those in photoreceptor cell specification in Drosophila(10) and vulval cell differentiation in Caenorhabditis elegans(11), suggesting that general rules for cell-type specification could apply among all metazoans.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED MED GENET,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	ALBEROLAILA, J (corresponding author), UNIV WASHINGTON,DEPT IMMUNOL,SL-15,SEATTLE,WA 98195, USA.			alberola-ila, Jose/0000-0003-2439-553X				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGERTON M, 1990, INT IMMUNOL, V2, P501, DOI 10.1093/intimm/2.6.501; EISENMANN DM, 1994, CURR OPIN GENET DEV, V4, P508, DOI 10.1016/0959-437X(94)90065-B; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; SEGER R, 1994, J BIOL CHEM, V269, P25699; SEGER R, 1992, J BIOL CHEM, V267, P25628; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; SWAT W, 1992, EUR J IMMUNOL, V22, P2367, DOI 10.1002/eji.1830220928; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; VONBOEHMER H, 1991, J EXP MED, V174, P1001, DOI 10.1084/jem.174.5.1001; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383	29	360	362	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					620	623		10.1038/373620a0	http://dx.doi.org/10.1038/373620a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854419				2022-12-28	WOS:A1995QG99700056
J	JOLIET, V; DEMMA, M; PRYWES, R				JOLIET, V; DEMMA, M; PRYWES, R			INTERACTION WITH RAP74 SUBUNIT OF TFIIF IS REQUIRED FOR TRANSCRIPTIONAL ACTIVATION BY SERUM RESPONSE FACTOR	NATURE			English	Article							RNA POLYMERASE-II; TERNARY COMPLEX-FORMATION; INITIATION-FACTOR; DOMAIN; CDNA; SRF; DNA	A FEW general transcription factors, in particular TFIID and TFIIB, have been found to bind transcriptional activators(1). Here we show that the general transcription factor TFIIF is also a target for a transcriptional activator, namely serum response factor (SRF), which binds to the c-fos promoter. Using a yeast interaction assay, we find that SRF binds the RAP74 subunit of TFIIF and that SRF's transcriptional activation domain is the region involved in this binding. Further, RAP74's central charged cluster domain is required for binding to SRF's activation domain. Deletion of this domain impairs RAP74's ability to support SRF-activated transcription in vitro but has Little effect on the protein's basal transcription activity or its ability to support SP1-activated transcription. The correlation of SRF-RAP74 binding with transcriptional activation suggests that RAP74 is a critical target for SRF-activated transcription.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University								ASO T, 1992, NATURE, V355, P461, DOI 10.1038/355461a0; BENGAL E, 1991, MOL CELL BIOL, V11, P195; CHANG CH, 1993, J BIOL CHEM, V268, P20482; DALTON S, 1992, CELL, V88, P597; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1989, J BIOL CHEM, V284, P8913; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V386, P466; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LIU SH, 1993, J BIOL CHEM, V268, P21147; MUELLER CGF, 1991, EMBO J, V10, P4219, DOI 10.1002/j.1460-2075.1991.tb05000.x; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; PRYWES R, 1992, NUCLEIC ACIDS RES, V20, P513, DOI 10.1093/nar/20.3.513; SHAW PE, 1992, EMBO J, V11, P3011, DOI 10.1002/j.1460-2075.1992.tb05371.x; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WANG BQ, 1993, PROTEIN EXPRES PURIF, V4, P207, DOI 10.1006/prep.1993.1027; YONAHA M, 1993, NUCLEIC ACIDS RES, V21, P273, DOI 10.1093/nar/21.2.273; ZHU H, 1994, J BIOL CHEM, V269, P3489	23	73	75	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					632	635		10.1038/373632a0	http://dx.doi.org/10.1038/373632a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854423				2022-12-28	WOS:A1995QG99700060
J	SHAYWITZ, BA; SHAYWITZ, SE; PUGH, KR; CONSTABLE, RT; SKUDLARSKI, P; FULBRIGHT, RK; BRONEN, RA; FLETCHER, JM; SHANKWEILER, DP; KATZ, L; GORE, JC				SHAYWITZ, BA; SHAYWITZ, SE; PUGH, KR; CONSTABLE, RT; SKUDLARSKI, P; FULBRIGHT, RK; BRONEN, RA; FLETCHER, JM; SHANKWEILER, DP; KATZ, L; GORE, JC			SEX-DIFFERENCES IN THE FUNCTIONAL-ORGANIZATION OF THE BRAIN FOR LANGUAGE	NATURE			English	Article							SENSORY STIMULATION; ASYMMETRY	A MUCH debated question is whether sex differences exist in the functional organization of the brain for language(1-4). A long-held hypothesis posits that language functions are more likely to be highly lateralized in males and to be represented in both cerebral hemispheres in females(5,6), but attempts to demonstrate this have been inconclusive(7-17). Here we use echo-planar functional magnetic resonance imaging(18-21) to study 38 right-handed subjects (19 males and 19 females) during orthographic (letter recognition), phonological (rhyme) and semantic (semantic category) tasks. During phonological tasks, brain activation in males is lateralized to the left inferior frontal gyrus regions; in females the pattern of activation is very different, engaging more diffuse neural systems that involve both the left and right inferior frontal gyrus. Our data provide clear evidence for a sex difference in the functional organization of the brain for language and indicate that these variations exist at the level of phonological processing.	YALE UNIV,SCH MED,DEPT NEUROL,NEW HAVEN,CT 06510; HASKINS LABS INC,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT DIAGNOST RADIOL,NEW HAVEN,CT 06510; UNIV TEXAS,SCH MED,DEPT PEDIAT,HOUSTON,TX 77030; YALE UNIV,BECTON ENGIN & APPL SCI CTR,DEPT APPL PHYS,NEW HAVEN,CT 06520	Yale University; Yale University; Haskins Laboratories; Yale University; University of Texas System; Yale University	SHAYWITZ, BA (corresponding author), YALE UNIV,SCH MED,DEPT PEDIAT,POB 208064,NEW HAVEN,CT 06510, USA.		Constable, R. Todd/ABE-8038-2021; Fletcher, Jack/AAX-2931-2020; fletcher, jack/Q-5975-2019	Constable, R. Todd/0000-0001-5661-9521; 				BRADSHAW JL, 1978, BRAIN LANG, V5, P166, DOI 10.1016/0093-934X(78)90016-0; Bryden M.P., 1988, HDB DICHOTIC LISTENI, P1, DOI DOI 10.1002/ACP.2350040307; Demonet J. F., 1993, Human Brain Mapping, V1, P39, DOI 10.1002/hbm.460010105; DEMONET JF, 1992, BRAIN, V115, P1753, DOI 10.1093/brain/115.6.1753; DEMONET JF, 1994, BRAIN, V117, P671, DOI 10.1093/brain/117.4.671; EFRON R, 1990, DECLINE FALL HEMISPH, P1; FRACKOWIAK RSJ, 1994, TRENDS NEUROSCI, V17, P109, DOI 10.1016/0166-2236(94)90119-8; FRISTON KJ, 1994, HUMAN BRAIN MAPPING, V1, P69; HALPERN D, 1992, SEX DIFFERENCES COGN, P1; HAMPSON E, 1992, P357; HARSHMAN R, 1983, LANGUAGE BRAIN, V3; HELLIGE JB, 1993, HEMISPHERIC ASYMMETR, P1; HINES M, 1990, HORMONES BRAIN BEHAV, V1, P51; INGLIS J, 1981, SCIENCE, V212, P693, DOI 10.1126/science.7221560; KULYNYCH JJ, 1994, CEREB CORTEX, V4, P107, DOI 10.1093/cercor/4.2.107; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LACCINO J, 1993, LEFT BRAIN RIGHT BRA, P1; LEVY J, 1972, BIOL BEHAVIOR; LUKATELA G, 1991, J EXP PSYCHOL HUMAN, V17, P951, DOI 10.1037/0096-1523.17.4.951; MCCARTHY G, 1993, P NATL ACAD SCI USA, V90, P4952, DOI 10.1073/pnas.90.11.4952; MCGLONE J, 1977, BRAIN, V100, P775, DOI 10.1093/brain/100.4.775; MCGLONE J, 1980, BEHAV BRAIN SCI, V3, P215, DOI 10.1017/S0140525X00004398; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; PETERSEN SE, 1993, ANNU REV NEUROSCI, V1, P509; PUGH KR, 1994, J EXP PSYCHOL HUMAN, V20, P807, DOI 10.1037/0096-1523.20.4.807; SHAYWITZ BA, 1995, HUM BRAIN MAPP, V2, P21; Talairach J., 1988, COPLANAR STEREOTAXIC; TENG EL, 1981, NEUROPSYCHOLOGIA, V19, P235, DOI 10.1016/0028-3932(81)90107-X; VOYER D, 1990, BRAIN COGNITION, V13, P18, DOI 10.1016/0278-2626(90)90037-O; WITELSON SF, 1992, J COMP NEUROL, V323, P326, DOI 10.1002/cne.903230303	30	973	997	1	82	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					607	609		10.1038/373607a0	http://dx.doi.org/10.1038/373607a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QG997	7854416				2022-12-28	WOS:A1995QG99700052
J	LI, P; ALLEN, H; BANERJEE, S; FRANKLIN, S; HERZOG, L; JOHNSTON, C; MCDOWELL, J; PASKIND, M; RODMAN, L; SALFELD, J; TOWNE, E; TRACEY, D; WARDWELL, S; WEI, FY; WONG, W; KAMEN, R; SESHADRI, T				LI, P; ALLEN, H; BANERJEE, S; FRANKLIN, S; HERZOG, L; JOHNSTON, C; MCDOWELL, J; PASKIND, M; RODMAN, L; SALFELD, J; TOWNE, E; TRACEY, D; WARDWELL, S; WEI, FY; WONG, W; KAMEN, R; SESHADRI, T			MICE DEFICIENT IN IL-1-BETA-CONVERTING ENZYME ARE DEFECTIVE IN PRODUCTION OF MATURE IL-1-BETA AND RESISTANT TO ENDOTOXIC-SHOCK	CELL			English	Article							INTERLEUKIN-1-BETA CONVERTING ENZYME; DEATH GENE CED-3; CELL-DEATH; APOPTOSIS; PROTEASE; PRECURSOR; RECEPTOR; SURVIVAL; IDENTIFICATION; MONOCYTOGENES	IL-1 beta-converting enzyme (ICE) cleaves pro-IL-1 beta to generate mature IL-1 beta. ICE is homologous to other proteins that have been implicated in apoptosis, including CED-3 and Nedd-2/Ich-1. We generated ICE-deficient mice and observed that they are overtly normal but have a major defect in the production of mature IL-1 beta after stimulation with lipopolysaccharide. IL-1 alpha production is also impaired. ICE-deficient mice are resistant to endotoxic shock. Thymocytes and macrophages from the ICE-deficient animals undergo apoptosis normally. ICE therefore plays a dominant role in the generation of mature IL-1 beta, a previously unsuspected role in production of IL-1 alpha, but has no autonomous function in apoptosis.			LI, P (corresponding author), BASF BIORES CORP,100 RES DR,WORCESTER,MA 01605, USA.							ALEXANDER HR, 1991, J EXP MED, V173, P1029, DOI 10.1084/jem.173.4.1029; AYALA JM, 1994, J IMMUNOL, V53, P2592; BLACK RA, 1988, J BIOL CHEM, V263, P9437; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CAR BD, 1994, J EXP MED, V179, P1437, DOI 10.1084/jem.179.5.1437; CARRUTH LM, 1991, J BIOL CHEM, V266, P12162; CASANO FJ, 1994, GENOMICS, V20, P474, DOI 10.1006/geno.1994.1203; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DINARELLO CA, 1993, JAMA-J AM MED ASSOC, V269, P1829, DOI 10.1001/jama.269.14.1829; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HAZUDA DJ, 1988, J BIOL CHEM, V263, P8473; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; HOWARD AD, 1991, J IMMUNOL, V147, P2964; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; HUDIG D, 1993, CURR OPIN IMMUNOL, V5, P90, DOI 10.1016/0952-7915(93)90086-8; KOBAYASHI Y, 1990, P NATL ACAD SCI USA, V87, P5548, DOI 10.1073/pnas.87.14.5548; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MILLER DK, 1993, J BIOL CHEM, V268, P18062; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Sambrook J, 1989, MOL CLONING LABORATO; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; STRANGE R, 1992, DEVELOPMENT, V115, P49; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Togni PD, 1994, SCIENCE, V264, P703; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YOUNG PR, 1988, J CELL BIOL, V107, P447, DOI 10.1083/jcb.107.2.447; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	51	1277	1328	0	22	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					401	411		10.1016/0092-8674(95)90490-5	http://dx.doi.org/10.1016/0092-8674(95)90490-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859282	Bronze			2022-12-28	WOS:A1995QG47000006
J	ROSSING, P; TARNOW, L; NIELSEN, FS; BOELSKIFTE, S; BRENNER, BM; PARVING, HH				ROSSING, P; TARNOW, L; NIELSEN, FS; BOELSKIFTE, S; BRENNER, BM; PARVING, HH			SHORT STATURE AND DIABETIC NEPHROPATHY	BRITISH MEDICAL JOURNAL			English	Article							MICROALBUMINURIA; HYPERTENSION; HEIGHT		DANISH COMP CTR RES & EDUC,UNI C,DK-8200 AARHUS N,DENMARK; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School	ROSSING, P (corresponding author), STENO DIABET CTR,DK-2820 GENTOFTE,DENMARK.		rossing, peter/AAZ-3415-2021; rossing, peter/AAH-7879-2021	rossing, peter/0000-0002-1531-4294; Tarnow, Lise/0000-0002-8735-966X				BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BRENNER BM, 1994, AM J KIDNEY DIS, V23, P171, DOI 10.1016/S0272-6386(12)80967-X; GOULD MM, 1993, BMJ-BRIT MED J, V306, P240, DOI 10.1136/bmj.306.6872.240; KUH D, 1989, INT J EPIDEMIOL, V18, P663, DOI 10.1093/ije/18.3.663; PARVING HH, 1988, BMJ-BRIT MED J, V296, P156, DOI 10.1136/bmj.296.6616.156	5	64	64	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 4	1995	310	6975					296	297		10.1136/bmj.310.6975.296	http://dx.doi.org/10.1136/bmj.310.6975.296			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF717	7866171	Green Published			2022-12-28	WOS:A1995QF71700025
J	STOOP, R; POO, MM				STOOP, R; POO, MM			POTENTIATION OF TRANSMITTER RELEASE BY CILIARY NEUROTROPHIC FACTOR REQUIRES SOMATIC SIGNALING	SCIENCE			English	Article							LEUKEMIA INHIBITORY FACTOR; SPINAL-CORD NEURONS; NEUROMUSCULAR SYNAPSES; SYMPATHETIC NEURONS; RECEPTOR COMPONENT; SCIATIC-NERVE; FACTOR CNTF; ADULT-RAT; CULTURE; EXPRESSION	Neurotrophic factors participate in the development and maintenance of the nervous system. Application of ciliary neurotrophic factor (CNTF), a protein that promotes survival of motor neurons, resulted in an immediate potentiation of spontaneous and impulse-evoked transmitter release at developing neuromuscular synapses in Xenopus cell cultures. When CNTF was applied al the synapse, the onset of the potentiation was slower than that produced by application at the cell body of the presynaptic neuron. The potentiation effect was abolished when-the neurite shaft was severed from the cell body. Thus, transmitter secretion from the nerve terminals is under immediate somatic control and can be regulated by CNTF.	COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA	Columbia University								ADLER R, 1979, SCIENCE, V204, P1434, DOI 10.1126/science.451576; ALLEN RD, 1982, SCIENCE, V218, P1127, DOI 10.1126/science.6183744; ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BLAIR LAC, 1983, J NEUROSCI, V3, P1430; BLOTTNER D, 1989, NEUROSCI LETT, V105, P316, DOI 10.1016/0304-3940(89)90640-X; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; COHEN MW, 1987, J NEUROSCI, V7, P2849; CURTIS R, 1993, NATURE, V365, P253, DOI 10.1038/365253a0; DAN Y, 1992, SCIENCE, V256, P1570, DOI 10.1126/science.1317971; DAN Y, 1992, NATURE, V359, P733, DOI 10.1038/359733a0; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; Davis S, 1993, Curr Opin Neurobiol, V3, P20, DOI 10.1016/0959-4388(93)90030-3; ERNSBERGER U, 1989, NEURON, V2, P1275, DOI 10.1016/0896-6273(89)90312-7; EVERS J, 1989, J NEUROSCI, V9, P1523; FRIEDMAN B, 1992, NEURON, V9, P295, DOI 10.1016/0896-6273(92)90168-D; GRAFI G, 1993, FEBS LETT, V336, P403, DOI 10.1016/0014-5793(93)80846-M; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; IP NY, 1991, J NEUROSCI, V11, P3124; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KALBERG C, 1993, J NEUROCHEM, V60, P145, DOI 10.1111/j.1471-4159.1993.tb05832.x; Kandel E.R., 1991, PRINC NEUROSCI, V3rd ed.; KIDOKORO Y, 1988, P NATL ACAD SCI USA, V85, P1978, DOI 10.1073/pnas.85.6.1978; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MASIAKOWSKI P, 1991, J NEUROCHEM, V57, P1003, DOI 10.1111/j.1471-4159.1991.tb08250.x; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; ODOWD DK, 1983, NATURE, V303, P619, DOI 10.1038/303619a0; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; POPOV S, 1992, J NEUROSCI, V12, P77; Purves, 1985, PRINCIPLES NEURAL DE; RENDE M, 1992, GLIA, V5, P25, DOI 10.1002/glia.440050105; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; SENDTNER M, 1992, J CELL BIOL, V118, P139, DOI 10.1083/jcb.118.1.139; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SKAPER SD, 1986, DEV BRAIN RES, V24, P39, DOI 10.1016/0165-3806(86)90171-9; SPITZER NC, 1976, P NATL ACAD SCI USA, V73, P1641, DOI 10.1073/pnas.73.5.1641; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; Tabti N., 1991, CULTURING NERVE CELL, P137; XIE ZP, 1986, P NATL ACAD SCI USA, V83, P7069, DOI 10.1073/pnas.83.18.7069; YOUNG SH, 1983, NATURE, V305, P634, DOI 10.1038/305634a0	44	119	121	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	1995	267	5198					695	699		10.1126/science.7839148	http://dx.doi.org/10.1126/science.7839148			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839148				2022-12-28	WOS:A1995QE73300043
J	MCKEE, M; CLARKE, A				MCKEE, M; CLARKE, A			GUIDELINES, ENTHUSIASMS, UNCERTAINTY, AND THE LIMITS TO PURCHASING	BRITISH MEDICAL JOURNAL			English	Article								Recently government ministers have set out their vision of the future of purchasing. Ineffective treatments will be discarded and purchasing will be based on guidelines or protocols rather than activity. But have the advocates of this approach considered all the issues? This paper examines the challenges of balancing the desire for protocol based uniformity with the needs of individual patients, explores the extent to which existing purchasing structures can support this process, and questions whether such moves will actually lead to reduced costs. In each case it is concluded that oversimplistic analyses are likely to be misleading and that much of the current debate fails to recognise the complexity of health care.			MCKEE, M (corresponding author), LONDON SCH HYG & TROP MED,HLTH SERV RES UNIT,LONDON WC1E 7HT,ENGLAND.		McKee, Marc D/E-2187-2011; Clarke, Aileen/I-5679-2012; Mckee, Martin/E-6673-2018	McKee, Marc D/0000-0001-8349-965X; Clarke, Aileen/0000-0001-8299-3146; Mckee, Martin/0000-0002-0121-9683				ASSAF AR, 1993, NEW ENGL J MED, V329, P931, DOI 10.1056/NEJM199309233291307; AXELROD R, 1990, EVOLUTION COOPERATIO; BARRY MJ, 1988, JAMA-J AM MED ASSOC, V259, P3010, DOI 10.1001/jama.259.20.3010; BEESON PB, 1980, MEDICINE, V59, P79, DOI 10.1097/00005792-198003000-00001; BERNER ES, 1994, NEW ENGL J MED, V330, P1792, DOI 10.1056/NEJM199406233302506; BLACK NA, 1990, BRIT MED J, V300, P1551, DOI 10.1136/bmj.300.6739.1551; Boufford J I, 1993, Qual Health Care, V2, P249, DOI 10.1136/qshc.2.4.249; BUNKER J, 1994, BRIT MED J, V8, P1179; CHASSIN MR, 1993, MED CARE, V31, pYS37, DOI 10.1097/00005650-199305001-00006; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; COULTER A, 1993, BRIT MED J, V306, P236, DOI 10.1136/bmj.306.6872.236; DELAMOTHE T, 1993, BRIT MED J, V307, P218, DOI 10.1136/bmj.307.6898.218; FLOOD AB, 1992, ARCH INTERN MED, V152, P1507, DOI 10.1001/archinte.152.7.1507; GABBAY J, 1994, BRIT MED J, V308, P1117, DOI 10.1136/bmj.308.6937.1117; Gell-Mann Murray, 1994, QUARK JAGUAR, P124; Gill M, 1993, Qual Health Care, V2, P179, DOI 10.1136/qshc.2.3.179; Grimshaw J, 1993, Qual Health Care, V2, P243, DOI 10.1136/qshc.2.4.243; Grimshaw J M, 1994, Qual Health Care, V3, P45, DOI 10.1136/qshc.3.1.45; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; HAINES A, 1994, BRIT MED J, V308, P148; HARRIES U, 1994, J PUBLIC HEALTH MED, V16, P211, DOI 10.1093/oxfordjournals.pubmed.a042959; HAYWARD J, 1994, BMJ-BRIT MED J, V309, P823, DOI 10.1136/bmj.309.6958.823; HEISENBERG W, 1930, PHYSICAL PRINCIPLES; HUNTER D, IN PRESS J EPIDEMIOL; HUNTER DJW, 1994, J EPIDEMIOL COMMUN H, V48, P58, DOI 10.1136/jech.48.1.58; Iezzoni L I, 1990, Int J Technol Assess Health Care, V6, P272; KAHNEMAN D, 1984, AM PSYCHOL, V39, P341, DOI 10.1037/0003-066X.39.4.341; KASSIRER JP, 1994, NEW ENGL J MED, V330, P1895, DOI 10.1056/NEJM199406303302611; KASSIRER JP, 1994, NEW ENGL J MED, V330, P1824, DOI 10.1056/NEJM199406233302512; KIRKUP B, 1994, J PUBLIC HEALTH MED, V16, P256; LICTENSTEIN S, 1978, J EXPT PSYCHOL HUMAN, V4, P551; LUFT HS, 1980, MED CARE, V18, P940, DOI 10.1097/00005650-198009000-00006; MAWHINNEY B, VISION PURCHASING; MCKEE M, 1994, J ROY SOC MED, V87, P52; MUSHLIN AI, 1994, ARCH NEUROL-CHICAGO, V51, P67, DOI 10.1001/archneur.1994.00540130093017; OTTEN R, 1990, CHANGING VALUES MED; ROBERTS JA, 1993, J PUBLIC HEALTH MED, V15, P305, DOI 10.1093/oxfordjournals.pubmed.a042880; Sheldon T A, 1993, Qual Health Care, V2, P149, DOI 10.1136/qshc.2.3.149; SONG FJ, 1993, BMJ-BRIT MED J, V306, P683, DOI 10.1136/bmj.306.6879.683; STEVENS A, 1994, HLTH CARE NEEDS ASSE, V1; STIGGELBOUT AM, 1994, MED DECIS MAKING, V14, P82, DOI 10.1177/0272989X9401400110; STREINER DL, 1991, HLTH MEASUREMENT SCA; Sutherland S., 1994, IRRATIONALITY; VERKES RJ, 1990, CHANGING VALUES MED, P81; WENNBERG JE, 1990, NEW ENGL J MED, V323, P1202, DOI 10.1056/NEJM199010253231710; 1994, OECD EC SURVEYS 1993; 1994, NHSE EL9479; 1994, HLTH CARE ANAL, V2, P5; 1993, NHSE EL93115; NHSE EL9474; 1994, PRIORITIES PLANNING; 1993, PURCHASING HLTH FRAM	52	46	46	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 14	1995	310	6972					101	104		10.1136/bmj.310.6972.101	http://dx.doi.org/10.1136/bmj.310.6972.101			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QC223	7833698	Green Published			2022-12-28	WOS:A1995QC22300025
J	PASRICHA, PJ; RAVICH, WJ; HENDRIX, TR; SOSTRE, S; JONES, B; KALLOO, AN				PASRICHA, PJ; RAVICH, WJ; HENDRIX, TR; SOSTRE, S; JONES, B; KALLOO, AN			INTRASPHINCTERIC BOTULINUM TOXIN FOR THE TREATMENT OF ACHALASIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOWER ESOPHAGEAL SPHINCTER; PNEUMATIC DILATION; DILATATION; DILATORS; THERAPY	Background. Achalasia is a disorder of swallowing in which the lower esophageal sphincter fails to relax, We report the use of botulinum toxin, a paralytic agent, for the treatment of this condition. Methods. In a double-blind trial, 21 patients with achalasia received either 80 units of botulinum toxin or placebo, injected endoscopically into the lower esophageal sphincter, One week later, the response to treatment was assessed on the basis of changes in the symptom scores (measured on a scale from 0 to 9), pharyngoesophagograms, and results of esophageal manometric and scintigraphic studies, Patients who received placebo initially were subsequently treated with botulinum toxin, After six months, esophageal scintigraphy was repeated. Results. One week after treatment, the mean decrease in the symptom score was 5.4 points for the patients treated with botulinum toxin and 0.5 point for the placebo group (P=0.001), The mean decrease in the pressure of the lower esophageal sphincter was 33 percent in the treatment group, as compared with a mean increase of 12 percent in the placebo group (P=0.02), and the mean increase in the width of the opening of the lower esophageal sphincter was 204 percent in the treatment group, as compared with a mean decrease of 14 percent in the placebo group (P=0.02), Nineteen of the 21 patients treated with botulinum toxin had symptomatic improvement initially; after six months 14 patients were still in remission, This improvement was accompanied by a decrease in esophageal retention that was sustained at six months (46 percent, as compared with a pretreatment value of 77 percent; P=0.04), There were no serious adverse effects. Conclusions. Injection of botulinum toxin into the lower esophageal sphincter is an effective, safe, and simple method of treatment for achalasia, with results that are sustained for several months.	JOHNS HOPKINS MED INST,DIV GASTROENTEROL,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT RADIOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine			Kalloo, Anthony/AAY-9380-2020		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000035] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR00035] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AGGESTRUP S, 1983, GASTROENTEROLOGY, V84, P924; COCCIA G, 1991, GUT, V32, P604, DOI 10.1136/gut.32.6.604; CSENDES A, 1989, GUT, V30, P299, DOI 10.1136/gut.30.3.299; ECKARDT VF, 1992, GASTROENTEROLOGY, V103, P1732, DOI 10.1016/0016-5085(92)91428-7; GELFAND MD, 1989, AM J GASTROENTEROL, V84, P924; GROSS R, 1979, DIGEST DIS SCI, V24, P945, DOI 10.1007/BF01311951; HEITMANN P, 1969, SCAND J GASTROENTERO, V4, P1; HOLLOWAY RH, 1983, GASTROENTEROLOGY, V84, P771; HOLLOWAY RH, 1986, GASTROENTEROLOGY, V90, P924, DOI 10.1016/0016-5085(86)90869-3; JANKOVIC J, 1991, NEW ENGL J MED, V324, P1186, DOI 10.1056/nejm199104253241707; KATZ P, 1994, AM J GASTROENTEROL, V89, P969; MAKHLOUF GM, 1991, TXB GASTROENTEROLOGY, V1, P61; PASRICHA PJ, 1994, ANN INTERN MED, V121, P590, DOI 10.7326/0003-4819-121-8-199410150-00006; PASRICHA PJ, 1993, GASTROENTEROLOGY, V105, P1045, DOI 10.1016/0016-5085(93)90947-B; RICHTER JE, 1991, TXB GASTROENTEROLOGY, V1, P1083; ROBERTSON CS, 1989, GUT, V30, P768, DOI 10.1136/gut.30.6.768; STARK GA, 1990, AM J GASTROENTEROL, V85, P1322; TRAUBE M, 1991, DIGEST DIS SCI, V36, P257, DOI 10.1007/BF01318192; VANTRAPPEN G, 1980, GASTROENTEROLOGY, V79, P144	19	398	413	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 23	1995	332	12					774	778		10.1056/NEJM199503233321203	http://dx.doi.org/10.1056/NEJM199503233321203			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN442	7862180				2022-12-28	WOS:A1995QN44200003
J	SANCHEZGUERRERO, J; LIANG, MH; KARLSON, EW; HUNTER, DJ; COLDITZ, GA				SANCHEZGUERRERO, J; LIANG, MH; KARLSON, EW; HUNTER, DJ; COLDITZ, GA			POSTMENOPAUSAL ESTROGEN THERAPY AND THE RISK FOR DEVELOPING SYSTEMIC LUPUS-ERYTHEMATOSUS	ANNALS OF INTERNAL MEDICINE			English	Note							LOW PLASMA ANDROGENS; PROSPECTIVE COHORT; WOMEN; GLOMERULONEPHRITIS; PATHOGENESIS; SURVIVAL; MICE	Objective: To examine the relation between postmenopausal hormone use and development of systemic lupus erythematosus. Design: Prospective cohort study. Setting: Nurses' Health Study. Patients: 69 435 women aged 30 to 55 years in 1976 who reported that they had completed menopause and did not have systemic lupus erythematosus or any connective tissue disease were followed every 2 years from 1976 to 1990. These women were classified as never- or ever-(current and past) users of postmenopausal hormones. Measurements: Incidence rates of systemic lupus erythematosus and classification criteria from the American College of Rheumatology that were confirmed by chart review. Results: With never-users of postmenopausal hormones as the reference group, age-adjusted relative risks for systemic lupus erythematosus (n = 45 women) were 2.1 (95% CI, 1.1 to 4.0) for ever-users, 2.5 (CI, 1.2 to 5.0) for current users, and 1.8 (CI, 0.8 to 4.1) for past users. A proportional increase in the risk for systemic lupus erythematosus was observed that was related to the duration of use of postmenopausal hormones (test for trend, P = 0.011). Conclusions: Postmenopausal hormone therapy is associated with an increased risk for developing systemic lupus erythematosus.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health			Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	FOGARTY INTERNATIONAL CENTER [F05TW004573] Funding Source: NIH RePORTER; FIC NIH HHS [5F05 TW04573-02] Funding Source: Medline; NCI NIH HHS [CA 40396] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALARCONSEGOVIA D, 1984, J RHEUMATOL, V11, P588; COHEN JHM, 1983, J IMMUNOL, V131, P2767; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; GOLDMAN L, 1991, NEW ENGL J MED, V325, P800, DOI 10.1056/NEJM199109123251108; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; JUNGERS P, 1982, ARTHRITIS RHEUM, V25, P454, DOI 10.1002/art.1780250415; KARLSON EW, 1995, IN PRESS ANN EPIDEMI; KELLEY VE, 1980, CLIN IMMUNOL IMMUNOP, V16, P142, DOI 10.1016/0090-1229(80)90198-1; LAHITA RG, 1981, J CLIN ENDOCR METAB, V53, P174, DOI 10.1210/jcem-53-1-174; LAHITA RG, 1987, ARTHRITIS RHEUM, V30, P241, DOI 10.1002/art.1780300301; MASI AT, 1978, ARTHRITIS RHEUM-US, V21, P480, DOI 10.1002/art.1780210413; ROTHMAN KJ, 1979, PHS NIH791649 PUBL; ROUBINIAN JR, 1979, J CLIN INVEST, V63, P902, DOI 10.1172/JCI109390; ROUBINIAN JR, 1978, J EXP MED, V147, P1568, DOI 10.1084/jem.147.6.1568; Silman AJ, 1993, EPIDEMIOLOGY RHEUMAT, P163; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; Tosteson Anna N. A., 1994, P405	18	165	177	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	MAR 15	1995	122	6					430	433		10.7326/0003-4819-122-6-199503150-00005	http://dx.doi.org/10.7326/0003-4819-122-6-199503150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM266	7856991				2022-12-28	WOS:A1995QM26600005
J	BAUD, FJ; SABOURAUD, A; VICAUT, E; TABOULET, P; LANG, J; BISMUTH, C; ROUZIOUX, JM; SCHERRMANN, JM				BAUD, FJ; SABOURAUD, A; VICAUT, E; TABOULET, P; LANG, J; BISMUTH, C; ROUZIOUX, JM; SCHERRMANN, JM			TREATMENT OF SEVERE COLCHICINE OVERDOSE WITH COLCHICINE-SPECIFIC FAB FRAGMENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							DIGOXIN INTOXICATION; REVERSAL; ANTIBODIES; CELLS; DISPOSITION; TOXICITY; HEART; MICROTUBULES; MYOCYTES; TUBULIN		HOP FERNAND WIDAL, INSERM, U26, F-75475 PARIS, FRANCE; HOP FERNAND WIDAL, DEPT BIOPHYS, PARIS, FRANCE; PASTEUR MERIEUX SERUMS & VACCINS, LYON, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	BAUD, FJ (corresponding author), UNIV PARIS 07, HOP FERNAND WIDAL, 200 RUE FAUBOURG ST DENIS, F-75010 PARIS, FRANCE.		Scherrmann, Jean-Michel/I-1865-2017					ANTMAN EM, 1990, CIRCULATION, V81, P1744, DOI 10.1161/01.CIR.81.6.1744; BISMUTH C, 1977, NOUV PRESSE MED, V6, P1625; CAPLAN YH, 1980, J ANAL TOXICOL, V4, P153, DOI 10.1093/jat/4.3.153; CRIE JS, 1983, BIOCHEM J, V210, P63, DOI 10.1042/bj2100063; Ellenhorn M, 1988, MED TOXICOLOGY DIAGN, P1234; ELLWOOD MG, 1971, POSTGRAD MED J, V47, P129, DOI 10.1136/pgmj.47.544.129; FAVARELGARRIGUE.JC, 1975, CONCOURS MED, V97, P5183; GIBALDI M, 1982, PHARMACOKINETICS, V15; HASTIE SB, 1991, PHARMACOL THERAPEUT, V51, P377, DOI 10.1016/0163-7258(91)90067-V; HILL RN, 1975, ANN INTERN MED, V83, P523, DOI 10.7326/0003-4819-83-4-523; HOBSON CH, 1986, ANAESTH INTENS CARE, V14, P453, DOI 10.1177/0310057X8601400422; KLEIN I, 1983, CARDIOVASC RES, V17, P459, DOI 10.1093/cvr/17.8.459; LAMBERT H, 1981, Annales Medicales de Nancy et de l'Est, V20, P891; LAMPIDIS TJ, 1986, EXP CELL RES, V164, P463, DOI 10.1016/0014-4827(86)90044-3; LIMAS CJ, 1979, J MOL CELL CARDIOL, V11, P1137, DOI 10.1016/S0022-2828(79)80001-2; MERY P, 1994, INTENS CARE MED, V20, P119, DOI 10.1007/BF01707666; NATH K, 1978, P NATL ACAD SCI USA, V75, P319, DOI 10.1073/pnas.75.1.319; PERRET C, 1993, CATHETERISME CARDIAQ; RAPPAPORT L, 1988, INT REV CYTOL, V113, P101; ROBERTS WN, 1987, JAMA-J AM MED ASSOC, V257, P1920, DOI 10.1001/jama.257.14.1920; ROBERTS WN, 1987, JAMA-J AM MED ASSOC, V258, P2698; ROCHDI M, 1992, HUM EXP TOXICOL, V11, P510, DOI 10.1177/096032719201100612; ROUAN SKE, 1990, AM J PATHOL, V137, P779; RYBICKA K, 1978, J MOL CELL CARDIOL, V10, P409, DOI 10.1016/0022-2828(78)90362-0; SABOURAUD A, 1991, TOXICOLOGY, V68, P121, DOI 10.1016/0300-483X(91)90015-S; SABOURAUD A, 1993, DRUG METAB DISPOS, V21, P997; SABOURAUD AE, 1992, J PHARM PHARMACOL, V44, P1015, DOI 10.1111/j.2042-7158.1992.tb07084.x; SABOURAUD AE, 1992, J PHARMACOL EXP THER, V260, P1214; SAUDER P, 1983, HUM TOXICOL, V2, P169, DOI 10.1177/096032718300200201; SCHAUMANN W, 1986, EUR J CLIN PHARMACOL, V30, P527, DOI 10.1007/BF00542410; SCHERRMANN JM, 1989, TOXICOLOGY, V56, P213, DOI 10.1016/0300-483X(89)90134-0; SIMPSON P, 1982, CIRC RES, V50, P101, DOI 10.1161/01.RES.50.1.101; SMITH TW, 1976, NEW ENGL J MED, V294, P797, DOI 10.1056/NEJM197604082941501; STAHL N, 1979, AM J MED SCI, V278, P77, DOI 10.1097/00000441-197907000-00009; STAPCZYNSKI JS, 1981, ANN EMERG MED, V10, P364, DOI 10.1016/S0196-0644(81)80239-9; TERRIEN N, 1990, TOXICOL APPL PHARM, V104, P504, DOI 10.1016/0041-008X(90)90172-Q; THANHBARTHET CV, 1993, PHARMACEUT RES, V10, P692, DOI 10.1023/A:1018903614997; URTIZBEREA M, 1991, TOXICOL LETT, V58, P193, DOI 10.1016/0378-4274(91)90173-4; WOLFF J, 1980, J BIOL CHEM, V255, P7144	39	131	135	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 9	1995	332	10					642	645		10.1056/NEJM199503093321004	http://dx.doi.org/10.1056/NEJM199503093321004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK066	7845428				2022-12-28	WOS:A1995QK06600004
J	PARVIN, JD; MCCORMICK, RJ; SHARP, PA; FISHER, DE				PARVIN, JD; MCCORMICK, RJ; SHARP, PA; FISHER, DE			PRE-BENDING OF A PROMOTER SEQUENCE ENHANCES AFFINITY FOR THE TATA-BINDING FACTOR	NATURE			English	Article							CRYSTAL-STRUCTURE; MINOR-GROOVE; BOX COMPLEX; TFIID BINDS; DNA; PROTEIN; ELEMENTS	TATA-binding protein (TBP) binds the minor groove of the TATA element with the DNA bent 80 degrees towards the major groove(1-4). A constrained minicircle strategy(5) has been used to test the effect of DNA topology on the affinity of TBP for the TATA element. We report here that TBP bound to DNA which was slightly pre-bent towards the major groove with 100-fold higher affinity than unbent (linear) DNA of identical sequence and 300-foId higher affinity than DNA pre-bent towards the minor groove, Similar discrimination was observed with the holo-TFIID transcription complex. DNA topology, particularly bending, is determined by many factors including chromatin in cells and may, through changes in the affinity of the TATA factor, be important in the control of transcription.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)			Parvin, Jeffrey D/C-8955-2009					BAZETTJONES DP, 1994, SCIENCE, V264, P1134, DOI 10.1126/science.8178172; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KAHN JD, 1992, P NATL ACAD SCI USA, V89, P6343, DOI 10.1073/pnas.89.14.6343; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM JL, 1994, NAT STRUCT BIOL, V1, P621; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; KUDDUS R, 1993, NUCLEIC ACIDS RES, V21, P1789, DOI 10.1093/nar/21.8.1789; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E	19	163	165	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					724	727		10.1038/373724a0	http://dx.doi.org/10.1038/373724a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854460				2022-12-28	WOS:A1995QH92800062
J	FLYNN, JJ; WYSS, AR; CHARRIER, R; SWISHER, CC				FLYNN, JJ; WYSS, AR; CHARRIER, R; SWISHER, CC			AN EARLY MIOCENE ANTHROPOID SKULL FROM THE CHILEAN ANDES	NATURE			English	Article							OLIGOCENE; ARGENTINA; FOSSILS	PARTLY because of their poor fossil record, the relationships of neotropical platyrrhine monkeys to other groups of primates and to each other remain perhaps the most poorly known for any major primate clade(1). Here we report the discovery of a complete platyrrhine skull from the Andes of central Chile, by far the best preserved Tertiary primate cranium from South America. This find, coupled with recent phylogenetic analyses of higher groups of anthropoid primates(2-4), has the potential to revise substantially our understanding of platyrrhine interrelationships, indicating, among other points, significant modification to reconstruction of the ancestral platyrrhine morphotype and a likely African origin for New World monkeys. A 40Ar/39Ar radioisotopic date directly associated with the skull indicates an Early Miocene age(5), marking the first report of South American mammals of this age from outside Argentine Patagonia. Finally, this discovery demonstrates the enormous potential of vastly distributed, but virtually untapped, Andean volcaniclastic deposits to yield further insights into the origin and diversification of South American primates.	UNIV CALIF SANTA BARBARA, DEPT GEOL SCI, SANTA BARBARA, CA 93106 USA; UNIV CHILE, FAC CIENCIAS FIS & MATEMAT, DEPT GEOL, SANTIAGO, CHILE; INST HUMAN ORIGINS, CTR GEOCHRONOL, BERKELEY, CA 94709 USA	University of California System; University of California Santa Barbara; Universidad de Chile	FLYNN, JJ (corresponding author), FIELD MUSEUM NAT HIST, DEPT GEOL, ROOSEVELT RD & LAKE SHORE DR, CHICAGO, IL 60605 USA.							BEARD KC, 1994, NATURE, V368, P604, DOI 10.1038/368604a0; DEQUEIROZ K, 1992, ANNU REV ECOL SYST, V23, P449, DOI 10.1146/annurev.ecolsys.23.1.449; FLEAGLE JG, 1990, J HUM EVOL, V19, P61, DOI 10.1016/0047-2484(90)90012-Z; FLEAGLE JG, 1987, J HUM EVOL, V16, P483, DOI 10.1016/0047-2484(87)90036-4; FLEAGLE JG, 1983, FOLIA PRIMATOL, V41, P240, DOI 10.1159/000156135; Fleagle JG, 1988, PRIMATE ADAPTATION E; FLEAGLE JG, 1990, J HUM EVOL, V19; FLYNN JJ, SEPM SPECIAL PUBLICA; Ford S.M., 1986, P73; GINGERICH PD, 1982, AM J PHYS ANTHROPOL, V58, P81, DOI 10.1002/ajpa.1330580110; HERSHKOVITZ P, 1974, FOLIA PRIMATOL, V21, P1, DOI 10.1159/000155594; Hershkovitz P., 1977, P1; HOFFSTETTER R, 1969, CR ACAD SCI D NAT, V269, P434; Hoffstetter R., 1980, P103; Jerison HJ., 1973, EVOLUTION BRAIN INTE; Kay R.F., 1980, International Journal of Primatology, V1, P21, DOI 10.1007/BF02692256; Kay R.F., 1994, EVOL ANTHROPOL, V3, P32; KAY RF, 1990, J HUM EVOL, V19, P175, DOI 10.1016/0047-2484(90)90016-5; Martin R.D., 1990, PRIMATE ORIGINS EVOL; PASCUAL R, 1990, J HUM EVOL, V19, P23, DOI 10.1016/0047-2484(90)90011-Y; Rosenberger A.L., 1981, P9; ROSENBERGER AL, 1990, J HUM EVOL, V19, P209, DOI 10.1016/0047-2484(90)90017-6; Rusconi C., 1935, Revista Argentina de Paleontologia y Antropologia Ameghinia, V1, P39; RUSCONI C, 1935, REV ARGENTINA PALEON, V1, P103; RUSCONI C, 1935, REV ARGENTINA PALEON, V1, P71; SAMSON SD, 1987, CHEM GEOL, V66, P27, DOI 10.1016/0168-9622(87)90025-X; SIMONS EL, 1986, J HUM EVOL, V15, P205, DOI 10.1016/S0047-2484(86)80046-X; STEIGER RH, 1977, EARTH PLANET SC LETT, V36, P359, DOI 10.1016/0012-821X(77)90060-7; SWISHER CC, 1992, SCIENCE, V257, P954, DOI 10.1126/science.257.5072.954; TAUBER A, 1991, ACAD NAC CIENCIAS MI, V82; Taylor JR., 1982, INTRO ERROR ANAL, V2nd edition; Wyss A.R., 1994, American Museum Novitates, V3098, P1	32	64	70	0	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 16	1995	373	6515					603	607		10.1038/373603a0	http://dx.doi.org/10.1038/373603a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QG997	7854415				2022-12-28	WOS:A1995QG99700051
J	DOHERTY, M; JONES, A				DOHERTY, M; JONES, A			ABC OF RHEUMATOLOGY - FIBROMYALGIA SYNDROME	BRITISH MEDICAL JOURNAL			English	Article											DOHERTY, M (corresponding author), CITY HOSP,RHEUMATOL UNIT,NOTTINGHAM NG5 1PB,ENGLAND.			Doherty, Michael/0000-0002-5763-8326					0	22	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 11	1995	310	6976					386	389		10.1136/bmj.310.6976.386	http://dx.doi.org/10.1136/bmj.310.6976.386			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG721	7866219	Green Published			2022-12-28	WOS:A1995QG72100026
J	MARSHALL, JC; HALLIGAN, PW				MARSHALL, JC; HALLIGAN, PW			SEEING THE FOREST BUT ONLY HALF THE TREES	NATURE			English	Article							NEGLECT	IN visuo-spatial neglect after right hemisphere damage, patients fail overtly to notice and respond to stimuli on the side of space contralateral to lesion(1,2). Nonetheless, these neglected stimuli may covertly influence their performance in other tasks less direct than overt detection or identification(1). We report here a new type of dissociation between two forms of conscious perceptual awareness in a patient with left neglect. J.R. was shown hierarchical drawings in which a larger (global) form, such as a geometric figure or an alphabetic letter, is composed of smaller (local) forms (dots, circles, or letters). She gave accurate verbal reports of the global structure of these stimuli (Navon figures(3)), yet when required to cross out the smaller subfigures, she only cancelled those on the right of each global figure. Conscious perception of the whole does not automatically lead to visual awareness of all the parts thereof.	RIVERMEAD REHABIL CTR,OXFORD OX1 4XD,ENGLAND		MARSHALL, JC (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT CLIN NEUROL,NEUROPSYCHOL UNIT,OXFORD OX2 6HE,ENGLAND.		Halligan, Peter W/A-1669-2010	Halligan, Peter W/0000-0003-2784-6690				BOTTINI G, 1992, J NEUROL NEUROSUR PS, V55, P562, DOI 10.1136/jnnp.55.7.562; HALLIGAN PW, 1994, CORTEX, V30, P685, DOI 10.1016/S0010-9452(13)80244-4; HALLIGAN PW, 1994, NEUROPSYCHOLOGIA, V11, P167; Kinsbourne M, 1970, Trans Am Neurol Assoc, V95, P143; LADAVAS E, 1994, COGN NEUROPSYCHOL, V11, P57; MARSHALL JC, 1988, NATURE, V336, P766, DOI 10.1038/336766a0; NAVON D, 1977, COGNITIVE PSYCHOL, V9, P353, DOI 10.1016/0010-0285(77)90012-3; RIZZOLATTI G, 1990, REV NEUROL, V146, P626; ROBERTSON LC, 1992, NEUROPSYCHOLOGY CLIN, P70; SERGENT J, 1988, BRAIN, V111, P347, DOI 10.1093/brain/111.2.347	10	58	59	2	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 9	1995	373	6514					521	523		10.1038/373521a0	http://dx.doi.org/10.1038/373521a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QF724	7845464				2022-12-28	WOS:A1995QF72400059
J	DEKOK, YJM; VANDERMAAREL, SM; BITNERGLINDZICZ, M; HUBER, I; MONACO, AP; MALCOLM, S; PEMBREY, ME; ROPERS, HH; CREMERS, FPM				DEKOK, YJM; VANDERMAAREL, SM; BITNERGLINDZICZ, M; HUBER, I; MONACO, AP; MALCOLM, S; PEMBREY, ME; ROPERS, HH; CREMERS, FPM			ASSOCIATION BETWEEN X-LINKED MIXED DEAFNESS AND MUTATIONS IN THE POU DOMAIN GENE POU3F4	SCIENCE			English	Article							PERILYMPHATIC GUSHER; STAPES SURGERY; EXPRESSION; CHOROIDEREMIA; LINKAGE; COMPLEX; BRAIN; XQ21	Deafness with fixation of the stapes (DFN3) is the most frequent X-linked form of hearing impairment. The underlying gene has been localized to a 500-kilobase segment of the Xq21 band. Here, it is reported that a candidate gene for this disorder, Brain 4 (POU3F4), which encodes a transcription factor with a POU domain, maps to the same interval. In five unrelated patients with DFN3 but not in 50 normal controls, small mutations were found that result in truncation of the predicted protein or in nonconservative amino acid substitutions. These findings indicate that POU3F4 mutations are a molecular cause of DFN3.	UNIV NIJMEGEN HOSP, DEPT HUMAN GENET, 6500 HB NIJMEGEN, NETHERLANDS; UNIV LONDON, INST CHILD HLTH, LONDON WC1N 1EH, ENGLAND; UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, OXFORD OX3 9DU, ENGLAND	Radboud University Nijmegen; University of London; University College London; University of Oxford			Bitner-Glindzicz, Maria/A-4231-2009; Monaco, Anthony P/A-4495-2010; Cremers, Frans/A-5625-2014	Monaco, Anthony P/0000-0001-7480-3197; Cremers, Frans/0000-0002-4954-5592; van der Maarel, Silvere/0000-0001-8103-711X				BACH I, 1992, AM J HUM GENET, V51, P38; BACH I, 1992, HUM GENET, V89, P620; Bergstrom L, 1971, Otolaryngol Clin North Am, V4, P369; BITNERGLINDZICZ M, 1994, J MED GENET, V31, P916, DOI 10.1136/jmg.31.12.916; BRUNNER HG, 1988, HUM GENET, V80, P337, DOI 10.1007/BF00273647; COTTER PD, 1992, GENOMICS, V13, P211, DOI 10.1016/0888-7543(92)90223-F; COUCKE P, 1994, NEW ENGL J MED, V331, P425, DOI 10.1056/NEJM199408183310702; CREMERS CWRJ, 1985, ARCH OTOLARYNGOL, V111, P249; CREMERS FPM, 1990, NATURE, V347, P674, DOI 10.1038/347674a0; CREMERS FPM, 1989, GENOMICS, V4, P41, DOI 10.1016/0888-7543(89)90312-1; DEKOK YJM, UNPUB; DOUVILLE PJ, 1994, MAMM GENOME, V5, P180, DOI 10.1007/BF00352353; FRIEDMAN TB, 1994, AM J HUM GENET, V55; GLASSCOC.ME, 1973, ARCH OTOLARYNGOL, V98, P82; GUILFORD P, 1994, HUM MOL GENET, V3, P989, DOI 10.1093/hmg/3.6.989; GUILFORD P, 1994, NAT GENET, V6, P24, DOI 10.1038/ng0194-24; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; HUBER I, 1994, HUM MOL GENET, V3, P1151, DOI 10.1093/hmg/3.7.1151; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; LALWANI AK, 1993, AM J HUM GENET, V53, P1027; LEMOINE C, 1992, P NATL ACAD SCI USA, V89, P3285, DOI 10.1073/pnas.89.8.3285; LEON PE, 1992, P NATL ACAD SCI USA, V89, P5181, DOI 10.1073/pnas.89.11.5181; MATHIS JM, 1992, EMBO J, V11, P2551, DOI 10.1002/j.1460-2075.1992.tb05320.x; MORTON NE, 1991, ANN NY ACAD SCI, V630, P16, DOI 10.1111/j.1749-6632.1991.tb19572.x; NANCE W E, 1971, Birth Defects Original Article Series, V7, P64; OKAMOTO K, 1993, J BIOL CHEM, V268, P7449; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PHELPS PD, 1991, NEURORADIOLOGY, V33, P326, DOI 10.1007/BF00587816; PIUSSAN C, IN PRESS AM J HUM GE; REARDON W, 1991, GENOMICS, V11, P885, DOI 10.1016/0888-7543(91)90011-3; RYAN AF, 1991, ANN NY ACAD SCI, V630, P129, DOI 10.1111/j.1749-6632.1991.tb19581.x; SCHOENHAUT DS, 1986, GENE, V48, P55, DOI 10.1016/0378-1119(86)90351-3; SHAVERARNOS K, COMMUNICATION; THORPE P, 1974, S AFR MED J, V48, P587; WALLIS C, 1988, GENOMICS, V3, P299, DOI 10.1016/0888-7543(88)90119-X	37	319	329	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	1995	267	5198					685	688		10.1126/science.7839145	http://dx.doi.org/10.1126/science.7839145			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839145	Green Submitted			2022-12-28	WOS:A1995QE73300040
J	STUART, J; SPURGEON, PC; COOK, A				STUART, J; SPURGEON, PC; COOK, A			MANAGEMENT FOR DOCTORS - MAKING FINANCE WORK FOR YOU - STRATEGIC ISSUES IN CLINICAL DIRECTORATES .4.	BRITISH MEDICAL JOURNAL			English	Article									UNIV BIRMINGHAM,SCH MED,DEPT HAEMATOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,CTR HLTH SERV MANAGEMENT,BIRMINGHAM B15 2RT,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham								COOK AN, 1993, NEW FACE NHS, P46; GAMA R, 1992, J CLIN PATHOL, V45, P248, DOI 10.1136/jcp.45.3.248; MUTIMER D, 1992, J CLIN PATHOL, V45, P572, DOI 10.1136/jcp.45.7.572; PERRIN J, 1988, RESOURCE MANAGEMENT, P86; PETERS M, 1993, ANN CLIN BIOCHEM, V30, P52, DOI 10.1177/000456329303000109; 1991, PATHOLOGY SERVICES M	6	0	0	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 28	1995	310	6974					244	246		10.1136/bmj.310.6974.244	http://dx.doi.org/10.1136/bmj.310.6974.244			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE496	7866132	Green Published			2022-12-28	WOS:A1995QE49600032
J	WOODMAN, CBJ; THRELFALL, AG; BOGGIS, CRM; PRIOR, P				WOODMAN, CBJ; THRELFALL, AG; BOGGIS, CRM; PRIOR, P			IS THE 3-YEAR BREAST SCREENING INTERVAL TOO LONG - OCCURRENCE OF INTERVAL CANCERS IN NHS BREAST SCREENING PROGRAMS NORTH-WESTERN REGION	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; TRIAL	Objective-To report the detection rate of interval cancers in women screened by the NHS breast screening programme. Design-Detection of interval cancers by computer Linkage of records held by the screening centres in the North Western Regional Health Authority with breast cancer registrations at the regional cancer registry. Setting-North Western Regional Health Authority. Subjects-137421 women screened between 1 March 1988 and 31 March 1992 who had a negative screening result. Results-297 invasive interval cancers were detected. The rate of detection of interval cancers expressed as a proportion of the underlying incidence was 31% in the first 12 months after screening, 52% between 12 and 24 months, and 82% between 24 and 36 months. Conclusion-The incidence of interval cancers in the third year after breast screening approaches that which would have been expected in the absence of screening and suggests that the three year interval between screens is too long.	WITHINGTON HOSP,MANCHESTER BREAST SCREENING SERV,MANCHESTER M20 0PT,LANCS,ENGLAND		WOODMAN, CBJ (corresponding author), CHRISTIE HOSP NATL HLTH SERV TRUST,CTR CANC EPIDEMIOL,MANCHESTER M20 4QL,LANCS,ENGLAND.							ANDERSSON I, 1978, AM J ROENTGENOL, V130, P349, DOI 10.2214/ajr.130.2.349; BASSETT LW, 1987, RADIOLOGY, V165, P95, DOI 10.1148/radiology.165.1.3628795; CHAMBERLAIN J, 1993, BRIT MED J, V307, P353, DOI 10.1136/bmj.307.6900.353; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; FRISELL J, 1987, BREAST CANCER RES TR, V9, P219, DOI 10.1007/BF01806383; PATNICK J, 1994, NHS BREAST SCREENING, P16; PEETERS PHM, 1989, BRIT J CANCER, V59, P929, DOI 10.1038/bjc.1989.196; SHAPIRO S, 1982, JNCI-J NATL CANCER I, V69, P349; TABAR L, 1987, BRIT J CANCER, V55, P547, DOI 10.1038/bjc.1987.112; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; TABAR L, 1985, LANCET, V2, P829; VANDIJCK JAAM, 1993, CANCER, V72, P1933, DOI 10.1002/1097-0142(19930915)72:6<1933::AID-CNCR2820720623>3.0.CO;2-N; VERBEEK ALM, 1984, LANCET, V1, P1222	13	120	120	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 28	1995	310	6974					224	226		10.1136/bmj.310.6974.224	http://dx.doi.org/10.1136/bmj.310.6974.224			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE496	7866124	Green Published			2022-12-28	WOS:A1995QE49600022
J	CASSE, M; LEHOUCQ, R; VANGIONIFLAM, E				CASSE, M; LEHOUCQ, R; VANGIONIFLAM, E			PRODUCTION AND EVOLUTION OF LIGHT-ELEMENTS IN ACTIVE STAR-FORMING REGIONS	NATURE			English	Article							MASSIVE STARS; COSMIC-RAYS; GAMMA-RAYS; SOLAR; MODELS	COLLISIONS between cosmic rays (energetic protons and alpha-particles) and carbon, nitrogen and oxygen in the interstellar medium have been considered(1) to be the main source of lithium, beryllium and boron, through fragmentation of the larger nuclei. But this mechanism is unable to account for the observed Solar System abundances of the isotopes Li-7 and B-11. The recent detection of an excess of gamma-rays(2) in the direction of the star-forming region in the Orion cloud has been interpreted(3) as arising from the excitation of carbon and oxygen nuclei ejected from supernovae when they collide with the surrounding gas, which is primarily molecular and atomic hydrogen. Here we investigate the consequences of the two-body interactions of the ejected carbon and oxygen nuclei (and the alpha-particles ejected with them) with the hydrogen and helium in the surrounding gas, using a model developed previously(4-6). We show that these interactions offer a way to make lithium, beryllium and boron that is independent of the abundance of heavy elements in the surrounding medium. Such supernova-driven interactions, combined with the effect of galactic cosmic rays, can explain the observed Solar System abundances of these light elements.	CNRS,INST ASTROPHYS PARIS,F-75014 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	CASSE, M (corresponding author), CTR ETUD SACLAY,DSM,DAPNIA,SERV ASTROPHYS,F-91191 GIF SUR YVETTE,FRANCE.							ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BLOCMEN H, 1984, ASTRON ASTROPHYS, V139, P37; BLOEMEN H, 1994, ASTRON ASTROPHYS, V281, pL5; BROWN AGA, 1994, ASTRON ASTROPHYS, V289, P101; BURROWS DN, 1993, ASTROPHYS J, V406, P97, DOI 10.1086/172423; BYKOV A, 1994, ASTRON ASTROPHYS, V283, pL1; CASSE M, IN PRESS NCULEI COSM; CLAYTON DD, 1994, NATURE, V368, P222, DOI 10.1038/368222a0; CUNHA K, 1994, ASTROPHYS J, V426, P170, DOI 10.1086/174053; DUNCAN DK, 1992, ASTROPHYS J, V401, P584, DOI 10.1086/172088; EDVARDSSON B, IN PRESS ASTR ASTROP; FIELDS BD, IN PRESS ASTROPHYS J; GILMORE G, 1992, NATURE, V357, P379, DOI 10.1038/357379a0; KOZLOVSKY B, 1974, ASTROPHYS J, V191, pL43, DOI 10.1086/181542; MARTI K, IN PRESS NUCLEI COSM; MENEGUZZI M, 1971, ASTRON ASTROPHYS, V15, P337; MENEGUZZI M, 1975, ASTRON ASTROPHYS, V40, P99; MURPHY RJ, 1990, ASTROPHYS J, V351, P299, DOI 10.1086/168466; RAMATY R, 1979, ASTROPHYS J SUPPL S, V40, P487, DOI 10.1086/190596; RAMATY R, 1975, SPACE SCI REV, V18, P341, DOI 10.1007/BF00212911; RAMATY R, IN PRESS ASTROPHYS J; READ SM, 1984, ATOM DATA NUCL DATA, V31, P359, DOI 10.1016/0092-640X(84)90009-3; REEVES H, 1994, REV MOD PHYS, V66, P193, DOI 10.1103/RevModPhys.66.193; RYAN S, 1994, APJ, V388, P184; SPITE F, 1993, ORIGIN EVOLUTION ELE, P201; VANGIONIFLAM E, 1990, ASTROPHYS J, V364, P568, DOI 10.1086/169439; WEAVER TA, 1993, PHYS REP, V227, P65, DOI 10.1016/0370-1573(93)90058-L; WOOSLEY SE, 1993, ASTROPHYS J, V411, P823, DOI 10.1086/172886	28	114	114	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					318	319		10.1038/373318a0	http://dx.doi.org/10.1038/373318a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830765				2022-12-28	WOS:A1995QD40400050
J	HOLLANDER, GA; WANG, BP; NICHOGIANNOPOULOU, A; PLATENBURG, PP; VANEWIJK, W; BURAKOFF, SJ; GUTIERREZRAMOS, JC; TERHORST, C				HOLLANDER, GA; WANG, BP; NICHOGIANNOPOULOU, A; PLATENBURG, PP; VANEWIJK, W; BURAKOFF, SJ; GUTIERREZRAMOS, JC; TERHORST, C			DEVELOPMENTAL CONTROL POINT IN INDUCTION OF THYMIC CORTEX REGULATED BY A SUBPOPULATION OF PROTHYMOCYTES	NATURE			English	Article							T-CELL DEVELOPMENT; LYMPHOCYTES-T; MICE; MICROENVIRONMENT; DIFFERENTIATION; RESTORATION; RECEPTOR	T LYMPHOCYTES Of the alpha/beta T-cell receptor (TCR) lineage mature in the thymus, where they undergo a series of differentiation, expansion and selection events(1-7). For normal T-cell ontogeny to occur, thymocytes must interact physically with cortical and medullary thymic stroma cells(8-10). In parallel, interactions of the thymic stromal cells with TCR-positive thymocytes are necessary for the development of the thymic medulla(10-12). Comparable requirements for the differentiation of the cortex have not been defined, however. Here me analyse mutant mouse strains to assess the function of early prothymocytes in the induction of the thymic cortex. We find that animals with a developmental block at the earliest stage of T-lineage commitment lack a functional thymic cortex. This abnormality could be corrected in fetal but not adult animals by transplantation of either fetal or adult wild-type haematopoietic stem cells. Thus a developmentally restricted interaction of fetal stromal cells with early prothymocytes is required for the induction of a cortical microenvironment. In addition, a normal thymic architecture is necessary for sustained T-cell ontogeny.	BETH ISRAEL HOSP,DIV IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; ERASMUS UNIV ROTTERDAM,DEPT IMMUNOL,3000 DR ROTTERDAM,NETHERLANDS	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Erasmus University Rotterdam	HOLLANDER, GA (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115, USA.			Hollander, Georg/0000-0002-8790-0874				BOYD RL, 1991, IMMUNOL TODAY, V12, P71, DOI 10.1016/0167-5699(91)90161-L; BOYD RL, 1993, IMMUNOL TODAY, V14, P445, DOI 10.1016/0167-5699(93)90248-J; BRADLEY LM, 1992, J IMMUNOL, V148, P324; BUDD RC, 1987, J IMMUNOL, V138, P3120; GODFREY DI, 1994, J IMMUNOL, V152, P4783; GODFREY DI, 1993, J IMMUNOL, V150, P4244; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; IKUTA K, 1992, ANNU REV IMMUNOL, V10, P759; Jenkinson E J, 1990, Semin Immunol, V2, P51; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NEZELOF C, 1992, HISTOPATHOLOGY, V21, P499, DOI 10.1111/j.1365-2559.1992.tb00437.x; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; RITTER MA, 1993, IMMUNOL TODAY, V14, P462, DOI 10.1016/0167-5699(93)90250-O; ROBERTS R, 1990, MOUSE ITS REPRODUCTI, P253; SCOLLAY R, 1991, CURR OPIN IMMUNOL, V3, P204, DOI 10.1016/0952-7915(91)90051-2; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHORES EW, 1991, EUR J IMMUNOL, V21, P1657, DOI 10.1002/eji.1830210711; Shortman K, 1990, Semin Immunol, V2, P3; VANEWIJK W, 1984, AM J ANAT, V170, P311, DOI 10.1002/aja.1001700307; VANEWIJK W, 1991, ANNU REV IMMUNOL, V9, P591, DOI 10.1146/annurev.iy.09.040191.003111; VANEWIJK W, 1994, IMMUNOL TODAY, V15, P214, DOI 10.1016/0167-5699(94)90246-1; VANVLIET E, 1984, EUR J IMMUNOL, V14, P524, DOI 10.1002/eji.1830140608; VANVLIET E, 1985, EUR J IMMUNOL, V15, P677; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; WANG B, IN PRESS INT IMMUN; WANG BP, 1994, P NATL ACAD SCI USA, V91, P9402, DOI 10.1073/pnas.91.20.9402; YOKOYAMA WM, 1988, J IMMUNOL, V141, P369	27	236	239	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					350	353		10.1038/373350a0	http://dx.doi.org/10.1038/373350a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830770				2022-12-28	WOS:A1995QD40400062
J	WADA, A				WADA, A			A SPACE-TIME SLIDE-RULE	NATURE			English	Article								Akiyoshi Wada retired some years ago as a professor of physics at Tokyo University, where he was for many years one of those in Japan urging the fuller use of physical techniques in molecular biology notably in the automatic sequencing of DNA. Now he is the director of the interdisciplinary Sagami Chemical Research Center near Tokyo. The Wadarules reproduced on these pages (together with an explanatory note by Professor Wada) do not arise directly from the author's professional work, but are the product of a fertile and ingenious imagination exercised, in part no doubt, on long aircraft journeys. They are offered without restriction to those who may have use for them. It is simply necessary to photocopy the diagrams, to separate the main rule from the reference rule and to mount each part on stiff card in such a way as to be able to slide the latter against the former. While the Wadarules may have a general heuristic value for those who have the time to play with them, they mag have a particular educational value for young children and may be particularly useful for, say, science writers forever seeking graphic ways of dramatizing the large or small scale of some phenomenon (as in the phrase ''seems no bigger than a dime at a distance of 1 mile''). The rules can readily be amended to include objects with dimensions other than those shown. The annotation of the time rule leaves ample room for the addition of extra items, such as the average duration of the human heart-beat, the period of oscillation of ''middle C'' (0.00178 seconds) and the like.			WADA, A (corresponding author), SAGAMI CHEM RES CTR,4-4-1 NISHIOHNUMA,SAGAMIHARA,KANAGAWA 229,JAPAN.								0	1	1	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					R39	R40						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830749				2022-12-28	WOS:A1995QD40400047
J	OUSLANDER, JG; SCHNELLE, JF				OUSLANDER, JG; SCHNELLE, JF			INCONTINENCE IN THE NURSING-HOME	ANNALS OF INTERNAL MEDICINE			English	Article							LONG-TERM CARE; GERIATRIC URINARY-INCONTINENCE; ELDERLY INSTITUTIONALIZED MEN; PELVIC MUSCLE EXERCISE; URETHRAL CATHETERIZATION; DETRUSOR INSTABILITY; OLDER WOMEN; MANAGEMENT; BACTERIURIA; POPULATION	Urinary and fecal incontinence are prevalent, disruptive, and expensive health problems in the nursing home population. Nursing home residents who are incontinent of urine should have a basic diagnostic assessment, including a focused history and bladder record, a targeted physical examination, a urinalysis, and a determination of postvoid residual urine volume done by catheterization or ultrasonography. Potentially reversible conditions, such as fecal impaction and drug side effects, should be identified and treated. Selected residents should have further urodynamic evaluation or other diagnostic tests. Prompted voiding, a simple, noninvasive behavioral intervention, is effective in managing daytime urinary incontinence in one quarter to one third of incontinent nursing home residents. If it is to be effective over a long period of time, this intervention must be targeted to those residents most likely to respond. Selected nursing home residents will benefit from other behavioral interventions, drug therapy, or surgery. Because of the morbidity associated with it, long-term catheterization should only be used for specific indications. Like urinary incontinence, fecal incontinence may be caused by potentially reversible conditions. After such conditions have been excluded, fecal incontinence can generally be managed effectively by avoiding fecal impaction and by using a systematic bowel-training protocol.	UNIV CALIF LOS ANGELES, BORUN CTR GERONTOL RES, LOS ANGELES, CA USA	University of California System; University of California Los Angeles								BEESON PB, 1958, AM J MED, V24, P1, DOI 10.1016/0002-9343(58)90356-5; BENNETT CJ, 1984, UROLOGY, V24, P43, DOI 10.1016/0090-4295(84)90386-8; BRINK CA, 1990, J AM GERIATR SOC, V38, P368, DOI 10.1111/j.1532-5415.1990.tb03524.x; BURNS PA, 1993, J GERONTOL, V48, pM167; CAINE M, 1986, J UROLOGY, V136, P1; CASTLEDEN CM, 1985, AGE AGEING, V14, P303, DOI 10.1093/ageing/14.5.303; COLE HM, 1993, JAMA-J AM MED ASSOC, V270, P2975; COLLING J, 1992, J AM GERIATR SOC, V40, P135, DOI 10.1111/j.1532-5415.1992.tb01933.x; DIOKNO AC, 1988, J UROLOGY, V140, P567, DOI 10.1016/S0022-5347(17)41720-4; ELBADAWI A, 1993, J UROLOGY, V150, P1650, DOI 10.1016/S0022-5347(17)35866-4; ENGEL BT, 1990, J AM GERIATR SOC, V38, P361, DOI 10.1111/j.1532-5415.1990.tb03522.x; FANTL JA, 1991, JAMA-J AM MED ASSOC, V265, P609, DOI 10.1001/jama.265.5.609; FANTL JA, 1994, OBSTET GYNECOL, V83, P12; FINKBEINER AE, 1985, J UROLOGY, V134, P443, DOI 10.1016/S0022-5347(17)47234-X; GOLDSTEIN MK, 1989, J AM GERIATR SOC, V37, P991, DOI 10.1111/j.1532-5415.1989.tb07288.x; GRADY D, 1992, ANN INTERN MED, V117, P1038; HU TW, 1989, JAMA-J AM MED ASSOC, V261, P2656, DOI 10.1001/jama.261.18.2656; HU TW, 1994, AHCPR CLIN PRACTICE; KIRBY RS, 1987, BRIT J UROL, V60, P136, DOI 10.1111/j.1464-410X.1987.tb04950.x; Kunin C M, 1987, Am J Med, V82, P405, DOI 10.1016/0002-9343(87)90438-4; KUNIN CM, 1987, J AM GERIATR SOC, V35, P1001, DOI 10.1111/j.1532-5415.1987.tb04003.x; LAMHUT P, 1992, J AM GERIATR SOC, V40, P48, DOI 10.1111/j.1532-5415.1992.tb01828.x; LAPIDES J, 1983, FEMALE UROLOGY; LEPOR H, 1992, J UROLOGY, V147, P1554, DOI 10.1016/S0022-5347(17)37624-3; MADOFF RD, 1992, NEW ENGL J MED, V326, P1002; MARRON KR, 1983, J AM GERIATR SOC, V31, P278, DOI 10.1111/j.1532-5415.1983.tb04871.x; MCCLISH DK, 1991, OBSTET GYNECOL, V77, P281, DOI 10.1097/00006250-199102000-00025; Mohide E A, 1986, Clin Geriatr Med, V2, P639; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; MORRIS JN, 1991, RESIDENT ASSESSMENT; MUNCIE HL, 1990, J UROLOGY, V143, P507, DOI 10.1016/S0022-5347(17)40003-6; NICOLLE LE, 1987, ANN INTERN MED, V106, P682, DOI 10.7326/0003-4819-106-5-682; NICOLLE LE, 1983, NEW ENGL J MED, V309, P1420, DOI 10.1056/NEJM198312083092304; OUSLANDER J, 1993, J AM GERIATR SOC, V41, P371, DOI 10.1111/j.1532-5415.1993.tb06943.x; OUSLANDER J, 1988, J UROLOGY, V140, P1482, DOI 10.1016/S0022-5347(17)42080-5; OUSLANDER J, 1989, J AM GERIATR SOC, V37, P715, DOI 10.1111/j.1532-5415.1989.tb02232.x; OUSLANDER J, 1995, IN PRESS J AM GERIAT; OUSLANDER J, 1991, MED CARE NURSING HOM; OUSLANDER J, 1994, J AM GERIATR SOC, V11, pSA25; OUSLANDER J, 1993, J AM GERIATR SOC, pSA11; OUSLANDER JG, 1987, ARCH INTERN MED, V147, P286, DOI 10.1001/archinte.147.2.286; OUSLANDER JG, 1989, J AM GERIATR SOC, V37, P706, DOI 10.1111/j.1532-5415.1989.tb02231.x; OUSLANDER JG, 1987, J UROLOGY, V138, P1191, DOI 10.1016/S0022-5347(17)43546-4; OUSLANDER JG, 1987, J AM GERIATR SOC, V35, P1063, DOI 10.1111/j.1532-5415.1987.tb04922.x; OUSLANDER JG, 1986, J AM GERIATR SOC, V34, P83, DOI 10.1111/j.1532-5415.1986.tb05473.x; OUSLANDER JG, 1994, ANN INTERN MED, V120, P584, DOI 10.7326/0003-4819-120-7-199404010-00010; OUSLANDER JG, 1985, J AM GERIATR SOC, V33, P33, DOI 10.1111/j.1532-5415.1985.tb02857.x; OUSLANDER JG, 1982, JAMA-J AM MED ASSOC, V248, P1194, DOI 10.1001/jama.248.10.1194; OUSLANDER JG, 1994, J AM GERIATR SOC, V42, P1189, DOI 10.1111/j.1532-5415.1994.tb06987.x; OUSLANDER JG, 1987, J GERONTOL, V42, P631, DOI 10.1093/geronj/42.6.631; PANNILL FC, 1988, J AM GERIATR SOC, V36, P902, DOI 10.1111/j.1532-5415.1988.tb05783.x; RESNICK NM, 1987, JAMA-J AM MED ASSOC, V257, P3076, DOI 10.1001/jama.257.22.3076; RESNICK NM, 1989, NEW ENGL J MED, V320, P1, DOI 10.1056/NEJM198901053200101; RIBEIRO BJ, 1985, J AM GERIATR SOC, V33, P479, DOI 10.1111/j.1532-5415.1985.tb05459.x; SCHAPIRA M, 1991, J AM GERIATR SOC, V11, pSA4; SCHAPIRA M, 1994, J AM GERIATR SOC, V11, pSA24; SCHNELLE JF, 1990, GERONTOLOGIST, V30, P373, DOI 10.1093/geront/30.3.373; SCHNELLE JF, 1990, J AM GERIATR SOC, V38, P356, DOI 10.1111/j.1532-5415.1990.tb03521.x; SCHNELLE JF, 1993, J AM GERIATR SOC, V41, P1259, DOI 10.1111/j.1532-5415.1993.tb07312.x; SCHNELLE JF, 1990, HEALTH SERV RES, V25, P627; SCHNELLE JF, 1989, J AM GERIATR SOC, V37, P1051, DOI 10.1111/j.1532-5415.1989.tb06919.x; SCHNELLE JF, 1983, J APPL BEHAV ANAL, V16, P235, DOI 10.1901/jaba.1983.16-235; SCHNELLE JF, 1993, J AM GERIATR SOC, V41, P903, DOI 10.1111/j.1532-5415.1993.tb06753.x; SCHNELLE JF, 1993, J AM GERIATR SOC, V41, P910, DOI 10.1111/j.1532-5415.1993.tb06754.x; SCHNELLE JF, 1993, GERONTOLOGIST, V33, P114, DOI 10.1093/geront/33.1.114; SCHNELLE JF, 1991, MANAGING URINARY INC; SCHNELLE JF, 1993, INT UROGYNECOL J, V4, P89; STEWART RB, 1992, J AM GERIATR SOC, V40, P1217, DOI 10.1111/j.1532-5415.1992.tb03645.x; TERPENNING MS, 1989, J AM GERIATR SOC, V37, P411, DOI 10.1111/j.1532-5415.1989.tb02636.x; TOBIN GW, 1986, AGE AGEING, V15, P292, DOI 10.1093/ageing/15.5.292; WARREN JW, 1987, J INFECT DIS, V155, P1151, DOI 10.1093/infdis/155.6.1151; WARREN JW, 1989, ARCH INTERN MED, V149, P1535, DOI 10.1001/archinte.149.7.1535; WARREN JW, 1981, J UROLOGY, V125, P1; WARREN JW, 1988, J INFECT DIS, V158, P1341, DOI 10.1093/infdis/158.6.1341; WELLS TJ, 1990, J AM GERIATR SOC, V38, P333, DOI 10.1111/j.1532-5415.1990.tb03515.x; WELLS TJ, 1991, J AM GERIATR SOC, V39, P785, DOI 10.1111/j.1532-5415.1991.tb02701.x; WISEMAN PA, 1991, BMJ-BRIT MED J, V302, P994, DOI 10.1136/bmj.302.6783.994; ZORZITTO ML, 1989, AGE AGEING, V18, P195, DOI 10.1093/ageing/18.3.195; ZORZITTO ML, 1986, NEUROUROL URODYNAM, V5, P133, DOI 10.1002/nau.1930050202; 1992, PRESSURE ULCERS ADUL; 1992, URINARY INCONTINENCE; 1991, FED REGISTER, V56, P48865	82	83	85	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1995	122	6					438	449		10.7326/0003-4819-122-6-199503150-00007	http://dx.doi.org/10.7326/0003-4819-122-6-199503150-00007			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QM266	7856993				2022-12-28	WOS:A1995QM26600007
J	GREAVES, MW; WEINSTEIN, GD				GREAVES, MW; WEINSTEIN, GD			TREATMENT OF PSORIASIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DOUBLE-BLIND; ETRETINATE THERAPY; RADIATION PUVA; CYCLOSPORINE-A; RENAL-FUNCTION; SKIN-CANCER; METHOTREXATE; VULGARIS; CALCIPOTRIOL; PERSPECTIVES				GREAVES, MW (corresponding author), UNITED MED & DENT SCH,ST THOMAS HOSP,ST JOHNS INST DERMATOL,LONDON SE1 7EH,ENGLAND.							ARNETZ BB, 1985, PSYCHOSOM MED, V47, P528, DOI 10.1097/00006842-198511000-00003; ASHTON RE, 1983, J AM ACAD DERMATOL, V9, P173, DOI 10.1016/S0190-9622(83)70125-8; BAKER BS, 1993, BRIT J DERMATOL, V128, P493, DOI 10.1111/j.1365-2133.1993.tb00224.x; BAKER BS, 1984, BRIT J DERMATOL, V110, P37, DOI 10.1111/j.1365-2133.1984.tb07309.x; BAKER H, 1968, BRIT J DERMATOL, V80, P771, DOI 10.1111/j.1365-2133.1968.tb11947.x; BAKER H, 1966, BRIT J DERMATOL, V78, P161, DOI 10.1111/j.1365-2133.1966.tb12195.x; BERNSTEIN JE, 1986, J AM ACAD DERMATOL, V15, P504, DOI 10.1016/S0190-9622(86)70201-6; Cooper Kevin D., 1992, Journal of Dermatology (Tokyo), V19, P731; DIGIOVANNA JJ, 1986, NEW ENGL J MED, V315, P1177, DOI 10.1056/NEJM198611063151901; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; DUVIC M, 1987, ARCH DERMATOL, V123, P1622, DOI 10.1001/archderm.123.12.1622; DUVIVIER A, 1976, ARCH DERMATOL, V112, P1245, DOI 10.1001/archderm.112.9.1245; DWYER C, 1991, LANCET, V338, P764, DOI 10.1016/0140-6736(91)91493-E; ELDER JT, 1991, J INVEST DERMATOL, V96, P425, DOI 10.1111/1523-1747.ep12469889; ELLIS CN, 1987, J AM ACAD DERMATOL, V17, P787, DOI 10.1016/S0190-9622(87)70264-3; ELLIS CN, 1991, NEW ENGL J MED, V324, P277, DOI 10.1056/NEJM199101313240501; EYRE RW, 1991, PSORIASIS, P135; FARBER EM, 1991, INT J DERMATOL, V30, P8, DOI 10.1111/j.1365-4362.1991.tb05870.x; FARBER EM, 1991, INT J DERMATOL, V30, P270; FINNEN MJ, 1984, LANCET, V2, P1129; FISCHER T, 1991, PSORIASIS, P633; FREDRIKSSON T, 1978, DERMATOLOGICA, V157, P238, DOI 10.1159/000250839; FRITSCH PO, 1978, J INVEST DERMATOL, V70, P170; GHADIALLY R, 1992, J AM ACAD DERMATOL, V26, P387, DOI 10.1016/0190-9622(92)70060-S; GOLD MH, 1988, J AM ACAD DERMATOL, V19, P837, DOI 10.1016/S0190-9622(88)70242-X; GOLLNICK HPM, 1991, PSORIASIS, P725; GUPTA AK, 1991, ARCH INTERN MED, V151, P356, DOI 10.1001/archinte.151.2.356; HENSELER T, 1985, J AM ACAD DERMATOL, V13, P450, DOI 10.1016/S0190-9622(85)70188-0; INGRAM JT, 1953, BRIT MED J, V2, P591, DOI 10.1136/bmj.2.4836.591; JAMES VHT, 1967, LANCET, V2, P1059; KATAYAMA H, 1981, Journal of Dermatology (Tokyo), V8, P323; KORSTANJE MJ, 1992, BRIT J DERMATOL, V127, P501, DOI 10.1111/j.1365-2133.1992.tb14848.x; KRAGBALLE K, 1991, LANCET, V337, P988; KRAGBALLE K, 1989, ARCH DERMATOL, V125, P1647, DOI 10.1001/archderm.125.12.1647; KRAGBALLE K, 1991, LANCET, V337, P193, DOI 10.1016/0140-6736(91)92157-W; KRIPKE ML, 1983, J INVEST DERMATOL, V81, P87, DOI 10.1111/1523-1747.ep12542071; LANE AT, 1983, J AM ACAD DERMATOL, V8, P523, DOI 10.1016/S0190-9622(83)70059-9; LARSEN FG, 1993, J INVEST DERMATOL, V100, P623; LAZARUS GS, 1979, ARCH DERMATOL, V115, P1183, DOI 10.1001/archderm.115.10.1183; LEIGH IM, 1985, BRIT J DERMATOL, V113, P53, DOI 10.1111/j.1365-2133.1985.tb02044.x; LEUNG DYM, 1993, J INVEST DERMATOL, V100, P225, DOI 10.1111/1523-1747.ep12468941; LIEM WH, 1992, J INVEST DERMATOL, V98, P602; Lomholt G, 1963, PSORIASIS PREVALENCE; LOWE NJ, 1984, J AM ACAD DERMATOL, V10, P69, DOI 10.1016/S0190-9622(84)80046-8; MACLENNAN A, 1961, BRIT J DERMATOL, V73, P439, DOI 10.1111/j.1365-2133.1961.tb14996.x; MANSBRIDGE JN, 1987, J INVEST DERMATOL, V89, P253, DOI 10.1111/1523-1747.ep12471216; MCCULLOUGH JL, 1983, PSORIASIS CELL PROLI, P347; MELSKI JW, 1977, J INVEST DERMATOL, V68, P328, DOI 10.1111/1523-1747.ep12496022; MIHATSCH MJ, 1992, BRIT J DERMATOL, V126, P621; MOREL P, 1992, J AUTOIMMUN, V5, P465, DOI 10.1016/0896-8411(92)90006-C; MORIMOTO S, 1986, BRIT J DERMATOL, V115, P421, DOI 10.1111/j.1365-2133.1986.tb06236.x; MOY RL, 1985, ARCH DERMATOL, V121, P1297, DOI 10.1001/archderm.121.10.1297; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; ORFANOS CE, 1976, BRIT J DERMATOL, V95, P101, DOI 10.1111/j.1365-2133.1976.tb15541.x; PARKER S, 1984, BRIT J DERMATOL, V110, P215, DOI 10.1111/j.1365-2133.1984.tb07470.x; Pathak M.A., 1977, PSORIASIS, P262; PECKHAM PE, 1987, ARCH DERMATOL, V123, P1303, DOI 10.1001/archderm.123.10.1303; PERRY HO, 1968, ARCH DERMATOL, V98, P178, DOI 10.1001/archderm.98.2.178; PITTELKOW MR, 1981, ARCH DERMATOL, V117, P465, DOI 10.1001/archderm.117.8.465; ROENIGK HH, 1988, J AM ACAD DERMATOL, V19, P145, DOI 10.1016/S0190-9622(88)80237-8; SAURAT JH, 1988, DERMATOLOGICA, V177, P218, DOI 10.1159/000248567; SCHAEFER H, 1989, BRIT J DERMATOL, V102, P571; STADLER R, 1990, PHARM SKIN, V2, P329; STERN RS, 1986, J AM ACAD DERMATOL, V15, P546, DOI 10.1016/S0190-9622(86)70206-5; STERN RS, 1984, NEW ENGL J MED, V310, P1156, DOI 10.1056/NEJM198405033101805; STERN RS, 1990, NEW ENGL J MED, V322, P1093, DOI 10.1056/NEJM199004193221601; STERN RS, 1988, J INVEST DERMATOL, V91, P120, DOI 10.1111/1523-1747.ep12464137; STERN RS, 1980, LANCET, V1, P732, DOI 10.1016/S0140-6736(80)91231-3; STERN RS, 1989, J INVEST DERMATOL, V92, P300; STERN RS, 1991, ORAL PSORALEN PHOTOC, P603; SWERLICK RA, 1986, J INVEST DERMATOL, V87, P367, DOI 10.1111/1523-1747.ep12524838; TOMFOHRDE J, 1994, SCIENCE, V264, P1141, DOI 10.1126/science.8178173; TURPEINEN M, 1991, BRIT J DERMATOL, V124, P358, DOI 10.1111/j.1365-2133.1991.tb00597.x; VANNESS MM, 1989, ANN INTERN MED, V111, P473, DOI 10.7326/0003-4819-111-6-473; WALDMANN TA, 1993, IMMUNOL TODAY, V14, P264, DOI 10.1016/0167-5699(93)90043-K; WEINSTEIN G, 1973, ARCH DERMATOL, V108, P36, DOI 10.1001/archderm.1973.01620220008002; WEINSTEIN GD, 1985, J INVEST DERMATOL, V85, P579, DOI 10.1111/1523-1747.ep12283594; WEINSTEIN GD, 1993, J AM ACAD DERMATOL, V28, P454, DOI 10.1016/0190-9622(93)70067-4; WEINSTEIN GD, 1971, ARCH DERMATOL, V103, P33, DOI 10.1001/archderm.103.1.33; WEINSTEIN GD, 1990, J INVEST DERMATOL, V95, pS49, DOI 10.1111/1523-1747.ep12505777; WEINSTEIN MZ, 1984, DERMATOL CLIN, V2, P507, DOI 10.1016/S0733-8635(18)30965-3; WOLF R, 1990, DERMATOLOGICA, V181, P51, DOI 10.1159/000247861; WONG RL, 1993, IMMUNOL TODAY, V14, P69, DOI 10.1016/0167-5699(93)90061-O; YOUNG E, 1970, BRIT J DERMATOL, V82, P510, DOI 10.1111/j.1365-2133.1970.tb02214.x; ZACHARIAE H, 1990, BRIT J DERMATOL, V122, P127, DOI 10.1111/j.1365-2133.1990.tb02890.x	85	281	299	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 2	1995	332	9					581	588		10.1056/NEJM199503023320907	http://dx.doi.org/10.1056/NEJM199503023320907			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ090	7838193				2022-12-28	WOS:A1995QJ09000007
J	COOK, DJ; GUYATT, GH; JAESCHKE, R; REEVE, J; SPANIER, A; KING, D; MOLLOY, DW; WILLAN, A; STREINER, DL				COOK, DJ; GUYATT, GH; JAESCHKE, R; REEVE, J; SPANIER, A; KING, D; MOLLOY, DW; WILLAN, A; STREINER, DL			DETERMINANTS IN CANADIAN HEALTH-CARE WORKERS OF THE DECISION TO WITHDRAW LIFE-SUPPORT FROM THE CRITICALLY ILL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE; RESOURCE-ALLOCATION; RATIONING DECISIONS; RESUSCITATE ORDERS; MEDICAL-CARE; INEVITABILITY; VARIABILITY; TECHNOLOGY; DIRECTIVES; ATTITUDES	Objective.-To examine the attitudes of health care workers regarding the withdrawal or life support. Design.-Cross-sectional survey. Participants.-Attending staff, house staff, and intensive care unit (ICU) nurses in 37 Canadian university-affiliate hospitals. Main Outcome Measures.-Health care workers' ratings of the importance of 17 factors considered in the decision to withdraw life support, and their ratings of five levels of care ranging from comfort measures to intensive care in two of 12 different clinical scenarios. Results.-We surveyed 1361 respondents (149 of 167 potentially eligible ICU attending staff, 142 of 173 ICU house staff, and 1070 of 1455 ICU nurses, with response rates of 89%, 82% and 74%, respectively). The most important factors were likelihood of surviving the current episode, likelihood of long-term survival, premorbid cognitive function, and age of the patient. In choosing the level of care for the patient scenarios, the same option was chosen by more than 50% of respondents in only one of 12 scenarios; opposite extremes of care were chosen by more than 10% of the respondents in eight of 12 scenarios. Respondent characteristics affecting choices included the number of years since graduation, the city and province in which they worked, the number of beds in their ICU, and their assessment of the likelihood that they would withdraw life support in comparison with their colleagues (P<.001 for all comparisons). Conclusions.-While ICU health care workers consistently identify a number of patient factors as important in decisions to withdraw care, there is extreme variability, which may be explained in part by the values of individual health care providers.	MCMASTER UNIV, FAC HLTH SCI, DEPT MED, HAMILTON, ON L8N 3Z5, CANADA; MCMASTER UNIV, FAC HLTH SCI, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON, ON, CANADA; MCGILL UNIV, JEWISH GEN HOSP, DEPT SURG, MONTREAL, PQ H3T 1E2, CANADA	McMaster University; McMaster University; McGill University			Embrett, Mark G./H-4466-2014; Streiner, David/E-6563-2011	Embrett, Mark G./0000-0002-3969-0219; Streiner, David/0000-0003-0610-6271				ALEMAYEHU E, 1991, CAN MED ASSOC J, V144, P1133; BONE RC, 1990, CHEST, V97, P949, DOI 10.1378/chest.97.4.949; BYTH PL, 1990, ETHICAL ATTITUDES ME; COOK DJ, 1992, CURRENT PULMONOLOGY; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; EVANS RW, 1983, JAMA-J AM MED ASSOC, V249, P2208, DOI 10.1001/jama.249.16.2208; EVANS RW, 1983, JAMA-J AM MED ASSOC, V249, P2047; Feinstein AR, 1987, CLINIMETRICS, P141, DOI DOI 10.2307/J.CTT1XP3VBC.13; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; GUYATT GH, 1986, CAN MED ASSOC J, V134, P889; JAVITT JC, 1991, NEW ENGL J MED, V325, P1418, DOI 10.1056/NEJM199111143252005; LOEWY EH, 1987, NEW ENGL J MED, V317, P1465, DOI 10.1056/NEJM198712033172308; LUCE JM, 1988, CHEST, V94, P621, DOI 10.1378/chest.94.3.621; MCCRARY SV, 1989, JAMA-J AM MED ASSOC, V265, P2411; MOLLOY DW, 1993, HUM MED, V9, P70; MOLLOY DW, 1991, CAN MED ASSOC J, V145, P307; PEARLMAN RA, 1982, ANN INTERN MED, V97, P420, DOI 10.7326/0003-4819-97-3-420; SCHROEDER SA, 1979, NEW ENGL J MED, V300, P1306, DOI 10.1056/NEJM197906073002304; SINGER DE, 1983, NEW ENGL J MED, V309, P1155, DOI 10.1056/NEJM198311103091905; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; SPRUNG CL, 1992, CRIT CARE MED, V20, P320; SPRUNG CL, 1990, JAMA-J AM MED ASSOC, V263, P2211, DOI 10.1001/jama.263.16.2211; VINCENT JL, 1990, INTENS CARE MED, V16, P256, DOI 10.1007/BF01705162; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; YOUNGNER SJ, 1985, JAMA-J AM MED ASSOC, V253, P54; ZIMMERMAN JE, 1986, JAMA-J AM MED ASSOC, V255, P351, DOI 10.1001/jama.255.3.351; ZOOK CJ, 1980, NEW ENGL J MED, V302, P996, DOI 10.1056/NEJM198005013021804	28	304	309	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	1995	273	9					703	708		10.1001/jama.273.9.703	http://dx.doi.org/10.1001/jama.273.9.703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QH814	7853627				2022-12-28	WOS:A1995QH81400028
J	DAMMER, U; POPESCU, O; WAGNER, P; ANSELMETTI, D; GUNTHERODT, HJ; MISEVIC, GN				DAMMER, U; POPESCU, O; WAGNER, P; ANSELMETTI, D; GUNTHERODT, HJ; MISEVIC, GN			BINDING STRENGTH BETWEEN CELL-ADHESION PROTEOGLYCANS MEASURED BY ATOMIC-FORCE MICROSCOPY	SCIENCE			English	Article							SPONGE MICROCIONA-PROLIFERA; AGGREGATION FACTOR; MARINE SPONGE	Measurement of binding forces intrinsic to adhesion molecules is necessary to assess their contribution to the maintenance of the anatomical integrity of multicellular organisms. Atomic force microscopy was used to measure the binding strength between cell adhesion proteoglycans from a marine sponge. Under physiological conditions, the adhesive force between two cell adhesion molecules was found to be up to 400 piconewtons. Thus a single pair of molecules could hold the weight of 1600 cells. High intermolecular binding forces are likely to form the basis for the integrity of the multicellular sponge organism.	UNIV BASEL HOSP,DEPT RES,CH-4031 BASEL,SWITZERLAND; UNIV BASEL,INST PHYS,CH-4056 BASEL,SWITZERLAND; ETH ZURICH,INST BIOCHEM 2,CH-8092 ZURICH,SWITZERLAND	University of Basel; University of Basel; Swiss Federal Institutes of Technology Domain; ETH Zurich			Popescu, Octavian/O-2134-2019; Misevic, Gradimir/D-8294-2016; Popescu, Octavian/C-4027-2011; Popescu, Octavian/E-4942-2010; Anselmetti, Dario/F-1664-2011	Popescu, Octavian/0000-0002-2597-7155; Misevic, Gradimir/0000-0001-5047-2936; Popescu, Octavian/0000-0002-2597-7155; Anselmetti, Dario/0000-0002-8720-4369				ANSELMETTI D, 1994, EUROPHYS LETT, V27, P365, DOI 10.1209/0295-5075/27/5/006; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; CAUDWELL CB, 1973, BIOCHEMISTRY-US, V12, P3051; DAMMER U, 1994, IN PRESS MAR NATO AS; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; GUTIERREZ C, 1979, J IMMUNOL METHODS, V29, P57, DOI 10.1016/0022-1759(79)90125-X; HARMANSON GT, 1992, IMMOBILIZED AFFINITY; HELM CA, 1991, P NATL ACAD SCI USA, V88, P8169, DOI 10.1073/pnas.88.18.8169; HUMPHREYS S, 1977, J SUPRAMOL STR CELL, V7, P339, DOI 10.1002/jss.400070307; HUMPHREYS T, 1963, DEV BIOL, V8, P27, DOI 10.1016/0012-1606(63)90024-1; JUMBLATT JE, 1980, BIOCHEMISTRY-US, V19, P1038, DOI 10.1021/bi00546a032; LECKBAND DE, 1992, SCIENCE, V255, P1419, DOI 10.1126/science.1542789; LEE GU, 1994, LANGMUIR, V10, P354, DOI 10.1021/la00014a003; MISEVIC GN, 1987, J BIOL CHEM, V262, P5870; MISEVIC GN, 1993, J BIOL CHEM, V268, P4922; RADMACHER M, 1994, SCIENCE, V265, P1577, DOI 10.1126/science.8079171; RICE DJ, 1983, J BIOL CHEM, V258, P6394; SPILLMANN D, 1993, J BIOL CHEM, V268, P13378; WAGNER P, UNPUB; WINTER WT, 1977, J MOL BIOL, V117, P761, DOI 10.1016/0022-2836(77)90068-7; [No title captured]	22	356	368	0	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1173	1175		10.1126/science.7855599	http://dx.doi.org/10.1126/science.7855599			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855599	Green Submitted			2022-12-28	WOS:A1995QJ23700039
J	WEBSTER, MA; MOLLON, JD				WEBSTER, MA; MOLLON, JD			COLOR CONSTANCY INFLUENCED BY CONTRAST ADAPTATION	NATURE			English	Article							MECHANISMS; ILLUMINANT	VISUAL sensitivity is controlled by at least two distinct types of adaptation: light adaptation adjusts sensitivity to the mean luminance and colour in the stimulus(1), and contrast adaptation adjusts sensitivity to the variations in luminance and colour(2-5). Light adaptation is thought to be important in maintaining the perceived colour of objects despite changes in illumination ('colour constancy'), compensating for the mean changes in the light reflected from scenes under different illuminants(6). But for naturalistic colour signals, we show here that changes in an illuminant can also alter colour contrasts in images (how colours are distributed around the mean) enough to alter the state of contrast adaptation. Thus perceived colour under different illuminants may also be noticeably influenced by contrast adaptation.	UNIV CAMBRIDGE,DEPT EXPTL PSYCHOL,CAMBRIDGE CB2 3EB,ENGLAND	University of Cambridge	WEBSTER, MA (corresponding author), UNIV NEVADA,DEPT PSYCHOL,RENO,NV 89557, USA.		Mollon, John/C-3520-2009; Mollon, John/U-2631-2019	Mollon, John/0000-0001-8533-033X; Mollon, John/0000-0001-8533-033X; Webster, Michael/0000-0001-8262-7525				AREND LE, 1993, J OPT SOC AM A, V10, P2134, DOI 10.1364/JOSAA.10.002134; ATICK JJ, 1993, VISION RES, V33, P123, DOI 10.1016/0042-6989(93)90065-5; BARLOW HB, 1989, VISION CODING EFFICI, P363; BRAINARD DH, 1992, J OPT SOC AM A, V9, P1433, DOI 10.1364/JOSAA.9.001433; BROWN RO, 1991, INVEST OPHTH VIS SCI, V32, P1214; COHEN J, 1964, PSYCHON SCI, V1, P369, DOI 10.3758/BF03342963; DZMURA M, 1986, J OPT SOC AM A, V3, P1662, DOI 10.1364/JOSAA.3.001662; FLANAGAN P, 1989, Investigative Ophthalmology and Visual Science, V30, P130; GEORGESON M A, 1985, Spatial Vision, V1, P103, DOI 10.1163/156856885X00125; JUDD DB, 1964, J OPT SOC AM, V54, P1031, DOI 10.1364/JOSA.54.001031; KRAUSKOPF J, 1986, VISION RES, V26, P23, DOI 10.1016/0042-6989(86)90068-4; KRAUSKOPF J, 1982, VISION RES, V22, P1123, DOI 10.1016/0042-6989(82)90077-3; MACLEOD DIA, 1979, J OPT SOC AM, V69, P1183, DOI 10.1364/JOSA.69.001183; MACLEOD DJA, 1985, CENTRAL PERIPHERAL M; STILES WS, 1959, P NATL ACAD SCI USA, V45, P100, DOI 10.1073/pnas.45.1.100; VONKRIES J, 1970, FESTSCHRIFT A LUDWIG; WEBSTER MA, 1991, NATURE, V349, P235, DOI 10.1038/349235a0; WEBSTER MA, 1993, J OPT SOC AM A, V10, P1332, DOI 10.1364/JOSAA.10.001332; WEBSTER MA, 1994, VISION RES, V34, P1993, DOI 10.1016/0042-6989(94)90028-0; WORTHEY JA, 1982, J OPT SOC AM, V72, P74, DOI 10.1364/JOSA.72.000074; WORTHEY JA, 1986, J OPT SOC AM A, V3, P1708, DOI 10.1364/JOSAA.3.001708; Yarbus A.L., 1967, EYE MOVEMENTS VISION, DOI 10.1007/978-1-4899-5379-7; ZAIDI Q, 1993, BIOL CYBERN, V69, P415, DOI 10.1007/BF01185413; [No title captured]	24	98	98	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					694	698		10.1038/373694a0	http://dx.doi.org/10.1038/373694a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854451				2022-12-28	WOS:A1995QH92800053
J	ASHBY, EC; ASHFORD, NS; CAMPBELL, MJ				ASHBY, EC; ASHFORD, NS; CAMPBELL, MJ			POSTURE, BLOOD VELOCITY IN COMMON FEMORAL VEIN, AND PROPHYLAXIS OF VENOUS THROMBOEMBOLISM	LANCET			English	Note							COMPRESSION; THROMBOSIS	Might leg elevation and avoidance of poor postures provide better prophylaxis against venous thromboembolism than heparin or mechanical methods? 12 supine subjects tilted in 3 degrees increments from 6 degrees leg-down to 12 degrees leg-up showed linear increase in mean peak blood velocity and reduction in calibre in the common femoral vein (colour-duplex ultrasound). Between horizontal and 6 degrees leg-up, velocity was increased by 17% and diameter reduced by 14%.: A ranking of mean peak velocities in six postures (sitting; standing; trunk raised 35 degrees to legs which were first horizontal and then tilted up 6 degrees; supine, first horizontal then 6 degrees leg-up) showed significant increases in velocity between consecutive positions.	CHICHESTER HOSP,CHICHESTER,W SUSSEX,ENGLAND; UNIV SOUTHAMPTON,DEPT MED STAT,SOUTHAMPTON,HANTS,ENGLAND	University of Southampton								ANDREWS B, 1993, BRIT J SURG, V80, P198, DOI 10.1002/bjs.1800800221; ASHBY EC, 1993, LANCET, V142, P1562; CLAGETT PG, 1988, ANN SURG, V208, P227; COMEROTA AJ, 1992, AM J SURG, V164, P265, DOI 10.1016/S0002-9610(05)81083-9; COMEROTA AJ, 1989, SURGERY, V106, P301; FLANC C, 1969, LANCET, V1, P477; MATHEWS JNS, 1990, BRIT MED J, V300, P230; MONETA GL, 1988, J VASC SURG, V8, P285; NICOLAIDES AN, 1992, 1991 EUR CONS STAT W; 1992, BRIT MED J, V305, P567	10	27	29	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					419	421		10.1016/S0140-6736(95)90402-6	http://dx.doi.org/10.1016/S0140-6736(95)90402-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853951				2022-12-28	WOS:A1995QG90400010
J	BONADONNA, G; ZAMBETTI, M; VALAGUSSA, P				BONADONNA, G; ZAMBETTI, M; VALAGUSSA, P			SEQUENTIAL OR ALTERNATING DOXORUBICIN AND CMF REGIMENS IN BREAST-CANCER WITH MORE THAN 3 POSITIVE NODES - 10-YEAR RESULTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADJUVANT CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; AXILLARY NODES; CYCLOPHOSPHAMIDE; METHOTREXATE; FLUOROURACIL	Objective.-To improve current adjuvant results in patients with resectable mammary carcinoma and more than three positive axillary lymph nodes. Design.-A prospective randomized study was carried out to compare the effectiveness of four courses of doxorubicin hydrochloride followed by eight courses of cyclophosphamide, methotrexate, and fluorouracil (CMF) (sequential regimen) vs two courses of CMF alternated with one course of doxorubicin for a total of 12 courses (alternating regimen). All drug courses were recycled every 3 weeks. The median duration of follow-up at the time of current analysis was 9 years. Setting.-The study was conducted on patients operated on for primary unilateral breast cancer at the Istituto Nazionale Tumori of Milan, Italy. Adjuvant chemotherapy was delivered in the outpatient clinic of the Division of Medical Oncology. Patients.-A total of 405 women were entered into the study, 403 of whom met the protocol criteria. Patient characteristics were fairly well balanced between the two treatment groups, with the exception of extent of nodal involvement: 38% with more than 10 positive nodes were randomized to the alternating regimen compared with 29% in the sequential regimen (P=.08). Main Outcome Measure.-Relapse-free and total survival at 10 years after surgery estimated according to the Kaplan-Meier product limit method. Results.-Treatment outcome was significantly superior for patients who received the sequential regimen compared with those given the alternating chemotherapy. The relapse-free survival was 42% vs 28% (P=.002) and total survival was 58% vs 44% (P=.002), respectively. The benefit of the sequential regimen was evident in all patient subsets. Treatment was fairly well tolerated, but we documented four cases of congestive heart failure, which was fatal in two patients. Conclusions.-Current findings indicate that in women with extensive nodal involvement, sequential chemotherapy with doxorubicin followed by CMF yields superior results compared with the alternating administration of the same regimens or with classical CMF.			BONADONNA, G (corresponding author), IST NAZL TUMORI,DEPT MED,DIV MED ONCOL,VIA VENEZIAN 1,I-20133 MILAN,ITALY.				NCI NIH HHS [N01-CM-07338] Funding Source: Medline; DIVISION OF CANCER TREATMENT [N01CM007338] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER TREATMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Treatment & Diagnosis)		BONADONNA G, 1985, BREAST CANCER RES TR, V5, P95, DOI 10.1007/BF01805984; BONADONNA G, 1992, CANCER RES, V52, P2127; BONADONNA G, 1986, ANN INTERN MED, V104, P739, DOI 10.7326/0003-4819-104-6-739; BONADONNA G, 1976, NEW ENGL J MED, V294, P405, DOI 10.1056/NEJM197602192940801; BONADONNA G, 1975, CANCER CHEMOTH REP 3, V6, P381; BONADONNA G, 1981, NEW ENGL J MED, V304, P10, DOI 10.1056/NEJM198101013040103; BONADONNA G, IN PRESS N ENGL J ME; BONFANTE V, 1986, EUR J CANCER CLIN ON, V22, P1379, DOI 10.1016/0277-5379(86)90149-5; BUZZONI R, 1991, J CLIN ONCOL, V9, P2134, DOI 10.1200/JCO.1991.9.12.2134; COX DR, 1972, J R STAT SOC B, V34, P187; FISHER B, 1992, CANCER RES, V52, P2371; HARRIS JR, 1991, BREAST DISEASES; HENDERSON IC, 1994, CANCER, V74, P401; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Miller R. G., 1981, SURVIVAL ANAL; MOLITERNI A, 1991, J CLIN ONCOL, V9, P1124, DOI 10.1200/JCO.1991.9.7.1124; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; TANCINI G, 1983, J CLIN ONCOL, V1, P2, DOI 10.1200/JCO.1983.1.1.2; VALAGUSSA P, 1994, ANN ONCOL, V5, P209, DOI 10.1093/oxfordjournals.annonc.a058795; VALAGUSSA P, 1994, ANN ONCOL, V5, P803, DOI 10.1093/oxfordjournals.annonc.a059008; VALAGUSSA P, 1990, BREAST CANCER RES TR, V15, P137, DOI 10.1007/BF01806351; VERONESI U, 1990, EUR J CANCER, V26, P68; WOD WC, 1994, NEW ENGL J MED, V330, P1253; 1992, LANCET, V399, P71; 1992, LANCET, V399, P1	25	298	301	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	1995	273	7					542	547						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF686	7837388				2022-12-28	WOS:A1995QF68600023
J	JENKINSON, D				JENKINSON, D			NATURAL COURSE OF 500 CONSECUTIVE CASES OF WHOOPING-COUGH - A GENERAL-PRACTICE POPULATION STUDY	BRITISH MEDICAL JOURNAL			English	Article							PERTUSSIS	Objective-To describe the natural course of whooping cough. Design-Observational study of a general practice population. Setting-Discrete semirural East Midlands practice of 11 500 patients. Subjects-500 consecutive cases of whooping cough diagnosed clinically during 1977-92. Main outcome measures-Incidence of vomiting, whooping, apnoea, admission to hospital, and complications; duration and frequency of paroxysms. Pattern of spread. Results-The incidence in the practice population was 4347/100 000 population compared with a notification rate for England and Wales of 717/100 000. Most cases were relatively mild. 284 patients vomited after paroxysms, 242 whooped, and 57 had apnoea. Duration and frequency of paroxysms varied widely. Female and unimmunised patients suffered more severe disease. Bordetella was isolated from fewer immunised patients (24/96 v 63/122 unimmunised). Infection was usually spread through contacts with someone with clinical whooping cough. Five patients developed pneumonia, three of whom had been immunised. Three patients required hospital admission. Conclusions-Most cases of whooping cough are relatively mild. Such cases are difficult to diagnose without a high index of suspicion because doctors are unlikely to hear the characteristic cough, which may be the only symptom. Parents can be reassured that a serious outcome is unlikely. Adults also get whooping cough, especially from their children, and get the same symptoms as children. The difficulty of early diagnosis and probability of missed cases reinforces the need to keep the incidence low through immunisation in order to protect infants, who are the most vulnerable.			JENKINSON, D (corresponding author), KEYWORTH HLTH CTR,NOTTINGHAM NG12 5JU,ENGLAND.							CHRISTIE AB, 1970, INFECT DIS, P726; GROB PR, 1981, BRIT MED J, V282, P1925, DOI 10.1136/bmj.282.6280.1925; JENKINSON D, 1978, BRIT MED J, V2, P577; JENKINSON D, 1988, BRIT MED J, V296, P612, DOI 10.1136/bmj.296.6622.612; JENKINSON D, 1983, BRIT MED J, V287, P185, DOI 10.1136/bmj.287.6386.185; Kendrick P, 1939, AM J HYG, V29, P133, DOI 10.1093/oxfordjournals.aje.a118485; MARCOVITCH H, 1986, BRIT MED J, V292, P360, DOI 10.1136/bmj.292.6517.360; MILLER C, 1976, BRIT MED J, V2, P117; MILLER E, 1992, CDR REV, V2, P152; VESSELINOVAJENK.CK, 1978, J EPIDEMIOL COMMUNIT, V32, P194; 1981, BRIT MED J, V232, P23	11	48	50	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 4	1995	310	6975					299	302		10.1136/bmj.310.6975.299	http://dx.doi.org/10.1136/bmj.310.6975.299			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF717	7866173	Green Published			2022-12-28	WOS:A1995QF71700028
J	CHADWICK, D				CHADWICK, D			CONTROVERSIES IN MANAGEMENT - DO ANTICONVULSANTS ALTER THE NATURAL COURSE OF EPILEPSY - CASE FOR EARLY TREATMENT IS NOT ESTABLISHED	BRITISH MEDICAL JOURNAL			English	Article							SEIZURES; REMISSION				CHADWICK, D (corresponding author), WALTON CTR NEUROL & NEUROSURG,DEPT NEUROL SCI,LIVERPOOL L9 1AE,MERSEYSIDE,ENGLAND.							ANNEGERS JF, 1979, EPILEPSIA, V20, P729, DOI 10.1111/j.1528-1157.1979.tb04857.x; CHADWICK D, 1991, J NEUROL NEUROSUR PS, V54, P385, DOI 10.1136/jnnp.54.5.385; DELGADOESCUETA AV, 1984, NEUROLOGY, V34, P285, DOI 10.1212/WNL.34.3.285; FEKSI AT, 1991, LANCET, V337, P406, DOI 10.1016/0140-6736(91)91176-U; KERANEN T, 1993, BRIT MED J, V307, P483, DOI 10.1136/bmj.307.6902.483; Lerman Pinchas, 1992, P189; McNamara J O, 1986, Adv Neurol, V44, P303; PIACENCIA M, 1993, EPILEPSY RES, V14, P237; SHAFER SQ, 1988, EPILEPSIA, V29, P590, DOI 10.1111/j.1528-1157.1988.tb03767.x; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; 1993, NEUROLOGY, V43, P478	11	26	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 21	1995	310	6973					177	178		10.1136/bmj.310.6973.177	http://dx.doi.org/10.1136/bmj.310.6973.177			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD201	7833761	Green Published			2022-12-28	WOS:A1995QD20100029
J	FROST, H; MOFFETT, JAK; MOSER, JS; FAIRBANK, JCT				FROST, H; MOFFETT, JAK; MOSER, JS; FAIRBANK, JCT			RANDOMIZED CONTROLLED TRIAL FOR EVALUATION OF FITNESS PROGRAM FOR PATIENTS WITH CHRONIC LOW-BACK-PAIN	BRITISH MEDICAL JOURNAL			English	Article							FUNCTIONAL RESTORATION; OUTPATIENT TREATMENT; CLINICAL-TRIAL; FOLLOW-UP; DISABILITY; VALIDITY	Objective-To evaluate a progressive fitness programme for patients with chronic low back pain. Design-Single blind randomised controlled trial. Assessments were carried out before and after treatment by an observer blinded to the study and included a battery of validated measures. All patients were followed up by postal questionnaire six months after treatment. Setting-Physiotherapy department of orthopaedic hospital. Subjects-81 patients with chronic low back pain referred from orthopaedic consultants for physiotherapy. The patients were randomly allocated to a fitness programme or control group. Intervention-Both groups were taught specific exercises to carry out at home and referred to a back-school for education in back care. Patients allocated to the fitness class attended eight exercise classes over four weeks in addition to the home programme and backschool. Results-Significant differences between the groups were shown in the changes before and after treatment in scores on the Oswestry low back pain disability index (P<0.005), pain reports (sensory P<0.05 and affective P<0.005), self efficacy reports (P<0.05), and walking distance (P<0.005). No significant differences between the groups were found by the general health questionnaire or questionnaire on pain locus of control. A benefit of about 6 percentage points on the disability index was maintained by patients in the fitness group at six months. Conclusion-There is a role for supervised fitness programmes in the management of moderately disabled patients with chronic low back pain. Further clinical trials, however, need to be established in other centres to confirm these findings.			FROST, H (corresponding author), NUFFIELD ORTHOPAED CTR,OXFORD OX3 7LD,ENGLAND.		Fairbank, Jeremy/AAA-3411-2019	Frost, Helen/0000-0001-9241-8970				ASTRAND PO, 1987, ARCH PHYS MED REHAB, V68, P305; Baker DJ, 1989, BACK PAIN NEW APPROA, P174; BANDURA A, 1982, AM PSYCHOL, V37, P122, DOI 10.1037/0003-066X.37.2.122; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; DOLCE JJ, 1986, PAIN, V24, P365, DOI 10.1016/0304-3959(86)90122-3; FLOR H, 1991, 6TH P WORLD C PAIN A, P4229; GOLDBERG DP, 1978, MANUAL GENERAL HLTH; HARKAPAA K, 1989, SCAND J REHABIL MED, V21, P81; HAZARD RG, 1989, SPINE, V14, P157, DOI 10.1097/00007632-198902000-00003; JENSEN MP, 1993, PAIN, V55, P195, DOI 10.1016/0304-3959(93)90148-I; KEIJSERS J F E M, 1991, Physiotherapy Theory and Practice, V7, P177, DOI 10.3109/09593989109106969; KELLETT KM, 1991, PHYS THER, V71, P283, DOI 10.1093/ptj/71.4.283; KOES BW, 1992, BRIT MED J, V304, P601, DOI 10.1136/bmj.304.6827.601; KOHLES S, 1990, SPINE, V15, P1321, DOI 10.1097/00007632-199012000-00016; KORES RC, 1990, BEHAV RES THER, V28, P165, DOI 10.1016/0005-7967(90)90029-I; LINDSTROM I, 1992, PHYS THER, V72, P279, DOI 10.1093/ptj/72.4.279; MAIN CJ, 1991, PAIN, V46, P287, DOI 10.1016/0304-3959(91)90112-B; MANNICHE C, 1991, PAIN, V47, P53, DOI 10.1016/0304-3959(91)90011-L; MAYER TG, 1985, SPINE, V10, P482, DOI 10.1097/00007632-198507000-00002; MCQUADE KJ, 1988, CLIN ORTHOP RELAT R, V233, P198; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; MOFFETT JAK, 1986, SPINE, V111, P120; NICHOLAS MK, 1992, PAIN, V48, P339, DOI 10.1016/0304-3959(92)90082-M; NUTTER P, 1987, SPINE, V21, P137; POCOCK SJ, 1987, CLIN TRIALS PRACTICA; SINGH SJ, 1992, THORAX, V47, P1019, DOI 10.1136/thx.47.12.1019; SUTTON JR, 1990, EXERCISE, FITNESS, AND HEALTH, P217; WADDELL G, 1987, SPINE, V12, P632, DOI 10.1097/00007632-198709000-00002; WADDELL G, 1993, PAIN, V52, P157, DOI 10.1016/0304-3959(93)90127-B	29	196	200	1	25	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 21	1995	310	6973					151	154		10.1136/bmj.310.6973.151	http://dx.doi.org/10.1136/bmj.310.6973.151			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD201	7833752	Green Published			2022-12-28	WOS:A1995QD20100018
J	HAWTON, K; WARE, C; MISTRY, H; HEWITT, J; KINGSBURY, S; ROBERTS, D; WEITZEL, H				HAWTON, K; WARE, C; MISTRY, H; HEWITT, J; KINGSBURY, S; ROBERTS, D; WEITZEL, H			WHY PATIENTS CHOOSE PARACETAMOL FOR SELF-POISONING AND THEIR KNOWLEDGE OF ITS DANGERS	BRITISH MEDICAL JOURNAL			English	Article									JOHN RADCLIFFE HOSP,DEPT PSYCHOL MED,BARNES UNIT,OXFORD OX3 9DX,ENGLAND	University of Oxford	HAWTON, K (corresponding author), UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7JX,ENGLAND.							BRAY GP, 1993, BRIT MED J, V306, P157, DOI 10.1136/bmj.306.6871.157; GAZZARD BG, 1976, BRIT MED J, V1, P212, DOI 10.1136/bmj.1.6003.212; HAWTON K, 1992, BRIT MED J, V304, P1409, DOI 10.1136/bmj.304.6839.1409; OGRADY JG, 1991, BRIT MED J, V303, P221, DOI 10.1136/bmj.303.6796.221; SPOONER JB, 1993, PHARM J, V250, P706	5	84	85	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 21	1995	310	6973					164	164		10.1136/bmj.310.6973.164	http://dx.doi.org/10.1136/bmj.310.6973.164			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD201	7833757	Green Published			2022-12-28	WOS:A1995QD20100023
J	SIMINOSKI, K				SIMINOSKI, K			DOES THIS PATIENT HAVE A GOITER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THYROID SIZE; CLINICAL-ASSESSMENT; ULTRASOUND; FREQUENCY; IODINE; VOLUME; ACCURACY; DISEASE; GLAND				SIMINOSKI, K (corresponding author), UNIV ALBERTA, DEPT MED, DIV ENDOCRINOL & METAB, 362 HMRC, EDMONTON, AB T6G 2S2, CANADA.							BERGHOUT A, 1988, CLIN ENDOCRINOL, V28, P409, DOI 10.1111/j.1365-2265.1988.tb03672.x; BERGHOUT A, 1987, CLIN ENDOCRINOL, V26, P273, DOI 10.1111/j.1365-2265.1987.tb00784.x; BRANDER A, 1992, J CLIN ULTRASOUND, V20, P37, DOI 10.1002/jcu.1870200107; BROWN MC, 1978, ACTA RADIOL ONCOL, V17, P337, DOI 10.3109/02841867809127937; BURCH WM, 1987, CASE STUDIES ENDOCRI, P52; CLAIN A, 1986, HAMILTON BAILLEYS DE, P155; COOK IJ, 1989, AM J PHYSIOL, V257, pG748, DOI 10.1152/ajpgi.1989.257.5.G748; CROOKS J, 1967, LANCET, V2, P625; Daniels G, 1991, WERNER INGBARS THYRO, P572; Dingle P R, 1966, Clin Exp Immunol, V1, P277; EASTHAM RD, 1985, POCKET GUIDE DIFFERE, P220; EDWARDS CRW, 1990, MACLEODS CLIN EXAMIN, P66; GREENSPAN FS, 1991, BASIC CLIN ENDOCRINO, P213; GURNEY C, 1970, LANCET, V2, P1275; GUTEKUNST R, 1986, ACTA ENDOCRINOL-COP, V112, P494, DOI 10.1530/acta.0.1120494; GWINUP G, 1975, J CLIN ENDOCR METAB, V40, P37, DOI 10.1210/jcem-40-1-37; HEGEDUS L, 1990, DAN MED BULL, V37, P249; HEGEDUS L, 1985, CLIN ENDOCRINOL, V22, P287, DOI 10.1111/j.1365-2265.1985.tb03242.x; HEGEDUS L, 1985, CLIN ENDOCRINOL, V23, P423, DOI 10.1111/j.1365-2265.1985.tb01100.x; HEGEDUS L, 1987, DAN MED BULL, V34, P121; HENNESSY W B, 1964, Med J Aust, V1, P505; HINTZE G, 1991, ACTA ENDOCRINOL-COP, V124, P12, DOI 10.1530/acta.0.1240012; HOLLINGSWORTH DR, 1963, MEDICINE, V42, P47, DOI 10.1097/00005792-196301000-00003; HULL OH, 1955, ARCH PATHOL, V59, P291; Jaffe RH, 1930, ARCH PATHOL, V10, P887; JARLOV AE, 1991, J INTERN MED, V229, P159, DOI 10.1111/j.1365-2796.1991.tb00324.x; JARLOV AE, 1991, DAN MED BULL, V38, P87; KATLIC MR, 1985, ANN THORAC SURG, V39, P391, DOI 10.1016/S0003-4975(10)62645-8; KEARNS JE, 1967, TREATMENT HYPERTHYRO, P16; KILPATRICK R, 1963, BMJ-BRIT MED J, P29; LADENSON PW, 1991, WERNER INGBARS THYRO, P901; MACLENNAN R, 1969, ENDEMIC GOITER, P67; MALAMOS B, 1970, ENDOKRINOLOGIE, V56, P232; MANDART G, 1975, INT J NUCL MED BIOL, V2, P185, DOI 10.1016/S0047-0740(75)80009-X; MERCER R D, 1975, Cleveland Clinic Quarterly, V42, P319; PEREZ C, 1958, Bull World Health Organ, V18, P217; PERRILD H, 1990, AM J PSYCHIAT, V147, P1518; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; SHAPIRA JD, 1990, ART SCI BEDSIDE DIAG, P236; Silink K, 1966, ENDEMIC GOITRE ALLIE, P33; SIMINOSKI K, 1994, HEAD NECK-J SCI SPEC, V16, P21, DOI 10.1002/hed.2880160106; SMITH RN, 1967, BRIT MED J, V1, P129, DOI 10.1136/bmj.1.5533.129; TAMAYO SG, 1993, J GEN INTERN MED, V8, P69, DOI 10.1007/BF02599986; TANNAHILL AJ, 1978, CLIN ENDOCRINOL, V8, P483, DOI 10.1111/j.1365-2265.1978.tb02185.x; TROTTER WR, 1962, BRIT J PREV SOC MED, V16, P16; TROWBRIDGE FL, 1975, PEDIATRICS, V56, P82; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; WILLIAMS JW, 1992, ANN INTERN MED, V117, P705, DOI 10.7326/0003-4819-117-9-705; WILLIAMS RH, 1949, AM J MED, V7, P702, DOI 10.1016/0002-9343(49)90409-X; WINSA B, 1990, ACTA ENDOCRINOL-COP, V122, P722, DOI 10.1530/acta.0.1220722	50	19	19	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 8	1995	273	10					813	817		10.1001/jama.273.10.813	http://dx.doi.org/10.1001/jama.273.10.813			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ750	7861577				2022-12-28	WOS:A1995QJ75000035
J	YARMOLINSKY, A				YARMOLINSKY, A			SUPPORTING THE PATIENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											YARMOLINSKY, A (corresponding author), UNIV MARYLAND,BALTIMORE,MD 21228, USA.							JOHNSSON J, 1995, AMA NEWS        0123, P35; JOHNSSON J, 1995, AM MED NEWS     0313, P1	2	7	7	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 2	1995	332	9					602	603		10.1056/NEJM199503023320912	http://dx.doi.org/10.1056/NEJM199503023320912			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ090	7838198				2022-12-28	WOS:A1995QJ09000012
J	GIOVANNUCCI, E; ASCHERIO, A; RIMM, EB; COLDITZ, GA; STAMPFER, MJ; WILLETT, WC				GIOVANNUCCI, E; ASCHERIO, A; RIMM, EB; COLDITZ, GA; STAMPFER, MJ; WILLETT, WC			PHYSICAL-ACTIVITY, OBESITY, AND RISK FOR COLON-CANCER AND ADENOMA IN MEN	ANNALS OF INTERNAL MEDICINE			English	Article							BODY-FAT DISTRIBUTION; COLORECTAL-CANCER; OCCUPATIONAL EXERCISE; ALCOHOL-CONSUMPTION; COLLEGE ALUMNI; GROWTH-FACTOR; BOWEL HABIT; YOUNG MEN; CELL-LINE; INSULIN	Objective: To determine whether physical inactivity and obesity increase risk for colon cancer and adenomas, which are precursors of cancer, and whether the abdominal distribution of obesity is an independent risk factor for these events. Design: Prospective cohort study. Setting: United States. Patients: 47 723 male health professionals, 40 to 75 years of age, who responded to a questionnaire mailed in 1986. Measurements: Questionnaires in 1986 about physical activity level and body mass index, and questionnaires in 1987 (31 055 respondents) about waist and hip circumferences. Between 1986 and 1992, 203 new patients were diagnosed with colon cancer and 586 were diagnosed with adenomas. Results: Physical activity was inversely associated with risk for colon cancer (high compared with low quintiles of average energy expenditure from leisure time activities: relative risk, 0.53 [95% CI, 0.32 to 0.88], P for trend = 0.03) after adjustment for age; history of colorectal polyp; previous endoscopy; parental history of colorectal cancer; smoking; body mass; use of aspirin; and intake of red meat, dietary fiber, folate, and alcohol. Body mass index was directly associated with risk for colon cancer independently of physical activity level. Waist circumference and waist-to-hip ratio were strong risk factors for colon cancer (waist-to-hip ratio greater than or equal to 0.99 compared with waist-to-hip ratio < 0.90: multivariate relative risk, 3.41 [CI, 1.52 to 7.66], P for trend = 0.01; waist circumference greater than or equal to 43 inches compared with waist circumference < 35 inches: relative risk, 2.56 [CI, 1.33 to 4.96], P for trend < 0.001). These associations persisted even after adjustment for body mass and physical activity. Similar associations were seen between obesity and physical inactivity and adenomas of 1 cm or more, but no association was observed for smaller adenomas. Height was also associated with a higher risk for colon cancer (height greater than or equal to 73 inches compared with height less than or equal to 68 inches: multivariate relative risk, 1.76 [CI, 1.13 to 2.74], P for trend = 0.02). Conclusions: The results support an inverse association between physical activity and risk for colon cancer, whereas height and obesity, particularly abdominal adiposity, are associated with an elevated risk.	HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, BOSTON, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	GIOVANNUCCI, E (corresponding author), CHANNING LABS, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 55075] Funding Source: Medline; NHLBI NIH HHS [HL35464] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055075] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; ALBANES D, 1989, AM J PUBLIC HEALTH, V79, P744, DOI 10.2105/AJPH.79.6.744; ALBANES D, 1988, CANCER RES, V48, P1658; ALBANES D, 1990, NUTR CANCER, V14, P69, DOI 10.1080/01635589009514078; Albanes D, 1990, Epidemiology, V1, P65, DOI 10.1097/00001648-199001000-00014; ALBANES D, 1988, JNCI-J NATL CANCER I, V80, P772, DOI 10.1093/jnci/80.10.772; BALLARDBARBASH R, 1990, CANCER RES, V50, P3610; BINGHAM SA, 1989, GASTROENTEROLOGY, V97, P1389, DOI 10.1016/0016-5085(89)90381-8; BJORK J, 1993, SCAND J GASTROENTERO, V28, P879, DOI 10.3109/00365529309103129; BJORNTORP P, 1991, DIABETES CARE, V14, P1132, DOI 10.2337/diacare.14.12.1132; BOSTICK RM, 1994, CANCER CAUSE CONTROL, V5, P38, DOI 10.1007/BF01830725; BOYLE P, 1985, INT J CANCER, V36, P9, DOI 10.1002/ijc.2910360103; BROWNSON RC, 1989, AM J EPIDEMIOL, V130, P675, DOI 10.1093/oxfordjournals.aje.a115389; CHUTE CG, 1991, CANCER CAUSE CONTROL, V2, P117, DOI 10.1007/BF00053131; COENEN C, 1992, AM J GASTROENTEROL, V87, P292; DEVERDIER MG, 1990, INT J CANCER, V46, P985, DOI 10.1002/ijc.2910460606; DONAHUE RP, 1987, LANCET, V1, P821; FRASER G, 1993, CANCER CAUSE CONTROL, V4, P45, DOI 10.1007/BF00051713; FREDRIKSSON M, 1989, CANCER, V63, P1838; GARABRANT DH, 1984, AM J EPIDEMIOL, V119, P1005, DOI 10.1093/oxfordjournals.aje.a113805; GARLAND C, 1985, LANCET, V1, P307, DOI 10.1016/S0140-6736(85)91082-7; GERHARDSSON M, 1988, INT J EPIDEMIOL, V17, P743, DOI 10.1093/ije/17.4.743; GERHARDSSON M, 1986, AM J EPIDEMIOL, V123, P775, DOI 10.1093/oxfordjournals.aje.a114306; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GIOVANNUCCI E, 1994, J NATL CANCER I, V86, P192, DOI 10.1093/jnci/86.3.192; GIOVANNUCCI E, 1994, J NATL CANCER I, V86, P183, DOI 10.1093/jnci/86.3.183; GIOVANNUCCI E, 1995, IN PRESS CANCER CAUS; GIOVANNUCCI E, 1994, JNCI-J NATL CANCER I, V54, P2390; GRAHAM S, 1988, AM J EPIDEMIOL, V128, P490, DOI 10.1093/oxfordjournals.aje.a114997; HILL M, 1978, PATHOGENESIS COLOREC, P158; HIRSCH J, 1956, GASTROENTEROLOGY, V31, P274; HOPKINS WG, 1991, AM J EPIDEMIOL, V133, P73, DOI 10.1093/oxfordjournals.aje.a115805; HYAMS DE, 1974, BRIT MED J, V1, P107, DOI 10.1136/bmj.1.5898.107; KATO I, 1990, JPN J CANCER RES, V81, P1101, DOI 10.1111/j.1349-7006.1990.tb02520.x; KISSEBAH AH, 1982, J CLIN ENDOCR METAB, V54, P254, DOI 10.1210/jcem-54-2-254; KLATSKY AL, 1988, AM J EPIDEMIOL, V128, P1007; KOENUMA M, 1989, JPN J CANCER RES, V80, P51, DOI 10.1111/j.1349-7006.1989.tb02244.x; KOIVISTO V A, 1986, Diabetes Metabolism Reviews, V1, P445; KROTKIEWSKI M, 1983, J CLIN INVEST, V72, P1150, DOI 10.1172/JCI111040; LEE IM, 1992, J NATL CANCER I, V84, P1326, DOI 10.1093/jnci/84.17.1326; LEE IM, 1991, J NATL CANCER I, V83, P1324, DOI 10.1093/jnci/83.18.1324; LEMARCHAND L, 1992, CANCER CAUSE CONTROL, V3, P349, DOI 10.1007/BF00146888; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; LITTLE J, 1993, BRIT J CANCER, V67, P177, DOI 10.1038/bjc.1993.31; MILNE JS, 1972, GERONTOL CLIN, V14, P56, DOI 10.1159/000245372; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; NEUGUT AI, 1991, J NATL CANCER I, V83, P359, DOI 10.1093/jnci/83.5.359; OETTLE GJ, 1991, GUT, V32, P941, DOI 10.1136/gut.32.8.941; PAFFENBARGER RS, 1987, AM J CLIN NUTR, V45, P312, DOI 10.1093/ajcn/45.1.312; PETERS RK, 1989, CANCER RES, V49, P5459; PHILLIPS RL, 1985, JNCI-J NATL CANCER I, V74, P307; POLEDNAK AP, 1976, CANCER, V38, P382, DOI 10.1002/1097-0142(197607)38:1<382::AID-CNCR2820380155>3.0.CO;2-V; POTTER JD, 1993, EPIDEMIOL REV, V15, P499, DOI 10.1093/oxfordjournals.epirev.a036132; REGENSTEINER JG, 1991, DIABETES CARE, V14, P1066, DOI 10.2337/diacare.14.11.1066; RICCARDI G, 1991, DIABETES CARE, V14, P1115, DOI 10.2337/diacare.14.12.1115; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; RIMM EB, 1990, AM J EPIDEMIOL, V131, P1068, DOI 10.1093/oxfordjournals.aje.a115598; Rothman K, 1986, MODERN EPIDEMIOLOGY; SEVERSON RK, 1989, AM J EPIDEMIOL, V130, P522, DOI 10.1093/oxfordjournals.aje.a115366; SICONOLFI SF, 1985, AM J EPIDEMIOL, V122, P101, DOI 10.1093/oxfordjournals.aje.a114068; SLATTERY ML, 1988, AM J EPIDEMIOL, V128, P989; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; VENA JE, 1985, AM J EPIDEMIOL, V122, P357, DOI 10.1093/oxfordjournals.aje.a114116; VENA JE, 1987, AM J CLIN NUTR, V45, P318, DOI 10.1093/ajcn/45.1.318; WATKINS LF, 1990, INT J CANCER, V45, P372, DOI 10.1002/ijc.2910450227; WHITTEMORE AS, 1990, JNCI-J NATL CANCER I, V82, P915, DOI 10.1093/jnci/82.11.915; WILLETT W, 1989, NATURE, V338, P389, DOI 10.1038/338389a0; WILLETT W, 1990, NUTR EPIDEMIOLOGY, P217; WINICK M, 1966, J NUTR, V89, P300, DOI 10.1093/jn/89.3.300; WOLF AM, 1994, INT J EPIDEMIOL, V23, P991, DOI 10.1093/ije/23.5.991; WU AH, 1987, BRIT J CANCER, V55, P687, DOI 10.1038/bjc.1987.140; 1992, CANCER FACTS FIGURES	74	751	765	0	59	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1995	122	5					327	334		10.7326/0003-4819-122-5-199503010-00002	http://dx.doi.org/10.7326/0003-4819-122-5-199503010-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ085	7847643				2022-12-28	WOS:A1995QJ08500002
J	WILCOX, A; SKJAERVEN, R; BUEKENS, P; KIELY, J				WILCOX, A; SKJAERVEN, R; BUEKENS, P; KIELY, J			BIRTH-WEIGHT AND PERINATAL-MORTALITY - A COMPARISON OF THE UNITED-STATES AND NORWAY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VITAL-STATISTICS	Objective.-To compare perinatal mortality in the United States and Norway, using a new analytic approach based on relative birth weight. Design.-Comparison of linked birth and perinatal death records for US and Norwegian births from 1986 through 1987, the most recently available 2-year period. Setting.-Norway and the United States. Participants.-A total of 7 445 914 US births and 105 084 Norwegian births. Interventions.-None. Main Outcome Measure.-Perinatal weight-specific mortality after adjustment for each country's own mean birth weight. Results.-The higher rate of perinatal death in the United States compared with Norway is due to an excess of preterm deliveries in the United States. Low-weight, preterm births comprise 2.9% of US births compared with 2.1% of Norwegian births. If the United States could eliminate this slight excess of preterm delivery, perinatal mortality in the United States would decrease to the level in Norway. Unexpectedly, the survival of newborns at any given birth weight is virtually the same in the United States and Norway when newborns' birth weights are considered relative to their own nation's mean weight. Conclusions.-Low rates of perinatal mortality in the Scandinavian countries have usually been attributed to the heavier weights of their newborns. Higher mortality among US infants is in fact due entirety to a small excess of preterm deliveries. The lighter weights of US newborns at term appear not to affect perinatal survival. Furthermore, the apparent survival advantage of low-weight US newborns (used by policymakers as evidence of superior US intensive neonatal care) may be at [east partly an artifact. When weight-specific mortality rates are adjusted to relative birth weight, low-weight newborns have the same survival in Norway as in the United States. The prevention of excess mortality among US infants depends on the prevention of preterm births, not on changes in mean birth weight.	UNIV BERGEN,MED INFORMAT & STAT SECT,BERGEN,NORWAY; FREE UNIV BRUSSELS,SCH PUBL HLTH,BRUSSELS,BELGIUM; CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,HYATTSVILLE,MD 20782	University of Bergen; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	WILCOX, A (corresponding author), NIEHS,EPIDEMIOL BRANCH,POB 12233,RES TRIANGLE PK,NC 27709, USA.		Wilcox, Allen J/C-7723-2019	Wilcox, Allen J/0000-0002-3376-1311				BUEKENS P, 1993, AM J OBSTET GYNECOL, V168, P937, DOI 10.1016/S0002-9378(12)90849-2; ERICKSON JD, 1982, JAMA-J AM MED ASSOC, V247, P987; GUYER B, 1982, NEW ENGL J MED, V306, P1230; HOFFMAN HJ, 1984, PERINATAL EPIDEMIOLO, P491; MORTON NE, 1967, GENETICS INTERRACIAL, P86; NOTZON F, 1992, P INT COLLABORATIVE, V3, pV3; ROOTH G, 1980, LANCET, V1, P639; SKJAERVEN R, 1988, INT J EPIDEMIOL, V17, P830, DOI 10.1093/ije/17.4.830; TAFFEL S, 1982, VITAL HLTH STATIS 21, V93; VENTURA SJ, 1994, MONTHLY VITAL STATIS, P1; WEGMAN ME, 1991, PEDIATRICS, V88, P1081; WEGMAN ME, 1993, PEDIATRICS, V92, P743; WILCOX A, 1990, J PEDIATR-US, V116, P7, DOI 10.1016/S0022-3476(05)81638-5; WILCOX AJ, 1986, INT J EPIDEMIOL, V15, P188, DOI 10.1093/ije/15.2.188; WILCOX AJ, 1992, AM J PUBLIC HEALTH, V82, P378, DOI 10.2105/AJPH.82.3.378; WILCOX AJ, 1983, AM J EPIDEMIOL, V118, P857, DOI 10.1093/oxfordjournals.aje.a113704; WILCOX AJ, 1993, AM J EPIDEMIOL, V137, P1098, DOI 10.1093/oxfordjournals.aje.a116613; WILCOX AJ, 1983, INT J EPIDEMIOL, V12, P314, DOI 10.1093/ije/12.3.314; 1992, FACTORS CONTRIBUTING	19	68	70	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	1995	273	9					709	711		10.1001/jama.273.9.709	http://dx.doi.org/10.1001/jama.273.9.709			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH814	7853628				2022-12-28	WOS:A1995QH81400029
J	BABBITT, PC; MRACHKO, GT; HASSON, MS; HUISMAN, GW; KOLTER, R; RINGE, D; PETSKO, GA; KENYON, GL; GERLT, JA				BABBITT, PC; MRACHKO, GT; HASSON, MS; HUISMAN, GW; KOLTER, R; RINGE, D; PETSKO, GA; KENYON, GL; GERLT, JA			FUNCTIONALLY DIVERSE ENZYME SUPERFAMILY THAT ABSTRACTS THE ALPHA-PROTONS OF CARBOXYLIC-ACIDS	SCIENCE			English	Article							ESCHERICHIA-COLI; MANDELATE RACEMASE; CRYSTAL-STRUCTURE; NUCLEOTIDE-SEQUENCE; PSEUDOMONAS-PUTIDA; LACTONIZING ENZYME; D-GALACTONATE; CARBON ACIDS; DNA-SEQUENCE; CLONING	Mandelate racemase and muconate lactonizing enzyme are structurally homologous but catalyze different reactions, each initiated by proton abstraction from carbon. The structural similarity to mandelate racemase of a previously unidentified gene product was used to deduce its function as a galactonate dehydratase. in this enzyme superfamily that has evolved to catalyze proton abstraction from carbon, three variations of homologous active site architectures are now represented: lysine and histidine bases in the active site of mandelate racemase, only a lysine base in the active site of muconate lactonizing enzyme, and only a histidine base in the active site of galactonate dehydratase. This discovery supports the hypothesis that new enzymatic activities evolve by recruitment of a protein catalyzing the same type of chemical reaction.	UNIV ILLINOIS, DEPT BIOCHEM, URBANA, IL 61801 USA; BRANDEIS UNIV, ROSENSTIEL BASIC MED SCI RES CTR, WALTHAM, MA 02254 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA	University of Illinois System; University of Illinois Urbana-Champaign; Brandeis University; Harvard University; Harvard Medical School	BABBITT, PC (corresponding author), UNIV CALIF SAN FRANCISCO, SCH PHARM, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA.		Petsko, Gregory/AAO-7962-2020	Huisman, Gjalt/0000-0003-1955-1120	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040570] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-40570, GM-34572] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDRICH TL, 1987, GENE, V52, P185, DOI 10.1016/0378-1119(87)90045-X; BABBITT PC, UNPUB; BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BURLAND V, 1993, GENOMICS, V16, P551, DOI 10.1006/geno.1993.1230; BURLINGAME RP, M69160 GENB ACC; COOPER RA, 1978, ARCH MICROBIOL, V118, P199, DOI 10.1007/BF00415730; DEACON J, 1977, FEBS LETT, V77, P201, DOI 10.1016/0014-5793(77)80234-2; DOLNICK BJ, 1993, NUCLEIC ACIDS RES, V21, P1747, DOI 10.1093/nar/21.8.1747; DOLNICK BJ, COMMUNICATION; DONALD A, 1979, J BIOL CHEM, V254, P2132; EGAN SE, 1992, J BACTERIOL, V174, P4638, DOI 10.1128/JB.174.14.4638-4646.1992; EIGLMEIER K, 1987, MOL MICROBIOL, V1, P251, DOI 10.1111/j.1365-2958.1987.tb01931.x; Gerlt J.A., 1992, CURR OPIN STRUC BIOL, V2, P736; GERLT JA, 1993, BIOCHEMISTRY-US, V32, P11943, DOI 10.1021/bi00096a001; GERLT JA, 1992, J AM CHEM SOC, V114, P5928, DOI 10.1021/ja00041a004; GOLDMAN A, 1987, J MOL BIOL, V194, P143, DOI 10.1016/0022-2836(87)90723-6; HASSON M, UNPB; HAYDON DJ, 1991, FEMS MICROBIOL LETT, V79, P291, DOI 10.1016/0378-1097(91)90101-F; HUISMAN GW, 1994, SCIENCE, V265, P537, DOI 10.1126/science.7545940; JENSEN RA, 1976, ANNU REV MICROBIOL, V30, P409, DOI 10.1146/annurev.mi.30.100176.002205; JENSEN RA, 1987, COLD SPRING HARBOR S, V52; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; LANDRO JA, 1994, BIOCHEMISTRY-US, V33, P635, DOI 10.1021/bi00169a003; LEBIODA L, 1988, NATURE, V333, P683, DOI 10.1038/333683a0; NEIDHART DJ, 1991, BIOCHEMISTRY-US, V30, P9264, DOI 10.1021/bi00102a019; NEIDHART DJ, 1990, NATURE, V347, P692, DOI 10.1038/347692a0; PETSKO GA, 1993, TRENDS BIOCHEM SCI, V18, P372, DOI 10.1016/0968-0004(93)90091-Z; RANSOM SC, 1988, BIOCHEMISTRY-US, V27, P540, DOI 10.1021/bi00402a006; SCHNEIDER D, 1993, J GEN MICROBIOL, V139, P2559, DOI 10.1099/00221287-139-11-2559; SHAFER SL, UNPUB; TAYLOR KT, 1991, THESIS U MARYLAND CO; TSOU AY, 1990, BIOCHEMISTRY-US, V29, P9856, DOI 10.1021/bi00494a015; WEDEKIND JH, IN PRESS BIOCHEMISTR	34	138	139	2	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 24	1995	267	5201					1159	1161		10.1126/science.7855594	http://dx.doi.org/10.1126/science.7855594			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855594				2022-12-28	WOS:A1995QJ23700034
J	NAYAR, SK; OREN, M				NAYAR, SK; OREN, M			VISUAL APPEARANCE OF MATTE SURFACES	SCIENCE			English	Article								All visual sensors, biological and artificial, are finite in resolution by necessity. As a result, the effective reflectance of surfaces in a scene varies with magnification. A reflectance model for matte surfaces is described that incorporates the effect of macroscopic surface undulations on image brightness. The model takes into account complex physical phenomena such as masking, shadowing, and interreflections between points on the surface, and it predicts the appearance of a wide range of natural surfaces. The implications of these results for human vision, machine vision, and computer graphics are demonstrated with both real and rendered images of three-dimensional objects. In particular, objects with extremely rough surfaces produce silhouette images devoid of shading, precluding visual perception of the object's shape.			NAYAR, SK (corresponding author), COLUMBIA UNIV,DEPT COMP SCI,NEW YORK,NY 10027, USA.							BUHL D, 1968, J GEOPHYS RES, V73, P16; Chandrasekhar S., 1950, RAD TRANSFER; Cohen M.F., 1993, RADIOSITY REALISTIC; DAVINCI L, 1959, TREATISE PAINTING; FORSYTH D, 1989, 1989 P IEEE C COMP V; GEIST B, 1975, BRANCUSI SCULPTURE D; HAPKE B, 1963, J GEOPHYS RES, V68, P15; HAPKE BW, 1993, SCIENCE, V260, P509, DOI 10.1126/science.260.5107.509; HERING RG, 1970, AIAA PROGR ASTRONAUT, V23, P337; Horn BKP, 1989, SHAPE SHADING; Janson H. W., 1991, HIST ART; KOENDERINK JJ, 1983, J OPT SOC AM, V73, P6; Kubelka P., 1931, Z TECHNISCHE PHYS, V12, P593, DOI DOI 10.4236/MSCE.2014.28004; Lambert J.H., 1760, PHOTOMETRIA SIVE MEN; Minnaert M, 1941, ASTROPHYS J, V93, P403, DOI 10.1086/144279; Nayar Shree K., 1991, IJCV, V6, P3; OPIK E, 1924, PUBLICATIONS OBSERVA, V26, P1; OREN M, IN PRESS INT J COMPU; Oren M., 1994, P ACM SIGGRAPH; ORLOVA NS, 1956, ASTRON ZH, V33, P93; RAMACHANDRAN VS, 1988, NATURE, V331, P163, DOI 10.1038/331163a0; SIEGEL R, 1956, THERMAL RAD HEAT TRA; SMITH BG, 1967, J GEOPHYS RES, V72, P16; SMITH JA, 1980, PHOTOGRAMM ENG REM S, V46, P1183; STRONG DS, 1979, LEONARDO EYE; TORRANCE KE, 1967, J OPT SOC AM, V57, P1105, DOI 10.1364/JOSA.57.001105; WESTHEIMER G, 1980, MED PHYSL, V1, pCH16; Woodham R. J., 1980, OPTICAL ENG, V19, P1	28	51	51	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1153	1156		10.1126/science.7855592	http://dx.doi.org/10.1126/science.7855592			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855592				2022-12-28	WOS:A1995QJ23700032
J	DICKERSIN, K; EVERETT, D; FELDON, S; HOOPER, F; KAUFMAN, D; KELMAN, S; LANGENBERG, P; NEWMAN, NJ; WILSON, PD; ZAM, SZ				DICKERSIN, K; EVERETT, D; FELDON, S; HOOPER, F; KAUFMAN, D; KELMAN, S; LANGENBERG, P; NEWMAN, NJ; WILSON, PD; ZAM, SZ			OPTIC-NERVE DECOMPRESSION SURGERY FOR NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY (NAION) IS NOT EFFECTIVE AND MAY BE HARMFUL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SHEATH DECOMPRESSION; CLINICAL PROFILE; FORM	Objective.-To assess the safety and efficacy of optic nerve decompression surgery compared with careful follow-up alone in patients with nonarteritic anterior ischemic optic neuropathy (NAION). Design.-The Ischemic Optic Neuropathy Decompression Trial (IONDT) is a randomized, single-masked, multicenter trial. Setting.-Twenty-five US clinical centers. Participants.-The IONDT ceased recruitment on October 20, 1994, on the recommendation of its Data and Safety Monitoring Committee. The preliminary results presented herein are based on data as of September 8, 1994, from 244 patients with NAION and visual acuity of 20/64 or worse. One hundred twenty-five patients had been randomized to careful follow-up, and 119 had been randomized to surgery, with 91 and 95, respectively, having completed 6 months of follow-up. Intervention.-Patients in the surgery group received optic nerve decompression surgery and follow-up ophthalmologic examinations; those in the careful follow-up group received ophthalmologic examinations at the same times as the surgery group. Main Outcome Measures.-Gain or loss of three or more lines of visual acuity on the New York Lighthouse chart at 6 months after randomization, as measured by a technician masked to treatment assignment. Results.-Patients assigned to surgery did no better when compared with patients assigned to careful follow-up regarding improved visual acuity of three or more lines at 6 months: 32.6% of the surgery group improved compared with 42.7% of the careful follow-up group. The odds ratio (OR) for three or more lines better, adjusted for baseline visual acuity and diabetes, was 0.74 (95% confidence interval [Cl], 0.39 to 1.38). Patients receiving surgery had a significantly greater risk of losing three or more lines of vision at 6 months: 23.9% in the surgery group worsened compared with 12.4% in the careful follow-up group. The 6-month adjusted OR for three or more lines worse was 1.96 (95% Cl, 0.87 to 4.41). No difference in treatment effect was observed between patients with progressive NAION and all others. Conclusion.-Results from the IONDT indicate that optic nerve decompression surgery for NAION is not effective, may be harmful, and should be abandoned. The spontaneous improvement rate is better than previously reported.	UNIV MARYLAND,SCH MED,DEPT OPHTHALMOL,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore			Dickersin, Kay/A-4576-2008; Newman, Nancy/AAB-2532-2021	Trobe, Jonathan/0000-0003-0728-6729; Chalam, K V/0000-0002-0004-9416; Feldon, Steven/0000-0003-0603-9312; Varadarajan, Jaya/0000-0001-5640-8097; Elman, Michael/0000-0001-7726-9508; Chung, Sophia/0000-0001-7321-7225	NEI NIH HHS [EY09608, EY09545, EY09556] Funding Source: Medline; NATIONAL EYE INSTITUTE [U10EY009556, U10EY009545, U10EY009608] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARNOLD AC, 1994, J NEURO-OPHTHALMOL, V14, P66; BERI M, 1987, OPHTHALMOLOGY, V94, P1020; BOGHEN DR, 1975, BRAIN, V98, P689, DOI 10.1093/brain/98.4.689; Ederer F, 1975, Surv Ophthalmol, V19, P267; ELLENBERGER C, 1973, ARCH NEUROL-CHICAGO, V28, P182, DOI 10.1001/archneur.1973.00490210062008; HAYREH SS, 1981, ARCH NEUROL-CHICAGO, V38, P675, DOI 10.1001/archneur.1981.00510110035002; HAYREH SS, 1990, EYE, V4, P25, DOI 10.1038/eye.1990.4; JOHNSON LN, 1994, J NEURO-OPHTHALMOL, V14, P38; KELMAN SE, 1991, ARCH OPHTHALMOL-CHIC, V109, P667, DOI 10.1001/archopht.1991.01080050081034; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR, P296; REPKA MX, 1983, AM J OPHTHALMOL, V96, P478, DOI 10.1016/S0002-9394(14)77911-5; RIZZO JF, 1991, ARCH OPHTHALMOL-CHIC, V109, P1665; SERGOTT RC, 1989, ARCH OPHTHALMOL-CHIC, V107, P1743, DOI 10.1001/archopht.1989.01070020825022; SPOOR TC, 1991, AM J OPHTHALMOL, V111, P724, DOI 10.1016/S0002-9394(14)76779-0; SPOOR TC, 1993, OPHTHALMOLOGY, V100, P306; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WESTHEIMER G, 1979, ARCH OPHTHALMOL-CHIC, V97, P327; YEE RD, 1994, J NEURO-OPHTHALMOL, V14, P70; 1992, MANUAL OPERATIONS, P1	19	265	269	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	1995	273	8					625	632		10.1001/jama.1995.03520320035038	http://dx.doi.org/10.1001/jama.1995.03520320035038			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG748	7844872				2022-12-28	WOS:A1995QG74800027
J	DEVYNCK, MA				DEVYNCK, MA			DO CELL-MEMBRANE DYNAMICS PARTICIPATE IN INSULIN-RESISTANCE	LANCET			English	Editorial Material							RECEPTOR KINASE				DEVYNCK, MA (corresponding author), UNIV PARIS 05,NECKER MED SCH,DEPT PHARMACOL,PARIS,FRANCE.							ARNOLD RS, 1994, BIOCHEMISTRY-US, V30, P7747; BRUNEAU C, 1987, BIOCHIM BIOPHYS ACTA, V928, P297, DOI 10.1016/0167-4889(87)90189-3; HAMILTON JA, 1989, BIOCHEMISTRY-US, V28, P2514, DOI 10.1021/bi00432a025; LEWIS RE, 1987, BIOCHEM J, V248, P829, DOI 10.1042/bj2480829; NADIV O, 1994, BIOCHEM J, V298, P443, DOI 10.1042/bj2980443; SANG KHL, 1991, CLIN SCI, V80, P205, DOI 10.1042/cs0800205; SANG KHLQ, 1993, BRIT J CLIN PHARMACO, V36, P437, DOI 10.1111/j.1365-2125.1993.tb00392.x; SHINITZKY M, 1984, PHYSL MEMBRANE FLUID, V1, P1; SWEET LJ, 1987, FASEB J, V1, P55, DOI 10.1096/fasebj.1.1.3038645; VESSBY B, 1994, DIABETES, V43, P1353, DOI 10.2337/diabetes.43.11.1353; WATALA C, 1993, DIABETIC MED, V10, P13, DOI 10.1111/j.1464-5491.1993.tb01990.x; 1995, LANCET, V345, P357	12	25	25	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 11	1995	345	8946					336	337		10.1016/S0140-6736(95)90335-6	http://dx.doi.org/10.1016/S0140-6736(95)90335-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF722	7845111	Bronze			2022-12-28	WOS:A1995QF72200003
J	CHIANG, CM; ROEDER, RG				CHIANG, CM; ROEDER, RG			CLONING OF AN INTRINSIC HUMAN TFIID SUBUNIT THAT INTERACTS WITH MULTIPLE TRANSCRIPTIONAL ACTIVATORS	SCIENCE			English	Article							RNA POLYMERASE-II; TATA-BINDING PROTEIN; NF-KAPPA-B; FUNCTIONAL-ANALYSIS; LESS PROMOTER; EXPRESSION; COMPLEX; VP16; IDENTIFICATION; COACTIVATORS	TFIID is a multisubunit protein complex comprised of the TATA-binding protein (TBP) and multiple TBP-associated factors (TAFs). The TAFs in TFIID are essential for activator-dependent transcription, The cloning of a complementary DNA encoding a human TFIID TAF, TAF(II)55, that has no known homolog in Drosophila TFIID is now described. TAF(II)55 is shown to interact with the largest subunit(TAF(II)230) of human TFIID through its central region and with multiple activators-including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins-through a distinct amino-terminal domain. The TAF(II)55-interacting region of Sp1 was localized to its DNA-binding domain, which is distinct from the glutamine-rich activation domains previously shown to interact with Drosophila TAF(II)110. Thus, this human TFIID TAF may be a co-activator that mediates a response to multiple activators through a distinct mechanism.	ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021	Rockefeller University								BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; Chiang C M, 1993, Methods Mol Biol, V15, P189, DOI 10.1385/0-89603-244-2:189; Chiang C.-W., UNPUB; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHIANG CM, 1993, PEPTIDE RES, V6, P62; CHIANG CM, 1992, P NATL ACAD SCI USA, V89, P5799, DOI 10.1073/pnas.89.13.5799; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOFFMANN A, UNPUB; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; KAULEN H, 1991, MOL CELL BIOL, V11, P412, DOI 10.1128/MCB.11.1.412; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KOKUBO T, 1993, J BIOL CHEM, V268, P17554; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; REINBERG D, 1987, J BIOL CHEM, V262, P3310; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; TAKADA R, 1992, P NATL ACAD SCI USA, V89, P11809, DOI 10.1073/pnas.89.24.11809; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; YOON JB, 1994, MOL CELL BIOL, V14, P1776, DOI 10.1128/MCB.14.3.1776; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	49	362	369	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 27	1995	267	5197					531	536		10.1126/science.7824954	http://dx.doi.org/10.1126/science.7824954			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD403	7824954				2022-12-28	WOS:A1995QD40300044
J	SCHULZE, KL; BROADIE, K; PERIN, MS; BELLEN, HJ				SCHULZE, KL; BROADIE, K; PERIN, MS; BELLEN, HJ			GENETIC AND ELECTROPHYSIOLOGICAL STUDIES OF DROSOPHILA SYNTAXIN-1A DEMONSTRATE ITS ROLE IN NONNEURONAL SECRETION AND NEUROTRANSMISSION	CELL			English	Article							INTEGRAL MEMBRANE-PROTEIN; SYNAPTIC VESICLES; VESICULAR TRANSPORT; SYNAPTOTAGMIN; YEAST; RECEPTORS; RELEASE; FAMILY; FUSION	Cloning and characterization of the Drosophila syn taxin-1A gene, syx-1A, reveal that it is present in several tissues but is predominantly expressed in the nervous system, where it is localized to axons and synapses. We have generated an allelic series of loss-of-function mutations that result in embryonic lethality with associated morphological and secretory defects dependent on the severity of the mutant allele. Electrophysiological recordings from partial loss-of-function mutants indicate absence of endogenous synaptic transmission at the neuromuscular junction and an 80% reduction of evoked transmission. Complete absence of syx-1A causes subtle morphological defects in the peripheral and central nervous systems, affects nonneural secretory events, and entirely abolishes neurotransmitter release. These data demonstrate that syntaxin plays a key role in nonneuronal secretion and is absolutely required for evoked neurotransmission.	BAYLOR COLL MED,HOWARD HUGHES MED INST,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,DIV NEUROSCI,HOUSTON,TX 77030; UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 3EJ,ENGLAND	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; University of Cambridge				Bellen, Hugo/0000-0001-5992-5989	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; Arias A.M., 1993, DEV DROSOPHILA, P609; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BROADIE K, 1994, P NATL ACAD SCI USA, V91, P10727, DOI 10.1073/pnas.91.22.10727; BROADIE KS, 1993, J NEUROSCI, V13, P144; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; JOHNSTON PA, 1991, NEURON, V7, P101, DOI 10.1016/0896-6273(91)90078-E; LITTLETON JT, 1993, DEVELOPMENT, V118, P1077; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; LITTLETON JT, 1994, P NATL ACAD SCI USA, V91, P10888, DOI 10.1073/pnas.91.23.10888; METZKER ML, 1995, IN PRESS COMP APPL B; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; OCHMAN H, 1988, GENETICS, V120, P621; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PERIN MS, 1991, J BIOL CHEM, V266, P623; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; RIZKI MTM, 1978, GENETICS BIOL DROS B, V2, P397; SALVATERRA PM, 1987, MOL NEUROBIOL, V1, P247, DOI 10.1007/BF02936610; SALZBERG A, 1993, DEVELOPMENT, V117, P1309; Sambrook J, 1989, MOL CLONING LABORATO; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; Skaer H., 1993, DEV DROSOPHILA MELAN, V2, P941; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; VONMOLLARD GF, 1990, NATURE, V349, P79; WILCOX M, 1986, DROSOPHILA PRACTICAL; ZINSMAIER KE, 1994, SCIENCE, V263, P977, DOI 10.1126/science.8310297; ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2	40	258	262	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 27	1995	80	2					311	320		10.1016/0092-8674(95)90414-X	http://dx.doi.org/10.1016/0092-8674(95)90414-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7834751	Bronze			2022-12-28	WOS:A1995QD92400014
J	LUESCHER, IF; VIVIER, E; LAYER, A; MAHIOU, J; GODEAU, F; MALISSEN, B; ROMERO, P				LUESCHER, IF; VIVIER, E; LAYER, A; MAHIOU, J; GODEAU, F; MALISSEN, B; ROMERO, P			CD8 MODULATION OF T-CELL ANTIGEN RECEPTOR-LIGAND INTERACTIONS ON LIVING CYTOTOXIC T-LYMPHOCYTES	NATURE			English	Article							PHYSICAL ASSOCIATION; BETA-CHAIN; MOLECULES; BINDING; ACTIVATION; EXPRESSION; COMPLEX; KINASE; CD45	THYMOCYTES and class I major histocompatibility complex (MHC)-restricted cytotoxic T lymphocytes express predominantly heterodimeric alpha/beta CD8(1,2). By interacting with non-polymorphic regions of MHC class I molecules CD8 can mediate adhesion(3-6) or by binding the same MHC molecules that interact with the T-cell antigen receptor (TCR) function as coreceptor in TCR-ligand binding and T-cell activation(1,2). Using TCR photoaffinity labelling with a soluble, monomeric photoreactive H-2K(d)-peptide derivative complex(7), we report here that the avidity of TCR-ligand interactions on cloned cytotoxic T cells is very greatly strengthened by CD8. This is primarily explained by coordinate binding of ligand molecules by CD8 and TCR, because substitution of Asp 227 of K-d with LYS severely impaired the TCR-ligand binding on CD8(+), but not CD8(-) cells. Kinetic studies on CD8(+) and CD8(-) cells further showed that CD8 imposes distinct dynamics and a remarkable temperature dependence on TCR-ligand interactions. We propose that the ability of CD8 to act as coreceptor can be modulated by CD8-TCR interactions.	CTR IMMUNOL,INSERM CNRS MARSEILLE LUMINY,F-13288 MARSEILLE 9,FRANCE; FAC MED NECKER ENFANTS MALAD,INSERM,U373,F-75730 PARIS 15,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	LUESCHER, IF (corresponding author), UNIV LAUSANNE,LUDWIG INST CANC RES,LAUSANNE BRANCH,CH-1066 EPALINGES,SWITZERLAND.		Vivier, Eric/F-8939-2010; Romero, Pedro/S-6015-2017; Malissen, Bernard/AAK-4659-2020	Vivier, Eric/0000-0001-7022-8287; Romero, Pedro/0000-0002-9688-2882; Malissen, Bernard/0000-0003-1340-9342				BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; CARBONE AM, 1988, J IMMUNOL, V141, P1369; DIANZANI U, 1992, EUR J IMMUNOL, V22, P365, DOI 10.1002/eji.1830220212; DIANZANI U, 1992, J IMMUNOL, V148, P678; EICHMANN K, 1991, J IMMUNOL, V147, P2075; GALLAGHER PF, 1989, P NATL ACAD SCI USA, V86, P10044, DOI 10.1073/pnas.86.24.10044; GOLSTEIN P, 1982, IMMUNOL REV, V68, P5, DOI 10.1111/j.1600-065X.1982.tb01058.x; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; KARAKI S, 1992, J IMMUNOL, V149, P1613; LUESCHER IF, 1994, J BIOL CHEM, V269, P5574; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MICELI MC, 1993, ADV IMMUNOL, V53, P59, DOI 10.1016/S0065-2776(08)60498-8; NAKAYAMA K, 1994, SCIENCE, V263, P1131, DOI 10.1126/science.8108731; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; OROURKE AM, 1993, IMMUNOL TODAY, V14, P183; OROURKE AM, 1990, NATURE, V346, P187, DOI 10.1038/346187a0; RATNOFSKY SE, 1987, J EXP MED, V166, P1747, DOI 10.1084/jem.166.6.1747; ROMERO P, 1993, J EXP MED, V177, P1247, DOI 10.1084/jem.177.5.1247; ROMERO P, 1993, J IMMUNOL, V150, P3825; ROMERO P, 1994, J IMMUNOL METHODS, V171, P73, DOI 10.1016/0022-1759(94)90230-5; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; STRAUS DB, 1993, J EXP MED, V178, P1523, DOI 10.1084/jem.178.5.1523; SUZUKI S, 1992, EUR J IMMUNOL, V22, P2475, DOI 10.1002/eji.1830221002; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; TOMONARI K, 1990, INT IMMUNOL, V2, P1189, DOI 10.1093/intimm/2.12.1189; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WHEELER CJ, 1992, NATURE, V357, P247, DOI 10.1038/357247a0; WHITE J, 1989, J IMMUNOL, V143, P1822; YAMANE Y, 1991, CELL IMMUNOL, V136, P496, DOI 10.1016/0008-8749(91)90370-Q	30	207	211	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					353	356		10.1038/373353a0	http://dx.doi.org/10.1038/373353a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830771				2022-12-28	WOS:A1995QD40400063
J	RUDEL, T; SCHEUERPFLUG, I; MEYER, TF				RUDEL, T; SCHEUERPFLUG, I; MEYER, TF			NEISSERIA PILC PROTEIN IDENTIFIED AS TYPE-4 PILUS TIP LOCATED ADHESIN	NATURE			English	Article							HUMAN EPITHELIAL-CELLS; ANTIGENIC VARIATION; ESCHERICHIA-COLI; VIBRIO-CHOLERAE; PHASE VARIATION; GONORRHOEAE; SEQUENCE; GENE; MENINGITIDIS; ORGANIZATION	TYPE-4 pilus-mediated adherence of Neisseria gonorrhoeae and Neisseria meningitidis is considered to be a crucial early event in neisserial infections(1,2). In addition to the principal pilus subunit (pilin or PilE), both pathogens produce low quantities of a phase-variable PilC protein which is implicated in pilus biogenesis and pilus-mediated epithelial cell adherence(3,4). The identity, however, of the pilus adhesin has remained obscure(4,5). Here we describe the isolation of a PilC protein from a gonococcal overproducing strain and demonstrate its specific interaction with human epithelial cells. Our results are consistent with the cell and species tropisms of neisserial infections. Binding of PilC effectively competes with pilus-mediated, but not Opa-mediated(6), attachment of N. gonorrhoeae and of N. meningitidis, indicating that both pathogens interact with identical or very similar epithelial cell receptors. Immunogold electron microscopy using antisera raised against purified PilC and synthetic peptides locates PilC at the tip of gonococcal pill. PilC thus represents an essential pilus-associated adhesin, providing a rationale for selective protection against neisserial infections.	MAX PLANCK INST INFEKT BIOL,D-10117 BERLIN,GERMANY	Max Planck Society	RUDEL, T (corresponding author), MAX PLANCK INST BIOL,INFEKT BIOL ABT,SPEMANNSTR 34,D-72076 TUBINGEN,GERMANY.		Meyer, Thomas F. F/J-2485-2013	Meyer, Thomas F. F/0000-0002-6120-8679				GIRON JA, 1994, MOL MICROBIOL, V12, P71, DOI 10.1111/j.1365-2958.1994.tb00996.x; GIRON JA, 1991, SCIENCE, V254, P710, DOI 10.1126/science.1683004; HAAS R, 1992, MOL MICROBIOL, V6, P197, DOI 10.1111/j.1365-2958.1992.tb02001.x; HAGBLOM P, 1985, NATURE, V315, P156, DOI 10.1038/315156a0; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; JOHNSON SC, 1991, J INFECT DIS, V163, P128, DOI 10.1093/infdis/163.1.128; JONSSON AB, 1991, EMBO J, V10, P477, DOI 10.1002/j.1460-2075.1991.tb07970.x; KELLOGG DS, 1968, J BACTERIOL, V96, P596, DOI 10.1128/JB.96.3.596-605.1968; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; LEE KK, 1994, MOL MICROBIOL, V11, P705, DOI 10.1111/j.1365-2958.1994.tb00348.x; MAKINO S, 1991, EMBO J, V10, P1307, DOI 10.1002/j.1460-2075.1991.tb07649.x; Meyer T F, 1994, Curr Top Microbiol Immunol, V192, P283; MEYER TF, 1984, P NATL ACAD SCI-BIOL, V81, P6110, DOI 10.1073/pnas.81.19.6110; MUIR LL, 1988, INFECT IMMUN, V56, P1743, DOI 10.1128/IAI.56.7.1743-1747.1988; NASSIF X, 1994, P NATL ACAD SCI USA, V91, P3769, DOI 10.1073/pnas.91.9.3769; NASSIF X, 1993, MOL MICROBIOL, V8, P719, DOI 10.1111/j.1365-2958.1993.tb01615.x; OGIERMAN MA, 1993, GENE, V126, P51, DOI 10.1016/0378-1119(93)90589-U; PARGE HE, 1990, J BIOL CHEM, V265, P2278; POHLNER J, 1993, GENE, V130, P121, DOI 10.1016/0378-1119(93)90354-6; ROTHBARD JB, 1985, P NATL ACAD SCI USA, V82, P915, DOI 10.1073/pnas.82.3.915; RUDEL T, 1992, MOL MICROBIOL, V6, P3439, DOI 10.1111/j.1365-2958.1992.tb02211.x; SASTRY PA, 1983, FEBS LETT, V151, P253, DOI 10.1016/0014-5793(83)80080-5; SHAW CE, 1990, INFECT IMMUN, V58, P3042, DOI 10.1128/IAI.58.9.3042-3049.1990; SWANSON J, 1987, J EXP MED, V165, P1016, DOI 10.1084/jem.165.4.1016; VIRJI M, 1992, MOL MICROBIOL, V6, P1271, DOI 10.1111/j.1365-2958.1992.tb00848.x; VIRJI M, 1993, MOL MICROBIOL, V10, P10131; WANG JF, 1992, INFECT IMMUN, V60, P5267, DOI 10.1128/IAI.60.12.5267-5282.1992	27	240	248	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					357	359		10.1038/373357a0	http://dx.doi.org/10.1038/373357a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830772				2022-12-28	WOS:A1995QD40400064
J	GODLEE, F				GODLEE, F			WHO FELLOWSHIPS - WHAT DO THEY ACHIEVE	BRITISH MEDICAL JOURNAL			English	Article								Training health professionals is one of WHO's major strategies for improving health care in the developing world. The aim, to strengthen a country's own capacity rather than injecting expertise from outside, is in the best tradition of sustainable development. But how effective is this so called ''capacity building in human resources''? Since it accounted for $43m of WHO's budget in 1992-3 and is considered by WHO to be a major contribution to health in individual countries, it deserves detailed examination.			GODLEE, F (corresponding author), HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA 02215, USA.							DANIDA, 1991, EFFECTIVENESS MULTIL	1	11	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 14	1995	310	6972					110	112		10.1136/bmj.310.6972.110a	http://dx.doi.org/10.1136/bmj.310.6972.110a			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC223	7833702	Green Published			2022-12-28	WOS:A1995QC22300030
J	GERGEN, P; MCQUILLAN, GM; KIELY, M; EZZATIRICE, TM; SUTTER, RW; VIRELLA, G				GERGEN, P; MCQUILLAN, GM; KIELY, M; EZZATIRICE, TM; SUTTER, RW; VIRELLA, G			A POPULATION-BASED SEROLOGIC SURVEY OF IMMUNITY TO TETANUS IN THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIPHTHERIA IMMUNITY; VACCINATION; CHILDREN; REVACCINATION; IMMUNIZATION; ADULTS	Background. Vaccination rates are frequently considered a surrogate measure of protection. To provide more accurate estimates, serum levels of antibody against tetanus were measured as part of the third National Health and Nutrition Examination Survey (NHANES III), which studied a representative sample of the civilian, noninstitutionalized population of the United States. Methods. We measured tetanus antitoxin using a solid-phase enzyme immunoassay in serum samples from 10,618 persons six years of age and older who were examined during phase 1 of NHANES III in 1988 to 1991. Results. Overall, 69.7 percent of Americans six years of age and older had protective levels of tetanus antibodies (>0.15 IU per milliliter). The rate decreased from 87.7 percent among those 6 to 11 years of age to 27.8 percent among those 70 years of age or older, Among children 6 to 16 years of age, 82.2 percent had protective levels of tetanus antibodies, with little variation according to race or ethnicity. More men than women were immune (79.0 percent vs. 62.4 percent). Mexican Americans had a significantly lower rate of immunity (57.9 percent, P<0.05) than either non-Hispanic whites (72.7 percent) or non-Hispanic blacks (68.1 percent). Those with a history of military service, higher levels of education, or incomes above the poverty level were more likely to have protective antibody levels. Although the prevalence of immunity declined rapidly starting at the age of 40 years, most of the 107 cases of tetanus (with 20 deaths) reported in 1989 and 1990 occurred in persons 60 years of age or older, Conclusions. Despite the fact that effective vaccines against tetanus have been available since the 1940s, many Americans do not have immunity to tetanus, and the rates are lowest among the elderly There is an excellent correlation between vaccination rates (96 percent) and immunity (96 percent) among six-year-olds. However, antibody levels decline over time, and one fifth of older children (10 to 16 years of age) do not have protective antibody levels.	NIAID,BETHESDA,MD 20892; CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,HYATTSVILLE,MD 20782; US MATERNAL & CHILD HLTH BUR,ROCKVILLE,MD; CTR DIS CONTROL & PREVENT,NATL IMMUNIZATION PROGRAM,ATLANTA,GA 30333; MED UNIV S CAROLINA,DEPT MICROBIOL & IMMUNOL,CHARLESTON,SC 29425	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); Centers for Disease Control & Prevention - USA; Medical University of South Carolina								BALESTRA DJ, 1993, J GEN INTERN MED, V8, P405, DOI 10.1007/BF02599616; CROSSLEY K, 1979, JAMA-J AM MED ASSOC, V242, P2298, DOI 10.1001/jama.242.21.2298; EZZATI T, 1993, 1992 P SURV RES METH, P339; HINMAN AR, 1991, AM J DIS CHILD, V145, P559, DOI 10.1001/archpedi.1991.02160050085023; KAHN HA, 1989, STATISTICAL METHODS; KHARE M, 1994, IN PRESS 1994 P SURV; MARKS JS, 1979, PEDIATRICS, V64, P304; MYERS MG, 1982, JAMA-J AM MED ASSOC, V248, P2478, DOI 10.1001/jama.248.19.2478; Orenstein W A, 1990, J Health Care Poor Underserved, V1, P315; PETER G, 1994, 1994 RED BOOK REPORT, P458; Prevots Rebecca, 1992, Morbidity and Mortality Weekly Report, V41, P1; RUBEN FL, 1973, B WORLD HEALTH ORGAN, V48, P175; SHAH BV, 1991, SUDAAN USERS MANUAL; SIMONSEN O, 1989, DAN MED BULL, V36, P24; SIMONSEN O, 1986, J BIOL STAND, V14, P231, DOI 10.1016/0092-1157(86)90008-9; SIMONSEN O, 1986, ACTA PATH MICRO IM C, V94, P77; SIMONSEN O, 1984, LANCET, V2, P1240; SUTTER RW, 1990, AM J EPIDEMIOL, V131, P132, DOI 10.1093/oxfordjournals.aje.a115466; VIRELLA G, 1991, J CLIN LAB ANAL, V5, P43, DOI 10.1002/jcla.1860050108; VOLK VK, 1962, PUBLIC HEALTH REP, V77, P185, DOI 10.2307/4591451; WEISS BP, 1983, AM J PUBLIC HEALTH, V73, P802, DOI 10.2105/AJPH.73.7.802; 1994, MMWR-MORBID MORTAL W, V43, P282; 1994, MMWR-MORBID MORTAL W, V43, P57; 1992, DHHS PHS921387 NAT C; 1994, MMWR-MORBID MORTAL W, V43, P1; 1989, CURRENT POPULATION P, V60; 1994, MMWR-MORBID MORTAL W, V42, P985; 1988, CURRENT POPULATION P, V60; 1993, STATE IMMUNIZATION 1; 1993, 1993 WORLD BANK DEV, P8; 1991, CURRENT POPULATION P, V60; 1992, MMWR-MORBID MORTAL W, V41, P67; 1994, MMWR-MORBID MORTAL W, V43, P556	33	249	255	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 23	1995	332	12					761	766		10.1056/NEJM199503233321201	http://dx.doi.org/10.1056/NEJM199503233321201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN442	7862178	Green Published			2022-12-28	WOS:A1995QN44200001
J	LAPINLEIMU, H; VIIKARI, J; JOKINEN, E; SALO, P; ROUTI, T; LEINO, A; RONNEMAA, T; SEPPANEN, R; VALIMAKI, I; SIMELL, O				LAPINLEIMU, H; VIIKARI, J; JOKINEN, E; SALO, P; ROUTI, T; LEINO, A; RONNEMAA, T; SEPPANEN, R; VALIMAKI, I; SIMELL, O			PROSPECTIVE RANDOMIZED TRIAL IN 1062 INFANTS OF DIET LOW IN SATURATED FAT AND CHOLESTEROL	LANCET			English	Article							CORONARY HEART-DISEASE; RISK-FACTORS; CHILDREN	Interventions to avoid atherosclerosis might be more successful if launched early in life when eating and lifestyle patterns are formed, but dietary interventions have been limited by fears of diet-induced growth failure. We investigated the effects of a diet low in saturated fat and cholesterol on serum lipid concentrations and growth in 1062 healthy 7-month-old infants in a randomised study. Every 1-3 months, families in the intervention group received dietary advice aimed at adequate energy supply, with low fat intake (30-35% energy, polyunsaturated/ monounsaturated/saturated fatty acid ratio 1/1/1, and cholesterol intake <200 mg daily). Infants in control families consumed an unrestricted diet. 3-day food records were collected at ages 8 and 13 months. Growth was carefully monitored. Between 7 and 13 months serum cholesterol and non-high-density-lipoprotein cholesterol concentrations did not change significantly in the intervention group (mean change -0.03 [SD 0.72] mmol/L and 0.01 [0.67] mmol/L) but increased substantially in the control group (0.24 [0.64] mmol/L and 0.23 [0.60] mmol/L; p for difference in mean changes between groups <0 001). Daily intakes of energy and saturated fat were lower in the intervention than in the control group at 13 months (4065 [796] vs 4370 [748] kJ, p=0.033, and 9.3 [3.5] vs 14.5 [4.8] g, p<0.001, respectively), and intake of polyunsaturated fat was higher (5.8 [2.2] vs 4.4 [1.4] g, p<0.001). Growth did not differ between the groups and was as expected for children at this age. Serum cholesterol concentrations fell significantly in parents of intervention-group infants. The increases in serum cholesterol and non-high-density-lipoprotein cholesterol concentration that occur in infants between the ages of 7 and 13 months can be avoided by individualised diets, with no effect on the children's growth.	UNIV TURKU, DEPT PAEDIAT, TURKU, FINLAND; UNIV TURKU, DEPT MED, TURKU, FINLAND; SOCIAL INSURANCE INST, RES & DEV UNIT, TURKU, FINLAND	University of Turku; University of Turku	LAPINLEIMU, H (corresponding author), UNIV TURKU, CARDIORESP RES UNIT, KIINAMYLLYNKATU 10, SF-20520 TURKU, FINLAND.		Lapinleimu, Helena/AAT-8415-2021					DOUGHERTY RM, 1988, AM J CLIN NUTR, V48, P970, DOI 10.1093/ajcn/48.4.970; EHNHOLM C, 1982, NEW ENGL J MED, V307, P850, DOI 10.1056/NEJM198209303071403; ERKKOLA R, 1986, BIOL RES PREG PERIN, V7, P47; FRIEDMAN G, 1976, PEDIATRICS, V58, P655; GRUNDY SM, 1990, J LIPID RES, V31, P1149; KAPLAN RM, 1992, PREV MED, V21, P33, DOI 10.1016/0091-7435(92)90004-2; KLAG MJ, 1993, NEW ENGL J MED, V328, P313, DOI 10.1056/NEJM199302043280504; KNUIMAN JT, 1987, ARTERIOSCLEROSIS, V7, P612, DOI 10.1161/01.ATV.7.6.612; LAPINLEIMU H, 1994, ACTA PAEDIATR, V83, P383, DOI 10.1111/j.1651-2227.1994.tb18124.x; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; MCGILL HC, 1990, JAMA-J AM MED ASSOC, V264, P3018; NEWMAN TB, 1990, AM J DIS CHILD, V144, P851; NEWMAN WP, 1986, NEW ENGL J MED, V314, P138, DOI 10.1056/NEJM198601163140302; PESONEN E, 1990, EUR HEART J, V11, P53, DOI 10.1093/eurheartj/11.suppl_E.53; PYORALA K, 1985, CARDIOLOGY, V72, P35, DOI 10.1159/000173839; RASANEN L, 1991, ANN MED, V23, P73, DOI 10.3109/07853899109147934; RASANEN L, 1992, ACTA PAEDIATR, V81, P7, DOI 10.1111/j.1651-2227.1992.tb12069.x; ROSENTHAL SL, 1993, CLIN PEDIATR, V32, P135, DOI 10.1177/000992289303200302; SORVA R, 1990, ACTA PAEDIATR SCAND, V79, P490, DOI 10.1111/j.1651-2227.1990.tb11502.x; VARTIAINEN E, 1987, CARDIOVASCULAR RISK, P183; VIIKARI J, 1985, ACTA PAEDIATR SCAND, P103; WALTER HJ, 1988, NEW ENGL J MED, V318, P1093, DOI 10.1056/NEJM198804283181704; 1989, RECOMMENDED DIETARY; 1991, PEDIATRICS, V89, P495	24	169	171	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 25	1995	345	8948					471	476		10.1016/S0140-6736(95)90580-4	http://dx.doi.org/10.1016/S0140-6736(95)90580-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7861873				2022-12-28	WOS:A1995QH92900007
J	LEVINE, GN; KEANEY, JF; VITA, JA				LEVINE, GN; KEANEY, JF; VITA, JA			CHOLESTEROL REDUCTION IN CARDIOVASCULAR-DISEASE - CLINICAL BENEFITS AND POSSIBLE MECHANISMS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CORONARY HEART-DISEASE; HIGH-DENSITY-LIPOPROTEIN; ENDOTHELIUM-DEPENDENT RELAXATION; MIDDLE-AGED MEN; ARTERY DISEASE; SERUM-CHOLESTEROL; RISK-FACTORS; ATHEROSCLEROTIC LESIONS; MYOCARDIAL-INFARCTION; FOLLOW-UP		UNIV BOSTON HOSP, MED CTR, CARDIOL SECT, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, EVANS MEM DEPT MED, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, WHITAKER CARDIOVASC INST, BOSTON, MA 02118 USA	Boston University; Boston University				Keaney, John/0000-0002-0866-1837; Vita, Joseph/0000-0001-5607-1797				AMBROSE JA, 1986, J AM COLL CARDIOL, V7, P472, DOI 10.1016/S0735-1097(86)80455-7; AMBROSE JA, 1988, J AM COLL CARDIOL, V12, P56, DOI 10.1016/0735-1097(88)90356-7; ANDERSEN P, 1981, ACTA MED SCAND, V209, P199; ANDERSON TJ, 1995, NEW ENGL J MED, V332, P488, DOI 10.1056/NEJM199502233320802; ARONOW WS, 1994, AM J CARDIOL, V73, P702, DOI 10.1016/0002-9149(94)90938-5; ARONOW WS, 1989, J AM GERIATR SOC, V37, P501, DOI 10.1111/j.1532-5415.1989.tb05679.x; BADIMON JJ, 1989, LAB INVEST, V60, P455; BADIMON JJ, 1990, J CLIN INVEST, V85, P1234, DOI 10.1172/JCI114558; BARRETTCONNOR E, 1987, CORONARY HEART DISEA, P117; BENFANTE R, 1990, JAMA-J AM MED ASSOC, V263, P393, DOI 10.1001/jama.263.3.393; Bengtsson C, 1973, Acta Med Scand Suppl, V549, P1; BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V253, P2080; BLANKENHORN DH, 1993, ANN INTERN MED, V119, P969, DOI 10.7326/0003-4819-119-10-199311150-00002; BOGATY P, 1994, CIRCULATION, V90, P5, DOI 10.1161/01.CIR.90.1.5; BRENSIKE JF, 1984, CIRCULATION, V69, P313, DOI 10.1161/01.CIR.69.2.313; BROWN BG, 1986, CIRCULATION, V73, P653, DOI 10.1161/01.CIR.73.4.653; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CARLSON LA, 1988, ACTA MED SCAND, V223, P405; CHENG GC, 1993, CIRCULATION, V87, P1179, DOI 10.1161/01.CIR.87.4.1179; COX DA, 1989, CIRCULATION, V80, P458, DOI 10.1161/01.CIR.80.3.458; CREAGER MA, 1990, J CLIN INVEST, V86, P228, DOI 10.1172/JCI114688; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; DEUBNER DC, 1980, AM J EPIDEMIOL, V112, P135, DOI 10.1093/oxfordjournals.aje.a112963; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; DORR AE, 1978, J CHRON DIS, V31, P5, DOI 10.1016/0021-9681(78)90076-0; EGASHIRA K, 1994, CIRCULATION, V89, P2519, DOI 10.1161/01.CIR.89.6.2519; EGASHIRA K, 1993, J CLIN INVEST, V91, P29, DOI 10.1172/JCI116183; FALK E, 1992, CIRCULATION, V86, P30; FOLLAND ED, 1994, CIRCULATION, V89, P2005, DOI 10.1161/01.CIR.89.5.2005; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FRIED LP, 1987, AM J EPIDEMIOL, V125, P844, DOI 10.1093/oxfordjournals.aje.a114600; FRIEDMAN M, 1966, AM J PATHOL, V48, P19; FURCHGOTT RF, 1983, CIRC RES, V53, P557, DOI 10.1161/01.RES.53.5.557; FUSTER V, 1992, CIRCULATION, V86, P1; FUSTER V, 1990, CIRCULATION, V82, P47; FUSTER V, 1992, NEW ENGL J MED, V326, P310; FUSTER V, 1988, CIRCULATION, V77, P1213, DOI 10.1161/01.CIR.77.6.1213; GAGE JE, 1986, CIRCULATION, V73, P865, DOI 10.1161/01.CIR.73.5.865; GOLDBOURT U, 1990, ARTERIOSCLEROSIS, V10, P512, DOI 10.1161/01.ATV.10.4.512; GOLINO P, 1991, NEW ENGL J MED, V324, P641, DOI 10.1056/NEJM199103073241001; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GORDON JB, 1989, J CLIN INVEST, V83, P1946, DOI 10.1172/JCI114103; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; GOULD KL, 1990, J AM COLL CARDIOL, V15, P459, DOI 10.1016/S0735-1097(10)80078-6; HAGMAN M, 1988, AM J CARDIOL, V61, P530, DOI 10.1016/0002-9149(88)90759-X; HARRIS T, 1988, J AM GERIATR SOC, V36, P1023, DOI 10.1111/j.1532-5415.1988.tb04370.x; HASKELL WL, 1994, CIRCULATION, V89, P975, DOI 10.1161/01.CIR.89.3.975; Herrick JB, 1912, J AMER MED ASSOC, V59, P2015; HOLME I, 1985, AM J CARDIOL, V55, P40, DOI 10.1016/0002-9149(85)90296-6; HOLME I, 1985, PREV MED, V14, P279, DOI 10.1016/0091-7435(85)90057-X; HONG MK, 1992, AM J CARDIOL, V69, P176, DOI 10.1016/0002-9149(92)91300-S; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; KANNEL WB, 1971, ANN INTERN MED, V74, P1, DOI 10.7326/0003-4819-74-1-1; KANNEL WB, 1986, CORONARY HEART DISEA, P60; KEANEY JF, 1993, P NATL ACAD SCI USA, V90, P11880, DOI 10.1073/pnas.90.24.11880; KEMPEN HJ, 1987, J LAB CLIN MED, V109, P19; KLAG MJ, 1993, NEW ENGL J MED, V328, P313, DOI 10.1056/NEJM199302043280504; LAROSA JC, 1990, CIRCULATION, V81, P1721, DOI 10.1161/01.CIR.81.5.1721; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LEFROY DC, 1993, CIRCULATION, V88, P43, DOI 10.1161/01.CIR.88.1.43; LEREN P, 1970, CIRCULATION, V42, P935, DOI 10.1161/01.CIR.42.5.935; LEUNG WH, 1993, LANCET, V341, P1496, DOI 10.1016/0140-6736(93)90634-S; LEVY RI, 1984, CIRCULATION, V69, P325, DOI 10.1161/01.CIR.69.2.325; LEWIS B, 1987, EUR HEART J, V8, P77; LITTLE WC, 1988, CIRCULATION, V78, P1157, DOI 10.1161/01.CIR.78.5.1157; LOREE HM, 1992, CIRC RES, V71, P850, DOI 10.1161/01.RES.71.4.850; LOSCALZO J, 1990, NEW ENGL J MED, V323, P1337, DOI 10.1056/NEJM199011083231909; LOSKUTOFF DJ, 1977, P NATL ACAD SCI USA, V74, P3903, DOI 10.1073/pnas.74.9.3903; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MANNINEN V, 1988, JAMA-J AM MED ASSOC, V260, P641, DOI 10.1001/jama.260.5.641; MARCUM JA, 1985, BIOCHEM BIOPH RES CO, V126, P365, DOI 10.1016/0006-291X(85)90615-1; MARTIN MJ, 1986, LANCET, V2, P933; MILLER VM, 1985, AM J PHYSIOL, V248, pH432, DOI 10.1152/ajpheart.1985.248.4.H432; Muller C, 1938, ACTA MED SCAND, P75; NABEL EG, 1988, CIRCULATION, V77, P43, DOI 10.1161/01.CIR.77.1.43; NABEL EG, 1990, CIRCULATION, V81, P850, DOI 10.1161/01.CIR.81.3.850; NEATON JD, 1984, AM HEART J, V108, P759, DOI 10.1016/0002-8703(84)90669-0; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; NEWMAN WP, 1986, NEW ENGL J MED, V314, P138, DOI 10.1056/NEJM198601163140302; OBRIEN KD, 1993, J CLIN INVEST, V92, P945, DOI 10.1172/JCI116670; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; OKUMURA K, 1992, J AM COLL CARDIOL, V19, P752, DOI 10.1016/0735-1097(92)90513-M; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; PEDERSEN TR, 1994, LANCET, V344, P1383; PEKKANEN J, 1992, AM J EPIDEMIOL, V135, P1251, DOI 10.1093/oxfordjournals.aje.a116231; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; PHILLIPS AN, 1989, LANCET, V1, P718; PHILLIPS AN, 1988, BRIT HEART J, V60, P404; RADOMSKI MW, 1987, BRIT J PHARMACOL, V92, P639, DOI 10.1111/j.1476-5381.1987.tb11367.x; RADOMSKI MW, 1987, BRIT J PHARMACOL, V92, P181, DOI 10.1111/j.1476-5381.1987.tb11310.x; RICHARDSON PD, 1989, LANCET, V2, P941; RIDOLFI RL, 1977, AM HEART J, V93, P468, DOI 10.1016/S0002-8703(77)80410-9; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROMM PA, 1991, AM J CARDIOL, V67, P479, DOI 10.1016/0002-9149(91)90007-8; ROSE G, 1986, BRIT MED J, V293, P306, DOI 10.1136/bmj.293.6542.306; ROSSOUW JE, 1994, MED CLIN N AM, V78, P181, DOI 10.1016/S0025-7125(16)30182-1; RUBANYI GM, 1986, AM J PHYSIOL, V250, P1145, DOI 10.1152/ajpheart.1986.250.6.H1145; SACKS FM, 1994, LANCET, V344, P1182, DOI 10.1016/S0140-6736(94)90506-1; SCHINI VB, 1994, THROMBOSIS HEMORRHAG, P349; SCHMIDT SB, 1985, AM J CARDIOL, V55, P1459, DOI 10.1016/0002-9149(85)90953-1; SCHULER G, 1992, CIRCULATION, V86, P1, DOI 10.1161/01.CIR.86.1.1; SHERMAN CT, 1986, NEW ENGL J MED, V315, P913, DOI 10.1056/NEJM198610093151501; SHIMOKAWA H, 1989, CIRC RES, V64, P900, DOI 10.1161/01.RES.64.5.900; SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103; STAMPFER MJ, 1987, CORONARY HEART DISEA, P112; STARY HC, 1989, ARTERIOSCLEROSIS, V9, pI19; STARY HC, 1990, EUR HEART J, V11, P3, DOI 10.1093/eurheartj/11.suppl_E.3; STIKORAHM A, 1990, ARTERIOSCLEROSIS, V10, P1067, DOI 10.1161/01.ATV.10.6.1067; Thannhauser SJ, 1938, ANN INTERN MED, V11, P1662, DOI 10.7326/0003-4819-11-9-1662; TREASURE CB, 1995, NEW ENGL J MED, V332, P481, DOI 10.1056/NEJM199502233320801; UREN NG, 1994, NEW ENGL J MED, V330, P1782, DOI 10.1056/NEJM199406233302503; VANDENBERG EK, 1989, CIRCULATION, V79, P116, DOI 10.1161/01.CIR.79.1.116; VITA JA, 1992, CIRCULATION, V85, P1390, DOI 10.1161/01.CIR.85.4.1390; VITA JA, 1990, CIRCULATION, V81, P491, DOI 10.1161/01.CIR.81.2.491; VITA JA, 1989, J AM COLL CARDIOL, V14, P1193, DOI 10.1016/0735-1097(89)90416-6; WANG XL, 1994, CIRCULATION, V89, P1974, DOI 10.1161/01.CIR.89.5.1974; WATERS D, 1994, CIRCULATION, V89, P959, DOI 10.1161/01.CIR.89.3.959; WATERS D, 1993, CIRCULATION, V87, P1067, DOI 10.1161/01.CIR.87.4.1067; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; WEIS JR, 1991, FASEB J, V5, P2459, DOI 10.1096/fasebj.5.10.2065893; WHITE CW, 1984, NEW ENGL J MED, V310, P819, DOI 10.1056/NEJM198403293101304; WONG ND, 1989, AM J EPIDEMIOL, V130, P469, DOI 10.1093/oxfordjournals.aje.a115360; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YEUNG AC, 1991, NEW ENGL J MED, V325, P1551, DOI 10.1056/NEJM199111283252205; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2259, DOI 10.1001/jama.260.15.2259; ZEIHER AM, 1991, CIRCULATION, V83, P391, DOI 10.1161/01.CIR.83.2.391; 1975, JAMA-J AM MED ASSOC, V321, P360	131	590	609	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 23	1995	332	8					512	521		10.1056/NEJM199502233320807	http://dx.doi.org/10.1056/NEJM199502233320807			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH288	7830734				2022-12-28	WOS:A1995QH28800007
J	TRANSUE, ER				TRANSUE, ER			SHREDS OF A FLOWERED SHIRT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	1995	273	8					623	623		10.1001/jama.273.8.623	http://dx.doi.org/10.1001/jama.273.8.623			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG748	7844871				2022-12-28	WOS:A1995QG74800026
J	ANTO, JM; SUNYER, J				ANTO, JM; SUNYER, J			NITROGEN-DIOXIDE AND ALLERGIC-ASTHMA - STARTING TO CLARIFY AN OBSCURE ASSOCIATION	LANCET			English	Editorial Material							EXPOSURE				ANTO, JM (corresponding author), UNIV AUTONOMA BARCELONA,INST MUNICIPAL INVEST MED,IMAS,BARCELONA,SPAIN.		Anto, J M/H-2676-2014; Sunyer, Jordi/G-6909-2014	Anto, J M/0000-0002-4736-8529; Sunyer, Jordi/0000-0002-2602-4110				ARIS RM, 1993, AM REV RESPIR DIS, V148, P1363, DOI 10.1164/ajrccm/148.5.1363; BROUGHT GFJ, 1993, LR941 WARR SPRING LA; DEVALIA JL, 1993, EUR RESPIR J, V6, P1308; DEVALIA JL, 1994, LANCET, V344, P1668, DOI 10.1016/S0140-6736(94)90458-8; FOLINSBEE LJ, 1992, TOXICOL IND HEALTH, V8, P273; HARLOS DP, 1988, THESIS HARVARD SCH P; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; SAMET JM, 1993, AM REV RESPIR DIS, V148, P1258, DOI 10.1164/ajrccm/148.5.1258; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X	9	19	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					402	403		10.1016/S0140-6736(95)90395-X	http://dx.doi.org/10.1016/S0140-6736(95)90395-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853945				2022-12-28	WOS:A1995QG90400003
J	SHARP, D				SHARP, D			WORMS, SPIRALS, FLUKES AS CARCINOGENS	LANCET			English	Editorial Material																		SHARP DW, 1993, SCI WATCH, V4, P5; 1994, IARC MONGRAPHS EVALU, V61; 1994, IARC MONOGRAPHS EVAL, V59	3	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					403	404		10.1016/S0140-6736(95)90396-8	http://dx.doi.org/10.1016/S0140-6736(95)90396-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853946				2022-12-28	WOS:A1995QG90400004
J	BRUNO, A; JONES, WL; AUSTIN, JK; CARTER, S; QUALLS, C				BRUNO, A; JONES, WL; AUSTIN, JK; CARTER, S; QUALLS, C			VASCULAR OUTCOME IN MEN WITH ASYMPTOMATIC RETINAL CHOLESTEROL EMBOLI - A COHORT STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						EMBOLISM, CHOLESTEROL; RETINA; CEREBROVASCULAR DISORDERS; MYOCARDIAL INFARCTION; CEREBRAL INFARCTION	CEREBRAL INFARCTION; RISK-FACTORS; ARTERY; CONCOMITANTS; STENOSIS	Objective: To determine whether asymptomatic retinal cholesterol embolism is a risk factor for vascular events. Design: Cohort study with retrospectively selected controls. Setting: A Veterans Affairs medical center. Patients: 70 consecutive patients with asymptomatic retinal cholesterol emboli on dilated ocular examination in an eye clinic and 70 controls without retinal emboli. Controls were matched to patients for sex; age; prevalence of hypertension, diabetes mellitus, and ischemic heart disease; serum cholesterol level; and smoking history. Measurements: Stroke, myocardial infarction, and death. Results: During a mean follow-up of 3.4 years, stroke occurred at an annual rate of 8.5% among patients and 0.8% among controls (adjusted relative risk, 9.9; 95% Cl, 2.3 to 43.1; P = 0.002). Nineteen strokes occurred, 17 in patients and 2 in controls; all were nonfatal cerebral infarctions. Twelve of the 17 that occurred in patients were in a carotid artery territory ipsilateral to the qualifying retinal cholesterol embolus and 5 were in another vascular territory. Ocular infarction or hemorrhagic stroke did not occur. Nonfatal myocardial infarction or vascular death occurred at an annual rate of 7.7% among patients and 4.9% among controls (adjusted relative risk, 1.4; 95% Cl, 0.7 to 2.9; P = 0.39). Conclusion: Asymptomatic retinal cholesterol embolism is an important risk factor for cerebral infarction independent of commonly recognized vascular risk factors.	VET AFFAIRS MED CTR, OPTOMETRY SECT 112A, ALBUQUERQUE, NM 87108 USA; VET AFFAIRS MED CTR, NEUROL SERV 127, ALBUQUERQUE, NM 87108 USA; UNIV NEW MEXICO, DEPT MATH & STAT, ALBUQUERQUE, NM 87131 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of New Mexico					NCRR NIH HHS [MO1 RR00997] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000997] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BEAL MF, 1981, NEUROLOGY, V31, P860, DOI 10.1212/WNL.31.7.860; BOGOUSSLAVSKY J, 1985, ARCH NEUROL-CHICAGO, V42, P864, DOI 10.1001/archneur.1985.04060080042014; BRUNO A, 1992, STROKE, V23, P900, DOI 10.1161/01.STR.23.6.900; BULL DA, 1992, J CARDIOVASC SURG, V33, P401; BUNT TJ, 1986, J VASC SURG, V4, P559; CROUSE JR, 1987, STROKE, V18, P990, DOI 10.1161/01.STR.18.6.990; DAVID NJ, 1963, NEUROLOGY, V13, P708, DOI 10.1212/WNL.13.8.708; EHRENFEL.WK, 1966, ARCH SURG-CHICAGO, V93, P787; FABRIS F, 1994, STROKE, V25, P1133, DOI 10.1161/01.STR.25.6.1133; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GARRAWAY WM, 1979, STROKE, V10, P657, DOI 10.1161/01.STR.10.6.657; MAURIZI CP, 1968, ARCH PATHOL, V86, P528; PFAFFENBACH DD, 1973, AM J OPHTHALMOL, V75, P66, DOI 10.1016/0002-9394(73)90653-3; RICHARDS AM, 1965, AM J CARDIOL, V15, P696, DOI 10.1016/0002-9149(65)90359-0; RUSSELL RWR, 1968, LANCET, V2, P789; SAVINO PJ, 1977, ARCH OPHTHALMOL-CHIC, V95, P1185, DOI 10.1001/archopht.1977.04450070083005; SAVINO PJ, 1988, AMAUROSIS FUGAX, P90; SAYRE GP, 1959, ARCH INTERN MED, V103, P799, DOI 10.1001/archinte.1959.00270050121019; THURLBECK WM, 1957, NEW ENGL J MED, V257, P442, DOI 10.1056/NEJM195709052571002; 1990, SAS STAT USERS GUIDE, P1027	20	62	65	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1995	122	4					249	253		10.7326/0003-4819-122-4-199502150-00002	http://dx.doi.org/10.7326/0003-4819-122-4-199502150-00002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF769	7825759				2022-12-28	WOS:A1995QF76900002
J	DECOSAS, J				DECOSAS, J			TIME TO STOP CULTURING SILENCE	LANCET			English	Editorial Material											DECOSAS, J (corresponding author), REG AIDS PROGRAMME W & CENT AFRICA,ACCRA,GHANA.							BANG RA, 1989, LANCET, V1, P85; BRABIN L, 1995, LANCET, V345, P300, DOI 10.1016/S0140-6736(95)90281-3; MUELLER RD, 1991, CULTURE SILENCE REPR; 1993, WORLD DEV REPORT, P103	4	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					270	271		10.1016/S0140-6736(95)90270-8	http://dx.doi.org/10.1016/S0140-6736(95)90270-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE731	7837858				2022-12-28	WOS:A1995QE73100004
J	PAICE, E				PAICE, E			ABC OF RHEUMATOLOGY - PAIN IN THE HIP AND KNEE	BRITISH MEDICAL JOURNAL			English	Article											PAICE, E (corresponding author), WHITTINGTON HOSP,NHS TRUST,LONDON,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 4	1995	310	6975					319	322		10.1136/bmj.310.6975.319	http://dx.doi.org/10.1136/bmj.310.6975.319			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF717	7866179	Green Published			2022-12-28	WOS:A1995QF71700043
J	MADDUX, BA; SBRACCIA, P; KUMAKURA, S; SASSON, S; YOUNGREN, J; FISHER, A; SPENCER, S; GRUPE, A; HENZEL, W; STEWART, TA; REAVEN, GM; GOLDFINE, ID				MADDUX, BA; SBRACCIA, P; KUMAKURA, S; SASSON, S; YOUNGREN, J; FISHER, A; SPENCER, S; GRUPE, A; HENZEL, W; STEWART, TA; REAVEN, GM; GOLDFINE, ID			MEMBRANE GLYCOPROTEIN PC-1 AND INSULIN-RESISTANCE IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS	NATURE			English	Article							RECEPTOR TYROSINE KINASE; NUCLEOTIDE PYROPHOSPHATASE; FIBROBLASTS; MECHANISMS; EXPRESSION; GLUCOSE; CLONING; NIDDM; GENE	MOST patients with non-insulin-dependent diabetes mellitus are resistant to both endogenous and exogenous insulin(1). Insulin resistance precedes the onset of this disease(2-4), suggesting that it may be an initial abnormality. Insulin-receptor kinase activity is impaired in muscle, fibroblasts and other tissues of many patients with non-insulin-dependent diabetes mellitus(5), but abnormalities in the insulin-receptor gene do not appear to be the cause of this decreased kinase activity(6,7). Skin fibroblasts from certain insulin-resistant patients contain an inhibitor of insulin-receptor tyrosine kinase(8,9). Here we show that this inhibitor is a membrane glycoprotein, termed PC-1 (refs 10,11). We find that PC-1 activity is increased in fibroblasts from seven of nine patients with typical non-insulin-dependent diabetes mellitus. In addition, overexpression of PC-1 in transfected cultured cells reduces insulin-stimulated tyrosine kinase activity. These studies raise the possibility that PC-1 has a role in the insulin resistance of non-insulin-dependent diabetes mellitus.	UNIV CALIF SAN FRANCISCO,MT ZION MED CTR,DIV DIABET & ENDOCRINE RES,SAN FRANCISCO,CA 94115; GENENTECH INC,S SAN FRANCISCO,CA 94080; STANFORD UNIV,VET ADM MED CTR,PALO ALTO,CA 94304	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion; Roche Holding; Genentech; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Sasson, Shlomo/0000-0002-9343-526X; Henzel, William/0000-0003-2940-3797				BOGARDUS C, 1989, DIABETES, V38, P1423, DOI 10.2337/diabetes.38.11.1423; BUCKLEY MF, 1990, J BIOL CHEM, V265, P17506; FORSAYETH J, 1986, DIABETES, V35, P837, DOI 10.2337/diabetes.35.7.837; FUNAKOSHI I, 1992, ARCH BIOCHEM BIOPHYS, V295, P180, DOI 10.1016/0003-9861(92)90504-P; Greene S F, 1994, Obes Res, V2, P432; HARING H, 1989, DIABETES METAB REV, V5, P431; HARTMANN KKP, 1990, ENDOCRINOLOGY, V127, P2038, DOI 10.1210/endo-127-4-2038; HUANG R, 1994, J CLIN INVEST, V94, P560, DOI 10.1172/JCI117370; MADDUX BA, 1993, J CLIN ENDOCR METAB, V77, P73, DOI 10.1210/jc.77.1.73; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; MILAZZO G, 1992, CANCER RES, V52, P3924; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; ODA Y, 1991, J BIOL CHEM, V266, P16791; REAVEN GM, 1988, DIABETES, V35, P1595; REBBE NF, 1993, MOL IMMUNOL, V30, P87, DOI 10.1016/0161-5890(93)90429-F; SBRACCIA P, 1991, DIABETES, V40, P295, DOI 10.2337/diabetes.40.2.295; SUVA LJ, 1989, GENE, V77, P95, DOI 10.1016/0378-1119(89)90363-6; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; YOSHIDA H, 1983, J BIOCHEM-TOKYO, V93, P1641, DOI 10.1093/oxfordjournals.jbchem.a134303	21	288	299	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 2	1995	373	6513					448	451		10.1038/373448a0	http://dx.doi.org/10.1038/373448a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7830796				2022-12-28	WOS:A1995QE67000062
J	STEIN, A; STEIN, J; WALTERS, EA; FAIRBURN, CG				STEIN, A; STEIN, J; WALTERS, EA; FAIRBURN, CG			EATING HABITS AND ATTITUDES AMONG MOTHERS OF CHILDREN WITH FEEDING DISORDERS	BRITISH MEDICAL JOURNAL			English	Article									UNIV OXFORD,PARK HOSP CHILDREN,CHILD & ADOLESCENT PSYCHIAT SECT,OXFORD OX3 7LQ,ENGLAND; UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7JX,ENGLAND	University of Oxford; University of Oxford			Fairburn, Christopher/AAM-9792-2020; Fairburn, Christopher/AAG-6234-2019	Fairburn, Christopher/0000-0002-9673-9795; Stein, Alan/0000-0001-8207-2822; Stein, Jurgen/0000-0003-3558-3341	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1992, ICD 10 CLASSIFICATIO; FAIRBURN CG, 1990, AM J PSYCHIAT, V147, P401; FAIRBURN CG, IN PRESS INT J EAT D; SKUSE D, 1994, CHILD ADOL PSYCH CL, P467; STEIN A, 1994, J CHILD PSYCHOL PSYC, V35, P733, DOI 10.1111/j.1469-7610.1994.tb01218.x	5	29	29	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 28	1995	310	6974					228	228		10.1136/bmj.310.6974.228	http://dx.doi.org/10.1136/bmj.310.6974.228			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QE496	7866126	Green Published			2022-12-28	WOS:A1995QE49600024
J	GUARINO, LA; SMITH, G; DONG, W				GUARINO, LA; SMITH, G; DONG, W			UBIQUITIN IS ATTACHED TO MEMBRANES OF BACULOVIRUS PARTICLES BY A NOVEL TYPE OF PHOSPHOLIPID ANCHOR	CELL			English	Article							NUCLEAR POLYHEDROSIS-VIRUS; FATTY-ACID ACYLATION; CAPSID PROTEIN VP4; RNA-POLYMERASE; GLYCOSYL-PHOSPHATIDYLINOSITOL; NUCLEOTIDE-SEQUENCE; GENE REGION; IDENTIFICATION; SITE; CHROMATOGRAPHY	Purified budded virions of Autographa californica nuclear polyhedrosis virus (AcNPV) contain abundant amounts of free ubiquitin, which has an altered electrophoretic mobility on SDS gels as compared with standard ubiquitin. Phase extraction of virion proteins with Triton X-114 indicated that the modified form of ubiquitin behaved as an integral membrane protein. The membrane-bound form of ubiquitin was labeled with both phosphate and palmitate, and its electrophoretic mobility was altered by treatment with phospholipase A2 and a phosphatidylcholine-specific phospholipase D. Mild trypsin digestion indicated that the acyl group was not linked to the C-terminus of the protein. Acylated ubiquitin could not be radiolabeled with a membrane-impermeable Bolton-Hunter reagent unless virus was pretreated with detergent. Together, these experiments suggest that ubiquitin is attached to the inner face of the viral membrane by a novel type of phospholipid anchor.	INST BIOSCI & TECHNOL, CTR ADV INVERTEBRATE MOLEC SCI, COLLEGE STN, TX 77843 USA		GUARINO, LA (corresponding author), TEXAS A&M UNIV, DEPT ENTOMOL, COLLEGE STN, TX 77843 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044055] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44055] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGER M, 1984, EMBO J, V3, P713, DOI 10.1002/j.1460-2075.1984.tb01874.x; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRAUNAGEL SC, 1994, VIROLOGY, V202, P315, DOI 10.1006/viro.1994.1348; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; COX MJ, 1986, ANAL BIOCHEM, V154, P345, DOI 10.1016/0003-2697(86)90535-X; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROSS GAM, 1987, CELL, V48, P179, DOI 10.1016/0092-8674(87)90419-3; DEGROOT RJ, 1991, P NATL ACAD SCI USA, V88, P8967, DOI 10.1073/pnas.88.20.8967; DITMER JC, 1969, METHOD ENZYMOL, V14, P482; DRISCOLL J, 1992, CELL, V68, P823, DOI 10.1016/0092-8674(92)90024-7; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; DUNIGAN DD, 1988, VIROLOGY, V165, P310, DOI 10.1016/0042-6822(88)90691-5; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GAEDIGKNITSCHKO K, 1990, VIROLOGY, V175, P282, DOI 10.1016/0042-6822(90)90210-I; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; GUARINO LA, 1990, P NATL ACAD SCI USA, V87, P409, DOI 10.1073/pnas.87.1.409; GUARINO LA, 1990, VIROLOGY, V179, P1, DOI 10.1016/0042-6822(90)90266-T; HAAS AL, 1985, J BIOL CHEM, V260, P4694; HARLOW E, 1988, ANTIBODIES LABORATOR; HINGAMP PM, 1995, IN PRESS J VIROL, V69; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; KEMP LM, 1988, VIROLOGY, V166, P258, DOI 10.1016/0042-6822(88)90170-5; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOEB KR, 1992, J BIOL CHEM, V267, P7806; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MEYERS G, 1991, VIROLOGY, V180, P602, DOI 10.1016/0042-6822(91)90074-L; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PAUL AV, 1987, P NATL ACAD SCI USA, V84, P7827, DOI 10.1073/pnas.84.22.7827; PUTTERMAN D, 1990, VIROLOGY, V176, P633, DOI 10.1016/0042-6822(90)90035-P; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; REIN A, 1986, P NATL ACAD SCI USA, V83, P7246, DOI 10.1073/pnas.83.19.7246; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROBERTS TE, 1989, VIROLOGY, V172, P377, DOI 10.1016/0042-6822(89)90145-1; RODRIGUEZ JM, 1992, VIROLOGY, V186, P40, DOI 10.1016/0042-6822(92)90059-X; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUSSELL RLQ, 1993, J GEN VIROL, V74, P1191, DOI 10.1099/0022-1317-74-6-1191; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; Sambrook J, 1989, MOL CLONING; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; TAKAYAMA M, 1977, CLIN CHIM ACTA, V79, P93, DOI 10.1016/0009-8981(77)90465-X; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WELLS MA, 1969, METHOD ENZYMOL, V14, P178; ZHOU WJ, 1994, J VIROL, V68, P2556, DOI 10.1128/JVI.68.4.2556-2569.1994	49	67	86	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	1995	80	2					301	309		10.1016/0092-8674(95)90413-1	http://dx.doi.org/10.1016/0092-8674(95)90413-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7834750	Bronze			2022-12-28	WOS:A1995QD92400013
J	BULKLEY, GB				BULKLEY, GB			REACTIVE OXYGEN METABOLITES AND REPERFUSION INJURY - ABERRANT TRIGGERING OF RETICULOENDOTHELIAL FUNCTION	LANCET			English	Article							SUPEROXIDE-DISMUTASE; ENDOTHELIAL-CELLS; XANTHINE-OXIDASE; FREE-RADICALS; ISCHEMIA; ACTIVATION		JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD	Johns Hopkins University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031764] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31764] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BULKLEY GB, 1983, SURGERY, V94, P407; BULKLEY GB, 1993, BRIT J SURG, V80, P684, DOI 10.1002/bjs.1800800604; BULKLEY GB, 1993, ANN SURG, V218, P453; FLAHERTY JT, 1994, CIRCULATION, V89, P1982, DOI 10.1161/01.CIR.89.5.1982; FRIEDL HP, 1989, FASEB J, V3, P2512, DOI 10.1096/fasebj.3.13.2806779; GRANGER DN, 1981, GASTROENTEROLOGY, V81, P22; HERNANDEZ LA, 1987, AM J PHYSIOL, V253, pH699, DOI 10.1152/ajpheart.1987.253.3.H699; JOHNSON WD, 1991, AM HEART J, V121, P20, DOI 10.1016/0002-8703(91)90950-M; KOYAMA I, 1985, TRANSPLANTATION, V40, P590, DOI 10.1097/00007890-198512000-00003; LINDELL SL, 1991, TRANSPLANT P, V23, P2399; LIU TH, 1989, AM J PHYSIOL, V256, pH589, DOI 10.1152/ajpheart.1989.256.2.H589; MAYUMI T, 1993, FREE RADICALS BASIC, P438; PARKS DA, 1982, GASTROENTEROLOGY, V82, P9; RATYCH RE, 1987, SURGERY, V102, P122; REILLY PM, 1991, CARE SURG PATIENT, V4, P1; RIVA E, 1987, Cardiovascular Drugs and Therapy, V1, P133, DOI 10.1007/BF02125466; SCHNEEBERGER H, 1989, TRANSPLANT P, V21, P1245; URAIZEE A, 1987, CIRCULATION, V75, P1237, DOI 10.1161/01.CIR.75.6.1237	18	102	107	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					934	936		10.1016/S0140-6736(94)92276-4	http://dx.doi.org/10.1016/S0140-6736(94)92276-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7848422	hybrid			2022-12-28	WOS:A1994PJ28700017
J	CAPUTO, GM; CAVANAGH, PR; ULBRECHT, JS; GIBBONS, GW; KARCHMER, AW				CAPUTO, GM; CAVANAGH, PR; ULBRECHT, JS; GIBBONS, GW; KARCHMER, AW			ASSESSMENT AND MANAGEMENT OF FOOT DISEASE IN PATIENTS WITH DIABETES	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LOWER-EXTREMITY INFECTIONS; SENSORY-THRESHOLD; LIMB SALVAGE; ULCERS; CARE; ULCERATION; OSTEOMYELITIS; DIAGNOSIS; THERAPY; FEET		HARVARD UNIV, NEW ENGLAND DEACONESS HOSP, SCH MED, DEPT SURG, BOSTON, MA 02215 USA; HARVARD UNIV, NEW ENGLAND DEACONESS HOSP, SCH MED, DEPT MED, BOSTON, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	CAPUTO, GM (corresponding author), PENN STATE UNIV, COLL MED,MILTON S HERSHEY MED CTR,DEPT MED, DIV GEN INTERNAL MED, 500 UNIV DR, HERSHEY, PA 17033 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042912] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK 42912] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAMBERGER DM, 1987, AM J MED, V83, P653, DOI 10.1016/0002-9343(87)90894-1; BIRKE JA, 1986, LEPROSY REV, V57, P261; BIRKE JA, 1991, J PROSTHET ORTHOT, V4, P13; BOULTON AJM, 1986, DIABETIC MED, V3, P335, DOI 10.1111/j.1464-5491.1986.tb00775.x; BOULTON AJM, 1983, DIABETES CARE, V6, P26, DOI 10.2337/diacare.6.1.26; BOULTON AJM, 1990, DIABETIC MED, V7, P852, DOI 10.1111/j.1464-5491.1990.tb01318.x; Brand P.W., 1988, DIABETIC FOOT, P83; BURDEN AC, 1983, BRIT MED J, V286, P1555, DOI 10.1136/bmj.286.6377.1555; CAVANAGH PR, 1994, DIABETES CARE, V17, P201, DOI 10.2337/diacare.17.3.201; CAVANAGH PR, 1991, DISORDERS FOOT ANKLE, V2, P1864; CAVANAGH PR, 1993, DIABETIC FOOT, P199; CAVANAGH PR, 1992, FOOT, V294, P185; COLEMAN WC, 1984, J AM POD ASSOC, V74, P548, DOI 10.7547/87507315-74-11-548; COLEMAN WC, 1993, DIABETIC FOOT, P531; CTERCTEKO GC, 1981, BRIT J SURG, V68, P608, DOI 10.1002/bjs.1800680904; DAVIDSON JK, 1981, ED DIABETIC PATIENTS, P329; EDMONDS ME, 1987, FOOT DIABETES, P121; FRYKBERG RG, 1984, MANAGEMENT DIABETIC, P45; FYLLING CP, 1992, DIABETES SPECTRUM, V5, P358; GIBBONS GW, 1993, ARCH SURG-CHICAGO, V128, P576; GIBBONS GW, 1987, J VASC SURG, V5, P791, DOI 10.1067/mva.1987.avs0050791; GIBBONS GW, 1984, MANAGEMENT DIABETIC, P97; Gibbons GW, 1992, SEMIN VASC SURG, V5, P244; GIBBONS GW, 1991, CURRENT THERAPY VASC, P694; GRAYSON ML, 1990, 30TH INT C ANT AG CH, P127; GUPTA SK, 1990, J VASC SURG, V11, P348, DOI 10.1067/mva.1990.16967; HUTCHINSON JJ, 1990, AM J INFECT CONTROL, V18, P257, DOI 10.1016/0196-6553(90)90167-Q; Jones E W, 1985, Diabet Med, V2, P213; KEENAN AM, 1989, ARCH INTERN MED, V149, P2262, DOI 10.1001/archinte.149.10.2262; Knighton DR, 1993, DIABETIC FOOT, P247; KUCAN JO, 1981, J AM GERIATR SOC, V29, P232, DOI 10.1111/j.1532-5415.1981.tb01773.x; LESLIE CA, 1988, DIABETES CARE, V11, P111, DOI 10.2337/diacare.11.2.111; LINEAWEAVER W, 1985, ARCH SURG-CHICAGO, V120, P267; Lipsky B A, 1990, Infect Dis Clin North Am, V4, P409; LOGERFO FW, 1984, NEW ENGL J MED, V311, P1615, DOI 10.1056/NEJM198412203112506; LOGERFO FW, 1992, ARCH SURG-CHICAGO, V127, P617; MCGRATH MH, 1990, CLIN PLAST SURG, V17, P421; MCINTYRE KE, 1984, ARCH SURG-CHICAGO, V119, P450; MUELLER MJ, 1989, DIABETES CARE, V12, P384, DOI 10.2337/diacare.12.6.384; MYERSON M, 1992, J BONE JOINT SURG AM, V74A, P261, DOI 10.2106/00004623-199274020-00012; NEWMAN LG, 1991, JAMA-J AM MED ASSOC, V266, P1246, DOI 10.1001/jama.266.9.1246; PECORARO RE, 1990, DIABETES CARE, V13, P513, DOI 10.2337/diacare.13.5.513; PERRY JE, IN PRESS J BONE JOIN; PETERSON LR, 1989, AM J MED, V86, P801, DOI 10.1016/0002-9343(89)90476-2; POMPOSELLI FB, 1990, J VASC SURG, V11, P745, DOI 10.1067/mva.1990.19884; POMPOSELLI FB, 1991, ARCH SURG-CHICAGO, V126, P724; REIBER GE, 1992, DIABETES CARE, V15, P29, DOI 10.2337/diacare.15.1.S29; Sammarco GJ, 1991, FOOT DIABETES, P153; SAPICO FL, 1984, REV INFECT DIS, V6, pS171; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SOSENKO JM, 1990, DIABETES CARE, V13, P1057, DOI 10.2337/diacare.13.10.1057; SOULIER SM, 1986, J AM PODIAT MED ASSN, V76, P395, DOI 10.7547/87507315-76-7-395; STEED DL, 1992, DIABETES CARE, V15, P1598, DOI 10.2337/diacare.15.11.1598; TILLO TH, 1990, J AM PODIAT MED ASSN, V80, P211, DOI 10.7547/87507315-80-4-211; Ulbrecht JS, 1994, DIABETIC FOOT, V1, P441; ULBRECHT JS, 1994, DIABETIC FOOT, V1, P29; VEVES A, 1989, DIABETES CARE, V12, P653, DOI 10.2337/diacare.12.9.653; WHEAT LJ, 1986, ARCH INTERN MED, V146, P1935, DOI 10.1001/archinte.146.10.1935; WITKOWSKI JA, 1992, INT J DERMATOL, V31, P27, DOI 10.1111/j.1365-4362.1992.tb03514.x; YOUNG MJ, 1992, DIABETIC MED, V9, P55, DOI 10.1111/j.1464-5491.1992.tb01714.x; 1991, DHHS9150213 PUBL, P73	61	411	431	0	36	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 29	1994	331	13					854	860		10.1056/NEJM199409293311307	http://dx.doi.org/10.1056/NEJM199409293311307			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH530	7848417				2022-12-28	WOS:A1994PH53000007
J	WAX, PM				WAX, PM			ELIXIRS, DILUENTS, AND THE PASSAGE OF THE 1938 FEDERAL FOOD, DRUG AND COSMETIC ACT	ANNALS OF INTERNAL MEDICINE			English	Article							DIETHYLENE; CHILDREN	The Elixir Sulfanilamide disaster of 1937 was one of the most consequential mass poisonings of the 20th century. This tragedy occurred shortly after the introduction of sulfanilamide, the first sulfa antimicrobial drug, when diethylene glycol was used as the diluent in the formulation of a liquid preparation of sulfanilamide known as Elixir Sulfanilamide. One hundred five patients died from its therapeutic use. Under the existing drug regulations, premarketing toxicity testing was not required. In reaction to this calamity, the U.S. Congress passed the 1938 Federal Food, Drug and Cosmetic Act, which required proof of safety before the release of a new drug. The 1938 law changed the drug focus of the Food and Drug Administration from that of a policing agency primarily concerned with the confiscation of adulterated drugs to a regulatory agency increasingly involved with overseeing the evaluation of new drugs. The Elixir Sulfanilamide tragedy, its effect on drug regulations, and the history of other diethylene glycol and diluent mass poisonings are discussed.			WAX, PM (corresponding author), UNIV ROCHESTER, SCH MED, DEPT EMERGENCY MED, 601 ELMWOOD AVE, BOX 655, ROCHESTER, NY 14642 USA.							ANDERSON OE, 1964, J PUBLIC LAW, V13, P189; Barber H, 1934, GUYS HOSP REP, V84, P267; BENNETT IL, 1953, MEDICINE, V32, P431, DOI 10.1097/00005792-195312000-00002; BERMAN LB, 1957, ANN INTERN MED, V46, P611, DOI 10.7326/0003-4819-46-3-611; BOWIE MD, 1972, S AFR MED J, V46, P931; BROWN WJ, 1982, LANCET, V1, P1250; CALVERY H. 0., 1939, SOUTHERN MED JOUR, V32, P1105; CANTARELL MC, 1987, ANN INTERN MED, V106, P478, DOI 10.7326/0003-4819-106-3-478_2; Cavers DF, 1939, LAW CONTEMP PROBL, V6, P2, DOI 10.2307/1189727; CURME GO, 1952, GLYCOLS, P7; Domagk G, 1935, DEUT MED WOCHENSCHR, V61, P829, DOI 10.1055/s-0028-1129654; GEILING EM, 1939, JAMA-J AM MED ASSOC, V111, P919; Geiling EMK, 1937, J AMER MED ASSOC, V109, P1532; GERSHANIK J, 1982, NEW ENGL J MED, V307, P1384, DOI 10.1056/NEJM198211253072206; Haag HB, 1937, J PHARMACOL EXP THER, V59, P93; HEILMAIR R, 1993, ARCH TOXICOL, V67, P655, DOI 10.1007/BF01973688; Jackson CO, 1970, FOOD DRUG LEGISLATIO, P151; JANSSEN WF, 1964, J PUBLIC LAW, V13, P205; LEE PR, 1986, ANNU REV PUBL HEALTH, V7, P217, DOI 10.1146/annurev.publhealth.7.1.217; LITOVITZ TL, 1994, AM J EMERG MED, V12, P546, DOI 10.1016/0735-6757(94)90276-3; Long PH, 1937, J AMER MED ASSOC, V108, P32, DOI 10.1001/jama.1937.02780010034008; LOUIS S, 1967, AM HEART J, V74, P523, DOI 10.1016/0002-8703(67)90011-7; LYNCH KM, 1938, SOUTH MED J, V31, P134; McFadyen R E, 1976, Clio Med, V11, P79; MORGAN JP, 1982, JAMA-J AM MED ASSOC, V248, P1864, DOI 10.1001/jama.248.15.1864; OKUONGHAE HO, 1992, ANN TROP PAEDIATR, V12, P235, DOI 10.1080/02724936.1992.11747577; OREILLY JT, 1993, FDA; PANDYA SK, 1988, BRIT MED J, V297, P117, DOI 10.1136/bmj.297.6641.117; Regier CC, 1933, LAW CONTEMP PROBL, V1, P3, DOI 10.2307/1189447; Ruprecht HA, 1937, J AMER MED ASSOC, V109, P1537; Schnee J. E., 1978, PHARMACEUTICAL IND E, P9; Schoeffel EW, 1937, J AMER MED ASSOC, V109, P1532; SPINK WW, 1943, SULFANILAMIDE RELATE, P13; TENIN P, 1980, TAKING YOUR MED DRUG, P38; VARGA J, 1992, ANN INTERN MED, V116, P140, DOI 10.7326/0003-4819-116-2-140; von Oettingen WF, 1931, J PHARMACOL EXP THER, V42, P355; WINEK CL, 1978, CLIN TOXICOL, V13, P297, DOI 10.3109/15563657808988239; Young James Harvey, 1958, EMORY U Q, V14, P230; YOUNG JH, 1970, SAFEGUARDING PUBLIC, P147; 1962, PUBLIC HLTH REPORT, V77, P946; 1985, LANCET, V2, P254; 1937, JAMA-J AM MED ASSOC, V109, P1985; 1937, JAMA-J AM MED ASSOC, V109, P1367; 1938, JAMA-J AM MED ASSOC, V111, P1567; 1937, JAMA-J AM MED ASSOC, V109, P358; 1930, JAMA-J AM MED ASSOC, V94, P1940; 1937, JAMA-J AM MED ASSOC, V109, P1539; 1937, JAMA-J AM MED ASSOC, V109, P1128	48	136	140	3	29	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1995	122	6					456	461		10.7326/0003-4819-122-6-199503150-00009	http://dx.doi.org/10.7326/0003-4819-122-6-199503150-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QM266	7856995				2022-12-28	WOS:A1995QM26600009
J	HUGHESJONES, NC				HUGHESJONES, NC			RISK ASSESSMENT AND FACTOR-VIII CONCENTRATES	LANCET			English	Editorial Material											HUGHESJONES, NC (corresponding author), MRC CTR,MOLEC IMMUNOPATHOL UNIT,CAMBRIDGE CB2 2QH,ENGLAND.							ALLAN HP, 1993, SIDA HEMOPHILES MON; [Anonymous], 1992, RISK ANAL PERCEPTION; BLOOM AL, 1984, LANCET, V1, P1452; DESFORGES JF, 1983, NEW ENGL J MED, V308, P94, DOI 10.1056/NEJM198301133080209; FRASER L, 1984, GENERAL PRACTIT 1019, P3; HUGHESJONES NC, 1979, LECTURE NOTES HAEMAT; LAYFIELD F, 1987, SIZEWELL B PUBLIC EN; ROWE PM, 1994, LANCET, V344, P876, DOI 10.1016/S0140-6736(94)92838-X; 1984, LANCET, V2, P1433	9	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 25	1995	345	8948					502	503		10.1016/S0140-6736(95)90589-8	http://dx.doi.org/10.1016/S0140-6736(95)90589-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7861880				2022-12-28	WOS:A1995QH92900016
J	ELOMAA, O; KANGAS, M; SAHLBERG, C; TUUKKANEN, J; SORMUNEN, R; LIAKKA, A; THESLEFF, I; KRAAL, G; TRYGGVASON, K				ELOMAA, O; KANGAS, M; SAHLBERG, C; TUUKKANEN, J; SORMUNEN, R; LIAKKA, A; THESLEFF, I; KRAAL, G; TRYGGVASON, K			CLONING OF A NOVEL BACTERIA-BINDING RECEPTOR STRUCTURALLY RELATED TO SCAVENGER RECEPTORS AND EXPRESSED IN A SUBSET OF MACROPHAGES	CELL			English	Article							MONOCLONAL-ANTIBODY; MARGINAL ZONE; DOMAINS; CELLS; SPLEEN	A novel murine plasma membrane protein has been identified in subpopulations of macrophages. It has an intracellular N-terminal domain, a transmembrane domain, and an extracellular region with a short spacer, an 89 Gly-Xaa-Yaa repeat-containing collagenous domain, and a C-terminal cysteine-rich domain. In situ hybridization and immunohistochemical staining have localized the protein to a subset of macrophages in the marginal zone of the spleen and the medullary cord of lymph nodes. No expression was observed in macrophages of liver or lung. Transfected COS cells synthesized a native trimeric plasma membrane protein that bound labeled bacteria and acetylated LDL, but not yeast or Ficoll. The results suggest that the novel protein is a macrophage-specific membrane receptor with a role in host defense, as it shows postnatal expression in macrophages, which are considered responsible far the binding of bacterial antigens and phagocytosis.	UNIV OULU, BIOCTR, SF-90570 OULU, FINLAND; UNIV OULU, DEPT BIOCHEM, SF-90570 OULU, FINLAND; UNIV HELSINKI, DEPT PEDODONT & ORTHODONT, SF-00014 HELSINKI, FINLAND; UNIV OULU, BIOCTR, SF-90220 OULU, FINLAND; UNIV OULU, DEPT ANAT, SF-90570 OULU, FINLAND; UNIV OULU, DEPT PATHOL, SF-90570 OULU, FINLAND; FREE UNIV AMSTERDAM, DEPT CELL BIOL, 1085 BT AMSTERDAM, NETHERLANDS	University of Oulu; Finland National Institute for Health & Welfare; University of Oulu; University of Helsinki; University of Oulu; University of Oulu; University of Oulu; Vrije Universiteit Amsterdam			Tuukkanen, Juha/R-3728-2018	Tuukkanen, Juha/0000-0002-1723-6461				DIJKSTRA CD, 1985, IMMUNOLOGY, V55, P23; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; GORDON S, 1988, J CELL SCI, P1; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAAL G, 1986, IMMUNOLOGY, V58, P665; KRAAL G, 1992, INT REV CYTOL, V132, P31, DOI 10.1016/S0074-7696(08)62453-5; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P16922; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER WJ, 1980, J BIOL CHEM, V255, P1442; UNANUE ER, 1987, SCIENCE, V236, P551, DOI 10.1126/science.2437650; VANFURTH R, 1982, IMMUNOBIOLOGY, V161, P178, DOI 10.1016/S0171-2985(82)80072-7; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155	17	405	420	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 24	1995	80	4					603	609		10.1016/0092-8674(95)90514-6	http://dx.doi.org/10.1016/0092-8674(95)90514-6			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867067	Bronze			2022-12-28	WOS:A1995QJ60200012
J	JIANG, J; STRUHL, G				JIANG, J; STRUHL, G			PROTEIN KINASE-A AND HEDGEHOG SIGNALING IN DROSOPHILA LIMB DEVELOPMENT	CELL			English	Article							SEGMENT-POLARITY GENE; SITE-SPECIFIC RECOMBINATION; CELL-CELL COMMUNICATION; PATCHED GENE; EXPRESSION; WINGLESS; COMPARTMENT; MELANOGASTER; PRODUCT; ENCODES	The Drosophila hedgehog (hh) gene encodes a secreted protein involved in organizing growth and patterning in many developmental processes. Hh appears to act by inducing the localized expression of at least two other signaling molecules, decapentaplegic (dpp) and wingless (wg), which then govern cell proliferation and patterning in surrounding tissue. Here, we demonstrate that cyclic AMP (cAMP)-dependent protein kinase A (PKA) is essential during limb development to prevent inappropriate dpp and wg expression. We also show that a constitutively active form of PKA can prevent inappropriate dpp and wg expression, but does not interfere with their normal induction by hh. We propose that the basal activity of PKA imposes a block on the transcription of dpp and wg and that hh exerts its organizing influence by alleviating this block.			JIANG, J (corresponding author), COLUMBIA UNIV, COLL PHYS & SURG, HOWARD HUGHES MED INST, DEPT GENET & DEV, NEW YORK, NY 10032 USA.							BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BLAIR SS, 1992, DEVELOPMENT, V115, P21; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAMPBELL G, 1995, IN PRESS DEVELOPMENT; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CHOU TB, 1992, GENETICS, V131, P643; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P1661; DUNINBORKOWSKI OM, 1995, IN PRESS DEV BIOL; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HIDALGO A, 1990, DEVELOPMENT, V110, P291; Hooper J.E., 1992, Results and Problems in Cell Differentiation, V18, P1; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1994, CURR BIOL, V4, P347, DOI 10.1016/S0960-9822(00)00076-2; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; LANE ME, 1993, GENE DEV, V7, P1229, DOI 10.1101/gad.7.7a.1229; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MOHLER J, 1992, DEVELOPMENT, V115, P957; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; OBRIEN T, 1991, MOL CELL BIOL, V11, P5285, DOI 10.1128/MCB.11.10.5285; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; SEGAL D, 1985, GENETICS, V109, P119; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; STURTEVANT MA, 1993, GENE DEV, V7, P961, DOI 10.1101/gad.7.6.961; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TASHIRO S, 1993, GENE, V124, P183; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; XU T, 1993, DEVELOPMENT, V117, P1223	45	290	299	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 24	1995	80	4					563	572		10.1016/0092-8674(95)90510-3	http://dx.doi.org/10.1016/0092-8674(95)90510-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QJ602	7867064	Bronze			2022-12-28	WOS:A1995QJ60200008
J	SKAPEK, SX; RHEE, J; SPICER, DB; LASSAR, AB				SKAPEK, SX; RHEE, J; SPICER, DB; LASSAR, AB			INHIBITION OF MYOGENIC DIFFERENTIATION IN PROLIFERATING MYOBLASTS BY CYCLIN D1-DEPENDENT KINASE	SCIENCE			English	Article							RETINOBLASTOMA PROTEIN; EXPRESSION; MUSCLE; P21	Although the myogenic regulator MyoD is expressed in proliferating myoblasts, differentiation of these cells is limited to the G(0) phase of the cell cycle. Forced expression of cyclin D1, but not cyclins A, B, or E, inhibited the ability of MyoD to transactivate muscle-specific genes and correlated with phosphorylation of MyoD. Transfection of myoblasts with cyclin-dependent kinase (Cdk) inhibitors p21 and p16 augmented muscle-specific gene expression in cells maintained in high concentrations of serum, suggesting that an active cyclin-Cdk complex suppresses MyoD function in proliferating cells.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; CHILDRENS HOSP,DEPT PEDIAT HEMATOL ONCOL,BOSTON,MA 02115; DANA FARBER CANC INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute			Rhee, James/V-9973-2019		NIAMS NIH HHS [1F32AR08214-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR008214] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EMERSON CP, 1993, CURR OPIN GENET DEV, V3, P265, DOI 10.1016/0959-437X(93)90033-L; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P427, DOI 10.1093/oxfordjournals.jbchem.a123916; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; JAHN L, 1994, EXP CELL RES, V212, P297, DOI 10.1006/excr.1994.1147; KATO J, 1993, GENE DEV, V7, P331; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; NODA A, 1994, EXP CELL RES, V211, P98; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SKAPEK SX, UNPUB; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THORBURN AM, 1993, MOL BIOL CELL, V4, P705, DOI 10.1091/mbc.4.7.705; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	33	470	471	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 17	1995	267	5200					1022	1024		10.1126/science.7863328	http://dx.doi.org/10.1126/science.7863328			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG990	7863328				2022-12-28	WOS:A1995QG99000038
J	VARNUM, BC; YOUNG, C; ELLIOTT, G; GARCIA, A; BARTLEY, TD; FRIDELL, YW; HUNT, RW; TRAIL, G; CLOGSTON, C; TOSO, RJ; YANAGIHARA, D; BENNETT, L; SYLBER, M; MEREWETHER, LA; TSENG, A; ESCOBAR, E; LIU, ET; YAMANE, HK				VARNUM, BC; YOUNG, C; ELLIOTT, G; GARCIA, A; BARTLEY, TD; FRIDELL, YW; HUNT, RW; TRAIL, G; CLOGSTON, C; TOSO, RJ; YANAGIHARA, D; BENNETT, L; SYLBER, M; MEREWETHER, LA; TSENG, A; ESCOBAR, E; LIU, ET; YAMANE, HK			AXL RECEPTOR TYROSINE KINASE STIMULATED BY THE VITAMIN-K-DEPENDENT PROTEIN ENCODED BY GROWTH-ARREST-SPECIFIC GENE-6	NATURE			English	Article							BLOOD-COAGULATION; SEQUENCE; CDNA	THE Axl receptor tyrosine kinase was identified as a protein encoded by a transforming gene from primary human myeloid leukaemia cells by DNA-mediated transformation of NIH 3T3 cells(1-3). Axl is the founding member of a family of related receptors that includes Eyk(4), encoded by a chicken proto-oncogene originally described as a retroviral transforming gene, and c-Mer(5), encoded by a human proto-oncogene expressed in neoplastic B- and T-cell lines. The transforming activity of Axl demonstrates that the receptor can drive cellular proliferation. The function of Axl in non-transformed cells and tissues is unknown, but may involve the stimulation of cell proliferation in response to an appropriate signal, namely a ligand that activates the receptor. We report here the purification of an Axl stimulatory factor, and its identification as the product of growth-arrest-specific gene 6 (ref. 6). This is, to our knowledge, the first description of a ligand for the Axl family of receptors.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,DEPT MED,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill	VARNUM, BC (corresponding author), AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320, USA.		Liu, Edison/C-4141-2008					DECLERCK YA, 1991, J BIOL CHEM, V226, P3893; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FAGERSTAM L, 1991, TECHNIQUES PROTEIN C, V2, P65; FAUSSET PR, 1991, ELECTROPHORESIS, V12, P22, DOI 10.1002/elps.1150120106; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1994, J BIOL CHEM, V269, P1839; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; LIU E, 1988, P NATL ACAD SCI USA, V85, P1952, DOI 10.1073/pnas.85.6.1952; LUNDWALL A, 1986, P NATL ACAD SCI USA, V83, P6716, DOI 10.1073/pnas.83.18.6716; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551; OBRYAN JP, 1990, MOL CELL BIOL, V11, P5016; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935	15	402	430	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					623	626		10.1038/373623a0	http://dx.doi.org/10.1038/373623a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7854420				2022-12-28	WOS:A1995QG99700057
J	RASENACK, JWF; SCHLAYER, HJ; HETTLER, F; PETERS, T; PREISLERADAMS, S; GEROK, W				RASENACK, JWF; SCHLAYER, HJ; HETTLER, F; PETERS, T; PREISLERADAMS, S; GEROK, W			HEPATITIS-B VIRUS-INFECTION WITHOUT IMMUNOLOGICAL MARKERS AFTER OPEN-HEART-SURGERY	LANCET			English	Note							CHRONIC LIVER-DISEASE; SURFACE-ANTIGEN; DNA; IDENTIFICATION; SEQUENCE	Post-transfusion hepatitis is still an important problem, despite the screening of blood donors for hepatitis B (HBV) and C virus infections. We assessed whether HBV DNA might be detected by PCR in prospectively collected serum samples of patients with unexplained post-transfusion hepatitis but no immunological HBV markers. We found HBV DNA in 4 (20%) of 20 patients with unexplained post transfusion hepatitis and in 5 patients with mildly increased aminotransferases. The clinical course of these HBV infections was usually mild and self-limiting. Thus we found that low-titre, immunologically negative HBV infections do exist and might represent a significant cause of post-transfusion hepatitis.			RASENACK, JWF (corresponding author), UNIV FREIBURG,DEPT GASTROENTEROL & HEPATOL,D-79106 FREIBURG,GERMANY.							AZAR N, 1993, J HEPATOL, V18, P24, DOI 10.1016/S0168-8278(05)80006-6; BRECHOT C, 1985, NEW ENGL J MED, V312, P270, DOI 10.1056/NEJM198501313120503; CHAZOUILLERES O, 1994, LANCET, V343, P142, DOI 10.1016/S0140-6736(94)90934-2; LAI MY, 1990, HEPATOLOGY, V12, P575, DOI 10.1002/hep.1840120321; LUGASSY C, 1987, J INFECT DIS, V155, P64, DOI 10.1093/infdis/155.1.64; PETERS T, 1994, J MED VIROL, V42, P420, DOI 10.1002/jmv.1890420416; PREISLERADAMS S, 1993, NUCLEIC ACIDS RES, V21, P2258, DOI 10.1093/nar/21.9.2258; PREISLERADAMS S, 1993, ARCH VIROL, V133, P385, DOI 10.1007/BF01313777; THIERS V, 1988, LANCET, V2, P1273; WANG JT, 1991, J INFECT DIS, V163, P397, DOI 10.1093/infdis/163.2.397	10	18	19	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 11	1995	345	8946					355	357		10.1016/S0140-6736(95)90342-9	http://dx.doi.org/10.1016/S0140-6736(95)90342-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF722	7845117	Bronze			2022-12-28	WOS:A1995QF72200010
J	FERVEUR, JF; STORTKUHL, KF; STOCKER, RF; GREENSPAN, RJ				FERVEUR, JF; STORTKUHL, KF; STOCKER, RF; GREENSPAN, RJ			GENETIC FEMINIZATION OF BRAIN STRUCTURES AND CHANGED SEXUAL ORIENTATION IN MALE DROSOPHILA	SCIENCE			English	Article							CENTRAL NERVOUS-SYSTEM; MOTH MANDUCA-SEXTA; ANTENNAL LOBE; REPRODUCTIVE-BEHAVIOR; OLFACTORY GLOMERULI; COURTSHIP BEHAVIOR; MELANOGASTER; MOSAICS; RECOGNITION; INFORMATION	The neural basis of sexual orientation in Drosophila was studied by the production of males with regionally feminized brains. Such flies express the female form of the sex determination gene transformer in a limited number oi neurons under the control of GAL4 enhancer trap inserts. This method facilitated the creation of lines with a stable pattern of feminization. In tests of sexual preferences, flies that were feminized in a portion of the antennal lobes or in a subset of the corpora pedunculata (mushroom bodies) courted both males and females. These two brain structures, both of which are involved in olfactory processing, may function in the recognition of sex-specific pheromones, in the control of sex-specific behaviors, or both.	NYU,DEPT BIOL,NEW YORK,NY 10003; NYU,CTR NEURAL SCI,NEW YORK,NY 10003; UNIV FRIBOURG,INST ZOOL,CH-1700 FRIBOURG,SWITZERLAND	New York University; New York University; University of Fribourg								ANTONY C, 1982, J INSECT PHYSIOL, V28, P873, DOI 10.1016/0022-1910(82)90101-9; BAKER BS, 1980, GENETICS, V94, P383; BELOTE JM, 1987, P NATL ACAD SCI USA, V84, P8026, DOI 10.1073/pnas.84.22.8026; BRAND AH, 1993, DEVELOPMENT, V118, P401; CHRISTENSEN TA, 1993, J COMP PHYSIOL A, V173, P385, DOI 10.1007/BF00193512; COBB M, 1990, ANIM BEHAV, V39, P1058, DOI 10.1016/S0003-3472(05)80778-X; COBB M, 1985, BEHAVIOUR, V97, P182; DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280; EWING AW, 1983, BIOL REV, V58, P275, DOI 10.1111/j.1469-185X.1983.tb00390.x; FERVEUR JF, 1989, NEUROBIOLOGY OF SENSORY SYSTEMS, P397; FERVEUR JF, UNPUB; FISCHBACH KF, 1984, J EXP BIOL, V112, P65; FISHER JA, 1988, NATURE, V332, P853; FOELIX RF, 1989, CELL TISSUE RES, V258, P277, DOI 10.1007/BF00239448; GAILEY DA, 1989, GENETICS, V121, P773; HALL JC, 1977, BEHAV GENET, V7, P291, DOI 10.1007/BF01066800; HALL JC, 1979, GENETICS, V92, P437; HALL JC, 1982, Q REV BIOPHYS, V15, P223, DOI 10.1017/S0033583500004844; HALL JC, 1994, SCIENCE, V264, P1702, DOI 10.1126/science.8209251; HALL JC, 1978, BEHAV GENET, V8, P125, DOI 10.1007/BF01066870; HAMER DH, 1993, SCIENCE, V261, P321, DOI 10.1126/science.8332896; HANSSON BS, 1992, SCIENCE, V256, P1313, DOI 10.1126/science.1598574; HANSSON BS, 1991, J COMP NEUROL, V312, P264, DOI 10.1002/cne.903120209; HOMBERG U, 1989, ANNU REV ENTOMOL, V34, P477, DOI 10.1146/annurev.en.34.010189.002401; HOTTA Y, 1972, NATURE, V240, P527, DOI 10.1038/240527a0; ITO K, 1992, DEV BIOL, V149, P134, DOI 10.1016/0012-1606(92)90270-Q; JALLON JM, 1984, BEHAV GENET, V14, P441, DOI 10.1007/BF01065444; JALLON JM, 1982, CR HEBD ACAD SCI, V292, P1147; JALLON JM, 1979, BEHAV GENET, V9, P487; KELLEY DB, 1988, ANNU REV NEUROSCI, V11, P225; LEVAY S, 1991, SCIENCE, V253, P1034, DOI 10.1126/science.1887219; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MCKEOWN M, 1988, CELL, V53, P887, DOI 10.1016/S0092-8674(88)90369-8; MCROBERT SP, 1983, BEHAV GENET, V13, P517, DOI 10.1007/BF01065927; PAILLETTE M, 1991, Bioacoustics, V3, P247; PECHINE JM, 1988, J CHEM ECOL, V14, P1071, DOI 10.1007/BF01019336; POSSIDENTE DR, 1989, DEV BIOL, V132, P448, DOI 10.1016/0012-1606(89)90241-8; ROBERTSON HM, 1988, GENETICS, V118, P461; RODRIGUES V, 1988, BRAIN RES, V453, P299, DOI 10.1016/0006-8993(88)90170-9; ROSPARS JP, 1983, J COMP NEUROL, V220, P80, DOI 10.1002/cne.902200108; SCOTT D, 1988, ANIM BEHAV, V36, P1164, DOI 10.1016/S0003-3472(88)80075-7; SIEGEL RW, 1979, P NATL ACAD SCI USA, V76, P3430, DOI 10.1073/pnas.76.7.3430; SIMON JA, 1985, CELL, V40, P805, DOI 10.1016/0092-8674(85)90340-X; SINGH RN, 1985, INT J INSECT MORPHOL, V14, P296; STOCKER RF, 1983, CELL TISSUE RES, V232, P237, DOI 10.1007/BF00213783; STOCKER RF, 1989, BEHAV GENET, V19, P371, DOI 10.1007/BF01066165; STOCKER RF, 1994, CELL TISSUE RES, V275, P3, DOI 10.1007/BF00305372; STOCKER RF, 1990, CELL TISSUE RES, V262, P9, DOI 10.1007/BF00327741; Strausfeld NJ., 1976, ATLAS INSECT BRAIN, DOI 10.1007/978-3-642-66179-2; TAYLOR BJ, 1994, DEV GENET, V15, P275, DOI 10.1002/dvg.1020150309; Technau GM, 1984, J NEUROGENET, V1, P113, DOI 10.3109/01677068409107077; TOMPKINS L, 1986, TRENDS GENET, V2, P14, DOI 10.1016/0168-9525(86)90162-9; TOMPKINS L, 1983, GENETICS, V103, P179; VENARD R, 1989, NEUROBIOLOGY OF SENSORY SYSTEMS, P377; WITHERS GS, 1993, NATURE, V364, P238, DOI 10.1038/364238a0	55	188	190	0	20	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 10	1995	267	5199					902	905		10.1126/science.7846534	http://dx.doi.org/10.1126/science.7846534			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG207	7846534				2022-12-28	WOS:A1995QG20700064
J	VALONE, TJ; BROWN, JH				VALONE, TJ; BROWN, JH			EFFECTS OF COMPETITION, COLONIZATION, AND EXTINCTION ON RODENT SPECIES-DIVERSITY	SCIENCE			English	Article							CHIHUAHUAN DESERT; FOOD ADDITION; PRODUCTIVITY; COMMUNITY; REMOVAL	Analyses of long-term experimental data from the Chihuahuan desert. revealed that species diversity of other rodents was higher on plots from which kangaroo rats (Dipodomys spp.) had been removed. The difference was due to consistently higher colonization and lower extinction probabilities of small granivorous rodents in the absence of competitively dominant kangaroo rats. The results of this ecosystem experiment demonstrate the importance of both competitive exclusion and metapopulation dynamics for biological diversity in a natural community.	UNIV NEW MEXICO,DEPT BIOL,ALBUQUERQUE,NM 87131	University of New Mexico				Valone, Thomas/0000-0002-7657-3126				BOWERS MA, 1987, OECOLOGIA, V72, P77, DOI 10.1007/BF00385048; BOWERS MA, 1981, ECOLOGY, V63, P391; BOWERS MA, 1993, OECOLOGIA, V92, P242; BROWN JH, 1985, ECOLOGY, V66, P1545, DOI 10.2307/1938017; BROWN JH, 1989, ECOLOGY, V70, P1507, DOI 10.2307/1938209; BROWN JH, 1990, SCIENCE, V250, P1705, DOI 10.1126/science.250.4988.1705; BROWN JH, 1977, ECOLOGY, V58, P445, DOI 10.2307/1935620; CARPENTER S R, 1988, P119; CARPENTER SR, 1985, BIOSCIENCE, V35, P634, DOI 10.2307/1309989; CLARK CW, 1994, AM NAT, V143, P583, DOI 10.1086/285621; Cody M. L., 1975, ECOLOGY EVOLUTION CO; CONNELL JH, 1961, ECOLOGY, V42, P710, DOI 10.2307/1933500; Drake, 1986, ECOLOGY BIOL INVASIO; FRYE RJ, 1983, OECOLOGIA, V59, P74, DOI 10.1007/BF00388076; Gause G. F., 1934, STRUGGLE EXISTENCE; Gilpin M.E., 1991, METAPOPULATION DYNAM; HAIRSTON NG, 1989, ECOLOGICAL EXPT; HANSKI I, 1982, OIKOS, V38, P210, DOI 10.2307/3544021; HESKE EJ, 1993, OECOLOGIA, V95, P520, DOI 10.1007/BF00317436; HESKE EJ, 1994, ECOLOGY, V75, P438, DOI 10.2307/1939547; Hoffmeister D. F., 1986, MAMMALS ARIZONA; HORN HS, 1972, ECOLOGY, V53, P749, DOI 10.2307/1934797; Keddy P.A., 1989, COMPETITION; LEVINS R, 1969, Bulletin of the Entomological Society of America, V15, P237; Ludwig JA., 1988, STAT ECOLOGY; MAC ARTHUR ROBERT H., 1967; MacArthur R.H., 1972, pvii; PAINE RT, 1966, AM NAT, V100, P65, DOI 10.1086/282400; PARK T, 1948, ECOL MONOGR, V18, P265, DOI 10.2307/1948641; PIMM SL, 1988, AM NAT, V132, P757, DOI 10.1086/284889; PIMM SL, 1982, FOOD WEBS; Pimm SL, 1991, BALANCE NATURE ECOLO; PRESTON FW, 1962, ECOLOGY, V43, P185, DOI 10.2307/1931976; Ricklefs R.E., 1993, J EVOLUTION BIOL, DOI DOI 10.1046/J.1420-9101.1993.6020171.X; Roughgarden J, 1986, COMMUNITY ECOL, P333; SIMBERLOFF D, 1979, ECOLOGICAL DIVERSITY, P159; SLATKIN M, 1974, ECOLOGY, V55, P128, DOI 10.2307/1934625; TILMAN D, 1993, ECOLOGY, V74, P2179, DOI 10.2307/1939572; VANDERMEER JH, 1969, ECOLOGY, V50, P362, DOI 10.2307/1933884; [No title captured]	40	68	70	1	24	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 10	1995	267	5199					880	883		10.1126/science.7846530	http://dx.doi.org/10.1126/science.7846530			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG207	7846530				2022-12-28	WOS:A1995QG20700057
J	OCONNELL, S				OCONNELL, S			FORTNIGHTLY REVIEW - LYME-DISEASE IN THE UNITED-KINGDOM	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BORRELIA-BURGDORFERI; CLINICAL MANIFESTATIONS; DIAGNOSIS; MANAGEMENT; ARTHRITIS		SOUTHAMPTON GEN HOSP, PUBL HLTH LAB, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND	University of Southampton	OCONNELL, S (corresponding author), SOUTHAMPTON GEN HOSP, DEPT MICROBIOL, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND.							Afzelius A., 1910, ARCH DERMATOL SYPH, V101, P404, DOI DOI 10.1007/BF01832773; AGUEROROSENFELD ME, 1993, J CLIN MICROBIOL, V31, P3090, DOI 10.1128/JCM.31.12.3090-3095.1993; ANDERSON JF, 1989, REV INFECT DIS, V11, pS1451; ASBRINK E, 1984, ACTA DERM-VENEREOL, V64, P506; ASBRINK E, 1991, SCAND J INFECT DIS, P44; ASBRINK E, 1991, SCAND J INFECT DIS, P41; AXFORD JS, 1993, ANN RHEUM DIS, V52, P199, DOI 10.1136/ard.52.3.199; Buchwald A., 1883, VJSCHR DERM, V10, P553, DOI 10.1007/BF01833474; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; DONNELLY J, 1987, SERVICE MICROBIOLOGY, V4, P52; Garin C, 1922, J MED LYON, V71, P765; GINSBERG HS, 1993, AM J EPIDEMIOL, V138, P65, DOI 10.1093/oxfordjournals.aje.a116778; GOLIGHTLY MG, 1993, AM J CLIN PATHOL, V99, P168, DOI 10.1093/ajcp/99.2.168; Guy E. C., 1993, Reviews in Medical Microbiology, V4, P89; GUY EC, 1989, LANCET, V1, P484, DOI 10.1016/S0140-6736(89)91377-9; HAYWOOD GA, 1993, BRIT HEART J, V70, P15, DOI 10.1136/hrt.70.1.15; Herxheimer K, 1902, ARCH DERMATOL SYPH-G, V61, P57, DOI 10.1007/BF01933570; JOHNSON RC, 1994, 6TH P INT C LYM BORR, P1; LUFT BJ, 1993, ANN INTERN MED, V119, P518; O'Connell S, 1993, Commun Dis Rep CDR Rev, V3, pR111; O'Connell S., 1992, BR J DERMATOL S40, V127, P21; RAHN DW, 1991, SEMIN ARTHRITIS RHEU, V20, P201, DOI 10.1016/0049-0172(91)90017-T; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; SIGAL LH, 1988, NEUROLOGY, V38, P1439, DOI 10.1212/WNL.38.9.1439; STEERE AC, 1990, NEW ENGL J MED, V323, P219, DOI 10.1056/NEJM199007263230402; STEERE AC, 1993, JAMA-J AM MED ASSOC, V269, P1812, DOI 10.1001/jama.269.14.1812; STEERE AC, 1993, JAMA-J AM MED ASSOC, V270, P1369, DOI 10.1001/jama.270.11.1369b; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1977, ARTHRITIS RHEUM, V20, P7, DOI 10.1002/art.1780200102; STIERNSTADT G, 1993, ANN RHEUM DIS, V52, P387; VANDAM AP, 1993, CLIN INFECT DIS, V17, P708, DOI 10.1093/clinids/17.4.708	31	18	20	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 4	1995	310	6975					303	308		10.1136/bmj.310.6975.303	http://dx.doi.org/10.1136/bmj.310.6975.303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF717	7866174	Green Published			2022-12-28	WOS:A1995QF71700030
J	MUGLIA, L; JACOBSON, L; DIKKES, P; MAJZOUB, JA				MUGLIA, L; JACOBSON, L; DIKKES, P; MAJZOUB, JA			CORTICOTROPIN-RELEASING HORMONE DEFICIENCY REVEALS MAJOR FETAL BUT NOT ADULT GLUCOCORTICOID NEED	NATURE			English	Article							RESPIRATORY-DISTRESS SYNDROME; SURFACTANT; DEXAMETHASONE; EXPRESSION; SECRETION; STRESS	The body responds to stress by activation of the hypothalamic-pituitary-adrenal (HPA) axis and release of glucocorticoids. Glucocorticoid production in the adult regulates carbohydrate and amino-acid metabolism, maintains blood pressure, and restrains the inflammatory response(1). In the fetus, exogenous glucocorticoids accelerate maturation of lung(2) and gastrointestinal enzyme systems(3) and promote hepatic glycogen deposition(4). Corticotropin-releasing hormone (CRH), a 41-amino-acid neuropeptide produced in the paraventricular nucleus of the hypothalamus and many regions of the cerebral cortex(5,6), has been implicated in both the HPA axis(7) and behavioural responses(8) to stress. To define the importance of CRH in the response of the HPA axis to stress and fetal development, we have constructed a mammalian model of CRH deficiency by targeted mutation in embryonic stem (ES) cells(9). We report here that corticotropin-releasing hormone-deficient mice reveal a fetal glucocorticoid requirement for lung maturation. Postnatally, despite marked glucocorticoid deficiency, these mice exhibit normal growth, fertility and longevity, suggesting that the major role of glucocorticoid is during fetal rather than postnatal life.	HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School	MUGLIA, L (corresponding author), HARVARD UNIV, SCH MED, DIV ENDOCRINOL, 300 LONGWOOD AVE, BOSTON, MA 02115 USA.							AVERY ME, 1984, J PEDIATR-US, V104, P240, DOI 10.1016/S0022-3476(84)81000-8; BALLARD PL, 1989, ENDOCR REV, V10, P165, DOI 10.1210/edrv-10-2-165; BALLARD PL, 1979, GLUCOCORTICOID HORMO, P493; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRITCHLOW V, 1963, AM J PHYSIOL, V205, P807, DOI 10.1152/ajplegacy.1963.205.5.807; CROWLEY P, 1990, BRIT J OBSTET GYNAEC, V97, P11, DOI 10.1111/j.1471-0528.1990.tb01711.x; DALLMAN MF, 1993, FRONT NEUROENDOCRIN, V14, P303, DOI 10.1006/frne.1993.1010; DALLMAN MF, 1987, RECENT PROG HORM RES, V43, P113; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; GERTZ BJ, 1987, ENDOCRINOLOGY, V120, P381, DOI 10.1210/endo-120-1-381; JACOBSON L, 1989, ENDOCRINOLOGY, V124, P2144, DOI 10.1210/endo-124-5-2144; KOOB GF, 1993, CIBA F SYMP, V172, P277; LIGGINS GC, 1972, PEDIATRICS, V50, P515; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; MOOG F, 1953, J EXP ZOOL, V124, P329, DOI 10.1002/jez.1401240209; MUGLIA LJ, 1994, J CLIN INVEST, V93, P2066, DOI 10.1172/JCI117201; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; Orth DN, 1992, WILLIAMS TXB ENDOCRI, P489; PHELPS DS, 1991, AM J PHYSIOL, V260, pL146, DOI 10.1152/ajplung.1991.260.2.L146; POST M, 1986, J BIOL CHEM, V261, P2179; ROBERTS MM, 1993, NEUROENDOCRINOLOGY, V57, P388, DOI 10.1159/000126384; SASAKI A, 1984, J CLIN ENDOCR METAB, V59, P812; SEASHOLTZ A F, 1991, Molecular and Cellular Neuroscience, V2, P266, DOI 10.1016/1044-7431(91)90054-R; SPINEDI E, 1992, ENDOCRINOLOGY, V131, P2430, DOI 10.1210/en.131.5.2430; SUDA T, 1984, J CLIN ENDOCR METAB, V59, P861, DOI 10.1210/jcem-59-5-861; THOMPSON RC, 1987, MOL ENDOCRINOL, V1, P363, DOI 10.1210/mend-1-5-363; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VAMVAKOPOULOS NC, 1994, ENDOCR REV, V15, P409, DOI 10.1210/er.15.4.409; VENKATESH VC, 1993, AM J RESP CELL MOL, V8, P222, DOI 10.1165/ajrcmb/8.2.222	30	428	430	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 2	1995	373	6513					427	432		10.1038/373427a0	http://dx.doi.org/10.1038/373427a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7830793				2022-12-28	WOS:A1995QE67000056
J	COLBRIDGE, MJ; BAILY, GG; DUNBAR, EM; ONG, ELC				COLBRIDGE, MJ; BAILY, GG; DUNBAR, EM; ONG, ELC			ANTIBIOTICS CARRIED IN GENERAL-PRACTITIONERS EMERGENCY BAGS - 4 YEARS ON	BRITISH MEDICAL JOURNAL			English	Article									UNIV NEWCASTLE UPON TYNE,NEWCASTLE GEN HOSP,SCH MED,INFECT DIS UNIT,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND; N MANCHESTER GRP HOSP,DEPT TROP MED & INFECT DIS,MANCHESTER M8 6RB,LANCS,ENGLAND	Newcastle General Hospital; Newcastle University - UK				Ong, Edmund/0000-0002-6594-0509				BEGG N, 1992, BRIT MED J, V305, P133, DOI 10.1136/bmj.305.6846.133; CARTWRIGHT K, 1992, BRIT MED J, V305, P1343; ONG ELC, 1988, BRIT MED J, V297, P901, DOI 10.1136/bmj.297.6653.901; STRANG JR, 1992, BRIT MED J, V305, P141, DOI 10.1136/bmj.305.6846.141	4	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 7	1995	310	6971					29	30		10.1136/bmj.310.6971.29	http://dx.doi.org/10.1136/bmj.310.6971.29			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB060	7827551	Green Published			2022-12-28	WOS:A1995QB06000028
J	DEKLERK, ESMD; BLOMMERS, J; KUIK, DJ; BEZEMER, PD; FEENSTRA, L				DEKLERK, ESMD; BLOMMERS, J; KUIK, DJ; BEZEMER, PD; FEENSTRA, L			EFFECT OF HOMEOPATHIC MEDICINES ON DAILY BURDEN OF SYMPTOMS IN CHILDREN WITH RECURRENT UPPER RESPIRATORY-TRACT INFECTIONS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To investigate the intrinsic effects of individually prescribed homoeopathic medicines. Design-Randomised double blind placebo controlled study. Setting-Paediatric outpatient department of university hospital. Patients-175 children with frequently-recurring upper respiratory tract infections. Of the 170 children evaluable, 86 were randomised to homoeopathic medicines (47 boys, 39 girls; median age at start 4.2 years; median number of episodes in past year 4) and 84 to placebo (43 boys, 41 girls; median age at start 3.6 years; median number of episodes in past year 4). Main outcome measures-Mean score for daily symptoms, number of antibiotic courses, and number of adenoidectomies and tonsillectomies over one year of follow up. Results-The mean daily symptom score was 2.61 in the placebo group-and 2.21 in the treatment group (difference 0.41; 95% confidence interval -0.02 to 0.83). In both groups the use of antibiotics was greatly reduced compared:with that in the year before entering the trial (from 73 to 33 in the treatment group and from 69 to 43 in the placebo group). The proportion of children in the treatment group having adenoidectomies was lower in the treatment group (16%, 8/50) than in the placebo group (21%, 9/42). The proportion having tonsillectomies was the same in both groups (5%). Conclusion-Individually prescribed homoeopathic-medicines seem to add little to careful counselling of children with recurrent upper respiratory tract-infection in reducing the daily burden of symptoms, use of antibiotics, and need for adenoidectomy and tonsillectomy.	UNIV HOSP ST RAPHAEL,B-3000 LOUVAIN,BELGIUM		DEKLERK, ESMD (corresponding author), VRIJE UNIV AMSTERDAM,FAC GENEESKUNDE,VAKGRP EPIDEMIOL & BIOSTAT,1081 BT AMSTERDAM,NETHERLANDS.							BOYD H, 1983, WORLD HEALTH FORUM, V4, P102; CAMPBELL ACH, 1977, BRIT HOMOEOPATHIC J, V66, P20; COURT SDM, 1973, POSTGRAD MED J, V49, P771, DOI 10.1136/pgmj.49.577.771; DEKLERK ESM, 1993, EFFECTS HOMOEOPATHIC; DEKLERK ESM, 1986, SIMILIA SIMILIBUS CU, V16, P78; Pocock SJ., 2013, CLIN TRIALS PRACTICA; SCHWARTZ D, 1980, CLIN TRIALS; WILLIAMS RL, 1993, JAMA-J AM MED ASSOC, V270, P1314	8	40	42	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 19	1994	309	6965					1329	1332						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT625	7866080				2022-12-28	WOS:A1994PT62500019
J	GURALNIK, JM; FERRUCCI, L; SIMONSICK, EM; SALIVE, ME; WALLACE, RB				GURALNIK, JM; FERRUCCI, L; SIMONSICK, EM; SALIVE, ME; WALLACE, RB			LOWER-EXTREMITY FUNCTION IN PERSONS OVER THE AGE OF 70 YEARS AS A PREDICTOR OF SUBSEQUENT DISABILITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MAINTAINING MOBILITY; PHYSICAL-ACTIVITY; RISK-FACTORS; SELF-REPORT; LATE-LIFE; VALIDITY; HEALTH; ELDERS; COMMUNITY; CAPACITY	Background. Functional assessment is an important part of the evaluation of elderly persons. We conducted this study to determine whether objective measures of physical function can predict subsequent disability in older persons. Methods. This prospective cohort study included men and women 71 years of age or older who were living in the community, who reported no disability in the activities of daily living, and who reported that they were able to walk one-half mile (0.8 km) and climb stairs without assistance, The subjects completed a short battery of physical-performance tests and participated in a follow-up interview four years later. The tests included an assessment of standing balance, a timed 8-ft (2.4-m) walk at a normal pace, and a timed test of five repetitions of rising from a chair and sitting down. Results. Among the 1122 subjects who were not disabled at base line and who participated in the four-year follow-up, lower scores on the base-line performance tests were associated with a statistically significant, graduated increase in the frequency of disability in the activities of daily living and mobility-related disability at follow-up. After adjustment for age, sex, and the presence of chronic disease, those with the lowest scores on the performance tests were 4.2 to 4.9 times as likely to have disability at four years as those with the highest performance scores, and those with intermediate performance scores were 1.6 to 1.8 times as likely to have disability. Conclusions. Among nondisabled older persons living in the community, objective measures of lower-extremity function were highly predictive of subsequent disability. Measures of physical performance may identify older persons with a preclinical stage of disability who may benefit from interventions to prevent the development of frank disability.	NATL INST RES & CARE ELDERLY,HOSP I FRATICINI,DEPT GERIATR,FLORENCE,ITALY; UNIV IOWA,DEPT PREVENT MED & ENVIRONM HLTH,IOWA CITY,IA	IRCCS INRCA; University of Iowa	GURALNIK, JM (corresponding author), NIA,EPIDEMIOL DEMOG & BIOMETRY PROGRAM,7201 WISCONSIN AVE,RM 3C-309,BETHESDA,MD 20892, USA.		Simonsick, Eleanor/W-6864-2019		NIA NIH HHS [AG-10127-01, N01-AG-0-2106] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [N01AG002106, R01AG010127] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1980, INT CLASSIFICATION I; APPLEGATE WB, 1990, NEW ENGL J MED, V322, P1207; BOULT C, 1994, J GERONTOL, V49, pM28, DOI 10.1093/geronj/49.1.M28; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; BUCHNER DM, 1992, ANNU REV PUBL HEALTH, V13, P469, DOI 10.1146/annurev.publhealth.13.1.469; CORNONIHUNTLEY J, 1990, NIH90495 PUBL; CORNONIHUNTLEY JC, 1986, NIH862443 PUBL; CORTI MC, 1994, JAMA-J AM MED ASSOC, V272, P1036, DOI 10.1001/jama.272.13.1036; DOREVITCH MI, 1992, J CLIN EPIDEMIOL, V45, P791, DOI 10.1016/0895-4356(92)90057-T; DUNCAN PW, 1992, J GERONTOL, V47, pM93, DOI 10.1093/geronj/47.3.M93; ELAM JT, 1991, AM J PUBLIC HEALTH, V81, P1127, DOI 10.2105/AJPH.81.9.1127; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; Foley D J, 1992, J Aging Health, V4, P155, DOI 10.1177/089826439200400201; GURALNIK JM, 1989, J GERONTOL, V44, pM141, DOI 10.1093/geronj/44.5.M141; GURALNIK JM, 1993, AM J EPIDEMIOL, V137, P845, DOI 10.1093/oxfordjournals.aje.a116746; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; JETTE AM, 1987, J RHEUMATOL, V14, P15; Kane R.A., 1981, ASSESSING ELDERLY; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KELLYHAYES M, 1992, AM J PUBLIC HEALTH, V82, P841, DOI 10.2105/AJPH.82.6.841; KURIANSKY JB, 1976, J CLIN PSYCHOL, V32, P95, DOI 10.1002/1097-4679(197601)32:1<95::AID-JCLP2270320129>3.0.CO;2-J; LACROIX AZ, 1993, AM J EPIDEMIOL, V137, P858, DOI 10.1093/oxfordjournals.aje.a116747; MEENAN RF, 1987, J RHEUMATOL, V14, P20; MOR V, 1989, J CLIN EPIDEMIOL, V42, P895, DOI 10.1016/0895-4356(89)90103-0; NAGI SZ, 1976, MILBANK FUND Q, V54, P439, DOI 10.2307/3349677; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; POPE AM, 1991, DISABILITY AM NATION; REUBEN DB, 1992, J GERONTOL, V47, pM106, DOI 10.1093/geronj/47.4.M106; ROSOW I, 1966, J GERONTOL, V21, P556, DOI 10.1093/geronj/21.4.556; Rubin G., 1991, J AGING HEALTH, V3, P285, DOI [10.1177/089826439100300210, DOI 10.1177/089826439100300210]; SCHNEIDER EL, 1990, JAMA-J AM MED ASSOC, V263, P2335, DOI 10.1001/jama.263.17.2335; SEEMAN TE, 1994, J GERONTOL, V49, pM97, DOI 10.1093/geronj/49.3.M97; SMITH LA, 1990, J AM GERIATR SOC, V38, P993, DOI 10.1111/j.1532-5415.1990.tb04422.x; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1988, JAMA-J AM MED ASSOC, V259, P1190, DOI 10.1001/jama.259.8.1190; WILLIAMS ME, 1994, J AM GERIATR SOC, V42, P21, DOI 10.1111/j.1532-5415.1994.tb06068.x; WINOGRAD CH, 1994, J AM GERIATR SOC, V42, P743, DOI 10.1111/j.1532-5415.1994.tb06535.x; 1991, DHHS PHS9150213 PUBL	38	2787	2818	3	102	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 2	1995	332	9					556	561		10.1056/NEJM199503023320902	http://dx.doi.org/10.1056/NEJM199503023320902			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QJ090	7838189				2022-12-28	WOS:A1995QJ09000002
J	BARR, DA				BARR, DA			THE EFFECTS OF ORGANIZATIONAL-STRUCTURE ON PRIMARY-CARE OUTCOMES UNDER MANAGED CARE	ANNALS OF INTERNAL MEDICINE			English	Article							PREPAID GROUP-PRACTICE; FOR-SERVICE PATIENTS; PHYSICIAN SATISFACTION; MEDICAL-CARE; JOB-SATISFACTION; HEALTH-INSURANCE; SETTINGS; QUALITY; QUESTIONNAIRE; ENCOUNTERS	The advent of managed care in the United States brings with it more and larger organizations involved in providing primary care. Studies of organizations in general suggest that large managed care organizations will have difficulty providing high-quality primary care largely because of their complexity and the fragmentation of their work force. Existing data confirm that these organizations have shortcomings in both patient and physician satisfaction. There are few data to indicate whether such organizations can mitigate these problems by saving costs through economies of scale. To offset their inherent weaknesses, large primary care organizations need to ensure patients' accessibility to their physicians, the continuity of the physician-patient relationship, a care environment conducive to a high-quality physician-patient interaction, and the clinical autonomy of physicians. Much additional research needs to be done to further understand these issues.	STANFORD UNIV, STANFORD CTR ORG RES, STANFORD, CA USA	Stanford University								ALTMAN SH, 1981, ANNU REV PUBL HEALTH, V2, P117, DOI 10.1146/annurev.pu.02.050181.001001; ASTLEY WG, 1985, ORGAN STUD, V6, P201, DOI 10.1177/017084068500600301; BAILEY RM, 1968, GROUP PRACTICE, V17, P24; BAILEY RM, 1970, EMPIRICAL STUDIES HL, P255; BAKER LC, 1993, HEALTH AFFAIR, V12, P258, DOI 10.1377/hlthaff.12.suppl_1.258; BARR DA, 1993, THESIS STANFORD U ST; Bennett J E, 1981, Top Health Care Financ, V7, P25; BLANKFIELD RP, 1990, J FAM PRACTICE, V31, P69; BLAU PM, 1970, AM SOCIOL REV, V35, P201, DOI 10.2307/2093199; Bowen D.E., 1985, SERVICE ENCOUNTER, P127; BRESLAU N, 1978, MED CARE, V16, P850, DOI 10.1097/00005650-197810000-00005; BRODY DS, 1989, MED CARE, V27, P1027, DOI 10.1097/00005650-198911000-00004; Cashman S B, 1990, Health Care Manage Rev, V15, P47; CHILD J, 1973, ADMIN SCI QUART, V18, P168, DOI 10.2307/2392061; CLEARY PD, 1988, INQUIRY-J HEALTH CAR, V25, P25; COMANOR WS, 1969, ECONOMICA, V36, P304, DOI 10.2307/2551810; DAVIES AR, 1986, HEALTH SERV RES, V21, P429; DERBER C, 1991, RES SOCIOLOGY ORG, V8, P71; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; Donabedian A., 1982, EXPLORATIONS QUALITY, VII; ENGEL GV, 1969, J HEALTH SOC BEHAV, V10, P30, DOI 10.2307/2948503; ENTHOVEN AC, 1991, JAMA-J AM MED ASSOC, V265, P2532, DOI 10.1001/jama.265.19.2532; FRANK RG, 1987, SOC SCI MED, V24, P843, DOI 10.1016/0277-9536(87)90185-7; Freidson E., 1989, MED WORK AM ESSAYS H; FRIEND KE, 1977, PERS PSYCHOL, V30, P589, DOI 10.1111/j.1744-6570.1977.tb02329.x; Hackman J.R., 1980, WORK REDESIGN; HARRIS S, 1964, EC AM MED, P140; Holloway R L, 1989, J Am Board Fam Pract, V2, P87; IGLEHART JK, 1994, NEW ENGL J MED, V331, P63, DOI 10.1056/NEJM199407073310129; JONES GR, 1987, ACAD MANAGE J, V30, P197, DOI 10.2307/256270; KIBBE DC, 1993, J FAM PRACTICE, V36, P304; KIMBELL LJ, 1977, HEALTH SERV RES, V12, P367; KRAVITZ RL, 1990, MED CARE, V28, P502, DOI 10.1097/00005650-199006000-00003; LATANE B, 1979, J PERS SOC PSYCHOL, V37, P822, DOI 10.1037//0022-3514.37.6.822; LATANE B, 1981, PSYCHOL BULL, V89, P308, DOI 10.1037/0033-2909.89.2.308; LICHTENSTEIN R, 1984, MED CARE, V22, P56, DOI 10.1097/00005650-198401000-00005; Lichtenstein R L, 1984, Med Care Rev, V41, P139, DOI 10.1177/107755878404100301; LINN LS, 1985, MED CARE, V23, P1171, DOI 10.1097/00005650-198510000-00006; LIPSCOMB J, 1986, HEALTH SERV RES, V21, P635; LUFT HS, 1987, HLTH MAINTENANCE ORG; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; MARQUIS MS, 1983, MED CARE, V21, P821, DOI 10.1097/00005650-198308000-00006; McCallum J.R., 1985, SERVICE ENCOUNTER MA, V18, P35; McKibbin R C, 1977, Mod Healthc, V7, P71; MCKINLAY JB, 1988, INT J HEALTH SERV, V18, P191, DOI 10.2190/YEVW-6C44-YCYE-CGEU; MECHANIC D, 1983, MED CARE, V21, P338, DOI 10.1097/00005650-198303000-00006; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; MURRAY JP, 1987, J FAM PRACTICE, V24, P203; MURRAY JP, 1988, J FAM PRACTICE, V26, P576; NEWHOUSE JP, 1973, J HUM RESOUR, V8, P37, DOI 10.2307/144634; NORTH DC, 1986, I I CHANGE EC PERFOR, P9; OVER M, 1986, SOC SCI MED, V22, P351, DOI 10.1016/0277-9536(86)90134-6; RAFAELI A, 1989, ACAD MANAGE J, V32, P245, DOI 10.2307/256362; Robbins J A, 1993, Fam Med, V25, P17; ROBERTS JG, 1987, HEALTH SERV RES, V22, P637; ROEMER MI, 1973, MILBANK FUND Q, V51, P271, DOI 10.2307/3349556; RUBIN HR, 1993, JAMA-J AM MED ASSOC, V270, P835, DOI 10.1001/jama.270.7.835; SAFRAN DG, 1994, JAMA-J AM MED ASSOC, V271, P1579, DOI 10.1001/jama.271.20.1579; SAWARD EW, 1983, JAMA-J AM MED ASSOC, V250, P2820; SCHIFF GD, 1994, JAMA-J AM MED ASSOC, V272, P803, DOI 10.1001/jama.272.10.803; SCHULZ R, 1990, HEALTH SERV RES, V25, P43; SCHULZ R, 1988, MED CARE, V26, P750, DOI 10.1097/00005650-198808000-00002; SCHULZ R, 1992, J FAM PRACTICE, V34, P298; SHORE BE, 1986, MED CARE, V24, P580, DOI 10.1097/00005650-198607000-00002; SIMONIAN SJ, 1993, J DEV BEHAV PEDIATR, V14, P8; Sorensen A A, 1980, Group Health J, V1, P33; STEVENS F, 1992, SOC SCI MED, V35, P295, DOI 10.1016/0277-9536(92)90026-M; SUCHMAN AL, 1993, MED CARE, V31, P1083, DOI 10.1097/00005650-199312000-00002; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925; TESSLER R, 1975, J HEALTH SOC BEHAV, V16, P95, DOI 10.2307/2137003; Ware J E Jr, 1983, Eval Program Plann, V6, P291, DOI 10.1016/0149-7189(83)90009-5; Ware J E Jr, 1983, Eval Program Plann, V6, P247, DOI 10.1016/0149-7189(83)90005-8; WARE JE, 1988, MED CARE, V26, P393, DOI 10.1097/00005650-198804000-00008; WEAVER MJ, 1993, J GEN INTERN MED, V8, P135, DOI 10.1007/BF02599758; WEINBERGER M, 1981, SOC SCI MED-MED PSYC, V15, P239, DOI 10.1016/0271-5384(81)90019-3; WEINERMAN ER, 1964, AM J PUBLIC HEALTH N, V54, P880, DOI 10.2105/AJPH.54.6.880; WEISMAN CS, 1985, MED CARE, V23, P1179, DOI 10.1097/00005650-198510000-00007; Weiss G L, 1989, QRB Qual Rev Bull, V15, P180; Williamson O.E., 1975, MARKETS HIERARCHIES; WOLINSKY FD, 1982, HEALTH SERV RES, V17, P399; YANKAUER A, 1970, MED CARE, V8, P35, DOI 10.1097/00005650-197001000-00005; 1978, MANPOWER POLICY PRIM	83	78	79	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1995	122	5					353	359		10.7326/0003-4819-122-5-199503010-00006	http://dx.doi.org/10.7326/0003-4819-122-5-199503010-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QJ085	7847647				2022-12-28	WOS:A1995QJ08500006
J	THOMSON, SP; GIBBONS, RJ; SMARS, PA; SUMAN, VJ; PIERRE, RV; SANTRACH, PJ; JIANG, NS				THOMSON, SP; GIBBONS, RJ; SMARS, PA; SUMAN, VJ; PIERRE, RV; SANTRACH, PJ; JIANG, NS			INCREMENTAL VALUE OF THE LEUKOCYTE DIFFERENTIAL AND THE RAPID CREATINE KINASE-MB ISOENZYME FOR THE EARLY DIAGNOSIS OF MYOCARDIAL-INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE CHEST PAIN; EMERGENCY ROOM; STRESS; CORTISOL	Objective: To test whether automated measurements of cortisol-induced changes in the leukocyte differential can provide an early marker of myocardial infarction, especially when combined with the rapid creatine kinase-MB isoenzyme. Design: A prospective, blinded study of these measurements at the time of initial assessment in the emergency department. Setting: Large multispecialty clinic hospital. Patients: 511 consecutive patients presenting to the emergency department with chest pain. One hundred twenty-seven patients with infection, trauma, or metastatic cancer or receiving myelosuppressive or glucocorticoid therapy were excluded. Measurements: Automated leukocyte differentials,; rapid creatine kinase-MB levels, cortisol levels, and routine clinical measurements. Results: Of 69 patients with myocardial infarction, only 39% had diagnostic electrocardiographic ST-segment elevation. ST-segment elevation had a specificity of 99% and a positive predictive value of 93%. A relative lymphocytopenia (lymphocyte decrease < 20.3%) or elevated rapid creatine kinase-MB level (> 4.7 ng/mL) was more sensitive than ST-segment elevation (sensitivities of 58% and 56%, respectively) but less specific (specificities of 91% and 93%, respectively). The presence of both a relative lymphocytopenia and an elevated rapid creatine kinase-MB level had a sensitivity of 44%, a specificity of 99.7%, and a positive predictive value of 97% (95% CI, 80% to 99%). Both a relative lymphocytopenia and an elevated rapid creatine kinase-MB level were independent (P < 0.001) predictors of infarction in patients without ST-segment elevation. If myocardial infarction was suspected by the presence of both abnormal markers or ST-segment elevation, the sensitivity for early diagnosis increased from 39% (ST elevation alone) to 65% (CI, 52% to 76%); the specificity was 99%; and the positive predictive value was 94% (CI, 82% to 98%). Conclusions: The presence of both a relative lymphocytopenia and an elevated rapid creatine kinase-MB level was an accurate early marker of myocardial infarction that appeared to improve the sensitivity of early diagnosis compared with that of ST-segment elevation alone.	MAYO CLIN & MAYO FDN, DIV CARDIOVASC DIS & INTERNAL MED, ROCHESTER, MN 55905 USA	Mayo Clinic								ARROWOOD JA, 1989, CIRCULATION, V80, P1293, DOI 10.1161/01.CIR.80.5.1293; BAILEY RR, 1967, LANCET, V1, P970; BAIN RJI, 1992, INT J CARDIOL, V37, P145, DOI 10.1016/0167-5273(92)90201-D; BRAUNWALD E, 1994, CIRCULATION, V89, P1545; Braunwald E, 1994, CLIN PRACTICE GUIDEL; CHROUSOS GP, 1992, JAMA-J AM MED ASSOC, V267, P1244, DOI 10.1001/jama.267.9.1244; CHROUSOS GP, 1988, MECHANISMS PHYSICAL; CRAGG DR, 1991, ANN INTERN MED, V115, P173, DOI 10.7326/0003-4819-115-3-173; FAUCI AS, 1976, CLIN EXP IMMUNOL, V24, P54; GIBLER WB, 1990, ANN EMERG MED, V19, P1359, DOI 10.1016/S0196-0644(05)82598-3; GOLDMAN L, 1982, NEW ENGL J MED, V307, P588, DOI 10.1056/NEJM198209023071004; HAMM CW, 1992, NEW ENGL J MED, V327, P146, DOI 10.1056/NEJM199207163270302; JIANG NS, 1975, CLIN CHEM, V21, P387; KAHN SE, 1992, IMMUNOASSAY AUTOMATI, P293; KARLSON BW, 1990, CIRCULATION, V82, P1140, DOI 10.1161/01.CIR.82.4.1140; LEE TH, 1985, ARCH INTERN MED, V145, P65, DOI 10.1001/archinte.145.1.65; LEE TH, 1986, ANN INTERN MED, V105, P221, DOI 10.7326/0003-4819-105-2-221; Libman E, 1925, AM HEART J, V1, P25, DOI 10.1016/S0002-8703(25)90003-8; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; LOGAN RW, 1966, LANCET, V2, P521; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; NAITO Y, 1991, J CLIN ENDOCR METAB, V73, P111, DOI 10.1210/jcem-73-1-111; NELSON DH, 1952, J CLIN INVEST, V31, P843, DOI 10.1172/JCI102671; OBRIEN JF, 1992, IMMUNOASSAY AUTOMATI, P293; OHMAN EM, 1990, BRIT HEART J, V63, P335; PIERRE RV, 1987, AM J CLIN PATHOL, V87, P201, DOI 10.1093/ajcp/87.2.201; PULEO PR, 1990, CIRCULATION, V82, P759, DOI 10.1161/01.CIR.82.3.759; PULEO PR, 1994, NEW ENGL J MED, V331, P561, DOI 10.1056/NEJM199409013310901; ROUAN GW, 1989, AM J CARDIOL, V64, P1087, DOI 10.1016/0002-9149(89)90857-6; RUDE RE, 1983, AM J CARDIOL, V52, P936, DOI 10.1016/0002-9149(83)90508-8; RUMKE CL, 1977, DIFFERENTIAL LEUKOCY, P39; STERNBERG EM, 1992, ANN INTERN MED, V117, P854, DOI 10.7326/0003-4819-117-10-854; THOMSON SP, 1980, CLIN IMMUNOL IMMUNOP, V17, P506, DOI 10.1016/0090-1229(80)90146-4; ZACHARSKI LR, 1971, AM J CLIN PATHOL, V56, P148; 1992, KODAK EKTACHEM TEST	35	89	91	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1995	122	5					335	341		10.7326/0003-4819-122-5-199503010-00003	http://dx.doi.org/10.7326/0003-4819-122-5-199503010-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ085	7847644				2022-12-28	WOS:A1995QJ08500003
J	KIRCHGESSNER, CU; PATIL, CK; EVANS, JW; CUOMO, CA; FRIED, LM; CARTER, T; OETTINGER, MA; BROWN, JM				KIRCHGESSNER, CU; PATIL, CK; EVANS, JW; CUOMO, CA; FRIED, LM; CARTER, T; OETTINGER, MA; BROWN, JM			DNA-DEPENDENT KINASE (P350) AS A CANDIDATE GENE FOR THE MURINE SCID DEFECT	SCIENCE			English	Article							STRAND BREAK-REPAIR; COMBINED IMMUNE-DEFICIENCY; PLASMINOGEN-ACTIVATOR GENE; PRE-B CELLS; V(D)J RECOMBINATION; PROTEIN-KINASE; HUMAN CHROMOSOME-8; INSITU HYBRIDIZATION; KU PROTEIN; POLYMERASE-BETA	Severe combined immunodeficient (SCID) mice are deficient in a recombination process utilized in both DNA double-strand break repair and in V(D)J recombination. The phenotype of these mice involves both cellular hypersensitivity to ionizing radiation and a lack of B and T cell immunity. The catalytic subunit of DNA-dependent protein kinase, p350, was identified as a strong candidate for the murine gene SCID. Both p350 and a gene complementing the SCID defect colocalize to human chromosome 8q11. Chromosomal fragments expressing p350 complement the SCID phenotype, and p350 protein levels are greatly reduced in cells derived from SCID mice compared to cells from wild-type mice.	STANFORD UNIV,SCH MED,DEPT RADIAT ONCOL,STANFORD,CA 94305; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; ST JOHNS UNIV,DEPT BIOL SCI,JAMAICA,NY 11439	Stanford University; Harvard University; Massachusetts General Hospital; Saint John's University			Cuomo, Christina/L-2222-2019	Cuomo, Christina/0000-0002-5778-960X	NATIONAL CANCER INSTITUTE [R01CA015201, R37CA015201, R01CA037761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048026] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37761, CA 15201] Funding Source: Medline; NIGMS NIH HHS [GM48026] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; ATHWAL RS, 1994, MUTAT RES, V315, P239; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; BLIER PR, 1993, J BIOL CHEM, V268, P7594; BOSMA GC, 1988, J EXP MED, V167, P1016, DOI 10.1084/jem.167.3.1016; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BOSMA GC, 1989, IMMUNOGENETICS, V29, P54, DOI 10.1007/BF02341614; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANNIZZARO LA, 1988, CYTOGENET CELL GENET, V47, P121, DOI 10.1159/000132527; CARROLL AM, 1989, J IMMUNOL, V143, P1087; CARROLL AM, 1988, EUR J IMMUNOL, V18, P1965, DOI 10.1002/eji.1830181215; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CHANG C, 1993, CANCER RES, V53, P1244; CHEN DJ, 1992, GENOMICS, V13, P1088, DOI 10.1016/0888-7543(92)90023-L; CLEUTJENS CBJM, 1993, GENOMICS, V16, P520, DOI 10.1006/geno.1993.1220; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; COX DR, 1989, GENOMICS, V4, P397, DOI 10.1016/0888-7543(89)90347-9; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GIACCIA AJ, 1990, GENE CHROMOSOME CANC, V2, P248, DOI 10.1002/gcc.2870020314; GIACCIA AJ, 1990, AM J HUM GENET, V47, P459; GLASER T, 1989, GENOMICS, V6, P48; GOSS SJ, 1975, NATURE, V255, P680, DOI 10.1038/255680a0; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HAFEZPARAST M, 1993, SOMAT CELL MOLEC GEN, V19, P413, DOI 10.1007/BF01233246; HENDRICKSON EA, 1988, GENE DEV, V2, P817, DOI 10.1101/gad.2.7.817; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; ITOH M, 1993, RADIAT RES, V134, P362; JEGGO PA, 1992, P NATL ACAD SCI USA, V89, P6423, DOI 10.1073/pnas.89.14.6423; KIRCHGESSNER C, UNPUB; KIRCHGESSNER CU, 1993, CANCER RES, V53, P6011; KOMATSU K, 1993, HUM MOL GENET, V2, P1031, DOI 10.1093/hmg/2.7.1031; KURIMASA A, 1994, HUM GENET, V93, P21; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEWIS SM, 1988, CELL, V55, P1099, DOI 10.1016/0092-8674(88)90254-1; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MCBRIDE OW, 1990, CYTOGENET CELL GENET, V53, P108, DOI 10.1159/000132906; MILLER RD, 1993, GENOMICS, V16, P740, DOI 10.1006/geno.1993.1256; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; MORRIS CM, 1989, HUM GENET, V81, P339, DOI 10.1007/BF00283687; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; PROPST F, 1989, GENOMICS, V5, P118, DOI 10.1016/0888-7543(89)90094-3; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; ROWE LW, COMMUNICATION; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SPARU M, 1994, GENOMICS, V21, P208; Spurr N. K., 1995, Cytogenetics and Cell Genetics, V68, P147, DOI 10.1159/000133908; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TOMFOHRDE J, 1992, GENOMICS, V14, P144, DOI 10.1016/S0888-7543(05)80297-6; TRIPPUTI P, 1986, CYTOGENET CELL GENET, V42, P24, DOI 10.1159/000132245; VERHEIJEN JH, 1986, HUM GENET, V72, P153; WEIER HUG, 1991, HUM GENET, V87, P489; WELCH WJ, 1986, J CELL BIOL, V103, P2035, DOI 10.1083/jcb.103.5.2035; Wood S, 1993, Cytogenet Cell Genet, V64, P134; WOOD S, IN PRESS CYTOGENET C	70	576	585	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 24	1995	267	5201					1178	1183		10.1126/science.7855601	http://dx.doi.org/10.1126/science.7855601			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QJ237	7855601				2022-12-28	WOS:A1995QJ23700041
J	UEHARA, Y; MINOWA, O; MORI, C; SHIOTA, K; KUNO, J; NODA, T; KITAMURA, N				UEHARA, Y; MINOWA, O; MORI, C; SHIOTA, K; KUNO, J; NODA, T; KITAMURA, N			PLACENTAL DEFECT AND EMBRYONIC LETHALITY IN MICE LACKING HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR	NATURE			English	Article							SCATTER FACTOR; MOUSE TROPHOBLAST; MOLECULAR-CLONING; MET PROTOONCOGENE; MESSENGER-RNA; EXPRESSION; RAT; DIFFERENTIATION; IDENTIFICATION; PURIFICATION	HEPATOCYTE growth factor/scatter factor (HGF/SF) functions as a mitogen, motogen and morphogen for a variety of cultured cells(1-7). The genes for HGF/SF and its receptor (the c-met protooncogene product(8)) are expressed in many tissues during the embryonic periods and in the adult(9-14). HGF/SF is thought to mediate a signal exchange between the mesenchyme and epithelia during mouse development(15). To examine the physiological role of HGF/SF, we generated mutant mice with a targeted disruption of the HGF/SF gene. Here we report that homozygous mutant embryos have severely impaired placentas with markedly reduced numbers of labyrinthine trophoblast cells, and die before birth. The growth of trophoblast cells was stimulated by HGF/SF in vitro, and the HCF/SF activity was released by allantois in primary culture of normal but not mutant embryos. These findings suggest that HGF/SF is an essential mediator of allantoic mesenchyme-trophoblastic epithelia interaction required for placental organogenesis.	KANSAI MED UNIV,INST LIVER RES,MORIGUCHI,OSAKA 570,JAPAN; CANC INST,DEPT CELL BIOL,TOKYO 170,JAPAN; KYOTO UNIV,SCH MED,DEPT ANAT,KYOTO 606,JAPAN	Kansai Medical University; Japanese Foundation for Cancer Research; Kyoto University			Noda, Tetsuo/B-1667-2016; Minowa, Osamu/AAM-1238-2020					BARLOW PW, 1972, J EMBRYOL EXP MORPH, V27, P447; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHAN AML, 1988, ONCOGENE, V2, P593; DEFRANCES MC, 1992, DEVELOPMENT, V116, P387; DERENZO MF, 1991, ONCOGENE, V6, P1997; GARBISBERKVENS JM, 1987, PHARMACOKINETICS TER, P13; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MUNTENER M, 1977, ACTA ANAT, V98, P241; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; OKAJIMA A, 1990, EUR J BIOCHEM, V193, P375, DOI 10.1111/j.1432-1033.1990.tb19349.x; OKIGAKI M, 1992, BIOCHEMISTRY-US, V31, P95555; PEEL S, 1977, J ANAT, V124, P675; ROSSANT J, 1981, J EMBRYOL EXP MORPH, V62, P217; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; UEHARA Y, 1992, J CELL BIOL, V117, P889, DOI 10.1083/jcb.117.4.889; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; ZARNEGAR R, 1989, CANCER RES, V49, P3314	30	906	938	1	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 23	1995	373	6516					702	705		10.1038/373702a0	http://dx.doi.org/10.1038/373702a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QH928	7854453				2022-12-28	WOS:A1995QH92800055
J	LOPEZ, JR; ROJAS, B; GONZALEZ, MA; TERZIC, A				LOPEZ, JR; ROJAS, B; GONZALEZ, MA; TERZIC, A			MYOPLASMIC CA2+ CONCENTRATION DURING EXERTIONAL RHABDOMYOLYSIS	LANCET			English	Note							CALCIUM; DANTROLENE	Exertional rhabdomyolysis can destroy muscle but the pathophysiology is unknown. Using intracellular selective microelectrodes, we found that intracellular Ca2+ concentration ([Ca2+]i) was 1.27 (0.17) mu mol/L (median and interquartile range) in skeletal-muscle biopsy specimens from patients with exertional rhabdomyolysis compared with 0.12 (0.01) mu mol/L in controls. 3 days treatment with dantrolene, a drug that inhibits Ca2+ release from the sarcoplasmic reticulum, decreased [Ca2+]i to 0.22 (0.05) mu mol/L and accelerated patients' recovery. This study demonstrated that exertional rhabdomyolysis is associated with elevated [Ca2+]i, and that dantrolene has a beneficial effect in this syndrome.	HOSP MIL CARLOS ARVELO,DEPT MED INTERNA,CARACAS,VENEZUELA; MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,DIV CARDIOVASC DIS,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,CLIN PHARMACOL UNIT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic	LOPEZ, JR (corresponding author), INST VENEZOLANO INVEST CIENT,CTR BIOFIS & BIOQUIM,CARACAS,VENEZUELA.							DESMEDT JE, 1977, J PHYSIOL-LONDON, V265, P565, DOI 10.1113/jphysiol.1977.sp011731; Knochel James P., 1993, Current Opinion in Rheumatology, V5, P725; LOPEZ JR, 1992, ANESTHESIOLOGY, V76, P711, DOI 10.1097/00000542-199205000-00008; LOPEZ JR, 1989, CELL CALCIUM, V10, P223, DOI 10.1016/0143-4160(89)90005-5; LOPEZ JR, 1994, MALIGNANT HYPERTHERM, P134; MILNE CJ, 1988, SPORTS MED, V6, P93, DOI 10.2165/00007256-198806020-00004; POELS PJE, 1993, J NEUROL NEUROSUR PS, V56, P823, DOI 10.1136/jnnp.56.7.823; VANWINKLE WB, 1979, SCIENCE, V193, P1130	8	41	44	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					424	425		10.1016/S0140-6736(95)90405-0	http://dx.doi.org/10.1016/S0140-6736(95)90405-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853954				2022-12-28	WOS:A1995QG90400013
J	BONE, RC				BONE, RC			THE TASTE OF LEMONADE ON A SUMMER AFTERNOON	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	1995	273	7					518	518		10.1001/jama.273.7.518	http://dx.doi.org/10.1001/jama.273.7.518			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF686	7837373				2022-12-28	WOS:A1995QF68600001
J	TANG, TL; FREEMAN, RM; OREILLY, AM; NEEL, BG; SOKOL, SY				TANG, TL; FREEMAN, RM; OREILLY, AM; NEEL, BG; SOKOL, SY			THE SH2-CONTAINING PROTEIN-TYROSINE-PHOSPHATASE SH-PTP2 IS REQUIRED UPSTREAM OF MAP KINASE FOR EARLY XENOPUS DEVELOPMENT	CELL			English	Article							GROWTH-FACTOR RECEPTOR; PHOSPHOTYROSINE PHOSPHATASE; CAENORHABDITIS-ELEGANS; MESODERM INDUCTION; SH3 DOMAINS; MOTH-EATEN; PHOSPHORYLATION; EMBRYOS; GENE; ENCODES	SH-PTP2, the vertebrate homolog of Drosophila cork screw, associates with several activated growth factor receptors, but its biological function is unknown. We assayed the effects of injection of wild-type and mutant SH-PTP2 RNAs on Xenopus embryogenesis. An internal phosphatase domain deletion (Delta P) acts as a dominant negative mutant, causing severe posterior truncations. This phenotype is rescued by SH-PTP2, but not by the closely related SH-PTP1. In ectodermal explants, Delta P blocks fibroblast growth factor (FGF)and activin-mediated induction of mesoderm and FGF-induced mitogen-activated protein (MAP) kinase activation. Our results indicate that SH-PTP2 is required for early vertebrate development, acting as a positive component in FGF signaling downstream of the FGF receptor and upstream of MAP kinase.	BETH ISRAEL HOSP, MOLEC MED UNIT, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	TANG, TL (corresponding author), HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.			Sokol, Sergei/0000-0002-3963-9202; Freeman, Robert/0000-0003-1463-9748	NATIONAL CANCER INSTITUTE [R01CA049152, R37CA049152] Funding Source: NIH RePORTER; NCI NIH HHS [CA49152] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMAYA E, 1993, DEVELOPMENT, V118, P477; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BLISKA JB, 1992, J EXP MED, V176, P1625, DOI 10.1084/jem.176.6.1625; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; CASE RD, 1994, J BIOL CHEM, V269, P10467; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CORNELL RA, 1994, DEVELOPMENT, V120, P453; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DAWID IB, 1991, MESODERM INDUCTION; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DWORKINRASTL E, 1986, J EMBRYOL EXP MORPH, V91, P153; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GRAVES LM, 1994, P NATL ACAD SCI USA, V91, P1662, DOI 10.1073/pnas.91.5.1662; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HAN M, 1990, GENETICS, V126, P899; HARTLEY RS, 1994, DEV BIOL, V163, P521, DOI 10.1006/dbio.1994.1168; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; INNIS MA, 1990, PCR PROTOCOLS; ISAACS HV, 1994, EMBO J, V13, P4469, DOI 10.1002/j.1460-2075.1994.tb06769.x; ITOH K, 1994, DEVELOPMENT, V120, P2703; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLEIN PS, 1994, ENDOCR REV, V15, P326, DOI 10.1210/er.15.3.326; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LABONNE C, 1994, DEVELOPMENT, V120, P463; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; XIAO S, 1994, J BIOL CHEM, V269, P21244; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	80	301	309	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	1995	80	3					473	483		10.1016/0092-8674(95)90498-0	http://dx.doi.org/10.1016/0092-8674(95)90498-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859288	Bronze			2022-12-28	WOS:A1995QG47000014
J	TULJAPURKAR, S; LI, N; FELDMAN, MW				TULJAPURKAR, S; LI, N; FELDMAN, MW			HIGH SEX-RATIOS IN CHINA FUTURE	SCIENCE			English	Article							RECENT TRENDS; FERTILITY; POPULATION; BANGLADESH; PREFERENCE; MORTALITY; CHILDREN; BIRTH	In China in recent years, male live births have exceeded those of females by amounts far greater than those that occur naturally in human populations, a trend with significant demographic consequences. The resulting imbalance in the first-marriage market is estimated to be about 1 million males per year after 2010. These ''excess'' males were not easily accommodated in models with substantial changes in first-marriage patterns, The current sex ratio at birth has little effect on a couple's probability of having at least one son, so future increases in the sex ratio may well occur, especially given increasing access to sex-selective abortion.	XIAN JIAOTONG UNIV,INST POPULAT RES,XIAN 710049,PEOPLES R CHINA	Xi'an Jiaotong University	TULJAPURKAR, S (corresponding author), STANFORD UNIV,MORRISON INST POPULAT & RESOURCE STUDIES,DEPT BIOL SCI,STANFORD,CA 94305, USA.			Tuljapurkar, Shripad/0000-0001-5549-4245	NICHD NIH HHS [HD-16640] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016640] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BANISTER J, 1990, CHANGING FAMILY STRU, P263; BENNETT NG, 1983, SEX SELECTION CHILDR; BITTLES AH, 1993, URBAN ECOLOGY HLTH T, P244; CANGPING W, 1992, 1990 INT SEM CHIN PO; CHAHNAZARIAN A, SOC BIOL, V35, P214; CHOWDHURY MK, 1990, POPUL DEV REV, V16, P749, DOI 10.2307/1972966; COALE A, 1992, 1990 INT SEM CHIN PO; Coale A., 1984, RAPID POPULATION CHA; COALE AJ, 1991, POPUL DEV REV, V17, P517, DOI 10.2307/1971953; COALE AJ, 1991, SCIENCE, V251, P389, DOI 10.1126/science.251.4992.389; DASGUPTA M, 1987, POPUL DEV REV, V13, P77; DICKEMAN M, 1975, ANNU REV ECOL SYST, V6, P107, DOI 10.1146/annurev.es.06.110175.000543; FEENEY G, 1989, POPUL DEV REV, V15, P297, DOI 10.2307/1973706; GOLDMAN N, 1984, POPUL INDEX, V50, P5, DOI 10.2307/2736903; GREENHALGH S, 1994, POPUL DEV REV, V20, P365, DOI 10.2307/2137523; HULL TH, 1990, POPUL DEV REV, V16, P63, DOI 10.2307/1972529; JOHANSSON S, 1991, POPUL DEV REV, V17, P35, DOI 10.2307/1972351; JOHANSSON S, 1991, J OFFICIAL STAT, V7, P25; KEYFITZ N, 1990, WORLD POPULATION ANA; LAVELY W, 1990, DEMOGRAPHY, V27, P357, DOI 10.2307/2061373; LI J, 1994, MAY ANN M POP ASS AM; MUHURI PK, 1991, POPUL DEV REV, V17, P415, DOI 10.2307/1971948; PARK CB, 1983, DEMOGRAPHY, V20, P333, DOI 10.2307/2061246; PENG Y, 1994, 27TH SESS UN POP COM; SCHOEN R, 1981, DEMOGRAPHY, V18, P201, DOI 10.2307/2061093; SEN A, 1993, SCI AM, V268, P40, DOI 10.1038/scientificamerican0593-40; SWEET JA, 1987, AM FAMILIES HOUSEHOL, pCH2; ZENG Y, 1993, POPUL DEV REV, V19, P283; 1991, 10 PERCENT SAMPLING; 1983, MANUAL X INDIRECT TE	30	87	92	1	28	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 10	1995	267	5199					874	876		10.1126/science.7846529	http://dx.doi.org/10.1126/science.7846529			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QG207	7846529				2022-12-28	WOS:A1995QG20700055
J	ZUCKERMAN, B; FORVEILLE, T; KASTNER, JH				ZUCKERMAN, B; FORVEILLE, T; KASTNER, JH			INHIBITION OF GIANT-PLANET FORMATION BY RAPID GAS DEPLETION AROUND YOUNG STARS	NATURE			English	Article							T-TAURI STARS; POINT-SOURCE CATALOG; SAO STARS; GG-TAURI; DISK; EVOLUTION; ROTATION; EMISSION; HD-98800; NEBULA	ALTHOUGH stars form from clouds of gas and dust, there are insignificant amounts of gas around ordinary (Sun-like) stars. This suggests that hydrogen and helium, the primary constituents of planets such as Jupiter and Saturn, are not easily retained in orbit as a star matures. The gas-giant planets in the Solar System must therefore have formed rapidly. Models of their formation generally suggest that a solid core formed in less than or equal to 10(6) yr, followed by the accretion of the massive gaseous envelope in similar to 10(7) yr (refs 1-5). But how and when the gas of the solar nebula dissipated, and how this compares with the predicted timescale of gas-giant formation, remains unclear(6,7), in part because direct observations of circumstellar gas have been made only for stars either younger or older than the critical range of 10(6)-10(7) yr (refs 8-15). Here we report observations of the molecular gas surrounding 20 stars whose ages are likely to be in this range. The gas dissipates rapidly; after a few million years the mass remaining is typically much less than the mass of Jupiter. Thus, if gas-giant planets are common in the Galaxy, they must form even more quickly than present models suggest.	OBSERV GRENOBLE,ASTROPHYS GRP,F-38041 GRENOBLE,FRANCE; MIT,CTR SPACE RES,CAMBRIDGE,MA 02139	Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Massachusetts Institute of Technology (MIT)	ZUCKERMAN, B (corresponding author), UNIV CALIF LOS ANGELES,DEPT PHYS & ASTRON,LOS ANGELES,CA 90024, USA.							Adams F.C., 1993, PROTOSTARS PLANETS, P721; Beckwith S. V. W., 1993, PROTOSTARS PLANETS, VIII, P521; BECKWITH SVW, 1993, ASTROPHYS J, V402, P280, DOI 10.1086/172131; CHIAR JE, 1994, ASTROPHYS J, V426, P240, DOI 10.1086/174058; DANTONA F, 1994, ASTROPHYS J SUPPL S, V90, P467, DOI 10.1086/191867; DUTREY A, 1994, ASTRON ASTROPHYS, V286, P149; FEKEL FC, 1993, ASTROPHYS J, V419, pL89, DOI 10.1086/187144; FRANCHINI M, 1992, ASTRON ASTROPHYS, V256, P525; GREGORIOHETEM J, 1992, ASTRON J, V103, P549, DOI 10.1086/116082; HERBST W, 1988, ASTRON J, V96, P1949, DOI 10.1086/114941; HOBBS LM, 1985, ASTROPHYS J, V293, pL29, DOI 10.1086/184485; JENSEN ELN, 1994, ASTROPHYS J, V429, pL29, DOI 10.1086/187405; JURA M, 1993, ASTROPHYS J, V418, pL37, DOI 10.1086/187110; KAWABE R, 1993, ASTROPHYS J, V404, pL63, DOI 10.1086/186744; KOERNER DW, 1993, ASTROPHYS J, V408, pL93, DOI 10.1086/186839; KOERNER DW, 1993, ICARUS, V106, P2, DOI 10.1006/icar.1993.1154; Lin D.N.C., 1985, PROTOSTARS PLANETS, VII, P981; LISSAUER JJ, 1993, ANNU REV ASTRON ASTR, V31, P129, DOI 10.1146/annurev.aa.31.090193.001021; LISSAUER JJ, 1987, ICARUS, V69, P249, DOI 10.1016/0019-1035(87)90104-7; LISSAUER JJ, IN PRESS NEPTUNE; OMODAKA T, 1992, ASTROPHYS J, V396, pL87, DOI 10.1086/186523; OUDMAIJER RD, 1992, ASTRON ASTROPHYS SUP, V96, P625; Podolak M., 1993, PROTOSTARS PLANETS, P1109; PRINN RG, 1993, PROTOSTARS PLANETS, V3, P1005; RUDEN SP, 1991, ASTROPHYS J, V375, P740, DOI 10.1086/170239; SARGENT AI, 1991, ASTROPHYS J, V382, pL31, DOI 10.1086/186207; SARGENT AI, 1993, ANNU REV ASTRON ASTR, V31, P297; SAVOLDINI M, 1994, ASTRON ASTROPHYS, V285, P467; SKRUTSKIE MF, 1991, ASTRON J, V102, P1749, DOI 10.1086/115997; SODERBLOM DR, 1993, ASTROPHYS J SUPPL S, V85, P315, DOI 10.1086/191767; STENCEL RE, 1991, ASTROPHYS J SUPPL S, V75, P905, DOI 10.1086/191553; STEVENSON DJ, 1988, ICARUS, V75, P146, DOI 10.1016/0019-1035(88)90133-9; STROM SE, 1994, REV MEX ASTRON ASTR, V29, P23; TIELENS AGGM, 1991, ASTROPHYS J, V381, P181, DOI 10.1086/170640; WEINTRAUB DA, 1989, ASTROPHYS J, V344, P915, DOI 10.1086/167859; WETHERILL GW, 1991, SCIENCE, V253, P535, DOI 10.1126/science.253.5019.535; WETHERILL GW, IN PRESS PLANETARY S; WOLSZCZAN A, 1992, NATURE, V355, P145, DOI 10.1038/355145a0; YAMASHITA T, 1993, ASTROPHYS J, V402, pL65, DOI 10.1086/186701; ZUCKERMAN B, 1993, ASTROPHYS J, V406, pL25, DOI 10.1086/186778; ZUCKERMAN B, 1994, ASTROPHYS J, V414, P793; ZUCKERMAN B, IN PRESS CIRCUMSTELL	42	318	318	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 9	1995	373	6514					494	496		10.1038/373494a0	http://dx.doi.org/10.1038/373494a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7845460				2022-12-28	WOS:A1995QF72400049
J	BOROS, P; MILLER, CM				BOROS, P; MILLER, CM			HEPATOCYTE GROWTH-FACTOR - A MULTIFUNCTIONAL CYTOKINE	LANCET			English	Review							SERUM				BOROS, P (corresponding author), MT SINAI MED CTR,DEPT SURG,DIV LIVER TRANSPLANTAT,BOX 1038,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029, USA.		Miller, Cynthia/HHY-7259-2022	Miller, Cynthia/0000-0002-2883-6294				GANDINO L, 1994, J BIOL CHEM, V269, P1815; JOPLIN R, 1992, J CLIN INVEST, V90, P1284, DOI 10.1172/JCI115992; JUCKER M, 1994, LEUKEMIA RES, V18, P7, DOI 10.1016/0145-2126(94)90003-5; KAWAIDA K, 1994, P NATL ACAD SCI USA, V91, P4357, DOI 10.1073/pnas.91.10.4357; LIU ML, 1994, HEPATOLOGY, V19, P1521; LYON M, 1994, J BIOL CHEM, V269, P11216; MATSUMOTO K, 1992, P NATL ACAD SCI USA, V89, P3800, DOI 10.1073/pnas.89.9.3800; MATSUNAGA T, 1994, EXP CELL RES, V210, P326, DOI 10.1006/excr.1994.1045; MICHALOPOULOS G, 1984, CANCER RES, V44, P4414; MICHALOPOULOS GK, 1992, HEPATOLOGY, V15, P149, DOI 10.1002/hep.1840150125; MILLER SB, 1994, AM J PHYSIOL, V266, pF129, DOI 10.1152/ajprenal.1994.266.1.F129; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NUSRAT A, 1994, J CLIN INVEST, V93, P2055; OKAZAKI H, 1994, BIOCHIM BIOPHYS ACTA, V220, P291; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; ROSEN EM, 1993, SYM SOC EXP BIOL, V47, P227; RUSSELL WE, 1984, J CELL PHYSIOL, V119, P183, DOI 10.1002/jcp.1041190207; SAKAGUCHI H, 1994, HEPATOLOGY, V19, P1157, DOI 10.1002/hep.1840190513; SHIMA N, 1994, BIOCHEM BIOPH RES CO, V200, P808, DOI 10.1006/bbrc.1994.1523; SHIOTA G, 1994, BIOCHEM BIOPH RES CO, V200, P1099, DOI 10.1006/bbrc.1994.1563; SHIOTA G, 1994, HEPATOLOGY, V19, P962, DOI 10.1016/0270-9139(94)90297-6; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; WATANABE S, 1994, BIOCHEM BIOPH RES CO, V199, P1453, DOI 10.1006/bbrc.1994.1394; YAMASHITA J, 1994, CANCER RES, V54, P1630; ZIONCHECK TF, 1994, ENDOCRINOLOGY, V134, P1879, DOI 10.1210/en.134.4.1879	25	295	318	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					293	295		10.1016/S0140-6736(95)90279-1	http://dx.doi.org/10.1016/S0140-6736(95)90279-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE731	7837864				2022-12-28	WOS:A1995QE73100013
J	CUNNINGHAM, D				CUNNINGHAM, D			CONTROVERSIES IN MANAGEMENT - CHEMOTHERAPY FOR SOLID TUMORS - IMPORTANT PROGRESS IN TREATMENT	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ADJUVANT THERAPY; GASTRIC-CANCER				CUNNINGHAM, D (corresponding author), ROYAL MARSDEN HOSP, INST CANC RES, MED SECT, CANC RES CAMPAIGN, DOWNS RD, SUTTON SM2 5PT, SURREY, ENGLAND.			Cunningham, David/0000-0001-5158-1069				ALLENMERSH TG, 1994, LANCET, V344, P1255, DOI 10.1016/S0140-6736(94)90750-1; BAKKEVOLD KE, 1993, EUR J CANCER, V29A, P698, DOI 10.1016/S0959-8049(05)80349-1; CUNNINGHAM D, 1991, EUR J CANCER, V15, P2077; FINDLAY M, IN PRESS ANN ONCOL; FRIEDMAN HS, 1994, NEW ENGL J MED, V330, P504; HAGIWARA A, 1992, LANCET, V339, P629, DOI 10.1016/0140-6736(92)90792-2; HERMANS J, 1993, J CLIN ONCOL, V11, P1441, DOI 10.1200/JCO.1993.11.8.1441; HERSKOVIC A, 1992, NEW ENGL J MED, V326, P1593, DOI 10.1056/NEJM199206113262403; JAAKKIMAINEN L, 1990, J CLIN ONCOL, V8, P1301, DOI 10.1200/JCO.1990.8.8.1301; KATZ S, 1983, NEW ENGL J MED, V309, P1218, DOI 10.1056/NEJM198311173092005; MOERTEL C, 1992, P AN M AM SOC CLIN, V11, P161; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; MOERTEL CG, 1981, CANCER, V48, P1705, DOI 10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4; PYRHONEN S, 1993, ANN ONCOL, V3, P47; SCHEITHAUER W, 1993, BRIT MED J, V306, P752, DOI 10.1136/bmj.306.6880.752; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1994, NEW ENGL J MED, V330, P505	17	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 28	1995	310	6974					247	248		10.1136/bmj.310.6974.247	http://dx.doi.org/10.1136/bmj.310.6974.247			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE496	7866134	Green Published			2022-12-28	WOS:A1995QE49600034
J	HELDIN, CH				HELDIN, CH			DIMERIZATION OF CELL-SURFACE RECEPTORS IN SIGNAL-TRANSDUCTION	CELL			English	Review							PROTEIN-TYROSINE KINASE; HUMAN GROWTH-HORMONE; AFFINITY PHOSPHOTYROSYL PEPTIDE; INTERFERON-GAMMA; TRANSCRIPTION FACTOR; INTERMOLECULAR ASSOCIATION; EXTRACELLULAR DOMAIN; CYTOPLASMIC DOMAIN; CRYSTAL-STRUCTURE; TNF RECEPTOR				HELDIN, CH (corresponding author), LUDWIG INST CANC RES,CTR BIOMED,BOX 595,S-75124 UPPSALA,SWEDEN.							AUGET M, 1988, CELL, V55, P273; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BAZAN JF, 1993, CURR BIOL, V3, P603, DOI 10.1016/0960-9822(93)90009-D; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BLECHMAN JM, 1995, CELL, V80, P105; BOULTON TG, 1994, J BIOL CHEM, V269, P11645; CAMBIER JC, 1994, CURR OPIN GENET DEV, V4, P55, DOI 10.1016/0959-437X(94)90091-4; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CLARK MR, 1994, EMBO J, V13, P1911, DOI 10.1002/j.1460-2075.1994.tb06460.x; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUQUESNOY P, 1994, EMBO J, V13, P1386, DOI 10.1002/j.1460-2075.1994.tb06392.x; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GRECO A, 1992, ONCOGENE, V7, P237; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KAWAHARA A, 1994, MOL CELL BIOL, V14, P5433, DOI 10.1128/MCB.14.8.5433; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KRUSE N, 1992, EMBO J, V11, P3237, DOI 10.1002/j.1460-2075.1992.tb05401.x; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; Mui Alice L.-F., 1994, Progress in Growth Factor Research, V5, P15, DOI 10.1016/0955-2235(94)90015-9; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; OKADOME T, 1994, J BIOL CHEM, V269, P30753; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUPP E, 1994, EUR J BIOCHEM, V225, P29, DOI 10.1111/j.1432-1033.1994.00029.x; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SAVINO R, 1994, EMBO J, V13, P1357, DOI 10.1002/j.1460-2075.1994.tb06389.x; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAI K, 1992, SCIENCE, V259, P1808; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SOOS MA, 1989, BIOCHEM J, V263, P553, DOI 10.1042/bj2630553; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI T, 1994, FEBS LETT, V342, P124, DOI 10.1016/0014-5793(94)80485-0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULTSCH M, 1991, J MOL BIOL, V22, P865; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	112	1381	1452	0	61	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 27	1995	80	2					213	223		10.1016/0092-8674(95)90404-2	http://dx.doi.org/10.1016/0092-8674(95)90404-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7834741	Bronze			2022-12-28	WOS:A1995QD92400004
J	REYNOLDS, EH				REYNOLDS, EH			CONTROVERSIES IN MANAGEMENT - DO ANTICONVULSANTS ALTER THE NATURAL COURSE OF EPILEPSY - TREATMENT SHOULD BE STARTED AS EARLY AS POSSIBLE .17.	BRITISH MEDICAL JOURNAL			English	Article											REYNOLDS, EH (corresponding author), MAUDSLEY HOSP & INST PSYCHIAT,CTR EPILEPSY,LONDON SE5 8AZ,ENGLAND.							CHANDRA B, 1992, CLIN NEUROL NEUROSUR, V94, pS61; ELWES RDC, 1988, BRIT MED J, V297, P948, DOI 10.1136/bmj.297.6654.948; FEKSI AT, 1991, LANCET, V337, P406, DOI 10.1016/0140-6736(91)91176-U; Gowers WR, 1881, EPILEPSY OTHER CHRON; MUSICCO M, 1993, NEUROLOGY, V43, P478; REYNOLDS E H, 1989, Epilepsia, V30, P648; REYNOLDS EH, 1987, EPILEPSIA, V28, P97, DOI 10.1111/j.1528-1157.1987.tb03633.x; REYNOLDS EH, 1990, BRIT MED J, V301, P112; SUTULA T, 1992, J NEUROSCI, V12, P4173; 1991, LANCET, V337, P1175	10	48	50	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 21	1995	310	6973					176	177		10.1136/bmj.310.6973.176	http://dx.doi.org/10.1136/bmj.310.6973.176			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD201	7833760	Green Published			2022-12-28	WOS:A1995QD20100028
J	MCKENDRICK, MW				MCKENDRICK, MW			ACYCLOVIR FOR CHILDHOOD CHICKENPOX - COST IS UNJUSTIFIED	BRITISH MEDICAL JOURNAL			English	Article							NORMAL-CHILDREN; VARICELLA; ZOSTER				MCKENDRICK, MW (corresponding author), ROYAL HALLAMSHIRE HOSP,DEPT INFECT DIS & MED,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND.							BALFOUR HH, 1990, J PEDIATR-US, V116, P633, DOI 10.1016/S0022-3476(05)81618-X; BALFOUR HH, 1992, J PEDIATR-US, V120, P627, DOI 10.1016/S0022-3476(05)82495-3; BRUNELL PA, 1992, NEW ENGL J MED, V326, P1226; Bullowa JGM, 1935, AM J DIS CHILD, V49, P923; DUNKLE LM, 1991, NEW ENGL J MED, V325, P1539, DOI 10.1056/NEJM199111283252203; ENGLUND JA, 1990, J CLIN MICROBIOL, V28, P2327, DOI 10.1128/JCM.28.10.2327-2330.1990; HUFF JC, 1988, AM J MED, V85, P84; MOORE DA, 1991, AM J EPIDEMIOL, V133, P1161, DOI 10.1093/oxfordjournals.aje.a115828; PREBLUD SR, 1981, PEDIATRICS, V68, P14; ROSS AH, 1962, NEW ENGL J MED, V267, P369, DOI 10.1056/NEJM196208232670801	10	14	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 14	1995	310	6972					108	109		10.1136/bmj.310.6972.108	http://dx.doi.org/10.1136/bmj.310.6972.108			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC223	7833700	Green Published			2022-12-28	WOS:A1995QC22300027
J	RICHARDS, MA; SMITH, IE; DIXON, JM				RICHARDS, MA; SMITH, IE; DIXON, JM			ABC OF BREAST DISEASES - ROLE OF SYSTEMIC TREATMENT FOR PRIMARY OPERABLE BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article									ROYAL MARSDEN HOSP,LONDON SW3 6JJ,ENGLAND; WESTERN GEN HOSP,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; ROYAL INFIRM,EDINBURGH,MIDLOTHIAN,SCOTLAND	Royal Marsden NHS Foundation Trust; University of Edinburgh; Royal Infirmary of Edinburgh	RICHARDS, MA (corresponding author), GUYS HOSP,IMPERIAL CANC RES FUND,CLIN ONCOL UNIT,LONDON SE1 9RT,ENGLAND.								0	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 19	1994	309	6965					1363	1366		10.1136/bmj.309.6965.1363	http://dx.doi.org/10.1136/bmj.309.6965.1363			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT625	7866090	Green Published			2022-12-28	WOS:A1994PT62500037
J	SMITH, CP; PARLE, M; MORRIS, DJ				SMITH, CP; PARLE, M; MORRIS, DJ			IMPLEMENTATION OF GOVERNMENT RECOMMENDATIONS FOR IMMUNIZING INFANTS AT RISK OF HEPATITIS-B	BRITISH MEDICAL JOURNAL			English	Article									N MANCHESTER GRP HOSP,DEPT AUDIT,MANCHESTER M8 6RB,LANCS,ENGLAND; BOOTH HALL CHILDRENS HOSP,N MANCHESTER VIRUS LAB,MANCHESTER M9 7AA,LANCS,ENGLAND	Royal Manchester Children's Hospital	SMITH, CP (corresponding author), BOOTH HALL CHILDRENS HOSP,DEPT CHILD HLTH,MANCHESTER M9 7AA,LANCS,ENGLAND.							BIRNBAUM JM, 1992, AM J INFECT CONTROL, V20, P172, DOI 10.1016/S0196-6553(05)80142-7; BROOK MG, 1989, Q J MED, V264, P313; Waters J R, 1989, Can Dis Wkly Rep, V15, P29; 1992, IMMUNISATION INFECTI, P110	4	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 19	1994	309	6965					1339	1339		10.1136/bmj.309.6965.1339	http://dx.doi.org/10.1136/bmj.309.6965.1339			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT625	7866083	Green Published			2022-12-28	WOS:A1994PT62500024
J	WILLIAMSON, BD; MAN, KC; DAOUD, E; NIEBAUER, M; STRICKBERGER, SA; MORADY, F				WILLIAMSON, BD; MAN, KC; DAOUD, E; NIEBAUER, M; STRICKBERGER, SA; MORADY, F			RADIOFREQUENCY CATHETER MODIFICATION OF ATRIOVENTRICULAR-CONDUCTION TO CONTROL THE VENTRICULAR RATE DURING ATRIAL-FIBRILLATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NODAL REENTRANT TACHYCARDIA; SLOW-PATHWAY; ABLATION REGISTRY; JUNCTION; ENERGY; ANTERIOR; DEATH	Background. In some patients with atrial fibrillation, the Ventricular rate may be difficult to control with medications. We evaluated a radiofrequency catheter technique to modify atrioventricular conduction in atrial fibrillation in order to control the ventricular rate without creating pathologic atrioventricular block. Methods. We studied 19 consecutive patients with atrial fibrillation and uncontrolled ventricular rates refractory to drug therapy. They had had atrial fibrillation for a mean (+/-SD) of 5.5+/-4.9 years, had had 4.9+/-0.9 unsuccessful drug trials, and were 62+/-5 years old. Before the procedure, the maximal ventricular rate during exercise was 180+/-39 beats per minute. A total of 11+/-5 radiofrequency-energy applications were delivered to the posterior septal or midseptal right atrium, near the ostium of the coronary sinus. Results. Successful control of the ventricular rate without pathologic atrioventricular block was achieved in 14 of the 19 patients (74 percent). Persistent third-degree atrioventricular block requiring a permanent pacemaker occurred inadvertently in four patients (21 percent). Atrioventricular conduction was intentionally ablated in one patient. The 14 patients who had successful modification of conduction had persistent reductions in maximal ventricular rate during exercise (rate at three months, 126+/-24 beats per minute; P<0.01). These patients had resolution of symptoms related to rapid rates during 8+/-2 months of follow-up. One patient had a recurrence of a rapid ventricular rate but was again asymptomatic after a second modification procedure. One patient with dilated cardiomyopathy died suddenly, five months after a successful procedure. Conclusions. A catheter technique to modify atrioventricular conduction without creating pathologic atrioventricular block is feasible in the majority of patients with symptomatic atrial fibrillation and a rapid ventricular rate refractory to drug therapy.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,DIV CARDIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan								AKHTAR M, 1991, ANN INTERN MED, V114, P499, DOI 10.7326/0003-4819-114-6-499; BHARATI S, 1985, CHEST, V88, P883, DOI 10.1378/chest.88.6.883; EVANS GT, 1987, PACE, V10, P1395; EVANS GT, 1991, CIRCULATION, V84, P1924, DOI 10.1161/01.CIR.84.5.1924; FLECK RP, 1993, PACE, V16, P377, DOI 10.1111/j.1540-8159.1993.tb01597.x; GALLAGHER JJ, 1982, NEW ENGL J MED, V306, P194, DOI 10.1056/NEJM198201283060402; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; HAISSAGUERRE M, 1992, CIRCULATION, V85, P2162, DOI 10.1161/01.CIR.85.6.2162; HUANG SK, 1987, J AM COLL CARDIOL, V9, P349, DOI 10.1016/S0735-1097(87)80388-1; HUANG SKS, 1989, CIRCULATION, V80, P951, DOI 10.1161/01.CIR.80.4.951; JACKMAN WM, 1991, CIRCULATION, V83, P1562, DOI 10.1161/01.CIR.83.5.1562; JACKMAN WM, 1992, NEW ENGL J MED, V327, P313, DOI 10.1056/NEJM199207303270504; JANSE MJ, 1993, J CARDIOVASC ELECTR, V4, P561, DOI 10.1111/j.1540-8167.1993.tb01244.x; JAZAYERI MR, 1992, CIRCULATION, V85, P1318, DOI 10.1161/01.CIR.85.4.1318; KALBFLEISCH SJ, 1994, J AM COLL CARDIOL, V23, P716, DOI 10.1016/0735-1097(94)90759-5; KAY GN, 1992, CIRCULATION, V85, P1675, DOI 10.1161/01.CIR.85.5.1675; KUNZE KP, 1988, AM J CARDIOL, V61, P657, DOI 10.1016/0002-9149(88)90788-6; LANGBERG JJ, 1993, CIRCULATION, V87, P1551, DOI 10.1161/01.CIR.87.5.1551; LANGBERG JJ, 1991, AM J CARDIOL, V67, P142, DOI 10.1016/0002-9149(91)90436-O; LANGBERG JJ, 1989, CIRCULATION, V80, P1527, DOI 10.1161/01.CIR.80.6.1527; MITRANI RD, 1993, J AM COLL CARDIOL, V21, P432, DOI 10.1016/0735-1097(93)90686-U; MORADY F, 1993, J AM COLL CARDIOL, V21, P102, DOI 10.1016/0735-1097(93)90723-E; SCHEINMAN MM, 1984, CIRCULATION, V70, P1024, DOI 10.1161/01.CIR.70.6.1024; SCHEINMAN MM, 1982, JAMA-J AM MED ASSOC, V248, P851, DOI 10.1001/jama.248.7.851; SOUSA J, 1991, CIRCULATION, V84, P567, DOI 10.1161/01.CIR.84.2.567; THAKUR RK, 1993, J AM COLL CARDIOL, V22, P1706, DOI 10.1016/0735-1097(93)90600-6; WATHEN M, 1992, AM J CARDIOL, V70, P886, DOI 10.1016/0002-9149(92)90732-E; WU DL, 1993, J AM COLL CARDIOL, V21, P1612, DOI 10.1016/0735-1097(93)90376-C; YEUNGLAIWAH JA, 1991, J AM COLL CARDIOL, V18, P1753, DOI 10.1016/0735-1097(91)90516-C	29	209	211	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 6	1994	331	14					910	917		10.1056/NEJM199410063311404	http://dx.doi.org/10.1056/NEJM199410063311404			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ419	7848418				2022-12-28	WOS:A1994PJ41900004
